

Index

A

Agenaës syndrome, 2452
AAI. *See* Atlantoaxial instability
AAIDD. *See* American Association on Intellectual and Developmental Disabilities
AAN. *See* American Academy of Neurology
AAP. *See* American Academy of Pediatrics
Abacavir, for HIV, 2098t–2107t
Abatacept, 1469–1470
Abbreviations, in laboratory testing, 4472.e8t
ABCA3 deficiency, 2634t, 2684–2685
ABCD status, in emergency situations, 546
Abdomen
assessment in newborn, 1003
neuroblastoma with central necrosis, 3128f
physical examination of, 551
shock in, 607t
trauma to, 117–119
tuberculosis of, 1845
visceral blocks, in pain management, 694–695
Abdominal actinomycosis, 1734
Abdominal distention, 1099t, 2237–2238, 2238f
clinical hallmark of ascites as, 2509
in newborn, 1053–1054
Abdominal masses, 2237–2238, 2238f, 3133
malignancies in, 3082–3083
Abdominal migraine, 2390–2391, 2390t, 3644
Abdominal pain, 2234, 2234t–2235t
in acutely ill child, 549–550
appendicitis and, 2397–2398
chronic
alarm symptoms for, 2390t
diagnostic criteria for, 2391t
disorders, 2389–2391, 2389t–2390t
red flags for, 1577t
in schistosomiasis, 2215
Abdominal paracentesis, 2509
Abdominal trauma, secondary survey for, 576–577, 577f
Abdominal tumors, in children, 3133t
Abdominal wall defects, in delivery room, 1072–1073
Abdominoscrotal hydrocele, 3308
Abducent nerve (cranial nerve VI), in neurologic examination, 3553
Aberrant regeneration, 3928
Aberrant right subclavian artery, 2827t
Abetalipoproteinemia, 480–481, 880–881, 2340, 2965–2966, 3672
Ability. *See* Aripiprazole
Abnormal bleeding, malaria and, 2180
Abnormal development, of breast, 3329–3332
Abnormal Involuntary Movement Scale (AIMS), 227
Abnormal spinal curvatures, 4242
Abnormal uterine bleeding, 1211, 1213–1214, 1213t–1214t
ABO incompatibility, hemolytic disease of newborn caused by, 1125
Abortion, 1231–1234
epidemiology of, 1231–1234, 1232f, 1232t
methods of, 1232–1233, 1234f
Abortion care, 1231, 1233f–1234f
Abortive poliomyelitis, 1972
treatment of, 1977
Abrin-containing species, 722t
Abscess
bacterial, 4156, 4157f
brain, 3779–3781, 3779t
clinical manifestations of, 3780

Abscess (*Continued*)
CSF findings in, 3759t–3760t
diagnosis of, 3780, 3780f
etiology of, 3779–3780
pathology of, 3779
prognosis of, 3781
treatment of, 3780–3781, 3781t
breast, 3330–3331
infected urachal, 3288f
liver, 2474–2475
amebic, 2148, 2148f, 2475, 2475f
muscle, staphylococcal, 1696
orbital, 3973t
perianal, 2408–2409, 2408f–2409f
perirenal, 3265f
peritoneal, 2512
peritonsillar cellulitis and, 2567–2568
pulmonary, 2660–2661, 2661f, 2662t
retropharyngeal and lateral pharyngeal, 2566–2567, 2567f
secondary to sinusitis, 2557f
subperiosteal, 3973t, 3975
tuboovarian, PID and, 3341–3342
Absence seizures, 3598, 3600–3601
Absolute eosinophil count (AEC), 1293
Absolute lymphocyte count (ALC), 1312
after whole body irradiation, 4420t
Absolute neutrophil count (ANC), 1304, 1305t
Absorbed dose, 4413–4414
Absorption
folate, decreased, 2941
intestinal, 2277
vitamin B₁₂, impaired, 2942–2943
Abstinence, sex education and, 1231
Abuse and neglect, 114–129. *See also* Sexual abuse;
Substance abuse
advocacy for, 121
assessment of, 120
clinical manifestations of, 115–119, 115t, 116f, 117t
definitions, 114
etiology of, 115
fractures due to, 4278–4279, 4279t
general principles of
for addressing, 120–121
for assessing, 119–120
incidence and prevalence of, 114
global situation, 114
in United States, 115
medical child abuse, 127–128
outcomes of, 115
prevention of, 121
Abusive head trauma (AHT), 117, 120f, 3750
Academic problems, 304–305
diagnostic classification of, 300
neurodevelopmental dysfunction underlying, 304t
Acanthamoeba keratitis, drugs for, 2126t–2144t
Acanthocytosis, 2965–2966, 2966t
Acanthosis nigricans, 445f, 794t–795t, 4108–4109, 4109f
in T2DM, 3515
Accelerated junctional ectopic tachycardia, 2852
Acceleration, 1017
Acceptable macronutrient distribution ranges (AMDRs), 388t, 391
Access, in food security, 421
Access to care, in developing world, 544
Accessory nerve (cranial nerve XI), in neurologic examination, 3554
Accessory nipple, 3329, 3329f
Accessory tragi, 4044, 4044f
Accidental hypothermia, 640, 657
Acclimatization, hypobaric hypoxia and, 630–631
Accolate. *See* Zafirlukast

Accommodation
for dyslexia, 318
for neurodevelopmental dysfunctions, 307
ophthalmologic, 3914–3915
Accommodative esotropia, 3926
Accreditation, childcare, 184–185
Acculturation, 82, 82f
Accuracy
of laboratory testing, 4472.e3
in laboratory tests, 4472.e3
ACD. *See* Alveolocapillary dysplasia
ACE. *See* Angiotensin-converting enzyme
Aceruloplasminemia, 2950
Acetabular index, 4235
Acetabular labrum tears, 4308
Acetabulum, 4231
Acetaminophen
liver injury caused by, 2490
for migraine, 3646t–3647t
in pain management, 681–682, 681t
for patent ductus arteriosus, 1083
toxicity, 710–711, 710f, 710t
for yellow fever, 2072
Acetazolamide
for acute mountain sickness, 633, 633t
adverse effects of, 3611t
dosages of, 3609t–3610t
for periodic paralysis, 3850
Acetoacetyl-CoA thiolase deficiency, cytosolic, 831
N-acetylaspartic acid (NAA), 857–858
N-Acetylglutamate synthetase deficiencies, 851
Achalasia, 2261–2262, 2262f
Achondrogenesis
type I, 4347
type II, 4340
Achondroplasia, 2714–2715, 4345–4347
clinical manifestations of, 4345–4346
diagnosis of, 4345, 4346f–4347f
gain-of-function variant in, 732–733
genetics of, 4346–4347
Achromatopsia, 3910
Achromic nevus, 4065, 4065f
Acid
definition of, 509
excretion of, 512
secretion, in peptic ulcer disease, 2305
Acid burns, eye injuries and, 3979
Acid maltase deficiency, 906
Acid-base balance
clinical assessment of acid-base disorders, 513–514
disorders, 513t
metabolic acidosis, 514–518
metabolic alkalosis, 518–521
normal, 510–513
physiology of, 509–510
respiratory acidosis, 521–523
respiratory alkalosis, 523–525
tubular sites in, 511f
Acidemia, 513
isovaleric, 827–828
methylmalonic, 835–836
organic, 825–837, 826f
propionic, 833–835
Acidic agents, 2275
Acidification, tubular function in, 3233
Acidosis. *See also* Ketacidosis
cardiac arrest and, 567t
in CKD, 3250t
lactic, 515
metabolic. *See* Metabolic acidosis
in pyloric stenosis, 2279
respiratory, 513t, 521–523
with metabolic compensation, 617

Page numbers followed by “b” indicate boxes, “f” indicate figures, “t” indicate tables.

- Aciduria
argininosuccinic, 853
L-glyceric, 839
hereditary orotic, 945t, 953
3-hydroxy-3-methylglutaric, 832
3-methylglutaconic, 829–830, 830t
methylmalonic, with homocystinuria, 836–837
mevalonic, 832–833
 orotic, 2944
Acinar cell, 2423
Acinar dysplasia, 2634t
Acinus, 2423
ACL. *See* Anterior cruciate ligament
Acne, 4177–4185
 drug-induced, 4183, 4184f
 fulminans, 4179f, 4184–4185
 infantile, 4184, 4185f
 mid-childhood, 4184
 neonatal cephalic pustulosis, 4183, 4185f
PAPA syndrome, 1523
 severe truncal, 1489
Acne vulgaris, 4177–4181
 clinical manifestations of, 4178f–4179f, 4178t
 pathogenesis of, 4177, 4178f
 treatment for, 4178–4181, 4180t–4183t, 4181f, 4184f
Acoustic immittance testing, 3991, 4007, 4007f
Acoustic reflex threshold test, 3991
Acoustic trauma, 4023
Acquaintance rape, 1235
Acquired cholesteatoma, 4014
Acquired demyelinating syndromes (ADS), 3722
 with encephalopathy, 3707f, 3708
 MR imaging red flags for, 3724t
Acquired disorders
 aplastic anemia, HSCT for, 1353
 diffuse hair loss, 4140
 goiter, 3415
 heart disease, infective endocarditis, 2864–2871
 hypermethioninemia, 823
 hypopituitarism, 3368–3369
 hypothyroidism, 3408–3410
 inhibitors of coagulation, 3047f
 laryngotracheal stenosis, 2580–2581, 2581f
 localized hair loss, 4137, 4138t–4139t
 lymphocytic choriomeningitis virus infection, 2078
 myocardial, etiology of, 2879t
 neutropenia, 1304–1308
 of nose, 2548–2549
 epistaxis, 2548–2549
 foreign bodies, 2548
 partial lipodystrophy, 4133
 platelet function, 3058–3059
 polycythemia, 2999
 pure red blood cell anemia, 2934–2935
 syphilis, 1866
 trichorrhexis nodosa, 4140
Acquired forms
 of GH deficiency, 3366
 of growth hormone deficiency, 3366
 of multiple pituitary hormone deficiency, 3365
 of nephrogenic diabetes insipidus, 3374
Acquired generalized lipodystrophy (AGL), 4133
Acquired immunodeficiencies, 1661–1666
 fever and neutropenia, 1662–1663
 fever without neutropenia, 1664
 from infectious agents, 1661
 malignancies, 1661–1662, 1662f–1663f, 1663t
 transplantation, 1664–1666
Acquired immunodeficiency syndrome (AIDS), 1244, 2087–2117, 2087f
 antibody tests for, 4472.e4, 4472.e4t
 clinical manifestations of, 2092–2096, 2092t–2093t
 cardiovascular system, 2095
 central nervous system, 2094
 gastrointestinal and hepatobiliary tract, 2095
 hematologic and malignant diseases, 2095–2096
 infections, 2092–2094
 renal disease, 2095
 respiratory tract, 2094–2095
 skin manifestations, 2095
 diagnosis and testing of, 2096–2097, 2096f
 epidemiology of, 2089–2090
 etiology of, 2087–2089, 2088f
 Acquired immunodeficiency syndrome (AIDS)
 (Continued)
 laboratory screening, 1241t
 pathogenesis of, 2090–2092
 pattern of disease in, 2091
 prevalence in porphyria cutanea tarda, 973
 prevention of, 2113–2117
 prognosis of, 2113
 transmission of, 2089–2090
 treatment of, 2097–2113
 adherence, 2107–2108
 antiretroviral therapy, 2108
 combination therapy, 2097–2107, 2098t–2107t
 dosages, 2108
 initiation of therapy, 2108
 supportive care, 2109–2113, 2110t–2113t
 type 2, 2089
 visceral leishmaniasis, 2159
 Acquired inhibitors of coagulation, 3047
 Acquired long QT interval, 2861
 Acquired lymphopenia, 1312
 Acquired melanocytic nevus, 4061
 Acquired neutropenia, 1304–1308
 Acquired nystagmus, 3930
 Acquired pancytopenias, 3011–3013
 caused by marrow replacement, 3013
 clinical manifestations of, 3012
 complications of, 3013
 differential diagnosis of, 3012
 etiology and epidemiology of, 3011, 3011t–3012t
 laboratory findings of, 3012
 pathology and pathogenesis of, 3012
 prognosis of, 3013
 treatment of, 3012–3013
 Acquired pituitary insufficiency, 3366t
 Acquired thyroxine-binding globulin (TBG) deficiency, 3402
 Acquired toxoplasmosis, 2188–2189, 2195–2196
 Acrocyanosis, 1510, 2737
 Acrodermatitis enteropathica, 484, 2351, 4189, 4190t, 4191f
 Acrodynia, 4434
 Acrodyostosis, with hormone resistance, 3440
 Acromelic shortening, 4336
 Acromioclavicular joint separation, 4301, 4301f
 Acromioclavicular sprains, tennis and, 4329
 Acropustulosis, infantile, 4042–4043, 4043f
 ACTH. *See* Adrenocorticotrophic hormone
 ACTH-dependent Cushing syndrome, 3475–3476
 Actinic prurigo, 4096, 4097f
 Actinomyces, 1733–1735
 common clinical presentations of, 1734
 diagnosis of, 1733–1734
 differential diagnosis of, 1734–1735
 epidemiology of, 1733
 pathogenesis of, 1733
 prognosis of, 1735
 taxonomy and microbiology, 1733
 treatment of, 1735
 Actinomycosis
 abdominal and pelvic, 1734
 cerebral and other forms of, 1734
 cervicofacial, 1733f–1734f, 1734
 CNS, 1734
 thoracic, 1734
 Action tremor, 3678
 Activated charcoal
 multidose, 709
 single-dose, 708–709, 709t
 Activated partial thromboplastin time, 3024f, 3025, 3027t
 Activated PI3K delta syndrome, 1332t–1333t
 Active euthanasia, 53
 Active immunoprophylaxis, for cytomegalovirus (CMV), 2015
 Active sleep, of newborn, 149
 Active tone, in neuromuscular system, 3791
 Active vitamin D sterols, 3250
 Activins, 3486
 Activity restrictions, for Marfan syndrome, 4368
 Acupressure, 57–58
 in pain management, 693
 Acupuncture, 57–58
 in pain management, 693
 Acute abdominal pain, 2236t
 Acute acquired neutrophilia, 1313
 Acute bacterial meningitis, beyond the neonatal period, 3758–3772
 clinical manifestations in, 3761–3762
 complications in, 3771
 diagnosis in, 3762
 differential diagnosis in, 3762–3769, 3763t–3769t
 pathogenesis of, 3761
 pathology and pathophysiology of, 3760–3761
 prevention of, 3771–3772
 prognosis of, 3771
 treatment in, 3769–3771
 Acute bronchiolitis, 2585–2588, 2586f
 Acute bronchitis, 2588–2589, 2588t
 Acute cardiogenic liver injury, 2477
 Acute cellulitis, of external ear, 4002
 Acute cerebellar ataxia, 3672
 Acute cerebellitis, 3672
 Acute Chagas disease, 2164f, 2166
 Acute chest syndrome, of sickle cell anemia, 2973t
 Acute dacryocystitis, 3937, 3938f
 Acute disseminated encephalomyelitis (ADEM), 3705t–3707t, 3722–3725, 3966
 clinical manifestations of, 3724
 CSF findings in, 3759t–3760t
 differential diagnosis of, 3725, 3726t
 epidemiology of, 3723, 3723t–3724t
 laboratory findings in, 3724
 neuroimaging in, 3724, 3725f
 pathogenesis of, 3723–3724
 prognosis of, 3725
 treatment of, 3725
 Acute endocarditis, 1749
 Acute eosinophilic pneumonia, 2625–2627, 2626t
 Acute febrile neutrophilic dermatosis. *See* Sweet syndrome
 Acute febrile ulcerative acne, 4179f, 4184–4185
 Acute flaccid myelitis (AFM), 3728–3729, 3729f, 3730t, 3874, 3875f
 Acute flaccid paralysis, 3792–3793, 3795f, 3798t–3799f, 3874, 3875f
 Acute gastroenteritis, 2355–2376, 2356t–2360t
 bacterial diarrhea and, 2357t–2358t, 2365–2367, 2368t
 burden of childhood diarrhea and, 2355–2375
 Campylobacter in, 1790
 clinical manifestation of, 2364–2367
 diarrhea outbreaks and, 2356
 differential diagnosis of, 2356t–2359t, 2367–2370, 2369f, 2369t–2370t
 endemic diarrhea and, 2355, 2356t
 epidemiology of
 in low- and middle-income countries, 2359–2360, 2361f
 in middle- and high-income countries, 2355–2359
 food-borne pathogens and, 2355–2356, 2360t, 2362t–2364t
 host risk factors for, 2360
 intestinal and extraintestinal complications of, 2367, 2368t
 nosocomial diarrhea and, 2356–2359, 2357t–2358t
 pathogenesis of, 2356t–2359t, 2360–2364, 2364t, 2365f–2366f
 pathogens of, 2355, 2356t–2359t
 prevention of, 2373–2375
 protozoal diarrhea and, 2359t, 2367
 seasonality of pathogens and, 2356
 traveler's diarrhea and, 2375–2376
 treatment for, 2370–2373
 antibiotic therapy for, 2372–2373, 2373t–2375t
 enteral feeding and diet selection for, 2371–2372, 2372f
 hydration for, 2370t–2371t, 2371
 zinc supplementation for, 2372
 viral diarrhea and, 2356t, 2364–2365
 zoootic transmission of, 2356t–2359t, 2359
 Acute gastrointestinal allergy, 1445
 Acute generalized exanthematous pustulosis, 4038, 4038f
 Acute graft-versus-host disease, 4034
 Acute GVHD, 1357–1358, 1357f
 Acute hemolytic anemia, 2990
 Acute hemorrhagic cystitis, 3264

- Acute hemorrhagic edema, infantile, 1555, 1558f
 Acute hepatic necrosis, liver transplantation for, 2507
 Acute hepatitis
 approach to, 2473
 of unknown etiology, 2473t, 2473
 Acute hydrops, 2502
 Acute idiopathic pulmonary hemorrhage, of infancy, 2689–2690, 2699, 2699f
 Acute infectious laryngitis, 2570
 Acute infectious (suppurative) thyroiditis, 3411, 3412t
 Acute intermittent porphyria (AIP), 964–970, 964t–965t, 3899t
 Acute interstitial nephritis, 3244
 Acute intracranial trauma, 117
 Acute ischemic stroke, 3040–3041
 Acute kidney injury (AKI), 529, 3242–3247
 causes of, 3243t
 clinical manifestations of, 3244
 complications of, 3245t
 KDIGO staging of, 3242t
 laboratory findings of, 3244–3245
 neurologic symptoms in, 3246
 pathogenesis of, 3242–3244
 prognosis of, 3247
 in severe malaria, 2180
 treatment of, 3245–3247
 dialysis, 3246–3247
 medical management, 3245–3246
 Acute labyrinthitis, 3672
 Acute leukemia, Down syndrome and transient abnormal myelopoiesis and, 3104, 3104f
 Acute liver failure, 2494–2499
 in acetaminophen toxicity, 711
 clinical manifestations of, 2496, 2496f–2497f
 etiology of, 2494–2496, 2495t
 in hepatitis B, 2465
 idiopathic, 2495
 laboratory findings in, 2496–2497, 2497t, 2498f
 pathogenesis of, 2496
 pathology of, 2496
 prognosis for, 2499
 treatment of, 2497–2499, 2497t
 Acute lobar nephronia (acute lobar nephritis), 3263, 3267
 Acute lumbar strain, or contusion, 4306
 Acute lung injury, pulmonary pressure-volume relation in, 621f
 Acute lymphoblastic leukemia (ALL), 3097–3102
 age-related manifestations of, 3084
 cellular classification of, 3097, 3098t, 3099f
 clinical manifestations of, 3098, 3099f
 diagnosis of, 3098–3099
 differential diagnosis of, 3099
 epidemiology of, 3097
 etiology of, 3097, 3097t
 HSCT for, 1351–1352
 predisposing factors of, 3097
 prognosis of, 3102, 3102f
 prognostic factors for, 3100t
 supportive care, 3101
 survival rates of, 2–3
 treatment of, 3099–3101, 3099f, 3100t
 Acute mastoiditis, 4016–4020
 anatomy of, 4016
 clinical manifestations of, 4017, 4017t
 diagnosis and imaging of, 4017, 4017t, 4018f–4019f
 epidemiology of, 4016
 management of, 4017–4019
 microbiology of, 4016–4017, 4016t
 special situations of, 4019–4020, 4020f
 Acute meningococcal septicemia, 1739–1741, 1741f
 Acute mountain sickness (AMS), 631–633
 diagnosis of, 631–632, 631t
 epidemiology and risk factors of, 631
 management of, 632–633
 medications for, 633t
 pathophysiology of, 631
 periodic breathing in, 632
 prevention of, 633
 Acute myelogenous leukemia (AML), 1308, 3102–3103, 3103t, 3104f, 4033–4034
 Acute myeloid leukemia (AML), 3011
 HSCT for, 1352–1353
- Acute necrotizing encephalopathy, 3701–3702, 3701t, 3702f
 Acute necrotizing ulcerative gingivitis, 2250, 4149
 Acute nephritic syndrome, 3189
 Acute neurologic abnormalities, in infants of diabetic mothers, 1141
 Acute normovolemic hemodilution, 3016
 Acute orchitis, in testicular hypofunction, 3489
 Acute osteomyelitis, 4284
 Acute otitis externa (AOE), 4000f–4001f
 Acute otitis media
 adenoidectomy, 4013
 antimicrobial prophylaxis for, 4011–4012
 cholesteatoma, 4014, 4015f
 chronic suppurative, 4013
 clinical manifestations of, 4005
 complications of, 4013, 4014t
 diagnosis, 4004f, 4006–4007, 4006f
 etiology of, 4004–4005
 facial paralysis, 4013–4014
 immunoprophylaxis for, 4007–4008
 infectious dermatitis, 4013
 intracranial complications of, 4014–4016
 intratemporal complications, 4013
 labyrinthitis, 4014
 management of, 4012–4014, 4012t
 medical treatment, 4012–4013
 myringotomy
 and insertion of tympanostomy tubes, 4011
 and tympanocentesis, 4011
 possible developmental sequelae of, 4016
 treatment for, 4008–4011, 4008t–4009t, 4009f
 bacterial resistance, 4008–4010
 duration of, 4010
 first-line antimicrobial, 4010
 follow up, 4010
 second-line, 4009t, 4010–4011
 unsatisfactory response to first-line, 4010
 tube otorrhea, 4011–4012
 tympanic membrane perforation, 4013
 Acute palmoplantar eczema, 4091, 4092f
 Acute pancreatitis, 2426–2428
 clinical manifestations of, 2426
 complications of, 2429t
 diagnosis of, 2426
 etiology of, 2427t
 morphologic features of, 2429t
 prognosis of, 2428
 treatment of, 2428
 Acute paronychia, 4147f
 Acute parotitis, 2254
 Acute patellofemoral dislocation, 4229
 Acute pericarditis, 1749, 2889–2891
 Acute pericoronitis, 2250
 Acute peripheral palsy, etiology of, 3907t
 Acute phase, of schizophrenia, 287
 Acute phobic hallucinations, of childhood, 293
 Acute porphyrias, 964
 Acute poststreptococcal glomerulonephritis, 3189–3192
 clinical manifestations of, 3190
 complications of, 3190–3191
 diagnosis of, 3190–3191, 3190t–3191t, 3191f–3192f
 etiology and epidemiology of, 3189
 pathology of, 3188f–3189f, 3189
 prevention of, 3192
 prognosis of, 3192
 treatment of, 3192
 Acute primary peritonitis, 2511
 clinical manifestations of, 2511
 diagnosis and treatment of, 2511
 etiology and epidemiology of, 2511
 Acute promyelocytic leukemia, 3102
 Acute pulmonary histoplasmosis, 1932–1933, 1932f
 Acute purulent conjunctivitis, 3940–3941, 3941t
 Acute radiation syndrome, 4418, 4420t
 Acute recurrent pancreatitis, 2429–2431
 Acute rejection, in intestinal transplantation, 2354
 Acute renal failure, in SARS-Co-V, 2038
 Acute respiratory compromise (ARC), 47t
 Acute respiratory distress syndrome (ARDS), 613, 615, 615f
 drowning and, 639
 pediatric, definition of, 616t
 volume-pressure relationship in, 623f
- Acute respiratory failure, cystic fibrosis and, 2676
 Acute retroviral syndrome, 2090–2091
 Acute rheumatic carditis, 1712–1713
 Acute rheumatic fever, 2565
 associated with Sydenham chorea, 3673
 Acute salicylism, 711
 Acute secondary peritonitis, 2511
 clinical manifestations of, 2511
 localized, 2512
 treatment of, 2511
 Acute serous labyrinthitis, 4020
 Acute severe hypertension, 2918–2919
 Acute shortening, 4220–4221
 Acute sinusitis, orbital complications of, 2557f
 Acute stress reactions, 108
 Acute stroke, 3742
 Acute sunburn reaction, 4093, 4094f, 4094t
 Acute suppurative labyrinthitis, 4020
 Acute tubular injury, endogenous and exogenous toxins causing, 3243t
 Acute tubular necrosis, 3209–3210, 3210t, 3242–3244
 Acute tubulointerstitial nephritis, 3205, 3206t
 Acute ureteral obstruction, 3275
 Acute urticaria and angioedema, in food allergy, 1445
 Acute vasoocclusive pain, in sickle cell disease, 2969
 Acute viral meningoencephalitis, 3763t, 3769
 Acute weeping lesions, 4038
 Acute-onset uncontrollable crying, 156–157
 Acyanotic congenital heart disease
 obstructive lesions, 2787–2796
 aortic stenosis, 2790–2793
 coarctation of the aorta, 2793–2795
 infundibular pulmonary stenosis and double-chamber right ventricle, 2789–2790
 peripheral pulmonary stenosis, 2790
 pulmonary stenosis in combination with an intracardiac shunt, 2790
 pulmonary valve stenosis with intact ventricular septum, 2787–2789
 regurgitant lesions, 2797–2798
 congenital absence of the pulmonary valve, 2797
 congenital mitral insufficiency, 2797
 mitral valve prolapse, 2797–2798
 pulmonary valvular insufficiency, 2797
 tricuspid regurgitation, 2798
 Acyanotic congenital heart lesions, 2774–2775
 resulting in increased pressure load, 2775
 resulting in increased volume load, 2774–2775
 Acyclovir, 1950–1954
 ADA/APA consensus guidelines, 229t
 Adalimumab, 1481t
 for Crohn disease, 2321–2322
 Adamantanes, for influenza, 2022
 Adamantinoma, 3148
 Adams forward-bending test, 4243–4244, 4243f
 Adams-Oliver syndrome, 2764t–2766t
 ADAMTS13 deficiency, 3055, 3056t
 ADAMTS4, 3921
 Adaptive behavior, significant impairment in, 346
 Adaptive sports, 4332
 ADCC. *See* Antibody-dependent cellular cytotoxicity
 ADCY5-related dyskinesia, 3674–3677
 Addison disease, autoimmune, 3455
 Adefovir, for hepatitis B, 2467
 ADEM. *See* Acute disseminated encephalomyelitis
 Adenine, 944
 Adenine phosphoribosyl transferase (APRT)-associated disorders, 945t, 950–951
 Adenitis, in PFAPA, 1529
 Adenocarcinoma
 of colon and rectum, 3165–3166
 complication of GERD, 2268
 Adenoid cystic carcinoma, 2703f
 Adenoidectomy, 2564–2565
 for otitis media, 4013
 Adenooids, 2562–2566
 adenoidectomy, 2564
 chronic airway obstruction, 2565–2566
 clinical manifestations, 2562–2563
 normal function, 2562
 pathology, 2562
 Adenomatous polyposis coli-associated polyposis syndromes, 2412f, 2413–2414

- Adenomatous tumors, 2413–2414
- Adenopathy, 3069
- Adenosine, 2845t–2846t
- for pediatric resuscitation and arrhythmias, 563t
- Adenosine deaminase deficiency, 952, 1263t
- Adenosine deaminase deficiency 2 (DADA2), 1526–1527
- Adenosine kinase, disorders of, 952
- Adenosine monophosphate (AMP)-activated protein kinase γ 2 deficiency, 908
- Adenotonsillectomy, 208t
- Adenoviruses, 2034–2035
- acute respiratory disease, 2034
 - antiviral therapies for, 1953t–1954t
 - clinical manifestations of, 2034
 - complications of, 2035
 - diagnosis of, 2034–2035
 - disseminated, complication of HSCT, 1364
 - epidemiology of, 2034
 - etiology of, 2034, 2035t
 - gastrointestinal infections, 2034
 - hemorrhagic cystitis, 2034
 - in immunocompromised patients, 2034
 - in Kawasaki disease, 1544
 - ocular infections, 2034
 - pathogenesis of, 2034
 - prevention of, 2035
 - treatment of, 2035
 - vaccines, 1588t–1589t
- Adenylate kinase, disorders of, 952
- Adenylosuccinate lyase deficiency, 952
- Adenylosuccinate synthase, disorders of, 952
- Adequate intake (AI), 389t–390t, 391
- ADHD. *See* Attention-deficit/hyperactivity disorder
- Adherence, to asthma daily controller medication, 1396
- Adhesions
- intestinal, 2299–2300
 - labial, 3294f, 3323f
- Adhesive otitis media, 4016
- ADHR. *See* Autosomal dominant hypophosphatemic rickets
- Adie syndrome, 3922
- Adiposity rebound, 164
- Adjunctive therapies
- for *Mycoplasma pneumoniae*, 1890
 - for pertussis, 1763
 - poisoning, 711–713
- Adjustment problems, maternal depression and, 139f
- Adnexal torsion, 3342, 3343f
- ADOA. *See* Autosomal dominant optic atrophy
- Adolescent
- aggressive periodontitis in, 2249
 - brain-gut interaction disorders in, 2388–2391
 - breast
 - common masses in, 3332, 3332t
 - male disorders, 1210
 - contraception for, 1217–1228
 - barrier methods, 1227
 - combined hormonal contraceptives, 1221t, 1222–1225
 - condoms, 1227
 - effectiveness of contraceptive methods, 1217f
 - emergency contraception, 1225–1227, 1226t
 - fertility awareness-based methods, 1228
 - lactational amenorrhea method, 1228
 - long-acting reversible contraception, 1220–1221
 - progestin-only methods, 1221–1222
 - spermicides, 1227
 - withdrawal, 1228
 - development, 1158
 - implications for providers, parents, and policymakers, 1163
 - physical and social, 1158–1163
 - sexual orientation, gay, lesbian, bisexual, 1182–1185
 - drowning, 638
 - epidemiology of health problems, 1186
 - feeding of, 409–420
 - genital mycoplasmas in, 1893
 - health behaviors, 1187
 - health objectives, 1188t
 - healthcare, 54–55
 - access to, 1186
 - challenges in, 32–35, 34f
 - adolescent fathers, 1229
 - clinical manifestations of, 1228
 - counseling and initial management of, 1229
 - diagnosis of, 1228–1229, 1229t
 - epidemiology of, 1228–1231
 - etiology of, 1228
 - medical complications of mothers and babies, 1229–1230
 - preventive strategies of, 1231
 - psychosocial outcomes/risks for mother and child, 1230–1231
 - principles of healthy sleep, 205t–206t
 - psychosocial assessment, 216
 - red blood cell transfusions in, 3014–3015, 3014t
 - responses to death, 199
 - sexual assault, 1234–1238
 - clinical manifestations of, 1235–1236
 - epidemiology of, 1234–1235
 - interview and physical examination of, 1236
 - laboratory data of, 1236
 - prevention of, 1237–1238
 - treatment of, 1236–1237
 - types of, 1235
 - sleep
 - BEARS sleep screening algorithm, 215t
 - normal developmental changes in, 204t
 - with special needs, gynecologic care for, 3355–3356
 - STIs, 1239–1251
 - cervicitis, 1242
 - diagnosis, 1244–1246
 - epidemiology of, 1239–1240
 - epididymitis, 1241–1242
 - etiology of, 1239, 1239t
 - genital lesions and ectoparasites, 1243–1244
 - genital ulcer syndromes, 1243–1244
 - HIV, hepatitis B, and hepatitis C, 1244
 - pathogenesis of, 1240
 - pathologic vaginal discharge, 1246t
 - PID, 1242–1243, 1246t
 - prevention of, 1250–1251
 - reverse-sequence syphilis screening, 1247f
 - screening for, 1240, 1241t
 - signs and symptoms of, 1243t
 - treatment of, 1248–1250
 - uncomplicated bacterial, 1247t–1248t
 - uncomplicated genital warts and genital herpes, 1249t–1250t
 - urethritis, 1240–1241
 - vaginitis, 1242
 - substance use
 - alcohol, 1198–1199
 - amphetamines, 1206–1207
 - bath salts, 1208–1209
 - clinical manifestations of, 1197
 - cocaine, 1205–1206
 - complications of, 1198
 - diagnosis of, 1198
 - epidemiology of, 1194–1197
 - hallucinogens, 1204
 - inhalants, 1202–1203
 - marijuana, 1201–1202, 1201f
 - opiates, 1207–1208, 1208t
 - prevention of, 1198
 - prognosis of, 1198
 - risk and protective factors of, 1199t
 - screening for, 1197–1198
 - seriousness of drug abuse, 1194t
 - stimulant abuse and diversion, 1207
 - tobacco, 1199–1200
 - toxic syndromes, 1197
 - treatment of, 1198
 - suicide, disparities in, 14
 - teenage drivers, 96–97

- Adolescent (*Continued*)
- transition, 2843
 - treatment for gonococcal infections, 1750
 - truancy and, 282
 - violent behavior, 1189–1192
 - well-child care and, 85–89
- Adolescent assent, 54
- Adolescent females, menstruation in
- abnormal uterine bleeding, 1211, 1213–1214, 1213t–1214t
 - amenorrhea, 1211–1212, 1211t
 - dysmenorrhea, 1214–1216, 1215t
 - irregularities, 1210–1211
 - normal, 1210–1211, 1210t
 - PMS and PMDD, 1216
- Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (ARQLQ), 1381
- Adoption
- domestic, 72
 - genetic testing and, 729
 - international, 72–75
 - narrative, 74–75
 - pedigree symbols for, 737f
 - postadoption medical care, 73–75
 - preadoption medical record reviews, 72–73
- Adoption and Safe Families Act, 75
- ADPKD. *See* Autosomal dominant polycystic kidney disease
- Adrenal calcification, 3474
- Adrenal cortex
- regulation of, 3446–3447
 - zones of, 3444
- Adrenal gland
- adrenal medulla, 3444, 3449
 - function, impaired, in adrenoleukodystrophy, 870
 - histology and embryology, 3444
 - physiology, 3444–3449
 - steroid biosynthesis, 3444–3446
 - steroid hormone actions, 3447–3449
- Adrenal hypoplasia congenita, 3450, 3471
- Adrenal incidentaloma, 3474
- Adrenal insufficiency, 990
- Adrenal neoplasia, genes involved in, 3473t
- Adrenal rests, testicular, 3494
- Adrenal tumors, 3166–3168, 3166f, 3167t
- virilizing and feminizing, 3475
- Adrenalectomy, for adrenocortical carcinoma, 3474
- Adrenalin, for asthma, 1405t–1406t
- Adrenarche, 1158–1159, 3394, 3447
- delayed/absent, females with, 3397
- α_2 -Adrenergic agents, for spasticity, 4394
- Adrenergic agonists, for heart failure, 2898t
- α -adrenergic agonists, for heart failure, 2900
- β -Adrenergic agonists, for heart failure, 2900
- α -Adrenergic antagonists, for hypertension, 2918t
- β -Adrenergic antagonists
- for heart failure, 2898t
 - for hypertension, 2918t
- α_1 -adrenergic receptor agonist, toxidrome, 704t
- α_1 -adrenergic receptor antagonists, toxidrome, 704t
- β -adrenergic receptor blockers, poisoning, 701t, 707t–708t, 713
- Adrenocortical hyperfunction, etiologic classification of, 3475t
- Adrenocortical insufficiency, 3450–3462
- in critical care setting, 3459
 - primary, 3450–3458
 - acquired etiologies of, 3455–3457
 - biochemical findings, 3456t
 - causes of, 3451t–3452t
 - differential diagnosis of, 3457, 3457f
 - etiologies of, frequencies of, 3454t
 - inherited etiologies of, 3450–3455
 - laboratory findings of, 3457
 - other genetic etiologies for, 3454t
 - treatment of, 3457–3458
 - secondary, 3458–3459
 - causes of, 3453t
 - clinical presentation of, 3458–3459
 - laboratory findings of, 3459
 - treatment of, 3459
 - tertiary, 3458–3459
 - causes of, 3453t
 - clinical presentation of, 3458–3459
 - laboratory findings of, 3459
 - treatment of, 3459

- Adrenocortical tumors (ACT), 3166, 3472–3474
 adrenal calcification in, 3474
 adrenal incidentaloma in, 3474
 adrenocortical carcinoma in, 3472–3474
 Adrenocorticotropic hormone (ACTH), 3361, 3444
 deficiency, 3458
 excess secretion of, 3460
 for West syndrome, 3607
- Adrenogenital syndrome, pyloric stenosis and, 2279
- Adrenoleukodystrophy, 869–871, 3716
 clinical manifestations of, 870
 complications of, 871
 diagnosis of, 870
 epidemiology of, 869
 etiology of, 869
 genetic counseling and prevention, 871
 laboratory and radiographic findings of, 870
 pathogenesis of, 869
 pathology of, 869
 treatment of, 871
- Adrenomedullary dysfunction, in 21-hydroxylase deficiency, 3466
- ADSL*-associated disorders, 952
- Adult-onset 21-hydroxylase deficiency, 3334–3335
- Adult-onset diabetes mellitus, 3515
- Adults
 age functioning, and severity of intellectual disability, 360t
 care for, transitioning to, 1171
 congenital heart disease in, 2838–2843
 long-term medical considerations for, 2838–2839
 electrocardiogram of, 2749f
 genital mycoplasmas in, 1893
 GM_1 gangliosidosis, 3713
 hemoglobins in, 2925
 T-cell leukemia/lymphoma, 2117–2118
 treatment for gonococcal infections, 1750
- Advair. *See* Fluticasone/salmeterol
- Advance care planning, 60–61
- Advanced language skills, 325, 326–327
- Advanced life support (ALS), 534–535
 BLS vs., 535–536
- Advanced maternal age, 1025
- Advanced Trauma Life Support (ATLS), 546, 571, 608
- Adverse childhood experiences (ACEs), 5, 5t, 6f, 84, 99, 143
- Adverse drug events, 45t
- Adverse drug reactions (ADRs), 1453–1459
 antiretroviral agents, hypersensitivity to, 1458
 biologics, 1458
 to chemotherapeutic agents, 1458, 3089t–3090t
 diagnosis of, 1456
 drug metabolism, 1456
 drug-induced hypersensitivity syndrome, 1454t–1455t, 1456, 1457
 epidemiology of, 1453, 1454t
 hypersensitivity reactions, risk factors for, 1456
 insulin, 1459
 β -lactam hypersensitivity, 1457–1458, 1457t
 local anesthetics, 1459
 macrolides, 1458
 to NSAIDs, 1464–1465
 pathogenesis and clinical manifestations, 1455–1456
 to penicillins, 1456–1457, 1685t–1686t
 perioperative agents, 1459
 in premature infants, 1045t
 radiocontrast media, 1459
 Stevens-Johnson syndrome, 1455
 sulfonamides, 1458
 toxic epidermal necrolysis, 1455
 treatment, 1456–1459
 vaccines, 1458–1459
 varicella vaccine-associated, 2005
- Adverse effects
 of cannabis use, 1202t
 of cephalosporins, 1687t
 of growth hormone treatment, for hypopituitarism, 3371
- Advocacy
 for child abuse and neglect, 121
 e-cigarette or vaping product use-associated lung injury (EVALI), 2653
- AEC. *See* Absolute eosinophil count
- AED. *See* Automated electronic defibrillator
- AERD. *See* Aspirin-exacerbated respiratory disease
- Aeroallergens, 1374
 triggering atopic dermatitis, 1418
- Aerobic exercise, 447
- Aerodigestive disorders, 332
- Aeromonas*, 1796–1797
 clinical manifestations of, 1796–1797
 diagnosis of, 1797
 in enteritis, 1796
 epidemiology of, 1796
 etiology of, 1796
 in GI infections, 1797
 pathogenesis of, 1796
 prevention of, 1797
 in septicemia, 1797
 in skin and soft tissue infections, 1796–1797
 treatment of, 1797
- Aerophagia, 2389
- Aerosolized antibiotic therapy, for cystic fibrosis, 2674–2675
- Aerosolized saline, for bronchiolitis, 2030
- Aerospan. *See* Flunisolide
- Afamelanotide, for erythropoietic protoporphyrria, 4094–4095
- Affective bias, 48t
- Affirmations, in motivational interviewing, 134
- Affordability, in adolescents, 1165
- Afibrinogenemia, 3034
- Aflatoxins, 4413
- African tick-bite fever, 1900t–1902t
- African trypanosomiasis, 2161–2163
 clinical manifestations in, 2161–2162
 diagnosis of, 2162, 2162f
 epidemiology of, 2161
 etiology of, 2161
 hemolymphatic stage, 2162
 life cycle, 2161
 meningoencephalitic stage, 2162
 pathogenesis of, 2161
 prevention of, 2163
 treatment for, 2162–2163
- Afrin, for allergic rhinitis, 1384t
- Aftersdrop, in hypothermia, 659
- Afterload reducers, for heart failure, 2899–2900
- Agammaglobulinemia, 1277–1280
 autosomal recessive, 1277–1280
 due to absence of B cells, 1346
 X-linked, 1277, 1278t, 1279f–1281f, 1280t
- Age
 0–2 months, 151–156
 cognitive development, 152
 emotional development, 152
 implications for parents and pediatricians, 152–153
 physical development, 152–153
 2–6 months, 153–156
 cognitive development, 154–155
 communication, 155
 emotional development, 155
 physical development, 152f, 153–154, 153t, 155f
 6–12 months, 156
 cognitive development, 156
 communication, 156
 emotional development, 156
 implications for parents and pediatricians, 156
 physical development, 152f, 153t, 155f, 156
 12–18 months
 cognitive development, 158
 emotional development, 158
 implications for parents and pediatricians, 158
 linguistic development, 158
 physical development, 158
 18–24 months
 cognitive development, 158
 emotional development, 158–163
 implications for parents and pediatricians, 163
 linguistic development, 163
 physical development, 158
 childhood injuries and, 93–94
 gestational
 assessment at birth, 1042–1043, 1042f
 large-for, 1048–1049
 small-for, 1047–1048, 1047f
- Age (*Continued*)
 measures of pain specific to, 677–680
 at presentation
 intellectual disability by, 352t
 that mimic seizures, 3631t
- Age of onset
 of autoinflammatory syndromes, 1524t
 of puberty, 3386
- Age-dependent susceptibility, 1783
- Agency for Healthcare Research and Quality (AHRQ), 44
- Agenesis
 of cerebellar vermis, 3664–3672
 of corpus callosum, 3573, 3574f, 3574t–3575t
 pancreatic, 2422
 of penis, 3300
 pulmonary, 2599
 renal, 1053t, 3260–3261
 sacral, 3291
 vaginal, 3353
- Agglutination test, 2193
- Aggrecan-related spondyloepiphyseal dysplasias, 4344
- Aggression
 in childhood, 283
 Down syndrome and, 372–373
 injuries due to, 98
 medications for, 228t
- Aggressive periodontitis, 2242t
 in adolescents, 2249
 in children, 2249
- Aging macular degeneration (AMD), 1318, 1320
- Agitation
 medications for, 228t
 in pediatric palliative care, 65t–69t
- AGL. *See* Acquired generalized lipodystrophy
- Agnatined lentigines, 4064
- Agnosia, verbal auditory, 329
- Agonists receptors, defects in, 3051t–3052t
- α -Agonists, for anxiety disorders, 253
- β -Agonists, long-acting inhaled, for asthma, 1402
- β_2 -Agonists, inhaled, for transient tachypnea of newborn, 1088
- Agoraphobia, 246
 core diagnostic features and characteristics of, 252t
 diagnostic criteria for, 250t
- Agranulocytosis, 1304
- AGS. *See* Aicardi-Goutières syndrome
- AHR. *See* Airways hyperresponsiveness
- AHRQ. *See* Agency for Healthcare Research and Quality
- AHT. *See* Abusive head trauma
- aHUS. *See* Atypical hemolytic uremic syndrome
- Aicardi syndrome, 3619
 in corpus callosum, 3573
- Aicardi-Goutières syndrome (AGS), 663, 1530t, 1531–1532, 3891–3892
- Aichi virus, 2051
- AIHA. *See* Autoimmune hemolytic anemia
- AIMS. *See* Abnormal Involuntary Movement Scale
- AINs. *See* Autoimmune neutropenias
- Air, chemical pollutants in, 4427
- Air embolism, pulmonary, 2692
- Air leaks, pulmonary, 1097–1098
- Air pollutants, 4424
- Air pollution, bronchitis and, 2589
- Air-bone gap, 3990
- Airborne infection isolation (AII), 1620
- Airborne transmission, 1618
- Air-conducted signals, in audiology, 3990
- Airway
 abnormalities of, 332
 in acutely ill child, 551
 difficult, anesthetic implications in, 666t
 distal diseases, 2595–2598
 bronchiolitis obliterans, 2595, 2596f, 2596t
 follicular bronchitis, 2595–2596, 2597f, 2597t
 pulmonary alveolar microlithiasis, 2596–2598, 2598f
- foreign bodies in, 2578–2580
- maintainable, 552–554
- management of, 559–560
- patent, 552–554
- primary assessment of, 552–554, 555f
- primary survey for, 571
- in respiratory distress and failure, 618

- Airway clearance therapy, for cystic fibrosis, 2673
- Airway evaluation
anesthesia and, 664, 667t
with long-term mechanical ventilation, 2729
- Airway malformation, congenital pulmonary, 2599–2601, 2600f–2601f
- Airway management, for shock, 609–610
- Airway obstruction
chronic, 2565–2566
in delivery room, 1072
due to foreign body, 557, 557f
extrathoracic, 2514f
intrapulmonary, 2514f, 2516
flow volume loops in, 2520f
narrowing from other causes, 558
- Airways hyperresponsiveness (AHR), 1386
- AIS. *See* Arterial ischemic stroke
- Akathisia, 243t
- AKI. *See* Acute kidney injury
- Akinesthesia, 667, 669t
- AKT-related overgrowth spectrum, 3159–3160
- Alacrima, 3896, 3937–3938
- Alagille syndrome, 768t–769t, 2448, 2448t, 2449f, 2764t–2766t, 2770
- Alanine aminotransferase, 2442–2443
- Alarm fatigue, 47–49
- Alavert, for allergic rhinitis, 1383t
- Albendazole, 2144
for ascariasis, 2199
for cysticercosis, 2219
for echinococcosis, 2222
for enterobiasis, 2204
for gnathostomiasis, 2209
for hookworms, 2202
for loiasis, 2207–2208
for lymphatic filariasis, 2207
for microsporidia, 2154
for strongyloidiasis, 2205
for toxocariasis, 2210
for trichinellosis, 2211
for trichuriasis, 2203
- Albiglutide, for T2DM, 3542t
- Albinism, 817–820, 4071–4072, 4072f, 4072t
generalized, syndromic forms of, 819
localized, 820
major causes of, 818t
ocular, 819
oculocutaneous, 818–819
- Albright hereditary osteodystrophy, 3439
- Albumin, 2952–2953
reference intervals, 4472.e9t
- Albuterol
for asthma, 1405t–1406t
for BPD, 1086
for transient tachypnea of newborn, 1088
- ALC. *See* Absolute lymphocyte count
- Alcohol
abuse, in early childhood trauma, 75
acute intoxication, hypoglycemia and, 991
fetal alcohol spectrum disorder and, 1134
- Alcohol related birth defects (ARBD), diagnostic criteria for, 1139t
- Alcohol related neurodevelopmental disorder (ARND), diagnostic criteria for, 1139t
- Alcohol use
in adolescents, 1187t, 1199t
clinical manifestations, 1199
diagnosis, 1199
motor vehicle injuries, 97
pharmacology and pathophysiology, 1199
risk factors, 1198t
treatment, 1199
drowning, 638
SIDS risk factors and, 2534
- ALDH1A1*-related cutis laxa, 4376t
- Aldolase
in glycolytic pathway, 2989–2990
in malaria, 2173
- Aldolase-B, 912
- Aldosterone, 3240
deficiency, in 21-hydroxylase deficiency, 3463
potassium secretion and, 495
in renal sodium retention, 493–494
secretion regulation, 3447
- Aldosterone receptor antagonist, for hypertension, 2918t
- Aldosterone synthase deficiency, 3470–3471
- Alemtuzumab, 3256
- Alert, Verbal, Pain, Unresponsive (AVPU) Pediatric Response Scale, 555, 556
in multiple trauma, 574
- Alert fatigue, 47–49
- Alert Program, for FASD, 1138–1139
- Alert state, of newborn, 149
- Alexander disease, 3717, 3717f, 3899t
- Alexithymia, 237
- Alezzandrin syndrome, 4075
- Alfentanil, equianalgesic doses of, 685t
- Alice in Wonderland syndrome, 3633, 3638
- Alignment disorders of eye, 3925–3933
strabismus, 3925–3930, 3926t
- Aliphatic hydrocarbons, toxicity, 701t
- Alkali burns, eye injuries and, 3979
- Alkaline encrusted pyelitis/cystitis, 3264
- Alkalisis, 719
- Alkalosis
in pyloric stenosis, 2279
respiratory, 513t
- Alkaptonuria, 817
- ALL. *See* Acute lymphoblastic leukemia
- Allan-Herndon- Dudley syndrome, 3403–3404
- Allegra, for allergic rhinitis, 1383t
- Alleles
frequency, 800f
- Allele-specific oligonucleotides (ASOs), 758
- Allelic heterogeneity, 801
- Allergen
in allergic diseases, 1368
food. *See* Food allergy
- Allergen immunotherapy (AIT)
for asthma, 1403–1404
for atopic dermatitis, 1417
- Allergen skin testing, 1378
- Allergen-specific IgE (sIgE) levels, 1376, 1377t
- Allergen-specific immunotherapy, for allergic rhinitis, 1382
- Allergic bronchopulmonary aspergillosis, 1294, 1376, 2629–2630, 2629t, 2630f, 2670
cystic fibrosis and, 2675
- Allergic cluck, 1374
- Allergic conjunctivitis, 1375, 1382, 1422, 1423f, 3940t, 3942
- Allergic contact dermatitis, 4088–4090, 4090f
- Allergic diseases (hypersensitivity syndromes), 1929
associated with eosinophilia, 1294, 1295t
diagnosis of, 1374–1378
allergy history, 1374
diagnostic testing, 1375–1378
physical examination, 1374–1375
in vitro tests, 1375–1378, 1377t
in vivo tests, 1378
- key elements of, 1368–1371
allergen, 1368
antigen-presenting cells, 1370–1371
eosinophils, 1371
immunoglobulin E and receptors, 1371
innate lymphoid cells, 1370
mast cells, 1371
T cells, 1368–1370, 1369f–1370f
- Allergic gape, 1380
- Allergic reaction, insect allergy and, 1419
- Allergic rhinitis (AR), 1379–1385, 2552t
clinical manifestations of, 1379–1380, 1379f
complications of, 1380–1381
differential diagnosis of, 1380, 1380t, 1381f
early-phase of, 1379
etiology and classification of, 1379, 1379f
laboratory findings of, 1381
- Allergic rhinitis (AR) (*Continued*)
late-phase of, 1379
pathogenesis of, 1379
prognosis for, 1385
treatment of, 1381–1382, 1382t–1383t
- Allergic salute, 1374, 1379–1380
- Allergic shiners, 1375, 1375f, 1380
- Allergic tissue inflammation, mechanisms of, 1371–1372
- Allergy, 1367–1373
history of, 1374
latex, 1434–1435
associated with neuropathic bladder, 3290
meningocele and, 4401
- medical child abuse and, 128
- ocular, 1422–1425
- Allergy testing, in asthma, 1396
- Allgrove syndrome, 2261–2262, 3900
- Alligator bites, 4458t
- Allogeneic HSCT, 1351, 1352t
- Allotransplantation, of intestinal transplantation, 2354
- Alloimmune liver disease, gestational, 2459
- Alloimmune neonatal neutropenia, 1307
- Alloreactivity, donor vs. recipient NK cell, 1356
- Allostatic load, 5–6, 9–10
- All-terrain vehicles (ATVs), 97
- All-trans-retinoic acid, for acute promyelocytic leukemia, 3103
- Almotriptan, for migraine, 3646t–3647t
- Aloe vera, 56t–57t
- Alogliptin, for T2DM, 3542t
- Alopecia, 476, 3091, 4048, 4137, 4138t, 4160–4161
inborn errors of metabolism and, 809t–810t
toxic, 4140, 4140t
traction, 4137, 4139f
traumatic, 4137–4138
- Alopecia areata, 4138–4140
clinical manifestations of, 4139f–4140f
differential diagnosis of, 4138t–4139t
trachonychia and, 4145
treatment for, 4138–4140
- Alpelisib, for lymphatic malformations, 3066
- Alpers syndrome, 2484, 3855
- Alpers-Huttenlocher syndrome, 3697
- Alpha dystroglycan-related dystrophies (αDG-RD), 3818
- Alpha₁-antitrypsin deficiency, 2450–2451
- Alport syndrome, 3188–3189, 3254–3255, 3987t
clinical manifestations of, 3188
diagnosis of, 3188
genetics of, 3188
pathology of, 3187f, 3188
prognosis and treatment of, 3189
- ALPS. *See* Autoimmune lymphoproliferative syndrome
- ALS. *See* Amyotrophic lateral sclerosis
- Alström syndrome, 792t
- Altered mental status, in SLE, 1497t
- Alternating hemiplegia of childhood, 3686, 3754
- Alternative pathway, of complement system, 1316
deficiency of, 1320
- Altitude-associated illness, 630–636
acute mountain sickness in, 631–633
definitions of, 630
etiology of, 630–631
high-altitude cerebral edema (HACE) in, 631, 633–634
high-altitude pulmonary edema (HAPE) in, 634–635, 635f
- hypobaric hypoxia effects in, 630
sickle cell disease/trait and, 636
special considerations in, 635–636
travel with young infants and, 636
- Aluminum salts, 1587–1589
- Aluminum-containing antacids, 477
- Alveolar air equation, 2513
- Alveolar bone, 2247f
- Alveolar capillary dysplasia, with misalignment of pulmonary veins, 2634t
- Alveolar dead space, 614
- Alveolar echinococcosis, 2220
- Alveolar hydatidosis, 2222
- Alveolar P_{O_2} (Pao_2), 2513, 2520–2521, 2521f
- Alveolar pressure, 622, 629f

- Alveolar rhabdomyosarcoma, 3077
 Alveolar soft part sarcoma, 3139t–3140t
 Alveolar type, of rhabdomyosarcoma, 3136
 Alveolar ventilation, 2513
 Alveolar-arterial oxygen (A-aO₂), 2513–2515
 gradient, 617–618
 Alveolocapillary dysplasia (ACD), PPHN and, 1092–1093
 Alvesco. *See* Ciclesonide
 AMA. *See* American Medical Association
 Amantadine, 1956
 Amastia, 3329
 Amastigotes, 2163
 Amatoxins, 4442
 Amaurosis, 3915–3916, 3916t, 3918t–3919t
 Ambiguous genitalia, 2418–2420
 diagnostic approach to, 3504–3505, 3506f, 3506t, 3508t
 surgical management of, 3467–3468
 Amblyopia, 3915, 3925, 3933, 3970
 Ambriptan, 2834t
 Ambulance, 535
 ground vs. air, 541
 Ambulation, for myelomeningocele, 3563
 Ambulatory blood pressure monitoring, 2910–2911
 Ambulatory safety, 49–50
 AMC. *See* Arthrogryposis multiplex congenita
 AMD. *See* Aging macular degeneration
 AMDRs. *See* Acceptable macronutrient distribution ranges
 Amebiasis, 2147–2149
 clinical manifestations of, 2148
 complications of, 2148
 diagnosis and differential diagnosis of, 2148
 drugs for, 2126t–2144t, 2149t
 epidemiology of, 2147
 etiology of, 2147
 laboratory findings of, 2148
 pathogenesis of, 2147
 prevention of, 2149
 prognosis of, 2149
 treatment of, 2148–2149
 Amebic (*Naegleria*) meningoencephalitis, CSF findings in, 3759t–3760t
 Amebic colitis, 2148
 Amebic dysentery, 2367
 Amebic liver abscess, 2148, 2148f, 2475, 2475f
 Amebic meningoencephalitis
 drugs for, 2126t–2144t
 granulomatous, 2146, 2146f
 primary, 2145–2146
 Amegakaryocytic thrombocytopenia
 congenital, 3007–3008, 3056
 with radioulnar synostosis, 3056
 Amelogenesis imperfecta, 2241, 2241f
 Amenorrhea, 1211–1212, 1212f, 4322, 4324f
 in androgen insensitivity syndromes, 3512–3513
 cancer treatment and, 3339t
 American Academy of Neurology (AAN), genetic testing guidelines for ID/GDD/ASD, 347t
 American Academy of Pediatrics (AAP)
 genetic testing guidelines for ID/GDD/ASD, 347t
 Health Supervision Guidelines
 for Down syndrome, 364–367
 for trisomy 21, 364–367, 368t
 Pediatric Education for Prehospital Professionals, 544
 website, 539
 American Association for Cancer Research (AACR), 3076
 American Association on Intellectual and Developmental Disabilities (AAIDD), 346
 American College of Medical Genetics (ACMG), genetic testing guidelines for ID/GDD/ASD, 347t
 American Medical Association (AMA), 21
 American Sign Language (ASL), 341t
 American Society of Anesthesiologists Physical Status (ASA-PS), 664, 667t
 American Spinal Injury Association (ASIA), 4389, 4390f
 American trypanosomiasis, 2163–2168
 clinical manifestations of, 2165t–2166t, 2167
 diagnosis of, 2164f, 2167
 epidemiology of, 2163–2166, 2165t–2166t
 etiology of, 2163
 life cycle of, 2163, 2164f
 American trypanosomiasis (*Continued*)
 pathogenesis of, 2166–2167
 prevention of, 2168
 treatment of, 2167–2168
 Ametropic amblyopia, 3915
 AMH. *See* Antimüllerian hormone
 Amikacin, for drug-resistant tuberculosis, 1852t–1853t
 Amikacin sulfate, 1675t–1685t
 Amiloride, for primary aldosteronism, 3479
 Amino acids, 389t–390t, 393, 394t
 absorption, disorders of, 2349–2350
 branched-chain, 822f, 825
 formulas, 413
 large neutral, 813–814
 metabolism defects, 805t, 812–858
 N-acetylaspartic acid (NAA), 857–858
 affecting liver, 2455t
 cysteine, 824
 disorders of neurotransmitter metabolism, 844–848
 glutamic acid, 842–844, 843f
 glycine, 834f, 837–840
 hepatic dysfunction and, 808t
 hyperammonemia, 848–854
 lysine, 855–857, 855f
 methionine, 820–824, 821f
 in neonatal seizures, 3619–3620
 phenylalanine, 812–815
 proline, 838f, 841–842
 serine, 840–841, 840f
 tryptophan, 824, 825f
 tyrosine, 815–820
 urea cycle disorders, 848–854, 848f, 849t
 valine, leucine, and isoleucine, 825–837
 substitutions, 730–731
 sulfur-containing, 821f
 α-Aminoadipic semialdehyde dehydrogenase deficiency, 855
 γ-Aminobutyric acid (GABA)
 metabolism, disorders of, 846–847
 for spasticity, 4394
 transaminase deficiency, 847
 γ-Aminobutyric acid A receptor
 encephalitis associated with, 3705t–3707t
 encephalitis with antibodies against, 3703–3708, 3707f
 Aminoglycoside-modifying enzymes, 1672t
 Aminoglycosides, 1688
 enterococci resistance, 1722t–1723t
 against *M. tuberculosis*, 1832
 5-Aminolevulinic acid, 963
 δ-Aminolevulinic acid, 963
 δ-Aminolevulinic acid dehydratase porphyria, 965–966
 5-Aminosalicylates, for mild Crohn disease, 2320
 Aminosteroids, 669t
 Aminotransferase levels, causes of elevated serum, 2444t
 Amiodarone, 2845t–2846t
 goiter caused by, 3415
 for pediatric resuscitation and arrhythmias, 563t
 Amish lethal microcephaly, 458t
 Amitriptyline
 for migraine, 3646t–3647t
 for pain, 690t
 Amlodipine, 2834t
 Ammonia
 pathways of, 848f
 reference intervals, 4472.e9t
 Amnesia, 667
 Amnesic shellfish poisoning, 4445
 Amniocentesis, 1018t, 1025
 Amniotic bands, disruption sequence, 782f
 Amniotic constriction bands, 4043
 Amniotic fluid, 1000
 meconium-stained, 1071–1072
 volume, conditions associated with disorders of, 1014t
 Amniotic fluid (AF) volume, quantitative, 1018t
 Amotivational syndrome, 1202
 Amoxicillin, 1675t–1685t
 for acute otitis media, 4010
 for Lyme disease, 1885t
 for sinusitis, 2555
 Amoxicillin-clavulanate, 1675t–1685t
 for bite wound, 4459, 4459t
 for drug-resistant tuberculosis, 1852t–1853t
 for *Staphylococcus aureus*, 1697
 AMP-deaminase, disorders associated with, 951–952
 Amphetamine suspension extended release (Dyanavel XR), for ADHD, 225t–226t
 Amphetamines
 abuse, by adolescents, 1206–1207, 1206t
 for ADHD, 314
 as performance-enhancing aids, 4325t–4326t
 Amphotericin B, 1916–1917
 for coccidioidomycosis, 1939
 for paracoccidioidomycosis, 1941
 for sporotrichosis, 1942
 Amphotericin B deoxycholate, 1917t
 for blastomycosis, 1936
 Ampicillin, 1675t–1685t
 enterococci resistance, 1722t–1723t
 Ampicillin-sulbactam, 1675t–1685t
 Amyl nitrite, inhaled, 1203t
 Amylase, 2423
 reference intervals, 4472.e9t
 Amylase isoenzymes, reference intervals, 4472.e9t
 Amyloid A, serum, 1537
 Amyloid A (AA) amyloidosis, 1536
 Amyloidosis, 1536–1537
 Amylopectinosis, 904
 Amyopathic dermatomyositis, 4031–4032
 Amyoplasia, 3819, 3821, 3821f, 4271–4272
 Amyotrophic lateral sclerosis (ALS), juvenile forms of, 3874
 Anabolic-androgenic steroids, 4325, 4325t–4326t
 Anaerobic bacterial infection, 1828t
 botulism (*Clostridium botulinum*), 1817–1821
 clinical manifestations of, 1828–1829
 Clostridium difficile infection, 1825–1828
 diagnosis of, 1829, 1829t
 tetanus (*Clostridium tetani*), 1821–1824
 treatment of, 1829
 Anaerobic gram-negative bacilli, 1829
 Anaerobic gram-positive organisms, 1829
 Anafranil. *See* Clomipramine
 Anagen effluvium, 4140
 Anakinra, 1470, 1481t
 for amyloidosis, 1537
 Anal achalasia, 229t
 Anal fissure, 2408
 Analgesia, 667, 668t
 Analgesic ladder, 697, 697t
 Analgesics
 for intubation, 620t
 for migraine, 3646t–3647t
 poisoning, 710–711, 710t, 717t
 Analgesic-sedatives, 669t
 Analyzing quality data, 39–40
 Anaphase, 761
 Anaphase lag, 761
 Anaphylactic reactions, 1609
 insect allergy and, 1420
 Anaphylatoxin, 1316
 Anaphylaxis, 1436f, 1434–1440, 1434t, 1435f, 1590–1591, 2221
 AIT for, 1404
 clinical manifestations of, 1434t, 1436
 diagnosis of, 1437, 1437t
 epidemiology of, 1436, 1437t
 etiology of, 1439f, 1434–1435, 1435t
 idiopathic, 1436
 laboratory findings of, 1437
 pathogenesis of, 1435f–1436f, 1436
 prevention of, 1440, 1440t
 in shock, 601
 symptoms and signs of, 1434t
 treatment of, 1437–1440, 1438t, 1439f
 triggers, 1435t
Anaplasma phagocytophilum, 1911
 Anaplasmosis, 1655t–1656t, 1900t–1902t, 1911–1914
 clinical manifestations of, 1912
 complications and prognosis of, 1913–1914
 diagnosis of, 1913, 1913f
 differential diagnosis of, 1913
 epidemiology of, 1911–1912

Anaplasmosis (Continued)

etiology of, 1911
laboratory findings of, 1912
pathology and pathogenesis of, 1912
prevention of, 1914
transmission of, 1912
treatment of, 1913

Anaplastic ependymoma, 3120–3121

Anaplastic large cell lymphoma (ALCL), 3110t, 3115

Anastomoses, placental vascular, 1041

Anatomic abnormalities

associated with hematuria, 3213–3217
autosomal dominant polycystic kidney disease, 3214–3217, 3215t–3216t, 3217t
autosomal recessive polycystic kidney disease, 3213–3214, 3214f, 3215t–3216t
congenital anomalies, 3213
renal tumors, 3217
trauma, 3217

chronic recurrent aspiration and, 2609

wheezing in infants and, 2585t

Anatomic dead space, 614

Anatomic disorders, 2645t

causing hematuria, 3185t

Anatomic locations, descriptive terms, of bones, 4193, 4194f

ANC. See Absolute neutrophil count

Anchoring, 48t

Ancylotomiasis, 2201

Andersen disease, 900t–901t, 904, 3851, 3852t

Andersen-Tawil syndrome, 3840t, 3848, 3849t

Anderson disease, 2340–2341

Androgen action, defects in, 3511–3513

androgen insensitivity syndromes in, 3512–3513, 3512f, 3513t
dihydrotestosterone deficiency in, 3511–3512, 3511f

Androgen biosynthetic defects, screen for, 3505

Androgen insensitivity syndromes, 3512–3513, 3512f, 3513t

Androgenic drugs, exposure to, by women during pregnancy, 3507–3509

Androgenic hormones, 2415–2416

Androgenic lesions, of ovary, 3503

Androgens

adrenal

actions of, 3448–3449
secretion, regulation of, 3447

excess, 3475t, 3482t–3484t

Androstanedione

secretion, regulation of, 3446

testosterone precursors, 4325

ANE. See Acute necrotizing encephalopathy

Anemia, 2926–2929, 3092t–3093t

acquired aplastic, HSCT for, 1353

of acute kidney injury, 3246

associated with prematurity, 1046t

causes of, 2927t

in chemotherapy, 3091–3093

of chronic disease, 2935–2936, 2936f, 2948t

in CKD, 3250t, 3251–3252

congenital dyserythropoietic, 2937–2939, 2938f

differential diagnosis of, 2927–2929

global prevalence of, 2927t

hematuria and, 3185–3186

history and physical examination of, 2926

in HIV, 2095

iron-deficiency, 2944–2950

laboratory studies for, 2927

in malaria, 2170

megaloblastic, 2940–2944, 2940f, 2940t

microcytic, 2950–2952, 2951t, 2952f

morphologic findings in, 2930t

in newborn infant, 1118–1122, 1118t

classifications and key diagnostic modalities in, 1118–1120, 1118t, 1120f, 1121t
management principals of, 1122

physiologic nadir, 1118, 1119f

normocytic, 2929

physical findings, in evaluation of anemia, 2928t

physiologic, of infancy, 2939

in premature infants, 1046t

of renal disease, 2936–2937

thiamine-responsive megaloblastic, 2944

Anemia (Continued)

toxic causes of, 3895t
treated prior to renal transplantation, 3255
vitamin C deficiency and, 468

Anemia of prematurity, 3015

Anencephaly, 3565–3566, 3566f

Anesthesia, 664–675, 664t

awareness during, 674

general, 667–671

goals of, 664t

implications of, 666t

maintenance of, 672–673

fluid management, 672–673, 672t

postanesthetic complications, 673–675

temperature management, 672

postoperative nausea and vomiting, 674

preoperative preparation of, 665–667

parental presence, during induction of anesthesia, 667
preoperative fasting, 665–667, 667t

regional, 675

thermoregulation and malignant hyperthermia, 674

Anesthetic neurotoxicity, 675

Anesthetics, for intubation, 620t

Anetoderma, 4123

Aneuploidy, 763–766

autosomal, 760t

screening, 1028

sex chromosome, 760t, 770–771, 770t

Aneurysmal bone cyst (ABC), 3147, 3148f

Aneurysms, coronary artery, in Kawasaki disease, 1543, 1544f

Angelman syndrome, 742–743, 768t–769t, 773–774, 786t

imprinting and, 777

molecular mechanisms causing, 777t

uniparental disomy and, 773–774

Anger/aggression rating scales, 280t

Angiocardiography, 2761

Angioedema, 1375, 1426–1434

complement pathway deficiencies and, 1318

diagnosis, 1428

hereditary, 1318, 1320–1321

with C1-INH deficiency, treatment of, 1323, 1323t
of subglottic areas, 2570–2571

Angiofollicular lymph node hyperplasia, 3072, 3072f

Angiography

computed tomography

for brain death, 591t

of pulmonary emboli, 2696f

magnetic resonance, 2758

of cerebral artery infarction, 2972f

in neuroradiologic procedures, 3558–3559

for orthopedic evaluation, 4200

selective, for liver, 2445

Angiokeratoma circumscriptum, 4052

Angiokeratoma corporis diffusum, 3887, 4060

Angiokeratoma of Mibelli, 4059

Angiokeratomas, 894, 894f

Angiomata spider, 2439, 3162, 4059, 4059f

Angiomatoid fibrous histiocytoma, 3139t–3140t

Angiomyolipomas, 3211

in tuberous sclerosis, 3659

Angiosarcoma, 3164, 3164f

Angiostrongyliasis, 2208–2209

Angiostrongylus cantonensis, 2208

Angiostrongylus costaricensis, 2208–2209

Angiotensin-converting enzyme (ACE), in sarcoidosis, 1550

Angiotensin-converting enzyme (ACE) inhibitors, 3252

for cyclic vomiting syndrome, 2395

for heart failure, 2898–2899

for hypertension, 2918t

Angiotensin II, for shock, 610t

Angiotensin receptor blockers, for hypertension, 2918t

Angiotensin II receptor blockers

for heart failure, 2898–2899

for Marfan syndrome, 4368–4369

α angle, 4234

β angle, 4234

Angular cheilitis, 4147, 4148f

Anhidrosis, 4134

congenital insensitivity to, 3897, 3898t–3899t

Anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), 1274–1275

Anicteric leptospirosis, 1878–1879, 1878f

Anidulafungin, 1917t, 1921

Animal and human bites, 4457–4460

clinical manifestations of, 4457

complications in, 4457, 4458t

diagnosis of, 4457

epidemiology of, 4457

prevention of, 4460

treatment for, 4457–4460, 4458t–4459t

Animal filariae, infection with, 2208

Animal reservoirs, of rabies, fertility control of, 2083

Animism, 165

Anion gap

in metabolic acidosis, 515t, 517, 517f, 704–705

in toxicologic diagnosis, 705t

reference intervals, 4472.e9t

Anions, in ICF

and ECF, 486

and plasma, 486f

Aniridia, 780t, 3920, 3920f

Anisakiasis, drugs for, 2126t–2144t

Anisocoria, 3921, 3922f–3923f

Anisometropia, 3914

Anisometropic amblyopia, 3915

Anisopoikilocytosis, 2992f

Ankle

enthesitis, 1488f

sports-related injuries, 4311–4313

sprains, 4312, 4327

in basketball, 4328

Ankle-foot orthosis (AFO), 4402, 4402f

Ankyloglossia, 328, 410–411, 2253

Ankylosing spondylitis, 1483–1487

clinical manifestations and diagnosis of, 1483–1485

differential diagnosis of, 1486

epidemiology of, 1483

etiology and pathogenesis of, 1483

imaging of, 1485–1486, 1487f

juvenile, 1485

laboratory findings of, 1485–1486

lumbodorsal spine mobility, loss of, 1486f

prognosis of, 1487

radiographic sacroiliitis in, 1485, 1486f

treatment of, 1487

Ankyrin-1, in hereditary spherocytosis, 2956t

Ann Arbor Conference, 3107

Annular bands, 4210, 4211f

Annular pancreas, 2422

Anodontia, 2240, 4048

Anogenital index, 2293

Anomalous coronary arteries, 2813

Anomalous coronary vessels, 4295

Anomalous innominate artery, 2827t

Anomalous UPJ, 3279

Anonychia, 4142

Anopheles mosquito, 2168–2169

Anorectal abscess, 2317

Anorectal malformations, 2404–2408, 2404f

approach to the patient, 2406–2407, 2406f, 2406t

associated anomalies of, 2405, 2406t

embryology of, 2404–2405, 2405f–2406f

manifestations and diagnosis of, 2405–2406

high lesions in, 2406

low lesions in, 2405, 2405f

persistent cloaca in, 2406

rectal atresia in, 2406

operative repair of, 2407

outcome of, 2407–2408, 2407t

types of, by sex, 2407t

Anorectal manometry, 2296–2297

Anorectal plugs, 1100

Anorexia, 2234

appendicitis and, 2397–2398

liver disease and, 2442

in pediatric palliative care, 69t

Anorexia nervosa, 268, 269t, 275t, 4323

Anorexiants, 447

Anosmia, 3493, 3552

Anotia, 3995–3996

Anoxic-ischemic injury, in drowning, 638–639

Antacids, phosphorus-binding, 508

- Antagonism, in adolescence, 1163
 Anteater sign, 4206–4207, 4207f
 Antegrade continence enema procedure (ACE), 2407–2408
 Antegrade pressure-perfusion flow study, 3278–3279
 Antegrade pyelogram, 3278–3279
 Antenatal Bartter syndrome, 3240
 Antenatal corticosteroids, for RDS, 1080
 Antenatal hydronephrosis, 3275, 3276t
 Anterior auricular lymphadenopathy, 3070t
 Anterior cruciate ligament (ACL)
 injury, 4308
 basketball associated with, 4328
 soccer associated with, 4329
 rupture, 4230–4231, 4231f
 Anterior cutaneous nerve entrapment syndrome (ACNES), 695
 Anterior drawer sign, 4230
 Anterior drawer test, 4309f
 Anterior ectopic anus, 2405
 Anterior glenohumeral dislocation, 4301
 Anterior lenticonus, 3952
 Anterior pituitary cell types, 3359–3361
 adrenocorticotrophic hormone, 3361
 growth hormone, 3360
 luteinizing hormone and follicle-stimulating hormone, 3361
 prolactin, 3360
 thyroid-stimulating hormone, 3360–3361
 Anterior talofibular ligament, 4329
 Anterior urethral valves, 3285
 Anterior uveitis, 3940t, 3953t
 in Behcet disease, 1515
 in JIA, 1482f
 Anterolateral tibial bowing, 4218
 Anteromedial tibial bowing, 4217–4218, 4218f
 Anteversion, 4212
 Anthelmintic chemotherapy program, 2199–2200
 Anthelmintic drugs, 2202
 Anthrax, 4449, 4452t
 vaccine adsorbed, 1588t–1589t
 Anti N-methyl-D-aspartic acid (anti-NMDA) receptor encephalitis, 3674
 Anti-AChR antibodies, in myasthenia, 3864
 Antiandrogens
 in polycystic ovary syndrome, 3335f, 3337
 for pubertal blockade, 1176t
 Antiarrhythmic drugs, 2845t–2846t
 Antibacterial therapy, principles of, 1671–1690
 age- and risk-specific use of antibiotics, 1672–1674
 antibiotics commonly used in pediatric practice, 1674–1690
 Antibiotic therapy
 for acute bacterial meningitis
 duration of, 3769–3770
 initial, 3769, 3770t
 for acute gastroenteritis, 2372–2373, 2373t–2375t
 for appendicitis, 2402–2403
 for bite wound, 4459t
 for Crohn disease, 2320
 for cystic fibrosis, 2673–2674
 documentation of, 1691t
 intrapartum, 1149, 1151t
 for Lyme disease, 1885
 for meningococcal disease, 1742
 neuropathy associated with, 3893t–3894t
 oral, intravenous to, 1691t
 for pertussis, 1763, 1764t
 poisoning, 717t
 prescribing actions to improve, 1692–1693
 for preseptal cellulitis, 3974
 principles of therapy, 1671–1690
 age- and risk-specific use of antibiotics, 1672–1674
 antibiotics commonly used in pediatric practice, 1674–1690
 prophylactic
 for dental procedure, 2871t
 for hereditary spherocytosis, 2959
 for *Neisseria meningitidis* infection, 1745t
 resistance, of *Haemophilus influenza*, 1756
 for rheumatic fever, 1714
 for *Shigella*, 1779
 topical, 4040
 for vulvovaginal infections, 3322t
 Antibiotic “time-outs,” 1691t
 Antibodies
 Epstein-Barr virus (EBV) specific, detection of, 2008, 2009f
 in induction therapy
 IL-2, 3256
 T-cell, 3256
 TSH receptor-blocking, 3404
 Antibody deficiencies, other, 1345–1346
 Antibody-dependent cellular cytotoxicity (ADCC), 1286–1287
 Antibody-mediated rejection (ABMR), in renal transplantation, 3257
 Anticholinergic agents
 for asthma, 1404, 1405t–1406t
 for chronic recurrent aspiration, 2611
 for nocturnal enuresis, 3296
 Anticholinergic syndromes, 1197t
 Anticholinergic toxicidrome, 703t, 707t–708t, 716
 Anticipation, genetic, 747f
 Anticipatory guidance
 for children with disabilities, 4405
 in children’s health, 84–90
 in pediatric palliative care, 61–71
 sickle cell disease, 2976–2977
 additional screening, 2977
 echocardiography, 2977
 hydroxyurea, 2976
 immunizations, 2976
 prophylactic penicillin, 2976
 pulmonary and asthma screening, 2977
 red cell transfusion therapy, 2976–2977
 renal disease, 2977
 retinopathy, 2977
 spleen palpation, 2976
 transcranial Doppler ultrasound, 2976
 Anticoagulant therapy, 3042–3045, 3043t–3044t
 antiplatelet therapy, 3045
 for cerebral sinovenous thrombosis, 3748
 for DIC, 3048
 direct oral anticoagulants, 3044–3045
 low molecular weight heparin, 3043–3044
 thromboprophylaxis, 3045
 unfractionated heparin, 3042–3043
 warfarin, 3044
 Anticonvulsants
 for migraine, 3646t–3647t
 for pain, 690t
 poisoning, 717t
 Antideoxyribonuclease B titer, reference intervals, 4472, e9t
 Antidepressants, 224–226, 227t
 for migraine, 3646t–3647t
 poisoning, 716–717, 717t
 Antidiuretic hormone, 3362–3363
 reference intervals, 4472, e9t
 Antidopaminergic drugs, for migraine, 3648
 Anti-double-stranded DNA (anti-dsDNA), 1495t
 Antiemetic agents, poisoning, 717t
 Antiepileptic drugs (AED), 690–691, 1022, 3597
 adverse effects of, 3611t
 choice of
 according to seizure type and epilepsy syndrome, 3607–3608
 other considerations for, 3608–3612
 discontinuation of, 3616
 dosages of, 3609t–3610t
 hormones and, 3356
 initiating and monitoring therapy in, 3612–3613
 mechanisms of action of, 3606–3607, 3606f
 for migraine, 3648
 side effects of, 3613
 Antifibrinolytics, 3034
 for von Willebrand disease, 3037t
 Antifungal therapy, 1335, 1916–1921, 1917t, 4039–4040
 for allergic bronchopulmonary aspergillosis, 2630
 azoles, 1917–1920
 echinocandins, 1920–1921
 neuropathy associated with, 3893t–3894t
 polyenes, 1916–1917
 pyrimidine analogs, 1917
 for specific pathogens, 1918t
 Anti-GBM antibody syndrome, 2689
 Antigen challenge, by inhalation, 2615
 Antigen detection, in *Coccidioides* spp., 1938
 Antigen sources, hypersensitivity pneumonitis, 2613t
 Antigen-presenting cells (APCs), in allergic diseases, 1370–1371
 Anti-glomerular basement membrane disease (anti-GBM disease), 1553t, 2636–2637
 Anti-glomerular basement membrane (anti-GBM) glomerulonephritis, 3254–3255
 Antihistamines
 for atopic dermatitis, 1415
 for migraine, 3646t–3647t
 oral, for allergic rhinitis, 1381–1382, 1382t–1383t
 Antihistone antibodies, 1495t
 Antihypertensives
 for children, 2917f
 for migraine, 3646t–3647t
 Antiinflammatory therapy
 for cystic fibrosis, 2675
 for rheumatic fever, 1714
 Anti-La antibody (anti-SSB), 1495t
 Antimalarials
 for malaria, 2175–2176
 toxicity, 701t
 Antimetabolites, for atopic dermatitis, 1417
 Antimicrobial agents
 for brucellosis, 1809t
 for cholera, 1788t, 1787
 for cystic fibrosis lung infection, 2674t
 parenteral, treatment of *S. aureus* infection, 1698t
 for pharyngitis, 2560, 2561t
 Antimicrobial prophylaxis, in vesicoureteral reflux, 3273
 Antimicrobial resistance
 in *Enterococcus*, 1722–1723, 1722t–1723t
 in *Neisseria gonorrhoeae*, 1750
 patterns of, 1671, 1672t
 Antimicrobial stewardship, 1690–1693
 actions to improve antibiotic prescribing, 1692–1693
 commitment, 1692
 defining, 1690–1691
 development and implementation of local guidelines, 1692
 education, 1692
 harms from overuse, 1690
 inpatient, 1691–1692, 1691t
 outpatient, 1692–1693
 prospective audit and feedback *versus* preauthorization, 1692, 1692t
 tracking and reporting antimicrobial use measures, 1693
 Antimicrobial stewardship programs (ASPs), 1690–1691
 Antimicrobial therapy
 for brain abscess, 3781t
 for *Mycoplasma pneumoniae*, 1890
 for osteomyelitis, 4289–4291, 4290t
 for septic arthritis, 4293–4294
 use measure, 1693
 outcome measures, 1693
 tracking and reporting, 1693
 Antimigraine drugs, poisoning, 717t
 Antimony
 food-borne illness, 4411t–4413t
 food-borne noninfectious illnesses and, 2362t–2364t
 Antimüllerian hormone (AMH), 3348, 3482, 3486, 3488
 Antimycobacterial therapy, 1830–1835
 for *Mycobacterium leprae*, 1833–1834
 for *Mycobacterium tuberculosis*
 commonly used agents for, 1830–1832
 less commonly used agents for, 1832–1833
 nontuberculous mycobacteria, 1834–1835
 Antineoplastic agents, for adrenocortical carcinoma, 3474
 Antinephrin antibodies, 3254–3255
 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, 1552, 1553t, 1561–1564
 Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, 3341, 3703, 3705t–3707t, 3707f–3708f, 3709t–3710t
 Antinuclear antibody (ANA)
 in JIA, 1471, 1476t
 in rheumatic disease, 1462–1463
 in SLE, 1493–1494

- Antioxidant, in porphyria cutanea tarda, 973
- Antiparasitic therapy, 2125–2145
for helminths and ectoparasites, 2144–2145
albendazole, 2144
ivermectin, 2144
praziquantel, 2145
for protozoans, 2125–2144
artemisinin derivatives, 2125–2144
atovaquone/proguanil, 2125
nitazoxanide, 2125
tinidazole, 2125
- Antiphospholipid antibodies, 1495t
in SLE, 1496
- Antiphospholipid antibody syndrome (APS), 3040
in chorea, 3674
- Antiplasmin, deficiency, 3034
- Antiplatelet therapy, 3045
- Antiproliferative agents, 3256–3257
- Antipsychotics, 226–228, 228t
for delirium, 298
in pain management, 691
poisoning, 717–719
for schizophrenia, 290
side effects of, 227, 229t
- Antiquitin deficiency, 855
- Antiretroviral therapy
highly active, IRIS and, 1846
for HIV, 2098t–2107t
changing, 2108
monitoring, 2108–2109
resistance to, 2109
neuropathy associated with, 3893t–3894t
- Anti-ribonucleoprotein antibody (anti-RNP), 1495t
- Anti-Ro ± anti-La pregnancy, 1499f
- Anti-Ro antibody (anti-SSA), 1495t
- Antisecretory therapy, with pediatric dosages, 2307t
- Anti-Smith antibody (anti-Sm), 1495t
- Antispasmodic medications, 4395t
- Antistreptolysin-O titer, reference intervals, 4472.e9t
- Antithrombin deficiency, 3038t–3039t
- Antithyroid drugs, for hyperthyroidism, 3419–3420, 3420t
- Antitoxin, for diphtheria, 1727
- α_1 -Antitrypsin deficiency, 2460, 4130–4131
emphysema and, 2594
- Antituberculous drugs, neuropathy associated with, 3893t–3894t
- Antivenom, administration of, 4468, 4469t
- Antiviral therapy, 1950–1957
antiviral immune globulins, 1957
common cold, 2552
for COVID-19, 1953t–1954t, 1956–1957
for hepatitis, 1957
for herpesviruses, 1950–1955
acyclovir, 1950–1954
cidofovir, 1955
fomivirsen, 1955
foscarnet, 1955
ganciclovir and valganciclovir, 1954–1955
letermovir, 1955
maribavir, 1955
 penciclovir and famciclovir, 1954
 trifluridine, 1955
 valacyclovir, 1954
 vidarabine, 1955
licensed antiviral drugs, 1951t–1952t
non-HIV clinical conditions, 1953t–1954t
for respiratory syncytial virus, 1953t–1954t, 1955–1956
amantadine and rimantadine, 1956
baloxavir, 1956
oseltamivir, peramivir, and zanamivir, 1956
ribavirin, 1955–1956
for viral meningoencephalitis, 3774
- Antley-Bixler syndrome, 794t–795t, 3470–3471, 3507
- Antrochoanal polyp, 2550f
- Anus
assessment in newborn, 1004
imperforate, 3291
surgical conditions of, 2404–2410
- Anxiety, 1574
cystic fibrosis and, 2678
disparities in, 14–15
- Anxiety (*Continued*)
Down syndrome and, 373
medications for, 227t
in pediatric palliative care, 65t–69t, 70–71
selective mutism and, 330
in T1DM, 3535
- Anxiety disorders, 246–254, 247f, 247t, 257
 α -agonists for, 253
assessment of, 249
combination treatment of, 253
comorbidities of, 249, 253t
core diagnostic features and characteristics of, 252t
differential diagnosis of, 249, 253t
selective serotonin reuptake inhibitors for, 253
serotonin-norepinephrine reuptake inhibitor for, 253
treatment of, 249–253
- Anxiolytic agents, 226, 227t
- Aorta
coarctation of, 2761f, 2793–2795, 2841–2842
clinical manifestations of, 2793–2794
diagnosis of, 2794
pathophysiology of, 2793
relative frequency of, 2763t
treatment of, 2794–2795
- descending
calcification of, 2908f
intravascular stent in, 2762f
- Aortic aneurysm syndromes, 4366, 4367t
- Aortic arch
anomalies of, 2826
right, 2826
vascular rings, 2826, 2827t
- development of, 2733, 2734f
- interrupted, coarctation with other cardiac anomalies and, 2795–2796
- major branches and, 2756f
- Aortic insufficiency
in rheumatic heart disease, 2875
supravalvular ventricular septal defect with, 2784
- Aortic stenosis, 1035, 1036f, 2790–2793
clinical manifestations of, 2791
laboratory findings and diagnosis for, 2791–2792
prognosis of, 2792–2793
treatment of, 2792
- Aortic surgery, for Marfan syndrome, 4368
- Aortic valve stenosis, 2842
- Aortograms, 2518
- Aortopulmonary translocation, 2792
- Aortopulmonary window defect, 2786–2787
- AP50, 1317–1318
- APCs. *See* Antigen-presenting cells
- Apert syndrome, 794t–795t
in craniosynostosis, 3583
- Apgar score, evaluation of newborns, 1004, 1004t–1005t
- Aphakic glaucoma, 3970
- Aphthous stomatitis, 4147–4148, 4148f
in PFAPA, 1529
- Aphthous ulcers, 2252, 2252f, 2253t, 3323f
in HIDS, 1525f
- Apical heave, 2740
- Apical impulse, 2740
- Apids, 1419
- ApiFix, for idiopathic scoliosis, 4246–4247
- Aplasia
optic nerve, 3963
of parathyroid glands, 3434
pulmonary, 2599
red blood cell
with parvovirus B19 infection, 2934–2935
transient erythroblastopenia, 2934, 2934t
- Aplasia cutis congenita, 4044–4045, 4045t
- Aplastic anemia
acquired, 3011
HSCT for, 1353
inherited, 3000t, 3009–3010
moderate, 3012
severe, 3012
- Aplastic crisis
in sickle cell anemia, 2968
transient, in parvovirus B19 infection, 1989
- Apley compression test, 4309f
- Apnea, 548, 589, 1075–1076, 1075t
anesthetic implications in, 666t
central, 1075
in delivery room, 1070
GERD and, 2268
medical child abuse and, 128
neonatal, 1053
obstructive, 1075
in pertussis, 1762
postoperative, 675
of prematurity, 1075–1076, 1075t
as respiratory distress, 612–613
sleep apnea, obstructive, 206–209
that mimic seizures, 3631
- Apnea test, 589
- Apneustic breathing, as respiratory distress, 612–613
- Apocrine glands, 4025f, 4026
- Apophysitis, 4208, 4208f, 4307
- Apoptosis, 4415
- Apparent cause analysis, 43–44
- Apparent life-threatening events (ALTEs), 2541
- Apparent mineralocorticoid excess, 521, 3461–3462
- Appeal to authority, 48t
- Appendageal structures, of skin, 4026
- Appendicitis, 2208–2209
acute, 2397–2404
antibiotics for, 2402–2403
clinical features of, 2397–2398
diagnosis and treatment of, 2401–2402
differential diagnosis of, 2402
epidemiology of, 2397
imaging studies for, 2399–2401
computed tomography, 2400–2401, 2401f
magnetic resonance imaging, 2401
plain radiographs, 2399–2400, 2400f
ultrasound for, 2400
- incidental appendicoliths in, 2404
- interval appendectomy for, 2404
- laboratory findings in, 2399
- mortality in, 2397
- pathophysiology of, 2397–2399
- perforated, 2403
- physical examination for, 2398–2399, 2399f
- position of the appendix in, 2397–2398
- recurrent, 2404
- risk scoring systems, 2399, 2399t
- surgical intervention for, 2403
- uncomplicated, nonoperative management of, 2403–2404
- in acutely ill child, 550
- Appendicitis Risk Scoring Systems, 2399
- Appendicoliths, incidental, 2404
- Appendix testis, torsion of, 3307
- Appetite stimulation, in pediatric palliative care, 65t–68t
- Applied behavioral analysis (ABA), 372, 380
- Apraxia
childhood, of speech, 331, 333
oculomotor, 3637
- Apremilast, for Behcet disease, 1516
- APS. *See* Antiphospholipid antibody syndrome
- APSGN. *See* Acute poststreptococcal glomerulonephritis
- Aquagenic urticaria, 1428
- Aqueductal stenosis, 3564–3565, 3579f
- Arachidonic acid (ARA), 393
- Arachnoid cysts, in brainstem and cerebellar disorders, 3576
- ARBD. *See* Alcohol related birth defects
- Arborization, 2411
- Arboviral infections, 2058–2066
Chikungunya virus, 2062–2063, 2062f
Colorado tick fever, 2062
diagnosis of, 2058–2059
Eastern equine encephalitis, 2059–2060
etiology of, 2058–2059, 2059f–2060f
Japanese encephalitis, 2063–2064
La Crosse and California encephalitis, 2062
Powassan encephalitis, 2061–2062
prevention of, 2058–2059
St. Louis encephalitis, 2061
tick-borne encephalitis, 2064
- Venezuelan equine encephalitis, 2063

- Arboviral infections (*Continued*)
 West Nile encephalitis, 2061, 2061f
 Western equine encephalitis, 2060–2061
 Zika virus, 2064–2066
- Arbovirus, in viral meningoencephalitis, 3772
- ARC. *See* Acute respiratory compromise
- Arcuate uterus, 3352
- ARDS. *See* Acute respiratory distress syndrome
- Area under the curve, for antibiotics, 1673f
- Areola, 3328
- Argentine hemorrhagic fever, 2073
- Arginase 1 deficiency, 853–854
- Arginine vasopressin, 3361
 metabolism and action of, abnormalities of, 3375–3378
- Arginine:glycine amidinotransferase (AGAT), 840
- Arginosuccinate lyase deficiency, 853
- Argyll Robertson pupil, 3886
- ARRH. *See* Autosomal recessive hypophosphatemic rickets
- Ariboflavinosis, 461
- Aripiprazole (Abilify), for psychosis and mania, 228t
- Aristless-related homeobox gene, 2340
- Arm
 musculoskeletal pain syndrome, 1568t
 span, 172
- ARND. *See* Alcohol related neurodevelopmental disorder
- Arnold-Chiari malformations, 2261
- Arnuity Ellipta. *See* Fluticasone furoate
- Aromatase deficiency, in 46,XX DSD, 3507
- Aromatase inhibitors, for gynecomastia, 3496
- Aromatherapy, in pain management, 693
- Aromatic L-amino acid decarboxylase deficiency, 825f, 844, 3899t
- Arousal
 confusional, 209t
 modulation of, 149
- ARPKD. *See* Autosomal recessive polycystic kidney disease
- ARQLQ. *See* Adolescent Rhinoconjunctivitis Quality of Life Questionnaire
- Array comparative genomic hybridization (aCGH), 733f, 762, 765f
- Arrhenoblastoma, 3503
- Arrhythmias, 520
 genetics of, 2772t
 principles of antiarrhythmic therapy, 2844
 recognition and treatment of, 560–563, 563t
 sinus, and extrasystoles, 2844–2848
- Arrhythmogenic cardiomyopathy, 2861
- Arrhythmogenic right ventricular cardiomyopathy, 2861, 2879t, 2887
- Arrhythmogenic right ventricular dysplasia, 2770, 2860f
- Arrival visit, international adoption, 73, 73t
- Arsenic intoxication, 4431–4433, 4431f–4432f, 4432t
 clinical manifestations of, 4432, 4432t
 food-borne illness and, 2362t–2364t, 4411t–4413t
 laboratory findings of, 4433, 4433t
 pathophysiology of, 4431–4432
 pharmacokinetics of, 4431
 reduction strategies of, 4435t
 toxic levels of, 4433t
 in toxic neuropathies, 3892–3894
 treatment of, 4435, 4435t
- Art therapy, in pain management, 693
- Artemether/lumefantrine, 2125–2144
- Artemis deficiency, 1263t
- Artemisinin combination therapy (ACT), 2175
- Artemisinin derivatives, 2125–2144
- Arterial access, 570, 570f
- Arterial blood gases
 normal values, 513t
 values of, interpretation of, 2516t
- Arterial dissection, 3744–3745
- Arterial ischemic stroke (AIS), 3742–3747, 3742f, 3743t–3745t, 3746f
 perinatal, 3745t, 3746–3747, 3747f
- Arterial oxygen content (CaO₂), 2515
- Arterial switch (Jatene) procedure, 2813, 2814f
- Arterial tortuosity, 2908, 2909f, 2909t
- Arteriography, pulmonary, 2518
- Arteromesenteric duodenal compression syndrome, 2299
- Arteriopathy, 3743–3744
 cerebrovascular, in progeria, 959
- Arteriovenous fistulas, 2906–2907
 clinical manifestations of, 2907
 treatment of, 2907
- Arteriovenous malformation, 3750, 4052, 4052f
- Arteriovenous shunts, uncompensated placental, 1041t
- Arteritis
 giant cell, 1553t, 1555t
 Takayasu, 1553t, 1557–1559
- Artesunate, 2125–2144
 for malaria, 2175
- ARTHalgias, 1460
- Arthritis. *See also* Spondyloarthritides
 in alkaptonuria, 817
 in *Aspergillus* infection, 1931
 chronic, characteristics of ACR and ILAR Classification of Childhood, 1472t
 conditions associated with, 1581–1582
 in enterovirus infection, 1983
 enthesitis-related, 1472t, 1483–1484
 following rubella, 1967
 with IBD, 1485
 Lyme disease and, 1883–1884
 mumps and, 1971
Mycoplasma pneumoniae and, 1889
 PAPA syndrome, 1523
 septic, 4291–4294
 suggestive of rheumatic disease, 1461t
 suppurative arthritis syndrome, 1749
- Arthrochalasia, 4373
- Arthrogryposis, 3820–3828, 3820t, 3886, 4271–4275
 categories, etiologies, and classifications of, 3821–3822, 3821f–3822f, 3823t
 classification of, 4271–4272, 4273f
 diagnostic approach and laboratory evaluation of, 3823t–3825t
 differential diagnosis of, 3825–3826, 3826f–3827f
 etiology of, 4271, 4271f, 4272t
 fetal movement in, 3820–3821
 foot problems, 4272–4273, 4275f
 genetic counseling and prenatal diagnosis of, 3826–3828, 3827f
 hip problems, 4273–4275
 knee problems, 4273
 management of, 3828, 4272, 4274f
 upper extremity problems, 4273f, 4275
- Arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome, 2452
- Arthrogryposis multiplex congenita, 3820, 4271
 clinical classification of, 3822f
 definition of, 3820t
 major causes of, 3823t
- Arthropathy, in parvovirus B19 infection, 1989
- Arthropod bites, 4170–4171, 4170t–4171t
 clinical manifestations of, 4170–4171, 4170f–4171f
 treatment for, 4173, 4174t
- Arthus reactions, in tetanus, 1824
- Articulation disorders, 331
- Artificial hydration, 52
- Asbestos, 4425
- Ascariasis, 2198–2200
 clinical manifestations of, 2199
 diagnosis of, 2199, 2199f
 drugs for, 2126t–2144t
 epidemiology of, 2198–2199
 etiology of, 2198, 2199f
 pathogenesis of, 2199, 2199f
 prevention of, 2199–2200, 2200t
 treatment of, 2199
- Ascaris lumbricoides*, 2198
- Ascending amniotic infection, 1154
- Ascending infection, pathways of, 1145f
- Ascending undescended testis, 3302
- Ascertainment bias, 48t
- Ascites, 2509–2510
 causes of
 fetal, 2509t
 in infants and children, 2510t
 neonatal, 2510t
 chylous, 2510
 clinical hallmark of, 2509
 liver disease and, 2440
 portal hypertension and, 2505
- Ascorbic acid (vitamin C), 456t–457t, 468
 deficiency, 468–470, 4192
 clinical features of, 468, 469f
 differential diagnosis of, 469
 laboratory findings and diagnosis of, 468–469, 469f–470f
 prevention of, 470
 treatment of, 469
 dietary needs and sources of, 468
 excess, 468–470
 for methemoglobinemia, 2980
 toxicity, 470
- ASD. *See* Autism spectrum disorder
- Asenapine (Saphris), for psychosis and mania, 228t
- Aseptic meningitis, clinical conditions and infectious agents associated with, 3763t
- Ashworth scale, 4198, 4198t
- ASIA. *See* American Spinal Injury Association
- Asian tapeworm, 2215–2216
- Askin tumors, 3143
- Ask-Upmark kidney, 3262
- Asmanex. *See* Mometasone furoate
- Aspartate, α position 57, in DQB1, 3518–3519
- Aspartate aminotransferase, 2442–2443
 reference intervals, 4472.e9t
- Aspartylglucosaminuria, 887t, 921
- Aspergilloma, pulmonary, 1929
- Aspergillosis, 1929
 allergic bronchopulmonary, 1929, 2629–2630, 2629t, 2630f
 chronic pulmonary, 1929
 cutaneous, 1931
 invasive, complication of HSCT, 1363, 1363f
 invasive pulmonary, 1930–1931, 1930f
- Aspergillus*, 1255–1256, 1929–1931
- Asphyxia, multiorgan systemic effects of, 1062t
- Asphyxiating thoracic dystrophy, 2714, 4355, 4356f
- Aspiration, 2633
 acute, 2606–2608
 chronic recurrent, 2608–2612
 clinical presentation of, 2609
 conditions associated with, 2609t
 diagnosis of, 2609–2611, 2610t, 2611f
 management of, 2611–2612
 of foreign bodies, 1089–1091
 for ganglia, 4267
- Aspiration syndromes, 2606
 gastric contents, 2606
 hydrocarbon aspiration, 2606–2607, 2607f, 2607t
 prevention of, 2608
 principles of management of, 2607–2608
 prognosis for, 2608
 wheezing in infants and, 2585t
- Aspirin
 adverse reactions to, 1459
 for Kawasaki disease, 1546–1547
 in pain management, 681–682, 681t
 peptic ulcers and, 2306
 for platelet function, 3059
- Aspirin-exacerbated respiratory disease (AERD), 1380
- Asplenia, 3063
 congenital heart disease and, 2739t–2740t
- Assent, 51
- Assets, in healing-centered care, 5, 6f
- Assist-control mode, in invasive mechanical ventilation, 624
- Assisted reproductive technology symbols, 738f
- Assistive devices, 4402–4404
 assistive mobility, 4402–4403, 4404f
 orthoses, 4402, 4402f, 4403t
 prostheses, 4402
 robotic, 4404
 wheelchair, 4403–4404
- Assistive mobility devices, 4402–4403
- Astatic seizures, 3598
- Astelin, for allergic rhinitis, 1384t
- Asthma
 adherence to daily controller regimen, 1396
 airway narrowing and, 558
 anesthetic implications in, 666t
 in childcare, 193
 childhood, 1386–1410
 control of, 1395t

- Asthma (Continued)**
- epidemiology of, 1387
 - etiology of, 1386–1387, 1386f
 - management of, 1399t–1400t
 - persistent, risk factors for, 1387t
 - types of, 1387
 - clinical manifestations of, 1387–1389
 - diagnosis of, 1387–1389
 - differential diagnosis of, 1389–1391, 1390t
 - disparities in, 12, 18
 - fractional exhaled nitric oxide in, 1391t–1392t, 1392
 - irritant-induced, 2619
 - laboratory findings of, 1391–1392
 - long-term controller medications for, 1400–1404, 1401t
 - morbidity and mortality, risk factors for, 1408t
 - occupational and environmental, 2616, 2617t–2619t
 - pathogenesis of, 1387
 - peak expiratory flow monitoring, in, 1391t, 1392
 - physical examination in, 1374
 - prevention of, 1410
 - prognosis for, 1410
 - pulmonary function testing in, 1391–1392, 1391t
 - radiology in, 1392, 1393f
 - referral to specialist, 1400
 - screening, in sickle cell anemia, 2977
 - spirometry in, 1391, 1391f, 1391t
 - treatment of, 1392–1409, 1393f
 - control of factors contributing to asthma severity, 1396–1398, 1398t
 - patient education, 1396
 - pharmacotherapy, 1398–1400
 - regular assessment and monitoring, 1393–1396
 - triggers, 1388t
 - inhalation of *Aspergillus* conidia, 1929
 - vocal cord dysfunction vs., 1389–1390, 1390t
 - wheezing in infants and, 2585t, 2586
- Asthma exacerbations**
- as complication of common cold, 2554
 - emergency department management of, 1407f, 1408
 - expiratory wheezing during, 1389
 - home management of, 1408
 - hospital management of, 1408–1409
 - and management, 1405t–1406t, 1406–1408
 - severity, evaluation of, 1389t
 - special management circumstances, 1409
- Astigmatism, 3914**
- Astrocytoma, 3119–3120, 3119f–3120f**
- subependymal giant cell, 3657
- Astroviruses, 2050–2053**
- clinical manifestations of, 2051–2052
 - diagnosis of, 2052
 - differential diagnosis of, 2052
 - epidemiology of, 2051
 - etiology of, 2050–2051
 - laboratory findings of, 2052
 - pathogenesis of, 2051
 - prevention of, 2052–2053
 - prognosis for, 2052
 - treatment of, 2052
 - vaccines for, 2052–2053
- Asymmetric IUGR, 1048**
- Asymmetric nystagmus, 3931t**
- Asymmetry**
- breast, 3330, 3330f
 - labial, 3354
- Asymptomatic bacteriuria, 3266**
- Asymptomatic gonorrhea, 1748**
- Asymptomatic polycythemia, 1126**
- Ataxia, 3557, 3664–3673**
- cerebellar
 - acute, 3672
 - in varicella, 2002
 - in childhood, 3666t
 - episodic, 3636
 - in giant axonal neuropathy, 3887
 - hereditary, 3667t–3670t
 - hereditary spastic, 3670t
 - inherited, 3667t
 - with isolated vitamin E deficiency (AVED), 481
 - mitochondrial disease and, 935t
 - with oculomotor apraxia type 1, 3677
 - spastic-ataxic syndrome, 3671t
 - stroke and, 3754
 - Ataxia-telangiectasia, 774t, 1273–1274, 1345, 3077–3080, 3078t–3080t, 3501, 3672–3673, 3672f, 3677, 4060, 4070t–4071t
 - Atazanavir, for HIV, 2098t–2107t
 - Atelectasis, 2700, 4015–4016
 - clinical manifestations of, 2700
 - cystic fibrosis and, 2675
 - diagnosis of, 2700–2701, 2701f
 - pathophysiology of, 2700, 2700t
 - treatment of, 2701, 2701t
 - Atelectrauma, 621f, 629, 1084
 - Atelosteogenesis, type 2, 4348
 - Atenolol, 2845t–2846t
 - Athelia, 3329
 - Atherogenesis, blood lipids and, 872
 - Atheroma, 872
 - Atherosclerosis, 872, 872f
 - due to HSCT, 1365
 - Athetoid cerebral palsy, 3690t
 - Athetosis, 3673–3678
 - Athletes, nutrition and endocrine conditions in, 4322–4323, 4322f, 4323t, 4324f
 - Athletic pubalgia, 4308
 - Ativan. *See* Lorazepam
 - Atlantoaxial instability (AAI), associated with Down syndrome, 371
 - Atlantoaxial rotatory displacement (AARD), 4259–4260
 - ATLS. *See* Advanced trauma life support
 - ATN. *See* Acute tubular necrosis
 - Atomoxetine, for ADHD, 223–224, 225t–226t, 315
 - Atonic seizures, 3598
 - Atopic dermatitis (AD), 1375, 1410–1419, 1445, 4002
 - avoiding triggers, 1416t, 1418–1419
 - clinical manifestations of, 1411, 1412f–1413f
 - complications of, 1419
 - diagnosis and differential diagnosis of, 1411–1412, 1413t–1414t
 - etiology of, 1410
 - laboratory findings of, 1411
 - pathogenesis of, 1410–1411, 1411f
 - pathology of, 1410
 - prevention of, 1419
 - prognosis for, 1419
 - treatment of, 1412–1418, 1416f, 1416t–1417t
 - vulvar, 3321t–3322t
 - Atopic disease
 - immunologic basis of, 1367–1373
 - persistent atopy-associated asthma, 1388t
 - Atopic eczema. *See* Atopic dermatitis
 - Atopic keratoconjunctivitis (AKC), 1419, 1422t, 1423
 - Atopy, genetic basis of, 1372–1373, 1373f
 - Atovaquone, for babesiosis, 2185
 - Atovaquone-proguanil, 2125
 - for malaria prophylaxis, 1637, 2181t–2182t
 - Atransferrinemia, 2950
 - Atresia
 - biliary
 - liver transplantation for, 2507
 - neonatal cholestasis and, 2445–2447, 2446f
 - choanal, 1053t, 2545–2546, 2546f
 - congenital, of external auditory canal, 3996–3997, 3997f
 - intestinal, 2282–2285
 - jejunal and ileal, 2283–2284, 2283f–2284f
 - laryngeal, congenital, 2575, 2575f
 - pulmonary
 - with intact ventricular septum, 2805–2806
 - with tetralogy of Fallot, 2804–2805
 - rectal, 2406
 - tracheal, 2577
 - tricuspid, 2806–2808, 2806f
 - clinical manifestations of, 2807
 - diagnosis of, 2807, 2807f
 - treatment of, 2807–2808
 - urethral, 3284–3285, 3301
 - vaginal, 3353
 - Atria
 - enlargement, 2748–2749, 2751f
 - septation of, 2733
 - Atrial ectopic tachycardia, 2850–2852, 2851f
 - Atrial extrasystoles, 2844, 2848f
 - Atrial fibrillation, 2852–2853, 2853f, 2862f
 - Atrial natriuretic peptide, 3372
 - Atrial pacemaker, 2847f
 - Atrial septal defect, 2776, 2776f
 - ostium secundum defect, 2776–2779
 - physiology of, 2777f
 - relative frequency of, 2763t
 - sinus venosus, 2779
 - Atrioventricular block, 2858–2859, 2858f–2859f
 - Atrioventricular canal
 - complete, 2840
 - septation of, 2733
 - Atrioventricular septal defects, 2779–2781
 - clinical manifestations of, 2780
 - diagnosis of, 2780–2781
 - electrocardiogram of, 2780f
 - pathophysiology of, 2779–2780
 - physiology of, 2780f
 - prognosis of, 2781
 - treatment of, 2781
 - At-risk groups, for diarrheagenic *E. coli*, 1781t
 - Atrophy, 3554
 - corticosteroid-induced, 4120
 - macular, 4123
 - optic, 3966–3967, 3968t
 - peroneal muscular
 - axonal type, 3886
 - Charcot-Marie-Tooth disease, 3876–3886, 3877t–3879t
 - villous atrophy syndrome and, 2485
 - Atropine
 - autoinjector recommendations, 4455t
 - for pediatric resuscitation and arrhythmias, 563t
 - poisoning, 701t, 707t–708t, 719
 - Atrovent
 - for allergic rhinitis, 1384t
 - for asthma, 1405t–1406t
 - Attachment, 137
 - parent-infant
 - infant's role, 149–151
 - parental role, 148–149
 - Attempted suicide, 263–268
 - Attention, problems related to, 302
 - Attention-deficit/hyperactivity disorder (ADHD), 300, 309–315, 376–378
 - assessment for, 310f, 312f
 - clinical manifestations for, 309–311
 - developmental impacts, 311f
 - diagnosis of, 311–313, 311t
 - differential diagnosis for, 311t
 - disparities in, 14
 - Down syndrome and, 372
 - DSM-5, 310t
 - epidemiology of, 309
 - etiology of, 309
 - hearing loss in, 340
 - medications for, 222–224, 225t–226t, 2862
 - prevention of, 315
 - prognosis of, 315
 - treatment for, 313–315
 - Attribution error, 48t
 - Atypical absence seizures, 3598, 3601
 - Atypical antidepressants, poisoning, 717
 - Atypical antipsychotics, 691
 - Atypical BECTS, 3600
 - Atypical genitalia, diagnostic approach to, 3504–3505, 3506f, 3506t, 3508t
 - Atypical hemolytic uremic syndrome (aHUS), 1318
 - treatment of, 1323
 - Atypical melanocytic nevus, 4061
 - Atypical mole syndrome, 4061
 - Atypical mycobacterial infection, 4158–4159, 4159f
 - Atypical premature adrenarche, 3394
 - Atypical progeroid laminopathies, 962t
 - Atypical SMS, 1530t
 - Atypical squamous cells of undetermined significance (ASC-US), 2055
 - Atypical teratoid/rhabdoid tumor, 3124
 - AUB caused by ovulatory dysfunction (AUB-O), 1213
 - Audiologic assessment, of communication disorders, 332
 - Audiologic clinical evaluation, 3990–3992
 - acoustic immittance testing, 3991
 - audiometry, 3990, 3990f
 - auditory brainstem response, 3991–3992

- Audiologic clinical evaluation (*Continued*)
 behavioral observation audiometry, 3990–3991
 otoacoustic emissions, 3992
 play audiometry, 3990
 speech-recognition threshold, 3990
 visual reinforcement audiometry, 3990
- Audiometry, 3990
 in adolescents, 1170
 behavioral observation, 3990–3991
 play, 3990
 visual reinforcement, 3990
- Auditory brainstem response (ABR) test, 3991–3992
- Augmentation cystoplasty, complications of, 3290
- Augmentative and alternative communication (AAC), 336–339
 assessment, 337–338
 definition of, 336–339
 communicative interactions and, 336–337
 prevalence, 336
 specific assessment details, 337–338
 system, 336–337
 teams, 337
 types of, 337t
- Aura
 in focal seizures, 3599
 migraine with, 3643–3644
 migraine without, 3639–3643, 3642t, 3643f
 in seizures, 3589–3594
 in unprovoked seizures, 3597
- Auricle, 4021
- Auricular hematoma, 4331
- Auscultation
 of acutely ill child, 551
 of heart, 2742–2743
 of lung, 2513
- Auspitz sign, 4098
- Austerity measures, 26
- Authoritarian parenting, 143
- Authoritative parenting, 143, 1163
- Authority gradients, 44
- Autism, in myotonic muscular dystrophy, 3836
- Autism and Intellectual Disability Committee of the American Academy of Child and Adolescent Psychiatry (AACAP), genetic testing guidelines for ID/GDD/ASD, 347t
- Autism shut down syndrome. *See* Catatonia
- Autism spectrum disorder, 354, 372–383
 AAC and, 338–339
 assessment of, 379–380, 380t
 comorbid conditions, 377t–378t
 co-occurring conditions, 378–379
 definition of, 373
 diagnostic criteria for, 373–375, 374t
 developing, maintaining, and understanding relationships, 374
 restrictive and repetitive behavior, 374–375
 social communication and social interaction, 374, 375
 differential diagnosis of, 376–378
 disparities in, 15
 DSM-5, severity levels, 375, 376t
 epidemiology of, 375–376
 etiology of, 376, 378t
 first tier, 379
 genetic testing guidelines for, 347t
 hyporeactivity or hyperreactivity to sensory input, 375
 insistence on sameness, 374
 language disorders and, 329
 management of, 380–383
 complementary and alternative medicine, 383
 co-occurring conditions, 381–382
 educational, 380
 pharmacology, 382, 382t
 transition, 383
 nonverbal communicative behavior, 374
 outcome, 383
 restricted interests, 374–375
 screening for, 379
 second tier, 379–380
 social-emotional reciprocity, 374
 stereotyped motor movements/speech, 374
 symptoms of, 373–375
 treatment of, 380–383, 381f
- Autoantibodies
 autoimmune hepatitis and, 2487–2488
 in autoimmune polyglandular syndromes, 3429t–3430t
 C2 deficiency and, 1319
 specificity, rheumatic disease and, 1462t
- Autoantigens, in autoimmune polyglandular syndromes, 3429t–3430t
- Autofluorescence, 2524
- Autographs, 651–652
- Autoimmune Addison disease, 3455
- Autoimmune cytopenias, 1329–1330
 clinical manifestations of, 1330
 diagnosis of, 1330
 immunodeficiencies associated with, 1330
 pathophysiology of, 1329–1330, 1330t
 treatment of, 1330
- Autoimmune disorders
 hypoparathyroidism, 3436–3437
 hypersplenism and, 3063t
 myocarditis and, 2888t
 polyglandular syndromes 1 and, 3408, 3408t
 respiratory signs and symptoms, 2531t
 respiratory tract complication, 2531t
 T1DM and, 3548–3549
- Autoimmune encephalitis, 3702–3711, 3705t–3707t, 3773–3774
 acquired demyelinating syndromes with encephalopathy, 3708
 antigenic targets in, with associated psychiatric features, 220t
 anti-N-methyl-D-aspartate receptor encephalitis in, 3703
 associated with epilepsy and status epilepticus, 3711
 Bickerstaff encephalitis in, 3710
 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, 3710–3711
 CSF findings in, 3759t–3760t
 diagnostic approach to, 3703, 3704t–3707t
 Hashimoto encephalopathy in, 3708–3710
 opsoclonus-myoclonus and other types of rare brainstem-cerebellar encephalitis, 3710
 psychosis and, 287, 288f
 types of, 3711
 associated with antibodies against neuronal cell surface antigens, 3703–3708
- Autoimmune enteropathy, 2340
 chronic diarrhea and, 2378
- Autoimmune hemolytic anemia (AIHA), 2994
- Autoimmune hepatitis, 2487–2489
 acute hepatic failure and, 2494
 classification of, 2488t
 clinical manifestations of, 2487
 diagnosis of, 2488
 etiology of, 2487
 IBD-associated, 2476–2477
 laboratory findings in, 2487–2488
 pathology of, 2487
 prognosis of, 2489
 treatment of, 2489
- Autoimmune hypothesis, ROHHAD and, 2725
- Autoimmune interferonopathies, 1535
- Autoimmune limbic encephalitis, 3708
- Autoimmune lymphoproliferative syndrome (ALPS), 1331–1334, 1331f, 1331t–1333t
- Autoimmune myasthenia gravis, 3858
 clinical features of, 3859t–3860t
 clinical manifestations of, 3858, 3862t–3863t
 differential diagnosis of, 3861t
 ocular symptoms in, 3861t
- Autoimmune neutropenias (AINs), of infancy, 1307
- Autoimmune ovarian failure, 3501
- Autoimmune pancreatitis, 2431
- Autoimmune polyendocrine syndromes, associated with T1DM, 3548–3549
- Autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy, 2487
- Autoimmune polyendocrinopathy syndrome type 1 (APS-1), 2348, 3454–3455, 3518
- Autoimmune polyglandular syndromes, 3425–3430, 3427t–3428t
 autoantibodies in, 3429t–3430t
- Autoimmune polyglandular syndromes (*Continued*)
 chromosomal abnormalities associated with, 3430
 immune dysregulation-polyendocrinopathy-enteropathy X-linked, 3425–3428
 monogenic, 3425
 nongenetic, 3430
 polygenic, 3428–3430
 type 1, 2340, 3425
- Autoimmune POTS, 598
- Autoimmune psychosis, diagnostic criteria for, 288t
- Autoimmune regulator gene
 autoimmune hepatitis and, 2487
 variants in, 2487
- Autoimmune thyroid disease, in Turner syndrome, 3498
- Autoimmune thyroiditis, 3411
- Autoimmune type 1 diabetes mellitus, genes altering the risk of, 3518
- Autoimmune-mediated inflammatory brain disease, 3754
- Autoimmunity, 1507
 ALPS and, 1331–1332
 complement pathway deficiencies and, 1318
 primary immune deficiency diseases and, 1256–1257 in T1DM, 3520
- Autoinflammation with phospholipase C γ 2-associated antibody deficiency and immune dysregulation (APLAID), 1525–1526
- Autoinflammatory diseases, systemic
 bone disorders, 1523t
 clinical grouping by fever and skin manifestations, 1522t
 diagnostic clues, 1524t
 genetically complex, 1529
 CRMO, 1529, 1529f
 PFAPA, 1529
- mendelian
 APLAID, 1525–1526
 autoinflammation with enterocolitis, 1529
 Blau syndrome, 1524–1525
 DADA2, 1526–1527
 DIRA, 1528
 DITRA, 1528
 FCAS, 1528–1529
 interferonopathies, 1529
 Majeed syndrome, 1529
 PAPA syndrome, 1523
- Autoinflammatory interferonopathies, 1531–1535
- Autoinjectors, atropine and pralidoxime, 4455t
- Autoinoculation, 2204
- Autologous HSCT, 1356, 1356t
- Automated electronic defibrillator (AED), 564–565
- Automatisms, 3599, 3619
 motor, 1052
- Autonomic dysfunction
 causes of, 3899t
 management of, 3899t
- Autonomic dysreflexia, management of, 4389–4394, 4391f–4392f, 4391t
- Autonomic nervous system
 dysregulation
 CCHS and, 2720
 rapid-onset obesity with, 2724
 Guillain-Barré syndrome in, 3900
- Autonomic neuropathies, 3896–3900, 3897t–3899t
 Allgrove syndrome in, 3900
 congenital insensitivity to pain and anhidrosis in, 3897, 3898t–3899t
 familial dysautonomia in, 3896–3897, 3898t–3899t, 3900f
- Autonomic seizures, 3619
- Autonomic storms, 3633
- Autonomy, 156
 in adolescence, 1163
- Autonomy-driven framework, 51
- Auto-PEEP, assessment of, 628–629
- Autoresuscitation (gasping), SIDS and, 2537–2538
- Autosomal aneuploidy, 760t
- Autosomal dominant conditions
 dopa-responsive dystonia, 846
 hyper-IgE syndrome, 1276, 1276f
- Autosomal dominant hearing losses, 3984
- Autosomal dominant hypoparathyroidism, 3436

Autosomal dominant hypophosphatemic rickets (ADHR), 473t, 477
 Autosomal dominant IFN- γ R1 deficiency, 1342–1343
 Autosomal dominant inheritance, 735
 familial form of PHHI, 985
 Autosomal dominant variants, 934
 Autosomal dominant optic atrophy, 3699
 Autosomal dominant pedigree, 739f
 Autosomal dominant polycystic kidney disease (AD-PKD), 2501–2502, 3214–3217, 3215t–3216t, 3217f
 Autosomal liver phosphorylase kinase deficiency *PHKB* variant, 905
PHKG2 variant, 900t–901t, 905–906
 Autosomal recessive agammaglobulinemia, 1277–1280
 Autosomal recessive complete IFN- γ R1/IFN- γ R2 deficiency, 1342
 Autosomal recessive complete STAT2 deficiency, 1338
 Autosomal recessive conditions, 934
 cartilage hair hypoplasia, 1274
 dopa-responsive dystonia, 844
 Segawa syndrome, 844
 Autosomal recessive congenital ichthyoses, 4110–4116
 harlequin ichthyosis, 4110–4115
 lamellar ichthyosis and congenital ichthyosiform erythroderma, 4115–4116, 4115f–4116f
 nonbullos congenital ichthyosiform erythroderma, 4115–4116
 Autosomal recessive cutis laxa 1 (ARCL1), 4377
 Autosomal recessive cutis laxa 2 (ARCL2), 928–929, 4376t, 4377
 Autosomal recessive cutis laxa 3 (ARCL3), 4376–4377
 Autosomal recessive disease, pRTA and, 3234
 Autosomal recessive genetic SNHL, 3984–3985
 Autosomal recessive hypercholesterolemia, 876
 Autosomal recessive hyper-IgM, 1284–1285
 Autosomal recessive hypoparathyroidism, with dysmorphic features, 3435
 Autosomal recessive hypophosphatemic rickets (ARHR), 473t, 477
 Autosomal recessive IL-12 receptor beta 1 (IL-12RB1) deficiency, 1343
 Autosomal recessive inheritance, 735–738
 Autosomal recessive IRF9 deficiency, 1338
 Autosomal recessive pedigree, 740f
 Autosomal recessive polycystic kidney disease (ARPKD), 792t, 2500–2501, 3213–3214, 3214f, 3215t–3216t
 Autosomal recessively inherited congenital optic atrophy, 3966–3967
 Autumn crocus, toxicity, 722t
 Avacopan, for ANCA-associated vasculitis, 1563–1564
 Availability, in food security, 421
 Availability bias, 48t
 Avalglucosidase alfa, for Pompe disease, 907
 Avascular necrosis, 4236, 4284
 in sickle cell disease, 2971
 Aversive conditioning techniques, 240
 Avidity test, 2195
 AVN. *See* Avascular necrosis
 Avoidant/restrictive food intake disorder (ARFID), 268, 270t
 Avulsion, of periodontal structures, 2251–2252
 Avulsion fractures, 4300, 4300f, 4307
 Awareness-assessment-negotiation model, 83–84
 Axenfeld-Rieger syndrome, 768t–769t
 Axial spasms, in unprovoked seizures, 3598
 Axillary freckling, in neurofibromatosis, 3652–3654, 3655f
 Axillary hair, 3386
 Axillary lymphadenopathy, 3070t
 Axonotmesis, 4397
 AXR. *See* Aristaless-related homeobox gene
 Ayurvedic herbal medicine, 2492t
 Azaspiracid poisoning, 4445
 Azathioprine
 for atopic dermatitis, 1417
 for rheumatic diseases, 1470
 Azelaic acid, for acne vulgaris, 4180
 Azelastine, for allergic rhinitis, 1384t
 Azelastine/fluticasone, for allergic rhinitis, 1384t–1385t
 Azithromycin, 1675t–1685t
 for babesiosis, 2185
 for *Legionella*, 1811

Azithromycin (*Continued*)
 for *Mycoplasma pneumoniae*, 1890
 for nontuberculous mycobacteria infection, 1865
 for reactive infectious mucocutaneous eruption, 4078
 for *Shigella*, 1779
 for toxoplasmosis, 2196
 Azoles, 1917–1920
 Aztreonam, 1675t–1685t

B

B cell and antibody deficiencies, 1277–1285
 B lymphocytes
 depletion, for rheumatic diseases, 1470
 diffuse large B-cell lymphoma, 3110t, 3111
 Babbling, 324
 Babesiosis, 1655t–1656t, 2184–2186
 clinical manifestations of, 2185
 diagnosis of, 2185
 drugs for, 2126t–2144t
 epidemiology of, 2184, 2185f
 etiology of, 2184
 pathogenesis of, 2184
 prevention of, 2185–2186
 prognosis of, 2185
 treatment of, 2185
 Babinski sign, 3555–3556, 3673
 Baby Doe Regulations, 53
 Baby-led weaning, 414
 Bacillary angiomatosis (*Bartonella henselae*), 1816
 Bacillary dysentery, 1776
 Bacillary peliosis hepatis (*Bartonella quintana*), 1816
 Bacille Calmette-Guérin (BCG) vaccine, 30–31t, 1588t–1589t
 against tuberculosis, 1854–1855
Bacillus anthracis, 4449
Bacillus cereus, gastroenteritis and, 2356, 2357t–2358t
 Bacitracin, for blisters, 652–653
 Back
 low. *See* Low back injuries
 physical examination of, 551
 Back pain, 4200
 in children, 4252–4253, 4252t–4253t
 clinical evaluation of, 4252–4253, 4253t
 medical decision-making, 4253, 4253t
 radiographic and laboratory evaluation, 4253
 inflammatory, 1484t
 suggestive of rheumatic disease, 1461t
 Baclofen, 3694
 intrathecal, 4396
 for spasticity, 4394, 4395t
 Bacteremia
 acute gastroenteritis and, 2367
 anaerobic, 1829
Bartonella in, 1816
Campylobacter in, 1790
Moraxella catarrhalis in, 1760
 occult
Kingella kingae, 1754
 meningococcal, 1741
S. epidermidis, 1700
Salmonella, 1767–1768, 1770f
 in sickle cell anemia, 2968
Staphylococcus aureus, 1695
 transient, 2864–2865
 without associated focus, *Haemophilus influenza* in, 1758
 Bacterial agents, in infective endocarditis, 2865t
 Bacterial colonization, with long-term mechanical ventilation, 2729
 Bacterial conjunctivitis, 3940t
 Bacterial diagnostics, rapid diagnostic tests for, 1691t
 Bacterial diarrhea, 2357t–2358t, 2365–2367, 2368t
 Bacterial endocarditis, tetralogy of Fallot and, 2802
 Bacterial gastroenteritis, etiologies of, 2357t–2358t
 Bacterial infection
 associated with hemophagocytic syndrome, 3173t
 C2 deficiency and, 1319
 detected in breast milk, 1009t
 in differential diagnosis of Kawasaki disease, 1546t
 fever in older children, 1647, 1649f
 maternal, affecting fetus or newborn, 1013t

Bacterial infection (*Continued*)
 myocarditis and, 2888
 principles of antibacterial therapy, 1671–1690
 rhinosinusitis, 2555f
 tracheitis, 2572–2573
 in varicella, 2002
 Bacterial meningitis, 3758
 CSF findings in, 3759t–3760t
 fever without a focus, 1644
 Bacterial overgrowth
 proximal intestinal, 2342–2343
 small intestinal, chronic diarrhea and, 2377
 Bacterial pneumonia, 2644
 Bacterial resistance, and otitis media, 4008–4010
 Bacterial sepsis
 liver disease and, 2476
 neonates with, 1146–1147
 neutropenia and, 1305
 Bacterial susceptibility, innate defects with, 1341t
 Bactericidal activity, 1317
 Bacteriuria, asymptomatic, 3266
Bacteroides fragilis, 1828
 BAERs. *See* Brainstem auditory evoked responses
 Bag-mask device, for respiratory distress and failure, 619–620
 Bag-mask ventilation (BMV), 559, 559f
 Bailey-Bloch congenital myopathy, 3850
 Balance Error Scoring System (BESS), 4315
 Balanced diet, for megaesophagus, 2168
 Balanitis xerotica obliterans, 3297, 3298f
 Balantidiasis, 2151
 drugs for, 2126t–2144t
Balantidium coli, 2151
 Baller-Gerold syndrome, 2764t–2766t
 Balloon atrial septostomy, 2809
 Balloon valvuloplasty, 2792
 valvar pulmonary stenosis and, 2789f
 Baloxavir, 1956
 for influenza, 2024t
 Bamboo hair, 4141
 Bamforth-Lazarus syndrome, 3402
 Banana sign, 4400
 Bancroftian filariasis, 2206
 Band 3, in hereditary spherocytosis, 2956t
 Barakol, 2492t
 Barbiturates, 671
 Bardet-Biedl syndrome, 792t, 3351
 Barefoot running, 4331
 Bariatric medications, poisoning, 717t
 Bariatric surgery, 448, 449f
 Barium, in stomach, 2279f
 Barium contrast studies, for esophageal varices, 2272
 Barium enema
 with Hirschsprung disease, 2296f
 with severe constipation, 2294f
 Barium esophagogram
 of esophageal ulcerations, 2271f
 of GERD, 2266f
 Barium fluoroscopy, 2257, 2262, 2262f
 Barium swallow, diagnostic approach to respiratory disease, 2518
 Barlow provocative maneuver, 4233, 4233f
 Barometric pressure
 altitude-associated illness and, 630
 during transport physiology, 541
 Barotrauma, 622
 Barrett esophagus, complication of GERD, 2268
 Barth syndrome, 829, 1309t, 3855
Bartonella, 1812–1816
 bacillary angiomatosis, 1816
 bacillary peliosis hepatis, 1816
 bartonellosis (*Bartonella bacilliformis*), 1814–1815
 cat-scratch disease (*Bartonella henselae*), 1812–1814, 1812t
 trench fever (*Bartonella quintana*), 1815–1816
Bartonellosis (*Bartonella bacilliformis*), 1655t–1656t, 1814–1815
 Bartter syndrome, 497, 500, 504, 3240–3241, 3240t–3241t
 Basal cell carcinoma, 4188
 Basal cell nevus syndrome, 4188–4189
 Basal ganglia encephalitis, 3705t–3707t, 3711
 Basal layer, of epidermis, 4025

- Basal metabolic rate (BMR), 391
 Basal tryptase, insect allergy and, 1420
 Basal-bolus regimen, 3528
 Base, definition of, 509
 Base excess, reference intervals, 4472.e9t
 Baseball, injuries associated with, 4327–4328
 Base-rate neglect, 48t
 Basic interests, 51
 Basic life support (BLS), 535, 564
 ALS vs., 535–536
 Basilar-type migraine, 3644
 Basilar/vestibular migraine, 4020–4021
 Basketball, injuries associated with, 4328
 Basophilic, 1314
 Basophils, reference intervals, 4472.e9t
 Basson-Kornzweig syndrome, 2340
 Bath oils, 4039
 Bath salts
 abuse, by adolescents, 1208–1209
 as club drugs, 1195t–1196t
 Batten disease, 3716
 Batteries, toxicity, 724–725
 Bayley Scales of Infant and Toddler Development, Fourth Edition (BSID-4), 356
 Baylisascariasis, drugs for, 2126t–2144t
 BBPP. *See* Birth brachial plexus palsy
 β-cell immune deficiency, mitochondrial disease and, 935t
 β-cell lymphoproliferative disease, 3080–3081
 Beare-Stevenson syndrome, 794t–795t
 BEARS sleep screening algorithm, 215t
 Beau lines, in nail plate, 4144–4145, 4145f
 Becker muscular dystrophies (BMD), 2770, 3828–3835, 3833f
 clinical manifestations of, 3828–3832
 diagnosis of, 3832–3833
 genetic etiology and pathogenesis of, 3833f–3834f
 treatment of, 3834–3835
 Becker nevus (Becker Melanosis), 4066, 4066f
 Beckwith-Wiedemann syndrome (BWS), 985–986, 989f, 2764t–2766t, 3081, 3126t, 3131t–3132t, 3382, 3384t, 3472, 3473t
 adrenocortical tumors and, 3166
 hepatoblastoma and, 3153
 Beclomethasone
 for allergic rhinitis, 1384t–1385t
 for asthma, 1402t
 Beconase AQ, for allergic rhinitis, 1384t–1385t
 BECTS. *See* Benign childhood epilepsy with centrotemporal spikes
 Bed bugs
 bites, 4170t
 elimination of, 4171t
 Bed sharing, SIDS risk factors and, 2534
 Bedaquiline, for drug-resistant tuberculosis, 1852t–1853t
 Bedaquiline fumarate, against *M. tuberculosis*, 1833
 Bedroom, healthy sleep and, 205t
 Beef tapeworm, 2215–2216
 Behavior, 178
 aggressive, 283
 during first year of life, 154t
 lead exposure and, 4438
 Behavior rating scales, for ADHD, 312
 Behavior therapy, psychotherapy in, 231
 Behavioral activation, SSRI and, 224
 Behavioral arrest seizures, 3619
 Behavioral changes, in school violence, 102
 Behavioral conditions, that mimic seizures, 3637
 Behavioral development
 emerging patterns, 1–5 years of age, 163t
 fetal, 146
 Behavioral disorders, 232t
 assessment and interviewing
 aims of assessment, 216
 presenting problems, 216
 psychosocial interview, 216–218
 in childhood, 143
 in intellectual disability, 357
 medical child abuse and, 128
 obesity-associated comorbidities, 444t
 Behavioral family therapy, 233
 Behavioral health disparities, 14–15
 Behavioral issues, office intervention for, 89–90
 Behavioral observation audiometry, 3990–3991
 Behavioral parent training, 280
 Behavioral screening, 178–182
 comprehensive evaluation of, 181–182
 evidence-based tools for, 180t–181t
 implementation of, 182
 ongoing management of, 182
 referral and intervention of, 182
 screening test properties for, 181
 Behavioral staring, 3637–3638
 Behavioral states of newborn, 149
 Behavioral surveillance, 178–182
 components of, 179t
 comprehensive evaluation of, 181–182
 elements of, 178
 histories in, 179–180
 implementation of, 182
 observation in, 180
 ongoing management of, 182
 referral and intervention of, 182
 Behavioral theories, 140
 Behçet disease, 1514–1516, 1553t, 1565, 2312–2313, 4033
 clinical manifestations and diagnosis of, 1515–1516, 1515t
 epidemiology of, 1514
 etiology and pathogenesis of, 1514–1515
 treatment and prognosis of, 1516
 Behr optic atrophy, 3966–3967
 Beighton score, 4197, 4373f
 Bejel (*Treponema pallidum endemicum*), 1877
 Beliefs, strategies for, 130t
 Belimumab, 1470
 for systemic lupus erythematosus, 3197–3198
 Bell clapper deformity, 3306
 Bell palsy, 3553, 3222, 3907f, 3907t
 clinical manifestations of, 3907
 facial palsy at birth, 3908
 prognosis of, 3907
 treatment for, 3907
 Belladonna, toxicity, 722t
 Benign breast changes, 3331–3332
 Benign childhood epilepsy with centrotemporal spikes (BECTS), 3600
 Benign congenital hypotonia, 3820
 Benign epilepsy
 with focal seizures, 3590t–3591t, 3600
 with occipital spikes, 3600
 Benign familial hematuria, 3189
 Benign familial neonatal seizures, 3622
 Benign generalized epilepsies, 3601
 Benign hereditary chorea, 3674
 Benign hypercalcemia, familial, 3441
 Benign infantile familial convulsion syndromes, 3600
 Benign liver tumors, 3153
 Benign migratory glossitis, 4148, 4149f
 Benign motoric paroxysms in infancy, 3637
 Benign myoclonic epilepsy of infancy, 3601
 Benign myoclonus of infancy, 3637, 3679
 Benign neonatal convulsions, 3620
 Benign paroxysmal positional vertigo, 4020–4021
 Benign paroxysmal torticollis, 4259
 of infancy, 3635, 3685–3686
 Benign paroxysmal vertigo of childhood, 3633
 Benign sleep myoclonus, 3638
 Benign tumors
 of bone, 3144–3148, 3145t, 3146f
 subungual exostosis, 3145–3147, 3146f–3147f
 tibia, characteristic lesions of, 3147–3148
 vascular tumors of, 3148, 3148t
 thyroid, 3164
 in vascular anomalies, 3161–3162
 Benralizumab (anti-IL-5 R α ; Fasenra), for asthma, 1401t, 1404
 Bent bone dysplasia, 794t–795t
 Benzene
 inhaled, 1203t
 poisoning, 720
 Benzimidazole, for hookworms, 2202
 Benznidazole, for Chagas disease, 2168
 Benzocaine, toxicity, 701t
 Benzodiazepines, 669t, 671
 adverse effects of, 3611t
 for Dravet syndrome, 3607
 intoxication and withdrawal, 1206t
 for neonatal seizures, 3623
 in pain management, 691
 poisoning, 707t–708t
 for spasticity, 4394
 Benzoyl peroxide, for acne vulgaris, 4179
 Benztropine, 708t
 Bereavement, 197–198, 197t–198t
 approach to, 71
 Berger nephropathy, 3187–3188, 3187f
 Beriberi, 459
 Berlin definition, of acute respiratory distress syndrome, 617, 617t
 Bernard-Soulier syndrome, 3056, 3059
 Berylliosis, 2623–2624
 Best interests, 51
 Best vitelliform degeneration, 3960
 Beta-hydroxy-beta-methylbutyrate, as performance-enhancing aids, 4325t–4326t
 Bevacizumab, 3088t
 Bezoars, 2304, 2304f
 Biases, 45–46
 Bicarbonate, reference intervals, 4472.e9t
 Bicarbonate buffer system, 510
 Bicitra, 3250
 Bickerstaff encephalitis, 3705t–3707t, 3710
 Bicornuate uterus, 3352
 Bictegravir, for HIV, 2098t–2107t
 Bicultural, defined, 82
 Bicycle injuries, 92t, 97
 Bifid uvula, 2223
 Bilateral anorchia, 3510
 Bilateral pheochromocytoma, 3480f
 Bilateral renal agenesis, 3260–3261
 Bilateral Wilms tumor, 3509
 Bile acid
 disorders, chronic diarrhea and, 2378
 excretion, 2437
 malabsorption, 2341
 metabolism
 disorders of, liver and, 2455t
 impaired, 2437t
 synthesis defects, 2451
 Bile ducts
 congenital atresia of, 1111
 intrahepatic, cystic dilation of, 2501
 Bile secretion, 2437
 Bilharzia. *See* Schistosomiasis
 Biliary atresia
 liver transplantation for, 2507
 neonatal cholestasis and, 2445–2447, 2446f
 Biliary atresia splenic malformation (BASM) syndrome, 2445
 Biliary cirrhosis, focal, 2477
 Biliary disorders
 causing malabsorption, 2348–2349
 hepatic dysfunction and, 808t
 Biliary dyskinesia, 2504
 Biliary pseudolithiasis, 2503
 Biliary sludge, 2447–2448
 Biliary system, morphogenesis of, 2434–2437
 Biliary tract
 cystic diseases of, 2500–2502
 cystic fibrosis and, 2667
 Bilingual children, 165
 Bilingualism, 325t, 327
 Bilirubin, 2438
 encephalopathy, 1110
 gallstone formation, 2955
 inherited deficient conjugation of, 2454–2456
 metabolism, disorders of, liver and, 2455t
 total, reference intervals, 4472.e9t
 Biliteracy, definition of, 325t
 Binary toxin, 1825
 BinaxNOW Malaria Test, 2173
 Binge eating disorder (BED), 268
 Binocular vision testing, 3911
 Biobehavioral therapy, for migraine, 3649
 Biodiversity hypothesis, 1367

- Biofeedback, 58t
in pain management, 693
- Biologic agents, 3086
adverse reactions to, 1458
for asthma, 1404
for Crohn disease, 2321–2322
for JIA, 1481t
for rheumatic diseases, 1469–1470, 1469t
- Biologic influences, 136–137
- Biologic neurotoxins, 3895
- Biologic warfare, 109
- Biologic weapon, 108
- Biological and chemical terrorism, 4446–4455
anthrax, 4449
botulism, 4448, 4452t
chlorine, 4448–4449
clinical manifestations of, 4447–4450, 4448t
cyanide, 4448–4449
diagnosis in, 4450
epidemiology and pediatric-specific concerns in, 4446–4447
etiology of, 4446
lewisite, 4449–4450
mustard, 4449–4450
nerve agents, 4447–4448
phosgene, 4448–4449
plague, 4449
prevention of, 4450–4451
ricin, 4449
smallpox, 4449–4450
treatment for, 4451–4455, 4452t–4454t
tularemia, 4449
- Biomarkers, serum, for neonatal infection, 1148–1149
- Biomedical bias, 22
- Biomicroscopy, 3912
- Biophysical profile, 1015–1017, 1018t
- Biopsy
kidney, 3258
liver, 2444
for autoimmune hepatitis, 2488f
lung, 2525, 2615, 2636
muscle
in Duchenne muscular dystrophy, 3832
in myasthenia gravis, 3864, 3866
in neuromuscular disorders, 3794–3798
in periodic paralyses, 3848–3850
in spinal muscular atrophies, 3870, 3870f
of skin, 4027
- Biopsychosocial formulation, 221
- Biopsychosocial model, 136–142, 274–275
biologic influences, 136–137
- developmental domains and theories of emotion and cognition, 139–140
- natural systems in, 137f
- psychologic influences, 137
- social factors, 137–138
- statistics used in describing growth and development, 140–142
- unifying concepts, 138–139
- Biotin, 456t–457t
cycle, defects of, 828
deficiency, 464, 464f
dietary reference intake, 397t–403t
metabolic pathway, 822f
- Biotinidase deficiency, 828, 3603, 3622
- Biotin-responsive basal ganglia disease, 3684, 3686f
- Biotin-thiamine-responsive basal ganglia disease (BTBGD), 458, 458t
- Biotransformation, 2436–2437
- Biphasic fever, 1640–1641
- Biphasic (inspiratory and expiratory) positive airway pressure (BiPAP), 623
- Bipolar disorder, 247t–248t, 260–263
clinical course, 262–263
comorbidity, 262
definition of, 260, 260t
differential diagnosis of, 261–262
epidemiology of, 260
etiology of, 260
level of care, 262–263
pharmacologic treatment of, 262, 262t
presentation of, 261
prevention of, 263
- Bipolar disorder (*Continued*)
prognosis of, 262–263
psychotherapies for, 262
risk factors of, 260
screening of, 261
sequelae, 263
treatment of, 262
- Bipolar I disorder, 260
- Bipolar II disorder, 260
- Bipolaris* spp., 1947–1948
- Birbeck granule, 3168
- Bird-headed dwarfism. *See* Seckel syndrome
- Birth, sex designated (assignment) at, definition of, 1171
- Birth brachial plexus palsy, 4397–4399, 4397f–4398f
evaluation of, 4398–4399
physical examination of, 4397–4398
treatment of, 4399
- Birth defects, 1022
classification of, 778–781
deformations, 779
disruptions, 779
multiple anomalies, 779–781
- Birth rate, for teenagers, 1219f, 1229f
- Birt-Hogg-Dubé syndrome, 2703, 4185
- Birthweight
low, preterm birth and, 998
very low, infants, 1042
- Bisexuality, prevalence in youth, 1182, 1183f
- Bisphenol A, 4423
- Bisphosphonates, for osteoporosis, 4385
- Bite cells, 2991
- Bites. *See also* Animal and human bites
arthropod, 4170–4171, 4170t–4171t
caused by child abuse, 116
snake, 4466–4468
spider, 4468–4471
- Biting flies, 2207
- Bitot spots, 453–454, 454f
- Bitter orange, 57t
- BK polyomaviruses, 2085–2086, 2085t–2086t
- Black cohosh, 2492t
- Black hairy tongue, 4149
- Black measles, 1961
- Black pigmentation, of nail plate, 4144
- Black spot poison ivy dermatitis, 4089
- Black widow spider, 4469, 4470f
- Blackfoot disease, 4432
- Blackhead, 4177
- Blackwater fever, in malaria, 2180
- Bladder
anomalies of, 3285–3287
diverticula, 3287
extrophy, 3285–3286
urachal, 3287
control, in preschoolers, 164
dysfunction, 3268–3269
neurogenic, 4401
nonneurogenic neurogenic, 3293
obstruction of neck of, 3282
overactive, 3291, 3293
underactive, 3294
- Bladder-bowel dysfunction, 3270, 3291
- Blalock-Taussig shunt, 2803, 2804f
- Blast injuries, 107
- Blastocystis hominis*, antibiotic therapy for, 2373t–2375t
- Blastomyces* species, 1934
- Blastomycosis, 1655t–1656t, 1934–1936
clinical manifestations of, 1935, 1935f
diagnosis of, 1935–1936
epidemiology of, 1934
etiology of, 1934
extrapulmonary, 1935
pathogenesis of, 1934–1935
treatment of, 1936
- Blastomycosis-like pyoderma, 4154, 4155f
- Blau syndrome, 1524–1525, 1548
- Bleeding
abnormal uterine, 1211, 1213–1214, 1213t–1214t
esophageal, 2257
gastrointestinal, liver disease and, 2440
medical child abuse and, 128
portal hypertension and, 2505
- Bleeding (Continued)
tendency, in CKD, 3250t
vaginal, 3326–3328
vitamin K deficiency, 1127, 1127t
vulvovaginal, 3327f–3328f
- Bleomycin, indications and adverse reactions of, 3089t–3090t
- Blepharitis, 3935, 3940t
- Blepharospasm, 3935, 3969
- Blistering agents, 4449–4450
- Blistering cutaneous porphyrias, 965
- Blistering disorders, 4076
- Blistering distal dactylitis, 4154–4155, 4155f
- Blisters
in hand-foot-and-mouth disease, 1981f
sucking, 4041
- Bloch-Sulzberger disease. *See* Incontinentia pigmenti
- β-Blockers
for hypoglycemia, 991
for MFS, 4368
for portal hypertension, 2506
- Blocking therapy, radiation and, 4420–4421
- Blood
fetal, sampling of, 1019
peripheral, presence of numerous spirochetes, 1881f
- Blood anion gap, 3237
- Blood cholesterol screening, 881–884
- Blood concentrations, 705
- Blood culture
for fever without a focus, 1644
in meningitis, 3763
for osteomyelitis, 4289
- Blood disorders, 1116–1117, 3962
fetal therapy for, 1027t
hemolytic disease of fetus and newborn, 1123–1125, 1123t, 1125t
hemorrhage, 1126–1127
- nonimmune hydrops, 1128–1129, 1128f, 1129t, 1130f
- normal erythropoiesis and hemoglobin functions, 1116, 1117f
normal red blood cell indices in neonates and infants, 1116–1117, 1117f
- Blood doping, as performance-enhancing aids, 4325t–4326t
- Blood flow
fetal hepatic, 2434–2435
increased, cyanotic congenital heart disease and, 2812–2826
double-outlet right ventricle
with malposition of the great arteries (Taussig-Bing anomaly), 2815
without pulmonary stenosis, 2815
- D-transposition of the great arteries, 2812, 2812f
with intact ventricular septum, 2812–2813
- hypoplastic left heart syndrome, 2819–2822
- L-transposition of the great arteries, 2814–2815, 2815f
- single ventricle, 2818–2819
- total anomalous pulmonary venous return, 2815–2817, 2816f–2817f
- transposition of the great arteries, with ventricular septal defect, 2814
- truncus arteriosus, 2817–2818, 2817f
- pulmonary
decreased, cyanotic congenital heart disease, 2800–2811
obstructed, in newborn, 1054t
- Blood gases
abnormalities in, in respiratory failure, 617
- analysis, diagnostic approach to respiratory disease, 2513–2525
arterial, 513t
- Blood glucose, self-monitoring of, for T1DM, 3531–3532
- Blood karyotype, in ambiguous genitalia, 3505
- Blood lead level (BLL), 4436
- Blood lipids
atherogenesis and, 872
epidemiology of, 871–872
- Blood loss, in gastrointestinal tract, 2224
- Blood pressure
in adolescents, 1170
drugs that elevate, 2914t

- Blood pressure (*Continued*)

mean, in neonates, 1003f

measurement of, 2738

age-specific, 2744f–2745f

in children, 2910–2911

monitoring, in nephrotic syndrome, 3231t

screening, 2911t
- Blood studies, for febrile seizure, 3597
- Blood tests

complete blood count, reference intervals, 4472.e9t

concussion and, 4316
- Blood transfusions

for homozygous β -thalassemia, 2982–2983

risks of, 3020–3021

infectious, 3020–3021, 3020t, 3021f

noninfectious, 3020t, 3021, 3022f

for severe malaria, 2175

for sickle cell anemia, 2975–2977
- Blood types, checked prior to renal transplantation, 3256
- Blood vessels, disorders of, 2906–2908, 3060

arteriovenous fistulas, 2906–2907

Kawasaki disease, 2906, 2907f
- Blood-brain barrier (BBB), in vascular permeability, 3761
- Bloodstream infection, catheter-related, 1667–1668
- Bloody discharge, from nipple, 3331
- Bloom syndrome, 774t, 3077–3080, 3078t–3080t, 3131t–3132t, 4098
- Blount disease, 4215, 4217f–4218f
- BLS. *See* Basic life support
- Blue nevi, 4064–4065
- Blue rubber bleb nevus syndrome, 3157–3158, 3161f, 4052
- Blunt objects, ingestion of, 2303
- BMI. *See* Body mass index
- BMI-for-age, 423
- BMR. *See* Basal metabolic rate
- BMV. *See* Bag-mask ventilation
- “Bobo doll” experiment, 102–106
- Bochdalek hernia, 1094, 1094f
- Body checking, 4329–4330
- Body dysmorphic disorder, 3330
- Body fluids, composition of, 485–487

fluid compartments, 485–486

osmolality, 486–487

total body water (TBW), 485, 485f
- Body heat, maintenance in newborn, 1004–1005
- Body image

in adolescence, 1163

perceptions of, 167
- Body lice, bites, 4170t
- Body mass index (BMI), 172, 408–409, 423, 438, 439f–440f, 4384–4385
- Body proportions, male, 147f
- Body temperature, during inflammatory attacks, 1521f
- Boerhaave syndrome, 2271
- Bohn nodules, 2253
- Bohring-Opitz syndrome, 794t–795t
- Bolivian hemorrhagic fever, 2073
- Bonding, parent-infant, 1007–1008
- Bone

centers of ossification, 4193–4194

complications in, cystic fibrosis and, 2677

deformity of, 4197

glucocorticoid effects, 3448

growth and development of, 4193–4194, 4193t

health, in pubertal blockade, 1176, 1176t–1177t

metabolism, 3433–3434

Staphylococcus aureus, 1696

structure, growth, and hormonal regulation, 4377–4380, 4378f, 4379t–4380t
- Bone conduction aids, 341
- Bone disease

arthritis or extremity pain caused by, 1479t

in *Aspergillus* infection, 1931

autoinflammatory, 1523t

osteomyelitis

chronic recurrent multifocal, 1523t, 1529, 1529f

DIRA, 1528f

in tuberculosis, 1845, 1845f
- Bone health, of HSCT, 1365
- Bone infection, 4284
- Bone lesions, in Langerhans cell histiocytosis, 3169
- Bone marrow

morphology, in Pearson syndrome, 2933f

replacement, neutropenia secondary to, 1308
- Bone marrow aspirate

familial hemophagocytic lymphohistiocytosis and, 3172f

neuroblastoma cells in, 3129f
- Bone marrow disorders, risk for osteoporosis, 4384t
- Bone marrow failure, 3013

leukemia and, 3098
- Bone marrow failure syndromes, inherited

with pancytopenia, 2999–3010, 3000t–3001t

unclassified, 3010, 3011t
- Bone marrow transplantation

for acute myeloid leukemia, 2424

for adrenoleukodystrophy, 871

liver disease and, 2479, 2479t

for mucopolysaccharidoses, 942
- Bone neoplasms, 3141–3148

benign tumors and tumor-like processes of, 3144–3148, 3145t, 3146f

subungual exostosis, 3145–3147, 3146f–3147f

tibia, characteristic lesions of, 3147–3148

vascular tumors of, 3148, 3148t
- features of, 3145t

malignant tumors of, 3141–3144, 3141t, 3142f

Ewing sarcoma, 3143–3144, 3143f

osteosarcoma, 3141–3143, 3142f
- Bone-anchored hearing aid (BAHA), 341
- BoNT. *See* Botulinum toxin
- Boot top fractures, field skiing associated with, 4330
- Bordetella parapertussis*, 1761–1765
- Bordetella pertussis*, 1761–1765
- Borrelia*. *See* Relapsing fever
- Borrelia burgdorferi*, 1881–1887. *See also* Lyme disease
- BOS. *See* Bronchiolitis obliterans syndrome
- Bosentan, 2834t
- Bosniak classification, renal cyst, 3262
- Boston craniosynostosis, 794t–795t
- Botox injection, for chronic recurrent aspiration, 2611
- Botulinum antitoxin, 708t
- Botulinum toxin, 2262

for spasticity, 4394–4396
- Botulism (*Clostridium botulinum*), 1817–1821, 3866, 4448, 4452t

clinical manifestations of, 1818–1819, 1818f

complications of, 1820, 1821t

diagnosis of, 1819, 1819t

differential diagnosis of, 1819, 1820t

epidemiology of, 1817–1818, 1817f

etiology of, 1817

infantile, 3866

pathogenesis of, 1818

prevention of, 1821

prognosis for, 1820

supportive care for, 1820

treatment of, 1820
- Boutonneuse fever, 1900t–1902t, 1906–1907, 1907f
- Bovine spongiform encephalopathy, 2118
- Bowel

control, in preschoolers, 164

echogenic, 1026t

neurogenic, 4401
- Bowen disease, 4432
- Boyd’s classification, 4218
- Boys

BMI, 173f–174f

head circumference-for-age and weight-for-length percentiles, 159f

length-for-age and weight-for-age percentiles, 161f
- BPD. *See* Bronchopulmonary dysplasia
- Brace, for birth brachial plexus palsy, 4399
- Brachial palsy, 1068–1069, 1069f
- Brachycephaly, 784t

in craniosynostosis, 3583
- Brachydactyly, 784t
- Brachytherapy, in retinoblastoma, 3150
- Bradycardia, 555

predicting toxicity from vital signs in, 704t

as respiratory distress, 612–613
- Bradyarrhythmias, 555t, 561–562, 561f

in syncope, 592, 594t
- Bradycardia, 555
- Brain

abnormalities of, significant structural, 1136

development, in pubertal blockade, 1176–1177

growth, in first two years of life, 152f

hemorrhage, due to untreated hypertyremia, 490

irradiation, precocious puberty after, 3391

magnetic resonance imaging of, 2919f, 3558–3559

neural signature for dyslexia, 316f

structural development, in preschool years, 164

structure and function abnormalities, in childhood-onset fluency disorder, 334
- Brain abscess, 3779–3781, 3779t

clinical manifestations of, 3780

CSF findings in, 3759t–3760t

diagnosis of, 3780, 3780f

etiology of, 3779–3780

pathology of, 3779

prognosis of, 3781

tetralogy of Fallot and, 2802

treatment of, 3780–3781, 3781t
- Brain-adipose tissue-intestinal axis, 443f
- Brain death, 53, 589–592

after declaration of, 592

after neonatal hypoxic-ischemic encephalopathy, 1068
- Brain death, 53, 589–592, 591t

ancillary studies for, 589–592, 591t

clinical evaluation of, 589

apnea test, 589

checklist, 590f

neurologic examination, 589, 591t

diagnosis of, 589

documentation of, 592

epidemiology of, 589

objections to, 592

observation periods for, 589
- Brain injury

focal ischemic, 1066f

sports and, 4327

topography, in hypoxic-ischemic encephalopathy, 1063t

traumatic, 583–588

clinical manifestations of, 583

diagnosis and differential diagnosis of, 583

epidemiology of, 583

etiology of, 583

laboratory findings in, 583, 584f–586f

pathogenesis of, 583

pathology of, 583

prognosis of, 588

supportive care for, 588

treatment of, 583–588, 587f–588f
- Brain iron accumulation, with neurodegeneration, 3720, 3721t, 3722f
- Brain lesion, precocious puberty resulting from, 3390–3391, 3390f–3391f
- Brain malformations, 3818–3819, 3818f–3819f

congenital muscular dystrophies associated with, 3843

in neonatal seizures, 3619
- Brain tumors, 3117f. *See also* Central nervous system tumors, in childhood

age-related manifestations of, 3084

in ataxia, 3672

histology of, 3117f

MR imaging of, 3118–3119

pediatric, familial syndromes associated with, 3117t
- Brain-gut interaction disorders, 2385–2391, 2386f–2387f

defecation disorders and, 2388t, 2391, 2391t

in infants and toddlers, 2385–2388, 2387t–2388t

in older children and adolescents, 2388–2391
- Brain-lung-thyroid syndrome, 2634t, 3674
- Brainstem

disorders of, 3576–3577, 3577f–3578f

dysfunction, that mimic seizures, 3637
- Brainstem auditory evoked potentials, for brain death, 591t
- Brainstem auditory evoked responses (BAERs), 3560
- Brainstem aura, migraine with, 3642t, 3644
- Brainstem reflexes, absence of, 589
- Brainstem tumors, 3124–3125, 3125f

- Brainstem-cerebellar encephalitis, 3705t–3707t, 3710
 Branched-chain amino acids, 822f, 825
 Branched-chain amino acid transporter deficiency, 827
 Branched-chain α -ketoacid dehydrogenase kinase deficiency (BCKDK), 827
 Branchial cleft, 4044
 Branching enzyme deficiency, 904
 Branchiootorenal dysplasia 1 syndrome, 4044
 Branchiootorenal syndrome, 3987t
 Breast, 1210
 abscess, 411, 3330–3331
 development, 3328–3329, 3328f
 abnormal, 3329–3332
 examination
 annual, 3329
 in female adolescents, 1170
 health, 3328–3333
 infections, 3330–3331
 male disorders of, 1210
 mastalgia, 3331–3332
 nipple
 discharge from, 3331
 trauma and inflammation, 3331
 screening of, in transgender, 1180t
 self-awareness, 3329
 self-examination, 3329
 sexual maturity rating in, 1160f, 1160t
 Breast bud, 3328, 3386
 Breast masses, 3332–3333
 in adolescents, 3332, 3332t
 imaging of, 3333
 malignant, 3332
 management of, 3333, 3333f
 peripubertal, 3332
 recommendations for daughters of women with breast cancer, 3333
 risk reduction, 3333
 screening procedures, 3333
 Breast milk
 chemical pollutants in, 4427
 collection, 412
 jaundice, 1110
 and otitis media, 4003–4004
 supply, patterns of, 411t
 Breastfed infant, growth of, 412
 Breastfeeding, 149, 409–412, 409t, 411t
 contraindications to, 1008
 due to maternal health conditions, 410t
 drugs and, 1008
 hospital practices to encourage and support, 410t
 jaundice, 411, 1110–1111, 1111f
 during nuclear medicine examination, 4422, 4422t
 nurseries and, 1007–1008, 1007t
 promotion of exclusive, for acute gastroenteritis, 2373–2375
 recommendations on, 411t
 SIDS risk factors and, 2535
 Breath hydrogen test, for carbohydrate malabsorption, 2333
 Breath-holding spells, 281, 2541
 that mimic seizures, 3631–3632
 Breathing
 in acutely ill child, 551
 assessment in newborn, 1002
 control of, 2719
 difficult or noisy, in exclusion or inclusion in daycare, 187t–192t
 management of, 559–560
 periodic, 1075
 at altitude, 632
 primary assessment of, 552–554, 555f
 primary survey for, 571–573, 574t
 rescue, 558f, 559
 sleep-disordered, 206
 Breech deformation sequence, 781f
 Brentuximab vedotin, 3108–3109
 Brethine, for asthma, 1405t–1406t
 Brevetoxins, 4444–4445
 Brief interventions, 234–235
 Brief psychotic disorder, 285, 285t
 Brief resolved unexplained events (BRUE), 2541–2544
 additional history, 2542
 algorithm for, 2542f
 definition of, 2541
 epidemiology of, 2541
 historical features of, 2544t
 initial history of, 2541–2544
 management of, 2544
 physical examination of, 2542–2544
 symptom-based approach to, 2543t
 testing for, 2544
Bright Futures, 102, 4405
 Brill-Zinsser disease, 1911
 Brivaracetam
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Broad tapeworm, 2217
 Brodie abscess, 4285
 Bromhidrosis, 4135
 Bromide
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Bronchi
 neoplasms of, 2583–2584
 obstruction of, atelectasis and, 2700t
 Bronchial foreign bodies, 2580, 2580f
 Bronchial thermoplasty (BT), 2524–2525
 Bronchial tumors, 2584
 Bronchiectasis, 2658–2660
 central, 2630f
 conditions predisposing to, 2658t
 diagnosis of, 2659, 2659f
 pathophysiology and pathogenesis of, 2658, 2659f
 prognosis for, 2660
 treatment of, 2659–2660
 Bronchiolitis, 2585–2588
 acute, 2585–2588, 2586f
 airway narrowing and, 558
 clinical manifestations of, 2587, 2587t
 diagnostic evaluation of, 2587
 differential diagnosis and etiologies of, 2585t
 prevention of, 2588
 prognosis for, 2588
 respiratory syncytial virus (RSV) and, 2028
 treatment of, 2587–2588
 Bronchiolitis obliterans, 2595, 2596f, 2596t, 2633, 2636f
 Bronchiolitis obliterans organizing pneumonia, 2595
 Bronchiolitis obliterans syndrome (BOS), 2595
 Bronchitis, 2588–2589
 acute, 2588–2589, 2588t
 chronic, 2589
 plastic, 2589–2590, 2589f, 2589t
 Bronchoalveolar lavage, 2522, 2524–2525, 2699
 analysis of, in chronic recurrent aspiration, 2611
 for anti-glomerular basement membrane disease, 2637
 for hypersensitivity pneumonia, 2615
 for interstitial lung disease, 2636
 Bronchobiliary fistula, 2603, 2603f
 Bronchodilator response, in asthma, 1391–1392, 1391t
 Bronchodilators
 for airway obstruction, 558
 for BPD, 1086
 for cystic fibrosis, 2675
 Bronchogenic cysts, 2602, 2602f
 Bronchomalacia, 2581–2582
 Bronchoprovocation challenges, in asthma, 1391–1392
 Bronchopulmonary aspergillosis, allergic, 1929, 2629–2630, 2629t, 2630f
 Bronchopulmonary dysplasia (BPD), 995, 1084–1087, 2711–2712
 anesthetic implications in, 666t
 clinical manifestations of, 1084, 1085f, 2711
 definitions of, 1085t–1086t, 2712t
 diagnosis of, 1084–1085
 etiology and pathophysiology of, 1084
 in genital mycoplasmas, 1892
 incidence of, 1084
 in infants, 1075
 prevention of, 1085–1086
 Bronchopulmonary dysplasia (BPD) (*Continued*)
 prognosis for, 1087, 2712
 RDS and, 1080
 treatment of, 1086–1087, 2712
 Bronchoscopy, 2524–2525
 in anti-glomerular basement membrane disease, 2637
 for EVALI, 2653
 rigid, showing thick tracheal membranes, 2572f
 of vascular rings, 2827t
 Bronchospasm, 672
 Bronze baby syndrome, 1115
 Brown recluse spider, 4470, 4470f
 Brown syndrome, 3930, 3930f
 Brown-Vialetto-Van Laere (BVVL) syndrome, 461, 3874
Brucella, 1807–1809
 clinical manifestations of, 1807–1808
 diagnosis of, 1808
 differential diagnosis of, 1808
 epidemiology of, 1807
 etiology of, 1807
 pathogenesis of, 1807
 prevention of, 1809
 prognosis for, 1809
 treatment of, 1808–1809, 1809t
Brucella abortus, 1807
Brucella canis, 1807
Brucella melitensis, 1807
Brucella suis, 1807
 Brucellosis, 1655t–1656t, 1807
 Brudzinski sign, in acute meningitis, 3761–3762
 Brugada syndrome, 594t–595t, 2770, 2861, 2863f
Brugia malayi, 2206
Brugia timori, 2206
 Bruises, 115
 Brushfield spots, 784t
 Bruxism, 246
 BTBGD. *See* Biotin-thiamine-responsive basal ganglia disease
 β -type (brain) natriuretic peptide (BNP), 2896
 Bubonic plague, 1794
 Buccal space infection, 2248t
 Buccal sulcus, 2248f
 Buccinator muscle, 2248f
 Buckle fracture, 4277, 4278f
 Budapest criteria, for complex regional pain syndrome, 695t
 Budd-Chiari syndrome, 2505
 Budesonide
 for allergic rhinitis, 1384t–1385t
 for asthma, 1402t
 for Crohn disease, 2321
 for eosinophilic gastroenteritis, 2326
 Budesonide/formoterol (Symbicort), for asthma, 1401t
 Buffers, 510
 Bulbar involvement, in Guillain-Barré syndrome, 3900
 Bulbar poliomyelitis, 1973
 Bulbus cordis, 2732–2733
 Bulimia nervosa, 268, 269t
 in athletes, 4323
 Bulk, in motor examination, 3554
 “Bull eye” maculopathy, inborn errors of metabolism and, 809t–810t
 Bullae, 4027
 Bullous congenital ichthyosiform erythroderma, 4116, 4116f
 Bullous emphysema, 2593, 2593f
 Bullous impetigo, 1707, 4150
 Bullous morphea, 1508t
 Bullous myringitis, 4002
 Bullous pemphigoid, 4085–4086
 Bullying, 22, 101, 283
 consequences of, 101
 epidemiology of, 101
 intervention protocol, 283
 risk factors for, 101
 roles and nomenclature of, 101
 screening for, 102, 103f–105f
 treatment and prevention of, 102
 victims of, 283
 Bumetanide, for heart failure, 2898t

Bundle branch block, 2752
 Bunion, 4208–4209
 Buphthalmos, 3934, 3969
 Buprenorphine, 712
 equianalgesic doses of, 685t
 for neonatal abstinence syndrome, 1133t
 Bupropion, 717
 for depression and anxiety, 226, 227t
 Buried penis, 3298, 3299f
Burkholderia cepacia complex, 1802–1803
Burkholderia mallei (glanders), 1802
Burkholderia pseudomallei (melioidosis), 1802–1803, 1802f
 Burkitt leukemia, 3097
 Burkitt lymphoma, 2344, 3113–3115
 endemic, 2009
 oncogenesis of, 3077
 treatment regimens and outcome by staging, 3110t
 Burns injuries, 646–657
 anesthetic implications in, 666t
 classification of burns, 648–649, 649f–650f, 649t
 death rate, 92t
 due to child abuse, 116, 118f
 electrical, 654–655, 656t
 emergency care for, 647–648, 647t–648t, 648f
 epidemiology of, 646–647
 estimation of total body surface area for, 649, 650f
 first aid measures, 647
 indications for admission, 647, 647t
 lightning burns in, 655–657
 prevention of, 646, 646t
 Pseudomonas aeruginosa infections in, 1799–1800
 treatment of, 649–654
 fluid resuscitation, 650–651
 inhalation injury, 653
 nutritional support, 652
 outpatient management, 649–650, 650t, 651f
 pain relief and psychologic adjustment, 653–654
 prevention of infection and surgical management, 651–652, 652t
 reconstruction and rehabilitation, 654
 school reentry and long-term outcome, 654, 655t
 topical therapy, 652–653, 652t
 Burners
 football associated with, 4327
 wrestling associated with, 4330
 Burning hands syndrome, 4319
 Burnout, 10
 Burr cells, in acanthocytes, 2966
 Burrows, 4173
 Bursitis, 4310
 Burst suppression, in status epilepticus, 3629
 Buruli ulcer, 1862, 1863f
 Buschke-Ollendorff syndrome, 4066
 Bush-Francis Catatonia Rating Scale, 292–293
 Butane, inhaled, 1203t
 Butorphanol, equianalgesic doses of, 685t
 Butterbur, for migraine, 3646t–3647t
 Button battery
 in esophagus, 2273, 2274f
 ingestion, 2302–2303
 BWS. *See* Beckwith-Wiedemann syndrome
 Bypass strategies, for neurodevelopmental dysfunctions, 307

C

C1 esterase, 1315
 C1 inhibitor (C1-INH), 1316
 C1-INH deficiency, 1318, 1320
 acquired, 1321
 HAE with, treatment of, 1323, 1323t
 C1q deficiency, 1318
 C1r deficiency, 1318
 C1s deficiency, 1318
 C2 deficiency, 1319
 C3 cleavage, 1316
 C3 convertase, 1316
 C3 deficiency, 1319
 C3 glomerulonephritis (C3GN), 3194
 C3 receptors, 1317
 C3a, 1317

C3b, 1316
 C4 deficiency, 1319
 C4a, 1317
 C4-binding protein (C4-bp), 1316–1317
 deficiency of, 1321
 C5 deficiency, 1319–1320
 C5a, 1317
 C5b-9 complement complex, 1318
 C6 deficiency, 1319–1320
 C7 deficiency, 1319–1320
 C8 binding protein, in paroxysmal nocturnal hemoglobinuria, 2964
 C8 deficiency, 1319–1320
 C9 deficiency, 1319–1320
 Cabotegravir, for HIV, 2098t–2107t
 Cachexia, in pediatric palliative care, 69t
 CAD deficiency, 952–953
 CADASIL. *See* Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
 Cadmium, food-borne illness, 2362t–2364t, 4411t–4413t
 Café-au-lait macules, 4067–4068, 4068f, 4070t–4071t
 in neurofibromatosis type 1, 3652–3654, 3654f
 Caffeine
 for apnea, 1076
 as performance-enhancing aids, 4325
 Caffey disease, 4357–4358, 4358f
 CAH. *See* Congenital adrenal hyperplasia
 CAIS. *See* Complete androgen insensitivity syndrome
 Calabar swellings, 2207, 2208f
 Calcaneal apophysitis, 4208, 4300f, 4313
 Calcaneal stress fracture, 4313
 Calcaneovalgus foot, 4202, 4202f
 Calcaneovalgus foot, lateral tibial torsion associated with, 4214
 Calcification(s)
 arterial, caused by deficiency of CD73, 2908
 in Fabry disease, 3887
 generalized arterial calcification of infancy, 2908
 in JDM, 1503f
 subependymal, 3658f
 Calcineurin inhibitors
 in maintenance immunosuppression, 3256
 for nephrotic syndrome, 3230
 topical, 4040
 Calcinoses, in JDM, 1504
 Calcitonin, 3433–3434
 Calcitriol, produced by sarcoid macrophage, 1549
 Calcium
 conversion factor, 503t
 deficiency, rickets caused by, 473t, 476–477
 dietary reference intake, 396, 404t–407t
 excessive, hypercalcemia and, 3442t
 glucocorticoid effects, 3448
 homeostasis, 4378
 ionized, reference intervals, 4472.e9t
 reference intervals, 4472.e9t
 total, reference intervals, 4472.e9t
 tubular reabsorption of, 3233
 in vegetarian diets, 418
 Calcium channel blockers
 for hypertension, 2918t
 for migraine, 3646t–3647t
 poisoning, 701t, 707t–708t, 713–714
 Calcium channel periodic paralysis, 3840t
 Calcium chloride (10%), for pediatric resuscitation and arrhythmias, 563t
 Calcium disodium EDTA, 707t–708t
 Calcium gluconate, for pediatric resuscitation and arrhythmias, 563t
 Calcium homeostasis, 3433–3434, 3434f
 Calcium salts, 707t–708t
 Calcium stones, 3312t
 Calculi
 bladder, complication of augmentation cystoplasty, 3290
 renal, pathogenesis of, 3313–3315
 Caliciviruses, 2050–2053
 clinical manifestations of, 2051–2052
 diagnosis of, 2052
 differential diagnosis of, 2052
 epidemiology of, 2051

Caliciviruses (*Continued*)
 etiology of, 2050–2051
 laboratory findings of, 2052
 pathogenesis of, 2051
 prevention of, 2052–2053
 prognosis for, 2052
 treatment of, 2052
 vaccines for, 2052–2053
 Callus, 4276
 CALMs. *See* Café-au-lait macules
 Caloric testing, 3554
 Calorie boosters, for oral and enteral feeding, 437t
 Calretinin, 2296
 Calyceal dilation, 3275
 Calyceal diverticulum, 3262
 Camelback fever, 1640–1641
 Camphor, toxicity, 701t
 Campomelic dysplasia, 4349, 4349f
 Campomelic syndrome, 3509
 Campodactyly, 784t, 4268, 4268t
Campylobacter, 1788
 in acute gastroenteritis, 1790
 antibiotic therapy for, 2373t–2375t
 associated with human disease, 1789t
 in bacteremia, 1790
 clinical manifestations of, 1789–1790
 complications of, 1791
 Guillain-Barré syndrome, 1791
 reactive arthritis, 1791
 diagnosis of, 1790
 epidemiology of, 1788–1789
 etiology of, 1788
 in focal extraintestinal infections, 1790
 Guillain-Barré syndrome and, 3904
 pathogenesis of, 1789
 in perinatal infections, 1790
 prevention for, 1791
 prognosis for, 1791
 treatment of, 1791
Campylobacter coli, 1788
Campylobacter jejuni, 1788
 bacterial gastroenteritis and, 2357t–2358t
 CAMT. *See* Congenital amegakaryocytic thrombocytopenia
 Canagliflozin, for T2DM, 3542t
 Canakinumab, for amyloidosis, 1537
 Canal of Nuck. *See* Processus vaginalis
 Canale-Smith syndrome, 1331
 Canavan disease, 857–858, 858f
 Canavan spongy degeneration, 3717
 Cancer
 Candida infections in immunocompromised patient, 1924
 epidemiology of, 3073–3076, 3073f–3074f, 3074t–3076t
 excess, lifetime risks of excess, 4416, 4416f
 fertility and, 3338–3340
 molecular and cellular biology of, 2204–2206
 genes involved in oncogenesis of, 3077, 3078t
 oncogenesis, factors associated with, 3080–3081
 syndromes predisposing to, 3077–3080, 3078t–3080t
 principles of diagnosis, 3081–3084
 age-related manifestations of, 3083f, 3084
 early detection of, 3084
 ensuring diagnosis, 3084, 3085f, 3085t
 physical examination in, 3081–3084, 3083f
 signs and symptoms of, 3081
 staging, 3084, 3085t
 principles of treatment, 3086–3096, 3087f
 acute toxic effects and supportive care of, 3091–3093, 3092t–3093t
 amenorrhea and, 3339t
 chemotherapy as, 3088, 3088f, 3089t–3091t, 3090f
 diagnosis and staging of, 3086
 discussing the treatment plan with the patient and family, 3087–3088
 immunotherapy as, 3088–3091, 3092f
 late effects of, 3093–3096, 3096f
 multimodal, multidisciplinary approach of, 3086–3087, 3087f–3088f, 3088t
 oncologic emergencies in, 3092t–3093t
 palliative care of, 3096

- Cancer (*Continued*)

pharmacogenomics as, 3088, 3091f

radiation therapy as, 3091

surgery as, 3091

secondary

after HSCT, 1365

relationship with primary cancer, 4419t

Candida albicans, 2252

Candida infection, 1921–1924, 4164–4166, 4165t

causing infective esophagitis, 2269–2271

in diaper dermatitis, 4088

in immunocompetent children and adolescents, 1922–1923

in immunocompromised children and adolescents, 1923–1924, 1924t

maternal, affecting fetus or newborn, 1013t

neonatal, 1921–1922, 1923t

Candidal diaper dermatitis, 4164–4166, 4166f

Candidal granuloma, 4166

Candidal onychomycosis, 4146

Candidiasis
 - chronic mucocutaneous, 1924
 - congenital cutaneous, 4164
 - inhaled corticosteroids and, 1400–1401
 - intertriginous, 4166, 4166f
 - oral, 4164
 - oropharyngeal, 2252
 - perianal, 4166
 - vaginal, 4164
 - vulvovaginal, 1242
Canine scabies, 4175

Canine space infection, 2248t

Canker sores, 2252, 4147–4148, 4148f

Cannabinoid hyperemesis syndrome (CHS), 1202, 1202t, 2396

Cannabinoids, synthetic, toxidrome, 704t

Cannabis, 58

adverse effects, 1202t

in pediatric palliative care, 71

Cannabis hyperemesis syndrome, 2227

Canonical babbling, 156

Cantu syndrome, 2764t–2766t

Cao gio, 116

CAPD. *See* Cornell Assessment of Pediatric Delirium

Capillariasis, drugs for, 2126t–2144t

Capillaritis, pulmonary, 2688

Capillary hemangioma, 3936, 3936f

Capillary malformation, 4050–4051, 4051f

Capillary malformation–arteriovenous malformation syndrome (CM–AVM), 788t, 3160, 4060, 4060f

Capillary permeability, increased, 2604t, 2605

Caplacizumab, for thrombotic thrombocytopenic purpura, 3055

Capnography, volumetric, 616

CAPS. *See* Cryopyrin-associated periodic syndrome

Capsaicin, for erythromelalgia, 699

CAPTA. *See* Child Abuse Prevention and Treatment Act of 1984

Captopril, for heart failure, 2898t

Caput succedaneum, 1001, 1056

Car safety seats, 96f

CARASIL. *See* Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy

Carbamates, 719

Carbamazepine
 - adverse effects of, 3611t
 - dosages of, 3609t–3610t
Carbamoyl phosphate synthetase 1 deficiency, 851

Carbapenems, 1458, 1686–1687

Carbohydrate, 389t–390t, 394, 395f

absorption, disorders of, 2349

digestion, 2277

malabsorption, 2333t, 2347

chronic diarrhea and, 2378

metabolism, 2436

defects in, 898–930, 899f, 900t–901t

affecting liver, 2455t

congenital disorders of glycosylation, 921–930, 922f, 927t

fructose, 912–913

galactose, 910–912

glycogen storage disease, 898–910

Carbohydrate (*Continued*)

glycoprotein degradation and structure, 920–921

intermediary, associated with lactic acidosis, 913–919, 913f–914f, 914t

pentose, 919–920

Carbohydrate loading, in acute porphyria, 969–970

Carbohydrate ratio, 3528

Carbon dioxide (CO₂)

elimination of, in RDS, 1081

reference intervals, 4472.e9t

Carbon monoxide
 - diffusing capacity of, 2522
 - poisoning, 653, 707t–708t, 722–724
 - reference intervals, 4472.e9t
Carbonated soda, for phytobezoars, 2304

Carboplatin, indications and adverse reactions of, 3089t–3090t

γ-Carboxyglutamate (Gla), 481

Carboxyhemoglobin, in respiratory distress and failure, 616

Carboxylase deficiencies, multiple, 828

Carbuncle, 4156

Carcinogenesis, radiation, 4415

Carcinoid syndrome, 2414

Carcinoid tumor, 2383

of digestive tract, 2414

Carcinoma
 - of digestive tract, 2412t, 2413–2414
 - of exocrine pancreas, 2433
 - nasopharyngeal, Epstein–Barr virus (EBV), 2008–2009
 - thyroid, 3422–3424

clinical manifestations of, 3423

diagnosis of, 3423

medullary, 3423

pathogenesis of, 3422

prognosis of, 3423

treatment of, 3423
Card agglutination trypanosomiasis test (CATT), 2162

CARD9 deficiency, 1335

Cardiac allograft vasculopathy, 2905

Cardiac anomalies, 2577

Cardiac arrest, 564–568

advanced life support for, 565, 566f

basic life support for, 553f–554f, 564

cardiopulmonary resuscitation for, 564–565, 564f–565f

causes of, identification and treatment of, 565, 567t

defibrillation and antiarrhythmic medications for, 563t, 565, 566f

extracorporeal membrane oxygenation for, 566–568

overview of, 564

post–cardiac arrest care, 568, 568t

prevention of, 564

recognition of, 564

Cardiac arrhythmia, periodic paralysis with, 3840t

Cardiac assessment, in neuromuscular disorders, 3799, 3804t

Cardiac asystoles, in CCHS, 2720

Cardiac care, 3834

Cardiac catheterization, 2758–2762

diagnostic, 2759–2761

interventional, 2761–2762

Cardiac chambers, 2747f

enlargement of, 2747

Cardiac cycle, 2746f

Cardiac defects, 1035, 1036f

in Turner syndrome, 3497

Cardiac development, 2731–2734

Cardiac differentiation, 2733–2734

Cardiac disease
 - anxiety disorders and, 247t–248t
 - leading to cyanosis, 2799
 - liver disease and, 2477
 - medications for, 230
 - preventive monitoring of thalassemia, 2986
Cardiac drugs, neuropathy associated with, 3893t–3894t

Cardiac fibrosis, 1509

Cardiac function, developmental changes in, 2733–2734

Cardiac glycoside-containing plants, 722t

Cardiac imaging studies, 2758

Cardiac involvement
 - of mumps, 1971
 - in myotonic muscular dystrophy, 3836
Cardiac looping, 2731–2732

Cardiac magnetic resonance imaging (CMR), 2896

Cardiac manifestations
 - of Kawasaki disease, 1543
 - of systemic diseases, 2741t–2742t
 - of tuberous sclerosis, 3658f
Cardiac morphogenesis, 2731, 2732f

Cardiac output, thermodilution measurement of, 2761

Cardiac pacing, 2859

Cardiac progenitor zone, 2731

Cardiac septation, 2732–2733

Cardiac symptoms, BRUE and, 2543t

Cardiac syncope, 3632–3633

Cardiac tamponade, cardiac arrest and, 567t

Cardinal positions, 3910

Cardiocerebral channelopathies, 3616

Cardioembolic stroke, 3745

Cardiofaciocutaneous syndrome, 788t, 2764t–2766t, 4070t–4071t

Cardiogenic edema, pulmonary, 2605t

Cardiogenic shock, 560, 600, 601t, 602f, 2900–2901

clinical manifestations of, 605

management for, 610

pathophysiology of, 601

treatment of, 2901t

Cardiolipin, 829

Cardiomegaly, in infants of diabetic mothers, 1141

Cardiomyopathy, 2880t, 4295

arrhythmogenic right ventricular, 2879t, 2887

in Chagas disease, 2167

chemotherapy and, 3088

in CKD, 3250t

dilated, 2876–2882

in Duchenne muscular dystrophy, 3831

due to HSCT, 1365

endocardial fibroelastosis, 2887–2888

eiology of, 2879t

gene variants in, 2770

genetics of, 2771t

hypertrophic, 2884–2885

left ventricular noncompaction, 2887–2888, 2888f

metabolic disorders associated with, 808t

mitochondrial DNA abnormalities associated with, 2883t

nuclear DNA abnormalities associated with, 2882t

right ventricular, 2881f, 2887–2888

sudden death and, 2861

in syncope, 594t–595t, 596

Takotsubo, 2888

toxic, diphtheria, 1727

Cardiopulmonary arrests (CPAs), 47t

Cardiopulmonary interactions, in mechanical ventilation, 628

Cardiopulmonary resuscitation (CPR), 52

components of, 564–565, 564f–565f

duration of, 565–566

Cardiorespiratory management, of drowning victims, 642

Cardiorespiratory reflexes, 667

Cardiovascular complications, 674

Cardiovascular disease
 - addressed prior to renal transplantation, 3255
 - associated with prematurity, 1046t
 - epidemiology of, 871–872
 - manifesting as respiratory distress, 612–613, 614t
 - obesity-associated comorbidities, 444t
 - in progeria, 959
Cardiovascular Health Integrated Lifestyle Diet-1 (CHILD-1), 882

Cardiovascular Health Integrated Lifestyle Diet-2 (CHILD-2), 882

Cardiovascular medications, poisoning, 713–715

Cardiovascular symptoms, in newborn, 1148

Cardiovascular system
 - arsenic effects in, 4432t
 - in childhood lupus, 1497t
 - evaluation of, history and physical examination, 2737–2746
 - morbidity of perinatal and neonatal illness, 998t
 - shock in, 607t
 - SLE in, 1492t

- Cardiovascular/CNS syndrome, 4419
 Carditis, in rheumatic fever, 1712–1713
 Care coordination, 7
 for adult, 1171
Caring for Our Children, 183
 Carmustine, indications and adverse reactions of, 3089t–3090t
 Carney complex, 3379, 3473t, 3476, 4067
 Carnitine cycle, defects in, 864
 Carnitine palmitoyltransferase-IA deficiency, 864
 Carnitine palmitoyltransferase-II deficiency, 864
 Carnitine:acylcarnitine translocase deficiency, 864
 Caroli disease, 2500–2501
 β-Carotene, structure of, 451f
 Carotenodermia, 455
 Carotid arteries, dilation, in Takayasu arteritis, 1559f
 Carpenter syndrome, 794t–795t, 2764t–2766t
 Carrier testing, 729
 in spinal muscular atrophies, 3871
 Carriers
 asymptomatic, for diphtheria, 1728
 chronic GAS, 2561
 Carrion disease, 1814
 CAR-T cells. *See* Chimeric antigen receptor T cells
 Cartilage abnormalities, arthritis or extremity pain caused by, 1479t
 Cartilage matrix proteins, disorders involving, 4340–4344
 Kniest dysplasia, 4340–4341, 4341f
 lethal spondyloepiphyseal dysplasias, 4340
 mild spondyloepiphyseal dysplasia with premature onset arthrosis, 4341
 pseudoachondroplasia and multiple epiphyseal dysplasia, 4341–4343, 4343f–4344f
 Schmid metaphyseal dysplasia, 4343–4344, 4344f
 spondyloepiphyseal dysplasia congenita, 4340, 4342f
 Stickler syndrome/dysplasia, 4341, 4341t, 4343f
 type 2 collagenopathies, 4340
 Cartilage-hair hypoplasia, 1274, 1274f, 1309t, 3010, 4355–4356, 4356f
 Carvedilol, for heart failure, 2898t
 CAS. *See* Childhood apraxia of speech
 Casal neck, 462, 462f
 Casal's necklace, 4191
 Cascara, 2492t
 Case contacts, asymptomatic, for diphtheria, 1728
 Cash transfers, conditional and unconditional, 32, 34f
 Caspase-8 deficiency state (CEDS), 1332t–1333t
 Caspofungin, 1917t, 1920
 Cast syndrome, 2299
 Cast ulcers, 4284
 Castleman disease, 3072, 3072f
 Cat bites, 4457, 4458t
 Cat roundworm, 2209
 Catapres. *See* Clonidine
 Cataracts, 3949–3951, 3949f
 chromosomal defects, 3950
 congenital infection syndrome in, 3949
 in congenital rubella syndrome, 1968f
 developmental variants of, 3949
 differential diagnosis of, 3949, 3950t, 3951f
 drugs, toxic agents, and trauma, 3950, 3951f
 formation, radiation and, 4419
 inborn errors of metabolism and, 809t–810t
 mendelian inheritance, 3949
 metabolic disorders, 3949
 miscellaneous disorders, 3951
 in myotonic muscular dystrophy, 3836
 in prematurity, 3949
 prognosis of, 3951
 treatment of, 3951
 Catarrhal stage of pertussis, 1762
 Catatonia, 379
 in children and adolescents, 291–292, 292t–293t, 294f
 differential diagnosis of, 297t, 298
 Down syndrome and, 373
 CATCH 22, 2803
 Catch-up growth, 176
 Catecholamine synthesis, 3449
 Category I tracings, 1017–1019
 Category II tracings, 1017–1019
 Cathartics, 709
 Cathepsin C gene, 4119
 Catheter angiography, in neuroradiologic procedures, 3560
 Catheter-associated urinary tract infections, 45t
 Catheterization, cardiac, 2758–2762
 diagnostic, 2759–2761
 interventional, 2761–2762
 Catheters
 bloodstream infection, 1667–1668
 Candida infections associated with, 1924
 central venous, coagulase-negative staphylococci, 1700
 nontuberculous mycobacterial infections associated with, 1861t, 1863
 peritoneal dialysis, 1670
 prevention of infection, 1668
 skin and soft tissue infection associated with, 1667
 types, 1667
 urinary, 1668–1669
 Cathinones, toxidrome, 704t
 Cations, in ICF
 and ECF, 486
 and plasma, 486f
 Cat-scratch disease (*Bartonella henselae*), 1812–1814, 1812t
 clinical manifestations of, 1813–1814, 1813f
 complications of, 1814
 diagnosis of, 1814
 differential diagnosis of, 1814
 epidemiology of, 1812
 etiology of, 1812
 laboratory findings of, 1814
 pathogenesis of, 1812
 prevention of, 1814
 prognosis for, 1814
 treatment of, 1814
 Cat's-eye reflex, 3924
 CATT. *See* Card agglutination trypanosomiasis test
 Caudal dysplasia sequence, in infants of diabetic mothers, 1141f
 Caudal regression syndrome, 2405
 Caustics, 701t
 ingestions, 2273–2275, 2275t–2276t, 2276f
 Cavernomas, 3750
 Cavernous sinus thrombosis, 3973t
 Cavopulmonary isolation procedure, 2807–2808
 Cavus feet, 4207–4208, 4208f
 CBCT. *See* Cone beam computed tomography
 CBR. *See* Community-based rehabilitation
 CBT. *See* Cognitive-behavioral therapy
 CCA. *See* Congenital contractual arachnodactyly
 CCHS. *See* Congenital central hypoventilation syndrome
 CCLA. *See* Central conducting lymphatic anomaly
 CCSK. *See* Clear cell sarcoma
 CD36 deficiencies, 1263t
 CD3ε deficiencies, 1263t
 CD3ζ deficiencies, 1263t
 CD4+CD25+ Tregs, 1369–1370
 CD8 deficiency, 1273
 CD16 deficiency, 1288, 1289f, 1339t
 CD40 ligand deficiency, 1272
 CD45 deficiency, 1263t
 CD46/MCP deficiency, 1320
 CD59 deficiency, 1321–1322
 CD107a degranulation, 1289
 CDC. *See* Centers for Disease Control and Prevention
 CDD. *See* Congenital diarrheal disorders
 CDG-IIC. *See* Congenital disorder of glycosylation IIC
 "C-E" grip, in bag-mask ventilation, 559, 559f
 CEDS. *See* Caspase-8 deficiency state
 Cefadroxil, 1675t–1685t
 Cefazolin, 1675t–1685t
 for osteomyelitis, 4289
 Cefdinir, 1675t–1685t
 Cefepime, 1675t–1685t
 Cefixime, 1675t–1685t
 Cefoperazone sodium, 1675t–1685t
 Cefotaxime sodium, 1675t–1685t
 Cefotetan disodium, 1675t–1685t
 Cefoxitin, against nontuberculous mycobacteria, 1834–1835, 1834t
 Cefoxitin sodium, 1675t–1685t
 Cefpodoxime proxetil, 1675t–1685t
 Cefprozil, 1675t–1685t
 Ceftaroline, 1724
 for *Staphylococcus aureus*, 1697
 Ceftaroline fosamil, 1675t–1685t
 Ceftazidime, 1675t–1685t
 Ceftizoxime, 1675t–1685t
 Ceftriaxone
 for Lyme disease, 1885t
 for *Shigella*, 1779
 Ceftriaxone sodium, 1675t–1685t
 Cefuroxime, 1675t–1685t
 for bite wound, 4459t
 Cefuroxime axetil, for Lyme disease, 1885t
 Celecoxib, in pain management, 681t
 Celexa. *See* Citalopram
 Celiac disease, 2327–2331, 3549
 chronic diarrhea and, 2327–2328, 2377
 clinical presentation and associated disorders, 2327–2329, 2327f, 2328t–2329t
 clinical spectrum of, 2329
 diagnosis of, 2329, 2330f, 2330t
 diagnostic algorithm for, 2330f
 dietary therapy for, 2330t
 etiology and epidemiology of, 2327
 genetics and pathogenesis of, 2327
 liver disease and, 2476–2477
 non-celiac gluten sensitivity and, 2331
 nonresponsive, diagnostic algorithm for, 2331f
 pulmonary hemosiderosis and, 2690
 spectrum of gluten-related disorders in, 2331
 testing for, indications for, 2329t
 treatment for, 2329–2330, 2330t–2331t, 2331f
 Celiac plexus block, in pain management, 695
 Celiprolol, for vascular EDS, 4371–4372
 Cell death, 4415
 β-cell function
 genetic defects of, 3542–3546
 progressive loss of, preclinical autoimmunity with, 3520–3521, 3521f–3522f
 Cell membrane-associated protein, 1316–1317
 Cell motility disorders, 1297t–1298t
 Cell-mediated immunity, in tuberculosis, 1839–1840
 Cellular innate defense systems, 1144f
 Cellulitis, 4151–4152, 4151t
 Aeromonas, 1796–1797
 Haemophilus influenzae in, 1757
 orbital, 3940t, 3973t, 3974–3975, 3975f
 periocular, 2556, 3940t
 peritonsillar, and abscess, 2567–2568
 preseptal, 3940t, 3973–3974, 3974f
 Cementum, 2247f
 Center for Epidemiological Studies Depression Scale for Children (CES-DC), 218t
 Center-based fitness program, for children with disabilities, 4406t
 Center-edge angle of Wilberg, 4235, 4235f
 Centers for Disease Control and Prevention (CDC), 2211, 4446
 Time-Out Steps, 145t
 Centers of ossification, radiographic appearance of, 155t
 Central α-agonists, for hypertension, 2918t
 Central apnea, 1075
 BRUE and, 2541
 Central auditory processing disorders, 3983–3984
 Central conducting lymphatic anomaly, 3065, 3066f, 3151, 3161f
 Central cord lesion, 579
 Central cord syndrome, 3787
 Central core disease, 3813, 3813f–3814f, 3814t, 3849t
 Central cyanosis, in newborn, 1053
 Central diabetes insipidus, 490, 3239, 3373–3374, 3375t
 Central giant cell granuloma, 2254
 Central hearing loss, 3983–3984
 Central (hypopituitary) hypothyroidism, 3403t, 3404t
 thyrotropin deficiency, 3404
 Central line-associated bloodstream infections, 45t
 Central nervous system (CNS)
 abnormalities
 cancer and, 3082
 in pertussis, 1764
 blastomycosis, 1935

Central nervous system (CNS) (Continued)

causing SIDS, 2533t
childhood lupus in, 1497t
congenital anomalies, 3561–3583
anencephaly, 3565–3566, 3566f
cortical development, malformations of, 3566–3569, 3567t, 3568f
craniostenosis, 3582–3583, 3582t–3583t
dysgenesis of cranial nerves and posterior fossa, 3575–3577
encephalocoele, 3564–3565, 3565f
hydrocephalus, 3577–3582
causes of, 3578t
clinical manifestations of, 3579–3580
diagnosis and differential diagnosis of, 3580, 3580f
genetic abnormalities associated with, 3579t
hydranencephaly in, 3581, 3581f
pathophysiology and etiology of, 3579, 3579f
physiology of, 3577–3579
porencephaly in, 3581, 3581f
prognosis for, 3582
treatment of, 3582
midline defects, disorders with, 3569–3573
myelomeningocele, 3561–3563
clinical manifestations of, 3562, 3563f
etiology of, 3561
prevention of, 3561–3562
prognosis for, 3563
treatment of, 3562–3563
neural tube defects, 3561, 3562f
occult spinal dysraphism, 3563–3564, 3564f–3565f, 3565t
demyelinating disorders of, 3722–3741, 3723t–3724t
acute disseminated encephalomyelitis, 3722–3725, 3723t–3724t, 3725f, 3726t
multiple sclerosis, 3723t, 3726t, 3731–3733, 3732f, 3732t, 3734t–3737t
myelin oligodendrocyte glycoprotein-associated disorders, 3723t, 3726f, 3733–3738, 3739f
neuromyelitis optica spectrum disorders, 3723t, 3738–3741, 3740f, 3741t
optic neuritis, 3725–3727, 3726f
transverse myelitis, 3727–3731, 3727t–3728t, 3729f, 3730t, 3731f
depression, after use of inhalants, 1203t
glucocorticoid effects, 3448
HIV and, 2092
morbidity, of perinatal and neonatal illness, 998t
primary angitis of, 1565, 1565t–1566t
shock in, 607t
toxoplasmosis in, 2191–2192, 2192f
Central nervous system disorders, 1056
cerebrospinal fluid findings in, 3759t–3760t
cranium, 1056–1057
hypoxic-ischemic encephalopathy, 1062–1068
intraventricular hemorrhage and periventricular leukomalacia, 1058
Mycoplasma pneumoniae and, 1888–1889
neonatal traumatic head injuries, 1057–1058
peripheral nerve injuries, 1068–1069
in premature infants, 1046t
respiratory signs and symptoms, 2531t
respiratory tract complication, 2531t
spine and spinal cord, 1068
tuberculosis in, 1843–1845, 1844f–1845f
Central nervous system imaging, in neuromuscular disorders, 3794
Central nervous system infections, 1800t, 3758–3779
acute bacterial meningitis, beyond the neonatal period, 3758–3772
Aspergillus, 1931
brain abscess, 1828
eosinophilic meningitis, 3776–3779
in genital mycoplasmas, 1892
herpes simplex virus (HSV), 1995, 1998
Rickettsia rickettsii, 1904
viral meningoencephalitis, 3772–3776
Central nervous system tumors, in childhood, 3116–3125
astrocytoma, 3119–3120, 3119f–3120f
atypical teratoid/rhabdoid, 3124
of brainstem, 3124–3125, 3125f

Central nervous system tumors, in childhood (Continued)
choroid plexus, 3121
complications and long-term management of, 3125
craniopharyngioma, 3124
diagnosis of, 3118–3119, 3118f
embryonal, 3121–3124, 3122f–3123f
ependymal, 3120–3121, 3121f
epidemiology of, 3116
etiology of, 3116, 3117t
germ cell, 3124
histology of, 3117f
metastatic, 3125
optic pathway, 3117–3118
pathogenesis of, 3116, 3117f, 3118t
pineal parenchymal, 3124
posterior fossa, 3118t
specific, 3119–3125
spinal cord, 3117–3118
supratentorial primitive neuroectodermal, 3124
Central nervous system vasculitis, 3754–3757, 3755f
clinical manifestations of, 3755
diagnosis of, 3755–3756, 3756t–3757t, 3757f
epidemiology of, 3755
prognosis of, 3755
secondary, causes of, 3755t
treatment of, 3756–3757
Central neurogenic hyperventilation, as respiratory distress, 612–613
Central neurologic disease, in congenital muscular dystrophy, 3844
Central pontine myelinolysis, 490, 494, 531
Central precocious puberty, 3386–3390
clinical manifestations of, 3386–3387
differential diagnosis of, 3388–3389
laboratory findings of, 3387–3388
treatment of, 3389–3390
Central venous catheter infection, coagulase-negative staphylococci, 1700
Centrally mediated pain, 677
Centromere, 761–762, 762f
Centruroides exilicauda, 4471
Centruroides vittatus, 4471
Century Cures Act, 54
Cephalexin, 1675t–1685t
for *Staphylococcus aureus*, 1697
Cephalic index in deformational plagiocephaly, 3586
Cephalic tetanus, 1822
Cephalohematoma, 1001, 1056–1057, 1057f
Cephalometric radiographs, 2255
Cephalosporins, 1674–1686
adverse effects of, 1687t
for bacterial meningitis, 3769
parenteral and oral, 1686t
Cephalostat, 2255
Cephadrine, 1675t–1685t
Cerebellar ataxia
acute encephalitis, 3772
in varicella, 2002
Cerebellar disorders, 3576–3577, 3577f–3578f
Cerebellar fits, 3637
Cerebellar hypoplasia, 3818
Cerebellar mutism syndrome, language disorders and, 330
Cerebral angiography, for brain death, 591t
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 1566
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), 1566
Cerebral blood flow (CBF), for brain death, 592
Cerebral edema, 531
complication of hepatic encephalopathy, 2498–2499
drowning and, 639
high-altitude (HACE), 631, 633–634
in T1DM, 3527
Cerebral epidural abscess, CSF findings in, 3759t–3760t
Cerebral folate deficiency, 464, 3603, 3622
Cerebral gigantism, 3383–3384, 3383f
in megalencephaly, 3580
Cerebral glucopenia, 981t
Cerebral hemisphere, atrophy of, 3661f

Cerebral herniation, 581, 582f
Cerebral necrosis, 4418
Cerebral palsy, 3688–3695
AAC and, 338
associated with neuropathic bladder, 3291
benzodiazepines and, 4394
clinical manifestations of, 3689–3691, 3690t, 3691f
diagnosis of, 3691, 3692f, 3692t–3693t, 3694f
epidemiology and etiology of, 3688–3689, 3689f
treatment of, 3691–3695, 3695f
Cerebral salt wasting, 3376
treatment of, 3376–3378
Cerebral sinovenous thrombosis (CSVT), 3040, 3747–3749, 3748t, 3749f
Cerebral thromboses, tetralogy of Fallot and, 2802
Cerebral vasculitis, in arterial ischemic stroke, 3746t
Cerebral venous thrombosis, 2972
Cerebral ventricles, dilated in fetus, 1026t
Cerebrohepatorenal disease, 3854
Cerebro-ocular dysplasia-muscular dystrophy, 928
Cerebrospinal fluid (CSF)
in CNS infection, 3758, 3759t–3760t
in fever without a focus, 1644–1645, 1645t
in neurologic evaluation, 3557–3558
shunts
associated infection, 1669–1670
coagulase-negative staphylococci, 1700
Cerebrotendinous xanthomatosis (CTX), 881, 2341, 3949
Cerebrovascular arteriopathy, in progeria, 959
Ceroid lipofuscinoses, infantile, 887t
Cerumen, 3981, 3999
Cervical adenopathy, in lymphadenopathy, 3069
Cervical cap, 1227
Cervical cord neurapraxia, 4319
Cervical cytology, terminology for reporting, 2054t
Cervical ectopy, 1240f
Cervical fractures, 4319
Cervical lymphadenitis, in Kawasaki disease, 1544–1545
Cervical lymphadenopathy, 3070t
diphtheritic, 1726f
Cervical malignancies, 3346–3347
Cervical spine injuries, 4318–4320
burning hands syndrome, 4319
cervical fractures, 4319
congenital spinal stenosis, 4320
soft tissue injury, 4318
spear tackler's spine, 4318–4319
spinal cord injury, 4320
stingers, 4319
transient quadriplegia, 4319–4320, 4319t
Cervicitis, 1242
Cervicofacial actinomycosis, 1733f–1734f, 1734
Cervix
cancer screening, 3347
inflamed, 1242f
screening, in transgender, 1180t
CES. See Congenital esophageal stenosis
Cesarean section, problems associated with, 1014
CES-DC. See Center for Epidemiological Studies Depression Scale for Children
Cetirizine, for allergic rhinitis, 1383t
Cetuximab, 3088t
CFRD. See Cystic fibrosis-related diabetes
CFS. See Chronic fatigue syndrome
CFTR. See Cystic fibrosis transmembrane conductance regulator
CGD. See Chronic granulomatous disease
CGL. See Congenital generalized lipodystrophy
CGMs. See Continuous glucose monitoring systems
CH50, 1317–1318
Chagas disease, 2163–2168
Chagoma, 2166
Chalazion, 3936
Chambers
developmental processes for, 2733–2734
transcription factors, specific for, 2731
Chamomile, 56t
Chancroid, 1759
clinical manifestations of, 1759
complications of, 1759
diagnosis of, 1759
etiology and epidemiology of, 1759

Chancroid (*Continued*)
 signs and symptoms, 1243t
 treatment of, 1759

Channelopathies, 3754, 3848–3856
 with hypokalemic periodic paralysis, 3840t
 muscle, 3849t, 3850

Chaotic or multifocal atrial tachycardia, 2852

Chaparral leaf, 2492t

Char syndrome, 2764t–2766t

Charcot-Marie-Tooth disease, HSMN type IIa, 3876–3886, 3877t–3879t

CHARGE syndrome, 2545, 2739t–2740t, 2764t–2766t, 3987t

Charles Bonnet syndrome, 3638

Chaso/onshid, 2492t

CHD. *See* Congenital heart disease

Checking, lacrosse and, 4329

Chédiak-Higashi syndrome (CHS), 819, 1297t–1298t, 1301, 1309t, 1310, 3059–3060, 4072

Cheerleading, injuries associated with, 4331

Cheilitis, 2253

Cheilosis, riboflavin deficiency and, 461, 461f

Chelation therapy
 for acute arsenic and mercury poisoning, 4435
 for arsenic and mercury intoxication, 4435
 for lead poisoning, 4440, 4441t
 for thalassemia, 2983–2984, 2985t
 for Wilson disease, 2458

Chemical conjunctivitis, 3942

Chemical hepatotoxicity, 2490

Chemical injury, burn in, 647

Chemical pollutants, 4422–4430
 asbestos, 4425
 effects of, 4423t
 endocrine disruptors, 4426
 environmental carcinogens, 4426–4427
 lead, 4424
 mercury, 4424
 pesticides, 4425–4426
 physician's role in, 4427
 routes of exposure of, 4426–4427
 secondhand smoke, 4427–4428
 synthetic chemicals, 4424
 human health and, 4422–4427
 safety testing of, 4423–4424
 susceptibility to, 4423

thirdhand smoke, 4428

tobacco, 4427–4430

unconventional natural gas development (fracking), 4424–4427

Chemical Threat Risk Assessment, 4446

Chemical weapons, 108

Chemicals
 in abused inhalants, 1203t
 low molecular weight, 2619t

Chemokines, 1286–1287, 1372

Chemoprophylaxis
 group B *Streptococcus*, 1718–1720, 1719t, 1720f
 for influenza, 2024t, 2025–2026
 of malaria, 2181–2184
 for meningococcal meningitis, 3771

Chemosis, 1375

Chemotactic defect, 1297t–1298t

Chemotactic factor, 1317

Chemotaxis, 1296

Chemotherapeutic agents
 adverse reactions to, 1458
 indications and adverse reactions, 3089t–3090t

Chemotherapy
 for cancer treatment, 3088, 3088f, 3089t–3091t, 3090f
 for Ewing sarcoma, 3144
 for gastrointestinal tumors, 2414–2415
 for hepatocellular carcinoma, 3156
 for Hodgkin lymphoma, 3108, 3109t
 for non-Hodgkin lymphoma, 3113
 radiation-induced hypogonadism and, 3488–3489
 in retinoblastoma, 3150
 systemic, for hepatoblastoma, 3154–3155

Chemstrip, 3184

Chenodeoxycholic acid, 2437

Cherry-red spot, 3960, 3960f
 inborn errors of metabolism and, 809t–810t

myoclonus syndrome, 3716

Cherubism, 1523t

Chest
 assessment, in newborn, 1002
 deformity, in NOMID, 1528f
 funnel, 2713
 screening, in transgender, 1180t
 transillumination of, 2517
 ultrasound, 2517

Chest compression, 565

Chest pain, 2737
 differential diagnosis of, 2738t
 respiratory signs and symptoms, 2531t
 in SLE, 1497t
 suggestive of rheumatic disease, 1461t

Chest radiograph
 for anti-glomerular basement membrane disease, 2637
 for Bochdalek hernia, 1094f
 in *Coccidioides* spp., 1938, 1938f
 diagnostic approach to respiratory disease, 2517, 2517f
 for eosinophilic lung disease, 2625–2626, 2627f
 of HAPE, 635f
 of lobar calcified granuloma, 1838f
 physiology of congenital heart disease, 2799f
 of pulmonary alveolar microlithiasis, 2598f
 of tetralogy of Fallot, 2801f
 for transient tachypnea of newborn, 1088, 1089f
 of tuberculosis, 1839f, 1841f
 “water bottle” silhouette, 2890f

Chest tube, placement of, 570
 for pneumothorax, 1098

Chest wall, recoil of, 2520f

Cheyne-Stokes breathing, as respiratory distress, 612–613

CHH. *See* Cartilage-hair hypoplasia

Chiari crisis, myelomeningocele and, 3562

Chiari II malformation, hydrocephalus with, 3562

Chiari malformation
 in brainstem and cerebellar disorders, 3576, 3576f
 in encephalocele, 3564–3565
 in hydrocephalus, 3579–3580

Chiclero ulcer, 2158

Chikungunya virus, 2062–2063, 2062f

Chilblains (pernio), 661f, 662, 1510, 4132

Child abuse, 4278–4279, 4279t. *See also* Abuse and neglect
 in burn injuries, 646
 eye injuries related to, 3979, 3980f
 trauma caused by, 546

Child Abuse Prevention and Treatment Act of 1984 (CAPTA), 53

Child abuse specialist, referral to, 125

Child assent, 51

Child death, causes of, 24

Child health
 disparities, 8–22
 healthcare and, 10–15, 11t–12t
 interventions for, 15–16
 racism and, 16–22
 structural determinants of, root historical causes of, 8–16, 8f
 global, 23–35
 inequities, evidence-based interventions and innovations, 28t, 29–32, 29f
 social determinants of, 25–28, 25f

Child labor, chemical pollutants in, 4427

Child maltreatment
 BRUE and, 2543t
 disparities in, 14

Child Neurology Society (CNS), genetic testing guidelines for ID/GDD/ASD, 347t

Child protective services (CPS), 122

CHILD syndrome, ichthyosiform eruption in, 4118f

Child trafficking, 110–113
 approach to patient at risk for, 111–112, 112t
 clinical presentation of, 110–111
 examination and diagnostic testing in, 112–113
 exploitation, types of, 110t
 “red flags” for, 111t
 referrals and resources, 113, 113t
 risk factors for, 111t

Childcare, 183–195
 access, 185
 accreditation, 185
 and child behavior, 185–186
 children who are expelled from, 194
 and children with special needs, 186, 194–195
 closures, 184
 communicable diseases and, 1621–1625, 1621t
 antibiotic use and bacterial resistance, 1623
 blood-borne pathogens, 1622
 epidemiology, 1621
 gastrointestinal tract infections, 1622
 herpesviruses, 1622
 invasive organisms, 1622
 prevention, 1623, 1623t–1625t
 respiratory tract infections, 1621–1622
 skin diseases, 1622
 standards, 1623–1625
 consultation, referrals, and screening to improve access, 193–194
 consulting and partnering with, 195
 exclusion from group settings, 187t–192t
 high-quality, 183
 information resources, 194t
 integration of health and safety within quality practices, 183–184, 184t
 licensing, regulation, monitoring, and accreditation, 184–185
 other quality monitoring systems, 185
 preschool in, 183
 primary caregiving in, 183
 protection and promotion of child health, 193
 role of pediatricians in, 193–195
 screening and support for child development and health, 185–193
 settings of, 184, 187t–192t
 sick children, 186–193
 supporting parents regarding children’s health, 194

Child-directed speech, 328

Childhood
 asthma, 1386–1410
 control of, 1395t
 epidemiology of, 1387
 etiology of, 1386–1387, 1386f
 management of, 1388t, 1399t–1400t
 persistent, risk factors for, 1387t
 types of, 1387
 overgrowth in, 3382–3383

Childhood absence epilepsy, 3601

Childhood apraxia of speech (CAS), 331, 333, 339

Childhood Arthritis and Rheumatology Research Alliance (CARRA), 1504, 1506f

Childhood Cancer Survivor Study, 3116, 3076

Childhood glaucoma, 3968–3970
 clinical manifestations of, 3969–3970, 3970f
 diagnosis and treatment for, 3970, 3970t
 primary and secondary, 3969t

Childhood growth, 175

Childhood periodic syndromes, with migraine, 3644

Childhood psychoses, 285–294
 catatonia in children and adolescents, 291–292
 causes of, 287t
 hallucinations, 293
 spectrum disorders, 285–290

Childhood-onset fluency disorder, 333–335, 333t
 brain structure and function abnormalities in, 334
 diagnosis of, 333–334, 333t
 differential diagnosis of, 334
 epidemiology of, 334
 evaluation, 335
 genetics of, 334
 treatment of, 335

Child-onset stuttering, 333–334

Children
 affected by biologic and chemical agents, 4446–4447
 aggressive periodontitis in, 2249
 antihypertensive agents for, 2918t
 blood pressure measurement in, 2910–2911
 with congenital heart disease, evaluation and screening of, 2773–2775, 2773f
 with Crohn disease, 2318
 with disabilities, health and wellness for, 4404–4408

- Children (*Continued*)
- anticipatory guidance, counseling, and preventive care for, 4405
 - dental care, 4407
 - emotional health and leisure activities, 4407
 - health promotion, 4404–4405, 4405t
 - nutrition and obesity, 4407
 - physical activity and exercise, 4406–4407
 - role of healthcare providers, 4407–4408, 4408t
 - sleep and pain, 4407
 - electrocardiogram of, 2749f
 - feeding of, 409–420
 - granulocyte transfusion for, 3018
 - health of
 - changing pediatric world, 2–3
 - global statistics, 1–2
 - systems of care, 6–7
 - mortality rate, 23
 - in pediatric palliative care, 62, 63t
 - plasma transfusions in, 3019
 - platelet transfusions in, 3016, 3016t
 - prevalence of hypertension in, 2910, 2911t
 - red blood cell transfusions in, 3014–3015, 3014t
 - red cell aplasia in, 2935
 - renal cysts in, 3262, 3262t
 - renovascular hypertension in, 2917t
 - transient or intermittent, hypertension and, 2912t
 - traveling internationally, health advice for, 1626–1639
 - adolescent traveler, 1639
 - insect-borne infections, 1633–1634
 - malaria chemoprophylaxis, 1634–1637, 1635t–1636t
 - pediatric travel medicine consultation, 1626
 - returning traveler, 1637–1639, 1637t–1639t
 - routine childhood vaccinations required for pediatric travel, 1627–1628
 - diphtheria-tetanus-pertussis, 1627
 - Haemophilus influenzae* type b, 1627–1628
 - hepatitis A, 1628
 - hepatitis B, 1628
 - measles-mumps-rubella, 1628
 - pneumococcal vaccines, 1628
 - polio vaccine, 1628
 - respiratory viruses, 1628
 - varicella, 1628
 - safety and preventive counseling topics, 1626–1627
 - animal contact, 1627
 - health and evacuation insurance, underlying health conditions, and medications, 1626
 - safety and injury prevention, 1626–1627
 - specialized pediatric travel vaccinations, 1628–1632, 1630t–1631t
 - cholera, 1629
 - hepatitis A vaccination and preexposure immunoglobulin, 1629
 - Japanese encephalitis, 1629
 - meningococcal vaccines, 1629
 - rabies, 1629–1632
 - tuberculosis, 1632
 - typhoid, 1632
 - yellow fever, 1632
 - traveler's diarrhea, 1632–1633
 - management of, 1633
 - presumptive antibiotic treatment, 1633, 1633t–1634t
 - prevention of, 1633
 - Children with special health care needs (CSHCN), 6, 6t–7t, 76, 89, 4405
 - Children's Aggression Scale, 280t
 - Children's Allegra, for allergic rhinitis, 1383t
 - Children's Claritin, for allergic rhinitis, 1383t
 - Children's Friendship Training, for FASD, 1138
 - Children's Lake Louise Score (CLLS), 632, 632f
 - Childrens Oncology Group (COG), 3076, 3086, 3134
 - Children's Zyrtec, for allergic rhinitis, 1383t
 - Chimeric antigen receptor (CAR), 1351–1352
 - for acute lymphoblastic leukemia, 3101, 3102f
 - Chimeric antigen receptor T cells (CAR-T cells), 3090, 3092f
 - Chin trembling, hereditary, 3637
 - Chinese herbal medications, for atopic dermatitis, 1417
 - Chinese medicines, 2492t
 - Chiropractic healthcare, 57
 - Chitterlings, 1792
 - Chlamydia
 - life cycle of, in epithelial cells, 1894f
 - NAAT for, 125
 - reported cases by age, 1239f–1240f
 - Chlamydia pneumoniae*, 1893–1894, 1894f
 - Chlamydia psittaci*. See Psittacosis
 - Chlamydia trachomatis*, 1895–1897
 - conjunctivitis and pneumonia in newborns, 1896–1897
 - genital tract infections, 1895–1896
 - laboratory screening, 1241t
 - lymphogranuloma venereum, 1897
 - management guidelines, 1247t–1248t
 - trachoma, 1895
 - vulvovaginal infection, 3322t
 - Chloramphenicol
 - adverse reactions in premature infant, 1045t
 - enterococci resistance, 1723t
 - Chloride
 - dietary reference intake, 404t–407t
 - extracellular, 486
 - reference intervals, 4472.e9t
 - Chloride-losing diarrhea, 520–521
 - Chlorinated hydrocarbons, 4425–4426
 - Chlorine, toxicity, 4448–4449, 4454t
 - Chlorofluorocarbons, 4423
 - Chloromas, 3125
 - acute myelogenous leukemia and, 3102–3103
 - Chloroquine
 - for malaria chemoprophylaxis, 1634–1636
 - toxicity, 701t
 - Chlorosis, 2201
 - Chlorothiazide, for heart failure, 2897, 2898t
 - Chlorpheniramine maleate, for allergic rhinitis, 1383t
 - Chloropyrifos, 4425
 - Chlor-Trimeton, for allergic rhinitis, 1383t
 - Choanal atresia, 1053t, 2545–2546, 2546f
 - Cholangiocarcinoma, 2215
 - Cholangiocytes, 2435
 - Cholangiography, for liver, 2445
 - Cholangiohepatitis, 2215
 - Cholangitis, 2215
 - primary sclerosing, 2475–2476, 2476f
 - recurrent, liver disease and, 2442
 - Cholecalciferol, 3250
 - Cholecystitis, 2502–2504
 - Cholecystokinin, 2423
 - Choledochal cysts, 2422, 2447, 2500
 - Choledochal malformations, 2447, 2447f
 - Choledochoholithiasis, 2447–2448
 - Cholelithiasis, 2502–2504, 2961
 - conditions associated with, 2503t
 - Cholera, 1785–1788
 - clinical manifestations of, 1786, 1787f
 - complications of, 1787
 - diagnosis and differential diagnosis of, 1786–1787
 - epidemiology of, 1785
 - etiology of, 1785
 - laboratory findings of, 1786
 - pathogenesis of, 1785–1786, 1786f
 - prevention of, 1787–1788, 1788t
 - treatment of, 1787, 1788t
 - vaccine, 1588t–1589t
 - Cholera gravis, 1786
 - Cholestasis, 2438, 2445–2454
 - chronic diarrhea and, 2378
 - in IFALD, 2352
 - mechanistic classification of the etiologies of, 2441t
 - neonatal, 2445–2454, 2446f
 - in older child, 2454
 - persistent, suggested medical management of, 2453t
 - treatment algorithm for, 2443f
 - viral hepatitis and, 2461
 - Cholesteatoma, 4014, 4015f
 - congenital, 3998–3999, 3999f
 - Cholesterol, 389t–390t
 - biosynthesis, disorders of, inborn errors of metabolism associated with, 809t
 - low, 880–881
 - in steroid biosynthesis, 3444–3445
 - Cholesterol ester storage disease, 881, 897
 - Cholesterol gallstones, 2503
 - Cholesterol granuloma, 4016
 - Cholesterol synthesis, 831f
 - Cholesteryl ester transfer protein deficiency, 880
 - Cholic acid, 2437
 - Choline, 456
 - dietary reference intake, 397t–403t
 - Cholinergic crisis, 3858
 - Cholinergic syndrome, 1197t, 4447–4448
 - Cholinergic urticaria, 1427
 - Cholinergics, toxicodrome, 703t
 - Chondritis, of external ear, 4002
 - Chondrodysplasia genes, 4333–4334
 - Chondrodysplasia punctata, 4118
 - Chondrodysplasias, 4333–4334
 - Jansen-type metaphyseal, 3443
 - Chondroectodermal dysplasia, 4354
 - Chondrolysis, 4241
 - Chondromyxoid fibroma, 3145
 - Chondroosteodysplasias, 4333
 - Chorddee, without hypospadias, 3297, 3297f
 - Chorea, 243t, 3635–3636, 3673–3678
 - acquired, 3674t
 - childhood-onset, 3675t–3677t
 - in rheumatic fever, 1713
 - Sydenham, 3673
 - in rheumatic fever, 1713–1714
 - Chorea gravidarum, 3674
 - Choreic hand, 3673–3674
 - Choreoathetosis, 3678
 - Chorioamnionitis, 1154, 1752
 - in genital mycoplasmas, 1891–1892
 - histologic, 1145–1146, 1145f
 - Chorioepithelioma, 3502
 - Chorionic gonadotropin-secreting tumors, 3392
 - Chorionic villus sampling (CVS), 1025
 - Chorioretinal coloboma, 3963
 - Chorioretinitis, 3952–3953
 - toxoplasmosis and, 2188–2189
 - Choroid, gyrate atrophy of, 854
 - Choroid plexus, 3121
 - carcinoma, 3121
 - cysts, fetal, 1026t
 - papillomas, 3121
 - Choroiditis, 3940t, 3952–3953, 3954f
 - Chromatin regulatory disorders, 796–799
 - Coffin-Siris syndrome, 798–799, 798f
 - Cornelia de Lange syndrome, 797–798, 798f
 - Kabuki syndrome, 796, 796f, 797t
 - Rubinstein-Taybi syndrome, 796–797
 - Chromium, 483t
 - Chromosomal abnormalities
 - abbreviations for, 763t
 - associated with autoimmune polyglandular syndrome, 3430
 - of chromosome number, 763–766
 - aneuploidy and polyploidy, 763–766
 - of chromosome structure, 766–770
 - deletions and duplications, 767–770, 767t, 769t
 - insertions, 770
 - inversions, 767
 - isochromosomes, 770
 - marker and ring chromosomes, 770
 - microdeletions, 768t–769t
 - translocations, 766–767
 - malformations caused by, 781t
 - in newborns, incidence of, 760t
 - Chromosomal deletion syndromes, 786t
 - Chromosomal imbalance, 782–783
 - Chromosomal microarray (CMA), 379, 749
 - for neurodevelopmental disorders, 348t
 - Chromosomal translocation, 3078t
 - Chromosome analysis, 760–762, 762f
 - aCGH, 762, 765f
 - centromere position, 761–762, 762f
 - errors of cell division, 761
 - FISH, 762, 764f
 - GTG banding, 761
 - SNP array, 762
 - Chromosome disorders, 760–777
 - associated with congenital heart disease, 2739t–2740t
 - chromosome instability syndromes, 772–773, 774t
 - chromosome number, abnormalities of, 763–766
 - chromosome structure, abnormalities of, 766–770

- Chromosome disorders (*Continued*)
 identification of, 727
 intellectual disability caused by, 349t
 methods of chromosome analysis, 760–762, 762f
 FISH, 762, 764f
 GTG banding, 761
 SNP array, 762
 mosaicism, 771–773, 773t
 sex chromosome aneuploidy, 770–771, 770t
 uniparental disomy and imprinting, 773–777, 775f
- Chronic abdominal pain
 alarm symptoms for, 2390t
 diagnostic criteria for, 2391t
- Chronic acquired neutrophilia, 1313
- Chronic arsenic toxicity, in arsenic intoxication, 4432
- Chronic arthropathy, 3032
- Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, 1534
- Chronic autoimmune thrombocytopenic purpura, 3049f, 3054–3055
- Chronic benign neutropenia, 1311–1312
- Chronic bronchitis, 2589
- Chronic Chagas disease, 2166–2167
- Chronic compartment syndrome, 4311
- Chronic diarrhea, 2227, 2376–2384
 etiology of, 2377–2380, 2377t
 carbohydrate malabsorption and, 2378
 congenital diarrheal disorders as, 2378–2380, 2379t–2380t
 infectious, 2377, 2377t
 inflammatory/immunologic, 2377–2378
 liver and bile acids disorders in, 2378
 motility disorders in, 2378
 nonspecific diarrhea, including toddler's diarrhea, 2378
 pancreatic deficiency and, 2378
 protein-losing enteropathy in, 2378
 short bowel syndrome and, 2378
 evaluation of patients with, 2380–2381
 investigations for, 2381–2382, 2381t–2382t
 from neuroendocrine tumors, 2383–2384, 2384t
 pathophysiology of, 2376–2383, 2376f
 prevalent agents and conditions in, 2377t
 stepwise diagnostic approach to, 2382t
 treatment of, 2382–2383, 2383t
- Chronic disease, anemia of, 2948t
- Chronic eosinophilic pneumonia, 2627–2628
- Chronic fatigue syndrome (CFS), 1574, 1576–1581, 1579t
 clinical manifestations of, 1576f, 1580
 diagnosis of, 1580–1581, 1580f
 epidemiology of, 1578
 management of, 1581
 pathogenesis of, 1578–1579
 prognosis for, 1581
- Chronic graft-versus-host disease, 4034
- Chronic granulomatous disease (CGD), 1297t–1298t, 1346, 1660
 classification of, 1302t
 clinical manifestations of, 1302–1303, 1303f
 genetic counseling for, 1303
 genetics and pathogenesis of, 1301–1302, 1302f
 laboratory findings of, 1303
 prognosis for, 1303
 risk for pulmonary aspergillosis, 1931
 treatment of, 1303
- Chronic growth hormone excess, 3846
- Chronic GVHD, 1358–1359, 1358t, 1359f
- Chronic hemolytic anemias, with G6PD deficiency, 2988f, 2990f, 2992
- Chronic hepatitis
 approach to, 2473
 disorders producing, 2489t
- Chronic hypertension, 1020
- Chronic idiopathic musculoskeletal pain syndromes, 1567
- Chronic illness
 in adolescent, 55
 children with, 6
- Chronic infantile neurologic cutaneous and articular (CINCA) syndrome, 1519t–1520t, 1521f, 1536
- Chronic inflammation, bronchiectasis and, 2658
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 3900–3904
- Chronic inorganic mercury intoxication, 4434
- Chronic intestinal pseudoobstruction (CIPO), 2287–2291, 2287t–2289t
 clinical manifestations of, 2289–2290
 diagnosis of, 2290–2291, 2290f, 2290t
 treatment for, 2291
- Chronic kidney disease (CKD), 3247–3252
 clinical manifestations of, 3248
 etiology of, 3247, 3248t
 laboratory findings of, 3248
 pathogenesis of, 3248, 3249f
 progression of, 3252
 symptoms and signs of, 3251f
 treatment and management of, 3248–3252
 vitamin D deficiency and, 473t, 476
- Chronic kidney disease mineral and bone disorder (CKD-MBD), 3249–3250, 3251f
- Chronic labyrinthitis, 4020
- Chronic liver disease, autoimmune hepatitis and, 2487
- Chronic lower respiratory tract disease, indicators of, 2527t
- Chronic lung disease of prematurity. *See* Bronchopulmonary dysplasia
- Chronic lymphedema, 2206
- Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), 3705t–3707t, 3710–3711
- Chronic lymphocytic thyroiditis, 3408, 3411, 3412t, 3549
- Chronic malnutrition, 433–434, 2346–2347
- Chronic mastoiditis, 1800t
- Chronic meningococcemia, 1741f, 1742
- Chronic migraine, 3642t
- Chronic mucocutaneous candidiasis, 1335, 1661, 1924
- Chronic myelogenous leukemia (CML), 3104–3105
 HSCT for, 1353
 oncogenesis of, 3077
- Chronic myofascial pain syndrome, 1569–1570
- Chronic nodular disease, nontuberculous mycobacteria infection and, 1861t
- Chronic nonspecific diarrhea of toddlerhood, 2385
- Chronic nonspherocytic hemolytic anemia, 2992
- Chronic osteomyelitis, 4284
- Chronic overlapping pain conditions (COPCs), 1574–1581
 natural history of, 1574–1575
 pathophysiology of, 1575, 1575f–1576f
 predisposing factors of, 1574
 prevalence of, 1574–1576
 psychiatric comorbidities of, 1574
 symptom/disorder overlap of, 1574
 treatment of, 1575–1576
- Chronic pancreatitis, 2429–2431, 2430t
 classification of, 2430t
 factors contributing to etiology of, 2430t
 IgG4-related disease and, 2431t
 ultrasound and multidetector images in, 2431f
- Chronic paronychia, 4147f
- Chronic progressive disseminated histoplasmosis, 1933
- Chronic progressive external ophthalmoplegia (CPEO), 743t, 936–937, 3854
- Chronic pulmonary histoplasmosis, 1933
- Chronic pulmonary infections, nontuberculous mycobacterial and, 1864
- Chronic recurrent aspiration, 2608–2612
 clinical presentation of, 2609
 conditions associated with, 2609t
 diagnosis of, 2609–2611, 2610t, 2611f
 management of, 2611–2612
- Chronic recurrent multifocal osteomyelitis (CRMO), 1523t, 1529, 1529f, 4287, 4289f
- Chronic regional lymphadenitis, 1813
- Chronic rejection
 in intestinal transplantation, 2354
 in renal transplantation, 3258
- Chronic renal disease, 1020
- Chronic respiratory failure, cystic fibrosis and, 2676
- Chronic respiratory insufficiency, 2716–2730
 chronic respiratory failure, 2716–2718
 congenital central hypoventilation syndrome, 2718–2723, 2719t
- Chronic respiratory insufficiency (*Continued*)
 clinical manifestations of, 2721, 2722t
 differential diagnosis of, 2721, 2722t
 genetics in, 2719–2721, 2720t
 management of, 2721–2723
 long-term mechanical ventilation, 2716–2718
 adult transition in, 2718
 aerodigestive and communication considerations in, 2726–2727
 airway clearance in, 2717
 cardiopulmonary interactions and, 2727
 chest wall/thoracic configuration in, 2727
 developmental considerations for, 2727
 gas-exchange goals and ventilator strategies in, 2727
 goals and decision-making in, 2726–2730
 indications for, 2716t
 infections in, 2718
 inhalation medications in, 2711
 invasive positive pressure ventilation in, 2716–2717
 lived experience of, preparation of, 2727–2729
 monitoring for, 2717
 mucolytics and anticholinergics in, 2717
 noninvasive and transtracheal supports in, 2726
 nutrition in, 2718
 optimal ventilator support in, 2717
 physical, occupational, speech therapy in, 2717
 preparing for discharge in, 2717–2718
 projected interventions and needs and, 2727
 psychosocial considerations in, 2718
 routine health maintenance and, 2729
 supplemental oxygen in, 2717
 tracheal decannulation, 2729–2730
 transitioning from acute care to rehabilitation or community setting in, 2729
 rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation, 2723–2726
 clinical manifestations of, 2723–2724, 2724f
 diagnosis of, 2724, 2725f
- Chronic respiratory support, for BPD, 1087
- Chronic salicylism, 711
- Chronic serous otitis media, 329
- Chronic suppurative otitis media, 4013
- Chronic tubulointerstitial nephritis, 3205–3208, 3206t–3208t
- Chronic ulcerative colitis, 2309–2316
 clinical manifestations of, 2312, 2312f–2313f, 2312t
 diagnosis of, 2310t, 2312f, 2312t, 2313, 2314t–2315t, 2315f
 differential diagnosis of, 2312–2313, 2314t–2315t
 prognosis of, 2316
 treatment for, 2313–2316, 2316t
- Chronic ureteral obstruction, 3275
- Chronic urticaria
 diagnosis of, 1426, 1426t, 1428–1431, 1429t
 differential diagnosis of, 1430
- Chronic widespread pain syndrome, 1569–1570
- Chronic/recurrent symptoms, 2526–2531
 cough, 2526–2528
 judging seriousness of, 2526–2530
 lung infiltrates, 2529–2530
 stridor, 2528
 wheeze, 2529
- Chronotherapy, 214
- Chrysops*, 2207
- CHS. *See* Chédiak-Higashi syndrome
- Churg-Strauss syndrome, 2628. *See also* Eosinophilic granulomatosis with polyangiitis
- Chylomicro retention disease, 2340–2341
- Chylothorax, 2709–2711, 2710f–2711f
- Chylous ascites, 2510
- Ciclesonide
 for allergic rhinitis, 1384t–1385t
 for asthma, 1402t
- Cidofovir, 1955
- Cigarette smoking
 by adolescents, 1199–1200
 SIDS risk factors and, 2533–2534
- Ciguatera fish poisoning, 4444
 food-borne illness, 4411t–4413t
 food-borne noninfectious illnesses and, 2362t–2364t

CILA. *See* Community integrated living arrangement
 Cilia disorders, 2645t
 Ciliary structure and function, 2523, 2523f
 Ciliopathies, 791, 792f, 792t
 juvenile nephronophthisis and, 3205–3208
 Cimetidine, for cysticercosis, 2219
 CINCA (chronic infantile neurologic cutaneous and articular syndrome), 1519t–1520t, 1521f
 CIPA. *See* Congenital insensitivity to pain with anhidrosis
 CIPO. *See* Chronic intestinal pseudoobstruction
 Ciprofloxacin, 1675t–1685t, 4447, 4453
 for cyclosporiasis, 2153
 for *Shigella*, 1779
 Circadian rhythms, 201
 Circulation
 in acutely ill child, 551
 fetal, 2735, 2736f
 neonatal, 2735–2736
 persistent fetal, 1091–1093
 primary assessment of, 555
 primary survey for, 573–574, 574t–575t
 transitional, 2735
 Circulatory death, 53
 Circulatory dynamics, 2761f
 Circumcision
 complications of, 3298, 3299f
 newborn, 1006–1007
 Circumoral dysesthesias, 4444
 C-IRIS. *See* Cryptococcal-associated immune reconstitution inflammatory syndrome
 Cirrhosis, 2438
 focal biliary, 2477
 Indian childhood, 2459
 portal hypertension caused by, 2504–2505
 CISA network. *See* Clinical Immunization Safety Assessment network
 Cisapride, 2267
 Cisatracurium, 669t, 671
 for intubation, 620t
 Cisgender, definition of, 1172
 Cisplatin
 indications and adverse reactions of, 3089t–3090t
 for nasopharyngeal carcinoma, 3165
 Citalopram (Celexa), for depression and anxiety, 227t
 Citrin deficiency, 853, 2460
 Citrullinemia, 852–853
 type I, 852–853
 type II, 853
 CKK. *See* Cholecytokinin
Cladophialophora bantiana, 1947–1948
 Clarinex, for allergic rhinitis, 1382t–1383t
 Clarinex RediTabs, for allergic rhinitis, 1382t
 Clarithromycin, 1675t–1685t
 for *Mycoplasma pneumoniae*, 1890
 for nontuberculous mycobacteria infection, 1865
 Clascoterone, for acne vulgaris, 4180
 Clasp-knife phenomenon, 3555
 Class switch defects, 1283–1285
 Classic arthrogryposis, 4271–4272
 Classic Bartter syndrome, 3240
 Classic Ehlers-Danlos syndrome, 4369, 4372f–4373f
 Classic hemorrhagic disease of the newborn, 482
 Classic 21-hydroxylase deficiency, 3462–3463
 Classic Kawasaki disease, 1544
 Classic maple syrup urine disease, 825–826
 Classic porokeratosis of Mibelli, 4107
 Classic triad, 3117–3118
 Classical pathway, of complement system, 1315–1316, 1317f
 deficiency of, 1318–1319
 Classical phenylketonuria, 812–814
 Clavicle, 4264
 fractures, 4281, 4300–4301
 in delivery room, 1073
 Claw toe, 4210
 Clean air act, 4424
 Cleansing, acne and, 4179
 Clear cell adenocarcinoma, 3345
 Clear cell sarcoma, 3139t–3140t
 of kidney, 3135
 Clear communication, in pediatric palliative care, 61–62

Cleft lip and palate, 2242t, 2243–2244
 clinical manifestations of, 2243–2244, 2244f
 incidence and epidemiology of, 2243
 postoperative management of, 2244
 sequelae, 2244
 speech disorders and, 331
 treatment of, 2243–2244
 velopharyngeal dysfunction in, 2244
 Clefts, sternal, 2713–2714
 Cleidocranial dysplasia, 745t–746t, 2245, 4349–4350, 4349f
 CLIA. *See* Clinical Laboratory Improvement Amendments
 Climate, acne and, 4179
 Climate change, global, 4409
 Clindamycin, 1675t–1685t
 for acne vulgaris, 4179
 for babesiosis, 2185
 for bite wound, 4459t
 for dental infections, 2247–2248
 enterococci resistance, 1722t
 Clinic visits, productive, for asthma, 1396t
 Clinical deterioration, 44–45, 47t
 Clinical guidelines, in developing-world EDs, 546
 Clinical history, in hemostasis, 3024–3025
 Clinical Immunization Safety Assessment (CISA) network, 1590
 Clinical Laboratory Improvement Amendments of 1988 (CLIA), 4472,e4
 Clinical utility, of genetic testing, 750
 Clinical validity, 750
 Clinodactyly, 784t, 4268f
 CLIPPERS. *See* Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids
 Clitoral abnormalities, 3354
 Clitoromegaly, in female-appearing genitalia, 3506t
 Cloaca
 anomalies, 3354
 exstrophy, 3285
 Clobazam
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Clofazimine
 for drug-resistant tuberculosis, 1852t–1853t
 for Hansen disease, 1858–1859
 against *Mycobacterium leprae*, 1833–1834
 Clomipramine (Anafranil), for depression and anxiety, 226, 227t
 Clonal nevus, 4061
 Clonal polycythemia, 2997, 2998t
 Clonazepam
 for depression and anxiety, 227t
 dosages of, 3609t–3610t
 for Lennox-Gastaut syndrome, 3607
 Clonic seizures, 3619
 Clonidine, 689t
 for ADHD, 222–223, 225t–226t, 315
 for neonatal abstinence syndrome, 1133t
 for severe hypertension in children, 2919t
 for spasticity, 4394, 4395t
 toxicity, 701t, 714
 Clonorchiasis, 2214–2215
Clonorchis sinensis, 2214–2215, 2214f
 Clonus
 that mimic seizures, 3635
 toxicidrome, 704t
 Closed bite, malocclusion and, 2243
 Closed-loop obstructions, 2302
 Closed-loop systems, for T1DM, 3529, 3531f
Clostridium botulinum, 1817–1821
 in botulism, 4448
 clinical manifestations of, 1818–1819, 1818f
 complications of, 1820, 1821t
 diagnosis of, 1819, 1819t
 differential diagnosis of, 1819, 1820t
 epidemiology of, 1817–1818, 1817f
 etiology of, 1817
 pathogenesis of, 1818
 prevention of, 1821
 prognosis for, 1820
 supportive care for, 1820
 treatment of, 1820
Clostridium difficile infection, 1623t–1625t, 1825–1828
 antibiotic therapy for, 2373t–2375t
 clinical manifestations of, 1825
 diagnosis of, 1825–1826, 1825f, 1826t
 epidemiology of, 1825
 etiology of, 1825
 in nosocomial diarrhea, 2356–2359
 pathogenesis of, 1825
 prevention of, 1828
 prognosis for, 1826–1828
 recurrence, 1826–1828
 toxin, bacterial gastroenteritis and, 2357t–2358t
 treatment of, 1826, 1826t–1827t, 2372–2373
Clostridium perfringens
 acute gastroenteritis, 2356
 food poisoning, 1829
 toxins produced by, bacterial gastroenteritis and, 2357t–2358t
Clostridium tetani, 1821–1824
 Clothing ignition, 646
 Clouston syndrome, 4048–4050, 4049t–4050t
 CLOVES syndrome, 3131t–3132t, 3159, 3163f, 4188
 Cloxacillin sodium, 1675t–1685t
 Clubbing
 digital, 2513, 2515f
 nonpulmonary diseases associated with, 2515t
 of nails, 4143, 4143f, 4143t
 Clubfoot, 4202–4203, 4272, 4275f
 Clusterin, 1316–1317
 Cluttering, 333t
 Clutton joint, 1869, 1869t
 CMA. *See* Chromosomal microarray
 CMD. *See* Congenital muscular dystrophies
 CML. *See* Chronic myelogenous leukemia
 CMMRD. *See* Constitutional mismatch repair deficiency syndrome
 CMSs. *See* Congenital myasthenic syndromes
 CMT. *See* Charcot-Marie-Tooth disease
 CMV. *See* Cytomegalovirus
 CNLDO. *See* Congenital nasolacrimal duct obstruction
 CNS. *See* Central nervous system
 CO₂. *See* Carbon dioxide
 Coagulase-negative staphylococci (CoNS), 1699–1700
 late-onset infection and, 1143
 Coagulation, acquired inhibitors of, 3047
 Coagulopathies, 3204
 in liver disease, 3046, 3047t
 Coal, 4424
 Coalescent mastoiditis, 4018f
 Coarctation
 of aorta, 2761f, 2793–2795, 2795f, 2841–2842
 clinical manifestations of, 2793–2794
 diagnosis of, 2794
 pathophysiology of, 2793
 relative frequency of, 2763t
 treatment of, 2794–2795
 metamorphosis of, 2793f
 Coarse facial features, inborn errors of metabolism and, 809t–810t
 Coats disease, 3961, 3961f
 Coats plus syndrome, 3007
 Cobalamin (vitamin B₁₂), 456t–457t, 466–467
 absence of transport protein, 2943
 deficiency, 466–467, 2942–2944
 clinical manifestations of, 467, 467f, 2943
 diagnosis of, 467, 2943
 etiology of, 2942–2943
 laboratory findings of, 2943
 treatment of, 467, 2944
 dietary reference intake, 397t–403t
 impaired absorption, 2942–2943
 inadequate intake, 2942
 malabsorption, 2350
 metabolic pathway, 822f
 metabolism, 466f, 2943
 toxicity, 467
 Cobb angle, 4244, 4244f
 Cocaine
 abuse, by adolescents, 1205–1206, 1206t
 test, in oculosympathetic paresis, 3923–3924
Coccidioides spp. *See* Coccidioidomycosis

- Coccidioidomycosis, 1294, 1655t–1656t, 1936–1940
 clinical manifestations of, 1936–1937
 complicated pulmonary infection, 1937
 diagnosis of, 1938
 disseminated (extrapulmonary) infection, 1937, 1937t
 epidemiology of, 1936
 etiology of, 1936
 monitoring of, 1940
 natural history of, 1937f
 pathogenesis of, 1936
 prevention of, 1940
 primary, 1937, 1937f
 primary pulmonary, treatment of, 1939
 residual pulmonary, 1937
 surgical management of, 1939–1940
 treatment of, 1938–1940, 1939t
- Coccygeal pits, 3785–3786
- Cochlear device implantation, children with, 4019–4020
- Cochlear implants, 342–343, 3993, 3993f
- Cockayne syndrome, 962t, 4096–4097
- Codeine
 for burn injuries, 654
 in hepatic and renal dysfunction, 685t
- Code-mixing, bilingualism and, 327
- Code-switching, bilingualism and, 327
- Codman triangle, 4307
- Coenzyme Q10
 biosynthesis disorders, 3698
 for migraine, 3646t–3647t
- Coffin-Siris syndrome, 798–799, 798f, 2764t–2766t
- Cogan syndrome, 1553t, 1566, 1566t, 3946, 3984
- Cognitive and psychologic complications, sickle cell disease and, 2974
- Cognitive biases
 related to errors of attribution, 48t
 related to errors of context, 48t
 related to heuristic failure, 48t
- Cognitive development
 in adolescent, 1161–1162
 age 0–2 months, 152
 age 2–6 months, 154–155
 age 6–12 months, 156
 age 12–18 months, 158
 age 18–24 months, 158
 in middle childhood, 167–171
- Cognitive function, in T1DM, 3534
- Cognitive impairment, language disorders associated with, 329
- Cognitive theories, 139–140
- Cognitive-behavioral disorders, after traumatic brain injury, 4387, 4387t
- Cognitive-behavioral therapy (CBT), 231, 276, 279–280, 282, 308
 for anxiety disorders, 249
 in pain management, 692
 for somatic symptom and related disorders, 240
- Cognitively impaired child, measures of pain specific to, 680
- Cohen syndrome, 1309t
- Coins
 in esophagus, 2273, 2273f
 ingestion of, 2303
- Colchicine, for amyloidosis, 1537
- Cold agglutinin disease, 2995
- Cold allodynia, in ciguatera fish poisoning, 4444
- Cold antibodies, autoimmune hemolytic anemias associated with, 2995
- Cold hemagglutinins, in *M. pneumoniae*, 1889
- Cold injuries, 657–663
 frostbite, 659–662
 hypothermia, 657–659
 nonfreezing cold injury, 662
 soft tissue cold injury, 659
- Cold panniculitis, 4132, 4151
- Cold stress, 659, 1055
- Cold symptoms
 caused by HCoVs, 2038
 in exclusion or inclusion in daycare, 187t–192t
- Cold urticaria, 4132
- Cold water injury, in drowning, 640
- Cold water shock, 640
- Cold-induced fat necrosis, 662
- Cold-induced sweating syndrome, 3899t
- Cold-induced urticaria, hereditary diseases with, 1430t
- Colectomy, for fulminant colitis, 2316
- Colic, 156–157
 infant, 2385, 2388t
- Colipase, 2423
- Colistin, 1675t–1685t, 1690
- Colitis
 amebic, 2148
 chronic diarrhea and, 2377–2378
- Collaborative care, 234
- Collagenopathies, type 2, 4340
- Collagenosis, in fetal movement, 3821
- Collapse-consolidation lesion, of tuberculosis, 1839f
- Collecting duct, secretion of hydrogen ions in, 512f
- Collectins, 1316
- Collective violence, 1189–1190
- Collodion baby, 4110, 4115f
- Colloid goiter, 3415
- Colloid milium, 4095
- Colloids, 4039
 for burns, 651
- Coloboma
 chorioretinal, 3963
 of eyelid, 3936
 of iris, 3920, 3921f, 3921t
 optic nerve, 3964, 3964f
- Colon, 2277
- Color deficiency, 3910
- Color vision testing, 3910
- Colorado tick fever, 2062
- Colorectal cancer syndromes, general features of, 2412t
- Colorectal carcinoma (CRC), 2414, 3165
- Colpocephaly, in corpus callosum, 3573
- Colposcopy, in schistosomiasis, 2213
- Columbia Suicide Severity Rating Scale (C-SSRS)
 Screener, 268t
- Coma, 591t
- Combination antiretroviral treatment (cART), for HIV, 2089
- Combination therapies, antibiotics, 1673f
- Combined hormonal contraceptives, 1221t, 1222–1225
 for heavy bleeding, 1214
- Combined hormonal transdermal patches and vaginal rings, 1214
- Combined immunodeficiency, 1269t–1270t
 ataxia-telangiectasia, 1273–1274
 cartilage-hair hypoplasia, 1274, 1274f
 CD4 T-cell helper function, 1265–1272
 DNA repair defects in, 1267t–1268t
 genetic basis of, 1263t
 less profound than SCID, 1265, 1266t–1267t
 Wiskott-Aldrich syndrome, 1273
- Combined methylmalonic aciduria and homocystinuria, 836–837
- Combined mineral vitamin mix (CMV), 430
- Combined oral contraceptives, 1214, 1218t–1219t, 1223–1224
- Comedonal acne, 4177, 4178f
- Comedone, 4177
- Comet tails, in HAPE ultrasound, 635
- Comfrey, 2492t
- Comitant strabismus, 3925–3927, 3927f–3928f
- Commercial sexual exploitation of children (CSEC), 1235
- Commission on Accreditation of Medical Transport Systems (CAMTS), 542
- Common cause analysis, 43–44
- Common cold, 2035, 2551–2554
 clinical manifestations of, 2552
 complications of, 2553–2554
 conditions mimicking, 2552t
 diagnosis of, 2552
 epidemiology of, 2551
 etiology of, 2551
 laboratory findings of, 2552
 pathogenesis of, 2551–2552, 2551t
 prevention of, 2554
 treatment of, 2552–2553
 antiviral, 2552
 ineffective, 2553
 supportive and symptomatic, 2552–2553
- Common factors approach, 131–132, 133t
 demoralization, 132
 elicit concerns, 132
 emphasize hope, 132
 establish a plan, 132
 HEL²P³ mnemonic, 132, 132t
 respond to anger, 132
- Common variable immunodeficiency, 1282–1283, 1283f–1284f, 1309t, 1332t–1333t
- Common warts, 4166–4167, 4167f
- Commotio cordis, 2861–2862, 4327
- Commotio spinalis, 4319
- Communicable diseases, childcare and, 1621–1625, 1621t
 antibiotic use and bacterial resistance, 1623
 blood-borne pathogens, 1622
 epidemiology, 1621
 gastrointestinal tract infections, 1622
 herpesviruses, 1622
 invasive organisms, 1622
 prevention, 1623, 1623t–1625t
 respiratory tract infections, 1621–1622
 skin diseases, 1622
 standards, 1623–1625
- Communicating hydrocele, 2416
- Communication
 about life-altering illness, 51–52
 in adolescent healthcare, 54
 age 2–6 months, 155
 age 6–12 months, 156
 in critically ill newborn, 1052
 definition of, 325t
 dispatch center and, 540
 milestones in, 326t, 327f
 in pediatric palliative care, 61–71
- Communication disorders, 324–335
 clinical presentation of, 328
 diagnostic criteria for, 330t
 epidemiology of, 328
 etiology of, 328–329
 pathogenesis of, 329
- Community, context of, caring for child and youth in, 90
- Community acquisition, cytomegalovirus (CMV), 2010
- Community engagement, 15
- Community health workers (CHWs), 32
- Community integrated living arrangement (CILA), 362
- Community interventions, adolescent, 1164t–1165t
- Community violence, 99, 1189–1190
- Community-acquired pneumonia, 2642–2651
 clinical manifestations of, 2644–2645
 complications of, 2647–2648, 2647f–2648f, 2649t
 diagnosis of, 2645–2646, 2645f–2646f, 2646t
 etiology of, 2642–2648, 2643t–2644t
 pathogenesis of, 2642–2644
 prevention of, 2648
 prognosis for, 2647
 treatment of, 2646–2647
- Community-based interventions, 32
- Community-based rehabilitation (CBR), 362
- Comorbid conditions, asthma with, 1398
- Comorbidities
 childhood-onset fluency disorder and, 335
 of hEDS and POTS, 1574
 obesity with, 442
- Comparing quality, 40–41
- Compartment syndrome, 654–655, 4284
 necrotizing fasciitis and, 4152
- Compassionate communication, 61
- Compensated shock, 560, 600
- Compensation
 metabolic, respiratory acidosis with, 617
 respiratory, metabolic acidosis with, 617
- Compensatory overinflation, 2590
- Compensatory scoliosis, 4248–4250, 4249f
- Complement factor H (CFH), 1318
- Complement factor I (CFI), 1318
- Complement receptor 1 (CR1), 1316
 deficiency of, 1322
- Complement receptors, deficiency of, 1322–1323
- Complement regulation, deficiency of, 1320–1321, 1322t
 treatment of, 1323, 1323t

- Complement system, 1315–1323
 activation and control of, 1316f
 alternative pathway of, 1316
 deficiency of, 1320
 classical and lectin pathways of, 1315–1316, 1317f
 components of, 1315–1318, 1315t
 control mechanisms of, 1316–1317
 evaluation of, 1315–1318, 1318f, 1318t
 membrane attack complex, 1316
 participation in host defense, 1317–1318
 pathways of, 1315–1318
 deficiency of, 1318–1323, 1319t
- Complementary feeding, 413–414, 413t
- Complementary therapies, 56–58
 acupuncture in, 57–58
 cannabis in, 58
 dietary supplements in, 56, 56t
 efficacy of, 57
 safety of, 56–57, 57t
 massage and chiropractic in, 57
 mind-body therapies in, 57, 58t
- Complete androgen insensitivity syndrome (CAIS), 3512
- Complete blood count
 for fever without a focus, 1644
 for osteomyelitis, 4286
 reference intervals, 4472.e9t
- Complete fractures, 4277–4278
- Complete STAT1 deficiency, 1339t
- Complex chronic pain problems, management of, 699–700
- Complex febrile seizure, 3595
- Complex genetic disorders, caring for children with, 362–364, 362t–363t, 363f–364f
- Complex lymphatic anomalies, 3156–3157, 3160f
 central conducting, 3157, 3161f
 generalized, 3156, 3160f
 Gorham-Stout disease, 3156–3157, 3160f
 treatment of, 3157
- Complex lymphatic anomalies (CLAs), 3065
- Complex multisystem disorders, mitochondrial disease and, 935t
- Complex regional pain syndrome (CRPS), 698, 1571, 1573t, 3684
- Complex tics, 3636–3637
- Complex venous anomalies, 3157–3158, 3159f
- Compliance
 dynamic, 628
 in equation of motion, 620–621
 lung, decreased, 612, 614t
 static, 628
- Complicated grief, 200
- Complototype, 1320
- Component testing, 1378
- Composite hemangiendothelioma, 3162
- Composite serious harm index, 42
- Comprehensive malnutrition indicators, 433t
- Comprehensive Transition Programs (CTPs), 361
- Compressive optic neuropathy, 3748
- Compulsions, 243t
- Compulsive Valsalva-like maneuver, 3632
- Computed tomography (CT)
 for appendicitis, 2400–2401, 2401f
 chest, 2517–2518
 of chronic recurrent aspiration, 2610
 cranial, in neuroradiologic procedures, 3558
 for cystic fibrosis, 2670f
 for esophageal varices, 2272
 in Fabry disease findings, 3887
 high-resolution, of bronchiectasis, 2659f
 for liver, 2444–2445
 in neuromuscular diseases, 3794
 for orthopedic evaluation, 4200
 for osteomyelitis, 4286, 4288f
 of pancreatitis, 2428f
 reducing radiation from, 4417
 of retropharyngeal abscess, 2567f
 of septic arthritis, 4293
 of temporomandibular joint in JIA, 1477f
 for urinary tract obstruction, 3278
- Computed tomography angiography
 for brain death, 591t
 of pulmonary emboli, 2696f
- Concealed penis, 3299f
- Concentrated poverty, 8–9
- Concentrating mechanisms, tubular function in, 3233
- Conceptual skills, 346
- Conceptually Accurate Signed English (CASE), 341t
- Concerta. *See* Methylphenidate
- Concrescence, in teeth, 2240
- Concussion
 of periodontal ligament, 2251
 sports-related, 4314–4318
- Conditionally indispensable amino acids, 393–394, 394t
- Conditioning therapy, for nocturnal enuresis, 3296
- Condoms, 1218t–1219t, 1227
- Conduct disorder, 277–280, 1190t
 clinical course of, 277
 differential diagnosis of, 277
 disparities in, 15
 DSM-5, 279t
 epidemiology of, 277
 etiology of, 278
 level of care, 280
 prevention of, 278–279
 risk factors of, 278
 screening/case finding, 279
 sequelae of, 277–278
 treatment for, 279–280
- Conduction, in heat transfer, 657
- Conductive hearing loss (CHL), 329, 3983
- Condylomata acuminata, 4167–4168, 4167f
 vulvar, 3321t–3322t
- Condylomata lata, 1867–1868, 1869f
- Cone beam computed tomography, 2255
- Cone snails, 4472
- Confidentiality, in adolescents, 54, 1165
- Confined placental mosaicism, 1025
- Confirmation bias, 48t
- Conflict, global health and, 34f, 35
- Confluent and reticular papillomatosis (CARP), 4109, 4109f
- Conformal radiation, 3091
- Conformity, 1162
- Congenital abnormalities
 fetal therapy for, 1027t
 in folate transport and metabolism, 2941
 multiple, 779–781
 of platelet function, 3051t–3052t, 3059–3060, 3059t
- Congenital absence
 pulmonary valve, 2803
 vaginal, 3353
- Congenital adrenal hyperplasia (CAH), 3462–3471, 3462f–3463f
 in 46,XX DSD, 3506–3507
 aldosterone synthase deficiency in, 3470–3471
 diagnosis and treatment of, 3464t–3465t
 glucocorticoid-remediable aldosteronism, 3471
 by 11β-hydroxylase deficiency, 3468
 by 17-hydroxylase deficiency, 3469
 by 21-hydroxylase deficiency, 3462–3468, 3464t–3465t
 differential diagnosis of, 3466
 epidemiology of, 3463
 genetics in, 3463
 genotype-phenotype correlations in, 3465t
 laboratory findings in, 3466
 newborn screening for, 3466–3467
 pathogenesis and clinical manifestations of, 3463–3466
 prenatal diagnosis of, 3466
 treatment of, 3467–3468
- by 3β-hydroxysteroid dehydrogenase deficiency, 3468–3469
- lipoid, 3469–3470
- P450 oxidoreductase deficiency in, 3470
 screen for, 3505
- Congenital aganglionic megacolon, 2295–2298
 clinical manifestations of, 2293t, 2295–2296, 2295t, 2296f–2297f, 2298f
- diagnosis of, 2296–2297, 2296f
- pathology of, 2295
- treatment for, 2297–2298
- Congenital alveolar proteinosis, 1079
- Congenital amegakaryocytic thrombocytopenia (CAMT), 3007–3008, 3056
- cancer predisposition in, 3008
- clinical manifestations of, 3008
- diagnosis of, 3008
- etiology and epidemiology of, 3007–3008
- laboratory findings of, 3008
- therapy and prognosis of, 3008
- Congenital angular deformities, of tibia and fibula, 4216–4218
- anterolateral tibial bowing, 4218
- anteromedial tibial bowing, 4217–4218, 4218f
- postaxial hemimelia, 4217–4218
- posteriormedial tibial bowing, 4216
- tibial longitudinal deficiency, 4218
- Congenital anomalies, 2258–2260
 associated with hematuria, 3213
- congenital esophageal stenosis, 2260, 2260f
 esophageal atresia and tracheoesophageal fistula, 2258–2259, 2258f–2259f, 2259t
- in infants of diabetic mothers, 1141–1142
- of kidney and urinary tract (CAKUT), 3247, 3253
- laryngotracheoesophageal clefts, 2259–2260
- of larynx, trachea, and bronchi, 2573–2577
- life-threatening, 1053t
- in neonatal period, 1053
- of posterior fossa, 3664–3672
- of stomach, 2278–2281
- congenital gastric outlet obstruction as, 2278t, 2280, 2280t
- gastric duplication as, 2280–2281, 2280t
- gastric volvulus as, 2281
- hypertrophic gastropathy as, 2281
- hypertrophic pyloric stenosis, 2278–2280, 2278f–2279f, 2278t, 2280t
- Congenital anorchia, 3488–3489
- Congenital autosomal recessive NDI, 3374
- Congenital central hypoventilation syndrome (CCHS), 1075, 2718–2723, 2719t, 3899t
 clinical manifestations of, 2721, 2722t
 differential diagnosis of, 2721, 2722t
 genetics in, 2719–2721, 2720t
 management of, 2721–2723
- ROHHAD and, 2725
- Congenital chloride diarrhea, 2334t–2336t, 2350, 2381
- Congenital cholesteatoma, 4014
- Congenital clubfoot, 4202
- Congenital complete AV block, 2858
- Congenital contractual arachnodactyly (CCA), 4368
- Congenital corectopia, 3921
- Congenital cranial dysinnervation disorders (CCDDs), 3575–3576
- Congenital cutaneous candidiasis, 4164
- Congenital dermal melanocytosis, 4042, 4042f
- Congenital diaphragmatic hernia (CDH), 1031, 1031f, 1094–1096
- Congenital diarrheal disorders, chronic diarrhea and, 2378–2380, 2379t–2380t
- Congenital diffuse hair loss, 4140–4142
- Menkes kinky hair syndrome, 4141
 monilethrix, 4141, 4141f
- pili annulati, 4141
- pili torti, 4140–4141
- structural defects of hair, 4140
- trichorrhexis invaginata, 4141, 4141f
- trichorrhexis nodosa, 4140, 4141f
- trichothiodystrophy, 4141
- uncombable hair syndrome, 4141–4142, 4142f
- woolly hair disease, 4141
- Congenital disorder of glycosylation IIc (CDG-IIc), 1299
- Congenital disorders
 erythropoietic porphyria, 970–972
 of glycosylation, 921–930, 922f, 925f, 927t
 cardiomyopathy and, 808t
 hepatic dysfunction and, 808t
 inborn errors of metabolism associated with, 809t
 hepatic fibrosis, syndromes associated with, 2500t
 of lung, 2599–2603
 airway malformation, 2599–2601, 2600f–2601f
 bronchobiliary fistula, 2603, 2603f
 bronchogenic cysts, 2602, 2602f
 lung hernia, 2603

- Congenital disorders (*Continued*)
- pulmonary agenesis and aplasia, 2599
 - pulmonary hypoplasia, 2599
 - pulmonary lymphangiectasia, 2602, 2603f
 - pulmonary sequestration, 2601–2602, 2601f
 - lymphocytic choriomeningitis virus infection, 2078–2079
 - of nose, 2545–2547
 - tuberculosis, 1846
 - Congenital dyserythropoietic anemias, 2937–2939, 2938f
 - transcription factor-related, 2939
 - type I, 2937
 - type II, 2937–2938
 - type III, 2938
 - Congenital erythrocyte membrane disorders, 1119
 - Congenital erythropoietic porphyria, 970–972, 4094, 4095f
 - Congenital esophageal stenosis, 2260, 2260f
 - Congenital fibrinogen disorders, 3034
 - Congenital fibrosis, of extraocular muscles, 3575–3576
 - Congenital forms, of multiple pituitary hormone deficiency, 3364
 - Congenital gastric outlet obstruction, 2278t, 2280, 2280t
 - Congenital generalized lipodystrophy (CGL), 3546, 3547t, 4133
 - Congenital goiter, 3413, 3413f
 - Congenital Guillain-Barré syndrome, 3904
 - Congenital hearing loss, 1019–1020
 - Congenital heart disease (CHD), 2763–2772
 - cyanotic, 2774–2775
 - left-to-right shunt lesions, 2776–2787
 - regurgitant lesions, 2797–2798
 - resulting in increased pressure load, 2775
 - resulting in increased volume load, 2774–2775
 - associated with Down syndrome, 369
 - chromosomal aneuploidies and copy number variants associated with, 2767t–2769t
 - clinical genetic tests for, 2770t
 - coronary arteries unassociated with, 2828t
 - cyanotic, 2775
 - decreased pulmonary blood flow, 2800–2811
 - evaluation of the critically ill neonate, 2798–2799, 2799f
 - with increased pulmonary blood flow, 2812–2826
 - disease genes for, 2769t
 - ductus-dependent, 1053t
 - etiology of, 2763–2771
 - general principles of treatment of, 2835–2843
 - in adults, 2838–2843, 2839f
 - atrial septal defects, 2840
 - complete atrioventricular canal, 2840
 - interstage management of, 2838
 - left-to-right shunts, 2840
 - long-term management of, 2838
 - patent ductus arteriosus, 2840
 - postoperative management of, 2836–2838
 - risks in, 2839t
 - survival into adulthood without surgery, 2839t
 - ventricular septal defects, 2840
 - genetics of
 - arrhythmias, 2772t
 - genes and loci associated with, 2764t–2766t
 - isolated, 2773t
 - screening algorithm for, 2742f
 - malformations, anomalies of the aortic arch, 2826
 - obstructive lesion in
 - aortic stenosis, 2790–2793
 - coarctation of the aorta, 2793–2795
 - infundibular pulmonary stenosis and double-chamber right ventricle, 2789–2790
 - peripheral pulmonary stenosis, 2790
 - pulmonary stenosis in combination with an intracardiac shunt, 2790
 - pulmonary valve stenosis with intact ventricular septum, 2787–2789
 - pregnancy and, 2842
 - relative frequency of, 2763t
 - sudden death and, 2860, 2864t
 - Congenital hemangioma, 4057
 - Congenital hepatic fibrosis, 2500t, 2501
 - Congenital hereditary endothelial dystrophy, 3945
 - Congenital hereditary sensory pain syndromes, 3884t–3885t, 3888t, 3889–3892
 - Congenital high airway obstruction syndrome (CHAOS), 1033–1034, 1033f
 - Congenital hyperinsulinism, 988f
 - Congenital hyperthyroidism, 3421–3422
 - clinical manifestations of, 3421, 3421f
 - prognosis of, 3422
 - treatment of, 3421
 - Congenital hypogonadotropic hypogonadism, forms of, 3492t
 - Congenital hypomyelinating neuropathy, 3886
 - Congenital hypopituitarism, 3368, 3368t
 - Congenital hypoplastic anemia, 2931–2933
 - clinical manifestations of, 2931
 - diagnostic criteria for, 2932t
 - differential diagnosis for, 2932
 - epidemiology of, 2931
 - etiology of, 2931, 2931f
 - laboratory findings for, 2931–2932
 - prognosis of, 2933
 - range of congenital anomalies observed in, 2932t
 - treatment for, 2932–2933
 - Congenital hyporegenerative anemia, syndromes associated with, 1121t
 - Congenital hypothyroidism, 3402–3408
 - central (hypopituitary), 3404
 - clinical manifestations of, 3404–3405
 - epidemiology of, 3402
 - etiological classification of, 3402–3404, 3403t
 - laboratory findings of, 3405–3406
 - primary, 3402–3404
 - prognosis of, 3406–3408
 - thyroid function in preterm and low birthweight infants, 3404
 - treatment of, 3406
 - Congenital ichthyosiform erythroderma, 4115–4116, 4115f–4116f
 - Congenital infections, 1143, 1152–1154
 - caused by, 1155t
 - clinical manifestations of, 1152, 1155t
 - cytomegalovirus (CMV) in, 2012–2015, 2012t
 - diagnosis of, 1153–1154
 - general approach to, 1152
 - infectious agents in, 1154
 - intellectual disability caused by, 349t
 - pathogenesis of, 1152, 1152f, 1153t
 - prevention of, 1152, 1154t
 - in syphilis, 1868–1869, 1868f–1869f
 - Congenital insensitivity to pain with anhidrosis (CIPA), 3897, 3898t–3899t, 4134
 - Congenital kyphosis, 4251
 - Congenital lactase deficiency, 2347
 - Congenital large hyperlucent lobe, 2591–2592
 - Congenital lip pits, 2254
 - Congenital lobar emphysema, 2591–2592, 2591t, 2592f
 - Congenital Lyme disease, 1884
 - Congenital malaria, 2173
 - Congenital malformations, 781t
 - associated with congenital heart disease, 2739t–2740t
 - of ear, 3995–3999, 3995t
 - cholesteatoma, 3998–3999, 3999f
 - external auditory canal, stenosis or atresia of, 3996–3997, 3997f
 - inner ear, 3997–3998, 3998t
 - middle-ear, 3997
 - pinna, 3995–3996, 3996f
 - Congenital melanocytic nevus, 4061–4062, 4062f
 - Congenital methemoglobinemia, 2999
 - Congenital microvillus atrophy, 2337–2339
 - Congenital miosis, 3920–3921
 - Congenital mitral insufficiency, 2797
 - Congenital mitral stenosis, 2796
 - Congenital muscle fiber-type disproportion, 3809t, 3810–3811
 - Congenital muscular dystrophies, 3830t–3831t, 3843–3845, 3844f–3845f
 - Congenital muscular torticollis (CMT), 4258, 4259f
 - Congenital myasthenic syndromes (CMSs), 3858–3863
 - clinical features of, 3859t–3860t
 - ocular symptoms in, 3861t
 - Congenital mydriasis, 3921
 - Congenital myopathies, 3805
 - Congenital nail dysplasia, 4142
 - Congenital nasolacrimal duct obstruction (CNLDO), 3937, 3938t
 - Congenital nephrotic syndrome, 3226t, 3232, 3232t, 3254–3255
 - Congenital nonspherocytic hemolytic anemia, 2988
 - Congenital ocular motor apraxia, 3930
 - Congenital oculocutaneous albinism (OCA), 4071
 - Congenital omphalocele, 1131, 1131f
 - Congenital perilymphatic fistula, 3997–3998
 - Congenital peritoneal bands, 2509
 - Congenital phagocyte defects, 1346
 - Congenital polycythemia, 2998–2999
 - Congenital polyplasmid, 3061
 - Congenital pseudarthrosis, of clavicle, 4264, 4264f
 - Congenital ptosis, 3933, 3933f–3934f
 - Congenital pulmonary airway malformation, 1031–1033, 1032f
 - Congenital rib anomalies, 2715–2716
 - Congenital rickets, 475
 - Congenital rubella syndrome (CRS), 1965
 - Congenital scoliosis, 2715, 4247–4248, 4248f–4249f
 - Congenital sideroblastic anemia (CSA), 2950
 - Congenital sodium diarrhea, 2334t–2336t, 2351
 - Congenital subglottic stenosis, 2580
 - Congenital syphilis, 1866, 1871–1872, 2552t
 - diagnosis of, 1873t
 - late manifestations of, 1869t
 - prevention of, 1875
 - treatment of, 1875
 - Congenital talipes equinovarus (CTEV), 4202
 - Congenital thrombocytopenic syndromes, 3051t–3052t, 3057f–3058f
 - Congenital thyroxine-binding globulin (TBG) deficiency, 3402
 - Congenital toxoplasmosis, 2189–2190, 2191t, 2192f, 2195–2197
 - Congenital tufting enteropathy, 2339, 2351
 - Congenital varicella syndrome, 2001–2002, 2001f
 - Congenital vertical talus, 4203–4205, 4205f
 - Congenital vitamin D deficiency, 475
 - Congenital X-linked NDI, 3374
 - Congestive heart failure, dosage of drugs for, 2898t
 - Congestive splenomegaly, 3061
 - Conjoined twins, 1040
 - Conjugate vaccines, 1589, 1589t
 - Haemophilus influenza type b*, 1756t
 - meningococcal, 1745
 - pneumococcal, 2648
 - Conjugated hyperbilirubinemia, inherited, 2456
 - Conjunctiva, disorders of, 3939–3943
 - conjunctivitis, 3939–3942, 3940t
 - other disorders, 3942–3943
 - conjunctival nevus, 3943
 - conjunctivitis, 3939–3942, 3940t
 - C. trachomatis*, 1896–1897
 - granulomatous, 1813f
 - Haemophilus influenza* in, 1758
 - hemorrhagic, 1982
 - in Kawasaki disease, 1543f
 - in newborn, 1148
 - Connective tissue abnormalities, in arthrogryposis, 4271
 - Connective tissue diseases, 4028–4032
 - juvenile dermatomyositis, 4031–4032
 - lupus erythematosus, 4028–4031
 - morphea, 4032
 - risk for osteoporosis, 4384t
 - in secondary intracranial hypertension, 3783t
 - systemic sclerosis, 4032
 - Connective tissue nevus, 4066
 - CONS. See Coagulase-negative staphylococci
 - Consanguinity, 735
 - Conscious sedation, 676
 - Consciousness, disorders of, in traumatic brain injury, 4387t, 4387f
 - Consent
 - informed, legal exceptions to, 1168t
 - right to, minors, 1168
 - Constancy, 156
 - Constipation, 2232, 2292–2294, 2292t–2294t, 2294f
 - associated with neuropathic bladder, 3290
 - causes of, 2233t

- Constipation (*Continued*)
 differential diagnosis for, 2387–2388
 functional, 2386, 2391, 2391t
 opioid-induced adverse effects, 684t
 in pediatric palliative care, 65t–69t, 70
 potential alarm features in, 2388t
 Constitutional growth delay, 176
 Constitutional mismatch repair deficiency syndrome, 3077–3080, 4070t–4071t
 Constrictive pericarditis, 2891
 Consumptive hypothyroidism, 3409
 Contact allergy, 1424
 Contact burns, 655
 Contact dermatitis, 4002, 4087–4090, 4088f, 4089t, 4090f
 allergic, 4088–4090, 4090f
 diaper, 3323, 4088, 4088f, 4089t
 perianal, 1707–1708
 seborrheic, vulvar, 3321t–3322t
 vulvar, 3321t–3322t
 Contact factors, deficiencies of, 3033
 Contact isolation, 1620
 Contact tracing, in pandemic, 1584
 Contact-dependent co-stimulation, 1287
 Contaminated wounds, 1618
 Contiguous gene disorders, 727
 Contiguous gene syndromes, 768t–769t
 Contingency, 137
 Contingent feeding practices, 417
 Continuity of care, 76
 Continuous fetal heart rate monitoring, 1017
 Continuous glucose monitoring systems (CGMs), for T1DM, 3529
 Continuous murmur, 2743
 Continuous positive airway pressure (CPAP)
 nasal, in RDS, 1080
 for respiratory distress and failure, 619
 Continuous renal replacement therapy (CRRT), in acute kidney injury, 3246, 3246t
 Continuum-of-care model, in emergency medical services, 534, 534f, 544–547
 Contraception, 1217–1228, 2843
 in adolescents with special needs, 3356
 barrier methods, 1227
 combined hormonal contraceptives, 1221t, 1222–1225
 condoms, 1227
 emergency contraception, 1225–1227, 1226t
 epidemiology
 contraceptive counseling, 1219–1220
 contraceptive use, 1217–1219
 sexual activity, 1217–1219
 fertility awareness-based methods, 1228
 hormonal, advantages of, 1218t–1219t
 hormonal, polycystic ovary syndrome and, 3337
 lactational amenorrhea method, 1228
 long-acting reversible, 1220–1221
 minor consent laws for, 1168
 progestin-only methods, 1221–1222
 withdrawal, 1228
 Contraceptive patch, 3356
 Contraceptive ring, 3356
 Contractures, 3831, 4197
 of muscle, 3791
 Contralateral inguinal exploration, 2419–2420, 2420f
 Contrast radiographic study, 2265
 Contrast studies, of chronic recurrent aspiration, 2610
 Contrast voiding cystourethrogram, 3277
 Contrast-induced nephropathy, 3203
 Control, in preschoolers, 166
 Control mechanisms, of complement system, 1316–1317
 Control modes, in invasive mechanical ventilation, 624
 Control variable, in invasive mechanical ventilation, 624–625
 Controlled breathing, in pain management, 693
 Controlled hypothermia, 640
 Contusions
 lumbar, 4306–4307
 pulmonary, 576
 Conus medullaris syndrome, 579
 Convection, in heat transfer, 657
 Conventional phototherapy, 1114
 Conventional ventilator settings, 627
 Convergent nystagmus, 3930
 Conversion disorder, 235, 236t, 239t, 4456
 Conversion equivalents, 4415t
 Cooing, 324
 Cooley anemia (homozygous β -thalassemia), 2981–2986
 Coombs test, 2993
 Cooperative play, 165
 Coordinated benefits, comprehensive, in adolescents, 1165
 Coordination, in neurologic evaluation, 3557
 COPA syndrome, 2634t
 COPCs. *See* Chronic overlapping pain conditions
 Coping styles, in T1DM, 3534
 Copper, 483t
 deficiency, 2950
 food-borne illness, 2362t–2364t, 4411t–4413t
 low, mitochondrial disease and, 935t
 Copper histidine therapy, in Menkes disease, 3719–3720
 Coprine poisoning, 4443
 Coproporphyrin, hereditary, 975–976
 Copropraxia, 241
 Copy number variations, 733
 in language disorders, 328–329
 Cor pulmonale, cystic fibrosis and, 2676
 Coral snakes, 4467f
 Cordocentesis, 1018t, 1025
 Core myopathies, 3812–3816
 clinical manifestations of, 3813–3814
 central core disease, 3813, 3813f–3814f, 3814t
 multiminicore disease, 3813–3814, 3815f
 genetics of, 3815
 laboratory findings of, 3814–3815
 treatment and prognosis of, 3815–3816
 Corectopia, 3921
 Cori disease, 900t–901t, 903–904, 903f
 Cori-Forbes disease, 3851, 3852t
 Cornea, 3909
 abnormalities of, 3943–3947
 dendritic keratitis, 3945, 3947f
 dermoids, 3945, 3947f
 dystrophies, 3945, 3946t, 3947f
 interstitial keratitis, 3946, 3948t
 keratoconus, 3943, 3944f
 manifestations of systemic disease, 3946–3947
 megalocornea, 3943
 microcornea, 3943
 neonatal corneal opacities, 3943, 3944t
 Peters anomaly, 3944–3945, 3945f
 phlyctenules, 3945
 sclerocornea, 3943–3944
 ulcers, 3945, 3947f
 superficial abrasions of, 3977, 3977f
 clouding, inborn errors of metabolism and, 809t–810t
 Corneal dystrophies, 3945, 3946t, 3947f
 Corneal foreign body, superficial, 3978f
 Corneal reflex, 591t
 Corneal ulcers, 453–454, 3945, 3947f
 Cornelia de Lange syndrome, 797–798, 798f, 2764t–2766t
 Cornell Assessment of Pediatric Delirium (CAPD), 296f, 297
 Corner fractures, 4278–4279
 Cornification, disorders of, 4110, 4111t–4114t
 Cornified layer, of epidermis, 4025
 Cornoid lamella, 4107
 Coronar plane deformities, 4213f, 4215–4216
 genu valgum, 4216
 genu varum, 4215, 4216f, 4216t
 knock-knees, 4216
 tibia vara, 4215–4216, 4217f–4218f
 Coronary arteries
 abnormalities, in Kawasaki disease, 1540, 1541f
 anomalous origin of, 2828–2830
 fistula, 2787
 translocating, in Jatene procedure, 2814f
 Coronavirus disease 2019 (COVID-19), 3, 1566, 1566f, 1566t, 2039–2046, 2648–2651
 antiviral therapies for, 1953t–1954t, 1956–1957
 in child health, 25–28, 26f
 clinical criteria for, 2043t
 clinical manifestations of, 2042–2046, 2042t–2043t, 2044f–2047f, 2045t, 2649
 Coronavirus disease 2019 (COVID-19) (*Continued*)
 diagnosis of, 2046, 2049t, 2649–2650
 epidemiology of, 2039–2041, 2040f, 2041t
 pathogenesis of, 2041, 2042f
 post-acute sequelae of, 2045–2046, 2049t
 prevention of, 2050t, 2046, 2050t, 2651
 rashes reported in, 2045t
 treatment of, 2046, 2650–2651, 2651t
 vaccination status for, 2650t
 vaccine, 1344
 vaccine hesitancy in, 1611
 vaccines, 1588t–1589t
 Coronavirus NL63, 2038
 Coronaviruses, 2037–2046
 clinical manifestations of, 2038–2039
 diagnosis of, 2039
 epidemiology of, 2039–2041
 etiology of, 2037–2038
 Middle East respiratory syndrome coronavirus, 2039
 nonrespiratory manifestations of, 2038
 prevention of, 2039
 severe acute respiratory syndrome-associated coronavirus, 2038
 treatment of, 2039
 Coronin-1A deficiency, 1263t
 Corporal (physical) punishment, 145
 Corpus callosotomy, in epilepsy surgery, 3615
 Cortical development, malformations of, 3566–3569, 3567t, 3568f
 clinical manifestations and diagnosis of, 3566–3567
 etiology of, 3566
 Cortical hyperostosis, infantile, 4357–4358, 4358f
 Cortical necrosis, 3204
 Corticospinal tract, HSV infection, 1997f
 Corticosteroid therapy
 abrupt cessation of administration of, 3458
 for airway obstruction, 558
 altered sensitivity to, 3450–3462
 antenatal, for neonatal hemorrhage, 1061–1062
 for BPD, 1086–1087
 for caustic esophagitis, 2275
 for Crohn disease, 2321
 for Diamond-Blackfan anemia, 2932–2933
 for drug- or toxin-induced liver injury, 2493
 fluorinated, 1498
 for immune thrombocytopenia, 3054
 inhaled, for asthma, 1400, 1401t–1402t
 intranasal, 208t
 Legionella and, 1810
 in maintenance immunosuppression, 3257
 for meningitis, 3770–3771
 for minimal change nephrotic syndrome, 3228–3229
 for nodular lymphoid hyperplasia, 2414
 oral, for viral coup, 2571
 for *Pneumocystis jiroveci* pneumonia, 1947
 for psoriasis, 4100
 risk assessment for, 1403t
 for sarcoidosis, 1551
 of SLE, 1496
 synthetic, 3449
 systemic
 for asthma, 1401–1402, 1405t–1406t
 for atopic dermatitis, 1415
 for testicular adrenal rest tumors, 3467
 topical, 4039t, 4040
 for atopic dermatitis, 1413, 1417t
 for trigger thumb, 4270
 for tuberculosis, 1851–1853
 Corticosteroid-binding globulin deficiency, 3455
 Corticosteroid-induced atrophy, 4120, 4129, 4129f
 Corticosterone methyloxidase deficiency, 3470
 Corticotropin deficiency, 3458
 Corticotropinoma, 3381
 Cortisol
 deficiency, in 21-hydroxylase deficiency, 3463
 excess, 3475t
 reference intervals, 4472.e9t
 resistance, due to glucocorticoid receptor gene pathogenic variant, 3507
 secretion, 3446f
 regulation, 3446
 Cortisol-binding affinity, decreased, 3455
 Cortisol-growth hormone deficiency, hypoglycemia in, 990

- Cortisone reductase deficiency, 3460
Corynebacterium diphtheriae, 1724–1729
 Coryza, in SARS-CoV, 2038
 Costeff syndrome, 829
 Costello syndrome, 788t, 2764t–2766t, 3126t, 3382
 Costochondritis, 2234
 Co-trimoxazole, 1675t–1685t
 Cotton, burn injuries from, 646
 Cough
 assist device, 2716–2717
 clinical clues about, 2528t
 in common cold, 2553
 in exclusion or inclusion in daycare, 187t–192t
 recurrent/persistent, 2526–2528, 2527t
 respiratory signs and symptoms, 2531t
 Cough reflex, 591t
 chronic recurrent aspiration and, 2609
 Councilman bodies, 2072
 Counseling
 for children with disabilities, 4405
 in children's health, 84–90
 contraceptive, 1219–1220
 for cytomegalovirus (CMV), 2015
 individual and family, 308–309
 pregnancy, 1229
 for seizures, 3604, 3605t
 stages of change and strategies for, 131t
 Counter-regulatory hormones, 982
 Countertransference, 48t
 Cover tests, for strabismus, 3925, 3926f
 Covert toxocariasis, 2210
 Cover-uncover test, 3925
 COVID-19. *See* Coronavirus disease 2019
 Cow's milk
 hypersensitivity to, pulmonary hemosiderosis and, 2689–2690
 protein-based formulas, 412
 Coxa vara, 4239, 4240t
 Coxib drugs, in pain management, 682
Coxiella burnetii. *See* Q fever
 CPAP. *See* Continuous positive airway pressure
 CPAs. *See* Cardiopulmonary arrests
 CPR. *See* Cardiopulmonary resuscitation
 CPS. *See* Child protective services
 CR3/CR4 deficiency, 1322–1323
 Crackles, 2513
 Cradle cap, 4092, 4092f
 CRAFFT mnemonic tool, 1197–1198, 1197t
 Craig test, 4212
 Cramps, heat, 4320
 Cranial bruits, 3552
 Cranial CT angiography, in neuroradiologic procedures, 3558
 Cranial encephalocele, 3564
 Cranial index, in deformational plagiocephaly, 3586
 Cranial length, in deformational plagiocephaly, 3586
 Cranial nerves
 dysgenesis of, 3575–3577
 in neurologic examination, 3552–3554
 Cranial ultrasonography, in neuroradiologic procedures, 3558
 Cranial vault asymmetry, in deformational plagiocephaly, 3586
 Craniectomy, for traumatic brain injury, 586–588
 Cranioectodermal dysplasia, 794t–795t
 Craniofacial anomalies
 in Diamond-Blackfan anemia, 2932t
 otitis media and, 4005
 Craniofrontonasal syndrome, 794t–795t
 Craniopharyngioma, 3124, 3359
 Craniostenosis, 793, 793f, 794t–795t, 3551, 3582–3583, 3582t–3583t
 deformational plagiocephaly and, 3584–3586, 3585t
 Craniotabes, 470, 3552
 Cranium, disorders, 1056–1057
 Cranium bifidum, 3564
 Crazing, 2251t
 CRC. *See* Colorectal carcinoma
 CRD. *See* Chylomicron retention disease
 C-reactive protein (CRP), 1463t
 for osteomyelitis, 4286
 reference intervals, 4472.e9t
 Creams, 4038
 Creatine deficiency, 840, 840f, 3603
 Creatine kinase
 reference intervals, 4472.e9t
 in serum enzymes, 3793, 3799t
 Creatinine
 as performance-enhancing aids, 4325, 4325t–4326t
 reference intervals, 4472.e9t
 Creatinine clearance, reference intervals, 4472.e9t
 Cree myofibrillar myopathy, 3818f
 Creeping eruption, 2202
 Crescent formation, in Bowman's space, 3183
 Crescent sign, 1363
 Cretinism, endemic, 3413–3415
 clinical manifestations of, 3414
 etiology of, 3414
 pathogenesis of, 3414
 treatment of, 3414–3415
 Creutzfeldt-Jakob disease, 2119t, 2121, 2122t–2123t
 Cri du chat syndrome, 767t
 Cricopharyngeal achalasia, 2261
 Cricopharyngeal incoordination, 2261
 CRIES Neonatal Pain Assessment Scale, 680t
 Crigler-Najjar syndrome, 1107
 type I, 2455–2456
 type II, 2456
 Crimean-Congo hemorrhagic fever, 2073, 2075
 Criminal justice system, residential segregation and, 21
 Crisaborole (Eucrisa), 1414
 Crisponi syndrome, 663
 Critical care setting, adrenal insufficiency in, 3459
 Critical deterioration event, 47t
 Critical high airway obstruction syndrome, 1073f
 Critical illness myopathy, 3848
 Critical opening pressure, 622–623
 Critically ill newborn, 1051–1052
 evaluation of, with cyanosis and respiratory distress, 2798–2799, 2799f
 levels of neonatal care, 1051
 regionalized care of, 1051
 transport of, 1051–1052
 treatment of, 51–53
 Crizotinib, 3115
 CRMO. *See* Chronic recurrent multifocal osteomyelitis
 Crocodile bites, 4458t
 Crohn disease, 2310t, 2316–2322, 4033
 associated with AA amyloidosis, 1537
 behavior of, 2318f
 chronic diarrhea and, 2377–2378
 clinical manifestations of, 2311t, 2317f–2318f, 2317
 diagnosis of, 2318–2319, 2318f–2321f
 differential diagnosis of, 2314t–2315t, 2317–2318, 2319t
 prognosis of, 2322
 stenosis in, 2318f
 treatment for, 2320–2322
 Cromolyn sodium
 for allergic rhinitis, 1384t
 for eosinophilic gastroenteritis, 2326
 Crossbite, malocclusion and, 2243
 Crossed adductor response, 3556
 Crossed eyes, 3925
 Crossed renal ectopia, 3262f
 Cross-McKusick-Breen syndrome, 4071
 Crotalidae immune F(ab')2, 1586t
 Crotalidae-specific Fab antibodies, 708t
 Crotalinae, 4466–4467, 4467t
 Crotalinae polyvalent immune Fab antivenom, 4468, 4469t–4470t
 Croup, 2569
 spasmodic, 2570
 Crouzon syndrome, 794t–795t
 in craniostenosis, 3583
 Crow, Jim, 8–9
 Crowns of teeth, injuries to, 2251t
 CRP. *See* C-reactive protein
 CRPS. *See* Complex regional pain syndrome
 CRS. *See* Congenital rubella syndrome
 Crusts, 4027
 Crying
 during age 0–2 months, 152
 infant, 156–157, 157f
 Cryoglobulinemic vasculitis, 1553t, 1565, 1566t
 Cryohydrocytosis, 2963
 Cryoprecipitate, 3019
 for bleeding, 3046
 Cryopreserved amniotic membrane, for Stevens-Johnson syndrome, 4079–4080
 Cryopyrin-associated periodic syndrome (CAPS), 663, 1518
 Cryptic microdeletion, 765f
 Cryptococcal-associated immune reconstitution inflammatory syndrome (C-IRIS), 1926
Cryptococcus gattii, 1925–1927
 clinical manifestations of, 1926
 cutaneous infection and, 1926
 diagnosis of, 1926–1927
 epidemiology of, 1925
 etiology of, 1925
 meningitis/meningoencephalitis and, 1926
 pathogenesis of, 1925
 pneumonia and, 1926
 prevention of, 1927
 sepsis syndrome and, 1926
 skeletal infection and, 1926
 treatment of, 1927
Cryptococcus neoformans, 1925–1927
 clinical manifestations of, 1926
 cutaneous infection and, 1926
 diagnosis of, 1926–1927
 epidemiology of, 1925
 etiology of, 1925
 meningitis/meningoencephalitis and, 1926
 pathogenesis of, 1925
 pneumonia and, 1926
 prevention of, 1927
 sepsis syndrome and, 1926
 skeletal infection and, 1926
 treatment of, 1927
 Cryptogenic epilepsy, 3589
 Cryptogenic liver abscess, 2474f
 Cryptogenic organizing pneumonia, 2595
 Cryptorchidism, 3302–3304, 3489
 iatrogenic, inguinal hernia and, 2421
 unilateral, of testes, 3494
Cryptosporidia, in acute gastroenteritis, 2361–2364
 Cryptosporidiosis, drugs for, 2126t–2144t
Cryptosporidium, 2152
 antibiotic therapy for, 2373t–2375t
 parasitic gastroenteritis and, 2359t
 CSA. *See* Congenital sideroblastic anemia
 CSD. *See* Congenital sodium diarrhea
 CSF. *See* Cerebrospinal fluid
 CSHCN. *See* Children with special health care needs
 C-spine trauma, 576
 CSVT. *See* Cerebral sinus venous thrombosis
 CT. *See* Computed tomography
 CTE. *See* Congenital tufting enteropathy
 CTPs. *See* Comprehensive Transition Programs
 CTR9-associated WT predisposition, 3131t–3132t
 CTX. *See* Cerebrotendinous xanthomatosis
 Cued speech, 341t, 3993
 Cultural competency, 83
 Cultural group, 81
 Cultural humility, 22, 83
 Cultural issues, 81–84
 awareness-assessment-negotiation model, 83–84
 Cultural norms, to treatment, 53
 Cultural safety, 22
 Culturally informed care, 82–84, 82f
 Culture-negative neutrocytic ascites, 2511
 Cultures, 81–82
 in *Coccidioides* spp., 1938
 in context of healthcare, 82–83
 gonorrhea, 1749–1750
 identity and, 81–82
 in *M. pneumoniae*, 1889
 mycobacterial, in tuberculosis, 1848–1849
 Cupping, 116
 in rickets, 472, 473f
 Curcumin, for paracoccidioidomycosis, 1941
 Curly toes, 4209, 4210f
 Currant jelly stool, 2301
 Currarino triad, 2295–2296
 Curriculum modifications, 307
 Cushing disease, 3381
 Cushing reflex, in lumbar puncture, 3762

- Cushing syndrome, 521, 3475–3477, 3475t
 clinical manifestations of, 3476, 3477t
 differential diagnosis of, 3477
 etiology of, 3475–3476, 3476f
 laboratory findings of, 3477, 3478f
 treatment of, 3477
- Cushing triad, 548
- Cutaneous arteritis, 1553t
- Cutaneous bacterial infections, 4150–4159
 diphtheria, 1727
 ecthyma, 4154
 impetigo, 4150–4151
 staphylococcal scalded skin syndrome, 4153–4154
Staphylococcus aureus, 1695
- Cutaneous tissue infections, 4151–4153
- Cutaneous defects, 4043–4046
 accessory tragi, 4044
 amniotic constriction bands, 4043
 aplasia cutis congenita, 4044–4045
 branchial cleft, 4044
 cutis verticis gyrata, 4046
 dyskeratosis congenita, 4046
 focal dermal hypoplasia, 4046
 focal facial dermal dysplasias, 4045–4046
 pilonidal sinus and abscess, 4044
 preauricular sinuses and pits, 4044
 redundant skin, 4043
 skin dimples, 4043
 supernumerary nipples, 4044
 thyroglossal cysts and sinuses, 4044
- Cutaneous disease, in tuberculosis, 1845
- Cutaneous fungal infections, 4159–4166
 candidal, 4164–4166, 4165t
 dermatophytoses, 4160–4164, 4160f
 tinea versicolor, 4159–4160, 4160f
- Cutaneous infection, cryptococcosis and, 1926
- Cutaneous larva migrans, 2201, 2202f
 drugs for, 2126t–2144t
- Cutaneous leishmaniasis
 diffuse, 2158
 localized, 2158, 2159f
- Cutaneous lesions, associated with neurofibromatosis type 2, 3657t
- Cutaneous leukocytoclastic angiitis, 1553t
- Cutaneous lymphocyte-associated antigen, 1410
- Cutaneous manifestations
 grouping of autoinflammatory diseases by, 1522t
 of malignancy, 4033–4034
 of parvovirus B19, 1989–1990, 1989f
 of porphyria cutanea tarda, 973–974
 of SLE, 1492t
 of systemic diseases, 4028–4034, 4029t–4030t
 cutaneous reactions in setting of
 immunosuppression, 4034
 gastrointestinal diseases, 4033
 of malignancy, 4033–4034
 vasculitides, 4032–4033
 of TRAPS, 1526f
- Cutaneous mucormycosis, 1943, 1943f
- Cutaneous nevi, 4061–4066
 acquired melanocytic, 4061
 atypical melanocytic, 4061
 blue, 4064–4065
 congenital melanocytic, 4061–4062
 connective tissue, 4066
 epidermal, 4065–4066
 halo, 4063
 melanoma, 4062–4063
 nevus comedonicus, 4066
 nevus depigmentosus, 4065
 nevus of Ota and nevus of Ito, 4064
 nevus spilus, 4064
 smooth muscle hamartoma, 4066
 Spitz, 4063–4064
 zosteriform lentiginous, 4064
- Cutaneous polyarteritis nodosa, 1560–1561
- Cutaneous porphyrias, 964
- Cutaneous reactions, in setting of immunosuppression, 4034
- Cutaneous reactivity, atopic dermatitis and, 1411
- Cutaneous skeletal hypophosphatemia syndrome, 478
- Cutaneous sporotrichosis, 1941
- Cutaneous viral infections, 4166–4169
 molluscum contagiosum, 4169, 4169f
 wart, 4166–4169, 4167f–4168f
- Cutis laxa, 4375–4377, 4375f–4376f, 4376t–4377t
 autosomal dominant, 4375
 autosomal recessive, 4376–4377
 clinical manifestations of, 4375–4377, 4377t
 histology of, 4377
 treatment of, 4377
- Cutis marmorata, 4041
- Cutis marmorata telangiectatica congenita, 4041, 4041f, 4052, 4054f
- Cutis verticis gyrata, 4046
- Cutting, 284
- CVS. See Cycloid vomiting syndrome
- Cyanide poisoning, 653, 707t–708t, 4448–4449, 4454t
- Cyanobacteria, 4445
- Cyanosis, 1000, 2737
 abnormal hemoglobins causing, 2979
 BRUE and, 2541
 cardiac disease leading to, 2799
 central, 554
 in neonate, and respiratory distress, 2799
 in newborn, 1000
 central cyanosis, 1053
 differential diagnosis, 1054t
 in pertussis, 1762
 respiratory signs and symptoms, 2531t
- Cyanotic congenital heart disease, 2798–2799, 2799f
 decreased pulmonary blood flow, 2800–2811
 double-outlet right ventricle, 2808–2809, 2810f
 Ebstein anomaly of the tricuspid valve, 2809–2811, 2811f
 pulmonary atresia with intact ventricular septum, 2805–2806, 2805f
 tetralogy of Fallot, 2800–2804, 2800f
 with pulmonary atresia, 2804–2805
 transposition of the great arteries with ventricular septal defect and pulmonary stenosis, 2809
 tricuspid atresia, 2806–2808, 2806f–2807f
 extracardiac complications of, 2836t
 with increased pulmonary blood flow, 2812–2826
 double-outlet right ventricle
 with malposition of the great arteries (Taussig–Bing anomaly), 2815
 without pulmonary stenosis, 2815
 D-transposition of the great arteries, 2812, 2812f
 with intact ventricular septum, 2812–2813
 hypoplastic left heart syndrome, 2819–2822
 L-transposition of the great arteries, 2814–2815, 2815f
 single ventricle, 2818–2819
 total anomalous pulmonary venous return, 2815–2817, 2816f–2817f
 transposition of the great arteries, with ventricular septal defect, 2814
 truncus arteriosus, 2817–2818, 2817f
- Cyanotic congenital heart lesions, 2775
- Cyanotic heart disease, 2737, 2841
- Cyberbullying, 101, 283
- Cyclic hematopoiesis, 1308
- Cyclic neutropenia, 1304, 1308–1310, 1309t
- Cyclic vomiting syndrome, 2385, 2389t, 2392–2396, 2392f, 2394t–2396t, 3633
 algorithm for the evaluation of, 2393f
 comorbid disorders and, 2394
 diagnostic tests for, 2394t
 differential diagnosis for, 2394–2395, 2394t
 management of, 2395
 of migraine, 3644
 prevalence of, 2392
 red flags in, 2393f
- Cycling, injuries associated with, 4330
- Cyclobenzaprine, 689t
- Cyclooxygenase (COX) inhibitors, in pain management, 682
- Cyclopeptide (amatoxin) poisoning, 4442–4443
- Cyclophosphamide
 indications and adverse reactions of, 3089t–3090t
 for nephrotic syndrome, 3230
 for rheumatic diseases, 1466t–1468t, 1470
- Cycloplegia, 3912
- Cycloserine
 for drug-resistant tuberculosis, 1852t–1853t
 against *M. tuberculosis*, 1832
- Cyclospora*, 2153
 antibiotic therapy for, 2373t–2375t
- Cyclospora cayetanensis*, parasitic gastroenteritis and, 2359t
- Cyclosporiasis, drugs for, 2126t–2144t
- Cyclosporine, 2249–2250
 for atopic dermatitis, 1416–1417
 for psoriasis, 4100
- Cyclothymic disorder, 260, 261t
- Cylindrical bronchiectasis, 2658
- Cymbalta. See Duloxetine
- CYP21, in steroid 21-hydroxylase genes, 3463
- CYP21P, in steroid 21-hydroxylase genes, 3463
- Cyproheptadine
 for Cushing syndrome, 3477
 for migraine, 3646t–3647t
- Cystadenomas, 3341, 3342f
- Cystathione β -synthase deficiency, 820–821
- Cystathioninemia (cystathionuria), 823–824
- Cysteamine, for cystinosis, 3235
- Cysteine, metabolism defects, 824
- Cystic adenomatoid malformation, congenital, 2599–2601
- Cystic anomalies, renal, 3261–3262
- Cystic diseases of biliary tract and liver, 2500–2502
- Cystic echinococcosis, 2220
- Cystic fibrosis, 521, 2242t, 2423–2424, 2662–2678, 3313, 4190
 anesthetic implications in, 666t
 associated liver disease, 2448–2449
 chronic diarrhea and, 2378
 chronic infection in, 2664–2665
 clinical manifestations of, 2666–2667, 2666f
 complications of, 2662t
 diagnosis and assessment of, 2668
 diagnostic criteria for, 2668t
 epithelial channel defects, 2665f
 genetics of, 2662–2663
 genotype–phenotype correlations in, 734
 liver disease and, 2477–2479, 2478f, 2479t
 lung infection, antimicrobial agents for, 2674t
 pathogenesis of, 2664–2666
 pathology of, 2666
 prevalence of, 2663f
 prognosis for, 2678, 2678f–2679f
Pseudomonas aeruginosa in, 1800
 pulmonary infection in patients with, 2672t
 related diabetes, 2667, 2677
 screening for, 4472.e6
 survival rate, 2–3
 treatment for, 2671–2675
 intestinal complications, 2677
 pulmonary complications, 2675–2677
 variant, 2665f
- Cystic fibrosis transmembrane conductance regulator (CFTR)
 modulator therapies, 2672–2673, 2672t, 2673f
 other physiologic measures of, 2669
 pathogenic variants, 2664f
 related disorder, 2671, 2671f
 related metabolic syndrome, 2671
- Cystic fibrosis-related diabetes (CFRD), 3548
- Cysticercosis, 2218–2219, 2219f
- Cystine
 calculi, 3314
 poisoning, 724
- Cystinosis, 3234–3235
- Cystinuria, 2349, 3242, 3312f, 3313–3314, 3315t
- Cystitis
 acute, treatment of, 3267
 hemorrhagic, in adenoviruses, 2034
 infectious causes of, 3218
 symptoms of, 3264
- Cystoisospora*, 2153
- Cystoisosporiasis, drugs for, 2126t–2144t
- Cysts, 4027
 breast, 3332
 bronchogenic, 2602, 2602f
 choledochal, 2500
 choroid plexus, fetal, 1026t

- Cysts (*Continued*)
 dental lamina, 2253
 dentigerous, 2254
 eruption, 2254
 esophageal duplication, 2261
 neuroenteric, 2261
 paramesial urethral, 3301
 paraurethral, 3301, 3301f
 renal, and diabetes syndrome, 504
 saccular, 2576, 2576f
 splenic, pseudosplenomegaly and, 3061
 thyroglossal, 4044
 urachal, 3287
- Cytarabine, indications and adverse reactions of, 3089t–3090t
- Cytochrome P450 (CYP), 227
 CYP3A4, 2490
 in steroid biosynthesis, 3445f
 and susceptibility to porphyria cutanea tarda, 973
- Cytochrome P450 oxidoreductase (POR), 3507
- Cytochrome-c oxidase, 2483–2484
- Cytogenetic aberrations, 782–783
- Cytokine release syndrome, 3090–3091
- Cytokine storm, 1538
- Cytokines, 1286–1287
 in hematopoiesis, 2922f
 major sources and actions of, 1291f
 T-helper type 2, 1369f
- Cytomegalovirus (CMV), 1019–1020, 1586t, 2010–2015
 antiviral therapies for, 1953t–1954t
 clinical manifestations of, 2012–2013
 complication of HSCT, 1363
 in congenital infection, 2012–2015, 2012t–2013t
 diagnosis of, 2013–2015, 2014t
 epidemiology of, 2010–2012
 HIV in, prophylaxis to prevent, 2111t–2113t
 in immunocompromised host, 2012
 kidney transplant immunosuppression and, 3258
 mechanisms of disease associated with, 2011–2012
 neonatal infection, 1152
 in normal host, 2012
 pediatric heart transplantation and, 2904
 in perinatal infection, 2013
 in postintestinal transplantation, 2354
 prevention of, 2015
 active immunoprophylaxis, 2015
 counseling, 2015
 passive immunoprophylaxis, 2015
 sensorineural hearing loss and, 3984
 transfusion-associated, 3020
 treatment of, 2015
 in viral meningoencephalitis, 3772
 virus and host interaction, 2010
- Cytopenia, in hypersplenism, 3061
- Cytopenias, autoimmune, 1329–1330
 clinical manifestations of, 1330
 diagnosis of, 1330
 immunodeficiencies associated with, 1330
 pathophysiology of, 1329–1330, 1330t
 treatment of, 1330
- Cytosolic acetoacetyl-CoA thiolase deficiency, 831
- Cytotoxic antibody reactions, 1455
- Cytotoxic T lymphocyte antigen (CTLA4) haploinsufficiency, with autoimmune infiltration, 1332t–1333t
- D**
- Dabska tumor, 3162
- Dacryoadenitis, 3940t, 3973, 3974f
- Dacyrocystitis, 3937, 3940t, 3973, 3974f
- Dacryocystocele, 3937, 3938f
- Dacryostenosis, 3937
- Dactinomycin, indications and adverse reactions of, 3089t–3090t
- Dactylitis, in sickle cell anemia, 2969
- DAD. *See* Diffuse alveolar damage
- DAF. *See* Decay-accelerating factor
- DAH. *See* Diffuse alveolar hemorrhage
- DALD. *See* Dianzani autoimmune lymphoproliferative disease
- Dance, injuries associated with, 4332
- Dance therapy, in pain management, 693
- Dancer's fracture, 4332
- Dandy-Walker malformation
 in brainstem and cerebellar disorders, 3576, 3576f
 in encephalocele, 3564–3565
- Dangerous underwater breath-holding behaviors (DUBBs), 638
- Danon disease, 900t–901t, 908, 3851
- Dantrolene sodium
 for malignant hyperthermia, 3851
 for spasticity, 4394, 4395t
- Dapagliflozin, for T2DM, 3542t
- Dapsone
 for Hansen disease, 1858
 against *Mycobacterium leprae*, 1833
- Daptomycin, 1675t–1685t, 1690, 1724
 enterococci resistance, 1723t
 for *Staphylococcus aureus*, 1697
- Darier disease, 4105–4106, 4106f
- Dark-light cycle, 201
- Darunavir, for HIV, 2098t–2107t
- Dasatinib, 3088t
 for gastrointestinal stromal cell tumors, 2414–2415
- Date rape, 1237t
- Dating violence, 1189
- Daunorubicin, indications and adverse reactions of, 3089t–3090t
- Davidenkow syndrome, 3876
- Dawn phenomenon, in T1DM, 3534
- Daydreaming, that mimic seizures, 3637–3638
- Daytime frequency syndrome, of childhood, 3295
- DBGI. *See* Disorders of brain-gut interaction
- DBS. *See* Deep brain stimulation
- DDH. *See* Developmental dysplasia of the hip
- De Barys syndrome, 4376t
- De novo proline synthesis, disorders of, 842
- Dead space ventilation, 614, 2518–2519
 assessment of, 628–629
- Deaf Plus, 344, 344t
- DeafBlind project, 344
- Deaf/hard of hearing (D/H/H), 339–345
 academic considerations, 343–344
 anxiety, 344
 caused by pathogenic variants in mtDNA, 743t
 culture, 339–340
 early detection in, 340, 340t
 family journey, 344–345, 345t
 interventions for, 341–343
 cochlear implants, 342–343
 communication approaches in, 341, 341t–342t
 hearing aids, 341–342
 supports and factors influencing amplification decisions, 343
 technology in, 341–343
- language development in, 340
- language learning, 343
- mitochondrial disease and, 935t
- psychosocial well-being in, 344
- sensorineural, and renal anomaly syndrome, hypoparathyroidism and, 3435–3436
- Death
 causes
 among 15- to 19-year-olds, 1187t
 due to injuries, 92t
 leading causes in U.S., 2t–3t
 under-five, 1, 2f
 worldwide, 1
 children's responses to, 199
 declaration of, 53
 in family member, 197
 heart transplantation and, 2904f
 from human-made disasters, 197–198
 of natural catastrophes, 197–198
 neonatal, in relation to Apgar score, 1005t
 of parent or sibling, 196–197
 sudden, 2860–2864
- Death by neurologic criteria (DNC), 53
- DEB. *See* Dystrophic epidermolysis bullosa
- DEBONEL. *See* Dermacentor-borne necrosis and lymphadenopathy
- Debrancher deficiency, 903–904, 903f
- Debridement, 649
- Decay-accelerating factor (DAF), 1316–1317
 deficiency of, 1322
 in paroxysmal nocturnal hemoglobinuria, 2964
- Decelerations, of fetal heart rate, 1019t, 1019t
- Decimal factors, prefixes denoting, 4472.e8t
- Decision-making
 in adolescent, 1162
 in pediatric palliative care, 58–60, 60f, 60t
- Declaration of the Rights of the Child, 1
- Decompensated shock, 560
- Decontamination, poisoning, 706–709, 708t
 gastric lavage, 708
 single-dose activated charcoal, 708–709
 syrup of ipecac, 708
 whole-bowel irrigation, 709
- Deep brain stimulation (DBS), 3694
 in epilepsy surgery, 3615–3616
- Deep breathing, 58t
- Deep morphea, 1508t
- Deep sedation, 667, 668t, 676
- Deep tendon reflexes, in neurologic evaluation, 3556
- Deep venous thrombosis (DVT), 2692, 4284
 spinal cord injury and, 4389
- Deer tick, Lyme disease and, 1881
- DEET. *See* Diethyltoluamide
- Defecation disorders, 2391
- Deferasirox, 2983
- Deferiprone, 2983–2984
- Deferoxamine, 2975–2976
 for iron toxicity, 707t–708t, 715
- Defibrillation, 564–565
- Deficiency of adenosine deaminase 2 (DADA2), 1526–1527, 1560, 1561f
- Deficiency of IL-1 receptor antagonist (DIRA), 1528
- Deficiency of interleukin-36 receptor antagonist (DITRA), 1528
- Deficient brain growth, 1136
- Deficit therapy, 529–532
 adjusting therapy, 530–531, 530t
 clinical manifestation, 529, 529t
 fluid deficit, calculation of, 530
 hypernatremic dehydration, 531–532, 532f
 hyponatremic dehydration, 531
 laboratory findings, 529–530
 severe dehydration, approach to, 530, 530t
- Definitive therapy, for hyperthyroidism, 3420–3421
- Deformational plagiocephaly (DP), 3584–3587
 causes of, 3584
 craniosynostosis and, 3584–3586, 3585t
 epidemiology and etiology of, 3584
 history and physical examination for, 3584–3586,
 3585f–3586f, 3585t
 lateral and posterior, 3586t
 outcomes of, 3587
 risk factors for, 3584, 3584t
 treatment of, options of, 3587, 3587t
- Deformations, 779f
 resulting from uterine compression, 781f
- Deformity correction, 4220
- Degenerative ataxias, 3673
- Degludec, for T1DM, 3529
- Deglycosylation, congenital disorders of, 930
- Degranulation abnormalities, 1297t–1298t
- Dehydration, 1633
 from cholera, 1786, 1787f
 clinical evaluation of, 529t
 heat illness and, 4321
 hypernatremic, 529, 531–532, 532f
 hyponatremic, 529, 530t, 531
 polycythemia and, 1126
 severe, approach to, 530, 530t
 in severe wasting, 430
 systemic, 3375
 in T1DM, treatment of, 3524–3527
- Dehydroepiandrosterone (DHEA)
 action of, 3446
 secretion, regulation of, 3446
 testosterone precursors, 4325
- Dehydroepiandrosterone sulfate
 action of, 3446
 secretion of, 3446f
- Deiodination, defects in, 3403
- Déjerine-Sottas disease, 3886

- Del Castillo syndrome, 3489
 Delamanid
 for drug-resistant tuberculosis, 1852t–1853t
 against *M. tuberculosis*, 1833
 Delayed myelopathy, 4418
 Delayed-sleep-wake phase disorder (DSWPD), 214
 Delayed-type hypersensitivity reaction, 1455
 Deletions, 731, 732t, 767–770, 767t
 Delirium, 287–288, 294–299
 acute onset, 294–295
 assessment of, 295–297
 diagnosis of, 294–295, 295t
 differential diagnosis of, 297t, 298
 epidemiology of, 295
 etiology of, 295, 297t
 hyperactive, 295, 295t
 hypoactive, 295, 295t
 mixed, 295, 295t
 in pediatric palliative care, 65t–68t, 70
 rating scales of, 296f, 297
 subtypes of, 295t
 treatment of, 298–299
 course and sequelae, 299
 nonpharmacologic, 298, 298t
 pharmacologic, 298–299
 Delivery devices and inhalation technique, for asthma, 1406
 Delivery room emergencies, 1070–1073
 abdominal wall defects, 1072–1073
 airway obstruction, 1072
 injury during delivery, fractures, 1073
 meconium, 1071–1072
 neonatal encephalopathy, 1072
 neonatal resuscitation, 1070–1071, 1070f–1072f
 placental abruption, 1072
 pneumothorax, 1072
 pulmonary disorders, 1072
 Delivery strategies, effective, 29–32, 32f
 Delusions, 285
 Demeclocycline, 1675t–1685t
 Demographics, and high-risk infant, 1038t
 Demoralization, 132
 Demyelinating disorders, of central nervous system, 3722–3741, 3723t–3724t
 acute disseminated encephalomyelitis, 3722–3725, 3723t–3724t, 3725f, 3726t
 multiple sclerosis, 3723t, 3726t, 3731–3733, 3732f, 3732t, 3734t–3737t
 myelin oligodendrocyte glycoprotein-associated disorders, 3723t, 3726f, 3733–3738, 3739f
 neuromyelitis optica spectrum disorders, 3723t, 3738–3741, 3740f, 3741t
 optic neuritis, 3725–3727, 3726f
 transverse myelitis, 3727–3731, 3727t–3728t, 3729f, 3730t, 3731f
 Demyelination, 3754
 mitochondrial disease and, 935t
 Demystification, of neurodevelopmental dysfunctions, 307
 Dendritic keratitis, 3945, 3947f
 Dengue fever, 1637, 2067–2071
 clinical manifestations of, 2068
 complications of, 2070
 diagnosis of, 2069–2070, 2069f
 differential diagnosis of, 2070
 epidemiology of, 2067–2068, 2068f
 etiology of, 2067, 2067t
 laboratory findings of, 2070
 pathogenesis of, 2068
 prevention of, 2071
 prognosis for, 2070
 treatment of, 2070
 Dengue hemorrhagic fever, 2067–2071
 clinical manifestations of, 2069
 complications of, 2070
 diagnosis of, 2069–2070, 2069f
 differential diagnosis of, 2070
 epidemiology of, 2067–2068
 etiology of, 2067, 2067t
 laboratory findings of, 2070
 pathogenesis of, 2068
 prevention of, 2071
 prognosis for, 2070–2071
 treatment of, 2070
 Dengue shock syndrome (DHF/DSS), 2069
 treatment of, 2070
 Dengue vaccine, 1588t–1589t
 Dengue-like diseases, 2067
 Dennie-Morgan folds, 1375, 1375f
 Dens in dente, 2240
 Dens invaginatus, 2240
 Dense deposit disease, 3194
 Dense granule deficiency, 3059–3060
 Dent disease, 473t, 478, 507, 3242
 Dental abscess, 2247, 2247f
 Dental anomalies, craniosynostosis and, 794t–795t
 Dental assessment, diagnostic radiology in, 2255
 Dental care
 for children with disabilities, 4407
 with long-term mechanical ventilation, 2729
 Dental caries, 2246–2249
 clinical manifestations of, 2246–2247, 2247f
 complications of, 2247, 2247f–2248f, 2248t
 epidemiology of, 2246, 2246f
 etiology of, 2246, 2246f
 prevention of, 2248–2249, 2249t
 treatment for, 2247–2248
 Dental crowding, malocclusion and, 2243
 Dental development, growth and, 177, 178t
 Dental erosions, GERD and, 2268
 Dental lamina cysts, 2253
 Dental phenotypes, in progeria, 957
 Dental sealant, for dental carries, 2249
 Dental speech appliances, 2244
 Dental trauma, 2250–2252
 Dentatorubral-pallidoluysian atrophy, 745t–746t
 Dentigerous cysts, 2254
 Dentin, 2247f
 Dentin fracture, enamel and, 2251t
 Dentinogenesis imperfecta, 2241, 2241f, 2245, 4359
 Dentoalveolar infection, 2248t
 Denys-Drash syndrome (DDS), 3131t–3132t, 3232, 3255, 3481, 3501, 3509
 Deoxynivalenol, 4413
 Department of Health and Human Services (DHHS), 8
 Depo-Medrol (IM), for asthma, 1405t–1406t
 Depo-Provera, 1218t–1219t
 Depressed mottle responses, 1297t–1298t
 Depression
 in adolescents, 1169–1170
 among GLB youth, 1183
 causes of, 219t
 CNS, after use of inhalants, 1203t
 cystic fibrosis and, 2678
 differential diagnosis of, 297t, 298
 disparities in, 14–15
 Down syndrome and, 373
 maternal, 139f
 medications for, 227t
 in pediatric palliative care, 69t, 70–71
 in T1DM, 3535
 of teen mothers, after childbirth, 1230
 Depression-specific rating scales, 258t
 Depressive disorders, 254–260, 258t
 clinical course, 259
 comorbidity, 257–258
 definition of, 254
 diagnosis of, 256
 differential diagnosis, 257
 epidemiology of, 255
 etiology of, 256
 level of care, 259
 pharmacologic treatment of, 259
 prevention of, 260
 psychotherapies of, 259
 risk factors of, 256
 screening, 256
 sequelae, 259
 treatment of, 258–259
 Deprivation amblyopia, 3915
 Dermacentor-borne necrosis and lymphadenopathy (DEBONEL), 1900t–1902t
 Dermal decontamination, 706
 Dermal melanocytosis, congenital, 4042, 4042f
 Dermal sinus, congenital, 3564
 Dermatitis
 atopic, 1410–1419
 avoiding triggers, 1416t, 1418–1419
 clinical manifestations of, 1411, 1412f–1413f
 complications of, 1419
 diagnosis and differential diagnosis of, 1411–1412, 1413t–1414t
 etiology of, 1410
 laboratory findings of, 1411
 pathogenesis of, 1410–1411, 1411f
 pathology of, 1410
 prevention of, 1419
 prognosis for, 1419
 treatment of, 1412–1418, 1416t–1417t
 cancer and, 3091
 niacin deficiency and, 462
 Dermatitis herpetiformis (DH), 4086, 4086f
 Dermatofibroma, 4187, 4187f
 Dermatofibrosarcoma protuberans (DFSP), 3139t–3140t
 Dermatographism, 1378, 1428
 Dermatologic changes, in progeria, 956
 Dermatologic diseases, 4041–4043
 congenital dermal melanocytosis, 4042, 4042f
 cutis marmorata, 4041
 eosinophilic pustular folliculitis, 4043
 erythema toxicum, 4042, 4042f
 harlequin color change, 4041
 infantile acropustulosis, 4042–4043, 4043f
 milia, 4041
 nevus simplex, 4041
 sebaceous hyperplasia, 4041, 4041f
 sucking blisters, 4041
 transient neonatal pustular melanosis, 4042, 4042f
 vulvovaginal, 3323–3324
 Dermatologic evaluation, 4027–4038
 biopsy of skin, 4027
 history and physical examination of, 4027
 immunofluorescence studies, 4028
 potassium hydroxide preparation, 4027
 Tzanck smear, 4027–4028
 Wood lamp, 4027
 Dermatologic manifestations, of tuberous sclerosis, 3658f
 Dermatologic therapy, principles of, 4038–4040
 antifungal agents, 4039–4040
 bath oils, 4039
 colloids, 4039
 keratolytic agents, 4039
 lubricants, 4039
 pastes, 4039
 powders, 4039
 shampoos, 4039
 soaps, 4039
 tar compounds, 4039
 topical antibiotics, 4040
 topical corticosteroids, 4039t, 4040
 topical nonsteroidal antiinflammatory agents, 4040
 ultraviolet phototherapy, 4040
 wet dressings, 4038–4039
 Dermatomyositis, 3794
 calcifications in, 1506f
 Dermatophytes, 4160–4164, 4160f
 epidemiology of, 4160
 etiology of, 4160
 tinea capitis, 4160–4162, 4161f
 tinea corporis, 4162, 4162f
 tinea cruris, 4163
 tinea nigra palmaris, 4164
 tinea pedis, 4163, 4163f
 tinea unguium, 4164, 4164f
 Dermatoses
 acute febrile neutrophilic, 1582
 external ear, 4002
 in vulvovaginitis, 3323–3324
 Dermatosparaxis, 4373–4374
 Dermis, 4025f, 4026
 diseases of, 4119–4128
 Dermoid cyst, 3340–3341, 3943
 Dermoids
 corneal, 3945, 3947f
 nasal, 2547f

- Dermolipoma, 3943
 Desbuquois syndrome type 1 (*DBQ1*), 955
 Descemet's membrane, 3969
 Desflurane, 669t, 670
 Desloratadine, for allergic rhinitis, 1382t–1383t
 Desmoplastic small round cell tumor, 3168
 Desmopressin
 for bleeding, 3046
 for von Willebrand disease, 3036
 Desmopressin acetate
 for factor VIII deficiency, 3030–3032
 for nocturnal enuresis, 3296
 Destructive paranasal sinusitis, with intracranial extension, 1943
 Detemir, for T1DM, 3529
 Developing world, EMSC in, 544–547
 Developmental brain abnormality, intellectual disability caused by, 349t
 Developmental coordination disorder, 301
 Developmental delay, 179, 346–362
 in adopted children, 74
 anesthetic implications in, 666t
 disparities in, 15
 screening scheme for, 3551t
 Developmental disregard, 4399
 Developmental dissociation, 179
 Developmental dysfluencies, 165, 333–334
 Developmental dysplasia of the hip (DDH), 4231–4236
 clinical findings of, 4233–4234, 4233f
 infant, 4233, 4233f
 neonate, 4233
 walking child, 4234
 complications of, 4236
 diagnostic testing of, 4234–4235, 4235f
 radiography, 4234–4235, 4235f
 ultrasonography, 4234, 4234f
 epidemiology of, 4232
 etiology and risk factors, 4232
 pathoanatomy of, 4232
 treatment for, 4235–4236, 4236f
 Developmental encephalopathy, 3588
 Developmental epileptic encephalopathy, 3588
 Developmental hemostasis, 3028
 Developmental language disorder, 328
 Developmental milestones
 in early, middle, and late adolescence, 1158t
 in first two years of life, 153t
 Developmental models, 136–142
 biologic influences, 136–137
 developmental domains and theories of emotion and cognition, 139–140
 psychologic influences, 137
 social factors, 137–138
 statistics used in describing growth and development, 140–142
 unifying concepts, 138–139
 Developmental relationship-based intervention (DRBI), 380
 Developmental risk, 139
 Developmental screening, 180–181
 comprehensive evaluation of, 181–182
 evidence-based tools for, 180t–181t
 implementation of, 182
 ongoing management of, 182
 red flags in, 179t
 referral and intervention of, 182
 screening test properties for, 181
 Developmental stuttering, 333–334
 Developmental surveillance, 178–182
 components of, 179t
 comprehensive evaluation of, 181–182
 elements of, 178
 histories in, 179–180
 implementation of, 182
 observation in, 180
 ongoing management of, 182
 red flags in, 179t
 referral and intervention of, 182
 Developmental theories, 136–142
 Deviant development, definition of, 179
 Deviation, definition of, 179
 Deworming, 2202, 2218
 Dexamethasone, 3846
 for acute mountain sickness, 633, 633t
 for airway obstruction, 558
 for asthma, 1405t–1406t
 for HACE, 633–634
 indications and adverse reactions of, 3089t–3090t
 suppression test, in Cushing syndrome, 3477
 Dexedrine. *See* Dextroamphetamine
 Dexmedetomidine, 669t, 671, 689t
 for mechanical ventilation, 619
 Dexmethylphenidate, for ADHD, 225t–226t
 Dextroamphetamine, for ADHD, 225t–226t
 Dextrocardia, 2824
 Dextrose, 707t–708t
 for infants of diabetic mothers, 1142–1143
 for pediatric resuscitation and arrhythmias, 563t
DGAT1 variants, 2341
 DHE. *See* Dihydroergotamine
 DHHS. *See* Department of Health and Human Services
 Diabetes insipidus, 3372–3374
 central, 490, 3373–3374
 clinical parameters of, 3375t
 treatment of, 3374
 nephrogenic, 490, 3374
 treatment of, 3374
 in patient with polyuria, polydipsia, and hypernatremia, 3373
 physiology of water balance, 3372
 Diabetes mellitus, 3515–3549
 anesthetic implications in, 666t
 classification of, 3515–3517, 3516t
 cystic fibrosis and, 2667, 2677, 3548
 diagnostic criteria for, 3517t
 drugs for, 3548
 genetic syndromes associated with, 3547t, 3548
 gestational, 1140
 insulin-dependent, 516
 key features of, 3518t
 mitochondrial disease and, 935t
 other etiologies of, 3516
 other specific types of, 3515–3516, 3542–3549
 permanent neonatal, 3515–3516, 3543, 3544f
 prediabetes and, 3516–3517
 transient neonatal, 3515–3516, 3542–3543, 3544f
 type 1, 3515, 3517–3538
 anxiety and depression in, 3535
 autoantibodies in, 3521
 characteristics at presentation for, 3539t
 clinical manifestations of, 3523
 cognitive function in, 3534
 coping styles in, 3534
 diabetic nephropathy in, 3536–3537
 diabetic neuropathy in, 3537–3538
 diabetic retinopathy in, 3536, 3537t
 diagnosis of, 3523–3524
 eating disorders in, 3535–3536
 environmental factors in, 3519–3521
 epidemiology of, 3517, 3517f
 fear of self-injecting and self-testing, 3535
 genetics of, 3517–3519, 3521
 during infections, management of, 3535–3536, 3535t
 key features of, 3518t
 long-term complications, relation to glycemic control, 3536–3537
 nonadherence in, 3534–3535
 onset of clinical disease in, 3522
 other complications of, 3537–3538
 pancreas and islet transplantation and regeneration in, 3538
 pathogenesis and natural history of, 3520–3522, 3520f
 pathophysiology of, 3522–3523, 3523t
 prediction of, 3522
 prevention of, 3522
 prognosis for, 3538
 skeletal effects of, 3537
 during surgery, management of, 3536, 3536t
 treatment of, 3524–3528, 3524t
 type 2, 3515, 3538–3542
 characteristics at presentation for, 3539t
 clinical features of, 3539–3541
 complications of, 3542, 3543t
 Diabetes mellitus (*Continued*)
 environmental and lifestyle-related risk factors for, 3539
 epidemiology of, 3538–3539, 3540f
 epigenetics and fetal programming in, 3539
 genetics in, 3539
 key features of, 3518t
 natural history of, 3538, 3540f
 prevention of, 3542
 testing for, 3541t
 treatment of, 3541, 3542t
 Diabetic embryopathy, 1140
 Diabetic ketoacidosis, 1140
 treatment of, 3524, 3524t, 3525f–3526f, 3527
 Diabetic mothers, infants of, 987, 1140–1143
 clinical manifestations of, 1140–1142, 1141f
 morbidity in, 1141t
 pathophysiology of, 1140, 1140f
 prognosis for, 1143
 treatment of, 1142–1143, 1142f
 Diabetic nephropathy, in T1DM, 3536–3537
 Diabetic neuropathy, in T1DM, 3537–3538
 Diabetic retinopathy, 3961–3962, 3962f
 in T1DM, 3536, 3537t
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
 for ADHD, 309, 310t
 for brief psychotic disorder, 285t
 for catatonia, 292t
 for conduct disorder, 279t
 for gender dysphoria, 1173t
 for intermittent explosive disorder, 278t
 for oppositional defiant disorder, 278t
 for PMDD, 1216t
 for psychotic disorder due to another medical condition, 291t
 for schizophrenia, 286t
 for schizopreniform disorder, 286t
 for self-injurious behaviors, 284
 Diagnostic clues, to autoinflammatory syndromes, 1524t
 Diagnostic criteria
 of bronchopulmonary dysplasia, 1085t
 for fetal alcohol spectrum disorder, 1136
 for polycystic ovary syndrome, 334t
 of rheumatic fever
 major criteria, 1712–1713
 minor criteria, 1713–1714
 of staphylococcal toxic shock syndrome, 1699t
 Diagnostic error, 45–47, 48t–49t, 50f
 Diagnostic evaluation, of tall stature, 3385f
 Diagnostic imaging, 3086
 in fetal assessment, 1018t
 intrauterine, of fetal disease, 1024–1028, 1025t
 in JDM, 1502
 MRI of hypoxic-ischemic injury, 1066t
 of urinary tract obstruction, 3275–3276
 Diagnostic laboratory testing, for sarcoidosis, 2622
 Diagnostic momentum, 48t
 Diagnostic overshadowing, 340
 Diagnostic psychologic testing, for intellectual disability, 356
 Diagnostic radiology, in dental assessment, 2255
 Diagnostic testing
 ethics and, 729
 genetic, 749–751, 750f–751f
 for infective endocarditis, 2868f
 in porphyrias
 first-line, 965
 second-line, 965
 for subclinical porphyria, 965
 Diagnostic time-out, 49t
 Dialectical behavioral therapy (DBT), 231, 276
 Dialogic reading, 165
 Dialysis
 in acute kidney injury, 3246–3247
 peritoneal
 in acute kidney injury, 3246t, 3252–3253
 catheters, 1670
 in ESRD, 3252
 Diamond-Blackfan anemia, 2931–2933
 clinical manifestations of, 2931
 diagnostic criteria for, 2932t

- Diamond-Blackfan anemia (*Continued*)
 differential diagnosis for, 2932
 epidemiology of, 2931
 etiology of, 2931, 2931f
 laboratory findings for, 2931–2932
 osteosarcoma and, 3141
 prognosis of, 2933
 range of congenital anomalies observed in, 2932t
 treatment for, 2932–2933
- Dianzani autoimmune lymphoproliferative disease (DALD), 1332t–1333t
- Diaper dermatitis, 3323, 4088, 4088f, 4089t
 in immunocompetent patient, 1923
- Diaper rash, in exclusion or inclusion in daycare, 187t–192t
- Diaphragm
 barrier contraception, 1227
 eventration of, 1096
 pacing, for CCHS, 2721–2722
- Diaphragmatic hernia, 1053t, 1094–1096, 1094f
- Diaphyseal fractures, 4280
- Diaphysis, 4193
- Diarrhea, 527, 528t, 2227–2232
 acute, 533
 bacterial, in acute gastroenteritis, 2357t–2358t, 2368t
 burden of childhood, 2355–2375
Campylobacter species associated with, 1789t
 chloride-losing, 499–500
 clinical evaluation of, 2356t–2359t, 2367–2368, 2369f, 2370t
 combined oral contraceptives and, 1224f
 differential diagnosis of, 2233t
 early-onset, disorders leading to, 2334t–2336t
 endemic, 2355, 2356t
 in exclusion or inclusion in daycare, 187t–192t
 functional, 2378, 2385, 2388t
 infectious, 2377, 2377t
 antibiotic therapy for, 2373t–2375t
 measles and, 1961
 mechanisms of, 2232t
 from neuroendocrine tumors, 2383–2384, 2384t
 in newborn, 1054
 nonspecific, 2378
 nosocomial, 2356–2359, 2357t–2358t
 osmotic, 2376, 2376f
 outbreaks, 2356
 in pediatric palliative care, 69t, 70
 persistent, 2355, 2376
 antimicrobial treatment for, 2383t
 inborn errors of metabolism and, 809t–810t
 postinfectious, 2342
 prolonged, 2355
 protozoal, in acute gastroenteritis, 2359t, 2367
 protracted, 2376
 in schistosomiasis, 2215
 secretory, 2376, 2376f
 syndromic, 2339
 traveler's, 2375–2376
 viral, in acute gastroenteritis, 2356t, 2364–2367
- Diarrhetic shellfish poisoning, 4445
- Diastematomyelia, 3564, 3786–3787, 3787f
- Diastolic blood pressure, shock in, 607t
- Diastolic murmurs, 2745
- Diastrophic dysplasia, 4348, 4348f
- Diazepam, 689t
 dosages of, 3609t–3610t
 for spasticity, 4395t
 for tetanus, 1823
- Dibothrioccephalus* spp., 2217
- DIC. See Disseminated intravascular coagulation
- DICER1* syndrome, 3131t–3132t
- Dichlorodiphenyltrichloroethane (DDT), 4422
- Dichotomous trait, 801
- Diclofenac sodium, in pain management, 681t
- Dicloxacillin, 1675t–1685t
- DIDMOAD, 3545
- Diencephalic seizures, 3633
- Diencephalic syndrome, 3117–3118
- Dientamoeba fragilis* infection, 2204
 drugs for, 2126t–2144t
- Diet
 acne and, 4178–4179
 for acute gastroenteritis, 2371–2372, 2372f
- Diet (*Continued*)
 for celiac disease, 2330t
 for cystic fibrosis, 2676
 for dental carries, 2249
 for heart failure, 2897
 in T1DM, 3519–3520
- Dietary fiber, 394
- Dietary Guidelines for Americans, 388–391
- Dietary intake, inadequate
 of folate, 2940–2941
 of vitamin B₁₂, 2942
- Dietary reference intake (DRI), 388–391, 388t–390t, 391f, 394t
- Dietary sodium restriction, 3252
- Dietary supplements, 56, 56t
 efficacy of, 57
 hepatotoxic, 2492t
 poisoning, 717t
 safety of, 56–57, 57t
- Diethylcarbamazine
 for loiasis, 2207–2208
 for lymphatic filariasis, 2206–2207
- Diethyltoluamide (DEET), 2185–2186
- Differential Ability Scales-II (DAS-II), 356
- Differential agglutination test (HS/AC), 2195
- Diffuse alveolar damage (DAD), 2688
- Diffuse alveolar hemorrhage (DAH), 2688, 2688t
- Diffuse amplified pain syndromes, 1569–1571
- Diffuse cutaneous leishmaniasis, 2158
- Diffuse cutaneous mastocytosis, 4125
- Diffuse esophageal spasm, 2262
- Diffuse hyperkeratosis of palms and soles, 4118–4119, 4118f
- Diffuse large B-cell lymphoma, 3110t, 3113–3115
- Diffuse neonatal hemangiomatosis, 4056
- Diffuse pulmonary hemorrhage, 2699f
- Diffusely adherent *Escherichia coli*, 1783
- Diffusion, in respiratory failure, 615
- Digenic inheritance, 740
- Digenic pedigree, 742f
- DiGeorge critical region, 2766–2770
- DiGeorge syndrome, 768t–769f, 1275–1276, 1275f, 1345, 2803
- Digestion, intestinal, 2277
- Digestive system disorders, 1099, 1099t
- Digestive tract, tumors of, 2411–2415, 2412t
 adenomatous, 2413–2414
 adenomatous polyposis coli-associated polyposis syndromes as, 2412f, 2413–2414
- carcinoid, 2414
- carcinoma as, 2412t, 2413–2414
- gastrinoma as, 2414
- gastroenteric neuroendocrine as, 2414
- gastrointestinal stromal cell, 2414–2415, 2412f
 hamartomatous, 2411–2413, 2412f
- juvenile polyposis syndrome as, 2411
- leiomyoma as, 2414
- lymphoma as, 2414
- nodular lymphoid hyperplasia, 2414
- Peutz-Jeghers syndrome as, 2411–2413, 2412f–2413f
- phosphatase and tensin homolog hamartoma tumor syndromes as, 2413
- vascular, 2415
- Digestive tract disorders, major symptoms and signs of, 2224–2238, 2224t
 abdominal distention and abdominal masses as, 2237–2238
 abdominal pain as, 2234
 anorexia, 2234
 constipation, 2232
 diarrhea, 2227–2232
 dysphagia, 2225–2226
 gastrointestinal hemorrhage, 2234–2237
 nausea, 2226–2227
 regurgitation, 2226
 vomiting as, 2227
- Digestive tract phenomena, normal, 2223–2224, 2223f
- Digit sucking, malocclusion and, 2243
- Digital clubbing, 2513, 2515f
- Digitalis glycosides, for heart failure, 2900
- Digoxin, 2845t–2846t
 for heart failure, 2900
 poisoning, 714, 715t
- Digoxin-specific Fab antibodies, 707t–708t
- Dihydroergotamine (DHE), for migraine, 3646t–3647t, 3648
- Dihydroorotate dehydrogenase deficiency, 953
- Dihydropyrimidinase deficiency, 953–954
- Dihydropyrimidine dehydrogenase deficiency, 953–954
- Dihydropyrimidinuria, 953–954
- Dihydrotestosterone
 deficiency, 3511–3512, 3511f
 in polycystic ovary syndrome, 3335f
- Dilaceration, 2240
- Dilated cardiomyopathy, 595t, 2770
 clinical manifestations of, 2876
 echocardiogram of, 2880t
 etiology and epidemiology of, 2879t
 laboratory findings for, 2876–2880
 with lactic acidosis, mitochondrial disease and, 935t
 pathogenesis of, 2876
 prognosis and management of, 2880–2882
 sudden death and, 2861
- Dilated fixed pupil, 3921, 3922f
- Diltiazem, 2834t
- Dilation therapy, radiation and, 4420–4421
- Dimercaprol
 antidote for poisoning, 707t–708t
 for arsenic and mercury intoxication, 4435
- Dimercaptosuccinic acid scan, 707t–708t, 3267, 3268f
- Dinophysistoxins, 4445
- Diphallia, 3300
- Diphenhydramine, 708t
- Diphenoxylate, toxicity, 701t
- Diphtheria, 1724–1729, 2559, 2570
 clinical manifestations of, 1725–1727
 complications of, 1727
 toxic cardiomyopathy, 1727
 toxic neuropathy, 1727
- cutaneous, 1727
- diagnosis of, 1727
- epidemiology of, 1724–1725
- etiology of, 1724
- mucocutaneous infections, 1727
- pathogenesis of, 1725
- prevention of, 1728–1729
 asymptomatic carriers, 1728
 asymptomatic case contacts, 1728
 vaccine, 1728–1729
- prognosis of, 1728
- respiratory tract, 1725–1727, 1726f
- supportive care for, 1728
- treatment of, 1727–1728
- Diphtheria, tetanus, and pertussis (DTP), vaccine, 30–31t
- Diphtheria and tetanus toxoids adsorbed (DT), 1588t–1589t
- Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine, 1588t–1589t, 1591–1602, 1765
 with inactivated polio vaccine, *Haemophilus influenzae* type b, and hepatitis B (DTaP-IPV-Hib-HepB), 1588t–1589t
- with IPV and *Haemophilus influenzae* type b (Hib) (DTaP-IPV/Hib), 1588t–1589t
- Diphtheria antitoxin, 1586t, 1587
- Diphyllobothriasis, 2217, 2217f
- Diploid, 730
- Diplopia, 3915, 3919f
- Dipylidiasis, 2218
- Dipylidium caninum*, 2218
- DIRA (deficiency of IL-1 receptor antagonist), 1528
- Direct association, 801
- Direct DNA-based pathogenic variant testing, 749–750, 749t
- Direct inguinal hernias, 2416, 2420
- Direct oral anticoagulants (DOACs), 3044–3045, 3044t
- Direct tests, for pancreatic function, 2423
- Directed therapy, poisoning, 709
- Direct-to-consumer testing, 728–729
- Dirofilaria immitis*, 2208
- Dirofilaria repens*, 2208
- Dirofilaria tenuis*, 2208
- Disability
 primary assessment of, 555–556, 555t–556t, 556f
 primary survey for, 574–575, 575f
- Disabling pansclerotic morphea of childhood, 1508t

- Disaccharides, 393
- Disasters
humanitarian, 547
preparedness for, 538–539
- Disc edema, 3552–3553
- Discharge
bloody, 3331
from hospital, for premature infant, 1049–1050, 1049t
mucopurulent or sanguineous, 3353
nipple, 3331, 3331t
from normal newborn nursery, 1006t
vaginal, pathologic, 1246t
- Discipline
in parenting, 145, 145t
in preschoolers, 167
- Disclosure, of genetic testing, 729
- Discoid lateral meniscus (DLM), 4224–4225, 4225f
- Discoid lupus erythematosus (DLE), 4031, 4032f
- Discontinuation symptoms, SSRI and, 224
- Discourse, 301
- Discrepancy model, for math disabilities, 319
- Discrete papulovesicular lesions, 2558
- Discretionary Federal Grant Program, 1590
- Disease, prevention, 85
- Disease-modifying antirheumatic drugs, 1466t–1468t, 1481t
- Disequilibrium, 594t
- Disequilibrium syndrome, 486
- Disfluencies, 332
- Disk battery, in esophagus, 2273, 2274f
- Disk herniation, lumbar, 4306–4307
- Dislocated lens, inborn errors of metabolism and, 809t–810t
- Dislocation, occipitocervical, 580
- Disomy, uniparental, 773–777, 775f
- Disopyramide, 2845t–2846t
- Disorders of brain-gut interaction, 2385–2391
defecation disorders and, 2388t, 2391, 2391t
in infants and toddlers, 2385–2388, 2387t–2388t
in older children and adolescents, 2388–2391
- Disorders of pigmentation, 4067
- Disorders of sex development (DSD), 3503–3514
atypical or ambiguous genitalia, diagnostic approach to, 3504–3505, 3506f, 3506t, 3508t
diagnosis and management of, 3514
etiologic classification of, 3505t
genes mutated in, 3482t–3484t
infants with, evaluation of, key points in, 3507t
ovotesticular, 3508t, 3514
sex differentiation in, 3503–3505, 3504f, 3504t, 3506f
46,XX, 3506
androgenic drugs, exposure to, by women during pregnancy, 3507–3509
aromatase deficiency in, 3507
congenital adrenal hyperplasia in, 3506–3507
glucocorticoid receptor gene pathogenic variant in, 3507
virilizing maternal tumors in, 3507, 3508t
46,XY, 3509–3513
androgen action, defects in, 3511–3513
testicular differentiation, defects in, 3509–3510
testicular hormone production, deficiency of, 3510–3511
undetermined causes of, 3513
- Disorganized thinking, 285
- Disparities, 8
- Dispatch center, communications and, 540
- Disposition, of acutely ill child, 551–552
- Disrupted parenting, 195
- Disruption
of craniofacial structures, 779f
defined, 778t
in morphogenesis, 779
- Disruptive disorders, 277–280
- Disruptive mood dysregulation disorder (DMDD), 254–255, 257t
- Disseminated disease, in tuberculosis, 1839, 1842
- Disseminated infection
adenovirus, complication of HSCT, 1364
associated with *M. avium* complex, 1861t, 1864
coccidioidomycosis, 1937, 1937t
gonococcal, 1749
- Disseminated intravascular coagulation (DIC), 482, 1127, 3047–3048, 3092t–3093t
causes of, 3048t
clinical manifestations of, 3048
etiology of, 3048
laboratory findings of, 3048
- Disseminated leishmaniasis, 2158
- Disseminated mucormycosis, 1944
- Dissent, 51
- Dissociative shock, 560, 600, 601t, 602f
pathophysiology of, 603–604
- Distal arthrogryposis (DA), 3821, 4272
- Distal clavicular osteolysis, 4300–4301
- Distal humeral fractures, 4280, 4281f
- Distal intestinal obstruction syndrome, in cystic fibrosis, 2677
- Distal radial epiphysis, 4332
- Distal renal tubular acidosis, 473f, 479, 3234f, 3235–3236, 3236t, 3238f
- Distal subungual onychomycosis, 4145–4146
- Distractibility, 302–303
- Distraction, in pain management, 693
- Distributive shock, 560, 600, 601t, 602f
clinical manifestations of, 605
pathophysiology of, 601
- Diuretics
for acute kidney injury, 3245
for BPD, 1086
dosage of, 2898t
in children and adolescent, 2918t
for heart failure, 2897
- Diurnal incontinence, 3291–3292, 3292t
- Diurnal urge syndrome, 3293
- Diverticula, urethral, 3285
- Diverticulectomy, for Meckel diverticulum, 2287
- Diverticulitis, 2287
- Diverticulum
bladder, 3271f, 3287, 3287f
of left ventricle, 2830
- Diving, injuries associated with, 4329
- Divorce, 195–196
- Dizygotic twins, 1039
- Dizziness, 594t, 3981
- D-Lactate, reference intervals, 4472.e9t
- DLBCL. See Diffuse large B-cell lymphoma
- DLE. See Discoid lupus erythematosus
- DLM. See Discoid lateral meniscus
- DNA
double helix, 731f
methylation, 748f
mitochondrial, depletion syndrome, 2484
rearrangements, 733
- DNA ligase IV deficiency, 1263t
- DNA markers, in neuromuscular disorders, 3793
- DNA polymerases, 730
- DNA testing, cystic fibrosis and, 2669
- DNA-based pathogenic variant testing, direct, 749–750, 749t
- DNA-PK deficiency, 1263t
- DNAR. See Do-not-attempt resuscitation
- DNAse II deficiency, 1535
- DNC. See Death by neurologic criteria
- DOAC. See Direct oral anticoagulants
- Dobutamine
for heart failure, 2898t, 2900
for postarrest stabilization, 568t
for shock, 610t
- DOCK8 deficiency, 1276, 1276f
- Docosahexaenoic acid (DHA), 393
- Doctrine of double effect (DDE), 52–53
- Documentation
of genital examination, 3319
for physical abuse and neglect, 120
- Dog bites, 4457, 4458t
- Dog heartworm, 2208
- Dog roundworm, 2209
- Dolichostenomelia, 4364
- Doll experiment, 19
- Dolutegravir, for HIV, 2098t–2107t
- Domestic adoption, 72
- Dominant Bartter syndrome-like picture, 3242
- Dominant follicle, 3340
- Dominantly inherited infantile optic atrophy, 3966–3967
- Domoic acid, 4445
- Donabedian structure-process-outcome model, 542
- Donohue syndrome, 3546
- Donor
for HSCT
HLA-compatible sibling, 1352f
HLA-identical sibling, 1351
unrelated HLA-matched, 1355
for renal transplant, characteristics of, 3254
selection, for pediatric heart transplantation, 2902–2903
vs. recipient NK cell alloreactivity, 1356
- Do-not-attempt resuscitation (DNAR), 52
- Doose syndrome, 3601–3602
- L-Dopa, lifelong supplementation with, 815
- Dopamine
biosynthesis, 3449f
for heart failure, 2898t, 2900
for postarrest stabilization, 568t
for shock, 610t
- Dopamine β-hydroxylase deficiency, 846, 3632, 3899t
- Dopamine hypothesis, in ADHD, 309
- Dopamine-serotonin vesicular transporter disease, 847
- Dopa-responsive dystonia, 3680–3681
autosomal dominant form, 846
autosomal recessive form, 844
- Doppler echocardiography, 2755–2757, 2756f
for rheumatic heart disease, 2872, 2873f, 2873t–2874t
- Doppler ultrasound, transcranial, 2976
- Doravirine, for HIV, 2098t–2107t
- Doripenem, 1675t–1685t
- Dosages
adjustment, in CKD, 3252
of drugs, for heart failure, 2898t
- Double aortic arch, 2827f, 2827t
- Double quotidian fever, 1641
- Double-barrel colostomy, for perineal fistula, 2407
- Double-bubble sign, 2283, 2283f
- Double-elevator palsy, 3929f
- Double-outlet right ventricle, 2763t, 2808–2809, 2810f
with malposition of the great arteries, 2815
without pulmonary stenosis, 2815
- Double-sandwich IgM enzyme-linked immunosorbent assay (IgM-ELISA), 2193
- Down syndrome, 362–373, 778–779, 780t, 4262–4263, 4262f
aCGH in, 765f
acute leukemia and transient abnormal myelopoiesis and, 3104, 3104f
- American Academy of Pediatrics Health Supervision Guidelines for, 364–367, 368t
- clinical characteristics of, 364–371, 365f, 366t–367t
cardiac, 369
dental, 367–369
dermatology, 371
ears, 367
endocrine, 369
gastrointestinal, 369
genitourinary, 369–370
hematology-oncology, 371
immunology/allergy, 371
musculoskeletal, 371
neurology, 369
nose, 367
nutrition/obesity, 369
ophthalmology, 367
pulmonary, 369
sexuality and reproductive health, 370
sleep, 369
throat, 367
- developmental and behavioral characteristics of, 370t, 371–373
- cognition, 372
- motor skills, 371
- neurobehavioral challenges and disorders, 372–373
social and emotional development, 372
speech and language skills, 371–372
- natural birth prevalence of, according to maternal age, 1010f
- Downbeat nystagmus, 3931t
- Downstream, 18f
- Doxorubicin, indications and adverse reactions of, 3089t–3090t

- Doxycycline, 1675t–1685t
 for acne vulgaris, 4180
 for bite wound, 4459t
 for brucellosis, 1809t
 for *Legionella*, 1811
 for Lyme disease, 1885t
 for malaria prophylaxis, 1637, 2181t–2182t
 against nontuberculous mycobacteria, 1835
 for psittacosis, 1898
 Dracunculiasis, 2209
Dracunculus medinensis, 2209
 Dravet syndrome, 3596
 DRB1 deficiency, 1339t
 DRESS syndrome (drug rash with eosinophilia and systemic symptoms), 4035–4037, 4036f–4037f
 DRI. *See* Dietary reference intake
 Drop attack, in unprovoked seizures, 3598
 Droplet isolation, 1620
 Drowning, 91, 637–645
 deaths, prevention of, in developing world, 544
 epidemiology of, 637–638, 637f
 adolescents, 638
 alcohol use, 638
 children 1–4 years old, 637
 children less than 1 year old, 637
 ethnic disparities, 638
 global impact of, 638
 school-aged children, 637–638
 sports and recreation, 638
 underlying conditions, 638
 etiology of, 637
 management of, 640–644, 641f
 additional management issues, 643
 hospital-based evaluation and treatment, 642–643
 hypothermia management, 643–644
 initial evaluation and resuscitation, 641–642
 pathophysiology of, 638–640, 639f
 anoxic-ischemic injury, 638–639
 cold water injury, 640
 pulmonary injury, 639–640
 prevention of, 644–645, 645t
 prognosis of, 644
 Drowsy state, of newborn, 149
 Drug hypersensitivity syndrome (DRESS), 4080
 Drug induced malabsorption, 2354t–2356t
 Drug withdrawal, in neonatal seizures, 3620
 Drug-drug interactions, with isoniazid, 1831t
 Drug-facilitated rape, 1237t
 Drug-induced acne, 4183, 4184f
 Drug-induced allergic reactions, heterogeneity of, 1454t
 Drug-induced conditions
 in folate metabolism, 2942
 lupus, 1495, 1495t
 Drug-induced hemolytic anemia, 2995, 2995t
 Drug-induced hypersensitivity syndrome, adverse reactions to, 1455t, 1456, 1457t
 Drug-induced liver injury, acute hepatic failure and, 2495
 Drug-induced neutropenia, 1306–1307, 1307t
 Drug-induced thyroiditis, 3412
 Drug-related conditions, in secondary intracranial hypertension, 3783t
 Drug-resistant epilepsy
 with focal seizures, 3600
 with unprovoked seizures, 3598
 Drugs
 acute pancreatitis and, 2427t
 adverse reactions to, 1453–1459
 antiparasitic, 2126t–2144t
 and breastfeeding, 1008t
 for drug-resistant tuberculosis, 1851t–1853t
 etiologies, of primary adrenal insufficiency, 3455
 for hepatocyte injury, 2450
 increase risk of osteoporosis, 4384t
 liver injury induced by, 2490–2493
 pathologic spectrum of, 2493
 patterns of, 2493t
 prevention of, 2493
 prognosis of, 2493
 treatment of, 2493
 metabolism, immunity of, 1045
 misuse, by adolescents, 1187t
 taken during pregnancy effects on fetus, 1023t–1024t
 transfused through umbilical vein, 1027t
- Drugs (*Continued*)
 for tuberculosis, 1850t, 1849t, 1850t
 unsafe in acute porphyrias, 967, 968t
 use, during pregnancy, SIDS risk factors and, 2534
 Drugs of abuse, poisoning, 717t
 Drusen, of optic nerve, 3964, 3965f
 Dry, thickened skin, 4038
 Dry bite, 4466
 Dry drowning, 642
 Dry eye, 3937–3938
 Dry flushing, 4127–4128
 Dry mouth, 2254
 Dry pleurisy, 2654, 2655f
 Dry powder inhaler devices, for asthma, 1406
 Dry skin dermatitis, 4087, 4088f
 DSD. *See* Disorders of sex development
 DSM-5. *See* Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
 DSRCT. *See* Desmoplastic small round cell tumor
 DTaP and inactivated polio vaccine (DTaP-IPV), 1588t–1589t
 DTaP-hepatitis B-inactivated polio vaccine (DTaP-HepB-IPV), 1588t–1589t
 DTP. *See* Diphtheria, tetanus, and pertussis
 Dual porphiria, 964, 979
 Dual protection, in contraception, 1227
 Duane retraction syndrome, 3575
 Duane syndrome, 3929–3930
 Duane-radial ray syndrome, 2764t–2766t
 DUBBs. *See* Dangerous underwater breath-holding behaviors
 Dubin-Johnson syndrome, 2456
 Dubowitz syndrome, 3009–3010
 Duchenne muscular dystrophy (DMD), 3828–3835
 clinical manifestations of, 3828–3832, 3832f
 diagnosis of, 3832–3833, 3832f–3833f
 genetic etiology and pathogenesis of, 3833
 laboratory findings of, 3832
 treatment of, 3834–3835
 Duct cells, of pancreas, 2421
 Ductal ectasia, 3331
 Ductal plate, remodeling of, 2435
 Ductal remnants, 3354
 Ductus arteriosus, 2735
 Dulaglutide, for T2DM, 3542t
 Dulera. *See* Mometasone/formoterol
 Duloxetine
 for anxiety disorders, 253
 for depression, 224, 227t
 DUMBBELS, 719
 Dumping syndrome, with hypoglycemia, 991
 Dunphy sign, appendicitis and, 2398
 Duodenal atresia, 2282
 Duodenal obstruction, 2282–2283
 Duodenoduodenostomy, 2283
 DuoNeb nebulizer solution, for asthma, 1405t–1406t
 Dupilumab
 for asthma, 1401t, 1404
 for atopic dermatitis, 1416
 Dupixent. *See* Dupilumab
 Duplications
 chromosomal, 767–770, 769t
 complete vulvar, 3354
 gastric, 2280–2281, 2280t
 intestinal, 2286, 2286f
 of upper urinary tract, 3270–3271
 urethral, 3301
 DVT. *See* Deep venous thrombosis
 Dwarf tapeworm, 2217–2218
 Dye studies, of chronic recurrent aspiration, 2611
 Dymista, for allergic rhinitis, 1384t–1385t
 Dynamic compliance, 628
 Dyneins, 2679–2680
 Dysarthria, 332
 Dysautonomic crises, 3896, 3900f
 Dysbiosis. *See* Fecal microflora
 Dyscalculia, 305, 319
 Dyschezia, infant, 2386
 Dyscoria, 3921
 Dysdiadochokinesia, 3557
 Dysentery, 1798, 2227, 2355
 acute, differential diagnosis of, 2369t
 amebic, 2367
 bacillary, 1776
- Dyserythropoiesis, 2937, 3056
 Dyserythropoietic anemias, congenital, 2937–2939, 2938f
 transcription factor-related, 2939
 type I, 2937
 type II, 2937–2938
 type III, 2938
 Dysferlin (DYSF) gene, 3842
 Dysfibrinogenemia, 3034
 Dysfluency, 333, 333t
 developmental, 333–334
 types of, 334
 Dysfunctional family, 233
 Dysgammaglobulinemia, 4048
 Dysgenesis
 of cranial nerves and posterior fossa, 3575–3577
 renal, 3261–3262
 reticular, 1263t, 1264
 thyroid, 3402–3403
 Dysgerminomas, 3342–3343
 Dysglycemia, diagnostic criteria for, 3517
 Dysgraphia, 304–305, 321
 Dyshormonogenesis, 3403
 Dyskeratosis congenita, 1288, 1309t, 1310, 3006–3007, 4046f
 cancer risk and other complications in, 3007
 clinical manifestations of, 3006–3007
 diagnosis of, 3007
 etiology and epidemiology of, 3006, 3006f
 laboratory findings of, 3007
 pathology of, 3006
 prognosis of, 3007
 treatment of, 3007
 Dyskinesia
 biliary, 2504
 paroxysmal, that mimic seizures, 3635–3636, 3636t
 primary ciliary, 2679–2682
 clinical manifestations of, 2680–2681, 2681t
 diagnosis of, 2681–2682, 2681t
 genetics of, 2680, 2680f
 normal ciliary ultrastructure and function, 2679–2680, 2679f–2680f
 prognosis for, 2682
 treatment of, 2682
 Dyskinetic cerebral palsy, 3690t
 Dyslexia, 315–318, 3920
 clinical manifestations, 316
 definition of, 315, 315f
 diagnosis, 316–317
 epidemiology, 316
 family history and, 317
 management, 317–318
 neural signature for, 316f
 pathogenesis, 316, 316f
 prognosis, 318
 Dyslipidemia
 due to citrin deficiency, 853
 kidney transplant immunosuppression and, 3258–3259
 resulting from nephrotic syndrome, 3229
 in T2DM, 3543t
 Dysmenorrhea, 1214–1216, 1215t
 Dysmetria, 3557
 Dysmorphic features, inborn errors of metabolism
 associated with, 809t
 Dysmorphology, 778–787, 778t
 approach to facial anomalies, 783–787
 classification of birth defects, 778–781
 major malformations, 785t
 minor malformations, 785t
 molecular mechanisms of malformations, 781–783
 Dysmotility, 2261
 esophageal, 2261–2262
 Dysosteosclerosis, 4351t, 4353
 Dysostosis multiplex, 938–939, 941f
 inborn errors of metabolism and, 809t–810t
 Dyspepsia, functional, 2389–2391, 2389t
 Dysphagia, 2225–2226, 2225t, 2257, 2261, 3554
 in pediatric palliative care, 69t
 Dysphagia lusoria, 2261
 Dysphasia, developmental, 328
 Dysphasic auras, in migraine, 3643
 Dysphonia, inhaled corticosteroids and, 1400–1401

- Dysphoria, gender
definition of, 1172
DSM-5 for, 1173t
- Dysplasia, 778–779, 4232
bronchopulmonary, 2711–2712
clinical manifestations of, 2711
definitions of, 2712t
prognosis for, 2712
treatment of, 2712
defined, 778t
fibrous, polyostotic, 3392
renal, 3261–3262
- Dyspnea
in pediatric palliative care, 65t–69t, 69–70
respiratory signs and symptoms, 2531t
in SLE, 1497t
- Dyspraxia, 301
- Dystonia, 243t, 3680–3688
cerebral palsy, 3683
in childhood, 3682t–3683t
classification of, 3681t
diagnostic testing in, 3687t, 3688f
dopa-responsive
autosomal dominant form, 846
autosomal recessive form, 844
drug-induced, 3681–3682, 3688
inborn errors of metabolism and, 809t–810t
inherited primary, 3680–3681, 3684f
metabolic disorders, 3683–3684
mitochondrial disease and, 935t
other disorders, 3684–3686
treatment in, 3686–3688, 3686t
acute treatment, 3686–3687
chronic treatment, 3686t, 3687–3688
- Dystroglycanopathy, CMD form overlapping with, 3819
- Dystrophic epidermolysis bullosa (DEB), 4083t, 4083–4084, 4083t, 4084f
- Dystrophin, 3833
- Dystrophin-glycoprotein complex (DGC), 3818, 3818f
- Dysuria-hematuria syndrome, 3295
- DYT1 dystonia, 3680
- E**
- E₃ binding protein deficiency, 915
E₃ lipoamide dehydrogenase deficiency, 915
E₃ subunit deficiency, 827
- Eagle-Barrett syndrome, 3281
- Ear
assessment in newborn, 1002
congenital malformations of, 3995–3999, 3995t
cholesteatoma, 3998–3999, 3999f
external auditory canal, stenosis or atresia of, 3996–3997, 3997f
inner ear, 3997–3998, 3998t
middle-ear, 3997
pinna, 3995–3996, 3996f
in erythropoietic protoporphiria, 978f
minor malformations, 785t
physical examination of, 551
toxoplasmosis in, 2193
traumatic injuries of, 4021–4023
acoustic trauma, 4023
auricle and external auditory canal, 4021
fractures of, 4022–4023, 4022f
tympanic membrane and middle ear, 4021–4022, 4022f
- Ear disorders
clinical manifestations of, 3981, 3982t
evaluation of, 3981–3982
facial paralysis, 3981
physical examination of, 3983f
- Earache, in exclusion or inclusion in daycare, 187t–192t
- Eardrum retraction, 3982
- Early adolescents, development of, 1162
- Early ambulation, 4198
- Early amputation, 4223
- Early childhood
caries, 2246
trauma, leads to poor health outcomes, 75–76
well-child care and, 85
- Early decelerations, 1017
- Early developmental impairment, language disorders and, 329
- Early disseminated disease, in Lyme disease, 1883–1884, 1883f
- Early infantile epileptic encephalopathy, 3601
- Early localized disease, in Lyme disease, 1882–1883, 1883f
- Early myoclonic encephalopathy (EME), 3601
- Early-onset enteropathy, 1257, 1260t
- Early-onset infection, 1143
general approach to management of, 1149
in genital mycoplasmas, 1891–1892
pathogenesis of, 1144–1146
- Early-onset sarcoidosis (EOS), 1548
- Early-onset sepsis, aspiration and, 1089
- Early-onset systemic lupus erythematosus, 1257, 1259t–1260t
- Early-phase response, in allergen, 1371
- East African sleeping sickness, 2161
- EAST syndrome, 500, 504
- Eastern equine encephalitis, 2059–2060
- Eating disorders, 268–276
in adolescents, 1169–1170
in adopted children, 74
among GLB youth, 1184
in athletes, 4323
characteristics of, 268
clinical manifestations of, 270, 271t–273t
complications of, 274
differential diagnosis, 270–274
epidemiology of, 269–270
laboratory findings, 274
pathogenesis of, 270
pathology of, 270
prevention of, 276
prognosis of, 276
T1DM and, 3534–3536
treatment of, 274–276
interdisciplinary eating disorder team, 276
nutrition and physical activity, 275, 275t
primary care treatment, 275
principles guiding primary care treatment, 274–275
referral to mental health services, 276
supportive care, 276
- Ebola hemorrhagic fever, 2074, 2074f–2075f, 2075t
clinical manifestations of, 2076
- Ebola virus disease, 2074
vaccines, 1588t–1589t
- EBS. *See* Epidermolysis bullosa simplex
- Ebstein anomaly, of tricuspid valve, 2809–2811, 2811f
clinical manifestations of, 2809–2810
diagnosis of, 2810
treatment of, 2810–2811
- EBV. *See* Epstein-Barr virus
- Eccymosis, 3976–3977, 3976f
- Eccrine sweat glands, 4025f, 4026
- ECD. *See* Erdheim-Chester disease
- Echinacea, 56t
- Echinocandins, 1920–1921
for *Candida* infections, 1924
- Echinococcosis, 2220–2222
clinical manifestations of, 2221
diagnosis of, 2221–2222, 2221f–2222f
epidemiology of, 2220
etiology of, 2220, 2220f
pathogenesis of, 2220–2221
prevention of, 2222
prognosis of, 2222
treatment of, 2221f, 2222
- Echinococcus granulosus sensu lato*, 2220
- Echinococcus multilocularis*, 2220
- Echocardiography, 2754–2757
of atrial septal defect, 2776f
of atrioventricular septal defect, 2781f
coarctation of the aorta with hypoplastic transverse arch, 2794f
- Doppler, 2755–2757, 2756f
- of d-transposition of the great arteries, 2813f
- of Ebstein anomaly of tricuspid valve, 2811f
- fetal, 2757, 2757f
- for heart failure, 2895–2896, 2896f
- for infective endocarditis, 2871t
- in Kawasaki disease, 1544
- m-mode, 2754–2755
- Echocardiography (*Continued*)
of patent ductus arteriosus, in newborn, 2785f
of pericardial effusion, 2891f
for sickle cell disease, 2977
of tetralogy of Fallot, 2802f
- three-dimensional, 2757, 2757f
- transesophageal, 2754, 2757
- of tricuspid atresia, 2807f
- two-dimensional, 2755, 2755f–2756f
- valvar aortic stenosis with regurgitation, 2792f
valvar pulmonic stenosis, 2789f
- Echolalia, 241
- Echopraxia, 241
- E-cigarette or vaping product use-associated lung injury (EVALI), 724, 1204, 2651–2653
advocacy and prevention of, 2653
clinical manifestations of, 2653
diagnosis of, 2653, 2653f
epidemiology of, 2651
pathophysiology of, 2651–2652
treatment of, 2652f, 2653
- Eclipse nevi, 4061, 4061f
- ECMO. *See* Extracorporeal membrane oxygenation
- Eco-biodevelopmental framework, 6, 136–142
biologic influences, 136–137
developmental domains and theories of emotion and cognition, 139–140
for early childhood policies and programs, 138f
psychologic influences, 137
social factors, 137–138
statistics used in describing growth and development, 140–142
unifying concepts, 138–139
- Ecologic model of development, 137–138
- Economic disparities, 9
- ECPR. *See* Extracorporeal cardiopulmonary resuscitation
- ECT. *See* Electroconvulsive therapy
- Ecthyma, 4154, 4154f
- Ecthyma gangrenosum, 1800t, 4154
- ECTodermal dysplasias, 2245, 4046–4050
classification for, 4047t–4048t
clinical abnormalities in, 4046t
hidrotic, 4048–4050, 4049t–4050t
hypohidrotic, 4048, 4049f
- Ectoparasites
antiparasitic drugs for, 2144–2145
genital lesions and, 1244
- Ectopia, ureteral, 3271f
- Ectopia cordis, 2830
- Ectopia lentis, 3951–3952, 3951f
- Ectopia lentis et pupillae, 3921, 3952
- Ectopia lentis syndromes, 4367–4368, 4367t
- Ectopic pancreatic rests, 2422
- Ectopic pregnancy, 1230
- Ectopic ureter, 3280, 3280f, 3294f–3295f
- Ectopic ureterocele, 3280
- Ectrodactyly, 4049t–4050t
- Ectropion, 3934–3935
- Eculizumab
for hemolytic-uremic syndrome, 3202–3203
for paroxysmal nocturnal hemoglobinuria, 2964–2965
for PNH/aHUS, 1323
- Eczema, nonatopic, 1410
- Eczema herpeticum, 1994f
- Eczema vaccinatum, 1418–1419, 1418f
- Eczematous disorders, 4087–4092
acute palmoplantar eczema, 4091, 4092f
contact dermatitis, 4087–4090, 4088f, 4089t, 4090f
lichen simplex chronicus, 4091, 4091f
nummular eczema, 4090, 4091f
 pityriasis alba, 4090–4091, 4091f
seborrheic dermatitis, 4091–4092, 4092f
- Eczematous lesions, scabies and, 4173
- Edema
acute hemorrhagic, infantile, 1555, 1558f
bilateral, 426
brain, 585f
cerebral
complication of hepatic encephalopathy, 2498–2499
high-altitude (HACE), 631, 633–634
in erythromelalgia, 1573f

- Edema (Continued)**
- heat, 4320
 - indurative, in Kawasaki disease, 1543f
 - in newborn, 1000, 1055
 - pulmonary, 2604–2606
 - clinical manifestations of, 2605t, 2605
 - etiology of, 2604–2605, 2604t
 - pathophysiology of, 2604
 - treatment of, 2605–2606
 - resulting from nephrotic syndrome, 3223
 - treatment for, 3229
- Edematous malnutrition**, 426, 427f, 433
- Edinburgh postnatal depression scale (EPDS)**, 149, 150t
- Education**
- for child with intellectual disability, 360–361
 - continuing, for emergency medical services, 534–536
 - outreach for, of pediatric transport programs, 542
 - patient, for asthma, 1396
 - residential segregation and, 21
 - sexual, for adolescents with special needs, 3355
 - and teen mothers, 1230
- Educational underfunding**, 9
- Edwards syndrome**, 766t
- EEG. See** *Electroencephalography*
- Efavirenz**, for HIV, 2098t–2107t
- EFEMP2-related cutis laxa**, 4376t
- Effective dose**, 4413–4414
- Efloرنithine and nifurtimox (NECT)**, for human African trypanosomiasis, 2163
- EGIDs. See** *Eosinophilic gastrointestinal diseases*
- Egocentrism**, 165
- EHE. See** *Epithelioid hemangioendothelioma*
- Ehlers-Danlos syndrome (EDS)**, 3025, 3060, 4369–4374, 4371t, 4372f
- arthrochalasia, 4373
 - classic, 4369, 4372f–4373f
 - classification of, 4369–4374, 4370t–4371t
 - dermatosparaxis, 4373–4374
 - differential diagnosis of, 4374
 - general approach to management of, 4374
 - hypermobile, 4369–4371, 4371t, 4373f, 4374t–4375t
 - kypboscoliosis, 4373
 - vascular, 4371–4372
- Ehrlichia chaffeensis***, 1911
- Ehrlichia muris eauclairensis*** infection, 1900t–1902t
- Ehrlichiosis**, 1655t–1656t, 1900t–1902t, 1911–1914
- clinical manifestations of, 1912
 - complications and prognosis of, 1913–1914
 - diagnosis of, 1913, 1913f
 - differential diagnosis of, 1913
 - epidemiology of, 1911–1912
 - etiology of, 1911
 - laboratory findings of, 1912
 - pathology and pathogenesis of, 1912
 - prevention of, 1914
 - transmission of, 1912
 - treatment of, 1913
- 8p11 syndrome**, 768t–769t
- Eighth nerve deafness**, 1869t
- Eisenmenger physiology**, cyanotic congenital heart disease, 2836t
- ELANE gene**, 1308
- Elapidae**, 4466–4467, 4467t
- Elastance**, 620–621
- Elastography**, 2445
- Elastosis perforans serpiginosa (EPS)**, 4123–4124, 4124f
- Elbow**
- arthrogryposis in, surgery for, 4275
 - dislocation, 4303
 - disorders of, 4264–4265
 - nursemaid's, 4265, 4267f
 - Panner disease and osteochondritis of capitellum, 4264, 4265f
 - radial longitudinal deficiency, 4264–4265, 4265t–4266t, 4266f
 - musculoskeletal pain syndrome, 1568t
 - sports-related injuries, 4303–4305
 - acute injuries in, 4303–4305
 - chronic injuries in, 4303–4305
- Electric dishwasher detergent**, toxicity, 724
- Electrical burns**, 654–655, 656t
- Electrical status epilepticus in sleep (ESES)**, 3602–3603
- Electrocardiography (ECG)**, 2747–2753
 - adult, 2749f
 - anomalous origin of the left coronary artery, 2828f
 - of atrioventricular septal defect, 2780f
 - developmental changes, 2747–2748
 - of infant, 2750f
 - in neuromuscular disorders, 3799
 - of normal infant, 2748f
 - P waves, 2748–2749
 - for poisoning, 705, 706t
 - P-R and Q-T intervals, 2752
 - premature infant, 2750f
 - of premature infant, 2750f
 - QRS complex, 2749–2752
 - rate and rhythm in, 2748
 - ST segment and T-wave abnormalities, 2752–2753, 2753f
 - for tachyarrhythmias, 2854t
- Electroclinical seizures**, 3617–3619
- Electroconvulsive therapy (ECT)**, 290
- Electroencephalography (EEG)**
- amplitude-integrated, 1066t–1067t
 - for brain death, 589–592, 591t
 - for delirium, 298
 - for febrile seizure, 3596t, 3597
 - for focal seizures, 3599
 - in neurologic evaluation, 3560
- Electrolytes**
- abnormalities, 609
 - absorption, disorders of, 2350–2351
 - composition, 486
 - dietary reference intake, 396, 404t–407t, 408f
- Electromyography (EMG)**, 1819, 4450
- diagnostic, for JDM, 1502
 - in neuromuscular disorders, 3793–3794
- Electron microscopy**, in neuromuscular disorders, 3799
- Electron photomicrograph**, of cilium, 2679f
- Electron transfer flavoprotein**, 864–865
- Electron transfer flavoprotein dehydrogenase deficiencies**, 864–865
- Electron transfer pathway**, defects in, 864–865
- Electron transport chain**, 931f, 936–937
- Electronic cigarettes**, 1200
- Electronic fetal monitoring (EFM)**, 1014
- Electronic health**, adolescent, 1164t–1165t
- Electrophysiologic approaches**, to heart failure management, 2900–2901
- Elemental mercury**, intoxication, 4433
- Elephantiasis**, 2206
- Eletriptan**, for migraine, 3646t–3647t
- Elevated CSF protein**, in vascular permeability, 3761
- ELISA. See** *Enzyme-linked immunosorbent assay*
- Elliptocytosis**, hereditary, 2960–2961, 2960t
- Ellis-van Creveld syndrome**, 792t, 2764t–2766t, 4354–4355, 4355f
- Elongation factor genes**, variants in, 2485
- Eltrombopag**, for chronic ITP, 3054–3055
- Elvitegravir**, for HIV, 2098t–2107t
- EMA. See** *Eosin-5-maleimide*
- Embryonal tumors**, 3121–3124, 3122f–3123f
 - age-related manifestations of, 3084
- Embryonal type**, of rhabdomyosarcoma, 3136
- Embryonic development**, of kidney, 3260
- Embryonic gonadal differentiation**, genetic control of, 3481–3485
- Embryonic lymphatic development**, 3065
- Embryonic period**, 146, 147t
- Embryonic testicular regression syndrome**, 3509–3510
- Embryotoxin**, posterior, 2448f
- Emergence**, 673
- Emergency delirium**, 674
- Emergencies**
- delivery room, 1070–1073
 - neurologic, 581–588
 - neurocritical care principles in, 581–582, 582f, 583t
 - traumatic brain injury in, 583–588
 - oncologic, 3092t–3093t
 - Emergency contraception, 1225–1227, 1226t
 - Emergency department**, 537–539, 538t
 - disaster preparedness in, 538–539
 - guidelines for, 538t
 - risk adjustment tools in, 543–544
 - visits, for unintentional injury, 93f
 - Emergency medical services (EMS)**, 552
 - Emergency Medical Services for Children (EMSC)**, 534–547
 - disaster preparedness in, 538–539
 - Innovation and Improvement Center, 543
 - interfacility transport in, 540
 - pediatric prehospital care in, 536–537
 - primary care physician and office preparedness in, 534–539
 - principles applicable, 544–547
 - risk adjustment and outcomes measurement of, 542–544
 - system of, access to, 536
 - Emergency medical technicians (EMTs)**, 536
 - Emergency Medical Treatment and Active Labor Act (EMTALA)**, 542
 - Emergency mental health assessment**, 264
 - Emergency situations**, global health and, 35
 - Emergency transfer**, 47t
 - Emergency treatment**, of hyponatremia, 3377–3378
 - Emergency Triage Assessment and Treatment (ETAT)**, 546
 - Emergent fasciotomy**, 4282
 - Emery-Dreifuss muscular dystrophies (EDMD)**, 3829t–3831t, 3835
 - Emesis**, 1099t
 - EMG. See** *Electromyography*
 - Emmetropia**, 3912
 - Emollients**, for psoriasis, 4100
 - Emotional control**, 303
 - Emotional development**
 - in adopted children, 74
 - age 0–2 months, 152
 - age 2–6 months, 155
 - age 6–12 months, 156
 - age 12–18 months, 158
 - age 18–24 months, 158–163
 - developmental domains and theories, 139–140
 - in middle childhood, 171
 - in preschool years, 166 - Emotional health**, for children with disabilities, 4407
 - Emotional symptoms**, stuttering and, 334
 - Emotions**, strategies for, 130t
 - Empagliflozin**, for T2DM, 3542t
 - Emphysema**, 2590–2593
 - α_1 -antitrypsin deficiency and, 2594
 - bulbous, 2593, 2593f
 - lobar, congenital, 2591–2592, 2591t, 2592f
 - pulmonary interstitial, 1097–1098, 1098f
 - Empirical antireflux therapy**, 2266
 - Empyema**, 2654–2657
 - clinical manifestations of, 2656
 - complications of, 2656
 - epidemiology of, 2656
 - laboratory findings of, 2656, 2656f–2657f
 - pathology of, 2656
 - treatment of, 2656–2657
 - EMS. See** *Emergency medical services*
 - EMSC. See** *Emergency Medical Services for Children*
 - Emtricitabine**, for HIV, 2098t–2107t
 - En coup de sabre**, 1508t, 1509f
 - Enalapril**, for heart failure, 2898t
 - Enamel**, 2247f, 2250f
 - Enamel hypoplasia, 2242t
 - Enamel infraction, 2251t
 - Encephalitis**
 - autoimmune, 287, 288f
 - postnatal rubella and, 1967
 - in varicella, 2002 - Encephalocele**, 2547, 3564–3565, 3565f
 - Encephalomyopathy**, mitochondrial neurogastrointestinal, 953
 - Encephalopathies**, 3688–3711
 - autoimmune encephalitis in, 3702–3711, 3705t–3707t
 - in cat-scratch disease, 1814
 - cerebral palsy in, 3688–3695
 - glycine, 837–838
 - hepatic, 2494t
 - HIV and, 2094
 - hypoxic-ischemic, 1062–1068
 - lead, 4437, 4437t
 - liver disease and, 2440
 - mitochondrial encephalomyopathies in, 3695–3700

- Encephalopathies (*Continued*)
 progressive, 362, 362
 toxic causes of, 3895
 transmissible spongiform, 2118–2124
 Wernicke, 459
- Enchondroma, 3145
- Encopresis, 2293
- End of life, approaching, 71
- Endemic Burkitt lymphoma, 2009
- Endemic cretinism, 3413–3415
 clinical manifestations of, 3414
 etiology of, 3414
 pathogenesis of, 3414
 treatment of, 3414–3415
- Endemic diseases, 1583
- Endemic goiter, 3404, 3413–3415
 clinical manifestations of, 3414
 etiology of, 3414
 pathogenesis of, 3414
 treatment of, 3414–3415
- Endemic relapsing fever, 1880
- Endemic syphilis, 1877
- Endemic typhus, murine, 1909–1910
- Endobronchial ultrasound, 2524
- Endocardial cushions, 2733
- Endocardial fibroelastosis, 2887–2888
- Endocarditis, 1712, 1800t
 bacterial, tetralogy of Fallot and, 2802
Bartonella in, 1816
 caused by
 coagulase-negative staphylococci, 1700
 Staphylococcus aureus, 1695
 culture-negative, 2866t
 infective, 2864–2871
 prophylaxis, 2842
 for Marfan syndrome, 4368
- Endochondral ossification, 4193
- Endocrine disorders
 anesthetic implications in, 666t
 associated with prematurity, 1046t
 causing SIDS, 2533t
 fetal therapy for, 1027t
 liver disease and, 2440
 multiple endocrine neoplasia (MEN) syndromes,
 3431–3432, 3431t
 management of, 3432
 type 1, 3431–3432
 type 2, 3432
 type 2A, 3432
 type 2B, 3432
 in myotonic muscular dystrophy, 3836
 neuromuscular manifestations of, 3847t
 obesity-associated comorbidities, 442, 444f, 444t
 preventive monitoring of thalassemia, 2986
 in secondary intracranial hypertension, 3783t
- Endocrine disruptors, 4426
- Endocrine myopathies, 3846–3848
- Endocrine system
 in childhood lupus, 1497t
 hormones of hypothalamus and pituitary gland,
 3359–3363
 role in obesity, 441t
 toxoplasmosis in, 2191
- Endocrinopathies, 270–274, 2450
- Endodermal sinus tumors, 3327, 3342–3343, 3345
- Endodontic therapy, 2250–2251
- Endogenous Cushing syndrome, 3475
- Endogenous lipids, from liver, transport of, 874
- Endometrial ablation, 3356
- Endometrial adenocarcinoma, 3344–3345
- Endometrial screening, in transgender, 1180t
- Endometrial stromal sarcoma, 3344–3345
- Endometriomas, 3341
- Endometriosis, 1215, 3341
- Endophthalmitis, 1800t, 3940t, 3976, 3976t
 in *Aspergillus* infection, 1931
- Endophytic tumors, 3149
- Endoplasmic reticulum, 2436
- Endorectal pull-through procedure, 2297
- Endoscopic band ligation, for portal hypertension, 2506
- Endoscopic correction, of vesicoureteral reflux, 3274f
- Endoscopic retrograde cholangiopancreatography (ERCP), 2426, 2445, 2447
- Endoscopy, 2257, 2265, 2266f
 in eosinophilic gastroenteritis, 2326
 for hamartomatous tumors, 2411
 in peptic ulcer disease, 2305
 upper gastrointestinal, 1378
- Endotracheal intubation, 559–560, 560f
 in infectious upper airway obstruction, 2571–2572
 in respiratory distress and failure, 619–620
- End-stage renal disease (ESRD), 3247f, 3252–3253
 expected remaining years of life by, 3253f
 hemodialysis in, 3253
 incident rates of, 3254t
 peritoneal dialysis in, 3252
- Energy deposition (ED), 391
- Energy homeostasis, regulation of, 443f
- Energy requirements, 391
- Engorgement, 411
- Enhanced elimination, 709
- ENL. *See* Erythema nodosum leprosum
- Enophthalmos, 3971
- Entamoeba histolytica*
 antibiotic therapy for, 2373t–2375t
 parasitic gastroenteritis and, 2359t
- Entecavir, for hepatitis B, 2467
- Enteral feeding
 for acute gastroenteritis, 2371–2372, 2372f
 calorie boosters for, 437t
- Enteral nutrition
 for chronic diarrhea, 2382
 for Crohn disease, 2322
 for high-risk infant, 1044
- Enteric adenoviruses, 2051
- Enteric anendocrinosis, 2339
- Enteric fever (typhoid fever), 1639, 1655t–1656t,
 1771–1776
 clinical manifestations of, 1773–1774, 1774f, 1774t–
 1775t
 complications of, 1774, 1775t
 diagnosis of, 1774
 differential diagnosis of, 1775
 epidemiology of, 1771, 1772f
 etiology of, 1771
 pathogenesis, 1771–1773, 1773f
 prevention of, 1776
 prognosis for, 1776
 treatment of, 1775–1776
- Enteric hyperoxaluria, 3313
- Enteric infections, chronic diarrhea and, 2377
- Enteric string test, for intestinal strongyloidiasis, 2205
- Enteritis
 acute, in salmonellosis, 1767
Aeromonas in, 1796
Campylobacter, 1788
 trichinellosis and, 2211
 tuberculous, 1845
- Enterogastric *Escherichia coli*, 1782–1783
 hemorrhagic, 1783
- Enterobiasis, 2204, 2204f
- Enterobius vermicularis*, 2204, 2204f
 vulvovaginal infection, 3322t
- Enterococcus*, 1722–1724
 antimicrobial resistance in, 1722–1723, 1722t–1723t
 clinical manifestations of, 1723
 epidemiology of, 1722
 etiology of, 1722
 infections in older children, 1723
 neonatal infections, 1723
 pathogenesis of, 1722–1723
 prevention of, 1724
 treatment of, 1723–1724
 vancomycin-resistant enterococci in, 1723–1724
- Enterocolitis
Hirschsprung disease and, 2298
 necrotizing, 1058, 1102–1105
 clinical manifestations, 1103
 definition of, 1102–1103
 diagnosis, 1103–1104, 1104f–1105f
 epidemiology of, 1103
 pathology and pathogenesis, 1103, 1103f
 prevention, 1105
 prognosis, 1105
 signs and symptoms associated with, 1104t
 treatment, 1104–1105
- Enterocyte differentiation and polarization, defects of,
 2337
- Enterocyte dysfunction, causing intestinal failure, 2352t
- Enteroendocrine cells differentiation, defects in, 2339
- Enterohemorrhagic *Escherichia coli* (EHEC), bacterial
 gastroenteritis and, 2357t–2358t
- Enteroinvasive *Escherichia coli*, 1782
- Enterokinase (enteropeptidase) deficiency, 2348
- Enteropathogenic *Escherichia coli*, 1781–1782
- Enteroviruses
 nonpolio, 1979–1986
 clinical manifestations of, 1981–1984
 complications of, 1986
 diagnosis of, 1984–1985
 differential diagnosis of, 1985, 1985t
 epidemiology of, 1979–1980
 etiology of, 1979–1980, 1979t
 gastrointestinal and genitourinary manifestations
 of, 1982
 hand-foot-and-mouth disease, 1981, 1981f–1982f
 herpangina, 1981
 myocarditis and pericarditis, 1982
 myositis and arthritis, 1983
 neonatal infections, 1983–1984
 neurologic manifestations of, 1983
 nonspecific febrile illness, 1981
 ocular manifestations of, 1982
 pathogenesis of, 1980–1981
 prevention of, 1986
 prognosis for, 1986
 respiratory manifestations of, 1982
 in transplant recipients and patients with malignan-
 cies, 1984
 treatment of, 1985–1986
 in viral meningoencephalitis, 3772
- Enthesitis-related arthritis, 1472t, 1483–1484
- Entropion, 3934–3935
- Enucleation, in retinoblastoma, 3150
- Enuresis
 nocturnal, 3295–3296, 3295t
 clinical manifestations and diagnosis of,
 3295–3296
 epidemiology of, 3295
 pathogenesis of, 3295
 treatment of, 3296
 in sickle cell anemia, 2974
- Envenomations, 4466–4472
 general approach to, 4466
 Hymenoptera stings, 4471–4472
 marine, 4472
 scorpion stings, 4471
 snake bites, 4466–4468
 spider bites, 4468–4471
 wound care, 4466
- Environment
 childhood injuries and, 95
 high-stress, low-verbal, language disorders and, 331
 obesity and, 438
 role of, in language development, 328
 sleep of, infant, SIDS risk factors and, 2534–2535
- Environmental control, primary survey for, 575
- Environmental enteropathy, 2343
- Environmental exposure
 childhood cancer and, 3076
 control of, for hypersensitivity pneumonia, 2615
 eliminating and reducing problematic, in asthma,
 1396–1398
 food-borne diseases caused by, 4411–4413, 4411t–
 4413t
 SLE triggered by, 1490
- Environmental factors, in anti-glomerular basement
 membrane disease, 2637
- Environmental health, 4409–4413
 animal and human bites, 4457–4460
 biological and chemical terrorism, 4446–4455
 biological and chemical terrorism in, 4446–4455
 chemical pollutants, 4422–4430
 envenomations, 4466–4472

Environmental health (*Continued*)

food-borne diseases caused by environmental exposure, 4411–4413, 4411t–4413t
aflatoxins, 4413
deoxynivalenol, 4413
fumonisins, 4413
ochratoxin A, 4413
global climate change, 4409, 4410f
heavy metal intoxication, 4431–4435
lead poisoning, 4436–4441
localized environmental hazards, 4409, 4410t
mass psychogenic illness, 4456
monkeypox, 4461–4464
mycotoxins, 4409–4411
rat bite fever, 4460–4461, 4460f
toxic food exposure, 4441–4446
toxins vs. toxicants, 4409

Environmental injustice, 9

Environmental risk factors
for schizophrenia, 289
for SIDS, 2533–2535

Enzymatic defects, 2988–2992

glucose-6-phosphate dehydrogenase (G6PD) deficiency, 2990–2992, 2990f, 2991t, 2992f
pyruvate kinase deficiency, 2988–2989, 2988f, 2989t

Enzyme deficiencies, 2347–2348

Enzyme replacement therapy, 757
for Fabry disease, 3887
for mucopolysaccharidoses, 943, 943t

Enzyme succinate dehydrogenase, in pheochromocytomas, 3479

Enzyme-linked immunosorbent assay (ELISA), for Lyme disease, 1884–1885

Enzymes

aminoglycoside-modifying, 1672t
defects, of heme biosynthetic pathway, 963f

EOS, 4219, 4221f

Eosin-5-maleimide (EMA), in hereditary spherocytosis, 2956–2957

Eosinophilia, 2211

allergic diseases and, 1375–1376, 1376t
causes of, 1295t

Eosinophilic cystitis, 3264

Eosinophilic enteritis, 2201

Eosinophilic esophagitis, 1378, 2261, 2269, 2269f–2270f
in food allergy, 1443–1444

Eosinophilic fasciitis, 1508t

Eosinophilic gastroenteritis, 2326

Eosinophilic gastroenteropathy, chronic diarrhea and, 2377

Eosinophilic gastrointestinal diseases (EGIDs), 1294

Eosinophilic granuloma, 4023

in Langerhans cell histiocytosis, 3169

Eosinophilic granulomatosis with polyangiitis, 1553t, 1563t, 2628, 2628t

Eosinophilic lung disease, 2625–2632

acute eosinophilic pneumonia, 2625–2627, 2626t
allergic bronchopulmonary aspergillosis, 2629–2630, 2629t, 2630f

chronic eosinophilic pneumonia, 2627–2628

clinical manifestations of, 2625–2626

eosinophilic granulomatosis with polyangiitis, 2628, 2628t

etiology of, 2625, 2625t–2626t

hypereosinophilic syndrome, 2630–2632, 2630t, 2631f

Löffler syndrome, 2626

pathology and pathogenesis of, 2625

Eosinophilic meningitis, 2208, 3776–3779

clinical manifestations in, 3776–3779

diagnosis in, 3779

epidemiology of, 3776

etiology of, 3776

prognosis of, 3779

treatment in, 3779

Eosinophilic pustular folliculitis, 4043

Eosinophils, 1293–1295

in allergic disease, 1371

in bronchoalveolar lavage, 2627f

diseases associated with eosinophilia, 1293–1295

diverse properties of, 1294f

reference intervals, 4472.e9t

Eotaxins, 1293

EPDS. *See* Edinburgh postnatal depression scale

Ependymal tumors, 3120–3121, 3121f

Ependymomas, 3120–3121, 3121f

Ephelides, 4067

EPI. *See* Expanded Program on Immunization

Epilepharon, 3934–3935, 3935f

Epicanthal folds, 3934

Epicondylitis

lateral, 4304, 4306f

medial, 4304, 4305f

Epidemic disease, 1583

Epidemic keratoconjunctivitis, 3941

Epidemic relapsing fever, 1880

Epidemic typhus, 1900t–1902t

Epidemic (louse-borne) typhus, 1910–1911

clinical manifestations of, 1910–1911

epidemiology of, 1910

etiology of, 1910

prevention of, 1911

transmission of, 1910

treatment of, 1911

Epidermal diseases, 4098–4109

acanthosis nigricans, 4109f

Darier disease, 4105–4106, 4106f

Gianotti-Crosti syndrome, 4108, 4108f

keratosis pilaris, 4103–4104, 4104f

lichen nitidus, 4106, 4106f–4107f

lichen planus, 4107, 4107f

lichen spinulosus, 4104

pityriasis lichenoides, 4102–4103, 4103f

pityriasis rosea, 4104, 4104f

pityriasis rubra pilaris, 4104–4105, 4105f

porokeratoses, 4107, 4108f

psoriasis, 4098–4102, 4099f–4100f, 4101t–4102t

vulvar, 3321t–3322t, 3324

Epidermal nevi, 4065–4066, 4065t

Epidermal nevus syndrome, rickets and, 478

Epidermis, 4025, 4025f

Epidermolytic verruciformis, 1337, 1339t, 4166–4167

Epidermoid cysts, 4185

Epidermolysis bullosa, 4081, 4081t

dystrophic, 4083t, 4083–4084, 4083t, 4084f

Epidermolysis bullosa simplex (EBS), 4081, 4081t–4082t, 4083f

Epidermolytic hyperkeratosis, 4116

Epidermolytic ichthyosis, 4116, 4116f

Epидидимит, 1241–1242, 3307

Epidural anesthesia, in pain management, 696

Epidural hematoma, 584f

Epidural hemorrhage, 1057

Epigastric hernia, 2512

clinical presentation of, 2512

natural history of, 2512

Epigenetic imprinting, 148

Epiglottitis

acute, 2569–2570, 2570f

Haemophilus influenza in, 1757

airway narrowing and, 558

artificial airway and antibiotics, 2570

Epilepsia partialis continua, 3624

in unprovoked seizures, 3598

Epilepsy, 247t, 3588. *See also* Seizures

anxiety disorders and, 248t

autoimmune encephalitis associated with, 3711

psychosis associated with, 291

pyridoxine-dependent, 463

in severe malaria, 2181

Epilepsy of infancy with migrating focal seizures (EIMFS), 3600

Epilepsy syndrome choice of drug according to seizure type and, 3607–3608

generalized seizures, 3600–3603

language disorders and, 329

Epileptic encephalopathy, 3588

mitochondrial disease and, 935t

Epileptic encephalopathy with continuous spike waves in slow-wave sleep (CSWS), 3602–3603

Epileptic seizures, 3588

Epileptic spasms, 3619

Epileptic syndrome, 3588

Epileptogenesis, in seizures, 3603

Epileptogenic zone, in epilepsy surgery, 3615

Epimastigotes, 2163

Epinephrine

for bronchiolitis, 2030

deficiency, in hypoglycemia, 982

for heart failure, 2898t, 2900

nebulized racemic, 2571

for pediatric resuscitation and arrhythmias, 563t, 565

for postarrest stabilization, 568t

release, features associated with, 981t

for shock, 610t

EpiPen autoinjection device, for asthma, 1405t–1406t

Epiphora, 3969

Epiphyseal fractures, 4278

Epiphysiodesis, 4220–4221

Epiphysis, 4193, 4240, 4241f

Epiploic appendagitis, 2402

Episcleral plaque radiotherapy, for retinoblastoma, 3150

Episcleritis/scleritis, 3940t

Episodic ataxia, 3636

Episodic fever, in lymphatic filariasis, 2206

Episodic laryngospasm, 3850

Episodic or induced acute hemolytic anemia, 2990–2992

clinical manifestations of, 2991

diagnosis of, 2991–2992

etiology of, 2990

laboratory findings of, 2991

prevention and treatment of, 2992

Episodic tension-type headache, infrequent, 3652t

Epispadias, 3285, 3287f

incontinence in girls secondary to, 3294–3295

Epistaxis, 2548–2549

anatomy, 2548

causes of, 2549t

clinical manifestations, 2549

etiology, 2548–2549

in factor VII deficiency, 3033

prevention, 2549

treatment, 2549

Epitaxy, 3312

Epithelial barrier hypothesis, 1367, 1368f

Epithelial ovarian cancers, 3343–3344

Epithelioid angiomyomatosis, 1816

Epithelioid hemangioendothelioma, 3163–3164

Epithelioid hemangiomas, 3161–3162

Epithelioid sarcoma, 3139t–3140t

Epithelioid sarcoma-like hemangioendothelioma, 3163

Epiroclear lymphadenopathy, 3070t

Eplerenone, for primary aldosteronism, 3479

EPODE, 449–450

Epoprostenol, 2834t

Eprodiole disodium, for amyloidosis, 1537

EPS. *See* Elastosis perforans serpiginosa

Epstein pearls, 2254, 4148

Epstein syndrome, 3188

Epstein-Barr virus (EBV), 1255, 1256t, 2006–2009

chronic active, 1328–1329, 1328t

clinical manifestations of, 2007, 2007f

in CNS syndromes, 3772

complications of, 2008

diagnosis of, 2007–2008

differential diagnosis of, 2007–2008

diseases caused by, 2006t

epidemiology of, 2006

etiology of, 2006

heterophile antibodies detection, 2008

in intestinal transplantation, 2354

laboratory diagnosis of, 2008

lymphoproliferative disease, 1364

other primary immunodeficiencies associated with, 1328

nasopharyngeal carcinoma and, 3165

oncogenesis of, 2008–2009, 2009t, 3080–3081

endemic Burkitt lymphoma, 2009

Hodgkin lymphoma, 2009

lymphoproliferative disorder, 2008–2009

nasopharyngeal carcinoma, 2008–2009

pathogenesis of, 2006–2007

prevention of, 2009

prognosis for, 2009

role in Hodgkin lymphoma, 3106

specific antibodies detection, 2008, 2009f

- Epstein-Barr virus (EBV) (*Continued*)
 susceptibility disorders, 1326–1328, 1327t, 1328f
 clinical manifestations of, 1327–1328
 diagnosis of, 1327–1328
 pathophysiology of, 1327–1328
 treatment of, 1327–1328
 treatment of, 2009
 viral DNA detection, 2008
- Equation of motion, 620–621, 621f
- Equipment
 guidelines for, in developing world, 546–547
 resuscitation, 535, 535t
- Equivalent dose, 4413–4414
- Eradicating disparities, approaches to, 15–16
- Erb palsy, 4397
- ERCC6L2-related disorder, 3009
- Erdheim-Chester disease (ECD), 3169, 3170t, 3179
- Erector spinae plane block, in pain management, 694
- ERF-related craniostenosis, 794t–795t
- Ergocaliferol, 3250
- Ergogenic aids, 4325
- Erikson's psychosocial theory, 140t
- Erlotinib, 3088t
- Erosions, 4027
- Error
 harm vs., 42, 42f
 identifying and analyzing, 43–44
- Eruption cyst, 2254
- Eruptive lentiginosis, 4067
- Eruptive vellus hair cysts, 4186, 4187f
- Eruptive xanthomata, 875f
- Erysipelas, 1707, 4155
- Erysipeloid, 1524f, 4157
- Erythema
 erysipeloid, 1524f
 in JDM, 1500
 palmar, liver disease and, 2439
- Erythema infectiosum (fifth disease), 1988–1989, 1988f–1989f
- Erythema marginatum, in rheumatic fever, 1713, 1713f
- Erythema migrans, in Lyme disease, 1882–1883, 1883f
- Erythema multiforme, 4076–4078, 4149
 clinical manifestations of, 4076–4078, 4076f
 differential diagnosis of, 4078
 etiology of, 4076
 pathogenesis of, 4077
 pathology of, 4077–4078
 treatment of, 4078
- Erythema necroticans, 1858
- Erythema nodosum, 4129–4130
 clinical manifestation of, 4129, 4130f
 etiology of, 4129, 4129t
 histology of, 4129
 pathogenesis of, 4129
 treatment of, 4129–4130
- Erythema nodosum leprosum (ENL), 1857–1858
- Erythema toxicum, 4042, 4042f
- Erythrasma, 4027, 4157
- Erythroblastosis fetalis, 1123
- Erythrocyte enzymopathies, 1120
- Erythrocyte indices, reference intervals, 4472.e9t
- Erythrocyte mean corpuscular volume, 2923f
- Erythrocyte protoporphyrin (EP), 4437
- Erythrocyte sedimentation rate (ESR), 4286
- Erythrocyte zinc protoporphyrin, in iron-deficiency anemia, 2947t
- Erythrocytes, 2921
- Erythrocytic phase, in *Plasmodium* life cycle, 2169–2170
- Erythrokeratoderma variabilis, 4116–4117, 4116f
- Erythromelalgia, 698t, 699, 1571–1572, 1573f, 4034
- Erythromycin, 1675t–1685t
 for dental infections, 2247–2248
 enterococci resistance, 1722t
- Erythropoiesis
 fetal, 2924–2925
 ineffective, in β-thalassemia, 2983f
 normal, 1116, 1117f
- Erythropoiesis-stimulating agents (ESAs), 2936, 3251
- Erythropoietic porphyria, congenital, 970–972
 clinical manifestations, 971
 diagnosis and differential diagnosis, 972
 etiology, 970
- Erythropoietic porphyria, congenital (*Continued*)
 laboratory findings, 971–972
 pathology and pathogenesis, 970–971
 prevention and genetic counseling, 972
 prognosis, 972
 treatment, 972
- Erythropoietic protoporphyrina, 964–965, 965t, 977–979, 4094–4095, 4096f
 clinical manifestations, 978
 complications, 979
 diagnosis and differential diagnosis, 978–979
 epidemiology, 977–978
 etiology, 977
 laboratory findings, 978
 pathology and pathogenesis, 978
 prevention and genetic counseling, 979
 prognosis, 979
 treatment, 979
- Erythropoietin (EPO), 2924, 3014–3016, 4325t–4326t
- Eschar, single painless, 1908
- Escherichia coli*, 1780–1785
 causing spine infection, 4255
 diagnosis of, 1783–1784
 diarrheagenic, 1781t
 diffusely adherent, 1783
 early-onset infection and, 1143
 enteroaggregative, 1782–1783
 enteroaggregative hemorrhagic, 1783
 enterohemorrhagic, 2357t–2358t
 enteroinvasive, 1782
 enteropathogenic, 1782
 enterotoxigenic, 1781–1782
 antibiotic therapy for, 2373t–2375t
 prevention of illness, 1784–1785
Shiga toxin-producing, 1783
 treatment of, 1784, 1784f, 1784t
- Escitalopram (Lexapro), for depression and anxiety, 227t
- Eslicarbazepine
 adverse effects of, 3611t
 dosages of, 3609t–3610t
- Esmolol, for severe hypertension in children, 2919t
- Esodeviations, 3926
- Esophageal atresia, 2258–2259, 2258f–2259f, 2259t
- Esophageal bleeding, 2257
- Esophageal disease, anesthetic implications in, 666t
- Esophageal duplication cysts, 2261
- Esophageal dysphagia, 2225, 2225t
- Esophageal perforation, 2271–2272
- Esophageal rupture, 2271
- Esophageal stenosis, congenital, 2260, 2260f
- Esophageal strictures, 2275
- Esophageal varices, 2257, 2272, 2272f
- Esophageal wall, 2255–2256
- Esophagitis, 2257
 complication of GERD, 2268
 infective, 2269–2271
 pill, 2271, 2271f, 2271t
- Esophagogastroduodenoscopy, in peptic ulcer disease, 2305
- Esophagus, 2255–2257
 anatomy of, 2255–2256
 congenital anomalies of, 2258–2260
 diagnostic aids for, 2257
 embryology of, 2255–2257
 foreign bodies in, 2273, 2273f–2274f
 function of, 2256–2257, 2256f, 2256t
 obstructing and motility disorders of, 2261
- Espondia (mucosal leishmaniasis), 2158–2159
- Essential fatty acid deficiency, 393, 4190
- Essential pentosuria, 900t–901t, 919–920
- Essential thrombocythemia, 2997
- Essential tremor (ET), 3678
- Estimated average requirement (EAR), for vitamin A, 454–455, 454t
- Estimated delivery date (EDD), 1015
- Estimated energy requirement (EER), 388t
- Estimated fetal weight (EFW), 1015
- Estradiol-17β, 3487
- Estriol, 3487
- Estrogen, 3487
 excess, 3475t
 exogenous sources of, 3495
- Estrogen (*Continued*)
 gender-affirming hormone therapy and, 1178–1179, 1179t
 oral contraceptives, 3355
 in porphyria cutanea tarda, 973
 puberty blockers and, 1178t
 therapy of, risks with, 1179–1180
- Estrogenic lesions, of ovary, 3502–3503
- Estrogen-receptor assays, 3487
- Estrone, 3487
- Ethambutol
 for drug-resistant tuberculosis, 1852t–1853t
 for nontuberculous mycobacteria infection, 1865
 for tuberculosis, 1849t, 1832
- Ethanol
 abuse, 3892–3894
 association with porphyria cutanea tarda, 973
 intoxication, 1197
- Ethical issues, in genetic testing, 729
- Ethics
 in adolescent healthcare, 54–55
 in pediatric care, 51–55
 assent and parental permission, 51
 committees and ethics consultation, 53
 critically ill children in, treatment of, 51–53
 declaring death and organ donation, 53
 genetics, genomics, and precision medicine, 54
 justice and, 55
 neonatal, 53
 newborn screening, 54
 religious or cultural objections to treatment, 53
 research for, 55
- Ethionamide
 for drug-resistant tuberculosis, 1852t–1853t
 against *M. tuberculosis*, 1832
- Ethnic disparities, in drowning, 638
- Ethnicity
 adolescent health outcomes by, 1188t
 childhood cancer and, 3073
 childhood injuries and, 95
 providing diagnostic clues to autoinflammatory syndromes, 1524t
- Ethoxsuximide
 for absence seizures, 3607
 dosages of, 3609t–3610t
- Ethylene glycol, 516, 720–721
 poisoning, 707t–708t
 toxicity, 701t
- Etomidate, 669t, 670
- Etoposide, indications and adverse reactions of, 3089t–3090t
- Etravirine, for HIV, 2098t–2107t
- Eucrisa. *See* Crisaborole
- Euglobin clot lysis time, 3034
- Eulenburg disease, 3838
- Eustachian tube obstruction, parainfluenza viruses in, 2028
- Euthanasia, active, 53
- Euthyroidism, 3413
- Eutrombicula alfreddugesi*, 4175
- Euvolemic hyponatremia, 492t, 495
- Evan disease, 1329
- Evans syndrome, 2994, 3050–3052
- Evaporative, in heat transfer, 657
- Event analysis, 43–44
- Evidence-based psychotherapies, 233, 234t
- Evidence-based tools, 180t–181t
- Evoked potentials, in neurologic evaluation, 3560
- Ewing sarcoma, 3077, 3143–3144, 3143f
 clinical manifestations of, 3143
 diagnosis of, 3143–3144
 early detection of, 3084
 epidemiology of, 3143
 pathogenesis of, 3143
 prognosis of, 3144
 treatment of, 3144
- Ewingii ehrlichiosis*, 1900t–1902t, 1911
- Exacerbating factors, in porphyrias, 965t
- Exanthem subitum, 2016
- Excessive negative interstitial pressure, 2605
- Exchange transfusion, for hyperbilirubinemia, 1115, 1116f
- Excimer laser correction, for myopia, 3914

Excoriation, 4027
 Excretion
 bile acid, 2437
 magnesium, 502–503
 phosphorus, 506
 potassium, 495–496, 496t
 sodium, 489
 Excretory urogram, of intravesical ureterocele, 3281f
 Executive dysfunctions, 300
 early signs of, 305
 expression of, 308t
 treatment of, 307–308
 Executive functioning, 300, 302–303, 302t
 primary care approach to, 306t
 treatment of, 307–308
 writing disabilities and, 322
 Executive skills, math disabilities and, 320
 Exenatide, for T2DM, 3542t
 Exercise
 for children with disabilities, 4406–4407, 4406t
 intolerance, respiratory signs and symptoms, 2531t
 in T1DM, 3533
 Exercise challenges, in asthma, 1391–1392
 Exercise testing, 2758
 diagnostic approach to respiratory disease, 2523
 Exercise-associated hyponatremia, 4321, 4321f–4322f
 Exercise-induced anaphylaxis, in urticaria, 1430–1431
 Exercise-induced hematuria, 3218
 “Exergaming” programs, 4407
 Exfoliatins A and B, 1694
 Exfoliative dermatitis, 1419
 Exhaled tidal volume, 628
 Exhaustion, heat, 4320
 Exocrine pancreas, disorders of, 2423–2424
 Exocrine pancreatic function, 2336, 2338f, 2338t
 Exocrine pancreatic insufficiency, 2348
 mitochondrial disease and, 935t
 in Shwachman-Diamond syndrome, 3004
 Exodeviations, 3927
 Exogenous estrogens, 3327
 Exogenous (dietary) lipids, transport of, 873–874
 Exogenous obesity, 3382
 Exome sequencing, 727, 750
 in ectodermal dysplasia, 4046
 for neurodevelopmental disorders, 348t
 Exons, 730
 Exophthalmos, 3417f, 3971
 in Langerhans cell histiocytosis, 3169
 Exophytic tumors, 3149
 Exostoses, 4023
 of external ear, 4002
 Exotropia, intermittent, 3927
 Expanded Program on Immunization (EPI), 29
 Expansile skeletal hyperphosphatasia, 4383
 Expansion thoracoplasty, 4248
 Expectancies, strategies for, 130t
 Expedited partner therapy, 1250
 Expertise bias, 48t
 Expiratory phase maneuvers, 626
 Expiratory reserve volume, 2519
 Expiratory time, 627
 Explicit memory, 302
 Exploitation, types of, 110t
 Exposure
 primary assessment of, 556
 primary survey for, 575
 to radiation, effects on fetus, 1024
 teratogenic, medication and, 1021–1023
 in tuberculosis, 1836
 Expressive language, 170t, 325t
 Extrophy
 anomalies, 3286–3287
 bladder, 3285–3286
 clinical manifestations of, 3285, 3285f
 long-term prognosis of, 3286
 treatment of, 3286
 cloacal, 3285
 Extensor carpi ulnaris (ECU) tendinosis, 4328
 External auditory canal, congenital stenosis or atresia, 3996–3997
 External otitis, 1800t, 3999–4002
 clinical manifestations of, 3999
 diagnosis of, 3999–4001, 4000t

External otitis (*Continued*)
 etiology of, 3999
 external ear, diseases of, 4002
 prevention of, 4002
 treatment for, 4001–4002, 4001f
 External rewards, 170
 External-beam irradiation, in retinoblastoma, 3150
 Extracellular fluid (ECF), 485
 osmotic equilibrium in, 486
 Extracorporeal cardiopulmonary resuscitation (ECPR), 566–568
 Extracorporeal membrane oxygenation (ECMO), 566–568
 for congenital diaphragmatic hernia, 1095
 for heart failure, 2901
 for PPHN, 1093
 for refractory shock, 611
 Extracutaneous sporotrichosis, 1942
 Extragonadal manifestations, of McCune-Albright syndrome, 3392–3393
 Extrahepatic bile ducts, 2276
 Extrahepatic portal hypertension, 2504t
 Extrahepatic portal venous obstruction, 2272
 Extraintestinal focal infections
 Campylobacter, 1790
 Salmonella, 1768
 Extraintestinal infectious complications, of typhoid fever, 1775t
 Extraocular muscles, congenital fibrosis of, 3575–3576
 Extrapulmonary blastomycosis, 1935
 Extrapulmonary diseases
 Mycoplasma pneumoniae and, 1888–1889, 1889f
 with pulmonary manifestations, 2530
 Extrapulmonary infection, coccidioidomycosis, 1937, 1937t
 treatment of, 1939
 Extrapulmonary sequestration, 2602
 Extrapulmonary tuberculosis, 1851
 Extrapyramidal cerebral palsy, 3690t
 Extrasystoles, sinus arrhythmias and, 2844–2848
 Extremities
 assessment in newborn, 1004
 conditions causing pain in, 1479t
 deep vein thrombosis, 3040
 fractures, in delivery room, 1073
 Extremity trauma, secondary survey for, 577–578
 Extrinsic allergic alveolitis, 2612
 Extrusion, of periodontal structures, 2251
 Exudates, 2525
 Exudative pleural effusion, 2649t
 Eyberg Child Behavior Inventory, 280t
 Eye disorders
 in *Aspergillus* infection, 1931
 minor malformations, 785t
 Eye examination, 3909–3912, 3911t
 binocular vision, 3911
 biomicroscopy, 3912
 color vision testing, 3910
 external, 3911–3912
 frequency, in JIA, 1476t
 fundus, 3912
 ocular motility, 3910–3911
 ophthalmoscopy, 3912
 pupillary, 3910
 refraction, 3912
 slit-lamp, 1482f, 3912
 tonometry, 3912
 visual acuity, 3910
 visual field assessment, 3910
 Eye infections, adenoviruses, 2034
 Eye injuries, 3976–3980, 3976f
 chemical, 3979
 child abuse, 3979, 3980f
 corneal abrasions, superficial, 3977, 3977f
 ecchymosis and swelling, 3976–3977, 3976f
 fireworks-related, 3979
 foreign body involving the ocular surface, 3977–3978, 3977f–3978f
 handheld laser retinal, 3980, 3980f
 hyphema, 3978
 lacerations, 3977, 3977f
 open globe, 3978, 3978f
 optic nerve trauma, 3978

Eye injuries (*Continued*)
 orbital fractures, 3979
 penetrating wounds, 3979
 sports-related, 3979
 Eye irritation, in exclusion or inclusion in daycare, 187t–192t
 Eye lesions, vitamin A deficiency and, 453
 Eyelids
 abnormalities, 3933–3936
 blepharitis, 3935
 blepharospasm, 3935
 chalazion, 3936
 coloboma, 3936
 ectropion, 3934–3935
 entropion, 3934–3935
 epiblepharon, 3934–3935
 epicanthal folds, 3934
 hordeolum, 3936
 lagophthalmos, 3934
 lid retraction, 3934
 ptosis, 3933
 tumors, 3936
 ecchymosis and swelling, 3976–3977, 3976f
 lacerations of, 3977, 3977f
 upper, retraction of, 3418f
 Eyes
 growth and development of, 3909
 newborn
 assessment of, 1001–1002
 protection against gonococcal ophthalmia, 1005
 physical examination of, 550–551
 toxoplasmosis in, 2190f, 2192–2193
 Ezetimibe, 875–876

F

Fabry disease, 699, 887t, 894–895, 894t–895t, 3886–3887, 3899t, 4124
 Face
 fetal, ultrasonographic assessment, 1026f
 of newborn, 1001–1002
 Faces Scale, 679t
 Facet syndrome, 4306
 Facial angiomas, 3658f
 Facial anomalies, 783–787
 clinical signs of syndromes with, 784t
 diagnosis, 785
 genetic testing, 785–786, 786f
 history, 783–784
 imaging studies, 784
 laboratory studies, 785–786
 management and counseling, 786–787
 physical examination, 784, 784t, 785f
 Facial dysmorphism, 4048
 Facial morphology, characteristic, CCHS and, 2721, 2721f
 Facial myokymia, 3674–3677
 Facial nerve (CN VII)
 in neurologic examination, 3553
 palsy, 1069
 Facial palsy, at birth, 3908
 Facial paralysis, 3981
 in acute otitis media, 4013–4014
 Facility-specific treatment guidelines, 1691t
 Facioscapulohumeral muscular dystrophies, 3842–3843, 3843f
 Factitial panniculitis, 4132
 Factitious disorders, 235, 236t
 by proxy, 127–128
 Factitious fever, 1640–1641
 Factitious hypoglycemia, 987–989
 Factor I deficiency, 1318, 1320–1322
 Factor V deficiency, 3034
 combined with factor VIII, 3034
 Factor V Leiden pathogenic variant, 3038, 3038t–3039t
 Factor VII deficiency, 3033
 Factor VIII, 3038
 Factor VIII deficiency, 3029–3033, 3030f, 3031t
 combined with factor V, 3034
 Factor IX deficiency, 3029–3033, 3030f, 3031t
 Factor X deficiency, 3033
 Factor XI deficiency, 3033

- Factor XII-associated cold autoinflammatory syndrome, 663
- Factor XIII deficiency, 3034
- Factor B deficiency, 1320
- Factor D deficiency, 1320
- Factor H deficiency, 1318, 1320–1321
- Facultative anaerobes, 1828
- FAI. *See* Femoroacetabular impingement
- Failure mode and effects analysis (FMEA), 38, 38f, 43–44
- Failure of segmentation, 4260
- Failure to thrive (FTT), 433
- due to citrin deficiency, 853
 - in patients with progeria, 956–957
- Fainting, in syncope, 592
- Falls
- death rate, 92t
 - nonfatal injury, 98
- False-negative results, 750
- False-positive results, 750
- Famiclovir, 1954
- Familial adenomatous polyposis, 2413, 3153
- Familial adenomatous polyposis coli, 3473t
- Familial apolipoprotein A-I deficiency, 880
- Familial chilblain lupus (FCL), 660t, 663, 3892
- Familial chylomicronemia, 879, 879f
- Familial clustering, and pseudogenetic inheritance, 740–742
- Familial cold autoinflammatory syndrome (FCAS), 663, 1431, 1522t, 1527t, 1528–1529, 1536, 4132
- Familial combined hyperlipidemia, 877
- Familial defective apoB-100, 876
- Familial dysalbuminemic hyperthyroxinemia, 3402
- Familial dysautonomia, 3632, 3896–3897, 3898t–3899t, 3900f, 3937
- Familial dysbetalipoproteinemia, 877–879
- Familial episodic pain syndrome type 1, 3890
- Familial exudative vitreoretinopathy, 3961
- Familial glucocorticoid deficiency, 3450
- Familial hemiplegic migraine (FHM), 3633
- Familial hemophagocytic lymphohistiocytosis, 3168–3169, 3172f
- type 5, 2338
- Familial hyperalphalipoproteinemia, 880
- Familial hypercholesterolemia, 874
- Familial hyperphosphatasemia. *See* Juvenile Paget disease
- Familial hypertriglyceridemia, 879–880
- Familial hypobetalipoproteinemia, 881
- Familial hypocalciuric hypercalcemia, 3441, 3442t
- Familial intellectual disability, intellectual disability caused by, 349t
- Familial isolated pituitary adenoma syndrome, 3475
- Familial juvenile hyperuricemic nephropathy, 945t, 947
- Familial lecithin-cholesterol acyltransferase (LCAT) deficiency, 880
- Familial Mediterranean fever (FMF), 1297t–1298t, 1525t, 1536
- diagnosis and treatment, 1525t
- Familial nonhemolytic unconjugated hyperbilirubinemia, 2454–2456
- Familial osteochondritis dissecans, 4344
- Familial partial lipoatrophy, 3546
- Familial partial lipodystrophy (FPLD), 3546, 3547t, 4133
- Familial PGL syndromes, pheochromocytomas and, 3166
- Familial pheochromocytoma, 3126t
- Familial progressive hyperpigmentation and hypopigmentation syndrome, 4070t–4071t
- Familial renal adysplasia, 3261
- Familial retinoblastoma, 3077
- Familial secundum atrial septal defect (ASD), 2770
- Familial short stature, 176
- Familial spastic paraparesis, 3717
- Familial thoracic aortic aneurysm syndrome, 4367–4368, 4367t
- Familial tumoral calcinosis, 509
- Families Moving Forward and Parents and Children Together, for FASD, 1138
- Family
- context of, caring for child and youth in, 90
 - in emergency departments, 537–538
- Family (*Continued*)
- history
 - in evaluation of cardiovascular system, 2737
 - and pedigree notation, 735
 - moving or relocation, 196
 - psychotherapy, 233
 - support
 - during adoption process, 74
 - in transmissible spongiform encephalopathies, 2124
- Family-based control design, 801
- Family-centered care, in interfacility transport, 542
- Family-centered interviewing, 216
- Family counseling, of child with intellectual disability, 361
- Family First Prevention Services Act, 75
- Family Media Use Plan, 102
- Family partnership, patient and, learning from, 50
- Family support programs, 90
- Family systems theory, 137–138
- Family therapy, for anxiety disorders, 251–253
- Fanconi anemia, 774t, 2999–3004, 3012, 3077–3080, 3126t, 3131t–3132t, 4070t–4071t
- cancer risk and other complications in, 3003
 - clinical manifestations of, 3001–3003, 3002f, 3002t
 - diagnosis of, 3003
 - etiology and epidemiology of, 2999–3001
 - pathology of, 3001
 - prognosis of, 3004
 - treatment of, 3003–3004
- Fanconi syndrome, 473t, 478, 492, 507
- clinical manifestations of, 3234–3235
- Fanconi-Bickel syndrome, 900t–901t, 906
- FAO. *See* Food and Agriculture Organization
- FAP. *See* Familial adenomatous polyposis
- Farber disease, 887t, 896–897, 897f
- FAS. *See* Fetal alcohol syndrome
- FAS-associated death domain deficiency, 1332t–1333t
- Fasciitis, eosinophilic, 1508t
- Fasciola hepatica*, 2214
- Fascioliasis, 2214
- Fasciolopsis buski*, 2215
- FASD. *See* Fetal alcohol spectrum disorder
- Fasenra. *See* Benralizumab
- FAST. *See* Focused Assessment with Sonography in Trauma
- Fast Track, 278–279
- Fasting, effects on hypoglycemia, 980f, 981, 988f, 991
- Fat, 389t–390t, 391–393, 392f
- absorption, 2277
- Fat embolism syndrome, 2972
- Fat malabsorption, 2333t, 2334
- Fat transport, disorders of, 2350
- Fatal drowning, 637
- Fatal familial insomnia, 2118, 2119t
- Fatigue
- in pediatric palliative care, 64–69, 65t–69t
 - suggestive of rheumatic disease, 1461t
- Fatty acids
- disorders of, oxidation, 987–989
 - metabolism, disorders of, 805t
 - mitochondrial fatty acid β-oxidation, 859–865
 - oxidation, 2436
 - oxidation disorders
 - cardiomyopathy and, 808t
 - hepatic dysfunction and, 808t
 - neonatal hypoglycemia and, 806t
 - in vegetarian diets, 418
- Fatty aldehyde dehydrogenase (FALDH3A2), 4117
- Fatty liver, in T2DM, 3543t
- Fatty liver disease, nonalcoholic, 442, 2480–2482, 2481f
- Favus, 4160–4161
- Fazio-Londe syndrome, 3874
- FBLN5*-related cutis laxa, 4376t
- FCAS. *See* Familial cold autoinflammatory syndrome
- FCL. *See* Familial chilblain lupus
- FDE. *See* Fixed-drug eruption
- Feathering (Lichtenberg figures), in lightning burns, 655–656, 657f
- Febrile illness, nonspecific, 1981
- Febrile infection-related epilepsy syndrome (FIRES), 3595
- Febrile seizures, 3594–3597
- evaluation of, 3596–3597, 3597f
 - genetic and other factors leading to, 3595–3596, 3596f
 - measles and, 1961
 - risk factors for recurrence of, 3596t
 - treatment for, 3597, 3609t–3610t
- Febrile status epilepticus, 3595, 3623–3626
- Febrile ulceronecrotic Mucha-Habermann disease (FUMHD), 4103
- Febrile UTI, imaging studies in, 3267–3268, 3268t
- Fecal elastase test, 2423
- Fecal elastase-1 estimation, in exocrine pancreatic function, 2336
- Fecal microbiota transplantation (FMT), 1827t, 1828
- Fecal microflora (dysbiosis), 157
- Fechtner syndrome, 3188
- Federal Housing Authority (FHA), 8
- Federal policies, 8–10
- Federal services, for child with intellectual disability, 360–361
- Feeding
- cultural considerations in, 417, 418f
 - for Down syndrome, 371
 - during first year of life, 409–412
 - of high-risk infant, 1044
 - infant, SIDS risk factors and, 2535
 - intolerance, in digestive system disorders, 1099
 - in pediatric palliative care, 70
 - in school-aged children and adolescents, 415–416
 - toddlers and preschool-aged children, 414–415, 415t
 - practices in, 415
 - recommended intake and serving sizes for, 414–415, 415t
- Feeding practices, 415
- Felbamate
- adverse effects of, 3611t
 - dosages of, 3609t–3610t
 - for Lennox-Gastaut syndrome, 3607
- Female
- anorectal malformation in, 2407t
 - breast changes in, 1160f
 - imperforate anus in, 2404–2405, 2404f–2405f
 - incontinence in, 3294–3295
 - isosexual precocity in, 3387t
 - onset of puberty in, 1161f
 - peak height velocity in, 1161f
 - pubic hair changes in, 1159f
 - sexual development in, 1159
 - sexual maturity rating in, 1160t
 - urethral prolapse, 3301
- Female athlete triad, 4322, 4323t, 4324f, 4331
- Female genital mutilation (FGM), 3357–3358, 3357t
- Female genital schistosomiasis (FGS), 2213
- Female health, parametral urethral cyst, 3301
- Female hypogonadism, risk for osteoporosis, 4384t
- Female reproductive system, autonomic dysreflexia in, 4391t
- Female-appearing genitalia, 3506t
- Feminizing adrenal tumors, 3475
- Femoral anteversion, 4212, 4214f
- Femoral head, 4231
- Femoral hernia, 2416, 2420
- Femoral neck stress fracture, 4307–4308
- Femoral shaft fractures, 4282, 4282t
- Femoroacetabular impingement (FAI), 4308, 4329
- Fenfluramine, for Lennox-Gastaut syndrome, 3607
- Fenoldopam, for severe hypertension in children, 2919t
- Fentanyl, 670–671
- equianalgesic doses of, 685t
 - in hepatic and renal dysfunction, 685t
 - for intubation, 620t
 - in pain management, 683t
- Ferritin, reference intervals, 4472.e9t
- Ferrochelatase (FECH), 964t, 977, 4094–4095
- Fertility
- awareness-based contraception, 1228
 - cancer and, 3338–3340
 - male, inguinal hernia and, 2421
 - in pubertal blockade, 1176, 1177t
- Fetal akinesia, 782f
- in arthrogryposis, 3820
- Fetal akinesia deformation sequence, 4271, 4271f

Fetal akinesia sequence, 3858
 Fetal alcohol spectrum disorder (FASD), 1022, 1134–1139
 diagnostic criteria for, 1136
 diagnostic systems of, 1134–1136
 differential diagnosis of, 1136–1137
 dysmorphologic facial features of, 1135–1136, 1135f
 ear findings in, 1138f
 epidemiology of, 1134
 hand findings in, 1138f
 interventions and treatments of, 1138–1139
 outcomes of, 1137
 prevalence of, 1134
 Fetal alcohol syndrome, 779, 780t, 1022, 1138t, 2739t–2740t
 Fetal bradycardia, 1017
 Fetal breathing movements (FBMs), 1018t
 Fetal circulation, 2735
 Fetal cystoscopy, 1030
 Fetal disease
 intrauterine diagnosis, 1024–1028, 1025t
 treatment and prevention, 1028
 Fetal distress, 1015–1019
 biophysical profile, 1015–1017
 fetal heart rate
 three-tier interpretation of, 1020t
 variability of, 1017
 nonstress test, 1015–1017
 therapy for, 1027t
 Fetal echocardiography, 2757, 2757f, 2771–2772
 Fetal erythroblastosis, 1028
 Fetal erythropoiesis, 2924–2925
 Fetal growth and development, 175
 assessment of, 146–148
 behavioral, 146
 neurologic, 146, 148f
 psychologic changes in parents, 146–147
 somatic, 146
 threats to, 147–148
 Fetal growth restriction (FGR), 1013, 1015
 Fetal heart rate (FHR), reactive, 1018t
 Fetal hemoglobin, syndromes of hereditary persistence of, 2981–2987
 Fetal hepatic blood flow, 2434–2435
 Fetal lung fluid, clearance of, 1074
 Fetal maturity and dating, 1015
 Fetal programming, in T2DM, 3539
 Fetal surveillance, antepartum, 1015
 Fetal therapy ethics, 1028
 Fetal to neonatal circulatory transition, 2735–2736
 fetal circulation, 2735, 2736f
 neonatal circulation, 2735–2736
 persistent pulmonary hypertension, 2736
 transitional circulation, 2735
 Fetal tone, 1018t
 Fetal transfusion syndrome, 1042
 Fetal vesicostomy, 1030, 1031f
 FETO. *See* *Fetoscopic endoluminal tracheal occlusion*
 Fetomaternal hemorrhage (FMH), 1122
 Fetoplacental unit, 3446
 Fetoscopic endoluminal tracheal occlusion (FETO), for congenital diaphragmatic hernia, 1095
 Fetus, 1015–1028
 congenital diaphragmatic hernia, 1031
 congenital pulmonary airway malformation, 1031–1033
 ethics, 1028
 fetal centers, 1035–1037
 fetal period, 146
 growth and maturity, 1015, 1015f
 heart failure in, 2896t
 hemoglobin in, 2924
 intervention and surgery, 1028–1037, 1029t
 maternal conditions affecting, 1011t–1012t
 maternal disease, 1019–1021
 maternal infections, 1013t
 measurements, 1016f
 medication and teratogenic exposure and, 1021–1023
 mortality and morbidity, 992–999
 myelomeningocele, 1034–1035, 1035f
 nonobstructive renal disease, 1030–1031
 obstructive uropathy, 1028–1030
 overgrowth in, 3382–3383

Fetus (Continued)
 parvovirus B19 infection, 1989
 radiation effects, 1024
 repair, patient selection, 1037t
 teratogen effects, 1021–1022
 thyroid, 3401
 development, 3400
Fetus papyraceus, in aplasia cutis congenita, 4044–4045
 Fever, 548, 1638, 1640–1642
 associated with bacterial meningitis, 3771
 clinical features of, 1641
 in common cold, 2553
 Dengue, 2067–2071
 etiology of, 1640–1641, 1640t
 evaluation of, 1641, 1641t
 in exclusion or inclusion in daycare, 187t–192t
 high-spiking intermittent, in systemic JIA, 1477f
 in Kawasaki disease, 1541
 in malaria, 2170
 management of, 1641–1642
 maternal, classification of, 1156t
 in newborn, 1147–1148
 in older child, 1647–1651
 diagnosis of, 1647, 1648t
 evaluation of, 1649–1650
 general approach, 1647–1649
 management of, 1650–1651, 1650f
 pathogenesis of, 1640
 periodic
 with hyperimmunoglobulinemia D, 1521, 1525f, 1525t
 in PFAPA, 1529
 Pontiac, 1810–1811
 Q, 1914–1916
 clinical manifestations and complications of, 1915
 diagnosis and differential diagnosis of, 1915–1916
 epidemiology of, 1914
 etiology of, 1914
 laboratory findings of, 1915
 pathology and pathogenesis of, 1914–1915
 persistent localized infection, 1915
 prevention of, 1916
 primary (acute), 1915
 transmission of, 1914
 treatment of, 1916
 recommendations for management of, 1362t–1363t
 respiratory syncytial virus (RSV) and, 2030
 rheumatic, 1711–1715
 scarlet, 1707, 1707f
 in sickle cell anemia, 2968, 2968t
 in SLE, 1497t
 spotted fever group rickettsioses, 1899–1907, 1900t–1902t
 flea-borne spotted fever, 1900t–1902t, 1907
 Mediterranean spotted fever or boutonneuse fever, 1900t–1902t, 1906–1907, 1907f
 rickettsialpox (*Rickettsia akari*), 1900t–1902t, 1907
 Rocky Mountain spotted fever, 1899–1906, 1900t–1902t
 clinical manifestations of, 1904–1905, 1904f
 complications of, 1906
 diagnosis of, 1905
 differential diagnosis of, 1905
 epidemiology of, 1899, 1903f
 etiology of, 1899
 laboratory findings of, 1905
 pathology and pathogenesis of, 1903–1904, 1903f
 prevention of, 1906
 prognosis for, 1906
 supportive care for, 1905–1906
 transmission of, 1899–1903, 1903f
 treatment of, 1905
 suggestive of rheumatic disease, 1461t
 trench (*Bartonella quintana*), 1815–1816
 viral hemorrhagic, 2073–2077, 4452t
 Fever blisters, herpetic, 1993
 Fever of unknown origin (FUO), 1651–1658, 1652t
 diagnosis of, 1651–1657, 1654f
 history, 1651–1652
 laboratory evaluation, 1657, 1658f
 physical examination, 1654–1657, 1654t–1656t
 etiology of, 1651, 1653t

Fever of unknown origin (FUO) (*Continued*)
 in hypohidrotic ectodermal dysplasia, 4048
 management of, 1657–1658
 prognosis of, 1658
 Fever without a focus, in neonate and young infant, 1642–1646
 clinical manifestations of, 1642–1643
 diagnosis of, 1643–1644, 1643t
 urinary tract infection and bacterial meningitis, 1644
 viral respiratory illness, 1644
 etiology and epidemiology of, 1642, 1642t
 laboratory diagnosis of, 1644–1646
 blood culture, 1644
 cerebrospinal fluid, 1644–1645, 1645t
 complete blood count, 1644
 enterovirus testing, 1646
 herpes simplex virus testing, 1645–1646
 other diagnostic studies, 1646
 urinalysis, 1644
 prognosis of, 1646
 treatment of, 1646
 antimicrobials, 1646
 discharge from hospital, 1646
 Fexinidazole, for human African trypanosomiasis, 2163
 Fexofenadine HCl, for allergic rhinitis, 1383t
 FFP. *See* Fresh-frozen plasma
 FGID. *See* Functional gastrointestinal disorder
 FGS. *See* Female genital schistosomiasis
 FHA. *See* Federal Housing Authority
 FHLH. *See* Familial hemophagocytic lymphohistiocytosis
 FHM. *See* Familial hemiplegic migraine
 Fiber, 389t–390t, 394–395
 Fiberoptic endoscopic evaluation, of swallowing, 2257
 Fibrillation, atrial, 2862f
 Fibrinogen, 3034
 in disseminated intravascular coagulation, 3048
 Fibrinolysis, 3023
 Fibrinolytic system, tests of, 3028
 Fibroadenoma, 3332
 Fibroblast growth factor receptor 3 (FGFR3) chondro-dysplasia group, 4345–4347, 4345t
 Fibroblast growth factor-23 (FGF-23), 477
 Fibrocystin, in autosomal recessive polycystic kidney disease, 3213
 Fibrodysplasia ossificans progressiva, 4358
 Fibrofolliculomas, 4185, 4186f
 Fibromas, 2892, 3146, 3343
 periungual, 3659f
 Fibromyalgia, 698–699
 CFS and, 1579
 diagnostic criteria for, 1572t, 1573f
 Fibrosarcoma, 3139t–3140t
 Fibrosing colonopathy, in pancreatic insufficiency, 2425
 Fibrosis, congenital hepatic, 2500t, 2501
 Fibrotic lung disease, 2639–2641, 2639t–2641t, 2641f
 Fibrotic papules, atopic dermatitis and, 1411
 Fibrous dysplasia, 3147
 polyostotic, precocious puberty with, 3392
 Fibrous thyroiditis, 3412
 Fibula shaft fractures, 4282
 Fibular hemimelia, 4217
 Ficolin-3 deficiency, 1320
 Ficolins, 1316
 Fidaxomicin, 1690
 for *Clostridium difficile* infection, 1826
 Field hockey injuries associated with, 4330
 Fifth disease (erythema infectiosum), 1988–1989, 1988f–1989f
 Filaggrin, 1372, 1410–1411
 Filamin A syndrome, 2634t
 Filamins, disorders involving, 4357
 Filariasis
 drugs for, 2126t–2144t
 lymphatic, 2206–2207, 2207f
 in lymphedema, 3066–3068
 Filariform larvae, 2204
 Filtration, glomerular, 3181–3182, 3181f
 Fine motor, 179
 function, 301
 Fingers
 desquamation, in Kawasaki disease, 1543f
 trigger, 4269–4270, 4270f

- Fingerspelling, 341t
- Fire- and burn-related deaths, 91
- Fire and Street Safety, for FASD, 1138
- Firearm injuries, 98
- death rate, 92t
 - homicides, 1189f
 - unintentional, 98
- Firearms, 263
- FIRES. *See* Febrile infection-related epilepsy syndrome
- Fireworks, eye injuries related to, 3979
- First Optional Protocol (2000), 108–109
- First year of life, 151–157
- age
 - 0–2 months, 151–156
 - 2–6 months, 153–156
 - 6–12 months, 156
 - brain growth in, 152f
 - centers of ossification, radiographic appearance of, 155t
 - developmental milestones in, 153t
 - developmental trajectories, 151
 - emerging patterns of behavior during, 154t
 - sleep requirements in, 155f
- First-degree burns, 648
- First-degree frostbite, 660t, 662
- First-generation antipsychotic, 226–227
- First-line therapy, for labial agglutination, 3323
- Fish oil, for IgA nephropathy, 3188
- Fissured tongue, 2253, 4148
- Fissures, 4027
- FISTS mnemonic, 1190t
- Fistula
- arteriovenous, 2698f, 2906–2907
 - perianal, 2408–2409, 2409f
 - tracheoesophageal, 1053t, 2258–2259, 2258f–2259f, 2259t
 - urethral, 3301
- Fistulectomy, of fistula abscess, 2409
- Fistulotomy, of fistula abscess, 2409
- Fitz-Hugh-Curtis syndrome, 1752
- 504 plan, 323
- Fixed proteinuria, 3220–3222
- Fixed-drug eruption (FDE), 4037f, 4038
- FLACC pain scale, 680t
- Flaccid paralysis, acute, differential diagnosis of, 1975t–1976
- Flame burns, 646
- Flat warts, 4166–4167, 4167f
- Flatfoot, 164, 4205
- Flea bites, 4170t, 4171
- Flea control, 2218
- Flea-borne diseases, murine typhus, 1909–1910
- Flea-borne spotted fever, 1900t–1902t, 1907
- Flecainide, 2845t–2846t
- Fleischer ring, in keratoconus, 3943
- Flexible flatfeet, 4205–4206
- Flexible kyphosis, 4250
- Flexner-Wintersteiner rosettes, 3149
- FLIP. *See* Functional luminal imaging probe
- Flonase, for allergic rhinitis, 1384t–1385f
- Floor of mouth, 2248f
- Flourishing, disparities in, 15
- Flovent. *See* Fluticasone propionate
- Flow volume relationship, 2519–2520
- Fluconazole, 1917–1919, 1917t
- for paracoccidioidomycosis, 1941
- Fludrocortisone
- for POTS, 599t
 - for vasovagal syncope, 596t
- Fluency
- disorders of, 332
 - dyslexia and, 317
- Fluid and electrolyte treatment, 533
- in CKD, 3250
 - of *E. coli* infection, 1784
- Fluid collections, pancreatic, 2432–2433, 2432f
- Fluid compartments, 485–486, 485f
- Fluid deficit, calculation of, 530
- Fluid management, in renal transplantation, 3257
- Fluid replacement, for yellow fever, 2072
- Fluid restriction, for BPD, 1086
- Fluid resuscitation, for burn injuries, 650–651
- Fluid therapy, in diabetes insipidus, 3374
- Fluid-refractory and catecholamine-resistant shock, 611
- Fluids
- for bronchiolitis, 2030
 - in infants, 413
 - in toddler, 413
- Flukes, 2214–2215, 2214f
- infection, drugs for, 2126t–2144t
- Flumazenil, 707t–708t
- Flunarizine, for migraine, 3646t–3647t, 3649
- Flunisolide
- for allergic rhinitis, 1384t–1385t
 - for asthma, 1402t
- Fluorescence in situ hybridization (FISH), 762, 764f
- Fluoride, 483t
- for dental carries, 2248–2249, 2249t
- Fluorinated corticosteroids, for SLE, 1498
- 5-Fluorocytosine (5-FC), 1917
- Fluoroquinolones, against *M. tuberculosis*, 1832–1833
- Fluoroscopy, 2761
- diagnostic approach to respiratory disease, 2518
- Fluorosis, 2241
- Fluoxetine (Prozac), for depression and anxiety, 227t
- Flushing, 4127–4128, 4127t
- Fluticasone furoate
- for allergic rhinitis, 1384t–1385t
 - for asthma, 1402t
- Fluticasone propionate
- for allergic rhinitis, 1384t–1385t
 - for asthma, 1402t
- Fluticasone/salmeterol (Advair), for asthma, 1401t
- Flutter-like oscillations, 3933, 3933t
- Flying squirrel typhus, 1900t–1902t
- Fly-through imaging, 2760f
- FMEA. *See* Failure mode and effects analysis
- FMF. *See* Familial Mediterranean fever
- FMR1CGG repeat testing, for neurodevelopmental disorders, 348t
- Focal atrial tachycardia, 2851f
- Focal aware seizures, 3599
- Focal biliary fibrosis, 2478
- Focal cortical dysplasias, 3568
- Focal dermal hypoplasia, 4046
- Focal extraintestinal infections, *Campylobacter* in, 1790
- Focal facial dermal dysplasias, 4045–4046
- Focal necrotizing retinitis, in congenital toxoplasmosis, 2192–2193
- Focal segmental glomerulosclerosis (FSGS), 3228
- in ESRD, 3254–3255
 - primary, 3254–3255
 - recurrent, 3255
- Focal seizures, 3599–3600
- benign epilepsy syndromes with, 3590t–3591t, 3600
 - to bilateral tonic-clonic seizures, 3599–3600, 3599f–3600f
 - with impaired awareness, 3599
 - with preserved awareness, 3599
 - severe epilepsy syndromes with, 3600
- Focal therapy, in retinoblastoma, 3150
- Focalin. *See* Dexmethylphenidate
- Focused assessment with sonography in trauma (FAST), for multiple trauma, 575
- Focused surveillance and screening, 305
- Folate, 56, 464–465
- deficiency, 464–465
 - clinical manifestations of, 464
 - diagnosis of, 464–465
 - prevention of, 456t–457t, 465
 - treatment of, 465
- malabsorption, 2350
- metabolism of, 465f
- toxicity, 465
- Folic acid (folate)
- dietary reference intake, 397t–403t
 - inadequate intake, 2940–2941
 - malabsorption, 2941
 - metabolism
 - congenital abnormalities in transport and, 2941
 - drug-induced abnormalities in, 2942
 - for myelomeningocele, 3561
 - reference intervals, 4472.e9t
 - supplementation, 1028
- Folic acid (vitamin B₉), 456t–457t, 464
- deficiency, 779, 2940–2942
 - causes of, 2941t
- Folic acid (vitamin B₉) (*Continued*)
- clinical manifestations of, 2942
 - etiology of, 2940–2942
 - laboratory findings of, 2942
 - treatment of, 2942
- fortification, 1022
- for hereditary spherocytosis, 2957
- Folinic acid, 708t
- Folinic acid-responsive seizures, 3603
- Follicle-stimulating hormone (FSH), 3361
- Follicular bronchitis, 2595–2596, 2597t, 2597t
- Follicular carcinoma, 3422
- Follicular cyst, of ovary, 3502–3503
- Folliculitis, 4156, 4156f
- Folliculitis barbae, 4156
- Follistatin, 3487
- Fomepizole, 707t–708t
- Fomivirsen, 1955
- Fontan operation, modified, 2807–2808
- Fontan-associated liver disease (FALD), 2477
- Fontanel, 3551
- large anterior, 1001t
- Food
- adverse reactions to, 1442–1451
 - differential diagnosis of, 1443t
 - genetic and environmental risk factors of, 1442–1447
 - chemical pollutants in, 4427
 - environment of, obesity and, 438
 - as goitrogen, 3415t
 - triggering atopic dermatitis, 1418
- Food allergy, 1374, 1434–1435, 1434t, 1442–1451, 1442t–1443t
- anaphylaxis for, 1445
 - chronic diarrhea and, 2377
 - clinical manifestations, 1444–1445, 1444t
 - diagnosis, 1445–1447, 1446f, 1446t
 - genetics, 1442–1447
 - pathogenesis, 1443–1444
 - prevention, 1447, 1447t
 - treatment, 1447
- Food and Agriculture Organization (FAO), 421
- Food-borne illnesses, 4411t–4413t
- botulism, 1817, 1820t
 - listeriosis, 1732t
- Food-borne infection, *Campylobacter*, 1789
- Food-borne pathogens, acute gastroenteritis and, 2355–2356, 2360t, 2362t–2364t
- Food-borne trematodes, 2214
- Food environment, 417
- Food Insecurity Experience Scale, 421
- Food parenting, 416
- Food poisoning, 420
- C. perfringens* type A enterotoxin, 1829
 - nonbacterial, 4441–4446
 - Staphylococcus aureus*, 1696
- Food protein-induced allergic proctocolitis (FPIAP), in food allergy, 1448
- Food protein-induced enterocolitis syndrome (FPIES), in food allergy, 1448, 1449t–1450t
- Food protein-induced enteropathy, in food allergy, 1451
- Food protein-induced gastrointestinal syndromes, 1449t–1450t
- Food safety, 420
- Food Safety Modernization Act, 420
- Food security, 421–423
- future, 422–423
 - measurement of, 421–422
 - nutrition targets and, 422, 422t
 - poverty and, 422
- Foot
- abnormalities, meningomyelocele and, 4401
 - edema, in erythromelalgia, 1573f
 - minor malformations, 785t
 - musculoskeletal pain syndrome, 1568t
 - progression angle, 4212, 4214f
 - shape and position, 4212, 4215f
 - sports-related injuries, 4313
- Foot disorders, 4201–4211
- calcaneovalgus feet, 4202, 4202f
 - cavus feet, 4207–4208, 4208f
 - congenital vertical talus, 4203–4205, 4205f

- Foot disorders (*Continued*)
 hypermobile pes planus, 4205–4206, 4206f
 metatarsus adductus, 4201–4202, 4201f
 osteochondroses/apophysitis, 4208, 4208f
 painful foot, 4211, 4211t
 puncture wounds of foot, 4208
 shoes, 4211
 talipes equinovarus, 4202–4203, 4203f–4204f
 tarsal coalition, 4206–4207, 4206t, 4207f
 Football, injuries associated with, 4327
FOP. See Fibrodysplasia ossificans progressiva
 Foramen of Morgagni hernia, 1096
 Foramen ovale, 2733, 2735
 Forbes disease, 900t–901t, 903–904
 Forced expiratory airflow, in asthma, 1391
 Forced expiratory volume 1 (FEV₁), in respiratory disease, 2519–2520, 2519f
 Forced vital capacity (FVC), 2519–2520
Fordyce granules, 2254
Fordyce spots, 4148
 Forearm fractures, 4279–4280, 4280f
 Forefoot, 4201
 Foregut, 2276
 Foregut cysts, 2577
 Foreign bodies, 2552t, 4021
 in airway, 2578–2580, 2578f
 aspiration of, 1089–1091, 1375
 in acutely ill child, 549
 in esophagus, 2273, 2274f
 of nose, 2548
 red eye caused by, 3940t
 in stomach and intestine, 2302–2304
 blunt objects, 2303
 button batteries, 2302–2303
 coins, 2303
 magnets, 2303, 2303f
 sharp objects, 2304
 vaginal, 3326–3327, 3326f
 Foreign-born child, medical evaluation of, 78–81
 Forensic evidence collection, 1236
 Foreskin, hooded, 3297f
 Formicids, 1419
 Formula feeding, 412
 Foscarnet, 1955
Fosphénytoïn, for neonatal seizures, 3623
Fostemsavir, for HIV, 2098t–2107t
 Foster care, 75–78
 children and adolescents in, healthcare for, 76–78, 77t–78t
 epidemiology of, 75
 health issues in, 76, 77t
 language disorders and, 331
 legislation for, in United States, 75
Fostering Connections and Promoting Adoptions Act, 75
 Foster/kinship caregivers, 76–78, 78t
 Founder effect, 727
FOUR. See Full outline of unresponsiveness score
 Fourth Geneva Convention (1949), 108–109
 Fourth nerve palsy, 3928
 Fourth-degree frostbite, 660t, 662
 Fox-Fordyce disease, 4136
FPLD. See Familial partial lipodystrophy
 Fracking, 4424–4427
 Fraction of inspired oxygen, 627
 Fractional excretion of magnesium, 504
 Fractional exhaled nitric oxide (FeNO), 2522
 in asthma, 1391t–1392t, 1392
 Fractures, 4276–4284
 characteristics of, 4276–4277
 child abuse, 116, 118f–119f, 119t
 complications of, 4284
 in delivery room, 1073
 enamel, 2251t
 of lower extremity, 4281–4283
 femoral shaft fractures, 4282, 4282t
 hip fractures, 4281–4282
 metatarsal fractures, 4283
 proximal tibia fractures, 4282
 tibia and fibula shaft fractures, 4282
 toddler fractures, 4282–4283, 4282f
 toe phalangeal fractures, 4283
 triplane and Tillaux fractures, 4283, 4283f
 operative treatment of, 4283–4284
 Fractures (*Continued*)
 overgrowth, 4276
 patterns, 4276f, 4277–4279
 buckle or torus, 4277, 4278f
 child abuse, 4278–4279, 4279t
 complete fractures, 4277–4278
 epiphyseal fractures, 4278
 greenstick fracture, 4277, 4278f
 plastic deformation, 4277, 4277f–4278f
 remodeling, 4276, 4277f
 rib, hemithorax and, 2709f
 skull, in newborn, 1057
 specificity of radiologic findings for, 118t
 timetable of radiologic changes in, 119t
 of upper extremity, 4279–4281
 clavicular fractures, 4281
 distal humeral fractures, 4280, 4281f
 forearm fractures, 4279–4280, 4280f
 hand fractures, 4279
 phalangeal fractures, 4279
 proximal humerus fractures, 4280–4281
Fragile X syndrome, 383–387, 384t–385t, 742, 745t–746t, 2764t–2766t, 3494
 diagnostic testing for, 384
 evaluation and diagnosis of, 383–384, 385t, 386f
 family history and premutation carriers of, 384
 genetic testing for, 352
 management of, 385–387
 behavioral, 385–386
 educational, 385
 medical, 386–387
 math disabilities and, 319
 phenotypic and genetic effect of, 384t
Fragile X-associated tremor/ataxia syndrome (FXTAS), 384
Fragile XE syndrome (FRAXE), 383
 Fragmentation hemolysis, 2996, 2996t
 Framing effect, 48t
Franceschetti syndrome. See Mandibulofacial dysostosis
Francisella tularensis, 1803–1807
 clinical manifestations of, 1804–1805, 1805t
 diagnosis of, 1805–1806
 differential diagnosis of, 1806
 epidemiology of, 1803, 1804f
 etiology of, 1803
 pathogenesis of, 1803–1804
 prevention of, 1806–1807
 prognosis for, 1806
 treatment of, 1806, 1806t
 Frank R. Lautenberg Chemical Safety for the 21st Century Act, 4423
 Frankfurt plane, 172
 Frank-Starling relationship, 2893f
Fraser syndrome, 3481
Frasier syndrome, 3131t–3132t, 3509
FRC. See Functional residual capacity
FRDA. See Friedreich ataxia
Freckles. See Ephelides
Free recall, 302
 Free water clearance, decreased, 3376
Freeman-Sheldon syndrome, 4043
 Freeze-thaw phase, in frostbite, 661–662
Freiberg disease, 4313
Frenotomy, 410–411
Freon, inhaled, 1203t
 Frequency bias, 48t
Fresh-frozen plasma (FFP), 3019, 3033
 for bleeding, 3046
 for burns, 651
 Freud's psychosexual theory, 140t
 Friction burns, 646
Friedreich ataxia, 481, 745t–746t, 3673
 T1DM and, 3548
 Frontal lobe functioning
 attention, 300
 executive functioning, 302–303, 302t, 306f
 Frontal lobe maturation, and adolescent risk taking, 1186f
 Frontal plagiocephaly, in craniosynostosis, 3583
Frostbite, 659–662, 661f
 of auricle, 4021
 clinical presentation of, 662
 degrees of, 660t
 pathophysiology of, 661–662
 treatment for, 661f, 662
Frostnip, 662
Frovatriptan, for migraine, 3646t–3647t
Fructokinase, deficiency of, 900t–901t, 912
Fructose, disorders of
 hepatic dysfunction and, 808t
 neonatal hypoglycemia and, 806t
Fructose malabsorption, 2347
 chronic diarrhea and, 2378
Fructose metabolism, defects in, 900t–901t, 912–913
Fructose-1,6-bisphosphatase deficiency, 900t–901t, 913–915
Fructose-1,6-diphosphatase deficiency, 991
Fructose-1-phosphate aldolase, deficiency of, 912–913
Fructosuria, 900t–901t, 912
FSHD. See Facioscapulohumeral muscular dystrophies
Fucosidosis, 887t, 895
 Fuel combustion, 4424
Fukuda stepping test, 3554
Fukuyama type, of congenital muscular dystrophy, 3844
Full Outline of Unresponsiveness (FOUR) Score, 556, 582, 583t
Fulminant colitis, 2312
Fumarylacetoacetate hydrolase deficiency, 816
Fumonisins, 4413
Functional abdominal pain, 2234
 not otherwise specified, 2391
Functional constipation, 2292–2294, 2386, 2391, 2391t
Functional cysts, ovarian, 3340
Functional diarrhea, 2385, 2388t
Functional dyspepsia, 2389–2391, 2389t
Functional fiber, 394
Functional gastrointestinal disorder (FGID), 1574
Functional hypoplasmenin, 3063
Functional luminal imaging probe, 2257
Functional MRI, in neuroradiologic procedures, 3559
Functional neurologic symptom disorder, 2361
Functional residual capacity (FRC), 621–622, 1077, 2513
 pathophysiologic implications of, 2520
Functional (psychogenic) tremor, 3678
Functioning systems, in progeria, 959
Fundoplication, for GERD, 2267–2268
Fundus, 3909
Fundus eye examination, 3912
Fundus flavimaculatus. See Stargardt disease
Fungal endocarditis, 2869
Fungal infections
 associated with hemophagocytic syndrome, 3173t
 causing infectious pneumonia, 2643t
 cutaneous, 4159–4166
 candidal, 4164–4166, 4160f
 dermatophytes, 4160–4164, 4160f
 tinea versicolor, 4159–4160, 4160f
HIV and, 2093
 predisposition to, 1335, 1336t
 CARD9 deficiency, 1335
 IL-17F deficiency, 1337
 IL-17RA deficiency, 1337
 STAT1 gain-of-function, 1336–1337
Fungal meningitis, CSF findings in, 3759t–3760t
Fungemia, catheter-associated, 1928
Funnel chest, 2713
Furosemide
 adverse reactions in premature infant, 1045t
 for heart failure, 2897, 2898t
Furuncles, 4156, 4157f
Furunculosis, external ear, 4000t, 4002
Fusarium spp., 1948–1949
Fusion, in teeth, 2240
Fusion genes, 3077
Fusobacterium, 1828
Fussiness, 632
Futility, 51
Future food security, 422–423

G

- Gabapentin*
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 for migraine, 3646t–3647t
 in pain management, 689t–690t, 690–691

- Gag reflex, 591t, 3554
 Gain-of-function variants, 732–733
 Gait
 asymmetry, 4219
 cycle, 4198
 maturation, 4194, 4195t
 in neurologic evaluation, 3557
 trainers, 4403, 4404f
 Galactokinase deficiency, 900t–901t, 911, 3949
 Galactorrhea, 3331
 Galactose, 898
 metabolism, disorders of, 900t–901t, 910–912
 hepatic dysfunction and, 808t
 neonatal hypoglycemia and, 806t
 Galactose mutarotase deficiency, 900t–901t
 Galactose-1-phosphate uridyl transferase deficiency
 galactosemia, 910–911
 Galactosemia, 910, 2451, 3501, 3949
 with transferase deficiency, 900t–901t
 Galactosialidosis, 887t–888t, 920–921
 Galeazzi sign, 4219
 in DDH, 4233, 4233f
 Galen malformation, 3751f
 Gallbladder, 2276
 diseases of, 2502–2504, 2502t
 acute hydrops, 2502
 anomalies of, 2502
 biliary dyskinesia, 2504
 cholecystitis and cholelithiasis, 2502–2504
 Galloway-Mowat syndrome, 3232
 Gallstones, pigment, 2502–2503
 Gambian trypanosomiasis, 2161
Gambierdiscus toxicus, 4444
 GAN. *See* Giant axonal neuropathy
 Ganciclovir, 1954–1955
 for cytomegalovirus (CMV), 2015
 Gang warfare, 108
 Ganglion, 4267
 Gangliosidoses, 3711–3714, 3713f–3714f
 Gangrene, gas, 1829
 Gardner syndrome, 2413
 Garlic, 57t
 Gas gangrene, 1829
 Gastric contents, aspiration of, 2606
 Gastric disease, anesthetic implications in, 666t
 Gastric duplication, 2280–2281, 2280t
 Gastric fluid, loss of, 519, 527
 Gastric lavage, 708
 Gastric ulcer, 2257
 Gastric volvulus, 2281
 Gastrinoma, of digestive tract, 2414
 Gastroenteric neuroendocrine tumor, of digestive tract, 2414
 Gastroenteritis
 acute
 bacterial, etiologies of, 2357t–2358t
 Campylobacter in, 1790
 Salmonella, 1767
 Gastroenterologic system, manifestations of SLE, 1492t
 Gastroesophageal junction, 2255–2256
 Gastroesophageal reflux (GER), 2223, 4048
 asthma with, 1398
 treatment of, 1076
 Gastroesophageal reflux disease (GERD), 2257, 2262, 2264–2268
 chronic recurrent aspiration and, 2609
 clinical manifestations of, 2264, 2266t
 complications of, 2268
 congenital diaphragmatic hernia and, 1096
 diagnosis of, 2264–2266, 2266f–2267f
 epidemiology and natural history of, 2264, 2265t
 management of, 2266–2268
 pathophysiology of, 2264–2268
 Gastrointestinal bleeding
 in acute kidney injury, 3246
 liver diseases and, 2440
 Gastrointestinal decontamination, 706
 Gastrointestinal (GI) disease, 4033
 anesthetic implications in, 666t
 DIC caused by, 3048t
 eosinophilia caused by, 1295t
 hypomagnesemia and, 503t
 hyposplenism and, 3063t
 Gastrointestinal (GI) disease (*Continued*)
 medical child abuse and, 128
 medications for, 230
 obesity-associated comorbidities, 444t
 premature infants and, 1046t
 risk for osteoporosis, 4384t
 in tuberculosis, 1845
 Gastrointestinal hemorrhage, 2234–2237, 2237f, 2237t
 Gastrointestinal (GI) infections, *Aeromonas* in, 1797
 Gastrointestinal involvement, in Langerhans cell histiocytosis, 3169
 Gastrointestinal manifestations
 of Behget disease, 1515
 of enterovirus infections, 1982
 of food allergy, 1444–1445
 of Henoch-Schönlein purpura, 1554
 treatment of, 1514t
 Gastrointestinal microbiome, 2277
 in T1DM, 3519
 Gastrointestinal mucormycosis, 1943–1944
 Gastrointestinal stromal cell tumor (GIST)
 of digestive tract, 2414–2415
 pheochromocytomas and, 3479
 Gastrointestinal symptoms
 BRUE and, 2543t
 of migraine, 3644
 in SARS-CoV, 2038
 Gastrointestinal (GI) syndrome, 4419
 Gastrointestinal system
 arsenic effects in, 4432t
 autonomic dysreflexia in, 4391t
 complications of cystic fibrosis and, 2662t
 morbidities, of perinatal and neonatal illness, 998t
 Gastrointestinal tract disease, 1509
 Gastroschisis, 1053t, 1101–1102, 1102f
 Gastrotomy, for chronic recurrent aspiration, 2611
 GATA2 deficiency, 1288, 1343
 GATA2 haploinsufficiency, 1309t
 GATA2-related disorders, 3008–3009, 3009f
 Gatekeeper training, 268
 Gaucher disease, 890–891, 893f
 type I, 887t
 type II, 887t–888t
 type III, 887t
 Gay, lesbian, and bisexual (GLB) adolescents, 1182–1185
 Gaze-evoked nystagmus, 3931t
 Gaze-paretic nystagmus, 3931t
 GBM. *See* Glomerular basement membrane
 GBS. *See* Group B streptococcus
 GCS. *See* Glasgow Coma Scale
 GDD. *See* Global developmental delay
 Gefitinib, 3088t
 GEJ. *See* Gastroesophageal junction
 Gemination, in teeth, 2240
 Gender
 childhood cancer and, 3073
 childhood injuries and, 94
 Gender-affirmative care, 1173–1174
 Gender-affirming sex hormone therapy, 1178–1181
 criteria for, 1173t
 effects from, 1179t
 goals of, 1178
 monitoring protocol in, 1180
 options for, 1178, 1178t
 potential adverse effects of, 1179
 screening recommendations for, 1180t, 1181
 surgical therapy in, 1180
 treatment criteria and timing of, 1178
 Gender dimorphism, 269
 Gender expression, definition of, 1171
 Gender identification, in preschoolers, 165
 Gender identity, 1171–1181
 clinical presentation of, 1172
 definition of, 1171
 diagnostic evaluation of, 1172
 epidemiology of, 1172–1174
 mental health considerations for, 1174–1175
 puberty blockers for, 1175–1178
 alternative therapy side effects of, 1177
 bone health in, 1176, 1176t–1177t
 Gender identity (*Continued*)
 brain development in, 1176–1177
 fertility in, 1176, 1177t
 goals of, 1175
 metabolism in, 1177
 monitoring protocol in, 1177–1178, 1178t
 potential adverse effects of, 1175–1176
 treatment criteria and timing of, 1175
 treatment options of, 1175, 1176t
 Gender incongruence, definition of, 1172
 Gender nonbinary, definition of, 1172
 Gender role, definition of, 1171
 Genderfluid, definition of, 1172
 Genderqueer, definition of, 1172
 Gene amplification, 3078t
 Gene editing, 757–758
 Gene variants
 associated with hypoaldosteronism/pseudohypoaldosteronism, 3377t
 in hereditary spherocytosis, 2956t
 LMNA, in progeria, 959–960
 NLRP3, 1522
 TNFRSF1A, in TRAPS, 1522
 Gene replacement therapy, 728, 3873–3874, 3959
 Gene therapy, 757–758, 758f
 Gene-environment interaction, on genetic susceptibility to common diseases, 800f
 General anesthesia, 664, 667–671
 akinesia, 667, 669t
 amnesia, 667
 analgesia, 667, 668t
 complications during, 672
 definition of, 668t
 hypnosis, 667
 induction of, 671–672
 intravenous anesthetic agents, 670–671
 monitoring, 667
 General behavioral screening, tools for, 181t
 General developmental screening, tools for, 180t
 General examination, in neurologic evaluation, 3557
 General intellectual function, significant impairment in, 346
 General (broad-band) psychosocial screening instrument, 217
 General supportive care, for hereditary spherocytosis, 2957
 Generalized adenopathy, 3069, 3069t
 Generalized aggressive periodontitis, 2249
 Generalized albinism, 818–819
 syndromic forms
 Chédiak-Higashi syndrome, 819
 Hermansky-Pudlak syndrome, 819
 Generalized amyoplasia, 3819
 Generalized anxiety, 246
 core diagnostic features and characteristics of, 252t
 diagnostic criteria for, 249t
 Generalized Anxiety Disorder-7 (GAD-7), 218t
 Generalized arterial calcification of infancy, 2908
 Generalized epilepsy with febrile seizures plus (GEFS+), 3596
 Generalized glucocorticoid resistance, 3460
 Generalized hypotonia, 3792–3793, 3793t, 3794f, 3796t–3797t
 Generalized lipodystrophy, 4132–4133
 Generalized lymphadenopathy, monkeypox and, 4461–4463
 Generalized lymphatic anomaly, 3065, 3156, 3160f
 Generalized morphae, 1508t, 1509f
 Generalized motor seizures, 3601
 Generalized obstructive overinflation, 2592–2593
 Generalized seizure
 absence seizures in, 3600–3601
 benign generalized epilepsies in, 3601
 comparison of, in disorders that can mimic them, 3634t
 generalized motor seizures in, 3601
 related epilepsy syndromes and, 3600–3603
 severe generalized epilepsies in, 3593t, 3599f, 3601–3603, 3602t
 Generalized tetanus, 1822
 Genes
 in intrinsic disorders of myeloid precursor cells, 1309t
 thyroid development and, 3405t

- Genetic association studies, 800
 Genetic counseling, 753–756, 2771–2772
 in arthrogryposis, 3826–3828, 3827f
 diagnostic process, 754–755
 elements of, 753–756
 follow-up, 756
 genetic aspects of condition, 755
 indications for, 756t
 natural history of condition, 755
 for neurofibromatosis, 3655–3657, 3656f, 3657t
 nondirective counseling, 756
 prenatal diagnosis and prevention, 755
 recurrence risk, 755
 for spinal muscular atrophies, 3874
 support groups, 756
 therapies and referral, 756
 in transmissible spongiform encephalopathies, 2123–2124
- Genetic defects, of GH-IGF axis, 3367t
 Genetic disorders
 associated with rhabdomyosarcoma, 3136t
 burden of, 726–728
 complex, caring for children with, 362–364, 362t–363t, 363f–364f
 correction of, in human germline, 760
 genotype-phenotype correlations in, 733–734
 with increased pain threshold, 3889–3890, 3889f
 with painful peripheral neuropathies, 3888t, 3890–3892
 physiologic therapies, 756–757
 proteinuria or nephrotic syndrome and, 3224t
 renal cell carcinoma and, 3135
 replacement therapies, 757–760
 Genetic epilepsy, 3589
 Genetic factors, in anti-glomerular basement membrane disease, 2637
 Genetic forms
 of GH deficiency, 3366
 GH1, 3366
 GH-releasing hormone receptor, 3365–3366
 X-linked isolated, 3366
 of multiple pituitary hormone deficiency, 3364, 3365t
 HESX1, 3364
 LHX3 and *LHX4*, 3364
 POU1F1, 3364
 PROPI, 3364
 of nephrogenic diabetes insipidus, 3374
 Genetic imprinting, 742–743
 Genetic Information Nondiscrimination Act (GINA), 751
 Genetic load, 748f
 Genetic overgrowth syndromes, 4219
 Genetic risk factors, for schizophrenia, 289
 Genetic syndromes
 associated with diabetes mellitus, 3547t, 3548
 intellectual disability caused by, 349t
 Genetic target height range, 175
 Genetic testing, 749–760
 approaches for, 749t
 for breast cancer susceptibility genes, 3333
 for congenital heart disease, 2770t
 diagnostic, 749–751, 750f–751f
 direct-to-consumer, 728–729
 ethics issues, 729
 for fragile X syndrome, 352
 impacts of, 728
 in neurologic evaluation, 3560
 in neuromuscular disorders, 3791, 3798–3799
 pedigree symbols of related information, 739f
 pharmacogenetics, 751–753, 752f–753f, 755f
 predictive, 750
 predispositional, 751
 Genetic transmission, 735–748
 digenic inheritance, 740
 family history and pedigree notation, 735
 mendelian inheritance, 735–740
 multifactorial and polygenic inheritance, 744–748
 nontraditional inheritance, 742–743
 pseudogenetic inheritance and familial clustering, 740–742
 X-linked inheritance, 738–740
 Y-linked inheritance, 740
- Genetically modified organisms (GMOs), 418
 Genetics, 726–729
 basis of, severe combined immunodeficiency disorders, 1263t
 of Chédiak-Higashi syndrome, 1301
 in childhood asthma, 1386, 1391f
 of chronic granulomatous disease, 1301–1302, 1302f
 of common disorders, 799–802
 in congenital central hypoventilation syndrome, 2719–2721, 2720t
 of congenital heart disease, 2764t–2766t
 of cystic fibrosis, 2662–2663
 ethics in, 54
 of leukocyte adhesion deficiency, 1299
 in medicine, changing paradigm of, 728
 molecular, 730
 of obesity, 438–442, 441t
 of primary ciliary dyskinesia, 2680, 2680f
 role of, in language development, 328
 Genital abnormalities, associations of, 3506t
 Genital examination
 indications for, 3318
 preparation for, 3318
 Genital herpes, 1994
 treatment of, 1997
 Genital HPV infection, 4167–4168
 Genital lesions
 and ectoparasites, 1244
 warts, 2055, 2055f
 warts, and herpes, 1249t–1250t
 Genital mutilation, female, 3357–3358, 3357t
 Genital mycoplasmas, 1890–1893
 clinical manifestations of, 1891–1892, 1891t
 diagnosis of, 1892–1893
 epidemiology of, 1890
 etiology of, 1890
 genitourinary infections in, 1892
 intruterine and neonatal infections in, 1891–1892
 nongenital infections in, 1892
 pathogenesis of, 1891
 transmission of, 1891
 treatment of, 1893
 Genital tract, tuberculosis of, 1845–1846
 Genital tract infections
 Chlamydia trachomatis, 1895–1896
 mycoplasmal, 1892
 Genital ulcer syndromes, 1243–1244
 Genital ulcers, vulvar, 3323, 3324f
 Genitalia
 assessment in newborn, 1003–1004
 physical examination of, 551
 Genitourinary disease, in tuberculosis, 1845–1846
 Genitourinary infections, in genital mycoplasmas, 1892
 Genitourinary tract
 cystic fibrosis and, 2667
 gonococcus, 1747–1752
 manifestation of, enterovirus infections, 1982
 trauma, 3309–3311
 diagnosis of, 3309, 3310f–3311f
 treatment of, 3309–3311
 Genitourinary trauma, secondary survey for, 577
 Genome sequencing, 750
 Genome-wide association studies, 3080
 Genomic disorders, 727
 Genomic imprinting, 776f, 777
 oncogenesis and, 3081
 Genomics, ethics in, 54
 Genotype-phenotype correlations, in genetic disease, 733–734
 Genotypic classification, of primary mitochondrial hepatopathies, 2483t
 Gentamicin, 1675t–1685t
 for *Staphylococcus aureus*, 1697
 Genu valgum, 4216, 4230
 Genu varum, 4215, 4216f, 4216t
 Geographic tongue, 2253, 4148, 4149f
 Geophagia, 241
 GER. See Gastroesophageal reflux
 GERD. See Gastroesophageal reflux disease
 Germ cell aplasia, 3489
 Germ cell malignancy, 3302
- Germ cell tumors (GCTs), 3118f, 3124, 3150–3153, 3151f
 clinical manifestations and diagnosis of, 3151–3153, 3152f, 3152t
 epidemiology of, 3150
 ovarian, 3342–3343, 3343t
 pathogenesis of, 3150–3151, 3151f, 3151t
 prognosis of, 3153
 treatment for, 3153
 German measles, 1965
 Germander, 2492t
 Germinomas, 3152
 Geroderma osteodysplastica, 4376t
 Gerstmann-Sträussler-Scheinker syndrome, 2118, 2119t
 Gestational age
 assessment at birth, 1042–1043, 1042f
 large-for, 1048–1049
 small-for, 1047–1048, 1047f
 Gestational alloimmune liver disease, 2451–2452, 2452t, 2459
 acute hepatic failure and, 2495
 γ-Glutamyl transpeptidase, reference intervals, 4472.e9t
GH1, 3366
 GH-IGF axis, genetic defects of, 3367t
 Ghrelin, 3360, 3846
 Gianotti-Crosti syndrome, 4108, 4108f
 Giant axonal neuropathy (GAN), 3887, 3888f, 3888t
 Giant cell arteritis, 1553t, 1555t
 Giant cell pneumonia, 1961
 Giant congenital pigmented nevi, 4062, 4062f
 Giant papillary conjunctivitis (GPC), 1422t, 1423–1424
Giardia duodenalis, 2149–2151
 antibiotic therapy for, 2373t–2375t
 clinical manifestations of, 2150, 2150t
 diagnosis of, 2150
 epidemiology of, 2149–2150
 etiology of, 2149
 parasitic gastroenteritis and, 2359t
 prevention of, 2151
 prognosis of, 2151
 treatment of, 2151, 2151t
 Giardiasis, 2149–2151
 drugs for, 2126t–2144t
 Gigantism
 cerebral, 3383–3384, 3383f
 pituitary, excess growth hormone secretion and, 3378–3379
 Giggle incontinence, 3294
 Gilbert syndrome, 1110, 2454–2455, 2503
 Ginger, 56t
 Gingival hyperplasia, 2250
 Gingival margin, 2247f
 Gingivitis, 2249
 Gingivostomatitis, 2558
 herpetic, 1993, 1993f, 2252–2253, 2253f
GINS1 deficiency, 1288, 1288f
 Girls
 adolescent, gynecologic examination in, 3319
 BMI, 173f–174f
 prepubertal, gynecologic examination in, 3317–3319
 GIST. See Gastrointestinal stromal cell tumor
 Gitelman syndrome, 500, 504, 3240t–3241t, 3241–3242
 Gla-containing proteins, 481
 Glanders (*Burkholderia mallei*), 1802
 Glandular disease, tularemia, 1804–1805
 Glanzmann thrombasthenia, 3059
 Glanzmann thrombasthenia-like bleeding disorder, 1299
 Glargin, for T1DM, 3529
 Glasgow Coma Scale (GCS), 555t, 556, 574, 582, 583t, 4387
 Glaucoma, 3968–3970
 aniridia and, 3920
 clinical manifestations of, 3969–3970, 3970f
 congenital, 3917t–3918t
 diagnosis and treatment for, 3970, 3970t
 in megalocornea, 3943
 primary and secondary, 3969t
 GLB youth, 1182
 Glenn cavopulmonary anastomosis, 2830
 Glenn shunt, bidirectional, 2807, 2808f

- Glenoid labrum tears, 4302, 4303f
 Gliazide, for T2DM, 3542t
 Glimepiride, for T2DM, 3542t
 Gliomas, optic nerve, 3967–3968, 3968f
 in neurofibromatosis type 1, 3652–3654, 3655f
 Glipizide, for T2DM, 3542t
Global Allergic Rhinitis and its Impact on Asthma (ARIA), 1381
 Global burden and trends, in child health, 23–25
 Global climate change, 4409
 Global developmental delay, 346
 evaluation of, 353f, 354t
 genetic testing guidelines for, 347t
 language disorders and, 329
 Global health
 challenges in, 32–35
 child, 23–35
 socioeconomic and political roots of disparities in, 24f–26f, 25–26
 Global hypoxic-ischemic encephalopathy, 3754
 Global prevalence, of anemia, 2927f
 Global situation, of abuse and neglect, 114
 Global statistics
 causes of under-five deaths, 2f
 children's health, 1–2
 injuries, 91–92, 92f, 94f
Global Strategy for Women's, Children's and Adolescent's Health 2016–2030 maps, 28
 Globin genes, organization of, 2924f
 Globoid cell leukodystrophy, 3714
 Globus, 2225
 Glomangioma, 3158, 3162f
 Glomerular basement membrane (GBM), 3180
 Glomerular capillary wall, 3220, 3222f
 Glomerular diseases, 3180–3183, 3183f
 filtration, 3181–3182, 3181f
 glomerulus, anatomy of, 3180–3181, 3180f–3181f
 isolated, with recurrent gross hematuria, 3186–3195, 3187f
 acute poststreptococcal glomerulonephritis, 3189–3192
 Alport syndrome, 3188–3189
 Berger nephropathy, 3187–3188, 3187f
 immunoglobulin A nephropathy, 3187–3188, 3187f
 membranoproliferative glomerulonephritis, 3191t, 3193–3194
 membranous nephropathy, 3189f, 3192–3193, 3193f
 rapidly progressive glomerulonephritis, 3194–3195, 3195f, 3195t
 thin basement membrane disease, 3189
 pathogenesis of, 3182, 3183f
 pathology of, 3182–3183
 Glomerular filtration, 3181–3182, 3181f
 Glomerular filtration rate (GFR), 487–488, 3181
 in acute kidney injury, 3243f
 Glomerular proteinuria, 3218, 3220–3221, 3222f, 3222t
 Glomerulonephritis
 associated with systemic lupus erythematosus, 3196–3198
 clinical manifestations of, 3197
 diagnosis of, 3197
 pathogenesis and pathology of, 3196–3197, 3197t
 prognosis of, 3198
 treatment of, 3197–3198
 cellular location of injury during, 3183f
 manifestations of, 3184
 urine chemistries in, 3242–3244, 3244t
 Glomerulosclerosis, focal segmental, 3228
 in ESRD, 3254–3255
 primary, 3254–3255
 recurrent, 3255
 Glomerulus, anatomy of, 3180–3181, 3180f–3181f
 Glomus tumors, 4024
 Glomusvenous malformation, 3158, 3162f
 Glossitis, riboflavin deficiency and, 461, 461f
 Glossopharyngeal nerve (cranial nerve IX), in neurologic examination, 3554
 GLP-1 agonists, for nonalcoholic steatohepatitis, 2482t
 Glucagon, 713–714
 Glucagon stimulation test, 982
 Glucocorticoid receptor gene pathogenic variant, cortisol resistance due to, 3507
 Glucocorticoid-remediable aldosteronism, 521
 Glucocorticoid replacement, for 21-hydroxylase deficiency, 3467
 Glucocorticoid-remediable aldosteronism, 3471
 Glucocorticoid-remediable aldosteronism, primary aldosteronism and, 3479
 Glucocorticoids
 circulatory and renal effects, 3447–3448
 CNS effects, 3448
 effects on skin, bone, and calcium, 3448
 generalized resistance, 3460
 growth and, 3448
 immunologic effects, 3448
 for Kawasaki disease, 1547
 metabolic effects, 3447–3448
 for paroxysmal nocturnal hemoglobinuria, 2965
 for rheumatic diseases, 1465–1469, 1466t–1468t
 for Takayasu arteritis, 1559
 Glucocorticoid-suppressible hyperaldosteronism, primary aldosteronism and, 3479
 Glucocorticosteroids, for sarcoidosis, 2623
 Glucogeneogenesis disorders, 900t–901t, 913–915
 fructose-1,6-bisphosphatase deficiency, 913–915
 fructose-1,6-diphosphatase deficiency, 991
 neonatal hypoglycemia and, 806t
 phosphoenolpyruvate carboxykinase (PEPCK) disease, 915
 type I glycogen storage disease, 913
 Glucoprotein, cerebral, 981t
 Glucose, 393, 526, 898
 intolerance, in CKD, 3250t
 in maintenance fluids, 526
 reference intervals, 4472.e9t
 Glucose tolerance test (GTT), 4472.e9t
 in Cushing syndrome, 3477
 Glucose-galactose malabsorption, 2334t–2336t, 2347–2348
 Glucose-6-phosphatase (or translocase) deficiency (type I GSD), 898–903
 clinical manifestations, 898–902
 diagnosis of, 902
 hypoglycemia and, 991
 prognosis of, 903
 treatment of, 902
 Glucose-6-phosphate dehydrogenase (G6PD) deficiency, 1297t–1298t, 2980, 2990–2992, 2990f, 2991t, 2992f
 Glucosyltransferase-1 deficiency, 926
 clinical manifestations, 926
 diagnosis of, 926
 pathophysiology of, 926
 treatment of, 926
 Glucuronid transferase deficiency, 2455–2456
 partial, 2456
 Glutulis insulin, for T1DM, 3528–3529
 GLUT-1 deficiency syndrome, 3603
 Glutamic acid, metabolism defects, 842–844, 843f
 glutathione synthetase deficiency, 842–843
 glutathionemia, 844
 γ-Glutamyl transpeptidase, deficiency, 844
 γ-Glutamylcysteine synthetase deficiency, 843
 Glutaric aciduria type 1, 856
 Glutaryl-CoA dehydrogenase deficiency, 856
 Glutathione reductase, deficiency of, 1297t–1298t
 Glutathione synthetase deficiency, 842–843, 1297t–1298t
 Glutathionemia, 844
 Gluten-free diet, 2329
 Gluten-sensitive enteropathy, 2327f, 4086
 Glyburide, for T2DM, 3542t
 Glycemic control, in T1DM, 3533, 3536–3537
 Glycemic index, 394
 Glycine, metabolism defects, 834f, 837–840
 creatine deficiency, 840, 840f
 hyperglycemia, 837
 hyperoxaluria and oxalosis, 838–840
 hypoglycemia, 837
 nonketotic hyperglycemia, 837–838
 sarcosinemia, 838
 trimethylaminuria, 838
- Glycine cleavage enzyme system, 837
 Glycine N-methyltransferase deficiency, 823
 Glycogen, 898, 2436
 Glycogen storage disease (GSD), 898–910, 899f, 900t–901t, 989–990
 cardiomyopathy and, 808t
 hepatic dysfunction and, 808t
 hypoglycemia and, 991
 neonatal hypoglycemia and, 806t
 type 0a, 900t–901t, 906
 type 0b, 900t–901t, 908
 type 1b, 1309t, 1310–1311
 type I, 898–903, 913
 type II, 906–908
 type III, 903–904, 903f
 type IV, 904
 type V, 900t–901t, 909
 type VII, 900t–901t, 909–910, 2989–2990
 type IX, 905
 type IX α1, 900t–901t, 910
 type IX α2, 900t–901t, 905
 type IX β, 900t–901t, 905
 type IX γ2, 900t–901t, 905–906
 Glycogenin-1 deficiency, 908
 Glycogenoses, 3851
 clinical symptoms and classification of, 3852t
 Glycolytic enzyme deficiencies, 2989
 Glycopeptides, 1688
 enterococci resistance, 1723t
 Glycoprotein degradation and structure, disorders of, 920–921
 Glycosylated hemoglobin (HbA_{1c}), in T1DM, 3533
 Glycosylation, congenital disorders of, 921–930, 922f, 924t, 925f, 927t, 3819
 cardiomyopathy and, 808t
 hepatic dysfunction and, 808t
 inborn errors of metabolism associated with, 809t
 Glycosylphosphatidylinositol (GPIs), 921
 anchor biosynthesis, defects in, 928
 Glyoxylic acid, 838–839
 Glyphosate (roundup), 4425
 GM₁ gangliosidoses, 885, 887t–888t, 892f, 893t
 GM₁ gangliosidosis, 3711–3713, 3714f
 GM₂ gangliosidoses, 885–890, 887t, 3713–3714, 3714f
Gnathostoma spinigerum, 2209
 Gnathostomiasis, 3776
 drugs for, 2126t–2144t
 GnRH agonists, for pubertal blockade, 1175, 1176t
 GOF STAT3 variants, 1332t–1333t
 GOFSTAT1 defect, 1332t–1333t
 Goiter, 3413–3415
 acquired, 3415
 congenital, 3413, 3413f
 endemic, 3404
 cretinism and, 3413–3415
 intratracheal, 3413
 Goitrogens, 3415, 3415t
 Goldenhar syndrome, 2764t–2766t, 3987t
 Goldenseal, 57t
 Golgi homeostasis, disorders of, 929–930
 Golgi-α₁₂mannosidase-1 deficiency, 929
 Goltz–Gorlin syndrome, 4046
 Gonadal dysgenesis, 3151
 with Y chromosome, diagnosis of, 3508t
 Gonadal hormones, effect of total body irradiation, 1365
 Gonadal neoplasms, 3150–3153, 3151f
 clinical manifestations and diagnosis of, 3151–3153, 3152f, 3152t
 epidemiology of, 3150
 pathogenesis of, 3150–3151, 3151f, 3151t
 prognosis of, 3153
 treatment for, 3153
 Gonadarche, 1158–1159
 Gonadoblastomas, 3151, 3342–3343, 3503
 in 45,X/46,XY gonadal dysgenesis, 3500
 in Turner syndrome, 3498
 Gonadotropin-dependent/central precocious puberty, 3327
 Gonadotropin-independent causes, of isosexual precocious puberty, 3388–3389
 Gonadotropin-independent/peripheral precocious puberty, 3327

- Gonadotropins, isolated deficiency of, in hypogonadotropic hypogonadism, female, 3501
- Gonads, development and function of, 3481–3487
diagnostic testing for, 3487
ovaries, function of, 3486–3487
testes, function of, 3485–3486, 3485f
- Gonglylomiasis, drugs for, 2126t–2144t
- Gonococcal cervicitis, 1242f
- Gonococcal ophthalmia neonatorum, 1752
- Gonococcal pharyngeal infections, 2559
- Gonococcal urethral discharge, 1242f
- Gonococcus, 1747–1752
in septic arthritis, 4291
- Gonorrhea
asymptomatic, 1748
clinical manifestations of, 1748–1749
complications of, 1750–1752
diagnosis of, 1749–1750
disseminated gonococcal infection, 1749
epidemiology of, 1747
etiology of, 1747
NAAT for, 125
pathogenesis and pathology of, 1747–1748
prevention of, 1752
reported cases by age, 1239f
treatment of, 1248–1250, 1750, 1751t
uncomplicated, localized, 1748–1749
- Good Buddies, for FASD, 1138
- Goodpasture syndrome, 1563, 2689, 3199–3200, 3199f
- Gordon syndrome, 497, 3242
- Gorham-Stout disease, 3065, 3066f, 3156–3157, 3160f
- Gorlin sign, 4372f
- Gorlin syndrome, 768t–769t, 789–790, 4188–4189
- Gotttron papules, 4031–4032, 4032f
in JDM, 1500
suggestive of rheumatic disease, 1461t
- Gout, 947
- Gowers sign, 3555, 3556f
in JDM, 1500
- GPA. *See* Granulomatosis with polyangiitis
- GRACILE syndrome, 2485
- Graded challenge, 1457–1458
- Grading
of GVHD, 1358t, 1360t
of hydronephrosis, 3277t
of renal injuries, 3310t
of severity of germinal matrix intraventricular hemorrhage, 1059f
of vesicoureteral reflux, 3270f
- Graduated driver's licensing (GDL) programs, 97
- Graf technique, 4234, 4234f
- Graft *versus* host disease (GVHD), 1357–1360, 3092t–3093t
acute, 1357–1358, 1357f
chronic, 1358–1359, 1358t, 1359f
in HSCT, 1351, 1355
of liver, 2479
- Graft-*versus*-leukemia (GVL) effect, 1351
- Grafts
failure, 1359–1360
kidney, survival of, 3258
for liver, 2507–2508
- Graft-*versus*-host disease (GVHD), 2354, 4034, 4034f
due to HSCT, 1365
transfusion-associated, 3021
- Gram-negative bacterial infection
Aeromonas, 1796–1797
Bartonella, 1812–1816
bacillary angiomatosis, 1816
bacillary peliosis hepatis, 1816
bartonellosis (*Bartonella bacilliformis*), 1814–1815
cat-scratch disease (*Bartonella henselae*), 1812–1814
trench fever (*Bartonella quintana*), 1815–1816
- Brucella*, 1807–1809
- Campylobacter*, 1788
- chancroid (*Haemophilus ducreyi*), 1759
- cholera, 1785–1788
- Haemophilus influenza*, 1755–1758
- Kingella kingae*, 1752–1755
- Legionella*, 1810–1811
- Moraxella catarrhalis*, 1759–1761
- Neisseria gonorrhoeae* (gonococcus), 1747–1752
- Gram-negative bacterial infection (*Continued*)
Neisseria meningitidis (meningococcus), 1737–1746
pertussis (*Bordetella pertussis* and *B. parapertussis*), 1761–1765
Plesiomonas shigelloides, 1797–1798
Pseudomonas aeruginosa, 1799–1802
Salmonella, 1765–1776
enteric fever (typhoid fever), 1771–1776
nontyphoidal salmonellosis, 1765–1771
Shigella, 1776–1780
- Stenotrophomonas*, 1803
- tularemia (*Francisella tularensis*), 1803–1807
- Yersinia*, 1792–1795
plague (*Yersinia pestis*), 1794–1795
Yersinia enterocolitica, 1792–1793
Yersinia pseudotuberculosis, 1793–1794
- Gram-positive bacterial infections
Actinomyces, 1733–1735
diphtheria (*Corynebacterium diphtheriae*), 1724–1729
Enterococcus, 1722–1724
group A *Streptococcus*, 1706–1715
rheumatic fever, 1711–1715
group B *Streptococcus*, 1716–1720
- Listeria monocytogenes*, 1729–1732
- Nocardia*, 1735–1737
- non-group A or B streptococci, 1721–1722
- Staphylococcus*, 1693–1700
coagulase-negative staphylococci, 1699–1700
Staphylococcus aureus, 1693–1698
toxic shock syndrome, 1698–1699
- Streptococcus pneumoniae* (pneumococcus), 1701–1705
clinical manifestations of, 1702, 1702f
diagnosis of, 1702–1703
epidemiology of, 1701
etiology of, 1701
pathogenesis of, 1701–1702
prevention of, 1703–1705
prognosis of, 1703
treatment of, 1703
- Gram stain, gonorrhea, 1749–1750
- Granular layer, of epidermis, 4025
- Granulocytes, 1290
product, 3018
transfusion, 3018, 3018t
- Granulocytic sarcomas, acute myelogenous leukemia and, 3102–3103
- Granulocytopoiesis, primary disorders of, 1308–1310
- Granuloma
candidal, 4166
central giant cell, 2254
eosinophilic, 4023
Majocchi, 4162, 4162f
pyogenic, 3162, 4058–4059, 4059f
sarcoïd, 2623f
umbilical, 1131
- Granuloma annulare, 4120–4121, 4120f
- Granulomatosis with polyangiitis (GPA), 1553t, 2620–2622, 2621f, 2689
children with, 1562t
criteria for, 1562t
eosinophilic, 2628, 2628t
lower respiratory tract disease in, 1564f
- Granulomatous amebic meningoencephalitis, 2146, 2146f
- Granulomatous and lymphocytic interstitial lung disease (GLILD), 2624
- Granulomatous conjunctivitis, 1813f
- Granulomatous diseases, hypercalcemia and, 3441
- Granulomatous infections, in sarcoidosis, 1551, 1551t
- Granulomatous lung disease, 2620–2624
berylliosis, 2623–2624
granulomatosis with polyangiitis, 2620–2622, 2621f
eosinophilic, 2628, 2628t
in primary immune deficiency, 2624
- sarcoidosis, 2622–2623
clinical manifestations of, 2622
diagnostic laboratory testing for, 2622
epidemiology of, 2622
histopathology of, 2622, 2623f
pathogenesis of, 2622
- radiology for, 2623
treatment of, 2623
- Granulomatous vasculitis, 2621f
- Granulosa cell tumors, 3152–3153
- Granzymes, 1287
- Grapefruit, 57t
- Graphomotor, 323
function, 301
- Grasp response, 3556–3557
- Graves disease, 3416–3421
clinical manifestations of, 3417–3418, 3417f
conditions associated with, 3417t
differential diagnosis of, 3418–3419
epidemiology of, 3416–3417
etiology of, 3416–3417
laboratory findings of, 3418
treatment for, 3419–3421, 3420t
- Graves ophthalmopathy, 3418t, 3421
- Gray baby syndrome, 2437
- Gray platelet syndrome, 3059–3060
- Great arteries, malposition of, double-outlet right ventricle with, 2815
- Greater celandine, 2492t
- Green and Anderson method, 4220–4221
- Green tea leaf extract, 2492t
- Greenstick fracture, 4277, 4278f
- Greig cephalopolysyndactyly syndrome (GCPS), 789–790
- Grief, 197–198, 197t–198t
complicated, 200
role of pediatrician in, 199t, 200
uncomplicated, 197
- Grind test, 4228
- Griselli syndrome, type II, 1309t, 1310
- Gross body movement, 1018t
- Gross hematuria, common causes of, 3186t
- Gross motor, 179
function, 301
- Gross Motor Function Classification System (GMFCS), in spasticity, 4396f
- Grossly disorganized behavior, 285
- Ground current, in lightning burns, 655
- Ground itch, 2201
- Group A streptococcus (GAS), 1706–1715
bacteria other than, 2558–2559
clinical manifestations of, 1707–1708
complications of, 1710
PANDAS, 1710
poststreptococcal reactive arthritis, 1710
- diagnosis of, 1708–1709
differential diagnosis of, 1709
epidemiology of, 1706
etiology of, 1706–1710
pathogenesis of, 1706–1707
pharyngitis, 2558–2559
prevention of, 1710
prognosis of, 1710
recent infection, in rheumatic fever, 1713
treatment of, 1709–1710
- Group aquatics aerobic exercise program, for children with disabilities, 4406t
- Group B streptococcus (GBS), 1716–1720
clinical manifestations of, 1717, 1717t
diagnosis of, 1717–1718
early-onset infection and, 1143
epidemiology of, 1716, 1716f
etiology of, 1716
intrapartum prophylaxis, 1151t
laboratory findings of, 1718
pathogenesis of, 1716–1717
prevention of, 1718–1720
chemoprophylaxis, 1718–1720, 1719t, 1720f
maternal immunization, 1720
- prognosis of, 1718
in septic arthritis, 4291
treatment of, 1718, 1718t
- Group therapy, 276
- Group training class, for children with disabilities, 4406t
- Groups C and G streptococci, 1721
- Growing pains, 1569, 1570t
- Growing rods, for idiopathic scoliosis, 4246, 4246f
- Growth, 4193
abnormal, 176
evaluation of, 177

- Growth (*Continued*)

adolescent, 175–176

assessment of, 172–177, 175t

catch-up, 176

childhood, 175

considerations, 177

 obesity, 177

curves, 172–177, 176f

decreased, 177t

dental development and, 177, 178t

fetal, 175

increased, 177t

infantile, 175

normal, 175–176

techniques to measure, 172

Growth arrest, 4284

Growth chart, 172, 173f–176f

Growth delays

 in adopted children, 73

 constitutional, 3370

Growth disturbance, 4299

Growth factor receptors, 3077

Growth factors, in normal liver development, 2435t

Growth failure, 176

Growth faltering, 388

Growth hormone (GH), 3360

 excess secretion, pituitary gigantism and, 3378–3379

 acromegalic features of, 3378

 clinical features of, 3378

 diagnosis of, 3379

 treatment of, 3379

 insensitivity

 abnormalities of growth hormone receptor, 3366–3367

 classification of, 3368t

 post-receptor forms of, 3367–3368

 recombinant human (rHuGH), 3251

 underproduction (hypopituitarism), 3364–3371

Growth hormone deficiency, 990

 acquired forms of, 3366

 evaluation of suspected, 3369t

 genetic forms of, 3366

 GH1, 3366

 GH-releasing hormone receptor, 3365–3366

 X-linked isolated, 3366

Growth hormone-releasing hormone receptor, deficiency, 3365–3366

Growth impairment

 due to HSCT, 1365

 due to nephrotic syndrome, 3229

Growth patterns, variations in, malocclusion and, 2242–2243, 2242f

Growth plate, sports-related injuries, 4299–4300

Growth references, 172

Growth restriction, pattern of, 1016f

Growth retardation

 in CKD, 3250t

 pediatric heart transplantation and, 2904

Growth standards, 172

GRT. *See* Gene replacement therapy

GSD. *See* Glycogen storage disease

GTG banding, 761

Guanfacine, for ADHD, 223, 225t–226t, 315

Guanidinoacetate methyltransferase (GAMT), 840

Guanine, 944

Guanosine triphosphate (GTP), 814

Guided imagery, 58t

Guided self-help, 258

Guillain-Barré syndrome, 3900–3905

 Campylobacter in, 1791

 clinical manifestations of, 3900–3904, 3901f, 3901t–3904t, 3905f–3906f

 differential diagnosis of, 3902t–3903t

 laboratory findings and diagnosis of, 3901t, 3903t–3905t, 3904, 3905f–3906f

 in neuromuscular disorders, 3791

 poliomyelitis and, 1974

 prognosis of, 3905

 treatment for, 3904–3905, 3906f

Gum boil, 2253

Gun policy-based outcomes, 99f

Günther disease, 4094

Guttate psoriasis, 4098

GVHD. *See* Graft-versus-host disease

GWAS. *See* Genome-wide association studies

Gymnastics, injuries associated with, 4331–4332

Gymnast's wrist, 4265–4267, 4267f, 4299

Gynecologic problems

 bleeding, 3326–3328

 care for adolescents with special needs, 3355–3356

 history and physical examination for, 3317–3320

 neoplasms and prevention methods, for HPV, in adolescents, 3338–3347

 polycystic ovary syndrome and hirsutism, 3334–3338

 vulvovaginal and Müllerian anomalies, 3347–3354

 vulvovaginitis, 3320–3326

Gynecomastia, 3495–3496

Gyrate atrophy, of retina and choroid, 854

Gyromitrin poisoning, 4443
- H**
- H₁ antihistamine, for solar urticaria, 4096

H1N1 virus, 2020

H2-receptor antagonists, 2308

“Habit cough,” 2527–2528

Habit tic deformity, 4143

Habits, 241–246, 246t

Habitual dislocation, of patella, 4229

HACs. *See* Healthcare-associated conditions

HAE. *See* Hereditary angioedema

Haemophilus ducreyi, 1759

 clinical manifestations of, 1759

 complications of, 1759

 diagnosis of, 1759

 etiology and epidemiology of, 1759

 management guidelines, 1247t–1248t

 treatment of, 1759

Haemophilus influenzae, 1755–1758

 in bacteremia without associated focus, 1758

 in cellulitis, 1757

 in conjunctivitis, 1758

 diagnosis of, 1756

 epidemiology of, 1755–1756

 etiology of, 1755

 in invasive diseases in neonates, 1758

 in meningitis, 1757

 in orbital cellulitis, 1757

 in otitis media, 1758

 pathogenesis of, 1756

 antibiotic resistance, 1756

 immunity of, 1756, 1756t

 in pericarditis, 1758

 in pneumonia, 1757

 in presepal cellulitis, 1757

 prevention of, 1758

 prophylaxis for, 1758

 vaccine for, 1758

 in sinusitis, 1758

 in suppurative arthritis, 1757–1758

 in supraglottitis or acute epiglottitis, 1757

 vulvovaginal infection, 3322t

Haemophilus influenzae type b (Hib)

 in bacterial meningitis, 3760

 sensorineural hearing loss and, 3984

 vaccine, 30–31t

Hair collar sign, in aplasia cutis congenita, 4044–4045, 4045f

Hair disorders, 4137–4142

 alopecia areata, 4138–4140, 4138t–4139t, 4139f–4140f

 hypertrichosis, 4137, 4137t

 hypotrichosis and alopecia, 4137, 4138t

 traumatic alopecia, 4137–4138

Hair follicles, 4025f, 4026

Hair loss, in patients with progeria, 956

Hair pulling, 4137–4138

Haldol. *See* Haloperidol

Hall-Pallister syndrome, 3364

Hallucinations, 285

 of childhood, 293

 evaluation of, 294f

Hallucinogens, 1204

 classes of, 1205t

 lysergic acid diethylamide, 1204

 methylenedioxymethamphetamine, 1204

 phencyclidine, 1204–1205

Halo nevus, 4063, 4064f

Halo sign, 1363

Halogenated hydrocarbons, 720

Haloperidol (Haldol), for psychosis and mania, 226–227, 228t

Hamartin, 3657

Hamartomas

 hypothalamic, 3390

 pigmented, of iris, 3655f

 retinal, 3658f

Hamartomatous tumors, 2411–2413, 2412f

Hammer toe, 4210

Hand

 disorders of, 4267–4270

 camptodactyly, 4268, 4268t

 clinodactyly, 4268f

 fingertip injuries, 4269

 polydactyly, 4268, 4268t, 4269f

 syndactyly, 4269, 4270f, 4270t

 thumb hypoplasia, 4268–4269, 4269f

 trigger thumb and fingers, 4269–4270, 4270f

 fractures, 4279

 minor malformations, 785t

 in polyarticular JIA, 1476f–1477f

 in porphyria cutanea tarda, 974f

 radiographic changes in JIA, 1480f

Hand-foot-and-mouth disease, 1981, 1981f–1982f

Handedness, 164

Handheld laser pointers, eye injuries related to, 3980, 3980f

Handoffs, 47

Handwashing, 1789

 for echinococcosis, 2222

Hansen disease, 1855–1860

 classification of, 1856–1857, 1856f–1857f

 clinical manifestations of, 1857–1858

 diagnosis of, 1858

 epidemiology of, 1855–1856

 leprosy reactions in, 1857, 1859

 long-term complications of, 1860

 microbiology of, 1855

 nerve involvement of, 1857, 1857f

 ocular involvement of, 1857

 pathogenesis of, 1856

 prevention of, 1860

 skin involvement of, 1857

 treatment of, 1858–1859, 1858t–1859t

Hantavirus pulmonary syndrome, 2080–2081, 2080f

 clinical manifestations of, 2081

 diagnosis of, 2081

 differential diagnosis of, 2081

 epidemiology of, 2080–2081

 etiology of, 2080

 laboratory findings of, 2081

 pathogenesis of, 2081

 prevention of, 2081

 prognosis for, 2081

 treatment of, 2081

Haplogroup, 934

Haplod, 730

Haploididentical transplants, for HSCT, 1356

Haploinsufficiency, 731–732, 4339

Happy spitters, 2264

Haptens, in immune-mediated hemolysis, 2995t

Haptoglobin level, in hemolysis, 2953

Harlequin color change, 4041

Harlequin ichthyosis, 4110–4115

Harm

 error vs., 42, 42f

 identifying and analyzing, 43–44

Harmful algal blooms (HABs), 4445

Harrison groove, 470

Hartnup disease, 824, 2349, 4098, 4191

Harvest mite, 4175

Hashimoto encephalitis, 3705t–3707t

Hashimoto encephalopathy, 3708–3710

Hashimoto thyroiditis, 3391, 3411, 3549

 associated with myasthenia gravis, 3863

HAT. *See* Human African trypanosomiasis

Haverhill fever, 4460

Haw river syndrome, 745t–746t

Hawkinsinuria, 817

HAX1 gene, 1308

- Hazardous air pollutants (HAPs), 4424
 Hb Köln, in unstable hemoglobin disorders, 2978
 HCC. *See* Hepatocellular carcinoma
 HCoV-OC43, 2038
 HDS. *See* Herbal dietary supplement
 Head, in neurologic examination, 3551–3552, 3551f
 Head blocks, in pain management, 694
 Head circumference
 birth to 24 months, 159f
 measurement of, 172
 Head drop, in unprovoked seizures, 3598
 Head injuries
 ski- and snowboard-related, 97
 trauma, abusive, 117, 120f
 Head lice
 bites, 4170t
 drugs for, 4176t
 Head trauma, secondary survey for, 575–576
 Headaches, 3639–3652
 in acutely ill child, 549
 care, from a pediatric to an adult provider, 3650
 classification of, ICHD-3 beta code diagnosis, 3640t–3641t
 in exclusion or inclusion in daycare, 187t–192t
 in lymphatic filariasis, 2206
 migraine, 3639–3650
 with aura, 3643–3644
 with brainstem aura, 3642t, 3644
 chronic, 3642t
 classification and clinical manifestations of, 3639–3644
 diagnosis and differential diagnosis of, 3644, 3645t
 epidemiology of, 3639
 genetics in, 3642t
 treatment of, 3644–3650, 3646t–3647t
 with typical aura, 3642t
 vestibular, with vertigo, 3642t
 without aura, 3639–3643, 3642t, 3643f
 in neurocysticercosis, 2218
 primary, 3639
 red flags for, 1577t
 secondary, 3639, 3650–3651, 3651t
 in SLE, 1497t
 tension-type, 3652, 3652t
 HEADS/SF/FIRST mnemonic, in adolescents, 1169–1170, 1169t
 Head-tilt/chin-lift maneuver, 552–554, 555f
 Healing-centered care, 5, 6f
 Health, 421–431
 adolescents
 guidelines for, 1165, 1166t
 health behaviors, 1187t
 health outcomes, 1188t
 determinants of, 8–16, 8f
 and disease, in neonate exposed to pathogen, 1146f
 disparities in, 10–15
 medical and sexual, of GLB youth, 1185
 promotion, 85
 social determinants of
 in adolescent, 1159f
 COVID-19 and, 26–27, 26f
 supervision, in relation to sleep problems, 214
 Health anxiety, 247t–248t
 Health behavior, change, strategies for, 129–135
 common factors approach, 131–132, 133t
 demoralization, 132
 elicit concerns, 132
 emphasize hope, 132
 establish a plan, 132
 HEL^{2P³} mnemonic, 132, 132t
 respond to anger, 132
 motivational interviewing, 133–134, 134t
 shared decision-making, 134–135
 trantheoretical model of health behavior change, 131, 131t
 unified theory of behavior change, 129, 130f, 130t
 Health belief model, 141t
 Health beliefs history, 83, 83t
 Health disparity, definition of, 8
 Health information and communications technology (HICT), 35
Health Information for International Travel, 2181
 Health insurance, coverage of, in adolescents, 1165, 1166f
 Health InterNetwork Access to Research Initiative (HINARI), 547
 Health neighborhood, 7
 Health promotion, 4404
 for children with disabilities, 4404–4405, 4405t
 Health service sector, adolescent, 1164t–1165t
 Healthcare
 adolescent
 access to, 1186
 delivery to, 1165–1170
 legal issues in, 1168–1169
 screening procedures, 1169–1170
 screening recommendations for, 1167t
 culture in context of, 82–83
 preventive pediatric, 86f–87f
 quadruple aim for, 7f
 quality and value in, 36–41
 transition of, 1171t
 Healthcare provider, role in grief, 199t, 200
 Healthcare system
 disparities in, 10–15
 residential segregation and, 21
 Healthcare-associated conditions (HACs), 42, 44, 45t, 46f
 Health-related quality of life (HRQoL), congenital diaphragmatic hernia and, 1096
 Healthy behaviors
 adolescent, 1187t
 among 9th and 12th grade students, 1187f
 promotion of, in childcare, 193
 Healthy eating habits, in children, 450t
 Healthy Foster Care America website, 76
 Healthy Immigrant Paradox, 10
Healthy People 2030, 1188t
 Hearing, and understanding, milestones in, 326t
 Hearing aids, 341–342, 3992
 Hearing care, disparities in, 14
 Hearing impairment
 clinical audiologic evaluation of, 3990–3992, 3990f
 effects of, 3985–3986, 3988t
 identification of, 3986t, 3988–3990, 3989t
 language disorders and, 329
 Hearing loss, 376, 3981, 3983–3994
 associated with Down syndrome, 367
 chemotherapy and, 3093–3094
 in childcare, 193
 clinical evaluation, 3990–3992
 acoustic immittance testing, 3991
 audiometry, 3990, 3990f
 auditory brainstem response, 3991–3992
 behavioral observation audiometry, 3990–3991
 otoacoustic emissions, 3992
 play audiometry, 3990
 speech-recognition threshold, 3990
 visual reinforcement audiometry, 3990
 etiology of, 3984–3985, 3984t–3987t, 3988f–3989f
 genetic counseling, 3994
 idiopathic sudden sensorineural, 3985t, 3994
 incidence and prevalence of, 3983
 in progeria, 959
 screening of, 3985–3986, 3988t
 toxoplasmosis and, 2193
 treatment of, 3992–3994, 3993f, 3994t
 types of, 3983–3984
 Heart
 abnormal position of, 2822–2826
 assessment in newborn, 1002–1003
 physical examination of, 551
 rhythm of, 2844–2859
 sound, 2742–2743
 transplantation, pediatric, 2902–2906
 tumors of, 2892–2893
 Heart block, Lyme disease and, 1883
 Heart defects, 2242t
 Heart disease
 acquired, infective endocarditis, 2864–2871
 in *Aspergillus* infection, 1931
 chronology of presentation, 614t
 congenital, 2835–2843
 in adults, 2838–2843, 2839f
 atrial septal defects, 2840
 Heart disease (*Continued*)
 complete atrioventricular canal, 2840
 interstage management of, 2838
 left-to-right shunts, 2840
 long-term management of, 2838
 patent ductus arteriosus, 2840
 postoperative management of, 2836–2838
 pregnancy and, 2842, 2842f–2843f
 risks in, 2839t
 survival into adulthood without surgery, 2839t
 ventricular septal defects, 2840
 cyanotic, 2841
 rheumatic, 2872–2875
 Heart failure, 2737, 2843, 2893–2901
 angiotensin-converting enzyme inhibitors for, 2898–2899
 cardiogenic shock and, 2900–2901
 clinical manifestations of, 2894–2895
 congestive, dosage of drugs for, 2898t
 diagnosis of, 2895–2896
 diet for, 2897
 diuretics for, 2897
 etiology of, 2896t
 general physical examination for, 2738
 management, electrophysiologic approaches for, 2900–2901
 pathophysiology of, 2893–2894, 2893f, 2894t–2895t, 2895f
 treatment of, 2896–2900
 α- and β-adrenergic agonists, 2900
 additional therapies for, 2900
 β-blockers, 2899
 diet for, 2897
 digitalis glycosides for, 2900
 diuretics for, 2897
 general measures for, 2897
 phosphodiesterase inhibitors for, 2899–2900
 Heart rate
 fetal
 three-tier interpretation of, 1020t
 variability of, 1017
 in general physical examination, 2738
 shock and, 607t
 Heart transplantation, 2843
 Heartburn, 2257
 Heart-lung transplantation, 2905–2906
 Heat cramps, 4320
 Heat edema, 4320
 Heat exhaustion, 4320
 Heat illness, 4320, 4321t, 4327
 Heat index, 4322f
 Heat injuries, 4320–4322, 4321t
 Heat stroke, 4320–4321
 Heat syncope, 4320
 Heat tanay, 4320
 Heat transfer, mechanisms of, 657
 Heavy metal intoxication, 707t–708t, 4431–4435
 arsenic, 4431–4433, 4431f–4432f, 4432t
 clinical manifestations of, 4432, 4432t
 laboratory findings of, 4433, 4433t
 pathophysiology of, 4431–4432
 pharmacokinetics of, 4431
 reduction strategies of, 4435t
 toxic levels of, 4433t
 treatment of, 4435, 4435t
 mercury, 4433–4435, 4434t
 clinical manifestations of, 4434
 differential characteristics of, 4434t
 laboratory findings of, 4433t, 4434–4435
 pathophysiology of, 4434
 pharmacokinetics of, 4433–4434
 toxic levels of, 4433t
 treatment of, 4435, 4435t
 Hectic fever, 1640–1641
 HED. *See* Hypohidrotic ectodermal dysplasia
 Heel bisector line (HBL), 4212, 4215f
 Height measurement, 172
 Height velocity charts, 172–175
 Height-for-age, 423
 Heimlich maneuver, 557, 557f
 Heinz bodies, 2990, 3061
 HEL^{2P³} mnemonic, 132, 132t
Helicobacter, Guillain-Barré syndrome and, 3904

- Helicobacter pylori* gastritis, 2306, 2306f, 2307
 Heliotrope rash, 4031–4032
 in JDM, 1500
 Heliox, for airway obstruction, 558
 Helium-oxygen mixture, for respiratory distress and failure, 618
 Helmet therapy, for deformational plagiocephaly, 3587, 3587t
 Helmets, with face guards, 2252
 Helminthic diseases, antiparasitic drugs for, 2144–2145
 Hemagglutinins, cold, in *M. pneumoniae*, 1889
 Hemangioma, 3409
 clinical “red flags” associated with, 4056t
 infantile, 4054–4056, 4055f
 orbital, 3972–3973, 3973f
 subglottic, congenital, 2576, 2576f, 2583–2584
 Hemangiopericytoma infantile form, 3139t–3140t
 Hemarthrosis, 3029
 Hematemesis, 2231t
 Hematocolpos, 3351–3353, 3352f
 Hematocrit
 concentration, 2923f
 normal mean and lower limits of, 2926t
 reference intervals, 4472.e9t
 Hematologic abnormalities, *Mycoplasma pneumoniae* and, 1889
 Hematologic data, 2754
 Hematologic diseases
 anesthetic implications in, 666t
 hyposplenism and, 3063t
 in secondary intracranial hypertension, 3783t
 Hematologic issues, in pediatric palliative care, 70
 Hematologic manifestations
 of cat-scratch disease, 1814
 of SLE, 1492t
 Hematologic system
 arsenic effects in, 4432t
 autonomic dysreflexia in, 4391t
 oncologic emergencies in, 3092t–3093t
 Hematoma, 1108t, 3331
 epidural, 584f
 subdural, 584f–585f
 Hematometra, 3351, 3351f
 Hematopoiesis
 in human embryo and fetus, 2921
 major cytokine sources and actions to promote, 2922f
 Hematopoietic acclimatization, 630–631
 Hematopoietic stem cell transplantation (HSCT), 1300, 2933
 in acquired aplastic anemia, 1353
 for acquired pancytopenias, 3012
 in acute myeloid leukemia, 1352–1353
 in ALL, 1351–1352
 allogeneic or autologous, 1351, 1352t
 from alternative sources and donors, 1355–1356
 autologous, 1356, 1356t
 in CML, 1353
 donor vs. recipient NK cell alloreactivity, 1356
 haploidentical transplants, 1356
 from HLA-identical sibling donor, 1351, 1352f
 in immunodeficiency disorders, 1354
 infectious complications of, 1361–1364
 in inherited bone marrow failure syndrome, 1353–1354
 in inherited metabolic diseases, 1354
 in JMML, 1353
 late effects of, 1365–1366, 1366t
 in myelodysplastic syndromes, 1353
 in NHL and Hodgkin disease, 1353
 for osteopetrosis, 4352
 for paroxysmal nocturnal hemoglobinuria, 2965
 principles and clinical indications of, 1351–1354
 for sickle cell disease, 1354, 2975
 for thalassemia, 1354, 1354f, 2985–2986
 umbilical cord blood transplants, 1355
 unrelated donor transplants, 1355
 Hematopoietic syndrome, 4418–4419
 Hematopoietic system, development of, 2921–2925
 fetal erythropoiesis, 2924–2925
 fetal granulocytopoiesis, 2921–2922
 fetal thrombopoiesis, 2922–2924
 hematopoiesis in the human embryo and fetus, 2921, 2922f–2923f
 red cell life span in the fetus and neonate, 2925
 Hematuria
 anatomic abnormalities associated with, 3213–3217
 autosomal dominant polycystic kidney disease, 3214–3217, 3215t–3216t, 3217f
 autosomal recessive polycystic kidney disease, 3213–3214, 3214f, 3215t–3216t
 congenital anomalies, 3213
 renal tumors, 3217
 trauma, 3217
 clinical evaluation of, 3184–3186, 3185t–3186t, 3186f
 confused with vaginal bleeding, 3327
 lower urinary tract causing, 3218
 medical child abuse and, 128
 multisystem disease associated with, 3196–3204
 chronic infections, 3196
 coagulopathies and thrombocytopenia, 3204
 cortical necrosis, 3204
 glomerulonephritis, associated with systemic lupus erythematosus, 3196–3198
 Goodpasture disease, 3199–3200, 3199f
 hemolytic-uremic syndrome, 3200–3203
 IgA vasculitis nephritis, 3198–3199
 toxic nephropathy, 3203–3204, 3203t
 tubulointerstitial disease associated with, 3205–3212
 vascular diseases associated with, 3211–3212
 Heme biosynthetic pathway, in porphyrias, 963–964
 Hemiconvulsion-hemiplegia-epilepsy syndrome, 3626
 Hemidesmosomes, of basal cells, 4025
 Hemifacial microsomia, 2245
 Hemihyperplasia, 3153
 Hemimegalencephaly, 3568, 3568f
 Hemin, for acute porphyria, 969
 Hemiplegia, 3690t
 of childhood, alternating, 3635
 Hemiplegic migraine, 3643–3644
 Hemispherectomy, in epilepsy surgery, 3615
 Hemochromatosis, neonatal, 2459–2460
 Hemodialysis
 in ESRD, 3253
 for poisoning, 709, 721
 Hemoglobin, 2966
 abnormal
 causing cyanosis, 2979
 with increased oxygen affinity, 2979
 adult, 2925
 alterations of, by disease, 2925
 C, 2978, 2978f
 D, 2978
 E, 2978
 embryonic, 2924
 fetal, 2924–2925, 2925f
 syndromes of hereditary persistence of, 2981–2987
 in fetus and neonate, 2924
 in iron-deficiency anemia, 2947t
 normal mean and lower limits of, 2926t
 reference intervals, 4472.e9t
 tetramers, changes in, 2925f
 values for non-Hispanic Whites and Blacks, 2926t
 Hemoglobin disorders, 2966
 unstable, 2978–2979
 Hemoglobin functions, 1116, 1117f
 Hemoglobinopathies, 1120–1122, 2966–2987
 abnormal hemoglobin
 causing cyanosis, 2979
 with increased oxygen affinity, 2979
 disorders of, 805t, 2966
 hemoglobin C, 2978
 hemoglobin D, 2978
 hemoglobin E, 2978
 hereditary methemoglobinemia, 2979
 with deficiency of NADH cytochrome b5 reductase, 2979–2980
 hereditary persistence of fetal hemoglobin, syndromes of, 2981–2987
 liver disease and, 2479–2480
 sickle cell disease, 2966–2977
 sickle cell trait, 2977
 thalassemia syndromes, 2981–2987
 Hemoglobinuria, 3184, 3218
 Hemolysis, 2952, 2952f, 2988–2989
- Hemolytic anemia, 1119–1120, 1122f, 2953, 2954t
 clinical and laboratory features of, 2955t
 definitions and classification of, 2952–2953, 2952f, 2955t
 etiology of, 2954t
 nonimmune, 2953t
 secondary to other extracellular factors, 2996–2997
 Wilson disease and, 2457–2458
 Hemolytic disease of newborn
 caused by ABO incompatibility, 1125, 1125t
 caused by Rh incompatibility, 1123–1125, 1124f
 other etiologies of, 1125
 Hemolytic states, 1108t
 Hemolytic-uremic syndrome (HUS), 2996, 3052–3053, 3055, 3200–3203
 clinical manifestations of, 3201–3202
 diagnosis and differential diagnosis of, 3202
 etiology of, 3200–3201, 3200f, 3201t
 pathogenesis of, 3201
 pathology of, 3201
 prognosis and treatment of, 3202–3203
 Hemophagocytic lymphohistiocytosis (HLH), 1538, 1288, 1301, 1325–1326, 1326f, 1476–1477, 2480, 3168, 3171t, 3174f, 3176f, 3178f, 3178t
 primary, 1325–1326
 secondary, 1326
 Hemophagocytic syndrome, infections associated with, 3173t
 Hemophilia A, 3029
 Hemophilia B, 3029
 Hemoptysis, 2215, 2257
 cystic fibrosis and, 2675
 pulmonary, 2698–2700
 respiratory signs and symptoms, 2531t
 in SLE, 1497t
 strongyloidiasis and, 2205
 Hemorrhage, 585f
 adrenal glands and, 3455, 3455f
 brain, due to untreated hypernatremia, 490
 diffuse alveolar, 2688, 2688t
 extracranial, 1056f
 in newborn, 1126–1127
 hemorrhagic disease, 1126–1127
 intracranial-intraventricular, 1058, 1060t
 neonatal traumatic head injuries, 1057–1058
 subconjunctival and retinal, 1057
 pulmonary, 2698–2700
 clinical manifestations of, 2699
 epidemiology of, 2699
 etiology of, 2698–2699, 2698t
 laboratory findings and diagnosis of, 2699–2700, 2699f
 pathophysiology of, 2699
 treatment of, 2700
 subgaleal, 1057
 from umbilical cord, 1131
 in yellow fever, 2072
 Hemorrhagic conjunctivitis, 1982
 Hemorrhagic corpus luteum, 3340
 Hemorrhagic cystitis
 in adenoviruses, 2034
 causing hematuria, 3218
 Hemorrhagic fever
 dengue, 2067–2071
 with renal syndrome, 2074–2076
 viral, 2073–2077, 4452t
 Hemorrhagic measles, 1961
 Hemorrhagic pulmonary edema, 1099
 Hemorrhagic stroke, 3749–3752, 3750f–3752f, 3751t–3752t
 Hemorrhoids, 2408f–2410f, 2409
 Hemosiderin-laden macrophages (HLMs), 2689, 2699–2700
 Hemosiderosis, pulmonary, 2688–2691
 clinical manifestations of, 2690
 epidemiology of, 2688–2689
 etiology of, 2688, 2688t
 laboratory findings and diagnosis of, 2690–2691
 pathology of, 2689
 pathophysiology of, 2689–2690
 prognosis for, 2691
 treatment of, 2691

- Hemostasis, 3023–3028
 clinical and laboratory evaluation of, 3024–3025
 clinical history, 3024–3025
 developmental, 3028, 3028t
 laboratory tests, 3025–3028, 3026f, 3027t
 pathology of, 3023
 physical examination, 3025, 3025t
 process of, 3023, 3024f
Hemothorax, 2708–2709, 2709f
 in multiple trauma, 571–573
Henderson-Hasselbalch equation, 510
Henoch-Schönlein purpura (HSP); see IgA vasculitis
HEOA. See Higher Education Opportunity Act
Heparan sulfate, degradation of, 938f
Hepatic abscess, 2317
Hepatic and gallbladder involvement, in sickle cell anemia, 2969
Hepatic angiosarcomas, 3164
Hepatic crisis, in tyrosinemia type I, 816
Hepatic disease, medications for, 229–230
Hepatic disorders, hypersplenism and, 3063t
Hepatic encephalopathy, 2494t, 2496
Hepatic fibrosis, autosomal recessive polycystic kidney disease and, 3213
Hepatic glycogen storage disorders, 989–990
Hepatic injury, in acetaminophen toxicity, 711
Hepatic lipase deficiency, 880
Hepatic malignancies, 3153
Hepatic methionine adenosyltransferase (MAT I/MAT III) deficiency, 823
Hepatic porphyrias, 964
Hepatic sickle cell crisis, 2479–2480
Hepatic tumors, causing isosexual precocious puberty, 3392
Hepatitis
 acute
 approach to, 2473
 of unknown etiology, 2473t, 2473
 antiviral therapy for, 1957
 autoimmune, 2487–2489
 acute hepatic failure and, 2494
 classification of, 2488t
 clinical manifestations of, 2487
 diagnosis of, 2488
 etiology of, 2487
 IBD-associated, 2476–2477
 laboratory findings in, 2487–2488
 pathology of, 2487
 prognosis of, 2489
 treatment of, 2489
 clinical approach to, 2473f
 issues common to all forms of, 2461
 common biochemical profiles in the acute infectious phase, 2461
 differential diagnosis, 2461, 2462t
 pathogenesis of, 2461
 transfusion-associated, 3021
Hepatitis A, 1586, 1623t–1625, 2461–2464
 clinical manifestations of, 2462–2463
 complications of, 2463
 diagnosis of, 2463
 epidemiology of, 2462
 etiology of, 2461
 immune globulin for preexposure and postexposure prophylaxis against, 2464t
 prevention of, 2463–2464
 immunoglobulin in, 2463–2464
 vaccine in, 2464
 prognosis of, 2464
 serologic course of, 2463f
 treatment of, 2463
 vaccine for, 1588t–1589t, 1602–1605
Hepatitis A-hepatitis B vaccine (HepA-HepB), 1588t–1589t
Hepatitis B, 1244, 2464–2469, 3081, 3196
 chronic, causes of hepatitis flares in, 2466t
 clinical manifestations of, 2465–2466
 complications of, 2466
 diagnosis of, 2466
 epidemiology of, 2464–2465
 etiology of, 2464
 genotypes of, 2465
Hepatitis B (Continued)
 in immigrant children, 80
 natural history of, 2466f
 pathogenesis of, 2465
 postexposure prophylaxis for, 2469
 prevention of, 2467–2469
 universal vaccination for, 2467–2469
 prognosis of, 2469
 serologic course of, 2466f
 special populations in, 2469
 transmission of, strategy to eliminate, 2467t
 treatment of, 2467
 strategies for, 2467
 typical course of, 2470f
 typical interpretation of test results for, 2465t
 vaccines for, 30–31t, 1588t–1589t, 1591, 1605
 recommended doses of, 2468t
 schedules for, 2469t, 2461t
Hepatitis B immunoglobulin (HBIG), 1586t, 2464
Hepatitis B surface antigen (HBsAg), 2464
Hepatitis C, 2469–2471, 3081, 3409
 clinical manifestations of, 2470
 complications of, 2471
 diagnosis of, 2470–2471
 epidemiology of, 2469–2470
 etiology of, 2469
 genotype of, 2470
 laboratory screening, 1241t
 natural history of, 2470f
 pathogenesis of, 2470
 prevalence in porphyria cutanea tarda, 973
 prevention of, 2471
 prognosis of, 2471
 screening for, 2470
 screening for, in adolescents, 1170
 treatment of, 2471
 newer, 2472t, 2471
Hepatitis D, 2471–2472
 clinical manifestations of, 2472
 diagnosis of, 2472
 epidemiology of, 2471
 etiology of, 2471
 pathogenesis of, 2471
 prevention of, 2472
 treatment of, 2472
Hepatitis E, 2472–2473
 clinical manifestations of, 2473
 diagnosis of, 2473
 epidemiology of, 2472
 etiology of, 2472
 pathogenesis of, 2472
 prevention of, 2473
Hepatobiliary disease, in cystic fibrosis, 2677
Hepatoblastoma, 3153t, 3154f
 isosexual precocious puberty and, 3392
Hepatocellular carcinoma, 3081, 3155, 3155f
Hepatocellular damage, 1108t
Hepatocyte injury, 2450–2452
Hepatocytes, 2435
 ultrastructure of, 2435, 2435f
Hepatoerythropoietic porphyria, 975, 4094
Hepatomegaly, 806–807, 2438
 inborn errors of metabolism and, 809t–810t
 mechanisms of, 2439t
Hepatopathies, mitochondrial, 2483–2486
Hepatoperoenterostomy (Kasai) procedure, 2447f
Hepatopulmonary syndrome (HPS), 2442, 2505
Hepatorenal syndrome, 2440–2442
Hepatorenal tyrosinemia, 816
Hepatosplenomegaly, 1813–1814, 1813f
 inborn errors of metabolism and, 809t–810t
 in Langerhans cell histiocytosis, 3169
Hepatotropic viruses, features of, 2461t
Hepcidin, 2351
 in iron-deficiency anemia, 2947t
Heptavalent botulinum antitoxin, 1586t, 1587
Herald patch, 4104, 4104f
Herbal dietary supplement (HDS), 57t
Herbal remedies
 hepatotoxic, 2492t
 poisoning, 717t, 721, 723t
Herbal teas, 157
Herbalife, 2492t
Herbicides, 4425
Herbivore bites, 4458t
Hereditary amyloidoses, 1536
Hereditary angioedema (HAE), 1318, 1320–1321, 1428, 1432–1434, 1432f, 1433t–1434t
 with C1-INH deficiency, treatment of, 1323, 1323t
Hereditary autoinflammatory diseases, 1536
Hereditary chin trembling, 3637
Hereditary clotting factor deficiencies (bleeding disorders), 3029–3034
 antiplasmin or plasminogen activator inhibitor deficiency, 3034
 combined deficiency of factors V and VIII, 3034
 congenital fibrinogen disorders, 3034
 deficiencies of contact factors, 3033
 factor V deficiency, 3034
 factor VII deficiency, 3033
 factor VIII or factor IX deficiency, 3029–3033, 3030f, 3031
 factor X deficiency, 3033
 factor XI deficiency, 3033
 factor XIII deficiency, 3034
 prothrombin (factor II) deficiency, 3033
Hereditary conditions
 coproporphyria, 975–976
 tyrosinemia, 816
Hereditary disorders, 2645t
Hereditary elliptocytosis, 2950, 2960–2961, 2960t
Hereditary folate malabsorption (HFM), 464, 2350, 2941
Hereditary fructose intolerance (HFI), 900t–901t, 912–913, 2451
 chronic diarrhea and, 2378
Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease), 4059–4060, 4059f–4060f
Hereditary hydrocytosis, 2963
Hereditary hypophosphatemic rickets with hypercalcemia (HHRH), 473t, 478
Hereditary intrinsic factor deficiency (HIFD), 466, 2943
Hereditary methemoglobinemia, 2979, 2980f, 2980t
 with deficiency of NADH cytochrome b5 reductase, 2979–2980
Hereditary motor-sensory neuropathies (HMSNs), 3876–3892
 congenital hereditary sensory pain syndromes, 3889–3892
 congenital hypomyelinating neuropathy and Déjérine-Sottas disease, 3886
 Fabry disease, 3886–3887
 giant axonal neuropathy, 3887
 hypermyelinating neuropathy, 3887–3889
 leukodystrophies, 3889
 peroneal muscular atrophy, 3876–3886
 axonal type, 3886
 Charcot-Marie-Tooth disease, 3876–3886, 3877t–3879t
 Refsum disease and infantile Refsum disease, 3886
 Roussy-Lévy syndrome, 3886
Hereditary nonpolyposis colon cancer (HNPCC), 3165
Hereditary otic aciduria, 945t, 953
Hereditary periodic fever syndromes, 1518–1529
 autosomal recessive inheritance, 1518
 CAPS, 1522–1523
 familial Mediterranean fever, 1520–1521, 1525t
 HIDS, 1521, 1525f
 TRAPS, 1522, 1526t
Hereditary persistence of fetal hemoglobin (HPFH), 2925
 syndromes of, 2981–2987
Hereditary persistence of HbF (HPFH), 2980
Hereditary pyropoikilocytosis (HPP), 2950, 2960–2961
Hereditary retinoblastoma, 3149
 osteosarcoma in, 3141
Hereditary sensory autonomic neuropathy (HSAN), 3896, 3898t–3899t
Hereditary sensory autonomic neuropathy 1 (HSAN1), 3886
Hereditary sensory-motor neuropathies (HSMNs), 3874
Hereditary spastic paraplegias (HSPs), 3874
Hereditary spherocytosis (HS), 2955–2959
 clinical manifestations of, 2955, 2956f, 2958t, 2959f
 diagnosis of, 2956–2957, 2959f
 differential diagnosis of, 2957

- Hereditary spherocytosis (HS) (*Continued*)
 etiology of, 2955, 2956f–2957f, 2956t
 gene variants in, 2956t
 treatment of, 2957–2959
 general supportive care, 2957
 guidelines for splenectomy, 2957–2959
- Hereditary stomatocytosis syndromes, 2961–2963, 2962t, 2963f
- Hereditary thrombotic disorders, DIC caused by, 3048t
- Hereditary xanthinurias, 945t, 948–949
- Hereditary xerocytosis, 2961–2963, 2963f
- Heritability, 800f
 high degree of, 300
- Heritable arrhythmia syndrome susceptibility genes, 2855t–2857t
- Heritable arrhythmias, 2770
- Herlyn-Werner-Wunderlich syndrome, 3352
- Hermansky-Pudlak syndrome, 819, 3059–3060, 3059t, 4071, 4073t
 type II, 1309t
- Hernia
 Bochdalek, 1094, 1094f
 congenital diaphragmatic, 1094–1096
 diaphragmatic, 1053t, 1094–1096, 1094f
 epigastric, 2512
 foramen of Morgagni, 1096
 incarcerated, 2417–2418
 incisional, 2512
 lung, 2603
 paraesophageal, 1096
 predisposing factors for, 2416t
 recurrent, 2420–2421
 strangulated, 2417–2418
 umbilical, 1131
- Herniation
 cerebral, 581, 582f
 intervertebral disk, 4256–4257, 4257f
- Heroin addiction, in adolescents, 1207
- Her pangina, 1981
- Herpes gladiatorium, wrestling associated with, 4331
- Herpes labialis, 1993, 1997
- Herpes simplex virus (HSV), 1991–1998, 1994f, 4149
 in acute oropharyngeal infections, 1993, 1993f
 antiviral therapies for, 1953t–1954t
 central nervous system infections, 1995
 treatment of, 1998
 clinical manifestations of, 1993–1995
 cutaneous infections, 1993–1994, 1994f
 diagnosis of, 1996
 encephalitis, 1255
 encephalitis, predominant, 1338–1339, 1339t, 1340f
 epidemiology of, 1992
 etiology of, 1992
 of external ear, 4002
 in fever without a focus, 1645–1646
 in genital herpes, 1994
 treatment of, 1997
 in herpes labialis, 1993, 1996
 immunocompromised persons, infections in, 1995
 treatment of, 1998
 initial lesion, 1243, 1244f
 involvement in acute facial palsy, 3907f
 laboratory findings of, 1996, 1997f
 management guidelines, 1249t–1250t
 neonatal infection with, 1149
 nonprimary infection, 1991–1992
 ocular infections, 1994–1995
 treatment of, 1997
 pathogenesis of, 1992–1993
 perinatal infections, 1995, 1995f–1996f
 treatment of, 1998
 prevention of, 1998
 primary infection, 1991–1992
 prognosis for, 1998
 serologic assays, 1246
 in sporadic encephalitis, 3772
 treatment of, 1996–1998
 vulvar, 3321t–3322t
- Herpes simplex virus (HSV)-2, prevalence rates, 1240
- Herpes whitlow, 1994, 1994f, 1997
- Herpes zoster, 2002–2003, 2003f
 treatment of, 2004
 vaccine, 1588t–1589t
- Herpesviruses
 antiviral therapies for, 1950–1955
 acyclovir, 1950–1954
 cidofovir, 1955
 fomivirsen, 1955
 foscarnet, 1955
 ganciclovir and valganciclovir, 1954–1955
 letermovir, 1955
 maribavir, 1955
 penciclovir and famciclovir, 1954
 trifluridine, 1955
 valacyclovir, 1954
 vidarabine, 1955
 human herpesvirus 6 and 7, 2016–2018
 human herpesvirus 8, 2019
- Herpetic gingivostomatitis, 1993, 1993f, 2252–2253, 2253f
- Herring lateral pillar classification, 4238, 4239f
- Hers disease, 900t–901t, 904–905
- HESX1, 3364
- Heterochromia, 3924
- Heterodisomy, uniparental, 773
- Heterogeneity, epigenetic, 748f
- Heterophile antibodies detection, Epstein-Barr virus (EBV), 2008
- Heterophoria, 3925
- Heterophyes heterophyes*, 2215
- Heteroplasmy, 934
- Heterotaxy, primary ciliary dyskinesia and, 2681
- Heterotaxy syndrome, 2823f
 cardiosplenic, 2824t
 ciliopathies with, 2825t–2826t
- Heterotetrameric hemoglobin, 1116
- Heterotropia, 3925
- Heterozygous familial hypercholesterolemia, 876, 877t–878t
- Heuristics, 45–46
- Hexane, inhaled, 1203t
- Hexokinase, in glycolytic pathway, 2989–2990
- Hexose monophosphate pathway, enzymes of, 2988f, 2990
- H-ficolin deficiency, 1320
- HFNC. *See* High-flow nasal cannula
- HVF. *See* High-frequency ventilation
- HGA. *See* Human granulocytic anaplasmosis
- HHRH. *See* Hereditary hypophosphatemic rickets with hypercalcemia
- HHT-juvenile polyposis syndrome, 4059
- HHV-8. *See* Human herpesvirus 8
- Hiatal hernia, 2263, 2263f
- Hib conjugate vaccine (Hib), 1588t–1589t, 1602, 1605
- Hib vaccine, 1756t, 1757
- Hiccups, 3635
- HICT. *See* Health information and communications technology
- Hidden penis, 3298, 3299f
- Hidradenitis suppurativa, 4135–4136, 4136f
- Hidrotic ectodermal dysplasia, 4048–4050t, 4049t–4050t
- HIE. *See* Hypoxic-ischemic encephalopathy
- High ankle sprains, basketball and, 4328
- High myopia, in megalocornea, 3943
- High-altitude cerebral edema (HACE), 631, 633–634
- High-altitude headache, 631
- High-altitude pulmonary edema (HAPE), 634–635, 635f, 2605
 complications of, 635
 diagnosis of, 634–635
 differential diagnosis of, 635
 epidemiology and risk factors of, 634, 634t
 management of, 635
 physiology of, 634
 reentry, 635–636
- High-density lipoproteins
 familial deficiency of, 2963
 metabolism, disorders of, 880
 and reverse cholesterol transport, 874
- High-dose insulin euglycemia therapy, 713–714
- Higher Education Opportunity Act (HEOA), 361
- High-fidelity simulation, 43
- High-flow nasal cannula (HFNC)
 for apnea, 1076
 for bronchiolitis, 2030
 for RDS, 1080
 for respiratory distress and failure, 619
- High-frequency jet ventilation (HFJV), 627
- High-frequency oscillation (HFO), 627
- High-frequency ventilation (HFV), 626–627
 for RDS, 1081
- High-grade squamous intraepithelial lesions (HSILs), 2053
- High-quality childcare, 183
- High-reliability organizations, 44
- High-risk groups, for tuberculosis infection, 1838t
- High-risk infant, 1038–1050, 1038f
 extremely and very preterm infants, 1042–1046
 large-for-gestational-age, 1048–1049
 in multiple-gestation pregnancies, 1038–1042
 postterm infants, 1049
- High-risk pregnancy, 1010–1014, 1010f
 conditions associated with disorders of amniotic fluid volume, 1014t
 labor and delivery, 1014
 maternal factors, 1010t
 oligohydramnios, 1012
 polyhydramnios, 1012
 prenatal care, 1010–1012, 1013t
 selected factors associated with, 1010t
- High-voltage electrical burn, 654–655
- Higoumenakis sign, 1869t
- Hikojima strains, *Vibrio cholerae*, 1785
- Hilar lymphadenopathy, 3070t
- Hilgenreiner's line, 4234
- Hill-Sachs lesion, 4301
- Hindfoot, 4201
- Hindgut, 2276
- Hindsight bias, 43, 48t
- Hinman syndrome, 3272–3273, 3293
- Hip, 4231–4241
 development, meningomyelocele and, 4401
 disease, in systemic JIA, 1477f
 growth and development of, 4231
 musculoskeletal pain syndrome, 1568t
 sports-related injuries, 4307–4308
 vascular supply, 4231
- Hip click, for DDH testing, 4233
- Hip clunk, for DDH testing, 4233
- Hip dislocation, 4232
- Hip fractures, 4281–4282
- Hip pointer, 4329
- Hip subluxation, 4232
- HIPAA Privacy Rule, 1168
- Hirschberg corneal reflex test, 3925
- Hirschsprung disease, 2276–2277, 2284, 2295–2298, 2719, 3899t
 clinical manifestations of, 2293t, 2295–2296, 2295t, 2296f–2297f, 2298t
 diagnosis of, 2296–2297, 2296f
 medullary thyroid carcinoma and, 3164
 pathology of, 2295
 treatment for, 2297–2298
- Hirsutism, 3334–3338, 3338t, 4137
- Histamine, 1378
 scombrotoxic, 4411t–4413t
- Histamine 2 receptor antagonists, for GERD, 2264
- Histidine decarboxylase deficiency, 847
- Histiocytic disorders, 2254
 liver disease and, 2480
- Histiocytic necrotizing lymphadenitis, 3070
- Histiocytosis
 Langerhans cell, 3169–3172, 3175f–3176f
 treatment and prognosis of, 3172–3173, 3172f
 sinus, with massive lymphadenopathy, 3070–3071, 3179
- Histiocytosis syndromes, of childhood, 3168–3179, 3169t–3171t
 classification and pathology of, 3168–3169, 3170t–3171t, 3172f, 3173t, 3174f, 3176f
 hemophagocytic lymphohistiocytosis and, 3171t, 3174f, 3176–3179, 3178f, 3178t
 clinical manifestations of, 3176–3177, 3176f–3178f, 3178t
 treatment and prognosis of, 3171t, 3177–3179
 other, 3179
- Histocompatibility testing, 729
- Histologic subtypes
 of Hodgkin lymphoma, 3107f
 of non-Hodgkin lymphoma, 3111f

- Histology, terminology for reporting, 2054t
Histoplasmosis (*Histoplasma capsulatum*), 1655t–1656t, 1931–1934
 clinical manifestations of, 1932–1933
 diagnosis of, 1933
 epidemiology of, 1931–1932
 etiology of, 1931
 pathogenesis of, 1932
 progressive disseminated, 1932–1934
 pulmonary
 acute, 1932–1933, 1932f
 chronic, 1933
 treatment of, 1933–1934
- History**
 cardiovascular system, 2737
 family, and pedigree notation, 735
 focused peripartum, 999–1000
 for gynecologic problems, 3317
 in neurologic evaluation, 3550, 3551t
 past medical, and high-risk infant, 1038t
 of psychiatric treatment, 221
 in respiratory disease, 2513
HIV. See Human immunodeficiency virus
HIV-associated nephropathy, 3196
Hive, 1428
HIV-exposed infant, feeding of, for HIV prevention, 2115–2116, 2116t
HIV-infected children, routine childhood immunization schedule for, 2110t
HIV-seronegative host, nontuberculous mycobacteria infection and, 1861t
HIV-seropositive host, nontuberculous mycobacteria infection and, 1861t
HLA. See Human leukocyte antigen
HLH. See Hemophagocytic lymphohistiocytosis
HLMs. See Hemosiderin-laden macrophages
HME. See Human monocytic ehrlichiosis
HMG-CoA reductase inhibitors, 882–883
HMS. See Hyperreactive malarial splenomegaly
HMSNs. See Hereditary motor-sensory neuropathies
HNPCC. See Hereditary nonpolyposis colon cancer
Hodgkin lymphoma (HL), 2344, 3106–3109
 chemotherapy regimens for, 3109t
 clinical manifestations of, 3106
 diagnosis of, 3106–3107, 3107f–3108f, 3107t–3108t
 epidemiology of, 3106
 Epstein-Barr virus (EBV) and, 2009
 HSCT for, 1353
 Lugano classification for, 3107, 3107t
 pathogenesis of, 3106, 3107f, 3107t
 prognosis of, 3109, 3110t
 relapse of, 3109
 treatment for, 3086, 3108–3109, 3109t–3110t
Hoffa syndrome, 4310
HOLC. See Homeowners Loan Corporation
Holmes tremor, 3678
Holocarboxylase synthetase deficiency, 828
Holoprosencephaly, 780t, 783f, 785, 789, 3364, 3569–3570, 3573f
Holosystolic murmurs, 2743
Holt-Oram syndrome, 2764t–2766t
Home, monitoring in, in CCHS, 2722–2723
Home care, 61
Home visits, for newborn, 151
Homeowners Loan Corporation (HOLC), 8
Home-visiting programs, 144
Homicide
 death rates, 91, 92t, 93f
 firearm injuries, 98
 firearm-related, 1189f
Homocystinuria (homocystinemia), 3383, 3384t, 4367–4368, 4367t
 associated with thrombosis, 3038–3039
 caused by cystathionine β -synthase deficiency, 820–821
 caused by defects in methylcobalamin formation, 821–822
 caused by deficiency of methylenetetrahydrofolate reductase, 822–823
 methylmalonic aciduria combined with, 836–837
Homosexuality, prevalence in youth, 1182, 1183f
Homozygous achondroplasia, 4347
- Homozygous β -thalassemia**, 2981–2986
 chelation therapy, 2983–2984
 clinical manifestations of, 2981
 hematopoietic stem cell transplantation, 2985–2986
 hydroxyurea, 2985–2986
 iron overload monitoring, 2983
 laboratory findings of, 2981–2982
 management and treatment of, 2982–2986
 splenectomy, 2986
Homozygous familial hypercholesterolemia, 874–876, 875f
Homozygous hypobetalipoproteinemia, 2340
Hooded foreskin, 3297f
Hookah, 1200
Hookworms, 2200–2202
 clinical manifestations of, 2201
 diagnosis of, 2201–2202, 2201f
 drugs for, 2126t–2144t
 epidemiology of, 2200–2201
 etiology of, 2200–2202, 2201f
 pathogenesis of, 2201
 prevention of, 2202
 treatment of, 2202
Hordeolum, 3936
Horizontal suspension, 3554–3555
Hormonal contraceptives, 1218t–1219t
 combined, 1221t, 1222–1225
 polycystic ovary syndrome and, 3337
Hormone replacement therapy, 447
Hormone synthesis, disorders in, 3482t–3484t
Hormone therapy, gender-affirming, 1178–1181
 criteria for, 1173t
 effects from, 1179t
 goals of, 1178
 monitoring protocol in, 1180
 options for, 1178, 1178t
 potential adverse effects of, 1179
 screening recommendations for, 1180t, 1181
 surgical therapy in, 1180
 treatment criteria and timing of, 1178
Hormones
 gonadal, effect of total body irradiation, 1365
 of hypothalamus and pituitary gland, 3359–3363
 thyroid defects in, transport, 3403–3404
 thyroid studies of, 3401
Horner syndrome, 3126t, 3923–3924, 3923f, 3924t, 4397
 neuroblastoma and, 3128
Horseshoe kidney, 3263f
Hospice care, 71
Hospital, referring, responsibilities of, 542
Hospital-based care, in developing world, 546–547
Hospitalization
 for children with pneumonia, 2646t
 separation because of, 196
Host defense, complement system in, 1317–1318
Host factors, meningococcus, 1739
Hot tub folliculitis, 4156, 4157f
Household contacts, of patients with pertussis, 1763–1764
Household products, poisoning, 719–721
 caustics, 719
 hydrocarbons, 720
 pesticides, 719–720
 toxic alcohols, 720–721
Housing Act of 1949, 8–9
Housing projects, 8–9
Howell-Jolly bodies, 3061
 detection of, 3064t
Hoyeraal-Hreidarsson syndrome, 1288, 3007
HPP. See Hereditary pyropoikilocytosis
HPRT1-associated deficiency, 945t, 949–950, 951f
HPV. See Human papillomavirus
HRCT bronchiectasis, 2658
HRQoL. See Health-related quality of life
HRV-associated wheezing, 2036
HSCT. See Hematopoietic stem cell transplantation
HSD11B1 isozyme, 3460
HSMNs. See Hereditary sensory-motor neuropathies
HSP. See Henoch-Schönlein purpura
HSV. See Herpes simplex virus
Hughes-Stovin syndrome, 1515–1516
Human African trypanosomiasis (HAT), 2161
- Human bite**, 4457
Human bocaviruses
 clinical manifestations of, 1990
 complications of, 1991
 diagnosis of, 1990
 differential diagnosis of, 1991
 epidemiology of, 1987
 pathogenesis of, 1988
 prevention, 1991
 treatment of, 1991
Human botulism (IV), 1586t
Human chorionic gonadotropin (hCG), 1228–1229
Human factors engineering, 44
Human genetics, 730–734
 genetic variation, 730–733
 genotype-phenotype correlations in genetic disease, 733–734
 molecular genetics, 730
Human genome, 730
Human Genome Project, 734
Human granulocytic anaplasmosis (HGA), 1911
Human granulocytic ehrlichiosis, 1900t–1902t
Human growth hormone, as performance-enhancing aids, 4325t–4326t
Human herpesvirus 6 and 7 (roseola), 2016–2018
Human herpesvirus 8, 2019
 Kaposi carcinoma and, 3080–3081
Human immunodeficiency virus (HIV) infection, 1244, 2087–2117, 2087f
 antibody tests for, 4472.e4, 4472.e4t
Candida infections in immunocompromised patient, 1923–1924
 clinical manifestations of, 2092–2096, 2092t–2093t
 cardiovascular system, 2095
 central nervous system, 2094
 gastrointestinal and hepatobiliary tract, 2095
 hematologic and malignant diseases, 2095–2096
 infections, 2092–2094
 renal disease, 2095
 respiratory tract, 2094–2095
 skin manifestations, 2095
 diagnosis and testing of, 2096–2097, 2096f
 epidemiology of, 2089–2090
 etiology of, 2087–2089, 2088f
 laboratory screening, 1241t
 neuropathy and, 3895
 pathogenesis of, 2090–2092
 pattern of disease in, 2091
 prevalence in porphyria cutanea tarda, 973
 prevention of, 2113–2117
 prognosis of, 2113
 screening for, in adolescents, 1170
 sexual assault and, 1238f
 transmission of, 2089–2090
 treatment of, 2097–2113
 adherence, 2107–2108
 antiretroviral therapy, 2108
 combination therapy, 2097–2107, 2098t–2107t
 dosages, 2108
 initiation of therapy, 2108
 supportive care, 2109–2113, 2110t–2113t
 tuberculosis disease in children living with, 1846
 type 2, 2089
 visceral leishmaniasis, 2159
Human leukocyte antigen (HLA)
 in celiac disease, 2327
 class I, in T1DM, 3519
 compatible sibling donor for HSCT, 1351, 1352f
 Graves disease and, 3417
 haploidentical donor for HSCT, 1356
HLA-B27
 in reactive arthritis, 1488
 in spondyloarthritides, 1483
 unrelated matched donor for HSCT, 1355
Human metapneumovirus, 2032–2033
 clinical manifestations of, 2032, 2033t
 complications of, 2033
 diagnosis of, 2033
 differential diagnosis of, 2033
 epidemiology of, 2032, 2033f
 etiology of, 2032
 laboratory findings of, 2032–2033
 pathogenesis of, 2032

- Human metapneumovirus (*Continued*)
 pathology of, 2032
 prevention of, 2033
 prognosis for, 2033
 supportive care in, 2033
 treatment of, 2033
- Human milk
 beneficial properties of, 409t
 infectious agents detected in, 1009t
 for premature infants, 1044
 protective effect of, 410t
- Human monocytic ehrlichiosis (HME), 1900t–1902t, 1911
- Human papillomavirus (HPV), 1240, 1244, 2053–2057, 3081, 3345–3346
 clinical manifestations of, 2055
 complications of, 2056–2057
 diagnosis of, 2055–2056
 differential diagnosis of, 2056
 epidemiology of, 2053–2054, 2054t
 etiology of, 2053
 genital warts, 2055, 2055f
 laryngeal papillomatosis, 2055
 management guidelines, 1249t–1250t
 pathogenesis of, 2054–2055
 prevention, 2057
 prognosis for, 2057
 screening for, 3347
 skin lesions, 2055, 2055f
 squamous intraepithelial lesions and cancers, 2055
 susceptibility, predominant, 1337–1339
 treatment of, 2056
 vaccine, 30–31t
- Human papillomavirus vaccine 9-valent (9vHPV), 1588t–1589t, 1604
- Human parechoviruses, 1985
- Human T-cell lymphotropic virus-2, 2118
- Human tetanus immunoglobulin (TIG), for tetanus, 1823
- Human T-leukemia viruses (1 and 2), 2117–2118
 clinical manifestations of, 2117
 diagnosis of, 2117
 epidemiology of, 2117
 etiology of, 2117
 modes of transmission of, 2117
 prevention of, 2118
- Human trafficking, 106–107
- Humanitarian disasters, 547
- Humeral fractures
 distal, 4280, 4281f
 proximal, 4280–4281
- Hungry bone syndrome, 504, 507
- Hunter syndrome, 939–940, 940t
- Huntington disease, 742, 745t–746t, 3674
- Hurler disease, 938–939, 939f
- Hurler-Scheie disease, 939, 939f, 940t
- HUS. *See* Hemolytic-uremic syndrome
- Hutchinson syndrome, 3126t
- Hutchinson triad, 1869t
- Hutchinson-Gilford progeria syndrome, 956–962, 962t
 appearance, 961f
 clinical manifestations, 956–959, 957f–958f
 diagnosis and differential diagnosis, 960–961
 laboratory findings, 959
 molecular pathogenesis, 959–960
 treatment of, 961
- HYAL1* variants, 942
- Hyaline membrane disease, 1077–1083, 1079f
- Hyalinosis cutis et mucosae, 4122–4123
- Hyalohyphomycosis, 1948–1949
- Hyaloid vascular system, 3909
- Hyaluronidase deficiency, 940t
- Hybridization, array comparative genomic (aCGH), 733f
- Hydatid disease. *See* Echinococcosis
- Hydatidosis. *See* Echinococcosis
- Hydralazine
 for heart failure, 2898t
 for severe hypertension in children, 2919t
- Hydranencephaly, 3581, 3581f
- Hydration
 for acute gastroenteritis, 2370t–2371t, 2371
 cutaneous, for atopic dermatitis, 1412–1413
 in pediatric palliative care, 70
- Hydroa vacciniforme, 4095–4096
- Hydrocalycosis, 3279
- Hydrocarbon aspiration, 2606–2607, 2607f, 2607t
- Hydroceles, 3308, 3308f
 diagnosis of, 3308
 etiology of, 3308
 hernia and, 2416, 2416f
 treatment of, 3308
- Hydrocephalus, 3577–3582
 in bacterial meningitis, 3761
 causes of, 3578t
 with Chiari II malformation, 3562
 clinical manifestations of, 3579–3580
 in congenital toxoplasmosis, 2191–2192
 diagnosis and differential diagnosis of, 3580, 3580f
 genetic abnormalities associated with, 3579t
 hydranencephaly in, 3581, 3581f
 language disorders and, 330
 meningocele and, 4400
 pathophysiology and etiology of, 3579, 3579f
 physiology of, 3577–3579
 porencephaly in, 3581, 3581f
 posthemorrhagic, 1060
 prognosis for, 3582
 treatment of, 3582
- Hydrocodone, 713t
 in pain management, 683t
- Hydrocortisone, in newborn, 1055f
- Hydrogel, for toxic epidermal necrolysis, 4080
- Hydrogen ions
 cardiac arrest and, 567t
 secretion of, in collecting duct, 512f
- Hydrometrocolpos, with polydactyly, 3351
- Hydromorphone
 equianalgesic doses of, 685t
 in hepatic and renal dysfunction, 685t
 in pain management, 683t
- Hydronephrosis, 3275
 antenatal, 3275, 3276t
- Hydropneumothorax, loculated, 2657f
- Hydrops, acute, 2502
- Hydrops fetalis, 1123, 1124f, 1128f, 2987, 4094
 inborn errors of metabolism associated with, 809t
- Hydrothorax, 2708
- Hydroxocobalamin, 707t–708t, 724
 for cyanide poisoning, 4453
- 3-Hydroxy-3-methylglutaryl aciduria, 832
- 3-Hydroxy-3-methylglutaryl CoA synthase deficiency, mitochondrial, 831–832
- Hydroxyapatite, 470
- β -Hydroxy- β -methylglutaryl-CoA lyase deficiency, 865
- β -Hydroxy- β -methylglutaryl-CoA synthase deficiency, 865
- β -Hydroxybutyric aciduria, 847
- Hydroxychloroquine
 low-dose, for porphyria cutanea tarda, 975
 for rheumatic diseases, 1466t–1468t
- Hydroxycut, 2492t
- 11 β -Hydroxylase deficiency, 500
 congenital adrenal hyperplasia caused by, 3464t–3465t, 3468
- 17-Hydroxylase deficiency, 3510–3511
 congenital adrenal hyperplasia caused by, 3469
- 17 α -Hydroxylase deficiency, congenital adrenal hyperplasia caused by, 3464t–3465t
- 21-Hydroxylase deficiency, congenital adrenal hyperplasia by, 3462–3468, 3464t–3465t
 diagnosis of, 3508t
 differential diagnosis of, 3466
 epidemiology of, 3463
 genetics in, 3463
 genotype-phenotype correlations in, 3465t
 laboratory findings in, 3466
 newborn screening for, 3466–3467
 pathogenesis and clinical manifestations of, 3463–3466
 adrenomedullary dysfunction, 3466
 aldosterone and cortisol deficiency, 3463
 postnatal androgen excess, 3466
 prenatal androgen excess, 3463–3466
 prenatal diagnosis of, 3466
 treatment of, 3467–3468
- 21-Hydroxylase deficiency, congenital adrenal hyperplasia by (*Continued*)
 ambiguous genitalia, surgical management of, 3467–3468
 glucocorticoid replacement, 3467
 mineralocorticoid replacement, 3467
 prenatal, 3468
- Hydroxymethylbilane (HMB), 966
- 4-Hydroxyphenylpyruvate dioxygenase, primary deficiency of, 817
- 17 β -hydroxyprogesterone, 3466
- 17 β -hydroxysteroid dehydrogenase, 3511
- 3 β -Hydroxysteroid dehydrogenase deficiency, 3510
 congenital adrenal hyperplasia caused by, 3464t–3465t, 3468–3469
- 11 β -hydroxysteroid dehydrogenase isozyme, 3460
- Hydroxyurea
 for sickle cell disease, 2974–2976
 for thalassemia, 2985
- Hydroxyzine (Vistaril), for depression and anxiety, 227t
- Hygiene hypothesis, 1367
 in T1DM, 3519
- Hymen
 abnormalities of, 3352–3353
 types of, 124f, 3318f
- Hymenal membrane characteristics, 125f
- Hymenolepisis, 2217–2218
- Hymenolepis nana*, 2217–2218
- Hymenoptera, 1419, 1419f
 stings, 4471–4472
- Hyperacute bacterial conjunctivitis, 3940–3941, 3940t
- Hyperacute rejection, in renal transplantation, 3257
- Hyperadrenergic POTS, 598
- Hyperaldosteronism, 3846
- Hyperammonemia, 848–854
 acute, treatment of, 850–851, 850t
 clinical manifestations of, 848–849
 diagnosis, 849–850
 differential diagnosis of, 807t
 inborn errors of metabolism and, 809t–810t, 850t
 symptomatic, 852f
- Hyperamylasemia, differential diagnosis of, 2428t
- Hyperandrogenism, 3394
- Hyperargininemia, 853–854
- Hyperbaric oxygen (HBO), 724
- Hyperbilirubinemia, 2278
 clinical manifestations of, 1111, 1111t
 conjugated, 2438
 familial nonhemolytic unconjugated, 2454–2456
 incidence and prognosis of, 1111
 inherited conjugated, 2456
 in newborn, 1106–1115
 nomogram for risk assessment of, 4472.e8t
 pathologic, 1110
 prevention of, 1111–1112, 1112f–1113f
 treatment of, 1112–1115, 1114f–1115f, 1114t
 exchange transfusion, 1115, 1116f
 intravenous immunoglobulin, 1115
 phototherapy, 1114–1115
 unconjugated, 2438, 2440t
- Hyperbradykinism, 3899t
- Hypercalcemia, 3092t–3093t, 4131
 causes of, 3442t, 3443f
 Jansen metaphyseal dysplasia, 4347
 miscellaneous causes of, 3442–3443
 in vitamin D intoxication, 480
- Hypercalciuria, 3235–3236, 3313–3314
 hereditary hypophosphatemic rickets with, 473t, 478
 idiopathic, 3212
 renal, 3312
 therapy for urolithiasis caused by, 3315t
 in vitamin D intoxication, 480
- Hypercapnia, permissive, 1081
- Hypercholesterolemia, 875t
 familial, 874
 with hypertriglyceridemia, 877–879
 polygenic, 876–877
- Hypercoagulability, due to nephrotic syndrome, 3225
- Hypercyanotic attacks, paroxysmal, 2801
- Hyperdynamic precordium, 2740
- Hyperechoic rhabdomyoma, 3658f
- Hyperekplexia, 3635

- Hypereosinophilic syndrome, 1294–1295, 1296f, 2630–2632, 2630t, 2631f
- Hyperferritinemia, 605, 606t
- Hyperfiltration injury, 3248
- Hyperglycemia, 487
- cystic fibrosis and, 2677
 - fetal, 1140f
 - in refeeding syndrome, 432t
 - in T1DM, treatment of, 3524–3527
 - in toxicologic diagnosis, 705t
- Hyperglycinemia, 837
- nonketotic
 - infantile, 837–838
 - late-onset, 838
 - neonatal, 837
 - transient, 837
- Hypergonadotropic hypogonadism
- female, 3496–3501
 - etiology of, 3497t
 - Noonan syndrome in, 3500
 - other ovarian defects in, 3500–3501
 - Turner syndrome in, 3496–3499
 - clinical manifestations of, 3496–3498, 3497f
 - laboratory findings of, 3498
 - pathogenesis of, 3496
 - treatment of, 3498–3499
 - 45,X/46,XY gonadal dysgenesis in, 3499–3500, 3500f
 - XX gonadal dysgenesis in, 3499
 - XXX females in, 3500
 - XXXX females in, 3500
 - XXXXX females in, 3500
 - male, 3487–3491
 - clinical manifestations of, 3489
 - diagnosis of, 3489
 - etiology of, 3488t, 3497t
 - Klinefelter syndrome in, 3489–3491
 - Noonan syndrome in, 3489, 3500
 - other ovarian defects in, 3500–3501
 - Turner syndrome in, 3496–3499
 - 45,X males in, 3491
 - 45,X/46,XY gonadal dysgenesis in, 3499–3500, 3500f
 - XX gonadal dysgenesis in, 3499
 - XX males in, 3491
 - XXX females in, 3500
 - 47,XXX males, 3491
 - XXXX females in, 3500
 - XXXXX females in, 3500
- Hyperhidrosis, 4134, 4135t
- Hyper-IgD syndrome (HIDS), 1536–1537
- Hyper-IgE syndromes
- autosomal dominant, 1271t, 1276
 - autosomal recessive, 1297t–1298t
- Hyper-IgM syndrome, 1309t, 1660
- Hyper-IgM/CD40LG deficiency, 1345
- Hyperimmunoglobulinemia D with periodic fever (HIDS), 833, 1521, 1525f, 1525t
- Hyperinfection syndrome, 2205
- Hyperinsulinemia, fetal, 1140f
- Hyperinsulinemic hypoglycemia
- endocrine and metabolic causes of, 983t
 - syndromic forms of, 984t
- Hyperinsulinism, in hypoglycemia, 984–987, 987t, 989f
- Hyperinsulinemia-hyperammonemia syndrome, 3603
- Hyperkalemia, 3092t–3093t
- cardiac arrest and, 567t
 - in CKD, 3245, 3250t
 - clinical manifestations of, 497, 497f
 - diagnosis of, 498
 - electrocardiogram of, 2753f
 - etiology and pathophysiology, 496–497
 - treatment of, 498
- Hyperkalemic periodic paralysis, 3849t
- Hyperkalemic renal tubular acidosis, 515, 3236–3238, 3237t, 3238f
- Hyperkeratosis, toxic causes of, 3895t
- Hyperkeratotic plantar wart, 4166–4167, 4167f
- Hyperkinetic disorder, 311t
- Hyperkyphosis, 4250
- Hyperleukocytosis, 3092t–3093t
- Hyperlipidemia
- in CKD, 3248, 3250t
 - due to nephrotic syndrome, 3223
 - secondary causes of, 880t
- Hyperlipoproteinemias, 874–884
- Hypermagnesemia
- etiology and pathophysiology, 505
 - newborn, 1056
- Hypermethioninemia, 823
- acquired, 823
 - primary (genetic), 823
- Hypermobile Ehlers-Danlos syndrome, 598, 4369–4371, 4371t, 4373f, 4374t–4375t
- comorbidities of, 1574
- Hypermobile pes planus, 4205–4206, 4206f
- Hypermyelinating neuropathy, 3887–3889
- Hypernasal speech, speech disorders and, 331
- Hypernasality, 3981
- Hypernatremia
- causes of, 489t, 3373–3374
 - clinical manifestations of, 490
 - diagnosis of, 490–491
 - etiology and pathophysiology, 490
 - treatment of, 491
- Hypernatremic dehydration, 529, 531–532, 532f, 3239
- Hyperopia, 3912–3914
- Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, 854
- Hyperosmolality, 491, 492t
- Hyperosteoidosis, type VI, 4361
- Hyperostosis, ulna and tibia, 455f
- Hyperostotic fragile bones, 4351t
- Hyperoxaluria
- calcium stones caused by, 3313
 - and oxalosis, 838–840
 - primary, 3254–3255
 - type 1, 839
 - type 2, 839
 - type 3, 839–840
 - secondary, 839
 - urolithiasis caused by, 3315t
- Hyperoxia, avoidance of, 1081
- Hyperoxia test, 2799
- Hyperparathyroidism, 508, 3440–3443, 3846
- causes of hypercalcemia, 3441
 - clinical manifestations, 3441
 - differential diagnosis, 3441
 - etiology, 3440–3441
 - hypercalcemia and, 3442t
 - jaw tumor syndrome, 3440
 - laboratory findings, 3441
 - prognosis, 3441
 - treatment, 3441
- Hyperparathyroid-jaw tumor syndrome, 3131t–3132t
- Hyperphenylalaninemia
- caused by BH4 deficiency, 814–815, 814f
 - clinical manifestations, 814–815
 - diagnosis, 815
 - genetics and prevalence, 815
 - treatment, 815
 - neonatal screening for, 812
 - non-phenylketonuria, 812
- Hyperphosphatasia, 4383, 4383f
- Hyperphosphatasia-mental retardation syndrome, 4383
- Hyperphosphatemia, 508–509, 3092t–3093t, 3248
- Hyperpigmentation, in scleroderma, 1509f
- Hyperpigmented lesions, 4067–4068
- café-au-lait macules, 4067–4068
 - disorders of pigment, 4067
 - ephelides, 4067
 - incontinentia pigmenti, 4068
 - lentigines, 4067
 - postinflammatory pigmentary changes, 4068
- Hyperpituitarism, 3378–3384
- Hyperpnea, as respiratory distress, 612–613
- Hyperprolactinemia, 815, 3331t, 3380, 3381t, 3493
- drug-induced, 3380
- Hyperprolinemia, 847
- type I, 841
 - type II, 841, 855
- Hyperprostaglandin E syndrome, 3240
- Hyperpyrexia, 1641–1642
- Hyperreactive malarial splenomegaly (HMS), 2181
- Hyperreactivity to sensory input, 375
- Hypersegregation, 8–9
- Hypersensitivity, cow's milk, pulmonary hemosiderosis and, 2689–2690
- Hypersensitivity drug reactions, 1294
- Hypersensitivity pneumonia, 2612–2615
- antigen sources of, 2613t
 - clinical manifestations of, 2612, 2614t
 - diagnosis of, 2612–2614, 2614t
 - etiology of, 2612
 - laboratory for, 2614–2615
 - antigen challenge by inhalation, 2615
 - bronchoalveolar lavage, 2615
 - lung biopsy, 2615
 - radiology, 2614
 - pathogenesis of, 2612–2614
 - treatment of, 2615
- Hypersensitivity pneumonitis, nontuberculous mycobacteria infection and, 1861t
- Hypersensitivity syndromes. *See Allergic diseases*
- Hypersensitivity vasculitis, 1565, 1565t–1566t
- Hypersplenism, 3061, 3062t
- Hypertelorism, 3971
- Hypertension, 3248
- in acute kidney injury, 3246
 - in CKD, 3250t, 3252
 - clinical evaluation and, 2916t
 - clinical manifestations of, 2913
 - conditions associated with, 2911t
 - definition of, 2910
 - diagnosis of, 2914–2916
 - etiology and pathophysiology of, 2911–2912
 - evaluation of, 2913f–2914f
 - in 11 β -hydroxylase deficiency, 3468
 - kidney transplant immunosuppression and, 3258–3259
 - pediatric heart transplantation and, 2904
 - physical examination in, 2915t
 - portal, 2504–2506
 - clinical manifestations of, 2505
 - diagnosis of, 2505–2506
 - etiology of, 2504–2505, 2504f
 - liver disease and, 2439
 - pathophysiology of, 2505
 - prognosis of, 2506
 - treatment of, 2506
 - portopulmonary, 2442
 - predicting toxicity from vital signs in, 704t
 - prevalence of, in children, 2910, 2911t
 - prevention of, 2916–2917
 - pulmonary, 2831–2835
 - classification of, 2832t
 - developmental and genetic lung disease associated with, 2832t
 - drugs used for, 2834t
 - primary pulmonary hypertension, 2831–2832
 - pulmonary vascular disease, 2831–2835
 - systemic, 2910–2920
 - in T2DM, 3543t
 - treatment of, 2917–2920
- Hypertensive encephalopathy, 3754
- Hypertensive retinopathy, 3961, 3961f
- Hypothermia, 674
- anhidrosis and, 4134
 - malignant, 3849t
 - newborn, 1055
 - predicting toxicity from vital signs in, 704t
- Hypothymic temperament, 260
- Hyperthyroidism, 1020, 3381, 3384, 3413, 3415–3416
- associated with Down syndrome, 369
 - congenital, 3421–3422
- Hypertonic saline, for bronchiolitis, 2030
- Hypertrichosis, 3786, 3786f, 4137
- causes of, 4137t
 - congenital syndromes associated with, 4137t
- Hypertriglyceridemia, 879–880
- hypercholesterolemia with, 877–879
 - risk assessment and treatment of, 882–884, 883t, 884f
- Hypertrophic cardiomyopathy, 2881f, 2884–2885, 4295
- clinical manifestations of, 2884
 - diagnosis of, 2884, 2885f–2886f
 - echocardiograms of, 2881f
 - etiology and epidemiology of, 2879t
 - with lactic acidosis, mitochondrial disease and, 935t
 - pathogenesis of, 2884
 - prognosis and management of, 2884–2885, 2887f
 - sudden death and, 2861

- Hypertrophic gastropathy, 2281
 Hypertrophic osteoarthopathy, 1582, 2677
 Hypertrophic pyloric stenosis, 2278–2280, 2278f–2279f, 2278t, 2280t
 Hypertrophic scars, 4119
 Hypertrophy, 3554
 labial, 3354
 Hyperuricemia, 3092t–3093t
 HGprt-related, 950
 renal, 945t
 uric acid and, 947
 Hyperuricosuria, 3313–3314, 3315t
 Hypervirulent GBS adhesin (HvgA), 1716–1717
 Hyperviscosity, 1126
 Hypervitaminosis A, 455
 Hypervitaminosis D, 479–480, 3443
 Hypervolemic hyponatremia, 492–493, 492t
 Hyphema, 3924, 3978
 Hypnagogic hallucinations, 293
 Hypnopompic hallucinations, 293
 Hypnosis, 58t, 667
 Hypnotherapy, in pain management, 693
 Hypnotics, 669t
 Hypoalbuminemia, 2334–2336
 Hypoadosteronism, 3236, 3377t
 Hypobaric hypoxia, 630
 Hypobetalipoproteinemia, 2965–2966
 Hypocalcemia
 in acute kidney injury, 3245–3246
 causes of, 3435t
 evaluation of, 3436f
 in neonatal seizures, 3619
 newborn, 1055–1056
 secondary, hypomagnesemia with, 504
 in toxicologic diagnosis, 705t
 Hypocalcification, 2241
 Hypocalciuria, in Gitelman syndrome, 3241
 Hypochloremic metabolic alkalosis, in pyloric stenosis, 2278
 Hypochondriasis, 248t
 Hypochondrogenesis, 4340
 Hypochondroplasia, 4347
 Hypocitrice aciduria, 3315t
 Hypocomplementemic urticarial vasculitis, 1553t, 1565, 1566t
 Hypodontia, 4048
 Hypofunction
 of ovaries, 3496–3501, 3497t
 hypergonadotropic hypogonadism in, 3496–3501
 etiology of, 3497t
 Noonan syndrome in, 3500
 other ovarian defects in, 3500–3501
 Turner syndrome in, 3496–3499
 45,X/46,XY gonadal dysgenesis in, 3499–3500, 3500f
 XX gonadal dysgenesis in, 3499
 XXX females in, 3500
 XXXX females in, 3500
 XXXXX females in, 3500
 hypogonadotropic, 3501
 male
 etiologic classification of, 3488t
 primary, 3487–3491
 clinical manifestations of, 3489
 diagnosis of, 3489
 etiology of, 3488t
 Klinefelter syndrome in, 3489–3491
 Noonan syndrome in, 3489
 45,X males in, 3491
 XX males in, 3491
 47,XXX males, 3491
 secondary, 3488t, 3491–3494
 diagnosis of, 3493
 etiology of, 3492t
 other disorders with, 3493
 treatment of, 3493–3494
 without anosmia, 3492–3493
 Hypogonadotropic hypogonadism
 disorders associated with, 3396, 3396t
 female, 3397, 3501
 male, 3397, 3488t, 3491–3494
 diagnosis of, 3493
 etiology of, 3492t
 other disorders with, 3493
 treatment of, 3493–3494
 without anosmia, 3492–3493
 Hypohidrosis, 4134
 in Fabry disease, 3887
 Hypokalemia, 498–501, 3240
 causes of, 499t
 clinical manifestations of, 500, 501f
 diagnosis of, 500–501, 502f
 electrocardiogram of, 2752f
 etiology and pathophysiology, 498–500
 Hypoglycemia, 980–991, 3754
 cardiac arrest and, 567t
 in cholera, 1786
 classification, in infants and children, 982, 983t
 clinical features of, 982t
 clinical manifestations of, 981t, 982
 definition, 980, 980f
 diagnosis of, 982
 diagnostic algorithm for, 986f
 diagnostic evaluation, 985t
 disorders of, 984–989
 glucose homeostasis
 in newborn, 981–982, 981f
 in older infants and children, 981–982, 981f
 hyperinsulinism, 984–987
 inborn errors of metabolism and, 806t
 in infants of diabetic mothers, 987, 1140
 treatment for, 1142f
 in malaria, 2180
 management of, 983–984
 in neonatal seizures, 3619
 persistent or recurrent
 disorders of gluconeogenesis, 991
 glycogen storage disease, 991
 systemic disorders, 991
 postprandial, 991
 significance and sequelae, 981
 in toxicologic diagnosis, 705t
 treatment for, 987t
 Hypoglycemic reactions, in T1DM, 3533–3534
 Hypoglycemics, oral, toxicity, 701t, 715–716
 Hypoglycinemia, 837
 Hypoglycorrachia, 3761
 Hypogonadism
 female
 hypergonadotropic, 3496–3501
 etiology of, 3497t
 Noonan syndrome in, 3500
 other ovarian defects in, 3500–3501
 Turner syndrome in, 3496–3499
 45,X/46,XY gonadal dysgenesis in, 3499–3500, 3500f
 XX gonadal dysgenesis in, 3499
 XXX females in, 3500
 XXXX females in, 3500
 XXXXX females in, 3500
 hypogonadotropic, 3501
 male
 etiologic classification of, 3488t
 primary, 3487–3491
 clinical manifestations of, 3489
 diagnosis of, 3489
 etiology of, 3488t
 Klinefelter syndrome in, 3489–3491
 Noonan syndrome in, 3489
 45,X males in, 3491
 XX males in, 3491
 47,XXX males, 3491
 secondary, 3488t, 3491–3494
 diagnosis of, 3493
 etiology of, 3492t
 other disorders with, 3493
 treatment of, 3493–3494
 without anosmia, 3492–3493
 Hypogonadotropic hypogonadism
 disorders associated with, 3396, 3396t
 female, 3397, 3501
 male, 3397, 3488t, 3491–3494
 diagnosis of, 3493
 etiology of, 3492t
 other disorders with, 3493
 treatment of, 3493–3494
 without anosmia, 3492–3493
 Hypohidrosis, 4134
 in Fabry disease, 3887
 Hypokalemia, 498–501, 3240
 causes of, 499t
 clinical manifestations of, 500, 501f
 diagnosis of, 500–501, 502f
 electrocardiogram of, 2752f
 etiology and pathophysiology, 498–500
 Hypokalemia (*Continued*)
 in primary aldosteronism, 3479
 in refeeding syndrome, 432t
 treatment of, 501
 Hypokalemic hypochloremic metabolic alkalosis, 3240–3241
 Hypokalemic paralysis, 3848
 periodic, 3849t
 channelopathies with, 3840t
 Hypomagnesemia
 clinical manifestations of, 504
 diagnosis of, 504–505
 etiology and pathophysiology, 503–504
 in Gitelman syndrome, 3241
 in neonatal seizures, 3619
 in refeeding syndrome, 432t
 treatment of, 505
 Hypomanic episode, 260, 261t
 Hypomelanosis of Ito, 772–773, 4073, 4074f
 Hypomelanotic macules, 3658f
 Hyponatremia, 3092t–3093t
 in acute kidney injury, 3246
 in acute porphyria, 968
 causes of, 492t, 3375–3376
 clinical manifestations of, 493
 diagnosis, 493–494
 differential diagnosis of, 3375t
 etiology and pathophysiology, 491–493
 treatment of, 494–495, 3376
 Hyponatremic dehydration, 529, 530t, 531
 Hypoparathyroidism, 3434–3438, 3439t
 aplasia or hypoplasia of parathyroid glands, 3434
 associated with mitochondrial disorders, 3436
 autoimmune, 3436–3437
 autosomal dominant, 504, 3436
 autosomal recessive, with dysmorphic features, 3435
 idiopathic, 3437–3438
 sensorineural deafness, renal anomaly syndrome and, 3435–3436
 suppression of neonatal parathyroid hormone secretion because of maternal hyperparathyroidism, 3436
 surgical, 3436
 X-linked recessive, 3435
 Hypophosphatasia, 855–856, 3442, 4380–4382, 4381f
 causes of, 4382t
 diagnostic algorithm for, 4382f
 infantile, 4380
 perinatal, 4380
 subtypes and features of, 4381t
 Hypophosphatemia, 506–508
 etiology of, 506–508
 in refeeding syndrome, 432t
 Hypophosphatemic rickets
 hereditary, with hypercalcuria, 473t, 478
 with nephrolithiasis and osteoporosis, types 1 and 2, 478
 Hypophysitis, 3373–3374
 Hypopigmented lesions, 4071–4075
 albinism, 4071–4072
 melanoblast migration abnormalities, 4072–4075
 Hypopituitarism, 3364–3371
 clinical manifestations of, 3368–3369
 acquired form, 3368–3369
 congenital form, 3368
 complications and adverse effects of growth hormone treatment, 3371
 differential diagnosis of, 3370
 GH deficiency
 acquired forms of, 3366
 genetic forms of, 3366
 GH insensitivity, 3366–3368
 in hypogonadotropic hypogonadism, female, 3501
 laboratory findings of, 3369
 multiple pituitary hormone deficiency, 3364–3365
 acquired forms, 3365
 congenital forms, 3364, 3365t, 3367f
 genetic forms, 3364, 3365t
 radiologic findings of, 3369–3370, 3370f
 treatment of, 3370–3371
 Hypoplasia, 2241
 breast, 3330, 3330f
 cartilage-hair, 1274

Hypoplasia (*Continued*)
 optic nerve, 3963–3964, 3964f
 of parathyroid glands, 3434
 pulmonary, 2599
 renal, 3261–3262
 urethral, 3285, 3301

Hypoplastic breast tissue, 3330

Hypoplastic left heart syndrome, 2819–2822, 2819f–2822f
 clinical manifestations of, 2819–2820
 diagnosis of, 2820
 prevention for, 2822
 treatment for, 2820

Hypoplastic left ventricle, relative frequency of, 2763t

Hypoplastic nails, 4049t–4050t

Hypoplastic right ventricle, relative frequency of, 2763t

Hypopyon, 3924, 3945

Hyporeactivity, 375

Hyporegenerative anemia, 2939

Hypospadias, 3296–3297
 chordee without, 3297
 clinical manifestations of, 3296–3297
 in male-appearing genitalia, 3506t
 megameatal variant of, 3296
 treatment of, 3297
 varying forms of, 3297f

Hyposplenia, 3063

Hyposplenism, 3063, 3063t–3064t, 3064f

Hypotelorism, 3971

Hypotension, 548

in newborn, 1054

predicting toxicity from vital signs in, 704t

Hypothalamic hamartomas, 3390

Hypothermia, 657–659, 658f, 674

accidental, 657

cardiac arrest and, 567t

clinical presentation of, 658, 658t

complications of, 659

drowning and, 640

in newborn, 1055, 1147–1148

predicting toxicity from vital signs in, 704t

prevention of, 657–659

risk factors of, 657–658

treatment for, 659f–660f

Hypothyroidism, 483–484, 1020, 3402–3410, 3413, 3846

acquired, 3408–3410

clinical manifestations of, 3409–3410, 3409f, 3410t

diagnostic studies in, 3410

epidemiology of, 3408

etiology of, 3408–3409, 3408t

treatment and prognosis of, 3410

associated with Down syndrome, 369

congenital, 3402–3408

central (hypopituitary), 3404

clinical manifestations of, 3404–3405

epidemiology of, 3402

etiological classification of, 3402–3404, 3403t

laboratory findings of, 3405–3406

primary, 3402–3404

prognosis of, 3406–3408

thyroid function in preterm and low birthweight infants, 3404

treatment of, 3406

due to total body irradiation, 1365

precocious puberty and, 3391

primary, 3370

Hypotonia, 3555

Hypotrichosis, 4137, 4138t

Hypoventilation, 3711

in CCHS, 2719

in newborn, 1054t

predisposing factors, 206t

Hypovolemia

cardiac arrest and, 567t

urine chemistries in, 3244t

Hypovolemic hyponatremia, 491, 492t, 494

Hypovolemic POTS, 598

Hypovolemic shock, 560, 600, 601t, 602f

clinical manifestations of, 605

pathophysiology of, 601

in splenic trauma, 3063

Hypoxemia, cardiac arrest and, 554, 567t

Hypoxia

acute, 630

hypobaric, 630

Hypoxia-inducible factor (HIF), 630

Hypoxic-ischemic encephalopathy, 1062–1068, 1063t, 1067f

clinical manifestations of, 1063–1064, 1063t–1064t, 1064f

diagnosis of, 1064–1065

etiology of, 1062

neurophysiology studies for, 1065, 1066f

pathophysiology and pathology of, 1063, 1063t

treatment of, 1065–1067

Hypoxic ventilatory response (HVR), 630

Hypoxic-ischemic encephalopathy (HIE), 3689

in neonatal seizures, 3619

Hypsarrhythmia, 3601

I

Iatrogenic cryptorchidism, inguinal hernia and, 2421

Ibalizumab, for HIV, 2098t–2107t

IBD. *See* Inflammatory bowel disease

Ibotenic acid poisoning, 4443

Ibrexafungerp, 1921

IBS. *See* Irritable bowel syndrome

Ibuprofen

for migraine, 3646t–3647t

in pain management, 681t

for patent ductus arteriosus, 1083

poisoning, 712

iC3b receptor (CR3), 1316

Ice hockey, injuries associated with, 4329–4330

I-cell disease, 887t–888t, 897

ICH. *See* Intracranial hemorrhage

Ichthyoses

autosomal recessive congenital, 4110–4116

inborn errors of metabolism and, 809t–810t

keratinopathic, 4116

nonsyndromic, 4110

syndromic, 4117–4118

Ichthyosis hystrix, in epidermal nevus, 4065, 4066f

Ichthyosis vulgaris, 4110, 4113t–4114t, 4115f

ICP. *See* Increased intracranial pressure; Intracranial pressure

ICS/LABA therapy, combination of, 1402–1403

Icteric leptospirosis (Weil syndrome), 1878f, 1879

Icterus, 2438

in SLE, 1497t

Icterus neonatorum, 1110, 1110f

Id reaction, 4175

Idarubicin

indications and adverse reactions of, 3089t–3090t

for pediatric cancer, 3089t–3090t

IDEA. *See* Individuals with Disabilities Education Act

Identity, culture and, 81–82

Idiogenic osmoles, 531

Idiopathic anaphylaxis, 1436

Idiopathic central precocious puberty, 3388f

Idiopathic chronic neutropenia, 1312

Idiopathic hypercalcemia of infancy, 3442

Idiopathic hypercalciuria, 3212

Idiopathic hypersomnia, 213

Idiopathic hypoparathyroidism, 3437–3438

clinical manifestations of, 3437

differential diagnosis of, 3437–3438, 3438t

laboratory findings of, 3437

treatment of, 3437

Idiopathic infantile arterial calcification, 2908

Idiopathic intracranial hypertension, 3782–3785, 3782f

clinical manifestations of, 3782–3784, 3782f–3784t

diagnostic criteria for, 3784t

etiology of, 3782, 3783t

treatment of, 3784–3785

Idiopathic juvenile osteoporosis, 4384

Idiopathic motor nystagmus, congenital, 3930

Idiopathic musculoskeletal pain syndromes, differential diagnosis of, 1569t

Idiopathic neonatal hepatitis, 2452–2454, 2454t

Idiopathic nephrotic syndrome, 3226–3231

pathogenesis of, 3227f

pathology of, 3224t–3225t, 3226–3228, 3228f

prognosis of, 3231

Idiopathic pulmonary hemosiderosis (IPH), 2688

Idiopathic scoliosis, 4242–4247

classification of, 4242

clinical presentation of, 4243

epidemiology of, 4242

etiology of, 4242

natural history of, 4244–4245, 4244f

physical examination of, 4243–4244, 4244f

radiographic evaluation of, 4244, 4244f

treatment of, 4245–4247, 4246f–4247f

Idiopathic sudden sensorineural hearing loss, 3985t, 3994

Idiopathic ulcers, 2306

Idiosyncratic hepatotoxicity, 2490

IED. *See* Intermittent explosive disorder

IEM. *See* Inborn errors of metabolism

IFALD. *See* Intestinal failure associated liver disease

IFNAR1 deficiency, 1339t

IFNAR2 deficiency, 1339t

IFNGR. *See* Interferon- γ receptor

IFN- γ R defects, 1342–1343

Ifosfamide, indications and adverse reactions of, 3089t–3090t

IFSP. *See* Individualized family service plan

IgA deficiency, 1309t

IgA vasculitis, 1552–1556, 1553t, 2689, 3060, 3307,

4032–4033, 4033f

classification of, 1557t

clinical manifestations of, 1554, 1557f

complications of, 1555

diagnosis of, 1554–1555

differential diagnosis of, 1555

epidemiology of, 1554

laboratory findings of, 1555

pathogenesis of, 1554

pathology of, 1554

prognosis for, 1555–1556

treatment of, 1555

IgA vasculitis nephritis, 3198–3199

IgG indirect fluorescent antibody (IgG-IFA) test, 2193

IgM-IFA test, 2193

IGRA. *See* Interferon- γ release assay

IHCAs. *See* In-hospital cardiac arrests

IHH. *See* Idiopathic intracranial hypertension

IL-1 antagonists, 1466t–1468t, 1470, 1481t

IL-1 receptor antagonist, deficiency of, 1523–1524

IL-2 receptor antibodies, in induction therapy, 3256

IL-5, 1293

IL-6 receptor antagonist, 1466t–1468t, 1470, 1481t

IL-7Ra deficiency, 1263t

IL-17F deficiency, 1337

IL-17RA deficiency, 1337

IL-18BBP deficiency, 1339t

Ileal atresia, 2283–2284, 2283f–2284f

Ileocolic intussusception, 2300f

Ileocecal intussusception, 2302

Ileostomy, temporary, 2316

Ileus, 2299

Iliac crest contusion, 4329

Iliohypogastric nerve block, in pain management, 695

Ilioinguinal block, in pain management, 695

Iliopsoas abscess, 4286–4287

Iliotibial band (ITB) friction syndrome, 4310

Iliotibial band syndrome, knee pain caused by, 4331

Ilium, 4231

Ilizarov device, for limb lengthening, 4221–4223, 4223f

Illness

altitude-associated, 630–636

noninfectious, foodborne, 4411t–4413t

nonspecific febrile, 1981

Illness anxiety disorder, 235, 236t, 239t

Illusions, 293

Iloprost, 2834t

Imaging procedures, in *Coccidioides* spp., 1938, 1938f

Imaging studies

in children with febrile UTI, 3267–3268, 3269t

in rheumatic disease, 1463

in urinary tract obstruction, 3276–3279

Imatinib, 3088t

for acute lymphoblastic leukemia, 3100

for chronic myelogenous leukemia, 3105

for gastrointestinal stromal cell tumors, 2414–2415

Imerslund-Grasbeck syndrome, 466, 2943

Imidazolines, toxicity, 701t
 Iminoglycinuria, 2349–2350
 Imipenem-cilastatin, 1675t–1685t
 for drug-resistant tuberculosis, 1852t–1853t
 Imipramine, for nocturnal enuresis, 3296
 Imiquimod, for nongenital warts, 4168–4169
 Imitation, 165
 Immature teratoma, of ovary, 3342–3343
 Immersion, cold water, 640
 Immersion (trench) foot, 662
 Immersion injury patterns, 116, 118f
 Immigrant children, medical evaluation, 78–81
 Immobility, 3313–3314
 Immobilization
 hypercalcemia, 4391–4393
 prolonged, hypercalcemia from, 3443
 Immotile cilia syndrome, 2679–2682
 Immune and inflammatory lung disease, 2612–2641
 eosinophilic, 2625–2632
 acute eosinophilic pneumonia, 2625–2627, 2626t
 allergic bronchopulmonary aspergillosis, 2629–2630, 2629t, 2630f
 chronic eosinophilic pneumonia, 2627–2628
 clinical manifestations of, 2625–2626
 eosinophilic granulomatosis with polyangiitis, 2628, 2628t
 etiology of, 2625, 2625t–2626t
 hypereosinophilic syndrome, 2630–2632, 2630t, 2631f
 Löffler syndrome, 2626
 pathology and pathogenesis of, 2625
 granulomatous, 2620–2624
 berylliosis, 2623–2624
 granulomatosis with polyangiitis, 2620–2622, 2621f
 in primary immune deficiency, 2624
 sarcoidosis, 2622–2623
 hypersensitivity pneumonia, 2612–2615
 antigen sources of, 2613t
 clinical manifestations of, 2612, 2614t
 diagnosis of, 2612–2614, 2614t
 etiology of, 2612
 laboratory for, 2614–2615
 pathogenesis of, 2612–2614
 treatment of, 2615
 interstitial, 2632–2637
 anti-glomerular basement membrane disease, 2636–2637
 classification and pathology of, 2632–2633, 2632t–2634t
 diagnosis of, 2635–2636
 prognosis for, 2636
 treatment of, 2636
 occupational and environmental, 2616–2620, 2616t
 asthma, 2616, 2617t–2619t
 classification and pathogenesis of, 2616–2620
 high molecular weight antigens in, 2617t–2618t
 irritant-induced asthma, 2619
 low molecular weight chemicals in, 2619t
 reactive airways disease syndrome, 2619, 2620t
 Immune checkpoint inhibitors, 3090
 Immune complex small vessel vasculitis, 1553t
 Immune complexes, 1297t–1298t
 Immune dysfunction disorders, neutropenia in, 1311
 Immune dysregulation, 1324–1334
 autoimmune cytopenias and, 1329–1330
 clinical manifestations of, 1330
 diagnosis of, 1330
 immunodeficiencies associated with, 1330
 pathophysiology of, 1329–1330, 1330t
 treatment of, 1330
 autoimmune lymphoproliferative syndrome and, 1331–1334, 1331t–1333t
 eosinophilia caused by, 1295t
 Epstein-Barr virus and
 chronic active, 1328–1329, 1328t
 lymphoproliferative disease, other primary immunodeficiencies associated with, 1328
 susceptibility disorders, 1326–1328, 1327t, 1328f
 hemophagocytic lymphohistiocytosis and, 1325–1326, 1326f
 primary, 1325–1326
 secondary, 1326

Immune dysregulation (*Continued*)
 nuclear factor- κ B pathway defects and, 1334, 1334t
 tregopathies and, 1324, 1324f, 1325t
 very early onset inflammatory bowel disease and, 1329, 1329f
 Immune function disorders, neutropenia in, 1309t
 Immune globulins, antiviral, 1957
 Immune hemolytic anemia, 2993–2994, 2993t
 Immune reconstitution inflammatory syndrome (IRIS), 1846, 2094
 cryptococcal-associated, 1926
 Immune response, to tuberculosis, 1840f
 Immune system
 in nephrotic syndrome, 3223
 responsible for cold symptoms, 2551
 Immune thrombocytopenia, 3049–3055
 chronic autoimmune, 3049f, 3054–3055
 clinical manifestations of, 3050
 destructive, 3050t
 diagnosis and differential diagnosis of, 3050t, 3052–3053, 3053f
 epidemiology of, 3049
 laboratory findings of, 3050–3052, 3054f
 outcome, 3050
 pathogenesis of, 3049–3050
 sequestration in, 3050t
 treatment of, 3053–3054, 3054t
 Immune-mediated epilepsy, 3589
 Immune-related pancytopenias, 3010
 Immunity
 disorders, 2645t
 of *Haemophilus influenzae*, 1756, 1756t
 meningococcus, 1739
 RAG-independent adaptive, 1286
 in tuberculosis, 1839–1840, 1840f
 Immunization, 1344, 1345t
 active, 1587–1590, 1588t–1589t
 birth dose vaccines, 1611–1617
 booster doses, 1611
 eradication and elimination, 1616–1617
 primary infant series, 1611
 vaccination against outbreak-prone diseases for endemic areas, 1611, 1614t–1615t
 vaccine hesitancy and demand, 1616
 vaccine schedules in high-income countries, 1617
 vaccine supply and production, 1616, 1616t
 CKD, 3252
 coverage improvement for, 1609–1611, 1610t
 disparities in, 14
 in immigrant children, 81
 long-term mechanical ventilation and, 2729
 maternal, group B *Streptococcus*, 1720
 measles, 1963t
 medical exemptions to, 1609
 for nephrotic syndrome, 3231, 3231t
 passive immunity, 1585–1611, 1586t
 hyperimmune animal antisera preparations, 1586t, 1587
 intramuscular immunoglobulin, 1586–1587, 1586t
 intravenous immunoglobulin, 1586–1587, 1586t
 monoclonal antibodies, 1587
 practices, 1585–1617, 1585t
 international, 1611–1617, 1612t–1615t
 precautions and contraindications to, 1609
 prior to renal transplantation, 3256
 rabies, 2083
 recommended schedule, 1591–1604, 1593f–1599f, 1605f
 for sickle cell disease, 2976
 vaccination of children outside the United States, 1617
 vaccination system in the United States, 1590–1591, 1592t–1593t, 1600t–1601t, 1603t
 vaccine delivery, 1591
 vaccine financing, 1590
 vaccine policy, 1590
 vaccine production, 1590
 vaccine safety monitoring, 1590–1591
 vaccine hesitancy, 1611
 vaccines recommended in special circumstances, 1603t, 1604–1609, 1606t–1608t, 1610f

Immunocompromised persons, 1659–1667, 1659t
 acquired immunodeficiencies, 1661–1666
 fever and neutropenia, 1662–1663
 fever without neutropenia, 1664
 from infectious agents, 1661
 malignancies, 1661–1662, 1662f–1663f, 1663t
 transplantation, 1664–1666
 adenoviruses in, 2034
 antibiotics use in, 1673–1674
 CMV in, 2012
 herpes simplex virus (HSV) in, 1995
 treatment of, 1998
 in infection prevention and control, 1620
 Legionnaires disease, at risk for, 1810–1811
 parvovirus B19 infection, at risk for, 1989
 prevention of, 1666–1667
 primary immunodeficiencies, 1659–1661
 abnormalities of phagocytic system, 1659–1660
 β -cell defects (humoral immunodeficiencies), 1660
 combined B-cell and T-cell defects, 1661
 defective splenic function, opsonization, or complement activity, 1660
 T-cell defects (cell-mediated immunodeficiencies), 1660–1661
Pseudomonas aeruginosa infection, 1800, 1800f
T. cruzi infections in, 2167
 with toxoplasmosis, 2189, 2195, 2197
 Immunodeficiency
 arthritis or extremity pain caused by, 1479t
 and chromosome breakage syndrome, 2634t
 chronic diarrhea and, 2378
 eosinophilia caused by, 1295t
 HSCT for disorders of, 1354
 malabsorption and, 2344
 primary, granulomatous lung disease in, 2624
 pulmonary diseases associated with, 2632t
 respiratory signs and symptoms, 2531t
 respiratory tract complication, 2531t
 severe combined, 1288
 Immunodeficiency 21, 2634t
 Immunodeficiency centromere instability, 774t
 Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, 1324–1325, 1325f, 3411–3412, 3425–3428, 3518
 associated with T1DM, 3548
 chronic diarrhea and, 2378
 Immunofluorescence studies, 4028, 4028t
 Immunoglobulin
 for enterovirus infections, 1986
 for hepatitis A, 2463–2464
 and measles immunization, 1964t
 Immunoglobulin A
 nephropathy, 3187–3188, 3187f, 3254–3255
 reference intervals, 4472.e9t
 Immunoglobulin D, reference intervals, 4472.e9t
 Immunoglobulin E
 in allergic diseases, 1371
 reference intervals, 4472.e9t
 Immunoglobulin G
 reference intervals, 4472.e9t
 varicella-zoster virus, 2001
 Immunoglobulin G replacement therapy, 1346, 1347t–1348t
 indications for, 1346
 individualizing, 1349, 1349t
 vaccination while on, 1350
 Immunoglobulin M, reference intervals, 4472.e9t
 Immunohistochemistry, in neuromuscular disorders, 3798
 Immunologic deficiencies, in myotonic muscular dystrophy, 3836
 Immunologic disease, anesthetic implications in, 666t
 Immunologic manifestation, in childhood lupus, 1497t
 Immunology factors, in anti-glomerular basement membrane disease, 2636–2637
 Immunomodulators, for Crohn disease, 2321
 Immunoneuroses, 1268t
 Immunoproliferative small intestinal disease, 2344
 Immunoprophylaxis
 active, for cytomegalovirus, 2015
 passive
 for cytomegalovirus, 2015
 for respiratory syncytial virus (RSV), 2031
 Volume 1 pp. 1-2222 • Volume 2 pp. 2223-4472

- Immunosorbent agglutination assay (ISAGA), 2193
 Immunosuppressants, neuropathy associated with, 3893t–3894t
Immunosuppression
 complications of, after heart transplantation, 2904–2905
 for intestinal transplantation, 2353–2354
 for liver transplantation, 2508
 for renal transplantation, 3256–3257
 complications of, 3258–3259
 induction therapy, 3256
 maintenance, 3256–3257
 Immunosuppressive agents, steroid-sparing, for SLE, 1496
Immunotherapy
 for cancer treatment, 3088–3091, 3092f
 for Hodgkin lymphoma, 3108
 Impairment in written expression (IWE), 321
 Impalpable gonads, in male-appearing genitalia, 3506t
 Imperforate anus, 2404–2405, 2404f–2405f, 3291
 Imperforate hymen, 1003f, 3351
 Impetigo, 1623t–1625t, 4150–4151
 GAS infection, 1707
 Impila, 2492t
 Implantable orthopedic devices, associated infection, 1670
Implants
 hormonal contraceptives, 1218t–1219t, 1221
 progestin subdermal, 3356
 testicular, 3304
Implicit bias, 21–22
Implicit memory, 302
Imprinting
 epigenetic, 148
 genetic, 742–743
 genomic, 776f, 777
 Impulse oscillometry (IOS), 2522
 Impulse-control disorders, 277–280
IMR. See *Infant mortality rate*
 In utero positioning, 4193
 In vitro tests, in allergic diseases, 1375–1378, 1377t
 In vivo tests, in allergic diseases, 1378
 Inaba strains, *Vibrio cholerae*, 1785
 Inactivated polio vaccine (IPV), 1977–1978
 Inactivated vaccines, 1590
 Inapparent infection, poliovirus, 1972
 Inborn defects of steroidogenesis, 3450
 Inborn errors of immunity, 1252–1261, 1254f, 1340, 1340f
 infection red flags in, 1252–1256
 Aspergillus, 1255–1256
 Epstein-Barr virus, 1255, 1256t
 herpes simplex virus encephalitis, 1255
 mycobacterial infections, 1256
 recurrent invasive pneumococcal infections, 1254, 1255t
 recurrent sinopulmonary infections, 1253–1254
 sentinel bacterial infections, 1256
 severe *Candida*, 1255
 severe cryptosporidiosis, 1256
 severe papillomavirus, 1254–1255
 schema for diagnosis of, 1256, 1257t–1258t, 1259f
 with strong atopic diathesis, 1276
 Inborn errors of metabolism, 803–810, 804f, 3622
 associated with dysmorphic features, 809t
 associated with hydrops fetalis, 809t
 associated with neurologic and laboratory manifestations, 805t–806t
 associated with peculiar odor, 810t
 with autistic-like behaviors, 378t
 causing hyperammonemia, 850t
 clinical findings of, 811t
 of hepatocyte injury, 2451
 intellectual disability caused by, 349t
 laboratory findings of, 811t
 liver and, 2455t
 liver transplantation for, 2507
 metabolic acidosis and, 516
 newborn screening for, 803, 805t
 physical examination findings associated with, 809t–810t
 physiologic therapies for, 756
 stroke and, 3754
 summary of treatable, 355f
 treatment of, 807–810
 infant cerebral folate deficiency, 464
 infant cortical hyperostosis, 4357–4358, 4358f
 infantile demyelinating neuropathies, in HMSN, 3883t–3884t
 infantile digital fibroma, 4186
 infantile esotropia, 3926
 infantile fibrosarcoma, 3139t–3140t
 infantile GM₁ gangliosidosis, 3712–3713, 3714f
 infantile growth, 175
 infantile head atomic attacks, 3637
 infantile hemangioma, 3327, 4054–4056, 4055f
 infantile hemorrhagic edema, 4032–4033
 infantile idiopathic early-onset scoliosis (EOS), 4242
 infantile onset multisystem neurology endocrine and pancreatic disease (IMNEPD), 2424
 infantile parkinsonism, 844
 infantile poikilocytosis, 2950
 infantile Pompe disease (IPD), 900t–901t, 906–907
 infantile Refsum disease, 3886
 infantile spasms
 associated with Down syndrome, 369
 BRUE and, 2542
 infantile spinal muscular atrophy, 3793f
 infantile tremor syndrome, 3678
 infantile-onset pulmonary alveolar proteinosis, 2634t
 infantile-type neuronal ceroid lipofuscinosis (ICLN), 3716
Infants
 at-risk groups for SIDS, 2537–2538
 bonding with parent, 1007–1008
 botulism, 1817, 1818f
 chronology of heart disease in, 614t
 with congenital heart disease, evaluation and screening of, 2773–2775
 congenital hypothyroidism in, 3402, 3405f
 of diabetic mothers, 1140–1143
 clinical manifestations of, 1140–1142, 1141f
 morbidity in, 1141t
 pathophysiology of, 1140, 1140f
 prognosis for, 1143
 treatment of, 1142–1143, 1142f
 electrocardiogram of, 2750f
 feeding of, 409–420
 gynecologic examination in, 3317–3319
 hypoglycemia in, 982
 large-for-gestational-age, 1048–1049
 measures of pain specific to, 679t–680t, 680
 with myelomeningocele, 3562
 nephrotic syndrome in, 3232t
 platelet transfusions in, 3016–3017, 3016t
 postterm, 1049
 Pseudomonas aeruginosa in, 1801
 psychosocial assessment, 216
 sleep, normal developmental changes in, 204t
 term, hypoxic-ischemic encephalopathy in, 1064t
 travel with, high-altitude illness and, 636
 treatment for gonococcal infections, 1752
 wheezing in, bronchiolitis, 2585–2588
 clinical manifestations of, 2587, 2587t
 diagnostic evaluation of, 2587
 differential diagnosis and etiologies of, 2585t
 prevention of, 2588
 prognosis for, 2588
 treatment of, 2587–2588
Infarction
 periventricular hemorrhagic, 1058
 pulmonary, 2692–2697
 in spinal cord embolism, 3749
 infection prevention and control, 1618–1620
 for burn injuries, 651–652, 652t
 hand hygiene, 1618
 isolation, 1619–1620
 medical device-associated infection
 CSF shunts, 1669–1670
 intravascular access devices, 1668
 peritoneal dialysis catheters, 1670
 urinary catheters, 1670
 occupational health and clinician education, 1620
 patient and caregiver management in, 1620
 in premature infant, 1044–1045
 special populations in, 1620
 standard precautions, 1619–1620, 1619t
 transmission, 1618
 visitation and, 1620

- Infection-related neutropenia, 1304–1306, 1306t
- Infections
- acute, tonsils and adenoids, 2562
 - acute hepatic failure and, 2494
 - acute pancreatitis and, 2427t
 - in brain, 3754
 - brain injury from, 1058
 - breast, 3330–3331
 - bronchiectasis and, 2658
 - central nervous system, 3758–3779
 - acute bacterial meningitis, beyond the neonatal period, 3758–3772
 - eosinophilic meningitis, 3776–3779
 - viral meningoencephalitis, 3772–3776
 - chronic
 - hematuria and, 3196
 - tonsils and adenoids, 2562
 - in CKD, 3250t
 - complement pathway deficiencies and, 1318
 - congenital, intellectual disability caused by, 349t
 - DIC caused by, 3048t
 - epidemiology of, 1143–1150
 - etiologies, of primary adrenal insufficiency, 3455
 - helminthic, Löffler syndrome and, 2626
 - of hepatocyte injury, 2450
 - identified prior to renal transplantation, 3255
 - in immigrant children, 80–81
 - increased susceptibility to, due to nephrotic syndrome, 3229
 - incubation periods of, travel-related, 80t
 - maternal, affecting fetus or newborn, 1013t
 - neonatal, 1143, 1144f
 - clinical manifestations of, 1146–1148
 - general approach to management of, 1149
 - incidence of, 1143, 1144t
 - laboratory findings of, 1148–1149
 - microbiology of, 1143–1144
 - pathogens causing, 1145t
 - prevention of, 1149–1150
 - pediatric heart transplantation and, 2904
 - phagocyte disorders and, 1297t
 - in premature infants, 1146
 - recurrent, clinical evaluation of patients with, 1299f
 - in secondary intracranial hypertension, 3783t
 - triggering atopic dermatitis, 1418–1419, 1418f
 - umbilical, 1131
 - wheezing in infants and, 2585t
 - Infectious arteritis, 3744–3745
 - Infectious causes, of myocarditis, 288t
 - Infectious complications, of HSCT, 1361–1364, 1361f
 - Infectious diseases
 - arthritis or extremity pain caused by, 1479t
 - associated with eosinophilia, 1294, 1295t
 - BRUE and, 2543t
 - fetal therapy for, 1027t
 - hypoplasia and, 3063t
 - maternal, affecting fetus, 1019–1020
 - prevention of, in developing world, 544
 - public health response to, aims to, 1583
 - upper airway obstruction, 2568–2572
 - vulvovaginitis, 3320, 3322t - Infectious eczematoid dermatitis, 4002
 - Infectious epilepsy, 3589
 - Infectious mononucleosis, 2006
 - Infectious pericarditis, 2890–2891
 - Infectious pneumonia, 2643t
 - Infective endocarditis, 2864–2871
 - bacterial agents in, 2865t
 - cardiac conditions associated with highest risk of adverse outcome from, 2871t
 - clinical manifestations of, 2865–2866, 2867t
 - definition of, 2869t
 - diagnosis of, 2866–2868
 - epidemiology of, 2864–2865
 - etiology of, 2864
 - inability to eradicate, 2864
 - prevention of, 2869–2871
 - prognosis and complications of, 2868
 - prophylactic antibiotic regimens for, 2871t
 - treatment of, 2868–2869
 - uncommon pathogens causing, 2867t
 - Infective esophagitis, 2269–2271
 - Infertility
 - during adulthood, 1365
 - chemotherapy and, 3093–3094
 - Infiltrate, lung, granulomatosis with polyangiitis, 2621f
 - Infirmary model, 193
 - Inflammation
 - anemia of, 2929, 2935
 - brain injury from, 1058
 - causing low plasma retinol, 452
 - paronychia, 4146–4147, 4147f
 - Inflammatory bowel disease (IBD), 2309–2325, 2310t–2311t, 4033
 - arthritis with, 1485
 - characteristics, 1483t
 - chronic diarrhea and, 2377–2378
 - chronic ulcerative colitis as, 2309–2316
 - clinical manifestations of, 2312, 2312f–2313f, 2312t
 - diagnosis of, 2310t, 2312f, 2312t, 2313, 2314t–2315t, 2315f
 - differential diagnosis of, 2312–2313, 2314t–2315t
 - prognosis of, 2316
 - treatment for, 2313–2316, 2316t
 - Crohn disease as, 2310t, 2316–2322
 - clinical manifestations of, 2311t, 2317f–2318f, 2317
 - diagnosis of, 2318–2319, 2318f–2321f
 - differential diagnosis of, 2314t–2315t, 2317–2318, 2319t
 - prognosis of, 2322
 - treatment for, 2320–2322
 - liver disease and, 2475–2480
 - in Turner syndrome, 3498
 - very early onset, 1329, 1329f, 2310t, 2314t–2315t, 2323–2325, 2323t–2324t, 2325f, 2326t
 - Inflammatory disorders
 - arthritis or extremity pain caused by, 1479t
 - primary immune deficiency diseases and, 1258–1261
 - risk for osteoporosis, 4384t
 - Inflammatory edema, 3973t
 - Inflammatory enterocolitis, differential diagnosis of, 2369t
 - Inflammatory myofibroblastic tumor, 2702f
 - Inflammatory pseudotumor, 2584
 - Inflammatory response, neutrophil-mediated, 1292f
 - Inflammatory upper airway obstruction
 - bacterial tracheitis, 2572–2573
 - clinical manifestations, 2572
 - complications, 2573
 - diagnosis, 2572
 - prognosis, 2573
 - treatment, 2573
 - infectious, 2568–2572
 - clinical manifestation, 2569–2570
 - complications, 2571
 - differential diagnosis, 2570–2571
 - prognosis, 2572
 - treatment, 2571–2572
 - Infliximab, for Crohn disease, 2321
 - Influenza virus vaccine inactivated (IIV†), 1588t–1589t, 1602
 - Influenza virus vaccine live-attenuated, intranasal (LAIV), 1588t–1589t, 1602
 - Influenza viruses, 2020–2026, 2020f
 - antigenic variation in, 2020–2021, 2021f
 - antiviral medications for, 1953t–1954t, 2024t
 - clinical manifestations of, 2022
 - complications of, 2022
 - diagnosis and differential diagnosis of, 2022, 2023t
 - epidemiology of, 2020–2021
 - etiology of, 2020
 - in human, 2021t
 - laboratory findings of, 2022
 - pathogenesis of, 2021–2022
 - prevention of, 2025–2026
 - chemoprophylaxis in, 2024t, 2025–2026
 - vaccines for, 2025, 2025f
 - prognosis for, 2025
 - seasonal influenza, 2021
 - supportive care for, 2025
 - testing methods, 2023t
 - treatment of, 2022–2023, 2023t–2024t
 - Information, exchange and dissemination of, 547
 - Information and communications technology, health, 35
 - Informed consent, 51
 - legal exceptions to, 1168t
 - In frequent episodic tension-type headache, 3652t
 - Infundibular follicular cyst, 4185, 4186f
 - Infundibular pulmonary stenosis, 2789–2790
 - Infundibular stenosis, 3279
 - Infundibular urinary tract obstruction, 3275t
 - Infusions, of hepatocyte injury, 2450
 - Ingestions, 2273–2275
 - caustic, 2273–2275, 2275t–2276t, 2276f
 - foreign bodies, in esophagus, 2273, 2274f
 - Ingrown nail, 4146–4147, 4147f
 - Ingrown toenail, 4210–4211
 - Inguinal area, physical examination of, 551
 - Inguinal hernias, 2415–2421, 3309
 - ambiguous genitalia and, 2418–2420
 - clinical presentation and diagnosis of, 2417
 - complications of, 2420–2421
 - congenital indirect, 2415
 - contralateral inguinal exploration, 2419–2420, 2420f
 - direct, 2416
 - embryology and pathogenesis of, 2415–2417, 2416f
 - evaluation of acute inguinal-scrotal swelling, 2417–2420
 - in female-appearing genitalia, 3506t
 - femoral, 2420
 - iatrogenic cryptorchidism, 2421
 - incarceration of, 2417–2418, 2421
 - incidence of, 2416–2417, 2416t
 - indications for surgery, 2418–2419
 - laparoscopic, repair of, 2419
 - nonreducible, 2418
 - open, repair of, 2419
 - predisposing factors for, 2416t
 - recurrent, 2420–2421
 - vas deferens and male fertility, injury to, 2421
 - wound infection in, 2420
 - Inguinal lymphadenopathy, 3070t
 - Inguinal mass, in male-appearing genitalia, 3506t
 - Inhalant allergy, 1421
 - Inhalant use, by adolescents, 1202–1203
 - Inhalation
 - antigen challenge by, 2615
 - for cystic fibrosis, 2673
 - of elemental mercury vapor, 4434
 - Inhalation injury, 653
 - Inhalational anesthetics, 668, 669t
 - Inhaled corticosteroids, for BPD, 1086
 - Inhaled gases, for respiratory distress and failure, 618–619
 - Inhaled nitric oxide (INO)
 - for BPD, 1087
 - for congenital diaphragmatic hernia, 1095
 - for PPHN, 1093
 - for RDS, 1081
 - for respiratory distress and failure, 619
 - Inheritance
 - digenic, 740
 - multifactorial and polygenic, 744–748
 - nontraditional
 - genetic imprinting, 742–743
 - mitochondrial, 742
 - triplet repeat expansion disorders, 742
 - pseudodominant, 738
 - pseudogenetic, 740–742
 - X-linked, 738–740
 - Y-linked, 740
 - Inherited aplastic anemias, 3000t, 3009–3010
 - Inherited bone marrow failure syndromes
 - HSCT for, 1353–1354
 - with pancytopenia, 2999–3010, 3000t–3001t
 - unclassified, 3010, 3011t
 - Inherited conjugated hyperbilirubinemia, 2456
 - Inherited deficient conjugation of bilirubin, 2454–2456
 - Inherited diseases of muscle, myogenic regulatory genes and genetic loci of, 3805–3808
 - Inherited disorders of surfactant metabolism, 2683
 - pathology of, 2683
 - deficiency in surfactant protein B, 2683–2684
 - disease caused by variants in ABCA3, 2684–2685
 - disease caused by variants in *NKX2-1*, 2685
 - surfactant protein C-associated interstitial lung disease, 2684
 - treatment of, 2685–2686

- Inherited erythromelalgia, 3890, 3891f
 Inherited lymphopenia, 1312
 Inherited metabolic diseases, HSCT for, 1354
 Inherited neutropenia, 1308–1311, 1310f
 Inherited retinal dystrophies (IRDs), 3958–3959, 3958f–3959f
 Inherited thrombophilia, 2692, 3039
 Inherited tubular transport abnormalities, 3240–3242
 Bartter syndrome, 3240–3241, 3240t–3241t
 Gitelman syndrome, 3240t–3241t, 3241–3242
 other, 3241–3242
 Inhibin, 3486
 Inhibin B, 3486
 Inhibitory control (IC), 303
 In-hospital cardiac arrests (IHCA), 564
 Initial orthostatic hypotension (IOH), 597
 Injectable sympathomimetic epinephrine, for asthma, 1405t–1406t
 Injections, progestin-only methods, 1218t–1219t, 1221–1222
 Injuries
 deaths, in U.S., 92t
 kidney
 acute, 3242–3247
 chronic, 3247–3252
 during labor, fractures, 1073
 liver, drug- and toxin-induced, 2490–2493
 prevention of, 2493
 prognosis of, 2493
 treatment of, 2493
 lung
 acute, pulmonary pressure-volume relation in, 621f
 ventilator-induced, 629
 mechanism of, 4297–4299
 nonfatal, 91
 patterns of, 115t
 prevention of, in developing world, 544
 psychosocial consequences of, 98–99
 spine and spinal cord, during birth, 1068
 Injury control, 91–99
 mechanisms of injury, 95–98
 principles of, 92–93, 94t
 risk factors, 93–95
 scope of problem, 91–92
 global child injuries, 91–92
 mortality, 91
 nonfatal injuries, 91
 Innate immune lymphocytes, 1286
 Innate immune response, 1315
 Innate immunity, defects in, 1335–1343, 1346
 Innate lymphoid cells, in allergic diseases, 1370
 Inner ear, 4020–4021
 congenital malformations of, 3997–3998, 3998t
 Innocent murmur, 2745
 Innominate, aberrant, 2577
 Innominate artery, anomalous, 2827t
 Inorganic lead compounds, 4436
 Inorganic mercury salts, intoxication, 4433
 Inositol, 456
 Inotropic therapy, for PPHN, 1093
 Inpatient services, in developing-world hospitals, 547
 INRG. See International Neuroblastoma Risk Group
 Insect allergy, 1419–1421
 clinical manifestations of, 1420
 diagnosis of, 1420
 etiology of, 1419–1420
 pathogenesis of, 1420
 prevention of, 1421
 treatment of, 1420–1421
 Insecticide-treated bed nets, 2184
 Insertional periodontitis, 4227
 Insertions, 731, 732t, 770
 Insomnia
 of childhood, 203–205
 fatal familial, 2118, 2119t
 in pediatric palliative care, 65t–68
 Inspiration
 initiation of, 624–625
 termination of (cycle), 626
 Inspiratory capacity, 2519
 Inspiratory flow pattern, selection of, 627–628
 Inspiratory flow waveform, 626
 Inspiratory phase characteristics, 625–626
 Inspiratory time, 627
 appropriate, selection of, 627
 Inspired oxygen, fraction of, 627
 Inspissated bile syndrome, 1125
 INSSSI. See International Neuroblastoma Staging System
 Instability, chromosome instability syndromes, 772–773, 774t
 Institutional ethics committees, 53
 Institutional racism, 20–21, 20f
 Instruments inflicting injury, 116f
 Insulin, 707t–708t
 action, genetic defects of, 3546–3548
 adverse reactions to, 1459
 therapy, for T1DM, 3528–3529, 3528t, 3529f–3530f
 Insulin aspart, for T1DM, 3528–3529
 Insulin-dependent diabetes mellitus (IDDM), 516, 3515
 Insulin gene, abnormalities of, 3546
 Insulin pump, 3528
 Insulin resistance syndrome, prediabetes and, 3517
 Insulin sensitivity factor (ISF), 3528
 Insulin-like growth factor 1 (IGF-1), 3360
 gene abnormalities, 3368
 receptor, gene abnormalities, 3368
 Insulin-like growth factor (IGF) 2, overexpression of, 3472
 Insulin-like growth factor-binding protein abnormalities, 3368
 Insulin-like growth factor (IGF) deficiency, 3367t
 Insulin-mediated disorders, 984–987
 Insulinoma, 987
 Integrated Management of Childhood Illnesses (IMCI), 29–32, 33f, 546
 Integrative functioning, 592
 Integrative medicine, 56–58
 acupuncture in, 57–58
 cannabis in, 58
 dietary supplements in, 56, 56t
 efficacy of, 57
 safety of, 56–57, 57t
 massage and chiropractic in, 57
 mind-body therapies in, 57, 58t
 Integrative therapies, in pediatric palliative care, 71
 Integumentary system, autonomic dysreflexia in, 4391t
 Intellectual disability, 302, 346–362
 AAC and, 338
 clinical manifestations, 350–352, 350t–352t
 complications and associated conditions of, 356, 356t
 definition, 346
 diagnostic psychologic testing for, 356
 differential diagnosis of, 353–354
 epidemiology, 349
 etiological evaluation of, 352–353
 etiology, 347–349, 348t–349t
 evaluation of, 353f, 354t
 genetic testing guidelines for, 347t
 language disorders associated with, 329
 nonprogressive, 346
 outcomes of, 358t–359t, 361–362
 pathology and pathogenesis, 350
 physical examination for, 350t–352t
 prevention of, 356–357
 primary care, supportive care, and management of, 357–361
 treatment for, 357
 Intellectual functioning, clinical assessment of, 301–302
 Intellectual impairment
 in Duchenne muscular dystrophy, 3831
 in myotonic muscular dystrophy, 3836
 Intelligence, math disabilities and, 320
 Intelligence quotient (IQ), and reading, uncoupling over time, 315f
 Intensity-modulated radiation therapy, 3091
 Intensive symptom management, in pediatric palliative care, 71
 Intention tremor, 3678
 Intentional injury, deaths, 92t
 Intentional poisonings, 701
 Interactional abilities of neonates, 149
 Intercostal block, in pain management, 694
 Intercountry adoption, 72
 Intercultural awareness, development of, 82f
 Interdisciplinary assessment, for physical abuse and neglect, 119
 Interdisciplinary management, of intellectual disability, 357
 Interdisciplinary pediatric pain programs, 699–700
 Interfacility transport, 537
 educational outreach in, 542
 family-centered care in, 542
 ground vs. air ambulance in, 541
 medical control physician in, 540–541
 referring hospital responsibilities in, 542
 safety in, 542
 of seriously ill/injured pediatric patient, 540
 transport physiology in, 541
 transport team in, 541
 Interferon- α 2b (IFN- α 2b), for hepatitis B, 2467
 Interferon- γ , for atopic dermatitis, 1417
 Interferon- γ receptor (IFNGR), deficiency of, 1864
 Interferon- γ release assay (IGRA), in tuberculosis, 1847–1848, 1847t–1848t
 Interferon- γ /IL-12 pathway defects, 1346
 Interferonopathies, 1529–1535, 1530t, 1531f, 3890–3891
 autoimmune, 1535
 autoinflammatory, 1531–1535
 characteristic clinical phenotypes of, 1532f
 type I, 1533t
 Interferon-stimulated genes (ISGs), 1338
 Interim therapeutic restorations, for dental caries, 2247
 Intermediate (mild) maple syrup urine disease, 826
 Intermediate nephropathic cystinosis, 3234–3235
 Intermittent asthma, management of, 1399t–1400t
 Intermittent explosive disorder (IED), 277
 clinical course of, 277
 comorbidity of, 277
 differential diagnosis of, 277
 DSM-5, 278t
 epidemiology of, 277
 etiology of, 278
 prevention of, 278–279
 risk factors of, 278
 sequela of, 277–278
 treatment for, 279–280
 Intermittent fever, 1640–1641
 Intermittent hemodialysis, in acute kidney injury, 3246, 3246t
 Intermittent mandatory ventilation (IMV)
 definition of, 624
 synchronized, 624, 625f
 Intermittent maple syrup urine disease, 826
 Intermittent testicular torsion, 3306
 Internal rewards, 170
 Internal snapping hip syndrome, 4332
 Internalized racism, 19
 International adoption, 72–75
 postadoption medical care, 73–75
 preadoption medical record reviews, 72–73
 International agency for research on cancer (IARC), 4413
 International Federation of Emergency Medicine, 546
 International Neuroblastoma Risk Group (INRG), 3129
 International Neuroblastoma Staging System, 3127t, 3129
 International Pediatric Non-Hodgkin Lymphoma Response Criteria (IPNHLRC), 3114t
 International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLLS), 3112, 3113t
 International Standard Cytogenomic Array (ISCA)
 Consortium, genetic testing guidelines for ID/GDD/ASD, 347t
 Internet genetic reference sites, 726t
 Internuclear ophthalmoplegia, 3553
 Interparental conflict, 195
 Interpersonal coercive behavior, 283
 Interpersonal psychotherapy, 231
 Interpersonal racism, 19–20
 Interpersonal violence, 1189–1190
 Interphase, 761
 Intersectionality, 81–82
 Intersex, 3503–3504
 Interstitial cystitis, 3264
 Interstitial hypertrophic neuropathy, 3876
 Interstitial keratitis, 1869t, 3946, 3948t

- Interstitial lung disease, 2632–2637, 2634t
 anti-glomerular basement membrane disease, 2636–2637
 classification and pathology of, 2632–2633, 2632t–2634t
 diagnosis of, 2635–2636
 prognosis for, 2636
 treatment of, 2636
 wheeze and, 2529
- Interstitial nephritis, 3205, 3206t
 acute, 3244t
- Interstitial pressure, increased negative, 2604t
- Intertriginous candidiasis, 4166, 4166f
- Interventional catheterization, most common congenital heart defects in, 2839t
- Interventions
 behavioral, theories employed in, 140
 early, for conduct disorders, 279
 for neurodevelopmental dysfunctions, 308t
 for obesity, 445–448
 office, for behavioral and mental health issues, 89–90
- Intervertebral disk herniation, 4256–4257, 4257f
- Interviewing
 of adolescent, 1169
 clinical, in ADHD, 311–312
 psychosocial, 216–218
 of rape victims, 1236
- Intestinal atresia, 2282–2285
- Intestinal disorders, *Staphylococcus aureus*, 1696
- Intestinal duplication, 2286, 2286f
- Intestinal dysmotility, causing intestinal failure, 2352t
- Intestinal failure, intestinal transplantation in, 2352–2354, 2352t
- Intestinal failure associated liver disease (IFALD), 2346
- Intestinal flukes, 2215
- Intestinal grafts, types of, 2352–2353
- Intestinal iron absorption, 2351
- Intestinal lymphangiectasia, 2341–2342
- Intestinal neuronal dysplasia (IND), 2293t, 2296f, 2298–2299
- Intestinal obstruction, 1100–1102, 2282, 2285f
 congenital diaphragmatic hernia and, 1096
 in newborn, 1053t
- Intestinal pathogens, in immigrant children, 80
- Intestinal tract
 cystic fibrosis and, 2667, 2667f
 infection, 1800t
 stage of GVHD, 1358t
- Intestinal transplantation, in intestinal failure, 2352–2354
 allograft assessment of, 2354
 donor selection of, 2352–2353
 indications for, 2352, 2352t
 infections in, 2354
 operation, 2352–2353
 outcomes of, 2354
 postoperative management of, 2353–2354
 recipient operation, 2353, 2353f
 rejection and graft-versus-host disease in, 2354
 types of intestinal grafts for, 2352–2353, 2353f
- Intestines
 development of, 2276–2277
 foreign bodies in, 2302–2304
- Intimate partner violence (IPV), 99
- In-toeing gait, 4212–4213
- Intoxication
 alcohol, hypoglycemia and, 991
 amphetamines/cocaine, 1206t
 benzodiazepines, 1206t
 opiates, 1206t
 salicylate, 516, 991
 sedatives, 1197t
 vitamin D, findings in, 480
 water, hyponatremia due to, 493
- Intraabdominal infection, anaerobic, 1828
- Intracardiac shunt, pulmonary stenosis in, combination with, 2790
- Intracellular cholesterol metabolism, disorders of, 881
- Intracellular fluid (ICF), 485
 cations and anions, 486f
 osmotic equilibrium in, 486
- Intracranial aneurysms, autosomal dominant polycystic kidney disease, 3217
- Intracranial hemorrhage, 3050
 Intracranial hypertension, 3784, 3784f
 idiopathic, 3782–3785, 3782f
 clinical manifestations of, 3782–3784, 3782f–3784f
 diagnostic criteria for, 3784t
 etiology of, 3782, 3783t
 treatment of, 3784–3785
- Intracranial infections, in neonatal seizures, 3619
- Intracranial-intraventricular hemorrhage, 1058, 1060t
- Intracranial pressure (ICP), 581
 increased
 anesthetic implications in, 666t
 as oncologic emergency, 3092t–3093t
 secondary headaches in, 3651
- Intracranial tumors, causing precocious puberty, 3392
- Intractable headaches, emergency department treatments for, 3647–3648
- Intractable migraine, inpatient management of, 3648
- Intracultural variability, 82, 82f
- Intradermal technique, 1378
- Intraductal papilloma, 3331
- Intrahepatic bile duct
 cystic dilation, 2501
 formation, process of, 2436f
- Intrahepatic portal hypertension, 2504t
- Intraluminal impedance, GERD, 2266
- Intramembranous ossification, 4193
- Intranasal corticosteroids, 208t
 for allergic rhinitis, 1382, 1384t–1385t
- Intranasal decongestants, for allergic rhinitis, 1382
- Intraocular pressure (IOP), 3969
- Intraoral dental radiographs, 2255
- Intraosseous access, 570, 570f
- Intrapartum antibiotics, 1149, 1151t
- Intrapartum aspiration, 1089–1090
- Intrapartum infection, pathways of, 1145f
- Intrapulmonary right-to-left shunting, 2518–2519
- Intrapulmonary sequestration, 2601
- Intrapulmonary shunting, in respiratory failure, 614
- Intrarenal reflux, 3268f
- Intrastate conflicts, 107–108
- Intrathecal analgesia, in pain management, 696
- Intratracheal goiter, 3413
- Intrauterine device (IUD), 1218t–1219t, 1220–1221, 1222t
 copper, 1226
 progesterone, 3356
- Intrauterine Foley balloon placement, 1214
- Intrauterine growth restriction (IUGR)
 definitions, 1042
 factors associated with, 1043t, 1048t
 fetal therapy for, 1027t
 incidence, 1042
 small, infants, 1048t
- Intrauterine infections
 in genital mycoplasmas, 1891–1892
 pathogenesis of, 1152, 1155t
- Intrauterine inflammation or infection at birth (Triple I), 1154, 1156t
- Intrauterine vascular compromise, in arthrogryposis, 4271
- Intravascular access devices, 1667–1668
 catheter-associated skin and soft tissue infection, 1667
 catheter-related bloodstream infection, 1667–1668
 catheter types, 1667
 prevention of infection, 1668
- Intravenous anesthetic agents, 670–671
- Intravenous antibiotic therapy, for cystic fibrosis, 2675
- Intravenous immunoglobulin (IVIG)
 for gestational alloimmune liver disease, 2459–2460
 for hyperbilirubinemia, 1115
 for Kawasaki disease, 1546–1547
 for mucocutaneous bleeding, 3054
 for rheumatic diseases, 1466t–1468t, 1470, 1470t
- Intravenous lipid emulsion (ILE) therapy, 708t, 709, 714
- Intravenous solutions, 526, 527t
- Intraventricular hemorrhage (IVH), 995
- Intraventricular neurocysticercosis, 2218
- Intravitreal antibiotics, for endophthalmitis, 3976
- Intrinsic immunity, defects in, 1346
- Intrinsic renal acute kidney injury, 3242–3244
- Introns, 730, 732f
- Intrusion, of periodontal structures, 2251, 2251f
- Intubation
 endotracheal
 in infectious upper airway obstruction, 2571–2572
 in respiratory distress and failure, 619–620
 medications commonly used for, 620t
 rapid sequence, 619
- Intuniv. See Guanfacine
- Intussusception, 2300–2302
 acute gastroenteritis and, 2367
 clinical manifestations of, 2301
 diagnosis of, 2300f–2301f, 2301
 differential diagnosis of, 2301
 etiology and epidemiology of, 2300
 pathology of, 2300
 prognosis of, 2302
 treatment of, 2301–2302
- Invasive aspergillosis, 1930–1931
 HSCT complication, 1363, 1363f
- Invasive bacterial infections, susceptibility to, 1340, 1340f
- Invasive diseases
 GAS infection, 1708
Haemophilus influenzae in, 1758
Neisseria meningitidis, treatment of, 1743t
- Invasive mechanical ventilation, 623–626
 control modes in, 624
 assist-control mode as, 624
 intermittent mandatory ventilation mode as, 624
 control variable in, 624–625
 expiratory phase maneuvers in, 626
 initiation of inspiration, 624–625
 inspiratory phase characteristics of, 625–626
 support modes in, 625
 termination of inspiration (cycle) in, 626
- Invasive pneumococcal infections, 1701
 recurrent, 1254, 1255t
- Invasive positive pressure ventilation, 2716–2717
- Invega. See Paliperidone
- Inversion stress tilt test, 4311f
- Inversions, 767
- Involuntary movements, in motor examination, 3555
- Iodide goiter, 3415
- Iodine, 56t, 483t
 deficiency, 424, 483–484, 3404, 3413
 endemic goiter and cretinism, 3413–3415
 goiter, 3415
 exposure, congenital hypothyroidism and, 3404
 organification, defective, 3403
 in vegetarian diets, 418
- Ion transporter disorders, 4347–4348
 achondrogenesis type 1B and atelosteogenesis type 2, 4347–4348
 autosomal recessive multiple epiphyseal dysplasia, 4348
 diastrophic dysplasia, 4348, 4348f
- Ionizing radiation, biologic effects of, 4413–4422
- IOP. See Intraocular pressure
- I-PASS, 47
- IPEX. See Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
- IPH. See Idiopathic pulmonary hemosiderosis
- IPNHLRC. See International Pediatric Non-Hodgkin Lymphoma Response Criteria
- IPNLSS. See International Pediatric Non-Hodgkin Lymphoma Staging System
- Ipratropium bromide, for allergic rhinitis, 1384t
- IPSID. See Immunoproliferative small intestinal disease
- IPV. See Inactivated polio vaccine; Intimate partner violence
- IRAK1 deficiency, 1341t
- IRAK4 deficiency, 1340, 1341t
- IRDs. See Inherited retinal dystrophies
- IRF3 deficiency, 1339t
- IRF7 deficiency, 1339t
- IRF8 deficiency, 1288
- IRF9 deficiency, 1339t
- Iridocyclitis, 3940t, 3952, 3954f
- Iris, 3909
 abnormalities, 3920–3924
 aniridia, 3920, 3920f
 coloboma of, 3920, 3921f, 3921t
 heterochromia, 3924
 hypopyon, 3924

- Iris (*Continued*)

juvenile xanthogranuloma, lesion of, 3924

Lisch nodules, 3924

pigmented hamartomas of, 3655f

Iritis, 3952, 3954f

Iron, 56t, 483t

in development of porphyria cutanea tarda, 973

dietary reference intake, 396, 404t–407t

poisoning, 707t–708t, 714–715, 715t

reference intervals, 4472.e9t

responses to, 2949t

in vegetarian diets, 418

Iron deficiency, 396

as goitrogens, 3415

Iron-deficiency anemia, 2944–2950

causes of, 2945t

clinical manifestations of, 2944–2946

differential diagnosis of, 2946, 2948t

etiology of, 2944, 2945t

indicators of, 2947t

iron-refractory, 2948–2950

laboratory findings of, 2946, 2948f

prevention of, 2946

treatment of, 2946–2948

Iron metabolism

central role of hepcidin in, 2936f

defects of, 2950–2952

Iron overload

in sickle cell anemia, 2975–2976, 2985t

in thalassemia, 2983

Iron-refractory iron-deficiency anemia, 2948–2950

clinical manifestations of, 2949

differential diagnosis of, 2949–2950, 2949t

etiology of, 2948–2949

laboratory findings of, 2949

treatment of, 2950

Iron supplementation, 3251

Iron-binding capacity, reference intervals, 4472.e9t

Iron-deficiency anemia, 424, 1118–1119, 2201

Iron-refractory iron-deficiency anemia, 2950

Irradiation

brain, precocious puberty following, 3391

for Ewing sarcoma, 3144

for noninfectious risks of transfusion, 3021

whole body, 4418–4419

Irregularities, in menstrual cycle, 1210–1211

Irritability

medications for, 228t

in newborn, 1053

persistent, of acutely ill child, 551

Irritable bowel syndrome, 2389–2390, 2390t

Irritant contact dermatitis, 4087, 4088f

Irritant-induced asthma, 2619

Irritants, triggering atopic dermatitis, 1418

ISAGA. See Immunosorbent agglutination assay

Isavuconazole, 1917t, 1920

for mucormycosis, 1944

for paracoccidioidomycosis, 1941

Ischemia, classification of coronary anomalies based on, 2830t

Ischemic priapism, 3300

Ischium, 4231

Iselin apophysitis, 4313

Iselin disease, 4208, 4300

ISF. *See* Insulin sensitivity factor

ISG15 deficiency, 1530t, 1534–1535

Islet cell transplantation, in T1DM, 3538

Isochromosomes, 770

Isodisomy, uniparental, 773

Isoenzymes, reference intervals, 4472.e9t

Isoflurane, 669t, 670

Isolated aortitis, 1553t

Isolated congenital asplenia, 1341, 1341t

Isolated craniosynostosis, 3582t

Isolated enzyme deficiencies, 2424

Isolated gonadotropin deficiency, 3491–3493

Isolated IgG subclass deficiency, with normal immunoglobulin levels and normal quality antibody responses, 1349

Isolated renal disease, causing hematuria, 3185t

Isolation

of cases, in pandemic, 1584

in pertussis, 1763

Isolation fencing, 645

Isoleucine, metabolism defects, 825–837

Isoniazid

poisoning, 707t–708t

for tuberculosis, 1849t, 1830, 1831t, 1853

Isopropyl alcohol, 720

Isosexual precocious sexual development, 3502

Isotretinoin

for acne, 4180–4181

indications and adverse reactions of, 3089t–3090t

Isotype defects, 1285

Isovaleric acidemia, 827–828

Isovolumic hyponatremia, 494–495

Isradipine, for severe hypertension in children, 2919t

ITB. *See* Iliotibial band friction syndrome

Itching, in exclusion or inclusion in daycare, 187t–192t

ITP. *See* Immune thrombocytopenia

Itraconazole, 1917t, 1919

for blastomycosis, 1936

for paracoccidioidomycosis, 1941

for sporotrichosis, 1942

Ivemark syndrome, 3063

Ivermectin, 2144

for ascariasis, 2199

for gnathostomiasis, 2209

for hookworms, 2202

for lymphatic filariasis, 2207

for onchocerciasis, 2207

for strongyloidiasis, 2205

for trichuriasis, 2203

IVIG. *See* Intravenous immunoglobulin

IWE. *See* Impairment in written expression

Ixodes scapularis, Lyme disease and, 1881
- J**
- Jacobsen syndrome, 768t–769t

Jak3 deficiency, 1263t

Jamaican vomiting sickness, 989

Jansen metaphyseal dysplasia, 4347

Jansen-type metaphyseal chondrodysplasia, 3443, 4334, 4337f

Jansky-Bielschowsky syndrome, 887t, 3716

Janus kinase (JAK) inhibitors, for atopic dermatitis, 1417

Japanese encephalitis, 2063–2064, 3776

vaccine, 1588t–1589t

Jarcho-Levin syndrome, 4248

Jarisch-Herxheimer reaction, 1873, 1885

Jatene procedure, 2813, 2814f

Jaundice, 1099t, 2224, 2438

breastfeeding and, 411

diagnostic approach to infants with, 2445

in newborn, 1054, 1106–1115

associated with breastfeeding, 1110–1111, 1111f

clinical manifestations of, 1106

differential diagnosis of, 1106–1107, 1107t–1109t, 1109f

etiology of, 1106–1111, 1106f

physiologic, 1108t, 1110, 1110f

toxoplasmosis and, 2190–2191

Jaws, diseases of, 2254

JC polyomaviruses, 2086, 2086t

Jeavons syndrome, 3600–3601

Jejunal atresia, 2283–2284, 2283f–2284f

Jequirity bean, toxicity, 722t

Jervell-Lange-Nielsen syndrome, 595t, 3987t

Jeune asphyxiating thoracic dystrophy, 792t

Jeune syndrome, 2715f, 4248, 4355

JIA. *See* Juvenile idiopathic arthritis

Jin bu huan, 2492t

Jitteriness, seizures vs., 3619

JMML. *See* Juvenile myelomonocytic leukemia

Jogger's nipple, 3331

Johanson-Blizzard syndrome, 2424

Joint disease, in tuberculosis, 1845, 1845f

Joints

complications in, cystic fibrosis and, 2677

Staphylococcus aureus, 1696

Jones classification, 4218

Jones fracture, 4312

Joubert syndrome, 792t, 3672

in brainstem and cerebellar disorders, 3576–3577, 3577f–3578f

JPS. *See* Juvenile polyposis syndrome

J sign, 4229

Jugular venous pulse, 2740

Juice, in children, 413

Jumper's knee, basketball and, 4328

Junctional epidermolysis bullosa, 4081–4082, 4082t, 4083f

Justice, 51

pediatric ethics and, 55

Juvenile absence seizures, 3598, 3601

Juvenile amyotrophic lateral sclerosis, 3874

Juvenile delinquency, 1190

Juvenile dermatomyositis (JDM), 1460, 1500–1506, 1535, 4031–4032, 4032f

clinical manifestations, 1500–1502, 1503f

complications, 1506

diagnosis, 1502

diagnostic criteria for, 1502t

differential diagnosis, 1502

epidemiology, 1500

etiology, 1500

evaluation based on suspected diagnosis, 1463t

features of, 1504f

frequency of manifestations of, 1505t

laboratory findings, 1502–1504

pathogenesis, 1500

prognosis, 1506

treatment, 1504–1506

Juvenile diabetes, 3515

Juvenile GM₁ gangliosidosis, 3713

Juvenile GM₂ gangliosidosis, 3714

Juvenile granulosa cell tumors, 3343

of ovary, 3502–3503

Juvenile hallux valgus, 4208–4209, 4209f

Juvenile hypertrophy, 3330

Juvenile hypothyroidism, 3327

Juvenile idiopathic arthritis (JIA), 1460, 1471–1482

associated with AA amyloidosis, 1536

biologic therapies, 1469–1470

classification, 1471t–1472t

clinical manifestations, 1471–1477

CT scan of temporomandibular joint, 1477f

diagnosis, 1477–1478

differential diagnosis, 1478

epidemiology, 1471

etiology, 1471

evaluation based on suspected diagnosis, 1463t

knee, 1475f

laboratory findings, 1479–1480

macrophage activation syndrome, 1476–1477

micrognathia, 1474–1475

MRI

of knee, 1475f

of wrist, 1480f

oligoarthritis, 1471, 1474f

pathogenesis, 1471, 1475f

pharmacotherapy, 1481t

prognosis, 1482

radiograph of, 1477f

rash in, 1478f

shoulder, 1475f

subtypes, features of, 1473t

systemic, 1478, 1539, 1539t

treatment, 1480–1482

Juvenile laryngeal papillomatosis, 2053

Juvenile metachromatic leukodystrophy, 3715

Juvenile myelomonocytic leukemia (JMML), 3105

HSCT for, 1353

Juvenile myoclonic epilepsy, 3601

Juvenile nephronophthisis (JN), 3207t

Juvenile nephronophthisis (JN)-medullary cystic kidney disease complex (MCKD), 3205–3208

Juvenile osteochondritis dissecans (OCD), 4226, 4227f

Juvenile osteochondroses, 4357, 4357t

Juvenile Paget disease, 4383

Juvenile papillomatosis, 3332

Juvenile paresis, 1869t

Juvenile pilocytic astrocytoma, 3967

Juvenile plantar dermatosis, 4087

Juvenile POLG syndrome, 3699

Juvenile polymyositis (JPM), 1505t
 Juvenile polyposis syndrome, 2411, 2412f
 Juvenile primary fibromyalgia syndrome, 1569–1570, 1573t
 Juvenile recurrent parotitis, 1517
 Juvenile spring eruption, 4096
 Juvenile tabes, 1869t
 Juvenile tropical pancreatitis, 2431
 Juvenile type neuronal ceroid lipofuscinosis (JNCL), 3716
 Juvenile xanthogranuloma (JXG), 3169, 3179, 3924, 4187–4188, 4187f
 JXG. See Juvenile xanthogranuloma

K

Kabuki syndrome, 796, 796f, 797t, 2764t–2766t
 Kala-azar (visceral leishmaniasis), 2159
 Kallmann syndrome, 3396–3397, 3491, 4110
 Kaposi sarcoma (KS), 2019
 Kaposiform hemangioendothelioma, 3160–3161, 3163f, 4057, 4058f
 Kaposiform lymphangiomatosis, 3065
 Kapvay. See Clonidine
 Kartagener syndrome, 2679–2682
 Karyotype
 G-banded, 767f
 sex chromosome abnormalities, 770t
 Kasabach-Merritt phenomenon (KMP), 3160–3161, 4057–4060
 Kasabach-Merritt syndrome, 2996, 3055
 Katayama syndrome, 2212
 Kava, 2492t
 Kawasaki disease, 1540–1548, 1553t, 1699, 2906, 2907f, 4031t, 4033
 clinical manifestations of, 1541–1543, 1542f, 1542t
 complications of, 1547–1548
 diagnosis of, 548–549, 1544
 differential diagnosis of, 1544–1545, 1546t
 epidemiology of, 1540–1541
 etiology of, 1540
 laboratory and radiology findings of, 1543–1544, 1545t
 node-first, 1543, 1544f
 pathology of, 1541
 prognosis for, 1548
 shock syndrome, 1543
 treatment of, 1546–1547, 1547t
 Kayser-Fleischer ring, 2457f
KBTBD13 nemaline myopathy, 3812
 Kearns-Sayre syndrome (KSS), 2933, 3698, 3854
 caused by pathogenic variants in mtDNA, 743t
 spectrum disorder, 934
 Kegel exercises, 3293
 Keloid, 4119–4126, 4119f
 Keratinization disorders, 4110–4119
 autosomal recessive congenital ichthyoses, 4110–4116
 harlequin ichthyosis, 4110–4115
 lamellar ichthyosis and congenital ichthyosiform erythroderma, 4115–4116, 4115f–4116f
 collodion baby, 4110, 4115f
 of cornification, 4110, 4111t–4114t
 keratinopathic ichthyoses, 4116
 epidermolytic ichthyosis, 4116, 4116f
 nonsyndromic ichthyoses, 4110
 erythrokeratoderma variabilis, 4116–4117, 4116f
 ichthyosis vulgaris, 4110, 4113t–4114t, 4115f
 symmetric progressive erythrokeratoderma, 4117
 X-linked ichthyosis, 4110, 4115f
 syndromic ichthyoses, 4117–4118
 chondrodysplasia punctata, 4118
 diffuse hyperkeratosis of palms and soles, 4118–4119, 4118f
 mal de Meleda, 4119
 Netherton syndrome, 4114t, 4117–4118, 4117f
 palmoplantar keratodermas, 4118
 Papillon-Lefèvre syndrome, 4119
 Refsum syndrome, 4118
 Sjögren-Larsson syndrome, 4117
 Vohwinkel palmoplantar keratoderma, 4119
 Keratinocytes, 4025
 Keratinopathic ichthyoses, 4116

Keratitis, 1800t, 3940t
 in *Aspergillus* infection, 1931
 dendritic, 3945, 3947f
 interstitial, 3946, 3948t
 Keratoconus, 1375, 1423, 3943, 3944f
 Keratoderma blennorrhagica, 1488f
 Keratolytic agents, 4039
 Keratomalacia, 453–454
 Keratosis pilaris, 1375, 4103–4104, 4104f
 Kerion, 4160–4161, 4161f
 Kerner-Morrison syndrome, 3126t
 Kernicterus, 1111–1115
 clinical manifestations of, 1111, 1111t
 incidence and prognosis of, 1111
 in newborn, 1106–1115
 pathologic, 1110
 prevention of, 1111–1112, 1112f–1113f
 treatment of, 1112–1115, 1114f–1115, 1114t
 exchange transfusion, 1115, 1116f
 intravenous immunoglobulin, 1115
 phototherapy, 1114–1115
 Kernig sign, in acute meningitis, 3761–3762
 Ketamine, 669t, 670, 689t
 for intubation, 620t
 for status epilepticus, 3629
 Ketoacid, accumulation of, in T1DM, 3527
 Ketoacidosis, 830
 starvation, 516
 Ketogenic diet, in status epilepticus, 3629
 Ketone bodies, 831f
 Ketone body utilization, defects in, 865
 Ketone synthesis pathway, defects in, 862f, 865
 Ketorolac
 for migraine, 3646t–3647t, 3648
 in pain management, 681t
 17-ketosteroid reductase, deficiency of, 3511
 β-Ketothiolase deficiency, 830–831, 831f, 865
 Ketotic hypoglycemia, 989–991
 causes of, 990t
 idiopathic, 991
 Key driver diagrams (KDDs), 38, 38f
 KHE. See Kaposiform hemangioendothelioma
 Kidney biopsy, 3258
 Kidney disease
 associated with prematurity, 1046t
 end-stage, 3252–3253
 hemodialysis in, 3253
 peritoneal dialysis in, 3252
 nephrotic syndrome and, 3228
 polycystic
 autosomal dominant, 2501–2502
 autosomal recessive, 2500–2501
 Staphylococcus aureus, 1696
 Kidney Donor Profile Index (KDPI), 3254
 Kidney failure, 2242t
 Kidney injury, acute, 3242–3247
 causes of, 3243t
 clinical manifestations of, 3244
 complications of, 3245t
 KDIGO staging of, 3242t
 laboratory findings of, 3244–3245
 neurologic symptoms in, 3246
 pathogenesis of, 3242–3244
 prognosis of, 3247
 treatment of, 3245–3247
 dialysis, 3246–3247
 medical management, 3245–3246
 Kidneys, 3180
 anomalies in shape and position, 3262–3263
 arsenic effects in, 4432t
 associated physical findings, 3263
 congenital anomalies and dysgenesis of, 3260–3263
 embryonic development, 3260
 excretion of water, 488
 mineralocorticoid in, 3448
 neoplasms, 3130–3135
 clear cell sarcoma of, 3135
 mesoblastic nephroma, 3135
 pediatric renal tumors and, 3135
 renal cell carcinoma of, 3135
 rhabdoid tumor of, 3135
 Wilms tumor and, 3130–3135, 3131t

Kidneys (*Continued*)
 normal acid-base balance and, 509
 sodium balance and, 488
 Kidneys-ureters-bladder (KUB) radiograph, 4439
 Kikuchi-Fujimoto disease, 3070
 Kindler syndrome, 4084
 King Denborough syndrome, 3850
Kingella kingae, 1752–1755
 in bacterial arthritis, 4291
 causing spine infection, 4255
 clinical disease in, 1753, 1754t
 diagnosis of, 1754
 endocarditis and, 1754
 epidemiology of, 1752–1753, 1753f
 etiology of, 1752
 occult bacteremia, 1754
 osteomyelitis, 1753, 1754f
 pathogenesis of, 1753
 prevention of, 1755
 septic arthritis and, 1753
 in spondylodiscitis, 1753–1754
 treatment of, 1754–1755
 Kinky hair disease, 3719–3720
 Kinship care, 75–78
 children and adolescents in, healthcare for, 76–78, 77t–78t
 epidemiology of, 75
 health issues in, 76, 77t
 legislation for, in United States, 75
 Kleeblattschädel, 4345
 Kleine-Levin syndrome, diagnostic criteria for, 213, 213t
 Klein's line, 4240, 4241f
 Kleptomania, 282
 Klinefelter syndrome, 770t, 771, 3382, 3397, 3489–3491
 in gynecomastia, 3495
 Klippel-Feil syndrome, 4260–4261, 4260f
 Klippel-Trenaunay syndrome, 3158, 3162f, 4052, 4052f
 Klisis test, 4233, 4234f
 Klonopin. See Clonazepam
 Klumpke palsy, 4397
 Klumpke paralysis, 1068
 KMP. See Kasabach-Merritt phenomenon
 Knee, 4224–4231
 anatomy of, 4224
 disorders of
 anterior cruciate ligament rupture, 4230–4231, 4231f
 discoid lateral meniscus, 4224–4225, 4225f
 juvenile osteochondritis dissecans, 4226, 4227f
 Osgood-Schlatter disease, 4226–4228, 4227f–4228f
 patellofemoral instability, 4228–4230, 4229f
 patellofemoral pain syndrome, 4228
 popliteal cysts, 4225–4226
 musculoskeletal pain syndrome, 1568t
 normal development of, 4224
 range of motion of, 4224
 sports-related injuries, 4308–4310
 iliotibial band (ITB) friction syndrome, 4310
 initial treatment, acute, 4309–4310, 4309f
 Osgood-Schlatter disease, 4310
 patellar tendinitis, 4310
 patellofemoral pain syndrome, 4310
 Sinding-Larsen-Johansson disease, 4310
 Knee pain, 4308
 Kniest dysplasia, 4340–4341, 4341f
 Knock-knees, 164, 4216
 Kobayashi score, in Kawasaki disease, 1541
 Kocher-Debré-Séméaigne syndrome, 3405, 3846
 Koebner phenomenon, 4075, 4098
 Koebnerization, 4166–4167
 Kohlberg's theory of moral development, 140t
 Kohler disease, 4313
 Koilonychia, 4142, 4143f
 Kombucha, 2492t
 Konno procedure, 2792
 Koplik spots, in measles, 1958–1959, 1960f
 Kostmann disease, 1308
 Krabbe disease, 887t–888t, 896, 3714
 in leukodystrophies, 3889
 Krieger's ecosocial model, 998–999, 999f
 Krimsky method, of corneal reflex test, 3925
 KTS. See Klippel-Trenaunay syndrome

- Kugelberg-Welander disease, 3866, 3868–3869
 Kuru, 2119t, 2120
 Kwashiorkor, 426, 4190, 4191f
 Kyasanur Forest disease, 2073
 Kynurenine pathway, 780–781
 Kyphoscoliosis, 2715, 4373
 Kyphosis, 4250–4251, 4250t
- L**
- La Crosse and California encephalitis, 2062
 LAAHD. *See* Lethal arthrogryposis with anterior horn cell disease
 Labetalol, for severe hypertension in children, 2919t
 Labial adhesions, 3294f, 3323f
 Labial agglutination, 3321t–3322t, 3323
 Labor
 child trafficking for, 110–113
 detection of fetal compromise during, 1017
 and high-risk infant, 1038t
 Laboratory, long-term mechanical ventilation and, 2729
 Laboratory cardiac evaluation, 2746–2762
 radiologic cardiac assessment, 2746–2747
 Laboratory screening, 4472.e7t, 4472.e7
 Laboratory testing, 4472.e3–4472.e7, 4472.e3–4472.e7
 accuracy and precision of, 4472.e3
 of ADHD, 312–313
 for adolescents, 1170
 diagnostic
 for porphyrias, 965
 for subclinical porphyria, 965
 in disorders causing rickets, 473t, 474
 of Epstein-Barr virus (EBV), 2008
 in hemostasis, 3025–3028
 of influenza viruses, 2022
 neonatal screening tests in, 4472.e5t, 4472.e5
 pediatric laboratory medicine, common challenges in, 4472.e3
 predictive value of, 4472.e4
 of rape victims, 1237t
 rapid HIV antibody tests in, 4472.e5t, 4472.e4
 reference intervals for, 4472.e8
 abbreviations, 4472.e8t, 4472.e8t
 key to comments section, 4472.e9t
 prefixes denoting decimal factors, 4472.e8t
 reference values, 4472.e9t
 refining differential diagnosis in, 4472.e6
 for rheumatic disease, 1461–1463
 sensitivity, accuracy, and analytic testing in, 4472.e4
 thyroid function, 3407t–3408t
 treponemal, 1870
 of urolithiasis, 3313t
 Laboratory values, for obesity, 445t
 Labral injury, tennis and, 4328
 Labrum, 4231
 Labyrinthitis, 4014, 4020
 Lachman test, 4230, 4309f
 Lacosamide
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Lacrimal apparatus, 3937f
 Lacrimal system, disorders of, 3936–3938
 alacrima and dry eye, 3937–3938
 dacryostenosis, 3937, 3938t
 tear film, 3936–3937, 3937f
 Lacrosse, injuries associated with, 4329
 β-Lactams
 hypersensitivity, 1457–1458
 mechanisms of resistance to, 1672t
 Lactase deficiency, 2347
 Lactate dehydrogenase
 deficiency, 900t–901t
 reference intervals, 4472.e9t
 Lactational amenorrhea method, 1228
 Lactic acidosis, 514
 intermediary carbohydrate metabolism associated with, 913–919, 913f–914f, 914t
 Lactobacilli, on dental carries, 2246
 Lactobezoars, 2304
 Lactose intolerance, chronic diarrhea and, 2378
 Lactulose, 2342
 LAD. *See* Leukocyte adhesion deficiency
 Ladd bands, 2285
 Lafora body disease, 3602
 Lafora disease, 3716
 Lagevrio. *See* Molnupiravir
 Lagophthalmos, 1857, 3934
 2018 Lake Louise Acute Mountain Sickness Score, 631, 631t
 LAL. *See* Lysosomal acid lipase
 Lambdoidal craniostenosis, 3584
 Lamellar body, 1078f
 Lamellar ichthyosis, 4115–4116, 4115f–4116f
 Lamin A, in progeria, 959–960, 960f
 Laminopathy, 3835
 Laminotomy, 4256–4257
 Lamivudine
 for hepatitis B, 2467
 for HIV, 2098t–2107t
 Lamotrigine
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Lancefield C carbohydrate, 1706
 Landau-Kleffner epileptic aphasia syndrome, 3600
 Landau-Kleffner syndrome, 329, 378, 3602–3603
 Landmines, 107
 Langenskiöld classification, 4215–4216
 Langer-Giedion syndrome, 768t–769t
 Langerhans cell histiocytosis (LCH), 3148, 3169–3172, 3175f–3176f, 3409, 4034
 treatment and prognosis of, 3172–3173, 3172f
 Langerhans cells, in epidermis, 4025
 Language
 conversational and academic, 327
 definition of, 325t
 evaluation, 332
 milestones in, 326t, 327f
 problems with, 301
 in psychologic or mental health conditions, 330–331
 Language and autism screening, tools for, 181t
 Language and Literacy Training Math Interactive Learning Experience, for FASD, 1138–1139
 Language attrition, 327
 Language delay, misattributions of, 328
 Language development, 324–335
 in adopted children, 74
 variation in, drivers of, 328
 Language disorders, 328–331, 330t, 376
 assessment of, 332–333
 associated with cognitive impairment and intellectual disability, 329
 autism spectrum disorder and, 329
 clinical presentation of, 328
 diagnostic evaluation of, 332–333
 epidemiology of, 328
 etiology of, 328–329
 hearing impairment and, 329
 isolated, 328–329
 neurologic conditions and, 329–330
 pathogenesis of, 329
 psychosocial conditions and, 331
 screening of, 332
 treatment of, 333
 Language impairment, 328
 Language learning, in deaf/hard of hearing, 343
 Language nutrition, 328
 Language processes, for elementary school success, 170t
 Laparoscopic pyloromyotomy, for pyloric stenosis, 2279
 Laparoscopy, of anorectal malformations, 2407
 Large vessel disease, 1565
 Large-cell calcifying Sertoli cell tumors, of testes, 3494
 Large-for-gestational-age, 1048–1049
 Large neutral amino acids, 813–814
 Laron syndrome, 3366–3367
 Larva currens, 2205
 Laryngeal actinomycosis, 1734
 Laryngeal edema, 1432
 Laryngeal foreign bodies, 2579
 Laryngeal neoplasms, 2583–2584
 Laryngeal papillomatosis, in human papillomaviruses (HPVs), 2055
 juvenile, 2053
 Laryngeal spasm, chronic recurrent aspiration and, 2608–2609
 Laryngeal swelling, allergic, 2571
 Laryngitis, acute infectious, 2570
 Laryngocles, 2576, 2576f
 Laryngomalacia, 2573–2574, 2574f
 Laryngoscopy, 2523
 Laryngospasm, 672
 Laryngotracheal stenosis, 2580–2581
 Laryngotracheobronchitis, 2569
 Laryngotracheobronchoscopy, 2266
 Laryngotracheoesophageal clefts, 2259–2260, 2576–2577
 Larynx, congenital anomalies of, 2573–2577
 laryngeal webs and atresia, 2575, 2575f
 laryngocles and saccular cysts, 2576, 2576f
 laryngomalacia, 2573–2574, 2574f
 laryngotracheoesophageal cleft, 2576–2577
 posterior laryngeal cleft, 2576–2577
 Laser interstitial thermal therapy (LITT), in epilepsy surgery, 3615
 Laser pointers, 3963
 Laser therapy, 1035, 1036f, 4040
 Laser-assisted in situ keratomileusis (LASIK), 3914
 L-Asparaginase, indications and adverse reactions of, 3089t–3090t
 Lassa fever, 2074, 2076t
 LAT deficiency, 1263t
 Late adolescents, development of, 1162
 Late decelerations, 1017
 Late effects
 of cancer treatment, 3093–3096, 3094t–3095t, 3096f
 of HSCT, 1365–1366, 1366t
 Late infantile metachromatic leukodystrophy, 3714–3715
 Late infantile-type neuronal ceroid lipofuscinosis (LINCL), 3716
 Late/missed combined oral contraceptives, 1223f
 Late-onset nonketotic hyperglycinemia, 838
 Late-onset Pompe disease (LOPD), 900t–901t, 907
 Late-phase testicular torsion, 3306f
 Late sequelae, in arsenic intoxication, 4432
 Late syphilis, 1867–1868
 Latent nystagmus, 3931t
 Latent risk, 42
 Latent threats, identifying and analyzing, 43–44
 Late-onset infection, 1143
 pathogenesis of, 1146
 Late-onset neonatal GBS disease, 1717
 Late-phase response, in allergen, 1371
 Lateral collateral ligament, 4308–4309
 Lateral decubitus position, 3557
 Lateral deformational plagiocephaly, 3586, 3586f, 3586t
 Lateral elbow pain, 4304
 Lateral epicondylitis, 4304, 4306f
 Lateral penile curvature, 3297
 Lateral pharyngeal abscess, 2566–2567, 2567f
 Lateral pivot shift test, 4309f
 Lateral radiograph, of calcification of descending aorta, 2908f
 Lateral tibial torsion, 4214
 Latex allergy, 1434–1435
 associated with neuropathic bladder, 3290
 meningocele and, 4401
Latrodectus antivenin, 708t
Latrodectus spiders, 4469–4470, 4470f
 Latuda. *See* Lurasidone
 Laundry detergent packets, toxicity, 701t
 Lavage, bronchoalveolar, 2522, 2524–2525
 for anti-glomerular basement membrane disease, 2637
 for hypersensitivity pneumonia, 2615
 for interstitial lung disease, 2636
 Lavender, 56t
 LCA. *See* Leber congenital retinal amaurosis
 LCCS. *See* Lethal congenital contracture syndrome
 LCPD. *See* Legg-Calvé-Perthes disease
 Le Roy illness, 4456
 Lead, 4424
 reference intervals, 4472.e9t
 Lead lines, 4439
 Lead mobilization test, 4439
 Lead poisoning, 707t–708t, 3892–3894, 4436–4441
 assessment tools for, 4439
 clinical effects of, 4437–4438
 clinical symptoms of, 4438

- Lead poisoning (*Continued*)
 diagnosis of, 4438–4439, 4439f
 metabolism of, 4436–4437
 public health history of, 4436
 screening for, 4438–4439, 4439t
 sources of exposure in, 4436, 4437t
 treatment for, 4440–4441, 4441t
- Lean methodology, 37–38, 37f
- Learning disability (LD), 319
- Learning network model, 44
- Leber congenital amaurosis (LCA), 3918t–3919t
- Leber congenital retinal amaurosis (LCA), 3959
- Leber hereditary optic neuropathy (LHON), 743t, 3699, 3966, 3966f–3967f, 3967t
- Lectin pathways, of complement system, 1315–1316, 1317f
 deficiency of, 1320
- Leflunomide, for rheumatic diseases, 1465
- Left frontal and temporal lobes, damage in, language and, 330
- Left shift, neutrophils, 1313
- Left-sided obstructive lesions, 2841–2842
- Left-to-right shunt lesions, 2776–2787
 aortopulmonary window defect, 2786–2787
 atrial septal defect, 2776, 2776f–2777f
 atrioventricular septal defects, 2779–2781
 coronary artery fistula, 2787
 ostium secundum defect, 2776–2779
 partial anomalous pulmonary venous return, 2779
 patent ductus arteriosus, 2784–2786
 ruptured sinus of Valsalva aneurysm, 2787
 sinus venosus atrial septal defect, 2779
 supracristal ventricular septal defect with aortic insufficiency, 2784
 ventricular septal defect, 2781–2784
- Left ventricle, diverticulum of, 2830
- Left ventricular hypertrophy, 2750–2752, 2752f
- Left ventricular noncompaction, 2887–2888, 2888f
- Left-right laterality defects, primary ciliary dyskinesia and, 2681
- Left-to-right shunting, 2774
- Leg, musculoskeletal pain syndrome, 1568t
- Legal issues, in adolescent healthcare, 1168–1169
- Legg-Calvé-Perthes disease, 4237–4239, 4307
 classification of, 4238, 4239f
 clinical manifestations of, 4237
 diagnosis of, 4237–4238, 4238f, 4238t
 differential diagnosis of, 4238t
 epidemiology of, 4237
 etiology of, 4237
 natural history and prognosis of, 4238
 pathogenesis of, 4237
 treatment for, 4239
- Legionella*, 1810–1811
 clinical manifestations of, 1811
 diagnosis of, 1811
 epidemiology of, 1810
 etiology of, 1810
 pathogenesis of, 1810–1811
 prognosis for, 1811
 treatment of, 1811
- Legionella micdadei*, 1810
- Legionella pneumophila*, 1810
- Legionellosis, 1810
- Legionnaires disease, 1810
- Legius syndrome, 788t, 789, 3656–3657, 4068, 4070t–4071t
- Leg-length discrepancy, 4219–4223
 diagnosis and clinical findings of, 4219, 4220t
 radiographic evaluation of, 4219–4220
 treatment for, 4220–4223
- Leg-length inequality, 4250
- Leigh disease, 743t, 919
- Leigh subacute necrotizing encephalopathy, 3854
- Leigh syndrome, 3696, 3697f
- Leiomyoma, 3344
 of digestive tract, 2414
- Leiomyomatosis, gross hematuria and, 3188
- Leiomyosarcoma, 3139t–3140t
 uterine, 3344
- Leishmania*, 2155–2160
 characteristics of, 2156t
 life cycle, 2157f
- Leishmaniasis, 1655t–1656t, 2155–2160
 clinical manifestations of, 2158–2159
 diagnosis of, 2159–2160
 differential diagnosis of, 2159
 diffuse cutaneous, 2158
 disseminated, 2158
 drugs for, 2126t–2144t
 epidemiology of, 2157, 2158f
 etiology of, 2155
 laboratory findings of, 2159
 localized cutaneous, 2158, 2159f
 mucosal, 2158–2159
 pathogenesis of, 2157–2158
 pathology of, 2157
 prevention of, 2160
 treatment of, 2160
 visceral, 2159, 2159f
- Leisure activities
 for child with intellectual disability, 361
 for children with disabilities, 440t
- Leiter International Performance Scale, Third Edition (Leiter-3), 356
- Lémann score, in Crohn disease, 2317f
- Lemierre disease, 2567, 2568f
- Lemierre syndrome, 1828
- Lemon sign, 4400
- Length-for-age percentiles, birth to 24 months, 161f
- Lennox-Gastaut syndrome, 3601–3602
- Lens, abnormalities, 3949–3952
 anterior lenticonus, 3952
 cataracts, 3949–3951
 ectopia lentis, 3951–3952
 microspherophakia, 3952
 posterior lenticonus, 3952
- Lentigines, 4067
- Leprosy, 1855
 reactions, 1857, 1859
- Leptomeningeal involvement, 4062
- Leptospira*, 1878–1879, 1878f
- Leptospirosis, 1655t–1656t
 CSF findings in, 3759t–3760t
 in Kawasaki disease, 1544–1545
- Léri-Weill dyschondrosteosis (LWD), 740, 4350
- LES. See Lower esophageal sphincter
- Lesch-Nyhan disease, 950
- Letermovir, 1955
- Lethal arthrogryposis with anterior horn cell disease (LAAHD), 3821
- Lethal congenital contracture syndrome (LCCS), 3821
- Lethargy in newborn, 1052
- Leucine, metabolism defects, 825–837
- Leukemias, 3097–3105
 acute lymphoblastic, 3097–3102
 HSCT for, 1351–1352
 acute myelogenous, 3102–3103, 3103t, 3104f
 acute myeloid, HSCT for, 1352–1353
 adult T-cell, 2117–2118
 age-related manifestations of, 3084
 chemotherapy and, 3086–3087
 chronic myelogenous, 3104–3105
 HSCT for, 1353
 CSF findings in, 3759t–3760t
 infant, 3105
 juvenile myelomonocytic, 3105
 HSCT for, 1353
- Leukemoid reaction, 1313
- Leukocoria, 3924, 3924f, 3957
 in retinoblastoma, 3149, 3149f
- Leukocyte adhesion deficiency (LAD), 1297t–1298t, 1299–1301, 1300t, 1322, 1346
 clinical manifestations of, 1299–1300
 genetics and pathogenesis of, 1299
 laboratory findings of, 1300
 prognosis for, 1301
 treatment of, 1300
- Leukocyte count, reference intervals, 4472.e9t
- Leukocyte differential, 4472.e9t
- Leukocyte esterase, 3266
- Leukocytoclastic vasculitis, 1555t, 1565
 in cat-scratch disease, 1814
 conditions associated with, 1557t
- Leukocytosis, 1313–1314
 in pertussis, 1762
- Leukodystrophies, 3879t–3881t, 3889
 in neurodegenerative disorders, 3717–3718, 3717f–3719f, 3720t
- Leukoencephalopathy
 chemotherapy and, 3093–3094
 mitochondrial disease and, 935t
- Leukomalacia, periventricular, 1058, 1060f, 1061t
- Leukonychia, 4143
- Leukopenia, 1304–1312
 diagnostic approach for, 1305t
 in HIV, 2095
 inborn errors of metabolism and, 809t–810t
 lymphopenia and, 1312
 neutropenia and, 1304–1312
 acquired, 1304–1308
 acute, 1304
 causes of, 1306t
 chronic, 1304
 clinical manifestations of, 1304
 inherited, 1308–1311, 1310f
 laboratory findings of, 1304
 organ associated features and genetic subtypes of, 1311t
 treatment of, 1312
- Leukorrhea, physiologic, 3323
- Leukotrienes, 1371
 for asthma, 1403
- Levamisole, for nephrotic syndrome, 3230
- Levator muscle, 3977
- Levetiracetam
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 for migraine, 3646t–3647t
 for neonatal seizures, 3623
- Levocardia, 2824
- Levocetirizine, for allergic rhinitis, 1383t
- Levocetirizine dihydrochloride, for allergic rhinitis, 1382t
- Levofloxacin, 4447
 for drug-resistant tuberculosis, 1852t–1853t
- Levonorgestrel, 1227
- Lewisite, exposure, 4449–4450, 4454t
- Lexapro. See Escitalopram
- Lexicon, development of, 324, 325t
- Leydig cell aplasia, 3510
- Leydig cell tumors, of testes, 3494
- L-glyceric aciduria, 839
- LGMD. See Limb-girdle muscular dystrophies
- LGV. See Lymphogranuloma venereum
- Lhermitte sign, 4418
- LHON. See Leber hereditary optic neuropathy
- LHX3, 3364
- LHX4, 3364
- Lice, 4175
 bites
 vs. other arthropod bites, 4170t
 infestation, drugs for, 2126t–2144t
- Licensing, childcare, 184–185
- Lichen nitidus, 4106, 4106f–4107f
- Lichen planus, 4107, 4107f
- Lichen sclerosus (balanitis xerotica obliterans), 3297, 3326, 4121, 4121f, 4149
 vulvar, 3321t–3322t, 3323–3324, 3324f–3325f
- Lichen simplex chronicus, 4091, 4091f
- Lichen spinulosus, 4104
- Lichenification, 1411, 1413f, 4027
- Lid retraction, 3934
- Liddle syndrome, 500, 3242, 3462
- Lidocaine, 689t, 2845t–2846t
 for pain, 686
 for pediatric resuscitation and arrhythmias, 563t
- Life course-limited offenders, 1190
- Life course-persistent offenders, 1190
- Life cycle, of chlamydiae in epithelial cells, 1894f
- Life-course approach, in child health, 29
- Lifelong neutrophilia, 1313
- Lifestyle changes, polycystic ovary syndrome and, 3337
- Life-sustaining medical treatment (LSMT), 51, 52t
 withholding and withdrawing, 52–53
- Life-threatening illness, congenital anomalies, 1053t
- Li-Fraumeni syndrome, 3077, 3131t–3132t, 3472, 3473t
 adrenocortical tumors and, 3166
 osteosarcoma in, 3141

- Light sedation, definition of, 668t
 Light-chain amyloidosis, 3033
 Lightheadedness, 594t
 Lightning burns, 655–657, 657f
 Limb length discrepancy, 4243–4244
 Limb weakness, associated with acute flaccid paralysis, 3874
 Limb-girdle muscular dystrophies, 3829t–3830t, 3839–3842, 3840t–3841t
 Limbrel (flavocoxid), 2492t
 Limit dextrinosis, 903–904
 Limit testing, in preschool years, 166
 Limited intrauterine spacing, in arthrogryposis, 4271
 Limping, 4199–4200, 4199t
 Linagliptin, for T2DM, 3542t
 Lincosamides, 1689
 Lindane, toxicity, 701t
 Lindsay nails, 4143
 Linear energy transfer (LET), 4415
 Linear growth, in CKD, 3251
 Linear immunoglobulin A dermatosis, 4086–4087, 4087f
 Linear nevus sebaceous syndrome, 3656f, 3661–3662
 Linear no (dose) threshold (LNT) model, 4414
 Linear porokeratosis, 4107
 Linear scleroderma, 1508t, 1509f
 Linezolid, 1675t–1685t
 for drug-resistant tuberculosis, 1852t–1853t
 enterococci resistance, 1723t
 against *M. tuberculosis*, 1833
 for *Staphylococcus aureus*, 1697
 Linguistic development
 age 12–18 months, 158
 age 18–24 months, 163
 Linkage analysis, 750f
 Linkage disequilibrium, 801
 Linkage mapping, 799–800
 Linkage testing, 749, 749t
 Linoleic acid, 393
 α-Linolenic acid (ALA), 393
Linuče unguiculata, seabather's eruption and, 4177
 Lip
 cleft, 2243–2244
 in erythropoietic protoporphyrina, 978f
 Lip licker's dermatitis, 1375
 Lip trait, characteristic, in CCHS, 2724, 2725f
 Lipase, reference intervals, 4472.e9t
 Lipid amphotericin B, 1917t
 Lipid glycosylation, 921
 defects in, 928
 Lipid metabolism, 2436
 defects, 859–897, 2340, 3450–3453
 lipidoses, 884–897, 890f–892f
 lipoprotein metabolism and transport, disorder of, 871–884
 liver and, 2455t
 mitochondrial fatty acid β-oxidation, disorders of, 859–865, 860t–861t, 861f–862f
 mucolipidoses, 897
 very long chain fatty acids, disorders of, 865–871
 Lipid myopathies, 3856
 hereditary disorders in, 3857t
 Lipid nanoparticles (LNPs), 758–760
 Lipidoses, 884–897, 890f–892f
 cholesterol ester storage disease, 897
 clinical findings in, 887t
 Fabry disease, 894–895, 894t–895t
 Farber disease, 896–897, 897f
 fucosidosis, 895
 Gaucher disease, 890–891, 893f
 genetic and clinical characteristics of, 888t
 GM₁ gangliosidoses, 885, 892f, 893t
 GM₂ gangliosidoses, 885–890
 Krabbe disease, 896
 metachromatic leukodystrophy, 896
 multiple sulfatase deficiency, 896
 Niemann-Pick disease, 892–893
 Schindler disease, 895–896
 Wolman disease, 897
 Lipids transport, defects in, 2340
 Lipoatrophic diabetes, 3546, 3547t
 Lipodystrophy, 4132–4133
 in JDM, 1506
- Lipoid adrenal hyperplasia, 3464t–3465t, 3469–3470, 3510
 Lipoid proteinosis, 4122–4123
 Lipokinetix, 2492t
 Lipoma, 4188, 4188f
 Lipophilic drugs, 709
 Lipoproteins, 872, 873f, 874t
 metabolism and transport, disorder of, 871–884
 patterns, in children and adolescents, 881
 Liposarcoma, 3139t–3140t
 Lip-Philtrum Guide, 1135–1136, 1137f
 Liquid nitrogen, for common warts, 4168–4169
 Liraglutide, for T2DM, 3542t
 Lisch nodules, 3924
 in neurofibromatosis type 1, 3652–3654, 3655f
 Lisdexamfetamine (Vyvanse), for ADHD, 225t–226t
 Lisfranc sprain, 4313
 Lispro, for T1DM, 3528–3529
 Lissencephaly, 3568–3569, 3569f
 X-linked, 780t
Listeria monocytogenes, 1729–1732
 clinical manifestations of, 1730–1731
 diagnosis of, 1731
 differential diagnosis of, 1731
 epidemiology of, 1729–1730
 etiology of, 1729
 food-borne illness, 1732t
 neonatal listeriosis, 1730, 1731f, 1731t
 pathogenesis of, 1730
 pathology of, 1730
 postneonatal listeriosis, 1731
 in pregnancy, 1730
 prevention of, 1732
 prognosis of, 1731
 treatment of, 1731
 types of infections, 1730t
 Listeriosis, 1729
 Literacy skills, definition of, 324–326, 325t
 Lithiasis, urinary, 3311–3316
 Lithium, 228–229, 3892–3894
 poisoning, 717t
 Lithium carbonate
 goiter caused by, 3415
 for psychosis and mania, 228t
 Lithotripsy, 3315
 Little League elbow, 4300, 4303–4304, 4304f, 4327
 Little League shoulder, 4327, 4328f
 Live-attenuated quadrivalent influenza vaccine (LAIV4), 1589
 Live-attenuated vaccines, 1589–1590
 Liver, 2276
 abnormalities, porphyria cutanea tarda associated with, 973–974
 altered synthetic function of, hepatitis and, 2461
 architecture, 2434–2435
 arsenic effects in, 4432t
 biopsy of, 2444
 for autoimmune hepatitis, 2488f
 cystin diseases of, 2500–2502
 development of, processes involved in, 2434f
 excretory function of, 2437
 graft-versus-host disease of, 2479
 imaging procedures for, 2444–2445
 inborn errors of metabolism that affect, 2455t
 ketone body formation, 831f
 metabolic functions of, 2435–2437
 morphogenesis of, 2434–2437, 2435f
 neoplasms, 3153–3156, 3153t
 hepatoblastoma, 3153t, 3154f
 hepatocellular carcinoma, 3155, 3155f
 stage of GVHD, 1358t
 transplantation of, 2507–2508
 complications of, 2508
 contraindications to, 2507
 immunosuppression in, 2508
 indications for, 2507
 outcomes of, 2508
 technical innovations in, 2507–2508
 transport of, endogenous lipids from, 874
 ultrastructure of, 2435–2437
 venoocclusive disease of, 2479
 Liver abscess, 2474–2475
 amebic, 2148, 2148f, 2475, 2475f
 cryptogenic, 2474f
- Liver disease
 anesthetic implications in, 666t
 associated with systemic disorders, 2475–2482
 autosomal dominant polycystic, 2502
 biochemical tests for, 2442–2444
 causing malabsorption, 2348–2349
 chronic, autoimmune hepatitis and, 2487
 chronic diarrhea and, 2378
 coagulopathy in, 3046, 3047t
 evaluation of patients with possible, 2442–2445
 fatty
 nonalcoholic, 2480–2482, 2481f
 hemolytic anemias and, 2997
 intestinal failure associated, 2477, 2477t–2478t
 intestinal transplantation and, 2352
 manifestations of, 2438–2445
 clinical, 2438–2442
 pathologic, 2438–2442
 metabolic, 2454–2460
 α₁-antitrypsin deficiency, 2460
 citrin deficiency as, 2460
 Indian childhood cirrhosis as, 2459
 inherited deficient conjugation of bilirubin, 2454–2456
 Wilson disease as, 2457–2459, 2457t
 nonalcoholic fatty, 442, 2480–2482
 respiratory signs and symptoms, 2531t
 respiratory tract complication, 2531t
 Liver failure
 acute, 2494–2499
 in acetaminophen toxicity, 711
 clinical manifestations of, 2496, 2496f–2497f
 etiology of, 2494–2496, 2495t
 in hepatitis B, 2465
 idiopathic, 2495
 laboratory findings in, 2496–2497, 2497t, 2498f
 pathogenesis of, 2496
 pathology of, 2496
 prognosis for, 2499
 treatment of, 2497–2499, 2497t
 mitochondrial disease and, 935t
 neonatal, 2484
 Liver flukes, 2214–2215
 Liver glycogen synthase deficiency, 900t–901t, 906
 Liver glycogenoses, 898–906, 900t–901t
 Amylopectinosis, 904
 Andersen disease, 904
 Autosomal liver and muscle phosphorylase kinase deficiency, 905
 Autosomal liver phosphorylase kinase deficiency, 905–906
 Branching enzyme deficiency, 904
 Debrancher deficiency, 903–904, 903f
 Fanconi-Bickel syndrome, 906
 Glucose-6-phosphatase deficiency (type I GSD), 898–903
 Hers disease, 904–905
 Liver glycogen synthase deficiency, 906
 Muscle-specific phosphorylase kinase deficiency, 910
 Phosphorylase kinase deficiency, 905
 Polyglucosan disease, 904
 X-linked liver phosphorylase kinase deficiency, 905
 Liver injury, drug- and toxin-induced, 2490–2493, 2491t
 prevention of, 2493
 prognosis of, 2493
 treatment of, 2493
 Liver phosphorylase deficiency, 904–905
 Liver transplantation
 for acute porphyria, 970
 for hepatoblastoma, 3154–3155
 for hepatocellular carcinoma, 3156
 orthotopic, 2499, 2499t
 for portal hypertension, 2506
 Lixisenatide, for T2DM, 3542t
 L-Lactate, reference intervals, 4472.e9t
 LMOD3 nemaline myopathy, 3812
 LMWH. See Low molecular weight heparin
 Loa loa, 2207
 Lobar collapse, in allergic bronchopulmonary aspergillosis, 2630f
 Lobar emphysema, congenital, 2591–2592, 2591t, 2592f
 Lobular capillary hemangioma, 3162, 4058–4059, 4059f

- Local anesthesia, definition of, 668t
 Local anesthetic intoxication seizures, 3619
 Local anesthetics, 685–686, 688t
 Local anesthetics, adverse reactions to, 1459
 Localized aggressive periodontitis, in adolescents, 2249
 Localized albinism, 818t, 820
 piebaldism, 820
 Waardenburg syndrome, 820
 Localized cutaneous leishmaniasis, 2158, 2159f
 Localized environmental hazards, 4409, 4410t
 Localized intravascular coagulopathy, 4051–4052
 Localized lipotrophy, 4133
 Localized obstructive overinflation, 2591–2592
 Localized scleroderma. *See* Morphea
 Localized tetanus, 1822
 Lock jaw, 1821–1822
 Locus heterogeneity, 801
 Loeys-Dietz syndrome (LDS), 4363, 3384t, 4367t
 Löffler syndrome, 2205, 2626
 Lofgren syndrome, 2622
 Loiasis, 2207–2208, 2208f
Lomentospora prolificans, 1949
 Lomotil, toxicity, 701t
 Long bones, 4193, 4194f
 Long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, 863
 Long QT syndrome (LQTS), 595t
 Long-acting inhaled anticholinergics, for asthma, 1403
 Long-acting inhaled β -agonists, for asthma, 1402
 Long-acting reversible contraception implants, 1221
 IUDs, 1220–1221
 Longitudinal readiness checklists, 1171t
 Long QT syndrome, 733–734, 2752f, 2853–2855, 2861, 2862f
 genotype-phenotype, 2857f
 SIDS risk factors and, 2535
 Long-term complications, of Hansen disease, 1860
 Long-term mechanical ventilation, 2716–2718
 adult transition in, 2718
 aerodigestive and communication considerations in, 2726–2727
 airway clearance in, 2717
 cardiopulmonary interactions and, 2727
 chest wall/thoracic configuration in, 2727
 developmental considerations for, 2727
 gas-exchange goals and ventilator strategies in, 2727
 goals and decision-making in, 2726–2730
 indications for, 2716t
 infections in, 2718
 inhalation medications in, 2717
 invasive positive pressure ventilation in, 2716–2717
 lived experience of, preparation of, 2727–2729
 monitoring for, 2717
 mucolysis and anticholinergics in, 2717
 noninvasive and transtracheal supports in, 2726
 nutrition in, 2718
 optimal ventilator support in, 2717
 physical, occupational, speech therapy in, 2717
 preparing for discharge in, 2717–2718
 projected interventions and needs and, 2727
 psychosocial considerations in, 2718
 routine health maintenance and, 2729
 supplemental oxygen in, 2717
 tracheal decannulation, 2729–2730
 transitioning from acute care to rehabilitation or community setting in, 2729
 Long-term memory, 302
 Long-term video EEG monitoring, 3560
 Longitudinal vaginal septa, 3353
 Loop diuretics, 3252
 Loperamide, for traveler's diarrhea, 2375
 Lopinavir, for HIV, 2098t–2107t
 Loracarbef, 1675t–1685t
 Loratadine, for allergic rhinitis, 1383t
 Lorazepam
 for catatonia, 293
 for depression and anxiety, 227t
 dosages of, 3609t–3610t
 for intubation, 620t
 for neonatal seizures, 3623
 Lorcaserin, 447
 Loricrin, 4117
 Loss-of-function variants, 731–732
 Lotions, 4038
 Louse-borne diseases
 epidemic typhus, 1910–1911
 relapsing fever, 1880
 typhus, 1900t–1902t
 Low achieving (LA) in math, 319
 Low back injuries, 4305–4307
 facet syndrome, 4306
 lumbar disk herniation, strain, and contusion, 4306–4307
 other causes of, 4307
 spondylolisthesis, 4306
 spondylosis, 4305–4306
 Low back pain
 diving associated with, 4329
 football associated with, 4327
 Low birthweight (LBW), 2242t
 caused by preterm birth, 998
 child mortality and, 24
 sequela of, 1045t, 1050t
 Low-grade squamous intraepithelial lesion (LSIL), 2053
 Low molecular weight heparin (LMWH), 2696, 3043–3044
 Lowe syndrome, 3235
 Lower esophageal sphincter, 2255, 2264
 dysfunction of, 2261–2262
 Lower extremity
 assistive devices, 4402–4404
 fractures, 4281–4283
 Lower extremity blocks, in pain management, 695
 Lower leg exertional pain, 4310–4311
 Lower motor neuron diseases, 3821
 Lower urinary tract, hematuria in, 3185t, 3218
 Lower-body segment, 172
 Low-fidelity simulation, 43
 Low-grade astrocytomas (LGAs), 3119
 Low-renin hypertension, in glucocorticoid-suppressible hyperaldoosteronism, 3471
 Low-set ears, 784t
Loxosceles spiders, 4470–4471, 4470f–4471f
 LPI. *See* Lysinuric protein intolerance
 LRBA deficiency, 1332t–1333t
 LSMT. *See* Life-sustaining medical treatment
LTPBP4-related cutis laxa, 4376t
 Lubricants, 4039
 Lucio phenomenon, 1858
 Lugano classification, for Hodgkin lymphoma, 3107, 3107t
 Lujan syndrome, 3384t
 Lumbar plexus blocks, in pain management, 695
 Lumbar puncture
 in febrile seizure, 3596–3597
 in meningitis, 3759t–3760t, 3762
 in neonatal seizures, 3622
 in neurologic evaluation, 3557–3558
 Lumbar scoliosis, 4219
 LUMBAR syndrome, 3662
 Lumbosacral orthosis, 4254
 Lung
 assessment in newborn, 1002
 biopsy, 2525, 2615, 2636
 compartments of, 2605
 compliance of, 2521f
 congenital disorders of, 2599–2603
 airway malformation, 2599–2601, 2600f–2601f
 bronchobiliary fistula, 2603, 2603f
 bronchogenic cysts, 2602, 2602f
 lung hernia, 2603
 pulmonary agenesis and aplasia, 2599
 pulmonary hypoplasia, 2599
 pulmonary lymphangiectasia, 2602, 2603f
 pulmonary sequestration, 2601–2602, 2601f
 normal, volume-pressure relationship in, 623f
 normal acid-base balance and, 509
 normal appearance of, on chest radiography, 2517f
 physical examination of, 551
 primary, imaging characteristics of, 2702t
 recoil of, 2520f
 unilateral hyperlucent, 2591
 Lung Clearance Index (LCI), 2521
 Lung compliance, decreased, 612, 614t
 Lung disease, 2634t
 diffuse, in childhood, 2683–2687
 fibrotic, 2639–2641, 2639t–2641t, 2641f
 immune and inflammatory, 2612–2641
 eosinophilic, 2625–2632
 granulomatous, 2620–2624
 hypersensitivity pneumonia, 2612–2615
 interstitial, 2632–2637
 occupational and environmental, 2616–2620, 2616t
 Lung flukes, 2215
 Lung hernia, 2603
 Lung infiltrates
 granulomatosis with polyangiitis, 2621f
 recurrent/persistent, 2529–2530, 2529t
 Lung injury
 acute
 pulmonary pressure-volume relation in, 621f
 transfusion-related, 3021
 ventilator-induced, 629
 Lung percussion, 2513
 Lung secretions, examination of, 2522–2523
 Lung transplantation, 2905–2906
 cystic fibrosis and, 2676
 Lupus erythematosus, 4028–4031
 discoid, 4031, 4032f
 neonatal, 1498–1499, 4030–4031, 4032f
 systemic, 4028–4030, 4030f
 Lupus erythematosus profundus, 4130, 4130f
 Lupus nephritis, 3197, 3197t
 Lupus vulgaris, 4158
 Lurasidone (Latuda), for psychosis and mania, 228t
 Luspatercept, for thalassemia, 2984–2985
 Luteinizing hormone (LH), 3361
 in polycystic ovary syndrome, 3335f
 17,20-lipoxygenase deficiency, 3510–3511
 Lying, 282
 Lyme disease (*Borrelia burgdorferi*), 4472.e7, 1881–1887, 2184, 4291
 clinical manifestations of, 1882–1884, 1883t
 congenital, 1884
 diagnosis of, 1884–1885
 early disseminated disease, 1883–1884, 1883f
 early localized disease, 1882–1883, 1883f
 epidemiology of, 1882, 1882f
 etiology of, 1881
 laboratory findings of, 1884
 pathogenesis of, 1882
 pathology of, 1882
 prevention of, 1886–1887, 1886t, 1887f
 prognosis for, 1886
 serology in, 1884–1885
 transmission of, 1881–1882
 treatment of, 1885–1886, 1885t
 Lymph nodes, 3065
 infected with *M. avium*, 1862f
 subcarinal, 2261
 tuberculosis of, 1843, 1843f
 Lymphadenitis
 in lymphatic filariasis, 2206
 nontuberculous mycobacteria and, 1861–1862, 1861t
 tuberculous, 1843
 Lymphadenopathy, 2189, 3069–3072
 angiofollicular lymph node hyperplasia, 3072
 Castleman disease, 3072, 3072f
 chronic persistent or recurrent, ALPS and, 1331–1332
 diagnosis of, 3069–3070, 3069t–3071t
 diphtheritic cervical, 1726f
 histiocytic necrotizing lymphadenitis, 3070
 Kikuchi-Fujimoto disease, 3070
 Rosai-Dorfman disease, 3070–3071
 sinus histiocytosis with, 3070–3071
 tickborne, 1900t–1902t
 treatment of, 3069–3070
 Lymphangiectasia, 3157
 congenital pulmonary, 2602, 2603f
 Lymphangioliomyomatosis (LAM), 3068, 3658f
 Lymphangioma, 3936
 Lymphangiosarcoma, 3164
 Lymphangitis, 3068
 of extremity, in lymphatic filariasis, 2206

Lymphatic anomalies
complex, 3156–3157, 3160f
central conducting, 3157, 3161f
generalized, 3156, 3160f
Lymphatic capillaries, 3065
Lymphatic development, embryonic, 3065
Lymphatic filariasis, 2206–2207, 2207f
Lymphatic insufficiency, 2604t
Lymphatic malformations, 3065–3066, 3066f–3068f, 4052
Lymphatic system
anatomy and function of, 3065
arsenic effects in, 4432t
Lymphatic vessels, abnormalities of, 3065–3068
Lymphedema, 3066–3068, 3068t
Lymphedema-cholesterol syndrome, 2452
Lymphoblastic lymphoma (LBL), 3110t, 3115
Lymphocutaneous sporotrichosis, 1942
Lymphocytes
innate immune, 1286
reference intervals, 4472.e9t
Lymphocytic choriomeningitis virus, 2078–2080
acquired (postnatal) infection, 2078
clinical manifestations of, 2078–2079
complications of, 2079
congenital infection, 2078–2079
diagnosis of, 2079
differential diagnosis of, 2079
epidemiology of, 2078
etiology of, 2078
laboratory findings of, 2079, 2079f
pathogenesis of, 2078
prevention of, 2080
prognosis for, 2079–2080
supportive care in, 2079
treatment of, 2079
Lymphocytic interstitial pneumonia (LIP), HIV and, 2094
Lymphocytopenia, causes of, 1312t
Lymphocytosis, 1314
Lymphogranuloma venereum (LGV), 1897
Lymphohematogenous disease, in tuberculosis, 1842
Lymphoma, 2344, 3081–3082, 3106–3116
adult T-cell, 2117–2118
Burkitt, 3110t, 3113–3115
diffuse large B-cell, 3110t, 3113–3115
of digestive tract, 2414
early detection of, 3084
Hodgkin, 3106–3109
chemotherapy regimens for, 3109t
clinical manifestations of, 3106
diagnosis of, 3106–3107, 3107f–3108f, 3107t–3108t
epidemiology of, 3106
Lugano classification for, 3107, 3107t
pathogenesis of, 3106, 3107f, 3107t
prognosis of, 3109, 3110t
relapse of, 3109
treatment for, 3108–3109, 3109t
treatment regimens and outcome by staging, 3110t
late effects in children and adolescents with, 3116, 3116f
non-Hodgkin, 3109–3115
anaplastic large cell lymphoma, 3115
Burkitt lymphoma, 3113–3115
chemotherapy regimens for, 3113
clinical manifestations of, 3112–3113, 3113t
complications of, 3115
diffuse large B-cell lymphoma, 3113–3115
epidemiology of, 3109–3111
HSCT for, 1353
laboratory findings of, 3113, 3114f
lymphoblastic lymphoma, 3115
pathogenesis of, 3111–3112, 3111f–3112f
prognosis of, 3110t, 3115
relapsed, 3115
treatment for, 3110t, 3113–3115, 3114t
Lymphopenia, 1312
Lymphoproliferative disorders, EBV-related, 1364
Lymphorrhages, 3864
Lynch syndrome, 3165, 3472, 3473t
Lysergic acid diethylamide (LSD), 1204
Lysine, metabolism defects, 855–857, 855f
Lysinuric protein intolerance, 857, 2349, 2634t

Lysosomal acid α-1,4-glucuronidase deficiency, 906–908
Lysosomal acid lipase (LAL) deficiency, 2333, 2481
Lysosomal disorder, 2451
Lysosomal storage disorders, 884–897, 3715
cardiomyopathy and, 808t
genetic therapies for, 728
hepatic dysfunction and, 808t
inborn errors of metabolism associated with, 809t
Lytic granules, 1287
Lytic immunologic synapse, 1287

M

M protein, in GAS pharyngitis, 2559
Ma huang, 2492t
MAC. See *Mycobacterium avium* complex
Machado-Joseph disease, 745t–746t
Macitentan, 2834t
Macleod syndrome, 2591
Macrocephaly, 3551, 3567
inborn errors of metabolism and, 809t–810t
Macrocephaly-capillary malformation, 3159, 3163f
Macroductyly, 4210, 4211f
Macrodonia, 2240
Macroglossia, inborn errors of metabolism and, 809t–810t
Macrolides, 1689
adverse drug reactions to, 1458
against nontuberculous mycobacteria, 1835
resistant, in *Mycoplasma pneumoniae*, 1890
Macromastia, 3330
Macronutrients, 388–391
Macrophage activation syndrome (MAS), 1476–1477, 1478t, 1538–1540, 1539t, 3177
Macrophages, Hemosiderin-laden, 2689
Macrosomia, in infants of diabetic mothers, 1141f
Maculae ceruleae, 4177
Macular atrophy, 4123
Macular degeneration, factor H deficiency and, 1321
Macule, 4027
Maculopapular eruption, 2076
Madelung deformity, 4265, 4267f
Mafenide acetate, for burns, 652–653, 652t
Maffucci syndrome, 3145, 3162, 3502, 4059
Magical thinking, 165, 195
Magnesium, 56t
conversion factor, 503t
hypermagnesemia, 505
hypomagnesemia, 503–505
metabolism, 501–503
for migraine, 3646t–3647t
reference intervals, 4472.e9t
tubular reabsorption of, 3233
Magnesium sulfate, for pediatric resuscitation and arrhythmias, 563t
Magnetic resonance angiography (MRA), 2758
of cerebral artery infarction, 2972f
in neuroradiologic procedures, 3558–3559
for orthopedic evaluation, 4200
Magnetic resonance cholangiopancreatography (MRCP), 2426, 2447
Magnetic resonance imaging (MRI), 2758, 2759t, 2760f
for appendicitis, 2401
of astrocytoma, 3120f
for brain death, 591t
for brain tumors, 3118–3119
cerebral artery infarction, 2972f
chest, 2518
of ependymoma, 3121f
in Fabry disease findings, 3887
of hypoxic-ischemic injury, 1064f–1065f
of JIA
in knee, 1475f
in wrist, 1480f
for liver, 2445
of medulloblastoma, 3122f
of mixed germ cell tumor, 3118f
in neuromuscular diseases, 3794
for orthopedic evaluation, 4200
for osteomyelitis, 4286, 4288f
of pancreatitis, 2428f

Magnetic resonance imaging (MRI) (*Continued*)
of parotitis in Sjögren syndrome, 1517f
of pilocytic astrocytoma, 3120f
of selective neuronal injury, 1062f
of septic arthritis, 4293
visualization of sacroiliitis, 1486, 1487f
Magnetic resonance perfusion, for brain death, 591t
Magnetic resonance urography, 3278, 3279f
Magnetic resonance venography, in neuroradiologic procedures, 3558–3559
Magnets
ingestion of, 2303, 2303f
toxicity, 724
Maintainable airway, 552–554
Maintenance fluid, 525, 525t
selection of, 526–527
Maintenance immunosuppression, 3256–3257
calcineurin inhibitors, 3256
corticosteroids, 3257
mycophenolate mofetil, 3256
sirolimus, 3257
Maintenance of Certification (MOC), 36
Maintenance therapy, 525–529
Maintenance water, 526, 526t
variations in, 527, 527t–528t
Maitotoxin, 3, 4444
Majeed syndrome, 1523t, 1529, 4287
Majocchi granuloma, 4162, 4162f
Major aortopulmonary collateral arteries, 2800
Major depressive disorder (MDD), 247t–248t, 254, 255f–256f, 255t
Major histocompatibility complex/human leukocyte antigen-encoded susceptibility to type 1 diabetes mellitus, 3518
Mal de Meleda, 4119
Malabsorption
of bile acid, 2437t
folate, hereditary, 2941
pancreatic function test for, 2423
of vitamin D, 472
Malabsorption disorders, 2332–2351, 2333t
abetalipoproteinemia as, 2340
Aristaless-related homeobox gene variants in, 2340
autoimmune enteropathy, 2340
autoimmune polyglandular syndrome type 1, 2340
bile acid malabsorption, 2341
chronic malnutrition, 2346–2347
chylomicron retention disease, 2340–2341
clinical approach to, 2332, 2334f, 2334t–2336t
DGAT1 variants, 2341
enteric anendocrinosis, 2339
enterocyte differentiation and polarization as, defects of, 2337
enteroendocrine cells differentiation defects as, 2339
environmental enteropathy as, 2343
enzyme deficiencies as, 2347–2348
evaluation of, 2332–2336
fructose, 2347
glucose-galactose, 2347–2348
homozygous hypobetalipoproteinemia, 2340
immunodeficiency disorders and, 2344
immunoproliferative small intestinal disease and, 2344
intestinal infections and infestations associated with, 2342–2344
investigations for
carbohydrate malabsorption, 2332–2334
exocrine pancreatic function, 2336, 2338f, 2338t
fat malabsorption, 2333t, 2334
imaging procedures in, 2336
intestinal mucosal disorders, 2336
protein-losing enteropathy, 2334–2336
liver and biliary disorders causing, 2348–2349
microvillus inclusion disease as, 2337–2339, 2339f
Mitchell-Riley syndrome, 2340
proprotein convertase 1/3 deficiency, 2339–2340
protein-losing enteropathy as, 2341–2342, 2342f–2343f
rare inborn defects causing, 2349–2351
short bowel syndrome, 2345–2346, 2345f, 2345t
sitosterolemia as, 2341
suspected intestinal, evaluation of children with, 2332–2336

- Malabsorption disorders (*Continued*)
 Tangier disease as, 2341
 tricho-hepato-enteric syndrome, 2339
 tufting enteropathy as, 2339
 Whipple disease, 2343–2344
 Wolman disease, 2341
- Malar rash
 of neonatal lupus, 1492f
 of SLE, 1492f
 suggestive of rheumatic disease, 1461t
- Malaria, 1655t–1656t, 2168–2184
 clinical manifestations of, 2171–2173, 2172f, 2172t
 diagnosis of, 2171f, 2173
 drugs for, 2126t–2144t
 epidemiology of, 2169, 2169f
 etiology of, 2169
 HIV in, prophylaxis to prevent, 2111t–2113t
 long-term complications of, 2181
 oral antimalarial therapy, follow-up, for, 2176–2181
 pathogenesis of, 2169–2171, 2170f–2171f
 prevention of, 2181–2184, 2181t–2183t
 treatment of, 2173–2175, 2174f, 2176t–2180t
 general principles, 2173–2175
 severe, 2175–2176
 uncomplicated, 2175
- Malassezia*, 1928, 1928f
- Malayan filariasis, 2206
- Male
 anorectal malformation in, 2407t
 breast changes in, 1160f
 changes in body proportions, 147f
 fertility of, inguinal hernia and, 2421
 imperforate anus in, 2404–2405, 2404f–2405f
 isosexual precocity in, 3387t
 onset of puberty in, 1161f
 peak height velocity in, 1161f
 pubic hair changes in, 1159f
 reproductive system, autonomic dysreflexia in, 4391t
 sexual development in, 1159
 sexual maturity rating in, 1160t
- Male-appearing genitalia, 3506t
- Male athlete triads, 4322, 4323t, 4331
- Male genital schistosomiasis (MGS), 2213
- Male health
 breast disorders, 1210
 urethral diverticula, 3285
 urethral meatal stenosis, 3285
- Male hypogonadism, risk for osteoporosis, 4384t
- Male rape, 1236
- Malformations, 778–779
 anorectal, 2404–2408, 2404f
 defined, 778t
 inborn errors of development, 781–782
 lymphatic, 3065–3066, 3066f–3068f
 macrocephaly-capillary, 3159, 3163f
 molecular mechanisms of, 781–783
 peritoneal, 2509
 vascular, 3156, 3157t
- Malignancy
 DIC caused by, 3048t
 enterovirus infections in, 1984
 gynecologic, 3338
 hypercalcemia of, 3442
 infectious complications of, 3091t
 kidney transplant immunosuppression and, 3259
 monoclonal antibodies for, 3088t
 respiratory tract complication, 2531t
- Malignant astrocytomas, 3120
- Malignant disorders, eosinophilia caused by, 1295t
- Malignant gynecologic neoplasms, 3327
- Malignant hyperthermia, 3849t, 3850–3851
 anesthesia and, 674
- Malignant hyperthermia susceptibility (MHS), 3850
- Malignant masses, breast, 3332
- Malignant neoplasms
 epidemiology of, 3073
 in patients undergoing enterocystoplasty, 3290
- Malignant otitis externa, 1800t
- Malignant rhabdoid tumor, of kidney, 3135
- Malignant tumors
 of bone, 3141–3144, 3141t, 3142f
 Ewing sarcoma, 3143–3144, 3143f
 osteosarcoma, 3141–3143, 3142f
- Malignant tumors (*Continued*)
 of complex vascular anomalies, 3163–3164
 ovarian, in adolescents, 3343t
 thyroid, 3164–3165, 3165f, 3165t
 Mallet finger deformity, 4279
 Mallet toe, 4210
 Malnutrition, 421, 423, 433–437
 cancer treatment and, 3093
 chronic, 433–434, 2346–2347
 clinical manifestation, 433, 433t
 diagnosis of, 433–435
 edematous, 433
 etiology of, 433–435, 434f, 434t–435t
 prognosis of, 437
 severe acute, 426–431
 clinical manifestations of, 426, 426f
 community-based treatment of, 431, 431f
 emergency treatment of, 428, 428t
 pathophysiology of, 427
 rehabilitation for, 430–431
 stabilization, 428–430, 429t–431t
 treatment principles of, 427–431, 428f
 treatment of, 435–436, 436t–437t
- Malocclusion, 2242–2243
 crossbite, 2243
 dental crowding, 2243
 digit sucking, 2243
 open and closed bites, 2243
 variations in growth patterns in, 2242–2243, 2242f
- Malone antegrade continence enema procedure (MACE), 2407–2408
- Malpuech, Michels, Mingarelli, Carnevale (3MC) syndrome, 1320
- Malrotation, intestinal, 2282–2285, 2285f
- Maltreatment
 outcomes of, 115
 principles for addressing, 120–121
- Mammalian target of rapamycin (mTOR) inhibitors, 3257
- Mammary hypertrophy, 3330f
- Mammary primordium, 3328
- Mammary ridges, 3328
- Mandatory screening, 54
- Mandible, 2248f
 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome (MDPL), 962t
- Mandibuloacral dysplasia associated with MTX2 (MADA), 962t
- Mandibuloacral dysplasia type A (MADA), 962t
- Mandibuloacral dysplasia type B (MADB), 962t
- Mandibulofacial dysostosis, 2245
- Manganese, 483t
 transporter defect, 930
- Mania, medications for, 228t
- Manic episode, 260
- Manifest latent nystagmus, 3931t
- Mannitol, for traumatic brain injury, 585–586
- Mannose-binding lectin (MBL), 1315
- Mannose-binding lectin-associated serine proteases (MASPs), 1315, 1320
- Mannosephosphoisomerase deficiency, 926
 clinical manifestations, 926
 diagnosis of, 926
 pathophysiology of, 926
 treatment of, 926
- α-Mannosidosis, 887t, 921
- β-Mannosidosis, 887t
- Manometry, 2262, 2263f
 anorectal, 2296–2297
 esophageal, 2257
- Manual for the Health Care of Children in Humanitarian Emergencies*, 547
- MAOIs. See Monoamine oxidase inhibitors
- Maple syrup urine disease, 825–827, 990t
 caused by deficiency of E₃ subunit, 827
 classic, 825–826
 genetics and prevalence of, 827
 intermediate (mild), 826
 intermittent, 826
 in neonatal seizures, 3622
 thiamine-responsive, 826
- Marasmic-kwashiorkor, 426
- Marasmus, 426
- Maraviroc, for HIV, 2098t–2107t
- Marburg disease, 2074, 2076
- MARC. See Massachusetts Aggression Reduction Center
- Marcus Gunn jaw-winking ptosis, 3933, 3934f
- Marcus Gunn pupil, 3922–3923, 3923f
- Marfan syndrome, 3383, 3384t, 3951f, 4295, 4363–4369, 4364f–4365f
 clinical manifestations of, 4364–4365
 ocular system, 4365
 other systems, 4365
 skeletal system, 4364
 diagnosis of, 4365–4366, 4365t–4366t
 differential diagnosis of, 4366–4368, 4367t
 epidemiology of, 4363
 genetic counseling of, 4369
 genotype-phenotype correlations in, 734
- Maribavir, 1955
- Marijuana
 in pediatric palliative care, 71
 use, in adolescents, 1195t–1196t, 1201–1202, 1201f
 motor vehicle injuries, 97
- Marine envenomation, 4472
- Marinesco-Sjögren syndrome (MSS), CMD form overlapping with, 3819
- Marker chromosomes, 770
- Markers, tumor, 3342–3343, 3344t
- Marnier-Kuhn syndrome, 2658
- Maroteaux-Lamy syndrome, 939f, 940t, 942
- MAS. See Meconium aspiration syndrome
- Masculinization, 3337–3338
- Mask, for respiratory distress and failure, 618
- MASP-1, 1320
- MASP-2 deficiency, 1320
- MASPs. See Mannose-binding lectin-associated serine proteases
- Masquerade syndromes, 3954
- MASS phenotype, 4367t, 4368
- Mass psychogenic illness, 4456
 clinical features and diagnosis of, 4456
 treatment strategies for, 4456
- Massachusetts Aggression Reduction Center (MARC), 102, 103f–105f
- Massage, 57, 4294
 in pain management, 693
- Masses
 assessment in newborn, 1003
 of breast, 3332–3333
 in adolescents, 3332, 3332t
 imaging of, 3333
 malignant, 3332
 peripubertal, 3332
 recommendations for daughters of women with breast cancer, 3333
 risk reduction, 3333
 screening procedures, 3333
 nasal, congenital midline, 2546–2547, 2547f
 scrotal, 3305t
- Massive pulmonary hemorrhage, 1099
- Mast cell activation syndrome, 4126–4128, 4127t
- Mast cell disorders, 4126–4127, 4128f
- Mast cells, in allergic diseases, 1371
- Mastalgia, 3331–3332
- Masticator space infection, 2248t
- Mastitis, 411, 3330–3331
 neonatal, 1148
- Mastocytomas, 4125
- Mastocytosis, 1430, 4124–4126, 4125t–4126t, 4126f
- Mastoid process, 4016
- Mastoiditis, 3999–4000, 4013
 acute, 4016–4020
 anatomy of, 4016

- Mastoiditis (*Continued*)
 clinical manifestations of, 4017, 4017
 diagnosis and imaging of, 4017, 4017t, 4018f–4019f
 epidemiology of, 4016
 management of, 4017–4019
 microbiology of, 4016–4017, 4016t
 special situations of, 4019–4020, 4020f
- Masturbation, 166, 3637
- Maternal depression
 screen for, 222
 treatment of, 1022
- Maternal-derived androgens, sources of, 3507, 3508t
- Maternal diabetes, 1020
- Maternal diseases, in arthrogryposis, 4271
- Maternal hyperthermia, 1023
- Maternal immunologic diseases, 1020–1021
- Maternal infections, 2242t
- Maternal intrapartum antibiotic prophylaxis, 1716
- Math learning disability (MLD), 318–321
 broad cognitive processes, 320
 causes of, 320
 comorbidities of, 319–320
 definition of, 318–319
 epidemiology of, 319–320
 genetics, 319
 math specific processes, 320
 medical/genetic conditions, 319
 parent resources for child with, 321t
 prevalence of, 319
 risk factors for, 319
 treatment and interventions for, 320–321, 321t
- Mathematics disorder, 304t, 305
- Matrix, 3312
- Maturation, of frontal lobes, and adolescent risk taking, 1186f
- Mature cystic teratoma, 3340–3341
- Maturity-onset diabetes of the young (MODY), 3515–3516, 3543–3545
 clinical characteristics of, 3546t
 key features of, 3518t
 mitochondrial gene defects in, 3545
 MODY2, 3543
 MODY3, 3544, 3545f
- Maturity rating, 1043f
- Mauriac syndrome, 3537–3538
- Maxilla, 2248f
- Maxillary sinus, 2248f
- Maximal midexpiratory flow rate, 2521
- Maximum forced expiratory flow (FEF_{max}), 2519–2520, 2519f
- Maximum intensity projection, coronal, 2909f
- Mayer-Rokitansky-Küster-Hauser syndrome, 3260, 3353
 in XX gonadal dysgenesis, 3499
- Mayo endoscopic score, for ulcerative colitis, 2312f
- MBL. *See* Mannose-binding lectin
- MCA. *See* Medical child abuse
- McArdle disease, 900t–901t, 909, 3851, 3852t
- McCune-Albright syndrome (MAS), 478, 3147, 3378, 3392–3393, 3392f, 3415–3416, 3473t, 3502–3503, 4068, 4070t–4071t
 Cushing syndrome and, 3476
- McDonald criteria, for multiple sclerosis, 3733
- M-CHAT. *See* Modified Checklist for Autism in Toddlers
- McIsaac score, GAS pharyngitis, 2560t
- McKusick-Kaufman syndrome, 3351
- MCM4 deficiency, 1288, 1288f
- MCM10 deficiency, 1288, 1288f
- McMurray test, 4309f
- MCP. *See* Membrane cofactor protein
- MDA5 deficiency, 1339t
- MDGs. *See* Millennium Development Goals
- MDS. *See* Myelodysplastic syndromes
- Mean (statistical measurement), 140–142
- Mean airway pressure, ways to increase, 622f
- Mean arterial blood pressure, shock and, 607t
- Mean corpuscular hemoglobin (MCH), reference intervals, 4472.e9t
- Mean corpuscular hemoglobin concentration (MCHC), reference intervals, 4472.e9t
- Mean corpuscular volume (MCV), 2947t
 causes of, 2929t
 normal mean and lower limits of, 2926t
 reference intervals, 4472.e9t
 use of, 2926t, 2929f
- Mean harm score, 1193f
- Measles, 1586, 1605, 1623t–1625t, 1958–1964, 1959f
 clinical manifestations of, 1958–1959, 1960f
 complications of, 1961–1962, 1961t
 diagnosis of, 1960
 differential diagnosis of, 1960
 epidemiology of, 1958
 etiology of, 1958
 German, 1965
 in Kawasaki disease, 1544–1545
 laboratory findings of, 1960
 modified infection, 1959
 pathogenesis of, 1958
 pathology of, 1958
 prevention of, 1963–1964
 postexposure prophylaxis, 1964
 vaccine, 1963–1964, 1963t–1964t
- prognosis for, 1962
 roseola and, 2017–2018
 transmission of, 1958
 treatment of, 1962
 vaccine, 30–31t
- Measles, mumps, rubella, varicella (MMRV) vaccine, 1588t–1589t, 1589, 1602, 1971
- Measles, mumps, rubella (MMR) vaccine, 1588t–1589t, 1589, 1602, 1605–1608
- Measurement, accurate, 172
- Mebendazole
 for ascariasis, 2199
 for enterobiasis, 2204
 for hookworms, 2202
 for toxocariasis, 2210
 for trichuriasis, 2203
- Mechanical circulatory support, for heart failure, 2901
- Mechanical ventilation, 620–629
 additional ventilatory modalities in, 626–627
 in asthma exacerbations, 1409
 conventional ventilator settings of, 627
 critical opening pressure in, 622–623
 equation of motion in, 620–621
 functional residual capacity in, 621–622
 invasive, 623–626
 long-term, 2716–2718
 adult transition in, 2718
 aerodigestive and communication considerations in, 2726–2727
 airway clearance in, 2717
 cardiopulmonary interactions and, 2727
 chest wall/thoracic configuration in, 2727
 developmental considerations for, 2727
 gas-exchange goals and ventilator strategies in, 2727
 goals and decision-making in, 2726–2730
 indications for, 2716t
 infections in, 2718
 inhalation medications in, 2717
 invasive positive pressure ventilation in, 2716–2717
 lived experience of, preparation of, 2727–2729
 monitoring for, 2717
 mucolytics and anticholinergics in, 2717
 noninvasive and transtracheal supports in, 2726
 nutrition in, 2718
 optimal ventilator support in, 2717
 physical, occupational, speech therapy in, 2717
 preparing for discharge in, 2717–2718
 projected interventions and needs and, 2727
 psychosocial considerations in, 2718
 routine health maintenance and, 2729
 supplemental oxygen in, 2717
 tracheal decannulation, 2729–2730
 transitioning from acute care to rehabilitation or community setting in, 2729
- monitoring respiratory mechanics in, 628–629
 noninvasive, 623
 patient-ventilator asynchrony in, 627
 for RDS, 1081
 in respiratory distress and failure, 619–620
 strategies of, in various clinical situations, 628t
- Mechanical ventilation (*Continued*)
 time constant in, 622, 622f
 ventilator-induced lung injury in, 629
 weaning from, 629
- Mechanism of action
 antibacterial medications, 1675t–1685t
 antiviral drugs, 1951t–1952t
- Mechanistic target of rapamycin (mTOR), 3657
- Mechanobullous disorders, 4080–4084
 dystrophic epidermolysis bullosa, 4083t, 4083–4084, 4083t, 4084f
 epidermolysis bullosa, 4081, 4081t
 epidermolysis bullosa simplex, 4081
 junctional epidermolysis bullosa, 4081–4082, 4082t, 4083f
 Kindler syndrome, 4084
- Meckel diverticulum, 2286–2287, 2287f
- Meckel-Gruber syndrome, 792t
 in encephalocele, 3564
- Meconium aspiration syndrome (MAS), 1089–1090, 1090f
- Meconium ileus, 1100–1101, 1101f, 2284
 complicated, 1102f
 in cystic fibrosis, 2677
 cystic fibrosis and, 2423–2424
 uncomplicated, 1101f
- Meconium peritonitis, 1101, 2284
- Meconium plugs, 1100, 1100f
- Meconium staining
 of amniotic fluid, 1071–1072
 of infant skin, 1000f
- MECP2* gene region, 768t–769t
- Media violence, 99–100, 102
- Medial collateral ligament, 4308–4309
- Medial elbow pain, 4303–4304
- Medial epicondylitis, 4304, 4305f
- Medial tibial stress syndrome, 4310–4311, 4331
- Medial tibial torsion, 4212
- Median (statistical measurement), 140–142
- Mediastinal fibrosis, 1932–1933
- Mediastinal GCT, 3150
- Mediastinal granulomas, 1932–1933
- Mediastinal mass, 674–675
 from Hodgkin disease, 3106–3107, 3107f–3108f
 lymphatic malignancies and, 3081–3082, 3083f
 from non-Hodgkin disease, 3112–3113
- Medical air transport, 535–536
- Medical care
 gender-affirming, for adolescents, 1173t, 1175
 postadoption, 73–75
- Medical child abuse (MCA), 127–128
 clinical manifestations of, 127–128
 evaluation and diagnosis of, 128
 outcomes of, 129
- Medical clearance, 4294
- Medical conditions
 genetic aspects of, 755
 maternal
 affecting fetus or newborn, 1012t
 malformations caused by, 781t
 psychotic disorder due to, 291t
- Medical control, in emergency medical services, 536
- Medical control physicians (MCPs), 540–541
- Medical device-associated infection, 1618, 1667–1670
 antibiotics for, 1674
 central venous catheter, 1667
 CSF shunts, 1669–1670
 implantable orthopedic devices, 1670
 intravascular access devices, 1667–1668
 peritoneal dialysis catheters, 1670
 urinary catheters, 1668–1669
- Medical eligibility, for contraceptive use, 1221t
- Medical evaluation of the foreign-born child, 78–81
- Medical futility, 51
- Medical history, 221
- Medical home, 15, 90
 psychotherapy in, 233–235
- Medical neighborhood, 7
- Medical record, preadoption reviews, 72–73
- Medical referral, for sexual abuse, 123, 123f
- Medical-legal partnerships (MLPs), 7
- Medication reactions, 4034
- Medicational precocity, 3394
- Medication-overuse headaches (MOHs), 3650–3651

- Medications**
- for acute mountain sickness, 633t
 - for ADHD, 222–224, 225t–226t, 314–315
 - for anger-driven aggressive behavior, 280
 - to avoid, for delirium, 298–299
 - for depression and anxiety, 227t
 - for hepatocyte injury, 2450
 - for intubation, 620t
 - maternal, malformations caused by, 781t
 - for neonatal resuscitation, 1071
 - for neurodevelopmental dysfunctions, 308–309
 - for psychosis and mania, 228t
 - psychotropic, principles of, 222, 223t
- Meditation**, 58t
- Mediterranean spotted fever**, 1900t–1902t, 1906–1907, 1907f
- Medium-chain acyl-coenzyme A dehydrogenase deficiency**, 859–862
- clinical manifestations, 859
 - laboratory findings, 859–862
 - prognosis, 862
 - treatment of, 862
- Medium-chain triglycerides**, 392
- Medrol**. *See* Methylprednisolone
- Medroxyprogesterone acetate**
- for cyclic vomiting syndrome, 2395
 - intramuscular, 3356
- Medullary carcinoma**, thyroid, 3423
- Medullary sponge kidney**, 3236
- Medullary thyroid carcinoma**, 3164
- MEN2 and, 3432
- Medulloblastoma**, 3122f–3123f
- language disorders and, 330
- Mees lines**, 4143, 4431, 4432f
- Mefloquine**, for malaria prophylaxis, 1636, 2181t–2182t
- MEFV**, in familial Mediterranean fever, 1520
- Megacystis-megaureter syndrome**, 3270
- Megacystis-microcolon-intestinal hypoperistalsis syndrome**, 2297f, 2298t, 3282
- Megaesophagus**, 2167
- Megakaryocytes**, 2922–2924, 3016–3017
- Megakaryopoiesis**, 3049, 3049f
- Megalencephaly**, 3567
- Megaloblastic anemias**, 2217, 2940–2944, 2940f, 2940t
- folic acid deficiency, 2940–2942
 - inborn errors of metabolism and, 809t–810t
 - orotic aciduria, 2944
 - thiamine-responsive, 2944
 - vitamin B₁₂ deficiency, 2942–2944
- Megalocornea**, 3943
- Megalourethra**, 3281, 3301
- Megaprepucse**, 3299f
- Megaureter**, 3280–3281, 3282t, 3283f
- Mehta angle**, 4244
- Mehta casting**, 4245
- Meiosis**, 761
- Melamine**
- contamination, 4409
 - poisoning, 4446
- Melanoblast migration abnormalities**, 4072–4075
- Melanocortin-4 receptor (MC4R) deficiency**, 438–442
- Melanocytes**, 4025
- Melanoma**, 4062–4063, 4063t, 4189
- Melanonychia striata**, 4144
- Melarsoprol**, for human African trypanosomiasis, 2163
- MELAS**. *See* Mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes
- Melatonin**, 56t–57t
- for delirium, 298
- Melia**, 784t
- Melioidosis (*Burkholderia pseudomallei*)**, 1802f
- Melkersson-Rosenthal syndrome**, in sarcoidosis, 1551
- Melody stent-valve**, implantation of, 2762f
- Membrane attack complex (MAC)**, 1316
- Membrane cofactor protein (MCP)**, 1316–1317
- deficiency of, 1321
- Membranoproliferative glomerulonephritis (MPGN)**, 1319, 3191t, 3193–3194, 3254–3255
- Membranous and pseudomembranous conjunctivitis**, 3941–3942
- Membranous nephropathy (MN)**, 3189f, 3192–3193, 3193f, 3254–3255
- Membranous urethral injury**, 3310
- Memory**
- math disabilities and, 320
 - mechanisms of, 302
- Menaquinones**, 481
- Menarche**, 3329, 3467
- onset of, 1159–1160
 - premature, 3394
- Mendelian inheritance**, 735–740
- autoinflammatory diseases, 1518
 - autosomal dominant, 735
 - autosomal recessive, 735–738
 - pseudodominant, 738
 - X-linked, 738–740
- Menelaus method**, 4220–4221
- Meningitis**, 1319, 1749
- caused by *Staphylococcus aureus*, 1696
 - coccidioidal, treatment of, 1939
 - cryptococcosis and, 1926
 - CSF findings in, 3759t–3760t
 - Haemophilus influenzae* in, 1757
 - meningococcal, 1741
 - mumps and, 1970–1971
 - red flags for, 548
 - tuberculous, 1843–1844, 1844f
- Meningocele**, 3563
- Meningococcal B (MenB) vaccine**, 1588t–1589t, 1602, 1605
- Meningococcal conjugate vaccine against serogroups A, C, W135, and Y (MCV4)**, 1588t–1589t, 1605
- Meningococcal disease**, 1320
- clinical manifestations of, 1739–1742, 1740t–1741t
 - complications of, 1743
 - diagnosis of, 1742
 - differential diagnosis of, 1742
 - epidemiology of, 1738, 1738f
 - etiology of, 1737
 - host factors, 1739
 - immunity, 1739
 - pathogenesis and pathophysiology of, 1738–1739
 - prevention of, 1744–1746
 - prognosis of, 1743–1744
 - treatment of, 1742–1743
 - antibiotics, 1742
 - supportive care, 1742–1743
 - vaccination of, 1745–1746, 1746t
- Meningococcal meningitis**, 1741
- Meningococcal polysaccharide vaccine against serogroups A, C, W135, and Y (MPSV4)**, 1588t–1589t
- Meningococcal sepsis**, 1319
- Meningococcus**, 1737–1746
- Meningoencephalitis**, 3758
- amebic
 - drugs for, 2126t–2144t
 - granulomatous, 2146, 2146f
 - primary, 2145–2146
 - cryptococcosis and, 1926
 - mumps and, 1970–1971
- Meningomyelocele (spina bifida)**, 4400–4401
- adolescence and transition to adulthood, 4401
 - clinical implications of, 4400–4401, 4400t
 - etiology of, 4400
 - prenatal screening of, 4400
 - prevention of, 4400
- Meniscal tears**, 4309
- Menkes disease**, 484, 3719–3720, 3899t
- malabsorption and, 2351
- Menkes kinky hair syndrome**, 4141
- Menorrhagia**, in factor VII deficiency, 3033
- Menstrual activity**, 3386
- Menstruation**
- abnormal uterine bleeding, 1211, 1213–1214, 1213t–1214t
 - in adolescents with special needs, 3355–3356
 - amenorrhea, 1211–1212, 1212f
 - dysmenorrhea, 1214–1216, 1215t
 - estrogen-containing methods, 3355–3356
 - contraceptive patch, 3356
 - contraceptive ring, 3356
 - oral contraceptives, 3355
 - thromboembolism, 3356
 - irregularities, 1210–1211
 - nonhormonal methods, 3355
 - normal, 1210–1211, 1210t
 - PMS and PMDD, 1216
- Menstruation (Continued)**
- progestin-only methods, 3356
 - hormones and antiepileptic drugs, 3356
 - implants, 3356
 - intramuscular medroxyprogesterone acetate, 3356
 - oral progestins, 3356
 - progesterone intrauterine device, 3356
 - related disorders, 1210–1216
 - surgical methods, 3356
 - treatment of, 3355
- Mental disorders**, 248t
- preexisting, suicide and, 264
- Mental health**, 19
- action signs, 217, 217t
 - of GLB youth, 1185
 - issues, office intervention for, 89–90
 - of nonbinary youth, 1181
 - problems, malaria and, 2181
- Mental Health Rating Scales**, 218t
- Mental healthcare**, minor consent laws for, 1168
- Mental state**
- altered, in acutely ill child, 549
 - in neurologic examination, 3551
- Mental status**, examination, 221
- Meperidine**
- equianalgesic doses of, 685t
 - in hepatic and renal dysfunction, 685t
 - in pain management, 683t
- Mepolizumab**
- for ANCA-associated vasculitis, 1563–1564
 - for asthma, 1401t, 1404
- Mercaptocetyl glycine (MAG-3)**, 3278, 3278f
- 6-Mercaptopurine**, adverse reactions, 3089t–3090t
- Mercury**, 4424
- food-borne noninfectious illnesses and, 2362t–2364t
 - intoxication, 4433–4435, 4434t
 - clinical manifestations of, 4434
 - differential characteristics of, 4434t
 - food-borne illness, 4411t–4413t
 - laboratory findings of, 4433t, 4434–4435
 - pathophysiology of, 4434
 - pharmacokinetics of, 4433–4434
 - toxic levels of, 4433t
 - treatment of, 4435, 4435t
- Merkel cell polyomavirus**, 2084
- Merkel cells**, in epidermis, 4025
- Meropenem**, 1675t–1685t
- Merosin**, 3844–3845
- Merozoites**, 2169–2170, 2186
- MERRF**. *See* Myoclonic epilepsy and ragged red fibers
- MERS**. *See* Mild encephalopathy with a reversible splenial lesion
- Mesangial proliferation**, 3228
- Mesangiocapillary glomerulonephritis**, 3193–3194
- Mesangium**, 3180–3181
- Mesenteric cysts**, 2509
- Mesial temporal sclerosis**, 3600
- Mesoblastic nephroma**, 3135
- Mesomelic shortening**, 4336
- Meso-Rex bypass surgery**, 2272, 2272f
- Messenger RNA**, 730
- Metabolic acidosis**, 527, 529
- in acute kidney injury, 3245
 - in CKD, 3250
 - clinical manifestations, 516
 - complication of augmentation cystoplasty, 3290
 - diagnosis, 516–517, 520–521
 - etiology and pathophysiology, 514–516, 518–520
 - with respiratory compensation, 617
 - treatment, 521
- Metabolic alkalosis**, 527, 529
- causes of, 518t
 - chloride-resistant causes of, 521
 - diagnosis, 520–521
 - hypokalemia and, 499t
 - maintenance phase of, 519
 - treatment, 521
 - and volume depletion, 488
- Metabolic disorders**
- acute hepatic failure and, 2494–2495
 - anesthetic implications in, 666t
 - associated with cardiomyopathy, 808t
 - associated with hepatic dysfunction, 808t

- Metabolic disorders (*Continued*)
 associated with prematurity, 1046t
 bone structure, growth, and hormonal regulation, 4377–4380, 4378f, 4379t–4380t
 fetal therapy for, 1027t
 genetic, 803–807, 811f
 language disorders and, 330
 as oncologic emergency, 3092t–3093t
 screening for, 728
 Metabolic disturbances, in neonatal seizures, 3619–3620, 3621t
 Metabolic evaluation, of hypercalcemia, 3314t
 Metabolic liver disease, 2454–2460, 2455t
 α₁-antitrypsin deficiency, 2460
 citrin deficiency as, 2460
 clinical manifestations of, 2455t
 Indian childhood cirrhosis as, 2459
 inherited deficient conjugation of bilirubin, 2454–2456
 Wilson disease as, 2457–2459, 2457t
 Metabolic myopathies, 3848–3856
 glycogenoses in, 3851
 lipid, 3856
 malignant hyperthermia in, 3850–3851
 mitochondrial, 3851–3855
 periodic paroxysms in, 3848–3850
 vitamin E deficiency, 3856
 Metabolic stroke, 833
 Metabolic syndrome
 due to HSCT, 1365
 prediabetes and, 3517
 Metabolic system, shock in, 607t
 Metabolic testing, in neurologic evaluation, 3560
 Metabolism
 disorders of, neutropenia and, 1309t, 1310–1311
 in pubertal blockade, 1177
 Metacercaiae, 2214
 Metachromatic leukodystrophy, 887t, 896, 3714–3715
 Metacyclic trypanostigotes, 2163
¹²³I-metaiodobenzylguanidine (MIBG), in pheochromocytomas, 3480
 Metal metabolism disorders, liver and, 2455t
 Metalinguistics, 301
 Metamyelocytes, 1290
 Metaphase, 761
 Metaphase chromosome spreads, 761
 Metaphyseal bone overgrowth, in IL-1-mediated diseases, 1527f
 Metaphyseal chondrodysplasia, 4334
 Metaphyseal fraying, in rickets, 473f
 Metaphysis, 4193
 Metastatic Crohn disease, 4033
 Metastatic tumors, 3125
 Metatarsal fractures, 4283
 Metatarsal stress fractures, 4313
 Metatarsus adductus, 4201–4202, 4201f, 4215
 Metatarsus varus, 4201
 Metatropic dysplasia, 4356, 4357f
 Metformin, 716
 in polycystic ovary syndrome, 3337
 for T2DM, 3542t
 Methacholine challenge, 1378
 Methadone, 713t
 equianalgesic doses of, 685t
 in hepatic and renal dysfunction, 685t
 for neonatal abstinence syndrome, 1133
 in pain management, 683t
 Methanol, poisoning, 707t–708t, 720
 Methemoglobin, in respiratory distress and failure, 616
 Methemoglobinemia
 hereditary, 2979, 2980f, 2980t
 with deficiency of NADH cytochrome b5 reductase, 2979–2980
 in newborn, 1054t
 poisoning, 707t–708t
 Methicillin-resistant *Staphylococcus aureus* (MRSA), 1693
 Methicillin-susceptible *Staphylococcus aureus* (MSSA), 1695
 Methionine, metabolism defects, 820–824, 821f
 cystathioninemia (cystathioninuria), 823–824
 homocystinuria, 820–823
 hypermethioninemia, 823
 Methionine adenosyltransferase (MAT I/MAT III) deficiency, hepatic, 823
 Methotrexate
 adverse reactions, 3089t–3090t
 for atopic dermatitis, 1417
 for Crohn disease, 2321
 for psoriasis, 4100
 for rheumatic diseases, 1464–1465
 Methylsuximide, dosages of, 3609t–3610t
 Methyl isocyanate, exposure to, 4409
 Methyl mercury, intoxication, 4433
 Methyl salicylate, toxicity, 701t
 2-Methylacyl-CoA racemase deficiency (AMACR), 868
 Methylcobalamin formation, defects in, 821–822, 822f
 3-Methylcrotonyl-CoA carboxylase deficiency, 828–829
 Methylene blue
 1% solution, 707t–708t
 for shock, 610t
 Methylene chloride, 720
 inhaled, 1203t
 Methylenedioxymethamphetamine (MDMA), 1204
 Methylenetetrahydrofolate reductase deficiency, 822–823
 3-Methylglutaconic acidurias, 829–830, 830t, 1309t
 3-Methylglutaconyl-CoA hydratase deficiency, 829
 Methyltin. *See* Methylphenidate
 Methylmalonic acidemia, 835–836, 1309t
 Methylphenidate, for ADHD, 225t–226t, 314
 Methylprednisolone (Medrol), for asthma, 1405t–1406t
 Methylxanthines, for apnea, 1076
 Metoclopramide
 for CIPO, 2291
 for migraine, 3646t–3647t, 3648
 Metoprolol, for heart failure, 2898t
 Metronidazole, 1675t–1685t, 1690
 for bite wound, 4459t
 for *Clostridium difficile* infection, 1826, 1826t
 for Crohn disease, 2320
 for dracunculiasis, 2209
 for tetanus, 1823
 for trichomoniasis, 2155
 Mevalonate kinase deficiency (MKD), 832–833, 1521, 1536–1537
 Mevalonic aciduria, 832–833
 systemic involvement, 1521
 Mexiletine, 2845t–2846t
 Meyer-Rokitansky-Küster-Hauser syndrome, 3508–3509
 Mezlocillin sodium, 1675t–1685t
 MF59, 1587–1589
 MFM. *See* Myofibrillar myopathies
 MFQ. *See* Mood and Feelings Questionnaire
 MFS. *See* Marfan syndrome
 mGluR5 antibodies, encephalitis with, 3705t–3707t
 MGS. *See* Male genital schistosomiasis
 MHC class I deficiency, 1272–1273
 MHC class II deficiency, 1272
 MHS. *See* Malignant hyperthermia susceptibility
 MI. *See* Motivational interviewing
 Micafungin, 1917t, 1920–1921
 Michelis-Castrillo syndrome, 504
 Microadenomas, 3475
 Microaggressions, 22
 Microalbuminuria, 902, 3219, 3536
 in T2DM, 3543t
 Microangiopathic disorders, DIC caused by, 3048t
 Microangiopathic hemolytic anemia, 3048, 3055
 Microangiopathies, thrombotic, 2996t
 Microarray analysis
 hybridization signal in, 734f
 for intellectual disability, 352
 technique, 761–762
 Microbial deprivation hypothesis, 3519
 Microbial surface components recognizing adhesive matrix molecules (MSCRAMMs), 1694
 Microbicidal activity, 1297t–1298t
 Microbiologic studies, for cystic fibrosis, 2670
 Microbiology reports, 1691t
 Microbiota, gastrointestinal, 2277
 Microcephaly, 3551, 3566
 causes of, 3568t
 in congenital toxoplasmosis, 2191–2192
 inborn errors of metabolism and, 809t–810t
 Microcephaly vera, 3566
 Microcoria, 3920–3921
 Microcornea, 3943
 Microcytic anemias, 2927–2929, 2948t, 2950–2952, 2951t, 2952f
 Microdeletion, 767–770, 768t–769t, 770
 cryptic, 765f
 Microdontia, 2240
 Microduplication syndromes, 768t–769t, 770
 Micronutrient deficiencies, 423
 mineral, 483–484
 Micronutrients, 396, 397t–403t
 Micropenis, 3298–3300, 3300f
 in male-appearing genitalia, 3506t
 Microscopic hematuria, 3266
 Microscopic polyangiitis (MPA), 1553t, 1562t, 2689
 Microspherophakia, 3952
 Microsporidia, 2153–2154
 Microsporidiosis, drugs for, 2126t–2144t
 Microtia, 3995–3996, 3996f
 Microvillus inclusion disease, 2337–2339, 2339f
 Midazolam, 671
 for burn injuries, 654
 for intubation, 620t
 Mid-childhood acne, 4184
 Middle adolescents, development of, 1162
 Middle childhood, 167–171
 cognitive development, 167–171, 170t
 moral development, 171
 physical development, 167, 168f
 sleep, normal developmental changes in, 204t
 social and emotional development, 171
 well-child care and, 85–89
 Middle ear
 of child infected with *Mycobacterium abscessus*, 1863f
 congenital malformations of, 3997
 trauma to, 4021–4022, 4022f
 Middle East respiratory syndrome coronavirus, 2039
 Middle school children, neurodevelopmental function and dysfunction, 304
 Middle-ear pressure, normal, 3982
 Midgut, 2276
 Midline defects, disorders with, 3569–3573
 Midline nasal masses, congenital, 2546–2547, 2547f
 Midodrine
 for POTS, 599t
 for vasovagal syncope, 596t
 Midparental height, measurement of, 175
 Mid-upper arm circumference (MUAC), 423, 423f, 434–435
 Midureteral obstruction, 3280
 Mifepristone, for Cushing syndrome, 3477
 Migraine, 3639–3650
 abdominal, 2390–2391, 2390t
 with aura, 3643–3644
 with brainstem aura, 3642t, 3644
 chronic, 3642t
 classification and clinical manifestations of, 3639–3644
 development of, 157
 diagnosis and differential diagnosis of, 3644, 3645t
 epidemiology of, 3639
 genetics in, 3642t
 stroke and, 3753–3754
 that mimic seizures, 3633
 treatment of, 3644–3650, 3646t–3647t
 acute, 3645–3647
 behavioral therapy for, 3649
 preventive therapy for, 3648–3649
 with typical aura, 3642t
 vestibular, with vertigo, 3642t
 without aura, 3639–3643, 3642t, 3643f
 Migrainous infarction, 3753–3754
 Migrant children, 196
 Migrating motor complex, 2276–2277
 Migration, global health and, 35, 35f
 Migratory glossitis, 2253
 Migratory polyarthritides, 1712
 Mild acute pancreatitis, 2426
 Mild encephalopathy with a reversible splenial lesion (MERS), 3773
 Mild hypothermia, 659
 Mild macrocytosis, 2989

- Mild spondyloepiphyseal dysplasia, with premature onset arthrosis, 4341
- Milia, 4041
- Miliaria, 4134–4135, 4135f
- Miliary tuberculosis, 1841f, 1842, 4158
- Military families, 196
- Milium, 4185
- Milk
- cow
 - hypersensitivity, pulmonary hemosiderosis and, 2689–2690
 - protein-based formulas, 412
 - human
 - beneficial properties of, 409t
 - infectious agents detected in, 1009t
 - for premature infants, 1044
 - protective effect of, 410t
 - intake, insufficient, 411
- Millennium Development Goals (MDGs), 1, 27
- Miller Fisher syndrome (MFS), 3900, 3903t–3904t
- Miller syndrome, 953
- Miller-Dieker syndrome, 768t–769t, 786t
 - lissencephaly and, 3568–3569
- Milrinone
 - for heart failure, 2898t, 2899
 - for postarrest stabilization, 568t
 - for shock, 610t
- Milwaukee brace, 4251
- Minamata disease, 4433
- Mind-body therapies, 57, 58t
- Mindfulness meditation, in pain management, 693
- Mineral absorption, disorders of, 2350–2351
- Mineral deficiency, 4379
- Mineral supplements, for cystic fibrosis, 2677
- Mineralocorticoid escape phenomenon, 521
- Mineralocorticoid receptor, activating pathogenic variants in, 3461
- Mineralocorticoid replacement, for 21-hydroxylase deficiency, 3467
- Mineralocorticoids, 3448
 - altered end-organ sensitivity to, 3460–3461
 - excess, 2913t, 3475t
- Minimal change nephrotic syndrome (MCNS), 3223, 3225f, 3226–3231
- Minimalist running shoes, 4331
- Minimum alveolar concentration (MAC), 668
- Minimum Personal Risk Questionnaire, 4439t
- Minor electrical burns, 654
- Minoxidil, for severe hypertension in children, 2919t
- Minute volume, 2513
- Miracidia, 2214
- MIRM. *See* Mycoplasma-induced rash and mucositis
- Mirtazapine
 - for cyclic vomiting syndrome, 2395
 - for depression and anxiety, 226, 227t
- MIS-C. *See* Multisystem inflammatory syndrome in children
- Miscellaneous diseases, associated with eosinophilia, 1295, 1295t
- Missense variants, 730–731
- Mistletoe, 2492t
- Mitchell-Riley syndrome, 2340
- Mites, 4172
- Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency, 831–832
- Mitochondrial acetoacetyl-CoA thiolase (T_2) deficiency, 830–831, 831f
- Mitochondrial chromosome, 730
- Mitochondrial cytopathy, 3851–3852
- Mitochondrial depletion syndrome, of early infancy, 3854
- Mitochondrial disease, 931f, 932t, 933f
 - ataxia and, 3672
 - diagnosis of, 931–937
 - diagnostic testing for, 936–937, 936f
 - differential diagnosis of, 935t
 - expression of, 2484
 - genetic diagnostic testing for, 745f
 - hypoparathyroidism and, 3436
 - inheritance, 743t, 934
 - pedigree of, 742f
 - primary, 2483
 - treatment principles for, 937, 937f
 - when to suspect, 933–934, 933f, 934t
- Mitochondrial DNA (mtDNA) deletion, 2933
- Mitochondrial DNA depletion syndrome, 2484, 3697–3698, 3697t
- Mitochondrial dysfunction, toxic myopathies, 3847
- Mitochondrial encephalomyopathies, 3695–3700, 3695f
 - autosomal dominant optic atrophy, 3699
 - clinical manifestations of, 3696t
 - coenzyme Q₁₀ biosynthesis disorders in, 3698
 - diagnosis of, 3696t, 3699–3700, 3700t
 - juvenile POLG syndrome in, 3699
 - Kearns-Sayre syndrome in, 3698
 - Leber hereditary optic neuropathy, 3699
 - Leigh syndrome in, 3696
 - leukoencephalopathies, 3699
 - management of, 3700
 - mitochondrial DNA depletion syndrome in, 3697–3698
 - myoclonic epilepsy and ragged red fibers in, 3699
 - neurogastrointestinal, 3699
 - neurogenic muscle weakness, ataxia, and retinitis pigmentosa, 3699
 - nonsyndromic, 3699
 - reversible infantile respiratory chain deficiency in, 3698
- Mitochondrial encephalopathy with lactic acidosis and strokelike episodes (MELAS), 3698–3699, 3698f
- Mitochondrial fatty acid oxidation disorders, 859–865, 860t–861t, 861f–862f
 - carnitine palmitoyltransferase-IA deficiency, 864
 - carnitine palmitoyltransferase-II deficiency, 864
 - carnitine:acylcarnitine translocase deficiency, 864
 - electron transfer flavoprotein dehydrogenase deficiencies, 864–865
 - β -hydroxy- β -methylglutaryl-CoA lyase deficiency, 865
 - β -hydroxy- β -methylglutaryl-CoA synthase deficiency, 865
 - β -ketothiolase deficiency, 865
 - medium-chain acyl-coenzyme A dehydrogenase deficiency, 859–862
 - monocarboxylate transporter-1 deficiency, 865
 - plasma membrane carnitine transport defect, 864
 - short chain 2,3-enoyl-CoA hydratase deficiency, 863
 - short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency, 863
 - short chain acyl-CoA dehydrogenase (SCAD) deficiency, 863
 - succinyl-CoA:3-ketoacid-CoA transferase (SCOT) deficiency, 865
 - very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, 862–863
- Mitochondrial gene defects, in MODY, 3545
- Mitochondrial hepatopathies, 2451, 2483–2486
 - clinical manifestations of, 2484
 - diagnostic evaluation of, 2486
 - epidemiology of, 2483–2484
 - primary, 2484–2486
 - secondary, 2485–2486
 - tiered investigation in, 2486t
 - treatment of, 2486
- Mitochondrial inheritance, 742
- Mitochondrial leukoencephalopathies, 3699, 3700t
- Mitochondrial myopathies, 3851–3855, 3853t–3854t
 - clinical spectrum of, 3854t
 - diagnostic approach in, 3855f
- Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), 274, 953, 2291–2292, 3699
- Mitochondrial reactive oxygen species detoxification, deficiency of, 3454
- Mitochondrial replacement therapies, 760
- Mitochondrial respiratory chain defects
 - cardiomyopathy and, 808t
 - hepatic dysfunction and, 808t
- Mitochondrial trifunctional protein deficiency, 863
- Mitosis, 761
- Mitral insufficiency
 - congenital, 2797
 - in rheumatic heart disease, 2872–2873, 2874t
- Mitral regurgitation, 1712–1713
- Mitral stenosis, in rheumatic heart disease, 2873–2875, 2874f–2875f
- Mitral valve, prolapse, 2797–2798
- Mittelschmerz, 1215
- Mixed acid-base disorder, 513, 523
- Mixed connective tissue disease, 1461, 1463t, 4032
- Mixed gonadal dysgenesis, 3499–3500
- Mixed hearing loss, 3983
- Mixed hemolytic and hepatotoxic factors, 1108t
- Mixing studies, in hemostasis, 3026–3027
- MKD. *See* Mevalonate kinase deficiency
- MLD. *See* Math learning disability
- MLPs. *See* Medical-legal partnerships
- MMIHS. *See* Megacystis-microcolon-intestinal hypoplasia syndrome
- M-mode echocardiography, 2754–2755, 2754f–2755f
- MNDS. *See* Motor neuron diseases
- Mnemonic tools
 - CRAFFT, 1197–1198, 1197t
 - FISTS, 1190t
- MNGIE. *See* Mitochondrial neurogastrointestinal encephalomyopathy
- Mobile health, adolescent, 1164t–1165t
- Mobility issues, estrogen use and, 3356
- Mobility loss, lumbodorsal spine, 1486f
- Möbius syndrome, 3575, 3930
 - in facial palsy, 3908
- MOCS1 deficiency, 945t
- Mode (statistical measurement), 140–142
 - as conventional ventilator settings, 627
- Model for Improvement, 37
- Moderate hypothermia, 659
- Moderately severe acute pancreatitis, 2426
- Modifiable environmental risk factors, for SIDS, 2533–2535
- Modified Checklist for Autism in Toddlers (M-CHAT), 218t
- Modified Duke criteria, infective endocarditis, 2869t
- Modified Ferriman Gallwey score, 336f
- MODS. *See* Multiple organ dysfunction syndrome
- Modular Approach to Therapy for Children (MATCH), 233
- Modular therapy packages, 233
- MODY. *See* Maturity-onset diabetes of the young
- MOG. *See* Myelin oligodendrocyte glycoprotein
- MOHs. *See* Medication-overuse headaches
- Moisturizers, for atopic dermatitis, 1412–1413
- Molar tooth sign, 3664–3672, 3672f
 - in brainstem and cerebellar disorders, 3576–3577
- Molding therapy, for deformational plagiocephaly, 3587
- Molecular genetic markers, in hereditary neuromuscular diseases, 3793
- Molecular genetics, 730
- Molecular processing, disorders of, 1309t, 1310
- Molecularly targeted therapies, 3086–3087
- Molluscles, 1892
- Mollusca, 4472
- Molluscum contagiosum, 4169, 4169f
 - vulvar, 3321t–3322t, 3326f
- Molnupiravir (Lagevrio), 1956–1957
- Molybdenum, 483t
- Molybdenum cofactor deficiency, 824, 855, 945t, 948
- Mometasone, for allergic rhinitis, 1384t–1385t
- Mometasone furoate (Asmanex, Asmanex Twisthaler), for asthma, 1402t
- Mometasone/formoterol (Dulera), for asthma, 1401t
- Mondini dysplasia, 3988f
- Monilethrix, 4141, 4141f
- Moniliasis, 4164–4166, 4165t
- Monitored anesthesia care, definition of, 668t
- Monkeypox, 4461–4464
 - clinical course of, 4461–4463, 4461t, 4462f–4463f, 4464t
 - prevention of, 4463–4464
 - treatment, 4463–4464, 4465f–4466f
 - vaccination, 4464t
- Monkshood, toxicity, 722t
- Monoamine neurotransmitter metabolism, disorders of, 3683–3684
- Monoamine oxidase (MAO) deficiency, 845t, 846
 - in tryptophan metabolism, 825f
- Monoamine oxidase inhibitors (MAOIs), 224
 - poisoning, 701t, 717, 717t
- Monoamines, metabolic pathways of, 845f

Monoamino-monocarboxylic amino acid transporter (B⁰AT1), 824
 Monocarboxylate transporter-1 deficiency, 865
 Monoclonal antibodies, for pediatric cancers, 3088t
 Monocular elevation deficiency, 3929, 3929f
 Monocular nystagmus, 3931t
 Monocytes, reference intervals, 4472.e9t
 Monocytosis, 1313, 1314t
 Monogenic autoimmune polyglandular syndrome, 3425
 Monogenic diabetes, 3515–3516
 characteristics at presentation for, 3539t
 key features of, 3518t
 less common forms of, 3544–3545
 type 1, 3518
 Monomethylhydrazine, 4443
 Monounsaturated fatty acids, 392
 Monozygotic twins, 1039, 1040f
 Montelukast
 for allergic rhinitis, 1382t
 for asthma, 1401t, 1403
 for eosinophilic gastroenteritis, 2326
 Mood and Feelings Questionnaire (MFQ), 218t
 Mood disorders, 254–263
 depressive disorders, 254–260
 Mood stabilizers, 228–229, 228t, 262
 Moral development
 in adolescent, 1161–1162
 in middle childhood, 171
 in preschool years, 166
 Moral thinking, 166
Moraxella catarrhalis, 1759–1761
 acute otitis media, 1760
 bacteremia, 1760
 diagnosis of, 1760
 epidemiology of, 1759–1760
 etiology of, 1759
 otitis media with effusion, 1760
 pathogenesis of infection, 1760
 prevention of, 1761
 recurrent otitis media, 1760
 sinusitis, 1760
 treatment of, 1760–1761
 Morbidity
 in childhood lupus, 1497t
 new, 4–6, 4t
 rates, fetal, 147
 Morning glory disc anomaly, 3964, 3965f
 Moro reflex, 3556–3557
 Morphea 1507–1508, 4032, 4121–4122, 4122f
 Morphea profunda, 1508t
 Morphine, 670
 adverse reactions, in premature infant, 1045t
 equianalgesic doses of, 685t
 in hepatic and renal dysfunction, 685t
 for intubation, 620t
 for neonatal abstinence syndrome, 1133, 1133t
 in pain management, 683t
 in pediatric palliative care, 64
 Morphogenesis
 cardiac, 2731, 2732f
 of liver and biliary system, 2434–2437
 Morphology, development of, 324, 325t
 Morquio syndrome, 940t, 941–942
 Mortality
 in appendicitis, 2397
 for injuries, 91
 of pneumonia cases, 2642f
 rates
 fetal, 147, 992–999
 infant, 1
 injury, 92t
 neonatal, 1–2, 992–999
 under-five, 1, 2f, 23, 23f–24f
 trends, for malignant cancers, 3087f
 Morula cells, of Mott, 2161
 Morulae, 1913f
 Mosaic variegated aneuploidy, 3131t–3132t
 Mosaic wart, 4166–4167
 Mosaicism, 727–728, 766t, 771–773, 773t
 45,X/46,XY, 771
 generation of, 761f
 germline, 771
 Moseley straight-line graph, 4220–4221, 4222f

Mosquito, as vector, 2206
 Mosquito bites, 4170t
 Mother yaw, 1876
 MotherToBaby, 1021
 Motile cilia, 2679–2680
 Motility disorders, 2287–2299
 cell, 1297t–1298t
 chronic diarrhea and, 2378
 chronic intestinal pseudoobstruction in, 2287–2291, 2287t–2290t
 congenital aganglionic megacolon, 2293t, 2295–2298, 2295t, 2296f–2297f, 2298t
 encopresis and functional constipation, 2292–2294, 2292t–2294t, 2294f
 esophageal, 2261
 intestinal neuronal dysplasia in, 2293t, 2296f, 2298–2299
 mitochondrial neurogastrointestinal encephalomyopathy in, 2291–2292
 superior mesenteric artery syndrome, 2299
 Motion, in transport physiology, 541
 Motivational interviewing (MI), 133–134, 134t, 140
 for behavioral and mental health issues, 89–90
 Motivational therapy, for nocturnal enuresis, 3296
 Motocross, injuries associated with, 4330
 Motor developmental delay, 3792–3793
 Motor disorders, 241–246
 stereotypic movement disorder, 244–246
 clinical course, 245
 comorbidity, 245
 description of, 245
 differential diagnosis of, 245
 epidemiology of, 245
 etiology of, 245
 treatment of, 245
 tic disorders, 241–244, 242t
 assessment, 243
 clinical course, 242
 comorbidities, 242, 244f
 differential diagnosis of, 242, 243t
 epidemiology of, 242
 etiology of, 242, 244t
 screening, 243
 sequela, 243
 treatment of, 243–244, 246t
 Motor examination, in neurologic evaluation, 3554–3555
 Motor neuron diseases (MNDs), 3874–3875
 Motor neurons, disorders of, 3858–3875
 myasthenia gravis as, 3858–3866
 spinal muscular atrophies as, 3866–3874
 Motor seizures, 3619
 Motor tics, that mimic seizures, 3636–3637
 Motor vehicle injuries, 91, 95–97, 579
 all-terrain vehicles, 97
 occupants, 92t, 95–96
 pedestrian, 97–98
 teenage drivers, 96–97
 Mottled enamel, in kidney failure, 2242t
 Mountain sickness, acute (AMS), 631–633
 Mouse embryo, development in, 2825f
 Mouth, assessment in newborn, 1002
 Mouth guard, 2252
 Mouth sores, in exclusion or inclusion in daycare, 187t–192t
 Movement disorders, 3664–3688, 3664t, 3665f
 alternating hemiplegia of childhood in, 3635
 ataxias, 3664–3673
 athetosis, 3673–3678
 behavioral conditions in, 3637
 benign motoric paroxysms in infancy in, 3637
 benign paroxysmal torticollis of infancy in, 3635
 brainstem dysfunction in, 3637
 chorea, 3673–3678
 dystonia, 3680–3688
 episodic ataxias in, 3636
 of eye, 3925–3933
 congenital ocular motor apraxia, 3930
 flutter-like oscillations, 3933, 3933t
 nystagmus, 3930–3932, 3931f–3932f, 3931t–3932t
 ocular motor dysmetria, 3932, 3933t
 opsoclonus, 3932, 3933t
 hyperekplexia (stiff baby syndrome) and pathologic startles in, 3635

Movement disorders (*Continued*)
 motor tics in, 3636–3637
 myoclonus, 3679
 neonatal jitteriness and clonus in, 3635
 paroxysmal dyskinesias in, 3635–3636, 3636t
 Sandifer syndrome and rumination in, 3635
 sleep-related, 210
 that mimic seizures, 3631t, 3634t, 3635–3637
 tremor, 3673–3678
 Mowat-Wilson syndrome, 2764t–2766t
 Moxibustion, 57–58
 Moxidectin, for onchocerciasis, 2207
 Moxifloxacin, for drug-resistant tuberculosis, 1852t–1853t
 Moyamoya disease, 3744–3745, 3746f
 MPA. *See* Microscopic polyangiitis
 MPGN. *See* Membranoproliferative glomerulonephritis
 MRI. *See* Magnetic resonance imaging
 MSS. *See* Marinesco-Sjögren syndrome
 MTC. *See* Medullary thyroid carcinoma
 Mucha-Habermann disease, 1582
 Muckle-Wells syndrome (MWS), 663, 1522, 1522t, 1527f, 1536
 in urticaria, 1431
 Mucocele, 2254, 4148, 4148f
 Mucociliary clearance disorders, wheezing in infants and, 2585t
 Mucocolpos, 3352–3353
 Mucocutaneous disease, *Mycoplasma pneumoniae* and, 1889, 1889f
 Mucocutaneous infections, HSV, 1996–1997
 Mucocutaneous manifestations, of SLE, 1492f
 Mucolipidoses, 897
 type II. *See* I-cell disease
 type III. *See* Pseudo-Hurler polydystrophy
 type IV, 887t–888t
 type VII, 888t
 Mucopolysaccharidosis, 938–944, 940t, 4124, 4125f
 clinical entities, 938–942
 diagnosis of, 942
 differential diagnosis, 942
 plus syndrome, 940t, 942
 recognition pattern of, 939t
 treatment, 942–944, 943t–944t
 type I, 938–939
 type II, 939–940, 940t
 type III, 939f, 940–941, 940t, 941f
 type IV, 940t, 941–942
 type VI, 939f, 940t, 942
 type VII, 940t, 942
 type IX, 942
 Mucormycosis, 1942–1944, 1943f
 Mucosa, of small intestine, 2277
 Mucosa-associated lymphoid-tissue (MALT) lymphoma, 2344
 Mucosal defense, in peptic ulcer disease, 2305
 Mucosal disorders, intestinal, 2336
 Mucosal leishmaniasis, 2158–2159
 Mucosal neuroma syndrome, 4189
 Mucous membranes, disorder of, 4147–4149
 acute necrotizing ulcerative gingivitis, 4149
 angular cheilitis, 4147, 4148f
 aphthous stomatitis, 4147–4148, 4148f
 black hairy tongue, 4149
 Epstein pearls, 4148
 fissured tongue, 4148
 Fordyce spots, 4148
 geographic tongue, 4148, 4149f
 mucocele, 4148, 4148f
 noma, 4149
 oral hairy leukoplakia, 4149
 Muehrcke lines, 4143
 Muenke syndrome, 794t–795t
 in craniostenosis, 3583
 Mulberry lesion, in tuberous sclerosis, 3659f
 Mulberry molars, 1869t
 Mulch pneumonitis, 1660
 Müllerian agenesis, in XX gonadal dysgenesis, 3499
 Müllerian anomalies, 3347–3354, 3347t
 cervical anomalies, 3354
 clinical manifestations of, 3351
 embryology of, 3347–3348, 3348f
 epidemiology of, 3348–3351, 3349f–3350f

- Müllerian anomalies (*Continued*)
 genetic conditions associated with, 3347t
 laboratory findings of, 3351
 septate uterus, 3351–3352
 uterine anomalies, 3351–3352
 vaginal anomalies, 3352–3354
 vulvar and other anomalies, 3354
- Müllerian ducts, 3348
- Multibacillary leprosy, 1859t
- Multicentric Castleman disease, 2019, 3072
- Multichannel intraluminal impedance, 2257
- Multicystic dysplastic kidney, 3260, 3261f
- Multidimensional Treatment Foster Care, 280
- Multidisciplinary care, of children with cancer, 3087f
- Multidisciplinary Expert Consensus Panel, genetic testing guidelines for ID/GDD/ASD, 347t
- Multidrug therapy, for Hansen disease, 1858, 1858t–1859t
- Multidrug-resistant (MDR) tuberculosis, 1836
- Multifactorial and polygenic inheritance, 744–748
- Multifocal infantile hemangioma, 4056–4057, 4058f
- Multifocal lymphangioendotheliomatosis, 4056–4057
- Multifocal osteomyelitis, 1864
 chronic recurrent, 1529, 1529f
- Multilingualism, 325t, 327
- Multiliteracy, definition of, 325t
- Multilocular cyst, 3262
- Multilocular cystic nephroma, 3262
- Multilocus sequence typing, 1737
- Multiminicore disease (MmD), 3813–3814, 3815f
- Multinodular goiter, 3415
- Multiphasic disseminated encephalomyelitis (MDEM), 3723
- Multiple carboxylase deficiencies, 828
 biotinidase deficiency, 828
 caused by acquired biotin deficiency, 828
 holocarboxylase synthetase deficiency, 828
- Multiple endocrine neoplasia (MEN) syndromes, 3431–3432, 3431t, 3473t
 management of, 3432
 pheochromocytomas and, 3479
 type 1, 3431–3432, 3440, 3472, 3473t
 type 2, 3432
 type 2A, 3164, 3432
 type 2B, 3164, 3432, 4189
- Multiple epiphyseal dysplasia, 745t–746t, 4341–4343
- Multiple gestation, pedigree symbols for, 737f
- Multiple glycosylation pathways, defects in, 928–930
- Multiple hereditary osteochondrosis, 3144–3145
- Multiple lentigines syndrome, 4067, 4067t
 Noonan syndrome with, 788t
- Multiple organ dysfunction syndrome (MODS), 600
- Multiple pituitary hormone deficiency, 3364–3365
 acquired forms, 3365
 congenital forms, 3364, 3365t, 3367f
 genetic forms, 3364, 3365t
HESX1, 3364
LHX3 and *LHX4*, 3364
POU1F1, 3364
PROPI, 3364
- Multiple pterygium, 4271
- Multiple sclerosis, 3731–3733
 clinical manifestations of, 3731
 diagnosis and differential diagnosis of, 3723t, 3726t, 3733, 3734t–3735t
 epidemiology and risk factors of, 3731, 3732t
 imaging and laboratory findings of, 3732–3733, 3732f
 pathogenesis of, 3731
 prognosis of, 3733
 treatment for, 3733, 3735t–3737t
- Multiple subpial transections, in epilepsy surgery, 3615
- Multiple sulfatase deficiency, 896
- Multiple trauma, 571–578
 ATLS, 571
 disposition of, 578
 epidemiology of, 571
 primary survey in, 571–575
 airway, 571
 breathing, 571–573, 574t
 circulation, 573–574, 574t–575t
 disability/neurologic deficit, 574–575, 575f
 exposure and environmental control, 575
 psychologic and social support in, 578
- Multiple trauma (*Continued*)
 regionalization and trauma teams in, 571, 572f–573f, 573t
 secondary survey in, 575–578
 abdominal trauma, 576–577, 577f
 advanced imaging, 576t, 578, 578t
 extremity trauma, 577–578
 genitourinary trauma, 577
 head trauma, 575–576
 pelvic trauma, 577
 spinal trauma, 576
- Multiple-gestation pregnancies, 1038–1042
 complications, 1040–1041
 diagnosis, 1040
 etiology, 1039–1042
 incidence, 1039
 monozygotic vs. dizygotic twins, 1039, 1039f
- Multiplier method, in leg-length discrepancy, 4220–4221, 4222f
- Multisport athletes, 4326
- Multisystem disease, causing hematuria, 3185t
- Multisystem inflammatory syndrome in children (MIS-C), 1538, 1566, 2043–2045, 2047f, 2048t, 4033
- Multisystem medication reactions, 4035–4038, 4035t–4036t
 acute generalized exanthematous pustulosis, 4038
 drug rash with eosinophilia and systemic symptoms, 4035–4037, 4036f
 serum sickness-like reaction, 4037–4038
- Multisystem syndromes, associated with growth restriction, 3453–3454
- Multisystemic therapy, 280
- Multivitamins, 56t
- Mumps, 1623t–1625t, 1969–1971
 clinical manifestations of, 1969–1970, 1970f
 complications of, 1970–1971
 diagnosis of, 1970
 differential diagnosis of, 1970
 epidemiology of, 1969, 1969f
 etiology of, 1969
 in meningoencephalitis, 3772
 pathogenesis of, 1969
 pathology of, 1969
 prevention of, 1971
 prognosis for, 1971
 in T1DM, 3519
 treatment of, 1971
- Munchausen syndrome by proxy, 127–128
- Munson sign, in keratoconus, 3943
- Mupirocin, 1675t–1685t
- Murine (endemic or flea-borne) typhus, 1900t–1902t, 1909–1910
 clinical manifestations of, 1909–1910
 complications of, 1910
 diagnosis and differential diagnosis of, 1910
 epidemiology of, 1909
 etiology of, 1909
 laboratory findings of, 1910
 pathology and pathogenesis of, 1909
 prevention of, 1910
 supportive care in, 1910
 transmission of, 1909
 treatment of, 1910
- Murmurs, 2743
 continuous, 2743
 diastolic, 2745
 innocent, 2745
 systolic ejection, 2743
- Muscarine poisoning, 4443
- Muscimol poisoning, 4443
- Muscle abscess, staphylococcal, 1696
- Muscle biopsy
 in Duchenne muscular dystrophy, 3832
 in myasthenia gravis, 3864, 3866
 in neuromuscular disorders, 3794–3798
 in periodic paralyses, 3848–3850
 in spinal muscular atrophies, 3870, 3870f
- Muscle carnitine deficiency, 3856
- Muscle channelopathies, 3849t
- Muscle CPT deficiency, 3856
- Muscle development, brain malformations and, 3818–3819, 3818f–3819f
- Muscle developmental disorders, 3805–3828, 3805t–3808t, 3808f–3809f
 amyoplasia in, 3819
 arthrogryposis in, 3820–3828, 3820t, 3821f–3822f, 3823t–3825t, 3826f–3827f
 benign congenital hypotonia in, 3820
 brain malformations and muscle development in, 3818–3819, 3818f–3819f
 centronuclear myopathy in, 3808–3810
 congenital muscle fiber-type disproportion in, 3809t, 3810–3811
 core myopathies in, 3812–3816, 3813f–3815f, 3814t
 muscular dysgenesis, 3819–3820
 myofibrillar myopathies in, 3816–3818, 3818f
 myotubular myopathy in, 3808–3810
 nemaline rod myopathy in, 3811–3812, 3811f–3812f
- Muscle glycogen synthase deficiency, 900t–901t, 908
- Muscle glycogenoses, 900t–901t, 906–910
 Danon disease, 908
 lysosomal acid α -1,4-glucosidase deficiency, 906–908
 McArdle disease, 909
 with muscle energy impairment, 910
 muscle glycogen synthase deficiency, 908
 muscle phosphofructokinase deficiency, 909–910
 muscle phosphorylase deficiency, 909
 polyglucosan body myopathy 2, *GYG1* variant, 908–909
- Pompe disease, 906–908
PRKAG2 deficiency, 908
 Tarui disease, 909–910
- Muscle phosphofructokinase deficiency, 909–910
- Muscle phosphorylase deficiency, 909
- Muscle relaxants, 669t
 for Ehlers-Danlos syndrome, 4374
- Muscle spasm, in pediatric palliative care, 65t–68t
- Muscle weakness, in JDM, 1500, 1502t
- Muscle-eye-brain disease, in congenital muscular dystrophy, 3844
- Muscle-eye-brain disease spectrum, 928
- Muscles, imaging of, in neuromuscular disorders, 3794
- Muscle-specific phosphorylase kinase deficiency
PHKA1 variant, 900t–901t, 910
PHKB variant, 900t–901t, 905
- Muscular abnormalities, in arthrogryposis, 4271
- Muscular dysgenesis, 3819–3820
- Muscular dystrophies, 3828–3845, 3830t–3831t
 Becker, 3828–3835, 3833f–3834f
 congenital, 3830t–3831t, 3843–3845, 3844f–3845f
 Duchenne, 3828–3835, 3832f–3833f
 Emery-Dreifuss, 3829t–3831t, 3835
 facioscapulohumeral, 3842–3843, 3843f
 limb-girdle, 3829t–3830t, 3839–3842, 3840t–3841t
 myotonic, 3829t–3830t, 3836–3838, 3837f, 3838t–3840t
 pathophysiologic classification of, 3829t–3830t
- Muscular hemorrhages, 3029
- Muscular torticollis, in deformational plagiocephaly, 3584
- Musculoskeletal injury, management of, 4297–4313
 ankle, 4311–4313
 elbow, 4303–4305
 foot, 4313
 growth plate, 4299–4300
 hip and pelvis, 4307–4308
 imaging, 4299
 initial evaluation of, 4298
 knee, 4308–4310
 low back, 4305–4307
 lower leg exertional pain, 4310–4311
 mechanism of injury, 4297–4299
 shoulder, 4300–4303
- Musculoskeletal involvement, of Henoch-Schönlein purpura, 1554
- Musculoskeletal manifestations
 in childhood lupus, 1497t
 of SLE, 1492t
- Musculoskeletal pain syndromes, 1567–1572
 chronic idiopathic, 1567
 clinical manifestations of, 1567–1568
 complex regional, 1571, 1573t
 complications and prognosis of, 1568
 diagnosis and differential diagnosis of, 1567

Musculoskeletal pain syndromes (*Continued*)
 differential diagnoses of, 4299
 diffuse amplified, 1569–1571
 Ehlers-Danlos syndrome and, 4374, 4375f
 erythromalgia, 1571–1572, 1573f
 fibromyalgia, diagnostic criteria for, 1572t, 1573f
 growing pains, 1569, 1570t
 idiopathic, differential diagnosis of, 1569t
 inflammatory vs. noninflammatory causes of, 1568t
 red flags for, 1577t
 small fiber polyneuropathy, 1569, 1570f, 1571t–1572t
 treatment of, 1567–1568
 Musculoskeletal system, autonomic dysreflexia in, 4391t
 Mushroom poisoning, 4441–4443, 4442t
 autonomic nervous system, 4443
 central nervous system, 4443
 gastrointestinal, 4441–4443
 management of, 4442t
 renal, 4443
 Mushroom toxins, 4411t–4413t
 food-borne noninfectious illnesses and, 2362t–2364t
 Music therapy, in pain management, 693
 Mustard, exposure, 4449–4450, 4454t
 Mutism, selective, 330
 Mutual protection, in pediatric palliative care, 61–62
 MVID. *See* Microvillus inclusion disease
 MWS. *See* Mucke-Wells syndrome
 Myalgias, in lymphatic filariasis, 2206
 Myalgic encephalomyelitis (ME), 1576–1577, 1579t
 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), 1575, 1578f, 1579t, 1580f
 Myasthenia gravis (MG), 3858–3866
 autoimmune, 3858
 complications in, 3865
 congenital, 3858–3863
 laboratory findings and diagnosis, 3863–3864
 neuromuscular blockade, other causes of, 3866
 prognosis of, 3865
 rare other causes of, 3863–3865
 treatment for, 3859t–3860t, 3864–3865, 3865t
 Myasthenic crisis, 3858
 Myctoma, 1736
 Mycobacterial diseases
 differential diagnosis for, 1343
 Mendelian susceptibility to, 1341–1343, 1342f, 1343t
 Mycobacterial infections
 agents against
Mycobacterium leprae, 1833–1834
Mycobacterium tuberculosis, 1830–1833
 nontuberculous mycobacteria, 1834–1835, 1834t
 associated with hemophagocytic syndrome, 3173t
 as causes of infectious pneumonia, 2643t
Mycobacterium avium complex (MAC), 1860
 HIV in, prophylaxis to prevent, 2111t–2113t
Mycobacterium kansasi, 1860
Mycobacterium leprae, 1855–1860
 classification of, 1856–1857, 1856f–1857f
 clinical manifestations of, 1857–1858
 clofazimine against, 1833–1834
 dapsone against, 1833
 diagnosis of, 1858
 epidemiology of, 1855–1856
 leprosy reactions in, 1857, 1859
 long-term complications of, 1860
 microbiology of, 1855
 nerve involvement of, 1857, 1857f
 ocular involvement of, 1857
 pathogenesis of, 1856
 prevention of, 1860
 skin involvement of, 1857
 treatment of, 1858–1859, 1858t–1859t
Mycobacterium tuberculosis. *See also* Tuberculosis
 commonly used agents for, 1830–1832
 HIV in, prophylaxis to prevent, 2111t–2113t
 less commonly used agents for, 1832–1833
 Mycophenolate mofetil
 for atopic dermatitis, 1417
 in maintenance immunosuppression, 3256
 for rheumatic diseases, 1465, 1466t–1468t
 for steroid-resistant nephrotic syndrome, 3230
Mycoplasma genitalium. *See* Genital mycoplasmas
Mycoplasma hominis. *See* Genital mycoplasmas

Mycoplasma pneumoniae, 1887–1890
 adjunctive therapy for, 1890
 antimicrobial therapy for, 1890
 clinical manifestations of, 1888–1889
 diagnosis of, 1889
 epidemiology of, 1887–1888
 extrapulmonary disease and, 1888–1889, 1889f
 pathogenesis of, 1888
 prevention of, 1890
 prokaryotic organism, 1887
 respiratory tract disease and, 1888
 treatment of, 1889–1890
Mycoplasma-induced rash and mucositis (MIRM), 1889, 1889f, 4078
 Mycotoxins, 4409–4411
 MyD88 deficiency, 1340–1341, 1341t
 Mydriasis, 3912
 Myelin oligodendrocyte glycoprotein, 3708
 Myelin oligodendrocyte glycoprotein-associated disorders, 3733–3738
 clinical manifestations of, 3723t, 3733–3737
 imaging and laboratory findings of, 3726f, 3737, 3739f–3740f
 prognosis of, 3738
 treatment of, 3737–3738
 Myelinated nerve fibers, 3963
 Myelination, 151
 Myeloblast, 1290
 Myelocytes, 1290
 reference intervals, 4472.e9t
 Myelodysplastic syndromes (MDS), 1308, 2952f
 acquired pancytopenias and, 3011
 HSCT for, 1353
 Myeloid cells, acquired disorders of, 1306t
 Myelomeningocele, 1034–1035, 1035f, 3561–3563
 clinical manifestations of, 3562, 3563f
 etiology of, 3561
 math disabilities and, 319
 prevention of, 3561–3562
 prognosis for, 3563
 treatment of, 3562–3563
 Myelopathy
 delayed, 4418
 human T-cell lymphotropic virus-1-associated, 2118
 toxic causes of, 3895t
 Myeloperoxidase, 1292–1293
 Myeloperoxidase deficiency, 1297t–1298t, 1301
 Myelopoiesis, primary disorders of, 1309t
 Myelosuppression, chemotherapy and, 3088, 3091–3093
 MYH9-related thrombocytopenias, 3056
 Mylohyoid muscle, 2248f
 Myocardial damage, chemotherapy and, 3093–3094
 Myocarditis, 2888–2889
 bacterial infections and, 2888
 clinical manifestations of, 2889
 diagnosis of, 2889
 differential diagnosis of, 2889
 enteroviral, 1982
 epidemiology of, 2888
 etiology of, 2879t, 2888, 2888t
 measles and, 1961
 MRI findings in, 2889f, 2889t
 in mumps, 1971
 parvovirus B19, 1989
 pathophysiology of, 2888
 prognosis of, 2889
 sudden death and, 2861
 treatment of, 2889
 viral infections and, 2888
 Myocardium, diseases of, 2876–2889
 arrhythmogenic right ventricular cardiomyopathy, 2887
 classification of, 2877t–2878t
 dilated cardiomyopathy, 2876–2882
 endocardial fibroelastosis, 2887–2888
 hypertrophic cardiomyopathy, 2884–2885
 left ventricular noncompaction, 2887–2888, 2888f
 myocarditis, 2888–2889
 pediatric, etiology of, 2879t
 restrictive cardiomyopathy, 2886–2887
 Takotsubo cardiomyopathy, 2888
 Myoclonic astatic epilepsy, 3601–3602

Myoclonic encephalopathy in nonprogressive disorders, 3602
 Myoclonic epilepsy and ragged red fibers (MERRF), 3699
 caused by pathogenic variants in mtDNA, 743t
 Myoclonic seizures, 3619
 Myoclonus, 243t, 3679
 benign, of infancy, 3637
 clues relating to, 3681t
 etiologic classification of, 3680t
 toxidrome, 704t
 Myoclonus dystonia (DYT11), 3681
 Myofascial pain disorders, 698–699
 Myofibrillar myopathies, 3816–3818, 3817t, 3818f
 Myogenic regulatory genes, of inherited diseases of muscle, 3805–3808
 Myogenin gene, 3805
 Myoglobinuria, 3184
 statin-induced rhabdomyolysis with, 3846
 Myomaker gene, 3805
 Myonecrosis, 1829
 Myopathies, 3791
 in Guillain-Barré syndrome, 3901t
 mitochondrial disease and, 935t
 toxic causes of, 3895t
 Myophosphorylase deficiency, 3851
 neonatal form of, 3851
 Myopia, 3914, 3914f
 Myositis, in enterovirus infection, 1983
 Myositis ossificans, 4327
 Myositis-associated antibodies (MAA), 1501t
 Myositis-specific antibodies (MSA), 1501t
 Myostatin gene, 3805
 Myotonia, 3836, 3837f
 in neuromuscular disorders, 3791
 Myotonia congenita, 3791, 3838, 3849t
 Myotonic chondrodystrophy, 3838
 Myotonic dystrophy, 745t–746t, 747f
 congenital form, 3836–3837
 Myotonic muscular dystrophy, 3829t–3830t, 3836–3838
 Chondrodystrophy, 3838
 clinical manifestations of, 3836–3837, 3837f
 diagnosis of, 3837
 genetics of, 3837
 laboratory findings of, 3837
 Schwartz-Jampel disease, 3838
 treatment of, 3837–3838
 Myotubular myopathy, 3808–3810
 clinical manifestations of, 3809
 diagnosis of, 3809, 3809t
 genetics of, 3814t
 laboratory findings of, 3809
 pathogenesis of, 3808–3809
 prognosis of, 3820t
 treatment of, 3817t
 MyPlate, 415–416, 416f
 Myringotomy, for acute otitis media, 4011
 Myxedematous syndrome, 3414
 Myxomas, 2892, 2892f
 Myxopapillary ependymoma, 3120–3121

N

NAATs. *See* Nucleic acid amplification tests
 N-acetylcysteine, 707t–708t
 NADH cytochrome b5 reductase deficiency, hereditary methemoglobinemia with, 2979–2980
 Nadolol, 2845t–2846t
 Naftillin sodium, 1675t–1685t
 Nail disorders, 4142–4147
 congenital diseases with, 4142t
 nail changes associated with skin disease, 4145
 nail color changes, 4143–4144
 nail infection, 4145–4146
 nail separation, 4144–4145
 nail shape or size abnormalities, 4142–4143
 paronychial inflammation, 4146–4147, 4147f
 paronychia tumors, 4147
 pitting, in psoriatic arthritis, 1485f
 trachyonychia, 4145, 4146f
 Nail dystrophy, 4049t–4050t
 Nail infection, 4145–4146

- Nail-patella syndrome, 4142–4143, 4350, 4350f
- Nails, 4026
- NAIT. *See* Neonatal alloimmune thrombocytopenia
- Nalbuphine, equianalgesic doses of, 685t
- Nalidixic acid, 1675t–1685t
- Naloxone, 707t–708t, 712–713
for burn injuries, 654
for pediatric resuscitation and arrhythmias, 563t
- NAM. *See* National Academy of Medicine
- Nance-Horan syndrome, 2764t–2766t
- Nanophytes salmincola*, 2215
- NAP1/BI/027, 1825
- Naproxen, in pain management, 681t
- Narakas classification, 4397, 4398t
- Naratriptan, for migraine, 3646t–3647t
- Narcolepsy, 212–213, 212t
- Narcolepsy-cataplexy syndrome, 3638
- Narrow-band imaging, 2524
- Narrow-band instrument, 217
- Narrow-band ultraviolet light B (NBUVB), 4075
- Nasacort AQ, for allergic rhinitis, 1384t–1385t
- Nasal cannula, for respiratory distress and failure, 618
high-flow, 619
- Nasal continuous positive airway pressure (nCPAP)
for apnea, 1076
in RDS, 1080
- Nasal crease, 1379–1380
- Nasal flaring, 612
- Nasal images, diagnostic approach to respiratory disease, 2517
- Nasal nitric oxide (nNO), 2522
- Nasal obstruction, in common cold, 2553
- Nasal passage, 2248f
- Nasal polyps, 2550
clinical manifestations, 2550
cystic fibrosis and, 2677–2678
diagnosis and differential diagnosis, 2550
treatment, 2550
- Nasal septum, congenital defects of, 2546
- Nasal spray
for allergic rhinitis, 1382, 1384t
for migraine, 3646t–3647t
- Nasal surgery, for lip repair, 2243–2244
- NasalCrom, for allergic rhinitis, 1384t
- Nasogastric decompression, for ileus, 2299
- Nasogastric tube feedings, for chronic recurrent aspiration, 2611
- Nasolacrimal duct obstruction, congenital, 3937, 3938t
- Nasonex, for allergic rhinitis, 1384t–1385t
- Nasopharyngeal airway, 618
- Nasopharyngeal carcinoma, 3165
Epstein-Barr virus (EBV), 2008–2009
- Nasotracheal intubation, in infectious upper airway obstruction, 2571–2572
- Natal teeth, 2239–2240
- Nateglinide, for T2DM, 3542t
- National Academy of Medicine (NAM), 46–47
- National Cancer Institute (NCI), 3073, 3086
- National Child Traumatic Stress Network, 109
- National Collaborative Chicago-Based Congenital Toxoplasmosis Study (NCCCTS), 2189–2190
- National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP), 42
- National Emergency X-Radiography Utilization Study (NEXUS), 576
- National Hansen's Disease Program (NHD), 1858
- National Health and Nutrition Examination Survey (NHANES), 56, 172
- National Institute for Child Health and Development (NICHD), 1
- National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines, 3247t
- National organizations, involved in pediatric quality improvement, 41t
- National Pediatric Readiness Project (NPRP), 537
- National Poison Data System (NPDS), 700
- National School Lunch Program, 416, 416t
- National Vaccine Injury Compensation Program (VICP), 1591
- Native aortic valve, infective endocarditis and, 2865t, 2868f
- Natriuretic peptides, elevated concentrations of, 2897t
- Natural killer (NK) cells, 1286–1289
count and percentage of, 1289
cytotoxicity assay for, 1289
deficiency of, 1287–1288
classical, 1288
functional, 1288–1289, 1289f
treatment of, 1289
- development of, stages of, 1287f
- diagnostic tests of, 1289
- donor vs. recipient alloreactivity, 1356
- functions of, 1286
- markers, subsets, and maturation, 1286–1287
- spontaneous cytotoxicity of, 1287
- Naturalistic developmental behavioral intervention, 380
- Nausea, 2226–2227, 2227t
functional, 2388, 2389t
opioid-induced adverse effects, 684t
in pediatric palliative care, 65t–69t, 70
- NAVA. *See* Neuronally adjusted ventilatory assist
- Navajo neurohepatopathy, 2484–2485
- Navicular stress fracture, 4313
- NBAS. *See* Newborn Behavior Assessment Scale
- NBUVB. *See* Narrow-band ultraviolet light B
- NCCCTS. *See* National Collaborative Chicago-Based Congenital Toxoplasmosis Study
- NCC-MERP. *See* National Coordinating Council for Medication Error Reporting and Prevention
- NCGS. *See* Non-celiac gluten sensitivity
- NCI. *See* National Cancer Institute
- nCPAP. *See* Nasal continuous positive airway pressure
- NDI. *See* Nephrogenic diabetes insipidus
- NDRI. *See* Norepinephrine-dopamine reuptake inhibitor
- Near misses, 42
- Nebulized racemic epinephrine, 2571
- Nebulizers, for asthma, 1406
- NEC. *See* Necrotizing enterocolitis
- Neck, 4258–4263
anomalies of, in Diamond-Blackfan anemia, 2932t
assessment in newborn, 1002
cervical anomalies and instabilities, 4261–4263,
4261t, 4262f–4263f
- Klippel-Feil Syndrome, 4260–4261, 4260f
torticollis, 4258–4260, 4258t, 4259f
- X-ray of, showing subcutaneous emphysema, 2593f
- Neck blocks, in pain management, 694
- Neck muscle tone, in deformational plagiocephaly, 3584–3585
- Necrobiosis lipoidica, 4121, 4121f
- Necrotolytic migratory erythema, 4034
- Necrosis
avascular, 4236, 4284
in sickle cell disease, 2971
testicular, 3307f
- Necrotizing enterocolitis (NEC), 995, 1058, 1102–1105,
1128
clinical manifestations, 1103
definition of, 1102–1103
diagnosis, 1103–1104, 1104f–1105f
epidemiology of, 1103
pathology and pathogenesis, 1103, 1103f
prevention, 1105
prognosis, 1105
signs and symptoms associated with, 1104t
treatment, 1104–1105
- Necrotizing fascitis, 4152–4153
GAS infection, 1708
- Necrotizing otitis externa, 3999, 4000t, 4001–4002
- Necrotizing pancreatitis, 2432
- Necrotizing periodontal disease, 2250
- Necrotizing spider bites, 4470
- Necrotizing vasculitis, 1560
- Needle biopsies, in neuromuscular disorders, 3798
- Negative canal pressure, 3982
- Neglect, 114
- Neglectful parenting, 143
- Neisseria gonorrhoeae* infection, 1319, 1747–1752
asymptomatic gonorrhea, 1748
clinical manifestations of, 1748–1749
complications of, 1750–1752
diagnosis of, 1749–1750
epidemiology of, 1747
- Neisseria gonorrhoeae* infection (Continued)
etiology of, 1747
laboratory screening, 1241t
management guidelines, 1247t–1248t
pathogenesis and pathology of, 1747–1748
prevention of, 1752
treatment of, 1750, 1751t
uncomplicated, localized gonorrhea, 1748–1749
vulvovaginal infection, 3322t
- Neisseria meningitidis* infection, 1737–1746
antibiotics, 1742
clinical manifestations of, 1739–1742, 1740t–1741t
complications of, 1743
diagnosis of, 1742
differential diagnosis of, 1742
epidemiology of, 1738, 1738f
etiology of, 1737
host factors, 1739
immunity, 1739
in meningococcal meningitis, 3760
pathogenesis and pathophysiology of, 1738–1739
prevention of, 1744–1746
prognosis of, 1743–1744
in septic arthritis, 4291
supportive care, 1742–1743
treatment of, 1742–1743
vaccination of, 1745–1746, 1746t
- Nelson syndrome, 3477
- Nelson-Denny Reading Test, 317
- Nemaline myopathy, 3791
- Nemaline rod myopathy, 3811–3812, 3811f–3812f
- Neocytolysis, 2925
- Neohellichiosis, 1900t–1902t
- Neomycin sulfate, 1675t–1685t
- Neonatal abstinence syndrome (NAS), 1132–1134,
1132f, 1133t
- Neonatal alloimmune thrombocytopenia (NAIT),
1020–1021, 3057
- Neonatal appendicitis, frequency of presenting symptoms in, 2399f
- Neonatal atrial flutter, 2852f
- Neonatal breast hypertrophy, 3329
- Neonatal bullous impetigo, 4150
- Neonatal cephalic pustulosis, 4183, 4185f
- Neonatal cholestasis, 2445–2454, 2446f
biliary atresia and, 2445–2447
other syndromes associated with, 2452
- Neonatal circulation, 2735–2736
- Neonatal corneal opacities, 3943, 3944t
- Neonatal deaths, 23
- Neonatal diabetes, key features of, 3518t
- Neonatal disorders
child mortality and, 24
conjunctivitis, 3940t
hyperglycemia, 837
lupus erythematosus, 1498–1499, 1498f
- Neonatal encephalopathy, in delivery room, 1072
- Neonatal ethics, 53
- Neonatal gynecomastia, 3495
- Neonatal hemochromatosis, 2459–2460
- Neonatal hepatitis, idiopathic, 2452–2454, 2454t
- Neonatal hypoglycemia, inborn errors of metabolism and, 806t
- Neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome, 2452
- Neonatal infections, 1143, 1144f
Candida, 1921–1922, 1923t
clinical manifestations of, 1146–1148
Enterococcus in, 1723
enterovirus, 1983–1984
general approach to management of, 1149
in genital mycoplasmas, 1891–1892
herpes simplex virus (HSV) in, 1995
incidence of, 1143, 1144t
laboratory findings of, 1148–1149
microbiology of, 1143–1144
pathogens causing, 1145t
prevention of, 1149–1150
varicella, 2001
- Neonatal intrahepatic cholestasis, 853
- Neonatal jitteriness, 3635
- Neonatal liver failure, 2484
- Neonatal lupus erythematosus, 4030–4031, 4032f

- Neonatal mastitis, 3330–3331
 Neonatal mortality rates
 global statistics, 1–2
 low birthweight and, 998, 1038–1039
 Neonatal myotonia, 3850
 Neonatal myotonic dystrophy, 3837
 Neonatal opioid withdrawal syndrome (NOWS), 1023
 Neonatal passive AIN, 1307
 Neonatal period, 992
 Neonatal polycythemia, 1126
 Neonatal respiratory distress (NRD), primary ciliary dyskinesia and, 2680
 Neonatal screening tests, 4472.e6t, 4472.e5
 Neonatal seizures, 1052, 3617–3623
 diagnosis of, 3620–3622
 etiology of, 3617f, 3617t, 3619–3620, 3620t–3621t
 pathophysiology of, 3617
 prognosis of, 3622
 treatment for, 3622–3623
 types of, 3617–3619, 3618f, 3618t
 Neonatal sleep myoclonus, 3638
 Neonatal teeth, 2239–2240
 Neonatal tetanus, 1822
 Neonatal thrombocytopenia, 3053t, 3057
 Neonatal-onset multisystem inflammatory disease (NOMID), 663, 1518, 1522t, 1527f–1528f, 1536
 Neonates
 antibiotics use in, 1672
 critically ill, with cyanosis and respiratory distress, 2798–2799, 2799f
 genital mycoplasmas in, 1893
 granulocyte transfusion for, 3018
 hemoglobin in, 2924
 overgrowth in, 3382–3383
 plasma transfusions in, 3019
 platelet transfusions in, 3016–3017, 3016t
 red blood cell transfusions in, 3015
 sepsis in, 548
 vitamin A status in, 452
 Neonicotinoids, 4425
 Neoplasms
 acute hepatic failure and, 2495
 gonadal, 3150–3153, 3151f
 kidneys, 3130–3135
 laryngeal, 2583–2584
 liver, 3153–3156, 3153t
 malignant
 epidemiology of, 3073
 in patients undergoing enterocystoplasty, 3290
 ovarian, 3340–3342
 tonsillar, 2562
 tracheal, 2584, 2584f
 of vulva and vagina, 3327
 Neoplastic diseases, arthritis or extremity pain caused by, 1479t
 Neo-Synephrine, for allergic rhinitis, 1384t
 Nephroblastoma, 3130
 Nephrocalcinosis, 3212, 3312, 3443
 common causes of, 3315
 Nephrogenic diabetes insipidus (NDI), 490, 3238–3239, 3374
 treatment of, 3374
 Nephrogenic syndrome of inappropriate antidiuresis, 503
 hyponatremia and, 3375–3376
 Nephrolithiasis, 947
 Nephromegaly, 3214f
 Nephronophthisis, 792t
 autosomal recessive polycystic kidney disease and, 3213
 extrarenal manifestations associated with, 3208t
 Nephrons, 3180
 Nephropathic cystinosis, 3409
 Nephropathy
 HIV-associated, 3196
 immunoglobulin A, 3187–3188, 3187f, 3254–3255
 membranous, 3189f, 3192–3193, 3193f, 3254–3255
 polyomavirus, 3258
 sickle cell, 3211–3212
 toxic, 3203–3204, 3203t
 Nephrotic range proteinuria, 3222
 Nephrotic syndrome, 2172, 3222–3232
 clinical consequences of, 3223–3225
 edema in, 3223
 hypercoagulability as, 3225
 hyperlipidemia in, 3223
 increased susceptibility to infections as, 3223–3225
 congenital, 3226t, 3232, 3232t
 etiology of, 3222–3225, 3224t–3226t, 3225f
 idiopathic, 3226–3231
 pathology of, 3224t–3225t, 3226–3228, 3228f
 prognosis of, 3231
 immunizations in, 3231, 3231t
 implications of steroid-resistant, 3229–3230
 investigations in, 3229t
 managing the clinical sequelae of, 3229–3231
 minimal change, 3225f, 3228–3231
 pathogenesis of, 3223
 immune system role in, 3223
 podocyte role in, 3223, 3226t, 3227f
 relapse of, 3229
 secondary, 3224t–3226t, 3231–3232
 treatment for, 3228–3231, 3230f
 Nephrotoxins, renal syndromes produced by, 3203t
 Nerve ablation, in pain management, 696
 Nerve agents
 decontamination and management, 4454t
 sudden-onset neuromuscular syndrome, 4447–4448
 Nerve biopsy, in neuromuscular disorders, 3798–3799
 Nerve conduction velocity, in neuromuscular disorders, 3793
 Nerve involvement, in Hansen disease (*Mycobacterium leprae*), 1857, 1857f
 Nervous system, arsenic effects in, 4432t
 Nestor-Guillermo progeria syndrome (NGPS), 962t
 Netherton syndrome, 1372, 4114t, 4117–4118, 4117f
 Nettleship-Falls ocular albinism, 819
 Neural crest tumors, 2724
 Neural damage, in acute porphyrias, 967
 Neural plasticity, 151
 Neural tube defects (NTDs), 748, 779, 780t, 1020–1021, 1053t, 3561, 3562f, 4411
 bladder function in, 3288
 Neurally mediated syncope, 597, 597f, 3632
 Neuraminidase inhibitors, 1956
 Neurapraxia, 4397
 Neural axial analgesia, 675
 Neuritis, optic, 3965–3966
 Neuroacanthocytosis syndrome, 2966
 Neurobehavioral disorder associated with prenatal alcohol exposure (ND-PAE), diagnostic criteria for, 1139t
 Neurobehavioral impairment, 1136
 Neuroblastoma, 3083–3084, 3085f, 3125–3130
 clinical manifestations of, 3126t, 3127–3128, 3128f–3129f
 diagnosis of, 4472.e6, 3127t, 3128–3129, 3128f–3129f
 epidemiology of, 3125
 pathogenesis of, 3125–3127, 3126t–3127t
 pathology of, 3125
 treatment for, 3126t–3127t, 3129–3130
 Neurocognitive defects, congenital diaphragmatic hernia and, 1096
 Neurocognitive impairment, in malaria, 2181
 Neurocognitive performance, optimizing, in CCHS, 2723
 Neurocognitive status, 306–307
 Neurocristopathies, 3896
 Neurocristopathy syndrome, 3126t
 Neurocutaneous syndromes, 3652–3663, 3653t
 incontinentia pigmenti, 3662–3663, 3663f
 linear nevus sebaceous syndrome, 3656f, 3661–3662
 neurofibromatosis, 3652–3657
 PHACE syndrome, 3662
 Sturge-Weber syndrome, 3656f, 3659–3661, 3660f–3661f, 3660t
 tuberous sclerosis, 3656f, 3657–3659, 3658f
 clinical manifestations and diagnosis of, 3657–3659, 3658f–3659f, 3658t
 management of, 3659
 von Hippel-Lindau disease, 3661
 Neurocystercosis, 2218
 Neurodegeneration, brain iron accumulation with, 3684, 3685t, 3720, 3721t, 3722f
 Neurodegenerative disorders, 3711–3720, 3712t
 adrenoleukodystrophy in, 3716
 Alexander disease in, 3717, 3717f
 Canavan spongy degeneration in, 3717
 intellectual disability caused by, 349t
 language disorders and, 330
 leukodystrophies in, 3717–3718, 3717f–3719f, 3720t
 Menkes disease in, 3719–3720
 miscellaneous, 3717–3720
 neurodegeneration with brain iron accumulation in, 3720, 3721t, 3722f
 neuronal ceroid lipofuscinoses in, 3715–3716, 3715t, 3716f
 Pelizaeus-Merzbacher disease in, 3717
 Rett syndrome in, 3720
 sialidosis in, 3716
 sphingolipidoses in, 3711–3715
 gangliosidoses, 3711–3714, 3713f–3714f
 Krabbe disease, 3714
 metachromatic leukodystrophy, 3714–3715
 Neurodermatitis, 4002
 Neurodevelopmental disorders, genetic tests for, 348t
 Neurodevelopmental dysfunction, 300–309
 assessment and diagnosis, 305–307
 clinical manifestations, 303–305
 core neurodevelopmental functions, 301–303
 terminology and epidemiology, 300
 treatment, 307–308
 visual-spatial/visual-perceptual function, 301
 Neurodevelopmental evaluation, in communication disorders, 332
 Neurodevelopmental functions
 etiology and pathogenesis, 300–301
 frontal lobe functioning
 attention, 300
 executive functioning, 302–303, 302t, 306f
 intellectual function, 301–302
 language, 301
 memory, 302
 sensory and motor development, 301
 social cognition, 302
 Neurodevelopmental impairment, 1136
 Neurodevelopmental variation, 300
 Neuroendocrine cell hyperplasia of infancy, 2637–2639, 2638f
 Neuroendocrine deficits, brain tumors and, 3117–3118
 Neuroendocrine disorders, traumatic brain injury and, 4388
 Neuroendocrine tumors, diarrhea from, 2383–2384, 2384t
 Neuroenteric cysts, 2261, 2286
 Neurofibromatosis (NF), 478, 2584, 3077, 3379, 3652–3657
 clinical manifestations and diagnosis of, 3652–3654, 3654f–3655f, 3654t
 genetic counseling for, 3655–3657, 3656f, 3657t
 management of, 3655
 optic glioma in, 3655f
 type 1, 788t, 789, 3126t, 3473t, 3652–3654, 3655f, 4068, 4068f–4069f, 4069t–4071t
 pheochromocytomas and, 3479
 type 2, 3655–3656, 3657t, 4070t–4071t
 Neurofibromin, 3655
 NEUROG3, 2339
 Neurogastrointestinal encephalomyopathy, mitochondrial, 953
 Neurogenic bladder and bowel, 4401
 Neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), 3699
 Neurogenic pulmonary edema, 2605
 Neurogenic torticollis, 4259
 Neuroimaging
 in acute disseminated encephalomyelitis, 3724
 for adrenoleukodystrophy, 870, 870f
 in child, with headaches, 3645t
 for febrile seizure, 3597
 Neuroirritability, in pediatric palliative care, 65t–68t, 70
 Neuroleptic malignant syndrome, 228, 718, 3681
 Neurologic abnormalities, in arthrogryposis, 4271
 Neurologic complications
 associated with neurofibromatosis type 1, 3654
 of sickle cell disease, 2972, 2972f

- Neurologic conditions, language disorders and, 329–330
 Neurologic deficit, primary survey for, 574–575, 575f
 Neurologic development
 in adolescent, 1161–1162
 fetal, 146, 148f
 Neurologic disease
 anesthetic implications in, 666t
 manifesting as respiratory distress, 612–613
 medications for, 230
 obesity-associated comorbidities, 442, 444t
 respiratory patterns in, 615t
 Wilson disease and, 2458
 Neurologic dysfunction, HGPRT-related, 950
 Neurologic emergencies and stabilization, 581–588
 neurocritical care principles in, 581–582, 582f, 583t
 traumatic brain injury in, 583–588
 Neurologic evaluation, 3550–3560
 general examination in, 3557
 history in, 3550, 3551t
 neurologic examination and, 3550–3557
 coordination in, 3557
 cranial nerves in, 3552–3554
 head in, 3551–3552, 3551f
 mental state in, 3551
 sensory examination in, 3555–3556
 station and gait in, 3557
 reflexes in, 3556–3557
 special diagnostic procedures in, 3557–3560
 electroencephalography, 3560
 evoked potentials, 3560
 lumbar puncture and cerebrospinal fluid examination, 3557–3558
 neuroradiologic procedures, 3558–3560, 3559t
 specific and general genetic and metabolic testing, 3560
 Neurologic examination, 305, 3550–3557
 coordination in, 3557
 cranial nerves in, 3552–3554
 head in, 3551–3552, 3551f
 mental state in, 3551
 in newborn, 1004
 sensory examination in, 3555–3556
 station and gait in, 3557
 Neurologic lesions, associated with neurofibromatosis type 2, 3657t
 Neurologic management, of drowning victims, 642–643
 Neurologic manifestations
 of enterovirus infections, 1983
 of Henoch–Schönlein purpura, 1554
 Neurologic signs, of high-altitude cerebral edema, 633
 Neurologic symptom, BRUE and, 2543t
 Neurologic syndrome, 3414
 Neuromotor ability, 301
 Neuromuscular blockade, 671
 for intubation, 620t
 for mechanical ventilation, 628
 Neuromuscular disorders
 anesthetic implications in, 666t
 evaluation and investigation of, 3791–3799
 cardiac assessment in, 3799, 3804t
 clinical manifestations in, 3791–3793, 3792t–3793t, 3793f–3795f, 3796t–3797t
 genetic testing in, 3791
 laboratory findings in, 3793–3794
 muscle biopsy in, 3794–3798
 muscles and central nervous system imaging, 3794
 nerve biopsy in, 3798–3799
 gene variants of, 2883t
 respiratory signs and symptoms, 2531t
 respiratory tract complication, 2531t
 Neuromuscular junction disorders, in Guillain–Barré syndrome, 3901t
 Neuromuscular maturity, 1043f
 Neuromuscular scoliosis, 4248–4250, 4249f
 genetic syndromes and, 4248–4250, 4249f
 Neuromuscular transmission, disorders of, 3858–3875
 myasthenia gravis as, 3858–3866
 spinal muscular atrophies as, 3866–3874
 Neuromyelitis optica (NMO), 3966
 Neuromyelitis optica spectrum disorders, 3708, 3723t, 3738–3741
 clinical manifestations of, 3739
 diagnosis and differential diagnosis of, 3723t, 3741, 3741t
 epidemiology of, 3738
 imaging and laboratory findings of, 3739–3741, 3740f
 pathogenesis of, 3739
 prognosis of, 3741
 treatment for, 3741
 Neuromyotonia, 3850
 Neuronatal ceroid lipofuscinoses (NCLs), 3715–3716, 3715t, 3716f
 Neuronal heterotopias, 3569, 3570f
 Neuronal injury, seizure-related, 3604
 Neuronally adjusted ventilatory assist (NAVA), for RDS, 1081
 Neuroorthopedic syndrome, 3786
 Neuroathic bladder, 3271, 3288–3291, 3288t
 associated disorders, 3290–3291
 augmentation cystoplasty, complications of, 3290
 clinical manifestations and diagnosis of, 3288, 3289f
 neural tube defects, 3288–3290
 renal damage, 3288–3289, 3289f
 urinary incontinence, 3289–3290
 Neuropathic disorders, arthritis or extremity pain caused by, 1479t
 Neuropathic pain, 678t, 686, 688t
 Neuropathic pain syndrome, 695t, 697–698
 Neuropathic POTS, 598
 Neuropathies, 1301
 autonomic, 3896–3900, 3897t–3899t
 congenital hypomyelinating, 3886
 giant axonal, 3887, 3888f, 3888t
 hereditary motor-sensory, 3876–3892
 hypermyelinating, 3887–3889
 porphyric, 967–968
 toxic, 1727, 3892–3895, 3892t–3895t
 Neuropathology, CCHS and, 2721
 Neuropsychiatric symptoms, in SLE, 1492f
 Neuropsychologic abilities, meningomyelocele and, 4401
 Neuroradiologic procedures, in neurologic evaluation, 3558–3560, 3559t
 Neurostimulators, for TBI, 4387
 Neurotmesis, 4397
 Neurotoxic shellfish poisoning, 4444–4445
 Neurotransmitter metabolism, disorders of, 844–848
 aromatic L-amino acid decarboxylase deficiency, 825f, 844
 dopamine β-hydroxylase deficiency, 846
 GABA metabolism, disorders of, 846–847
 histidine decarboxylase deficiency, 847
 hyperprolinemia, 847
 monoamine oxidase A deficiency, 846
 tetrahydrobiopterin deficiency, 844–846
 tyrosine hydroxylase deficiency, 844
 Neurotransmitter precursors, supplementation with, 815
 Neurotransmitter transporter proteins, defects in, 847
 Neurovascular bundle, 2247f
 Neutral protamine Hagedorn (NPH), 3528
 Neutropenia, 1304–1312, 1659–1660, 3092t–3093t
 acquired, 1304–1308
 acute, 1304
 in Barth syndrome, 829
 causes of, 1306t
 in chemotherapy, 3091–3093
 chronic, 1304
 clinical manifestations of, 1304
 inherited, 1308–1311, 1310f
 laboratory findings of, 1304
 organ associated features and genetic subtypes of, 1311t
 in pediatric patients, 1117
 recommendations for management of, 1362t–1363t
 treatment of, 1312
 Neutrophil migration, 1292
 Neutrophil mobility, direct inhibition of, 1297t–1298t
 Neutrophil (granulocyte) transfusions, 3018, 3018t
 Neutrophilia, 1313, 1314t
 Neutrophilic dermatosis, in CANDLE, 1529
 Neutrophils, 1290–1293, 1290t, 2921
 function of, 1291–1293, 1292f
 clinical disorders of, 1297t–1298t
 hematopoiesis, 1290
 maturation and kinetics, 1290
 phagocytic inflammatory response, 1290
 reference intervals, 4472.e9t
 Never events, 42
 Nevirapine, for HIV, 2098t–2107t
 Nevvoid basal cell carcinoma syndrome, 4188–4189
 Nevus anemicus, 4053–4054
 Nevus comedonicus, 4066
 Nevus depigmentosus, 4065, 4065f
 Nevus of Ito, 4064
 Nevus of Ota, 4064
 Nevus sebaceous (Jadassohn), 4065–4066, 4066f
 Nevus simplex, 4041, 4050–4051
 Nevus spilus, 4064, 4064f
 Newborn, 148–151
 anemia in, 1118–1122, 1118t
 classifications and key diagnostic modalities in, 1118–1120, 1118t, 1120f, 1121t
 management principals of, 1122
 physiologic nadir, 1118, 1119f
 breathing patterns in, 1074
 chronology of heart disease in, 614t
 congenital infections in, 1153–1154
 gynecologic examination in, 3317–3319
 implications for pediatrician
 assessing parent-infant interactions, 151
 optimal practices, 151
 teaching about individual competencies, 151
 maternal conditions affecting, 1011t–1012t
 maternal infections affecting, 1013t
 measures of pain specific to, 679t–680t, 680
 parent–infant attachment
 infant's role in, 149–151
 parental role in, 148–149
 physical examination of, 149
 testicular torsion in, 3307f
 thyroid, 3401
 transient hyperammonemia of, 854
 transient hypomagnesemia in, 504
 transient tyrosinemia of, 817
 Newborn Behavior Assessment Scale (NBAS), 151
 Newborn diseases
 invasive, *Haemophilus influenzae* in, 1758
 Newborn diseases, clinical manifestations, 1052–1056
 cold stress, 1055
 edema, 1055
 hypermagnesemia, 1056
 hyperthermia, 1055
 hypocalcemia, 1055–1056
 hypothermia, 1055
 Newborn pulmonary respiration, transition to, 1074
 clearance of fetal lung fluid in, 1074
 increased pulmonary blood flow in, 1074, 1074f
 Newborn screening, 54, 803, 804f, 805t, 1005–1006
 ethics and, 729
 in spinal muscular atrophies, 3871
 Newborns, 999–1008
 circumcision, 1006–1007
 effects of agents acting on pregnant women, 1023t–1024t
 nursery care, 1005–1006
 pain, 1053t, 1055t
 physical examination of, 1000–1004
 resuscitation and delivery room emergencies, 1070–1073, 1070f–1072f
 routine delivery room and initial care, 1004–1006
 sleep, normal developmental changes in, 204t
 New-onset diabetes after transplant (NODAT), 3256
 New-onset refractory status epilepticus (NORSE), 3624–3626, 3626f
 Next-generation sequencing (NGS), 380, 750, 751f
 NF. See Neurofibromatosis
 NF-kB disorders, 1529
 NF-kB essential modulator (NEMO) deficiency, 1345
 N-glycanase 1 deficiency, 930
 N-glycans, 921
 NHANES. See National Health and Nutrition Examination Survey
 NHDP. See National Hansen's Disease Program

- NHL. *See* Non-Hodgkin lymphoma
 Niacin (vitamin B₃), 456t–457t, 461–463
 deficiency, 461–463
 clinical manifestations of, 462, 462f
 diagnosis of, 462
 prevention of, 462
 treatment of, 463
 dietary reference intake, 397t–403t
 toxicity, 463
 Nicardipine, for severe hypertension in children, 2919t
 NICHD. *See* National Institute for Child Health and Development
 Nickel dermatitis, 4089, 4090f
 Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 1293f
 Nicotine
 action of, 1200
 replacement therapy, 1201t
 Nicotine-containing products, 724
 Niemann-Pick disease, 892–893
 type A, 887t–888t, 892
 type B, 887t, 892
 type C, 881, 887t–888t, 893
 Nifedipine, 2834t
 for acute mountain sickness, 633t
 for HAPE, 635
 Nifurtimox, for Chagas disease, 2168
 Night blindness, vitamin A deficiency and, 453
 Night terrors, 3638
 Nightmares, 209t, 3638
 Nijmegen syndrome, 774t
 Nikolsky sign, 4153, 4153f
 in Stevens-Johnson syndrome, 4078–4079
 Nilotinib, 3088t
 9q34 deletion syndrome, 768t–769t
 911 system, 536
 Nipple candidiasis, 410
 Nipple pain, 410
 Nipples
 accessory, 3329, 3329f
 discharge, 3331, 3331t
 NIPPV. *See* Noninvasive positive airway pressure ventilation
 Nissen fundoplication, for chronic recurrent aspiration, 2611
 Nitazoxanide, 2125
 for ascariasis, 2199
 for cyclosporiasis, 2153
 Nitrazepam, dosages of, 3609t–3610t
 Nitric oxide, inhaled
 for congenital diaphragmatic hernia, 1095
 for PPHN, 1093
 Nitrite poisoning, 4411t–4413t
 food-borne noninfectious illnesses and, 2362t–2364t
 Nitrites, 3266
 Nitrofurantoin, 1675t–1685t
 Nitroglycerin, for heart failure, 2898t
 Nitroprusside, for heart failure, 2898t, 2899
 Nitrous oxide (N₂O), 670, 1203t
 Nits, 4175
 NKX2-1 variants, disease caused by, 2685
Nocardia, 1735–1737
 clinical and radiographic manifestations of, 1736, 1736f
 diagnosis of, 1736
 epidemiology of, 1735–1736
 etiology of, 1735
 pathogenesis of, 1736
 prognosis of, 1737
 treatment of, 1736–1737
 Nociception, 3889
 Nocturnal autosomal dominant frontal lobe epilepsy, 3600
 Nocturnal confusional arousals, 3638
 Nocturnal enuresis, 3295–3296, 3295t
 clinical manifestations and diagnosis of, 3295–3296
 epidemiology of, 3295
 pathogenesis of, 3295
 treatment of, 3296
 Nodding syndrome, 2207, 3601–3602, 3630, 3630t
 Nodular goiter, 3414f
 Nodular lymphoid hyperplasia, 2414
 Nodular scabies, 4172–4173
 Nodules, 4027
 rheumatoid, 1474–1475, 1477f
 sarcoidosis, 1550f
 subcutaneous, in rheumatic fever, 1713
 subependymal, 3657
 thyroid, 3423–3424, 3424f, 3424t
 vocal, 2583
 Noise, in transport physiology, 541
 Noma, 4149
 NOMID. *See* Neonatal-onset multisystem inflammatory disease
 Non-5q13-associated SMAs, 3874
 Nonacademic problems, neurodevelopmental dysfunction underlying, 305
 Nonadherence, in T1DM, 3534–3535
 Nonalcoholic fatty liver disease, 442, 2480–2482, 2481f
 Nonalcoholic steatohepatitis (NASH), 2480
 off-label therapy for, 2482t
 Nonallelic homologous recombination, 734
 Nonallergic rhinitides, 1380
 Nonatopic eczema, 1410
 Nonbacterial food poisoning, 4441–4446
 Nonbacterial thrombotic embolus (NBTE), 2864–2865
 Nonbicarbonate buffers, 510
 Nonbinary youth, therapy for, 1181
 Nonblistering cutaneous porphyrias, 965
 Nonbullous congenital ichthyosiform erythroderma, 4115–4116, 4115f–4116f
 Nonbullous impetigo, 1707, 4150, 4150f
 Noncardiogenic pulmonary edema, 2605t, 634
 Non-celiac gluten sensitivity, 2331
 Nonclassic 3β-HSD deficiency, 3469
 Nonclassic 21-hydroxylase deficiency, 3466
 Nonclassical congenital adrenal hyperplasia, 3394
 Nonclonal polycythemia, 2998–2999, 2998t
 Noncomitant strabismus, 3927–3928, 3929t
 Noncommunicating Child's Pain Checklist—Postoperative Version, 680
 Noncommunicating rudimentary horn, 3351
 Nonconvulsive status epilepticus (NCSE), 291, 3624
 Nondairy alternatives, breastfeeding and, 413
 Nondirective counseling, 756
 Nondisjunction, 761
 Nonepileptic seizures, psychogenic, 3633
 Nonfatal drowning, 637
 Nonfatal injuries, 91
 Nonfreezing cold injury, 662
 chilblains (pernio), 661f, 662
 cold-induced fat necrosis, 662
 familial chilblain lupus, 663
 frostnip, 662
 immersion (trench) foot, 662
 Non-germ cell gonadal tumors, 3152–3153
 Nongonococcal urethritis, 1240–1241
 Non-group A or B streptococci, 1721–1722
 Non-Hodgkin lymphoma, 3109–3115
 age-related manifestations of, 3084
 anaplastic large cell lymphoma, 3115
 Burkitt lymphoma, 3113–3115
 chemotherapy and, 3086
 clinical manifestations of, 3112–3113, 3113t
 complications of, 3115
 diffuse large B-cell lymphoma, 3113–3115
 epidemiology of, 3109–3111
 HSCT for, 1353
 laboratory findings of, 3113, 3114f
 lymphoblastic lymphoma, 3115
 pathogenesis of, 3111–3112, 3111f–3112f
 prognosis of, 3110t, 3115
 relapsed, 3115
 treatment for, 3110t, 3113–3115, 3114t
 Non-IgE gastrointestinal food allergy disorders, 1448–1451
 clinical manifestations of, 1448, 1449t–1450t, 1450f
 epidemiology of, 1448–1451, 1451t, 1452f, 1453t
 Nonimmune hemolytic anemia, 2953t
 Nonimmune hydrops, 1128–1129, 1128f, 1129t, 1130f
 Nonimmune platelet destruction, 3055
 Noninfectious diseases, 1020–1021
 Noninfectious foodborne illness, 4411t–4413t
 Noninfectious pericarditis, 2891
 Non-insulin-dependent diabetes mellitus, 3515
 Noninvasive mechanical ventilation, 623
 Noninvasive positive airway pressure ventilation (NIPVV)
 physiologic benefits of, 623, 624f
 for RDS, 1080
 for respiratory distress and failure, 619
 Nonketotic hyperglycinemia
 infantile, 837–838
 late-onset, 838
 neonatal, 837
 in neonatal seizures, 3622
 Nonketotic hyperosmolar coma, in T1DM, 3527–3528
 Nonlactational mastitis, 3330–3331
 Nonliteral or figurative language skill, definition of, 324–326, 325t
 Nonmaleficence, 51
 Non-MHC/HLA genes, associated with T1DM risk, 3519
 Nonmodifiable environmental risk factors, for SIDS, 2533
 Nonmotor seizures, 3619
 Nonneurogenic neurogenic bladder, 3293
 Nonobstructive renal disease, 1030–1031
 Nonpalpable testes, 3302–3304
 Nonparalytic poliomyelitis, 1972–1973
 treatment of, 1977
 Non-phenylketonuria hyperphenylalaninemia, 812
 Nonpolio enteroviruses, 1979–1986
 Nonpolyalanine repeat expansion pathogenic variant (NPAPRV), 2719
 Nonprescription cough and cold remedies, poisoning, 717t
 Nonprogressive angiography-positive CNS vasculitis, 1566, 1566t
 Nonpropulsive rhythmic segmentation, 2277
 Non-rapid eye movement partial arousal disorders, 3638
 Nonreducible inguinal hernias, 2418
 Nonretentive encopresis, 2293
 Nonretentive fecal incontinence (NFI), 2293, 2391
 Nonrhabdomyosarcoma soft tissue sarcomas, 3139t–3140t
 Nonspecific febrile illness, enterovirus, 1981
 Nonspecific hypotonia, chronic recurrent aspiration and, 2609
 Nonspecific orbital inflammation (NSOI), 3971–3972, 3971f
 Nonspecific physical complaints, 305
 Nonspherocytic hemolytic anemia, 2990
 Non-SSRI antidepressants, 224, 227t
 Nonstandard therapies, for neurodevelopmental dysfunctions, 309
 Nonsteroidal antiinflammatory drugs (NSAIDs)
 for Ehlers-Danlos syndrome, 4374
 for heavy bleeding, 1214
 for JIA, 1481t
 for migraine, 3648
 in pain management, 681–682
 peptic ulcers and, 2306
 poisoning, 712
 for rheumatic disease, 1464–1469, 1466t–1468t
 topical, 4040
 Nonstress test, fetal, 1015–1017
 Nonsuicidal self-injury (NSSI), 283
 Nonsyndromic autosomal variants, intellectual disability caused by, 349t
 Nonsyndromic cleft palate, 331
 Nonsyndromic mitochondrial disorders, 3699
 Nonsyndromic neuropathies, in HMSN, 3877t–3879t
 Nonsyndromic orofacial clefts, 2244f
 Nonsynonymous variants, 730–731
 Nontherapeutic research, 55
 Nontransfusion-dependent thalassemia, 2986–2987
 Nontuberculous mycobacteria (NTM), 1860–1865
 cefoxitin against, 1834–1835
 clinical manifestations of, 1861–1864, 1861t, 1862f–1863f
 cystic fibrosis and, 2675–2676
 diagnosis of, 1864–1865, 1864t
 doxycycline against, 1835
 epidemiology of, 1860–1861
 etiology of, 1860
 HIV and, 2093
 macrolides against, 1835

- Nontuberculous mycobacteria (NTM) (*Continued*)
 pathogenesis of, 1861
 treatment of, 1865
 trimethoprim-sulfamethoxazole against, 1835
- Nontyphoidal *Salmonella* spp. infection, 1623t–1625t
- Nontyphoidal salmonellosis, 1765–1771
 acute enteritis, 1767
 bacteremia, 1767–1768, 1770f
 bacteremia as emerging disease in Africa, 1767, 1770f
 chronic *Salmonella* carriage, 1768
 diagnosis of, 1768–1769
 epidemiology of, 1766
 etiology of, 1766
 extraintestinal focal infections, 1768
 formation of *Salmonella*-containing vacuole, 1769f
 pathogenesis of, 1766–1767, 1769f
 prevention of, 1771
 prognosis for, 1771
 treatment of, 1769–1771
 virulence system of, 1768f
- Nonvascular emergency procedures, 570
- Nonvenereal treponemal infections, 1876–1877
- Noonan syndrome, 771, 787, 788t, 789f, 2764t–2766t, 3126t, 3489, 4070t–4071t
 clinical findings associated with, 789t
 in hypergonadotropin hypogonadism, female, 3500
 with lentigines, 4070t–4071t
 management of, 790t
 treatment of, 788
- Norepinephrine
 biosynthesis, 3449f
 for postarrest stabilization, 568t
 for shock, 610t
- Norepinephrine-dopamine reuptake inhibitor (NDRI), 226
- Normal gait, 4198
- Normative fears, in childhood and adolescence, 247f
- Normocytic anemia, 2929
- Norovirus, seasonality of, 2359
- Nortriptyline, in pain management, 690t
- Norwegian scabies, 4174, 4175f
- Nose
 acquired disorders of, 2548–2549
 epistaxis, 2548–2549
 foreign bodies, 2548
 congenital disorders of, 2545–2547
 in erythropoietic protoporphyrina, 978f
 of newborn, 1002, 2545
 saddle
 in congenital syphilis, 1868–1869, 1869f, 1869t
 in Wegener granulomatosis, 1564f
- Nosocomial diarrhea, 2356–2359
- Nosocomial infections, with cytomegalovirus, 2010–2011
- Nosocomial pneumonia, *Pseudomonas aeruginosa* infection, 1800–1801
- Nostrilla, for allergic rhinitis, 1384t
- NPARPV. *See* Nonpolysaccharide repeat expansion pathogenic variant
- NPH. *See* Neutral protamine Hagedorn
- NRD. *See* Neonatal respiratory distress
- NSAIDs. *See* Nonsteroidal antiinflammatory drugs
- NSOI. *See* Nonspecific orbital inflammation
- NSP4 protein, of rotavirus, 2361
- NTM. *See* Nontuberculous mycobacteria
- Nucala. *See* Mepolizumab
- Nuclear factor-k-B (NEMO) deficiency, 1343
- Nuclear factor-kB pathway defects, 1334, 1334t
- Nuclear medicine, 4414
 for orthopedic evaluation, 4200
- Nuclear scans, of chronic recurrent aspiration, 2610
- Nuclear translation, variants in, 2485
- Nucleic acid amplification tests (NAATs)
 for *Clostridium difficile* infection, 1826
 for gonorrhea and chlamydia, 125
 for *M. pneumoniae*, 1889
 for *Neisseria gonorrhoeae*, 1750
 for tuberculosis, 1848–1849
- Nucleic acid detection, in toxoplasmosis, 2195
- Nucleoside, for hepatitis B, 2466t
- Nucleoside reverse transcriptase inhibitors (NRTIs), for HIV, 2097
- Nucleotidase-associated pervasive developmental delay, 945t, 955
- Nucleotidases, disorders associated with, 955
- Number sense, 318–320
- Numerical Rating Scale (NRS), 679t
- Nummular eczema, 4090, 4091f
- Nursemaid's elbow, 4265, 4267f
- Nursery care
 and breastfeeding, 1007t, 1008
 in newborn, 1005–1006
 of premature infant, 1043–1045
 feeding, 1044
 parenteral nutrition, 1044
 prevention of infection, 1044–1045
 thermal control, 1043–1044
- Nursing-based intervention, 1691t
- Nurturant-authoritative approach, 274
- Nusinersen, 3871–3873
- Nutcracker syndrome, 3211
- Nutraceuticals, for migraine, 3649
- Nutrition, 52, 422
 affected by GERD, 2268
 for burn injuries, 652
 for children with disabilities, 4407
 cultural considerations in, 417, 418f
 Down syndrome and, 369
 enteral, for high-risk infant, 1044
 food safety, 420
 importance in acute kidney injury, 3246
 issues, across pediatric ages, 416–420
 eating at home, 416
 eating in childcare and school settings, 416
 eating outside the home, 417
 neutropenia related to, 1307
 parenteral, for high-risk infant, 1044
Shigella, 1779
 as supplements, 419–420
 for T1DM, 3530–3531, 3531t–3532t
- Nutrition targets, food security and, 422, 422t
- Nutritional assessment, prior to renal transplantation, 3255
- Nutritional dermatoses, 4189–4192
 acrodermatitis enteropathica, 4189, 4190t, 4191f
 cystic fibrosis, 4190
 essential fatty acid deficiency, 4190
 kwashiorkor, 4190, 4191f
 pellagra, 4191
 scurvy, 4192, 4192f
 vitamin A deficiency, 4192
- Nutritional disorders, in secondary intracranial hypertension, 3783t
- Nutritional rehabilitation, for chronic diarrhea, 2382
- Nutritional requirements, 388–409
 carbohydrates, 389t–390t, 394, 395f
 in CKD, 3248–3249
 dietary reference intake (DRI), 388–391, 388t–390t, 391f, 394t
 energy, 391
 fat, 389t–390t, 391–393, 392f
 fiber, 389t–390t, 394–395
 micronutrients, 396, 397t–403t
 nutritional adequacy, 408–409, 408t
 protein, 389t–390t, 393–394, 394t
 water, 396–408
- Nutritional supplements, 419–420, 436t
- Nutritional therapy, for cystic fibrosis, 2676
- Nystagmus, 3553, 3930–3932, 3931f–3932f, 3931t–3932t, 3981
 in giant axonal neuropathy, 3887
- Nystagmus retractorius, 3930
- I**
- Obesity, 438–450
 among GLB youth, 1184
 asthma with, 1398
 BMI, 438, 439f–440f
 brain-adipose tissue-intestinal axis regulation of
 energy homeostasis, 443f
 in childcare, 193
 for children with disabilities, 4407
- Obesity (*Continued*)
 cholesterol gallstones and, 2503
 comorbidities, 442
 diagnosis and management flow chart for, 446f
 disparities in, 12, 12f, 18
 Down syndrome and, 369
 endocrine and genetic causes of, 441t
 epidemiology of, 438
 etiology of, 438–442
 evaluation, 442–445
 growth and, 177
 identification, 442
 kidney transplant immunosuppression and, 3258–3259
 medications associated with, 445t, 448t
 morbid, in Prader-Willi syndrome, 775f
 nephrotic syndrome and, 3229
 pharmacotherapy for, 447
 prevention of, 448–450, 450t
 respiratory signs and symptoms, 2531t
 respiratory tract complication, 2531t
- Object permanence, 156, 158
- Obligate anaerobes, 1828
- Oblique talus, 4203–4204
- Obsessive-compulsive disorder (OCD), 246–254, 247t–248, 378
 abrupt-onset, 253–254
 diagnostic criteria for, 248t
 Down syndrome and, 373
 in hair pulling, 4137
 special considerations for, 253–254
- Obstructed hemivagina and ipsilateral renal anomaly syndrome (OHVIRA), 3352
- Obstruction
 acute pancreatitis and, 2427t
 bronchiectasis and, 2658
 of bronchus, atelectasis and, 2700t
 closed-loop, 2302
 duodenal, 2282–2283
 jejunal and ileal atresia, 2283–2284, 2283f–2284f
 nasal, in common cold, 2553
- Obstructive lesions, in congenital heart disease
 aortic stenosis, 2790–2793
 coarctation of the aorta, 2793–2795
 infundibular pulmonary stenosis and double-chamber right ventricle, 2789–2790
 peripheral pulmonary stenosis, 2790
 pulmonary stenosis in combination with an intracardiac shunt, 2790
 pulmonary valve stenosis with intact ventricular septum, 2787–2789
- Obstructive overinflation, 2590
- Obstructive shock, 560, 600, 601t, 602f
 clinical manifestations of, 605
 management for, 610
 pathophysiology of, 603
- Obstructive sleep apnea (OSA), 206–209, 1075, 2723–2724
 associated with Down syndrome, 369
- BRUE and, 2541–2542
 clinical manifestations of, 207
 diagnosis of, 207–208, 208t
 epidemiology of, 207
 etiology of, 206–207
 management of, 208t
 pathogenesis of, 207
 treatment of, 208–209
- Obstructive uropathy, 1028–1030
- Obturator internus sign, appendicitis and, 2398–2399
- OCA. *See* Congenital oculocutaneous albinism
- Occipital horn syndrome, 2351
- Occipital plagiocephaly, in craniostenosis, 3583
- Occipital-frontal transcranial diameter, in deformational plagiocephaly, 3586
- Occipitocervical dislocation, 580
- Occlusion, transcatheter, of ASD, 2778f
- Occult bacteremia, fever in older children, 1647
- Occult meningococcal bacteremia, 1741
- Occult spinal dysraphism, 3290–3291, 3563–3564, 3564f–3565f, 3565t
- Occult urinary tract infection, fever in older children, 1647, 1650t

- Occupational and environmental lung disease, 2616–2620, 2616t
asthma, 2616, 2617t–2619t
classification and pathogenesis of, 2616–2620
high molecular weight antigens in, 2617t–2618t
irritant-induced asthma, 2619
low molecular weight chemicals in, 2619t
reactive airways disease syndrome, 2619, 2620t
Occupational safety, 50
Occupational therapists, 307
Occupational therapy, for Down syndrome, 371
OCD. *See* Obsessive-compulsive disorder
Ochratoxin A, 4413
Ochronosis in alkaptonuria, 817
Octopus, 4472
Octreotide, 707t–708t, 715
 for CIPPO, 2291
 for portal hypertension, 2506
Ocular abnormalities
 gross hematuria and, 3188
 in progeria, 957
Ocular albinism, 818t
 OA₁ (Nettleship-Falls type), 819
Ocular allergies, 1422–1425
 allergic conjunctivitis, 1422, 1423f
 atopic keratoconjunctivitis, 1423
 clinical manifestations of, 1422–1424, 1422t
 contact allergy, 1424
 diagnosis of, 1424
 giant papillary conjunctivitis, 1423–1424
 treatment of, 1424, 1424t–1425t
 vernal keratoconjunctivitis, 1422–1423, 1423f
Ocular bobbing, 3553
Ocular cystinosis, 3234–3235
Ocular decontamination, 706
Ocular hemorrhage, types of, 3976f
Ocular infections, herpes simplex virus (HSV), 1994–1995, 1997
Ocular larva migrans (OLM), 2210
Ocular manifestations
 in childhood lupus, 1497t
 of enterovirus infection, 1982
 of herpes simplex virus, 1994–1995, 1997
 of SLE, 1492t
Ocular motility testing, 3910–3911
Ocular motor dysmetria, 3932, 3933t
Ocular neurocysticercosis, 2218
Ocular system, Marfan syndrome in, 4365
Ocular toxoplasmosis, 2189, 2195, 2197
Oculocephalic reflex, 591t
Oculocerebral renal syndrome of Lowe, 3949
Oculocutaneous albinism (OCA), 818t
 with abnormal melanin production, 4071
 OCA₁, 819, 4071, 4072f
 OCA₂, 819, 4071
 OCA₃, 819, 4071
 OCA₄, 819, 4071
 with organelle dysfunction, 4071–4072
Oculocutaneous tyrosinemia, 816–817
Oculoglandular tularemia, 1805
Oculomotor abnormalities, that mimic seizures, 3631t, 3637–3638
Oculomotor apraxia, 3637
Oculomotor nerve (cranial nerve III), in neurologic examination, 3553
Oculopharyngeal muscular dystrophy, 745t–746t, 3854
Oculosympathetic paresis, 3923
Oculovestibular reflex, 591t
ODD. *See* Oppositional defiant disorder
Odynophagia, 2225, 2225t
Office
 intervention, for behavioral and mental health issues, 89–90
 preparedness, in emergency medical services, 534–539
 system change, for quality improvement, 90
Ofloxacin, 1675t–1685t
Ogawa strains, *Vibrio cholerae*, 1785
Ogilvie syndrome, 2287–2289
O-glycans, 921
1,25(OH)₂D, produced by sarcoid macrophage, 1549
OHCA. *See* Out-of-hospital cardiac arrest
Ohtahara syndrome, 3601, 3677–3678
- Oil of cloves, 2492t
Ointments, 4038
Okadaic acid, 4445
Olanzapine (Zyprexa), for psychosis and mania, 228t
Older children
 antibiotics use in, 1672–1673
 brain-gut interaction disorders in, 2388–2391
 Enterococcus in, 1723
 fever in, 1647–1651
 diagnosis of, 1647, 1648t
 evaluation of, 1649–1650
 general approach, 1647–1649
 management of, 1650–1651
 lying in, 282
 measures of pain specific to, 679f, 680
Olecranon bursitis, 4303
Olfactory nerve (cranial nerve I), in neurologic examination, 3552
Oligoarthritis, 1472t–1473t
Oligodendrogliomas, 3120
Oligofructose, 395
Oligohydramnios, 1012–1013, 1014t, 3260–3261
 complex, 3213
Oligomeganephronia, 3262
Oligomenorrhea, 4322
Oligosaccharides, 394
Oligosaccharidoses, 887t
Oligospermia, formation, after localized radiation exposure, 4419
Olivopontocerebellar atrophies, 3673
Ollier disease, 3145, 3502
OLM. *See* Ocular larva migrans
Olympian brow, 1869t
Omalizumab
 for asthma, 1401t, 1404
 for atopic dermatitis, 1417
Omega-3 fatty acids, 56t
Omenetti syndrome, 1263, 1264f
Omental cysts, 2509
Omnaris, for allergic rhinitis, 1384t–1385t
Omphalitis, in newborn, 1148
Omphalocele, 1003, 1053t
 congenital, 1131, 1131f
Omphalomesenteric duct, remnants of, 2286–2287
Omsk hemorrhagic fever, 2073, 2075–2076
OnabotulinumtoxinA, for migraine, 3646t–3647t
Onasemnogene, 3873–3874
Onchocerca volvulus, 2207
Onchocerciasis, 2207
Oncogene activators, of pediatric tumors, 3078t
Oncogenes, 3077
Oncogenesis
 of Epstein-Barr virus (EBV), 2008–2009, 2009t
 genomic imprinting and, 3081
Oncologic disorders, hypoplasmin and, 3063t
Oncologic emergencies, 3092t–3093t
Oncology, anesthetic implications in, 666t
Oncotic pressure, decreased, 2604t, 2605
Ondansetron, for acute gastroenteritis, 2372
On-demand therapy, for HAE with C1-INH deficiency, 1323
1p deletion, 768t–769t
Onion bulb formations, 3876
Onion-skinning, Ewing sarcoma and, 3143–3144, 3143f
Onychia, candidal, 4166
Onycholysis, 4144, 4145f, 4145t
Onychomadesis, 4145f
Onychomycosis, 4145–4146, 4146f, 4146t
Oophoritis, mumps and, 1971
Opacification, of thorax, 2656f–2657f, 2711f
OPC. *See* Oropharyngeal candidiasis
Open bite, malocclusion and, 2243
Open globe injury, 3978, 3978f
Open hospice, 61
Open inguinal hernia repair, 2419
Open-ended questions
 in motivational interviewing, 134
 for physical abuse and neglect, 119
Ophelia syndrome, encephalitis with, 3705t–3707t
Ophthalmia neonatorum, 1749, 3939
Ophthalmitis, gonococcal, 1749
Ophthalmologic anomalies, in Diamond-Blackfan anemia, 2932t
- Ophthalmologic lesions, associated with neurofibromatosis type 2, 3657t
Ophthalmologic slit-lamp examination, in sarcoidosis, 1550
Ophthalmoplegia, mitochondrial disease and, 935t
Ophthalmoscopy, 3912
Opiates, abuse, by adolescents, 1207–1208, 1208t
Opioid use disorder, 1023
Opioids, 670–671
 in anesthesia, 669t
 in pain management, 682–685, 683t–687t
 in pediatric palliative care, 64
poisoning, 701t, 707t–708t
 during pregnancy, 1023
 toxicidrome, 703t
Opisthorchiasis, 2215
Opisthorchis spp., 2215
Opisthotonus, 1822, 3555, 3555f
Opportunistic infections
 Burkholderia cepacia, 1802
 chronic diarrhea and, 2377
 HIV and, 2092–2093
Oppositional defiant disorder (ODD), 277, 1190t
 clinical course, 277
 comorbidity of, 277
 differential diagnosis of, 277
 disparities in, 15
Down syndrome and, 373
DSM-5, 278t
epidemiology of, 277
etiology of, 278
prevention of, 278–279
sequelae of, 277–278
treatment for, 279–280
Opsoclonus, 3553, 3932, 3933t
Opsoclonus-myoclonus syndrome, 3637
and other types of rare brainstem-cerebellar encephalitis, 3705t–3707t, 3710
Opsoclonus-myoclonus-ataxia syndrome, 3126t, 3128, 3679
Opsonins, 1292
Opsonization, C3-mediated, 1315
Optic atrophy, 3966–3967, 3968t
Optic glioma, in neurofibromatosis type 1, 3652–3654, 3655f
Optic nerve
 abnormalities, 3963–3968
 aplasia, 3963
 coloboma, 3964
 drusen, 3964
 hypoplasia, 3963–3964
 Leber hereditary optic neuropathy, 3966
 morning glory disc anomaly, 3964
 optic atrophy, 3966–3967, 3968t
 optic nerve glioma, 3967–3968
 optic neuritis, 3965–3966
 papilledema, 3965
 tilted disc, 3964
 traumatic optic neuropathies, 3968
 mulberry lesion of, 3659f
 in neurologic examination, 3552–3553, 3552f
Optic nerve hypoplasia, 3373
 inborn errors of metabolism and, 809t–810t
Optic neuritis (ON), 3725–3727, 3726f
Optic neuropathy
 mitochondrial disease and, 935t
 toxic causes of, 3895t
Optic pathway tumors, 3117–3118
Optokinetic nystagmus, 3910
Oral allergy syndrome, 1444
Oral antibiotic therapy, for cystic fibrosis, 2674
Oral antihistamines, for allergic rhinitis, 1381–1382, 1382t–1383t
Oral antimalarial therapy, follow-up, for severe malaria, 2176–2181
Oral candidiasis, 2242t, 4164
 in immunocompetent patient, 1922–1923
Oral cavity, 2248f
 cleft lip and palate, 2243–2244
 dental caries, 2246–2249
 dental trauma, 2250–2252
 diagnostic radiology, in dental assessment, 2255
 disorders, associated with other conditions, 2242, 2242t

- Oral cavity (Continued)
- malocclusion, 2242–2243
 - periodontal diseases, 2249–2250
 - salivary glands, diseases of, 2254
 - soft tissues, common lesions of, 2252–2254
 - syndromes with oral manifestations, 2245, 2245f
- Oral cephalosporins, 1686t
- Oral contraceptives
- combined, 1218t–1219t
 - estrogen-containing, 3355
 - progestins, 3356
- Oral feeding, calorie boosters for, 437t
- Oral food challenges, 1378
- Oral hairy leukoplakia, 4149
- Oral health, disparities in, 13–14
- Oral hygiene, for dental carries, 2249
- Oral language, writing disabilities and, 322
- Oral lesions, 117
- in pediatric palliative care, 69t
- Oral manifestations, syndromes with, 2245, 2245f
- Oral mucosal neuromas, on tongue, 3165f
- Oral narratives, 328
- Oral pathology, in leukocyte adhesion deficiency type 1, 1300f
- Oral polio vaccine (OPV), 30–31t
- Oral reading, 317
- Oral rehydration, 1633
- Oral thrush, in immunocompetent patient, 1922
- Oral ulcers
- in Behcet disease, 1515, 1515f
 - in SLE, 1492f
 - suggestive of rheumatic disease, 1461t
- Orally administered polio vaccine (OPV), 1977–1978
- Orbit, of eye, 3979
- Orbital abnormalities, 3971–3973
- exophthalmos and enophthalmos, 3971
 - hypertelorism and hypotelorism, 3971
 - inflammation, 3971–3972
 - tumors of, 3972–3973
- Orbital apex syndrome, 3971
- Orbital cellulitis, 3940t
- Haemophilus influenzae* in, 1757
- Orbital fractures, 3979
- Orbital infections, 3973–3976
- dacryoadenitis, 3973
 - dacryocystitis, 3973
 - endophthalmitis, 3976
 - orbital cellulitis, 3973t; 3974–3975, 3975f
 - preseptal cellulitis, 3973–3974, 3974f
- Orbital inflammation, 3971–3972, 3971f–3972f
- Orchitis, mumps and, 1971
- Orellanine poisoning, 4443
- Organ donation, 53
- Organ dysfunction, in shock, 604t
- Organ involvement, in primary mitochondrial hepatopathies, 2483t
- Organ Procurement and Transplantation Network (OPTN), 3254
- Organic acid metabolism, disorders of, 805t
- Organic acidemias, 825–837, 826f
- branched-chain amino acid transporter deficiency, 827
 - branched-chain α -ketoadic dehydrogenase kinase deficiency, 827
 - cardiomyopathy and, 808t
 - combined methylmalonic aciduria and homocystinuria, 836–837
 - cytosolic acetoacetyl-CoA thiolase deficiency, 831
 - isovaleric, 827–828
 - β -ketothiolase deficiency, 830–831, 831f
 - maple syrup urine disease, 825–827
 - 3-methylglutaconic acidurias, 829–830, 830t
 - methylmalonic, 835–836
 - mevalonate kinase deficiency, 832–833
 - mevalonic aciduria, 832–833
 - mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency, 831–832
 - multiple carboxylase deficiencies, 828
 - propionic, 833–835
 - succinyl-CoA:3-oxoacid-CoA transferase deficiency, 832
- Organic acids, 2246
- Organic acidurias, inborn errors of metabolism associated with, 809t
- Organic foods, 418–419
- Organic lead compounds, 4436
- Organic mercury, intoxication, 4433
- Organic pollutants, persistent, 4425–4426
- Organic voice disorders, 332
- Organophosphate, 4447, 4451
- poisoning, 707t–708t, 719
- Organophosphate chemicals, 3866
- Oriental beriberi, 458
- Oriental sore, 2158
- Orientia tsutsugamushi*. See Scrub typhus
- Orificial tuberculosis, 4158
- Ornithine metabolism, disorders of, 854
- Ornithine transcarbamylase deficiency, 851–852
- Ornithodoros* ticks, relapsing fever and, 1880
- Ornithosis, 1897
- Orofacial granulomatosis, in sarcoidosis, 1551
- Orofaciodigital syndrome type I, 792t
- Oropharyngeal airway, 618
- Oropharyngeal candidiasis, 2252
- Oropharyngeal dysphagia, 2225, 2225t
- Oropharyngeal infections, herpes simplex virus (HSV), 1993, 1993f
- Oropharyngeal tularemia, 1805
- Orotic aciduria, 2944
- Oroya fever, 1814–1815
- Orphanages, language disorders and, 331
- Orthopedic evaluation, 4195–4200, 4195t
- back pain, 4200
 - laboratory studies of, 4200
 - limping, 4199–4200, 4199t
 - neurologic evaluation of, 4197–4199, 4198t–4199t
 - physical examination of, 4195–4197, 4196f
 - inspection, 4197
 - palpation, 4195–4197
 - range of motion, 4197, 4197t–4198t
 - inspection, 4195
 - radiographic assessment of, 4200
- Orthopedic growth and development, 4193–4194, 4193t
- centers of ossification, 4193–4194, 4194f–4195f, 4194t
 - gait/functional maturation, 4194, 4195t
 - in utero positioning, 4193
- Orthopedic problems
- complications, of JIA, 1482
 - obesity-associated comorbidities, 444t
- Orthophoria, 3925
- Orthopoxvirus, 4450, 4461
- Orthoradiogram, 4219
- Orthoses, 4402, 4402f, 4403t
- Orthostatic hypotension (OH), 597, 597f
- Orthostatic intolerance
- not otherwise specified (OI-NOS), 598
 - syndromes, 1579
- Orthostatic proteinuria, 3220, 3221f
- Orthostatic training, for vasovagal syncope, 596t
- Orthotopic liver transplantation, 2499, 2499t
- for portal hypertension, 2506
- Orthotopic ureterocele, 3280
- Ortolani test, 4233, 4233f
- Os odontoideum, 4262–4263
- Os trigonum, 4332
- OSA. See Obstructive sleep apnea
- Oseletaminvir, 1956
- for influenza, 2022, 2024t
- Osgood-Schlatter disease, 4310
- basketball associated with, 4328
 - soccer associated with, 4329
- Osgood-Schlatter (OS) disease, 4226–4228, 4227f–4228f
- Osler-Weber-Rendu disease, 2830, 4059–4060, 4059f–4060f
- Osmolality
- in acute kidney injury, 3244t
 - ICF and ECF, in equilibrium, 486–487
 - reference intervals, 4472.e9t
 - regulation of, 487–488
- Osmolar gap, elevated, in toxicologic diagnosis, 705t
- Osmoles, idiopathic, in hypernatremia, 491
- Osmotic diarrhea, 2232, 2376, 2376f
- Osseous bacillary angiomatosis lesions, 1816
- Osseous development, delay of, hypothyroid infants, 3406, 3408f
- Ossification centers, anatomic locations of, 4193–4194, 4194f–4195f, 4194t
- Ossifying fibroma, 2254
- Osteitis, 1854
- Osteitis pubis, 4308, 4329
- Osteoarthropathy, hypertrophic, 1582
- Osteoblast differentiation, defects in, 4362
- Osteoblastoma, 3146
- Osteocalcin, 4377–4378
- Osteochondritis
- of capitellum, 4264
 - in newborn with congenital syphilis, 1868, 1868f
- Osteochondritis dissecans (OCD), 4299, 4300f, 4304
- Osteochondroma, 3144
- Osteochondroses, 4208, 4208f
- of foot, 4313
 - juvenile, 4357, 4357t
- Osteoclast-poor autosomal recessive osteopetrosis, 4351t
- Osteodysplasias, 4333
- Osteodystrophy
- Albright hereditary, 3439
 - renal, 3246t, 3249
- Osteofibrous dysplasia, 3147–3148
- Osteogenesis imperfecta (OI), 2241, 4021, 4359–4363
- clinical manifestations of, 4359–4362
 - complications of, 4362
 - epidemiology of, 4359
 - etiology of, 4359
 - genetic counseling in, 4363
 - laboratory findings of, 4362
 - pathogenesis of, 4359
 - pathology of, 4359, 4360t
 - prognosis of, 4363
 - treatment of, 4362–4363
 - type I, 4359
 - type II, 4360
 - type III, 4361, 4361f–4362f
 - type IV, 4361
 - type V, 4361
 - type VII, 4361
 - type VIII, 4361
 - type IX, 4361
 - type X, 4362
 - type XI, 4362
- Osteoglophonic dysplasia, 794t–795t
- Osteoid, 470
- microfibrillar matrix of, 4378
- Osteoid osteoma, 3145–3146
- Osteoma, 4023
- Osteomalacia, 470
- risk factors for, 474t
 - tumor-induced, 478
- Osteomass, of external ear, 4002
- Osteomyelitis, 1800t, 4284–4291
- chronic recurrent multifocal, 1523t
 - clinical manifestations of, 4285, 4286t–4287t, 4287f
 - diagnosis of, 4285–4286
 - differential diagnosis of, 4286–4288
 - DIRA, 1528f
 - epidemiology of, 4284, 4285t
 - etiology of, 4284
 - Kingella kingae*, 1753, 1754f
 - pathogenesis of, 4285
 - radiographic evaluation of, 4286
 - treatment for, 4289–4291
- Osteonecrosis, 4241
- Osteoonychodysostosis, 4350
- Osteopathia striata, in focal dermal hypoplasia, 4046
- Osteopenia, 4322
- Osteopetrosis, 4021, 4351, 4353f
- clinical manifestations of, 4351, 4353f
 - dystosteosclerosis, 4351t, 4353
 - involving defective bone resorption, 4350–4353
 - pycnodysostosis, 4353
 - treatment for, 4352
- Osteoporosis, 4359, 4383–4385, 4384t, 4385f
- meningocele and, 4401
- Osteoporosis-pseudoglioma syndrome, 4384
- Osteosarcoma, 3141–3143
- clinical manifestations of, 3141–3142
 - diagnosis of, 3142, 3142f
 - early detection of, 3084

- Osteosarcoma (*Continued*)
 epidemiology of, 3141
Ewing tumors vs., 3141t
 parosteal, 3141
 pathogenesis of, 3141
 periosteal, 3141
 prognosis of, 3143
 telangiectatic, 3141
 treatment of, 3142
- Ostium secundum defect, 2776–2779
 clinical manifestations of, 2777
 complications of, 2778
 diagnosis of, 2777–2778, 2777f
 pathophysiology of, 2776, 2777f
 prognosis of, 2778–2779
 treatment of, 2778
- OSTM1*-related autosomal recessive osteopetrosis, 4351t
- Otalgia, 3981, 3982t, 4008t
- Otitic hydrocephalus, 4015
- Otitis externa, 3999–4002, 4329
- Otitis media, 4003–4016, 4003f–4004f
 acute or chronic serous, 329
 adhesive, 4016
 antimicrobial prophylaxis for, 4011–4012
 asymptomatic purulent, 4007
 chronic suppurative, 4013
 clinical manifestations of, 4005
 conjunctivitis-associated, 4007
 epidemiology of, 4003–4004
 etiology of, 4004–4005
 examination of tympanic membrane, 4005–4007
Haemophilus influenzae in, 1758
 immunoprophylaxis for, 4007–4008
 intracranial complications of, 4014–4016
Moraxella catarrhalis in, 1760
 physical sequelae of, 4015–4016
 possible developmental sequelae of, 4016
 prevention of, 4007
 treatment for, 4008–4011
- Otitis media with effusion
 management of, 4012–4014, 4012t
 adenoectomy, 4013
 cholesteatoma, 4014, 4015f
 complications of, 4013, 4014t
 decisions regarding, 4012
 facial paralysis, 4013–4014
 infectious dermatitis, 4013
 intratemporal complications, 4013
 labyrinthitis, 4014
 mastoiditis, 4013
 medical treatment, 4012–4013
 myringotomy and insertion of tympanostomy tubes, 4013
 tympanic membrane perforation, 4013
Moraxella catarrhalis in, 1760
 tympanometry in, 3991
- Otoacoustic emissions (OAE), 3987, 3992
- Otomastoiditis, 1863
- Otomycosis, 4001
Aspergillus, 1929–1930
- Otorrhea, purulent, 3981
- Otosclerosis, 4021
- Ottawa ankle rules, 4312, 4312f
- Outburst Monitoring Scale, 280t
- Outcome, of germinal matrix intraventricular hemorrhage, 1060t
- Outcome bias, 48t
- Outcome elements, for outcome measures, 542
- Outcome measures, in emergency medical services, 542–543, 543t
- Outcome-based approach, of outcome measures, 543
- Outflow tract obstruction, 3351
- Out-of-hospital cardiac arrest (OHCA), 564
- Out-of-hospital care, in developing world, 544–546
 access to, 544
 methods of transport for, 545–546
 prehospital care in, 544–545
- Out-of-wind phenomenon, 910
- Outpatient management, for burn injuries, 649–650, 650t, 651f
- Ovarian cyst, neoplasm, abscess, 2238f
- Ovarian neoplasm, 3340–3342
- Ovarian torsion, 3340
- Ovaries
 adnexal torsion, 3342
 cystadenomas, 3341
 cysts
 functional, 3340
 neonatal and pediatric, 3340, 3340f
 development of, 3485
 endometrioma, 3341
 function of, 3486–3487
 hypofunction of, 3496–3501, 3497t
 hypergonadotropic hypogonadism in, 3496–3501
 hypogonadotropic hypogonadism in, 3501
 lesions of, pseudoprecocity resulting from, 3502–3503
- malignant tumors, in adolescents, 3342–3344, 3343t
- PID, 3341–3342
- polycystic syndrome, 3334–3338
 screening in, in transgender, 1180t
- teratoma, 3340–3341
- tuboovarian abscess, 3341–3342
- Overactive bladder, 3293
- Overconfidence bias, 48t
- Overdose syndrome, opiate, 1208, 1209f
- Overfill hypothesis, of nephrotic edema, 3223
- Overfit solutions, 43
- Overgrowth, bacterial
 chronic diarrhea and, 2377
 proximal intestinal, 2342–2343
- Overgrowth syndromes, 3381, 3382f
 in childhood or adolescence, 3382–3383
 differential diagnosis of, 3383t
 in fetus and neonate, 3382–3383
 genetic, 3384t
Sotos syndrome, 3383–3384
- Overheating, SIDS risk factors and, 2534
- Overinflation, 2590–2593
- Overlap myositis, frequency of manifestations of, 1505t
- Overlap syndrome, 2475
- Overlapping fifth toe, 4209
- Over-pronation, 4331
- Overriding sutures, 3552
- Overtreatment, 3086
- Overuse injuries, 4297–4298, 4298t
- Overuse syndromes, 4329
- Overweight, 438–450
 BMI, 438, 439f–440f
 diagnosis and management flow chart for, 446f
 epidemiology of, 438
 etiology of, 438–442
 evaluation, 442–445
 identification, 442
 medications associated with, 448t
 pharmacotherapy for, 447
 prevention of, 448–450, 450t
 regulation of energy homeostasis, 443f
- Ovotesticular DSD, 3508t, 3514
- Ovulatory dysfunction (AUB-O), 1211
- Oxacillin sodium, 1675t–1685t
- Oxacillin-susceptible strains, for infective endocarditis, 2870t
- Oxalosis, 838–840, 3313
- Oxantel pamoate, for trichuriasis, 2203
- Oxazolidinones, 1689–1690
- Oxcarbazepine
 adverse effects of, 3611t
 dosages of, 3609t–3610t
- Oxidant threats, 2990
- β -Oxidation cycle, defects in, 859–863
- Oxidative phosphorylation disease, 900t–901t, 916–919, 917t, 918f, 920t
- 5-Oxoprolinase deficiency, 843
- 3-Oxothiolase deficiency, 830–831, 831f
- Oxycodone
 equianalgesic doses of, 685t
 in hepatic and renal dysfunction, 685t
 in pain management, 683t
- Oxygen administration
 for high-risk infant, 1044, 1045t
 for respiratory distress and failure, 618, 618t
- Oxygen affinity, increased, abnormal hemoglobins with, 2979
- Oxygen delivery, according to device and flow rates, 618t
- Oxygen therapy
 for asthma, 1405t–1406t
 for severe malaria, 2175
- Oxygenation
 assessment of, in respiratory failure, 617–618
 extracorporeal membrane, for congenital diaphragmatic hernia, 1095
 for RDS, 1081
- Oxygenation index (OI), 618
- Oxygenation saturation index (OSI), 618
- Oxygen-hemoglobin dissociation curve, 2516f
- Oxygen-hemoglobin saturation, 548
- Oxymetazoline, for allergic rhinitis, 1384t
- Oxymorphone, in hepatic and renal dysfunction, 685t
- Oxytocin, 3363
- Oxytrauma, 629

P

- p14 deficiency, 1309t
- P450 oxidoreductase deficiency, 3464t–3465t, 3470, 3507
- Pachygyria, 3568–3569
- Pacific box jellyfish, 4472
- Pacifier, SIDS risk factors and, 2535
- Pacing
 biventricular, in tetralogy of Fallot, 2804
 cardiac, 2859
- Packed red blood cells, infusion of, for burns, 651
- PAE. *See* Prenatal alcohol exposure
- Pain
 abdominal. *See* Abdominal pain
 assessment and measurement of, 677–680
 back. *See* Back pain
 cancer and, 3081
 characterization of, 4195t
 chest
 differential diagnosis of, 2738t
 suggestive of rheumatic disease, 1461t
 in children with disabilities, 4407
- congenital insensitivity to, 3897, 3898t–3899t
 definition and categories of, 677, 678f, 678t
 in extremities, conditions causing, 1479t
 in neonate, 1053t, 1055t
 in nipple, 410
 in patients with cancer, 3096
 in pediatric palliative care, 64, 65f, 65t–69t
 postoperative management, 675
 sickle cell, 2969–2971, 2970t–2971t
- Pain control medications, 691–692
- Pain disorder, paroxysmal extreme, 3633
- Pain management, 677–700
 age-specific and developmentally specific measures, 677–680, 679f
 antidepressant medications in, 686–689, 690t
 for cancer pain, 697, 697t
 cancer treatment and, 3093
 chronic and recurrent pain syndromes, 697–699
 conceptual framework for, 681–686
 considerations for special pediatric populations, 696–697
 invasive interventions for, 693–696
 nonpharmacologic treatment, 692–693, 692f
 for pain associated with advanced disease, 697
 pharmacologic treatment, 681–686
 unconventional medications in, 686–692, 689t, 690f
- Pain medications, for delirium, 299
- Pain perception syndrome, characterization of inherited loss of, 3884t–3885t
- Pain syndromes
 arthritis or extremity pain caused by, 1479t
 suggestive of rheumatic disease, 1460
- Painful foot, 4211, 4211t
- Painful gait, 4199–4200
- Painless gait, 4199–4200
- Painless papule, 1866–1867
- Painless thyroïditis, 3412, 3412t
- PAIS. *See* Partial androgen insensitivity syndrome
- Palate, cleft, 2243–2244
- Palatine tonsil, 2562
- Paley classification, 4218, 4218f
- Palilalia, 241

- Paliperidone (Invega), for psychosis and mania, 228t
 Palivizumab (monoclonal antibody), 1586t, 1587, 1957
 for wheezing in infants, 2588
 Palliative care, 52
 cancer treatment and, 3096
 Pallister-Hall syndrome, 789–790
 Pallister-Killian syndrome, 771–772
 Pallor, 1000
 Palmar erythema, liver disease and, 2439
 Palmitate, mitochondrial oxidation of, 862f
 Palmoplantar keratodermas, 4118
 Palpable gonad(s), in female-appearing genitalia, 3506t
 Palpable nonthrombocytopenic purpuric skin lesions, 4032
 Palpation, 4195–4197
 in deformational plagiocephaly, 3584
 of spleen, in sickle cell anemia, 2976
 Palpation- or trauma-induced thyroiditis, 3411
 Palpebral fissure, length of, 1135–1136, 1136f
 PALS. *See* Pediatric Advanced Life Support
 Palsy
 brachial plexus, 1068–1069, 1069f
 facial nerve, 1069
 p-Aminosalicylic acid (PAS), for drug-resistant tuberculosis, 1852t–1853t
 PAMPs. *See* Pathogen-associated molecular patterns
 PAN. *See* Polyarteritis nodosa
 Panayiotopoulos syndrome, 3899t
 Pancreas, 2421–2423, 2422f
 anatomic abnormalities, 2422
 fluid collections in, 2432, 2432f
 treatment of, 2432
 necrosis in, treatment of, 2432
 physiology, 2423
 transplantation, in T1DM, 3538
 Pancreas divisum, 2422
 Pancreatic agenesis, 2422
 Pancreatic buds, 2276
 Pancreatic deficiency, chronic diarrhea and, 2378
 Pancreatic enzyme replacement
 for cystic fibrosis, 2676–2677
 for pancreatic insufficiency, 2425, 2425t
 Pancreatic function tests, 2423
 in cystic fibrosis, 2669
 Pancreatic insufficiency
 disorders associated with, 2423
 treatment for, 2425
 Pancreatic neuroendocrine tumors (pNETs), syndromes associated with, 2433t
 Pancreatic panniculitis, 4131
 Pancreatic pseudocyst formation, 2432
 Pancreatic tumors, 2433
 Pancreatitis, 2426–2431
 acute, 2426–2428
 autoimmune, 2431
 chronic, 2429–2431, 2430f
 CT and MRI appearance of, 2428f
 cystic fibrosis and, 2667, 2677
 with DKA, 3527
 juvenile tropical, 2431
 mumps and, 1971
 Pancuronium, adverse reactions in premature infant, 1045t
 Pancytopenias
 acquired, 3011–3013
 caused by marrow replacement, 3013
 clinical manifestations of, 3012
 complications of, 3013
 differential diagnosis of, 3012
 etiology and epidemiology of, 3011, 3011t–3012t
 laboratory findings of, 3012
 pathology and pathogenesis of, 3012
 prognosis of, 3013
 treatment of, 3012–3013
 inherited bone marrow failure syndromes with, 2999–3010
 Pandemics, 3–4
 public health approach to, 1583–1585
 authorities and partners, 1583
 communication and education, 1584–1585
 mitigation/prevention, 1583
 preparedness, 1584
 recovery, 1584
 response, 1584
 Panencephalitis, subacute sclerosing, 1961–1962
 Panic disorder, 246
 core diagnostic features and characteristics of, 252t
 diagnostic criteria for, 249t
 Panner disease, 4264, 4265f, 4304, 4305f
 Panniculitis, 4129–4132
 cold, 4132
 factitial, 4132
 pancreatic, 4131
 post-steroid, 4130
 Panophthalmitis, 3953
 Panoramic radiograph, 2255, 2255f
 PANS. *See* Pediatric acute-onset neuropsychiatric syndrome
Panstrongylus megistus, 2163
 Pansystolic murmurs, 2743
 Panton-Valentine leukocidin, 1694
 Pantothene kinase-associated neurodegeneration, 2966, 3684, 3685f
 Pantothenic acid (vitamin B₅), 456t–457t
 dietary reference intake, 397t–403t
 PaO₂/FiO₂ ratio, 617
 PaO₂/PaCO₂ ratio, 618
 Pap smear, 3346f
 PAPA syndrome (syndrome of pyogenic arthritis with pyoderma gangrenosum and acne), 1523
 Papillary carcinoma, 3422
 Papillary intralymphatic angioendothelioma, 3162
 Papillary necrosis, 3209
 Papillary thyroid carcinoma, 3164
 Papilledema, 3083f, 3552–3553, 3552f, 3965, 3965f
 Papillitis, 3552–3553
 Papillomatosis
 laryngeal, in human papillomaviruses (HPVs), 2055
 juvenile, 2053
 respiratory, recurrent, 2583, 2583f
 Papillon-Lefèvre syndrome, 4119
 Papular acrodermatitis, 4108
 Papular urticaria, 1420, 4171, 4171f
 Papular-purpuric gloves-and-socks syndrome (PPGSS), 1989–1990, 1990f
 Papules, 4027, 4177, 4178f
 Gottron
 in JDM, 1500
 suggestive of rheumatic disease, 1461t
 painless, 1866–1867
 piezogenic, 4372f
 Paraaminosalicylic acid, against *M. tuberculosis*, 1833
 Paracentesis, abdominal, 2509
 Paracentric inversions, 767
 Parachute reflex, 3557f
Paracoccidioides brasiliensis, 1940–1941
 Paracoccidioidomycosis, 1940
 Paradoxical pupil reaction, 3924
 Paradoxical respiration, 579
 Paraesophageal hernia, 1096, 2263
 Paraganglioma syndrome, 3126t
 Paragangliomas, 3166, 3167t
 Paragonimiasis, 2215
Paragonimus westermani, 2215
 Parainfluenza viruses, 2026–2028
 clinical manifestations of, 2026, 2027f
 complications of, 2028
 diagnosis and differential diagnosis of, 2026–2027
 epidemiology of, 2026, 2027f
 etiology of, 2026
 pathogenesis of, 2026
 prevention of, 2028
 prognosis for, 2028
 treatment of, 2027–2028
 Paralysis
 acute flaccid, differential diagnosis of, 1975t–1976t
 pharmacologic, during mechanical ventilation, 628
 vocal cord, 2574–2575
 Paralytic poliomyelitis, 1973–1974
 treatment of, 1977
 with ventilatory insufficiency, 1974
 Paralytic shellfish poisoning, 4444
 Parameatal urethral cyst, 3301
 Paramedics, 536
 Parameningeal focus, CSF findings in, 3759t–3760t
 Paramyotonia, 3838
 Paramyotonia congenita, 3838, 3849t
 Paranasal sinuses obstruction, parainfluenza viruses in, 2028
 Paraneoplastic syndromes, ROHHAD and, 2725
 Parapharyngeal space infection, 2565
 Paraphimosis, 3297–3298, 3298f
 Parasagittal cerebral injury, MRI, 1065f
 Parasitic gastroenteritis, etiologies of, 2359t
 Parasitic infections
 associated with hemophagocytic syndrome, 3173t
 as causes of infectious pneumonia, 2643t
 drugs for, 2126t–2144t
 HIV and, 2093
 maternal, affecting fetus or newborn, 1013t
 principles of antiparasitic therapy, 2125–2145
 Parasomnias
 clinical manifestations of, 210
 epidemiology of, 209–210
 etiology of, 209
 treatment of, 210
 Parasuicidal behavior, suicide and, 264
 Parathyroid gland
 calcitonin, 3433–3434
 parathyroid hormone, 3433
 parathyroid hormone-related peptide, 3433
 Parathyroid gland disorders, 3433–3434
 hypoparathyroidism, 3434–3438
 pseudohypoparathyroidism, 3439–3440
 Parathyroid hormone (PTH), 3433
 insensitivity to, 3435t
 resistance, acrodysostosis with, 3440
 secretion, suppression of neonatal, 3436
 Parathyroid hormone-related peptide, 3433
 Parauethral cyst, 3301, 3301f
 Paravertebral block, in pain management, 694
 Parechoviruses, in viral meningoencephalitis, 3772
 Parenchymal injury, in inhalation injury, 653
 Parenchymal lung disease, 559
 Parenchymal neurocysticercosis, 2218
 Parent training program, 144, 144t
 Parental consent, 51
 Parental permission, 51
 Parental presence during induction (PPI), 665
 Parental psychopathology, 195
 Parental treatment, for HIV prevention, 2113–2115
 Parenteral cephalosporins, 1686t
 Parenteral nutrition
 for chronic diarrhea, 2382
 for high-risk infant, 1044
 Parent-infant attachment
 infant's role
 behavioral states, 149
 interactional abilities, 149
 modulation of arousal, 149
 mutual regulation, 149–151
 physical examination, 149
 parental role
 peripartum and postpartum influences, 149
 prenatal factors, 148–149, 148t
 Parent-infant bonding, 1007–1008
 Parenting
 in child behavioral problems, 143
 in child temperament, 143
 definition of, 143
 discipline/punishment in, 145, 145t
 importance of, 142
 as intervention, 143–144
 interventions, psychotherapy, 233
 positive, support and, 142–143
 role of family in, 142–143
 role of pediatrician and, 144–145
 styles, 143
 Parents
 death of, 196–197
 psychologic changes in, 146–147
 role in parent-infant attachment, prenatal factors, 148–149, 148t
 in self-injurious behavior, 284
 Pareto chart, 38, 38f
 Parinaud oculoglandular syndrome, 1813, 3942, 3942f
 Parinaud syndrome, 3117–3118, 3930
 Paris Agreement, 4409
 Parkes-Weber syndrome, 3160, 4052, 4053f
 Parkinsonism, infantile, 844
 Parkland formula, for burns, 650–651

- Paronychia, candidal, 4166
 Paronychial inflammation, 4146–4147, 4147f
 Paronychial tumors, 4147
 Parosteal osteosarcoma, 3141
 Parotid gland, mumps infection, 1970f
 Parotitis, 2254
 Paroxysmal cold hemoglobinuria, 2995
 Paroxysmal dyskinesias, 3684–3685
 exercise-induced, 3684–3685
 kinesigenic, 3684–3685
 nonkinesigenic, 3684–3685
 primary and secondary, 3687t
 that mimic seizures, 3635–3636, 3636t
 Paroxysmal extreme pain disorder (PEPD), 3889–3890
 Paroxysmal hypercyanotic attacks, 2801
 Paroxysmal movement, that mimic seizures, 3635–3637
 Paroxysmal nocturnal hemoglobinuria (PNH), 1318, 1320, 2964–2965
 acquired pancytopenias and, 3011
 classification of, 2965t
 clinical manifestations of, 2964
 complement-mediated lysis in, 2964f
 etiology of, 2964, 2964f
 laboratory findings of, 2964
 suggested criteria for, 2965t
 treatment of, 1323, 2964–2965, 2966f
 Paroxysmal nonkinesigenic dyskinesia (PNKD), 3677
 Paroxysmal stage of pertussis, 1762
 Paroxysmal sympathetic hyperactivity, 4388
 Paroxysmal tonic upgaze of childhood, 3637
 Paroxysmal vertigo, 4020–4021
 Paroxysms, that mimic seizures, 3631–3633, 3631t
 PARPV. *See* Polyalanine repeat expansion pathogenic variant
 Parrot fever, 1897
 Parry-Romberg syndrome, 1508t, 4121–4122
 Pars interarticularis fracture, 4328–4329
 Pars planitis, 3954
 Partial androgen insensitivity syndrome (PAIS), 3508t, 3512f, 3513
 Partial fetal alcohol syndrome (pFAS), diagnostic criteria for, 1139t
 Partial lipodystrophy, 3194, 4133
 Partial pressure of carbon dioxide (PCO_2), reference intervals, 4472.e9t
 Partial pressure of oxygen in inspired gas (PiO_2), 2513
 Partial rebreather masks, 618
 Partial small bowel obstruction, 2317
 Partial thromboplastin time (PTT), 3029, 3046
 in hemostasis, 3025–3026
 Parulis, 2253
 Parvovirus B19
 arthropathy, 1989
 clinical manifestations of, 1988–1990, 1988t
 complications of, 1991
 cutaneous manifestations of, 1989–1990, 1989f
 diagnosis of, 1990, 1990f
 differential diagnosis of, 1991
 epidemiology of, 1987
 erythema infectiosum (fifth disease), 1988–1989, 1988f–1989f
 fetal infection, 1989
 in immunocompromised persons, 1989
 myocarditis, 1989
 pathogenesis of, 1987–1988
 prevention of, 1991
 red cell aplasia with, 2934–2935
 transient aplastic crisis, 1989
 treatment of, 1991
 Parvoviruses, 1987–1991
 clinical manifestations of, 1988–1990
 complications of, 1991
 diagnosis of, 1990
 differential diagnosis of, 1991
 epidemiology of, 1987
 etiology of, 1987
 pathogenesis of, 1987–1988
 prevention of, 1991
 treatment of, 1991
 Pasireotide, for Cushing syndrome, 3477
 Passive immunoprophylaxis
 for cytomegalovirus (CMV), 2015
 for respiratory syncytial virus (RSV), 2031
 Passive rewarming measures, 643
 Passive tone, in neuromuscular system, 3791
 Past medical history, in acutely ill child, 550
 Pastes, 4039
 Pastia lines, in streptococcal pharyngitis, 2559
 Patau syndrome, 766t
 Patch, 4027
 hormonal contraceptive, 1218t–1219t, 1224, 1225f
 Patch testing, 1456
 Patellar apprehension test, 4228–4229
 Patellar dislocation, 4309
 Patellar stabilizing brace, 4229–4230
 Patellar tendinitis, 4310
 Patellar tilt test, 4228
 Patellofemoral instability, 4228–4230, 4229f
 Patellofemoral pain syndrome, 4228, 4310, 4331
 Patellofemoral stress, 4331
 Patent airway, 552–554
 Patent ductus arteriosus (PDA), 997, 2784–2786, 2840
 clinical manifestations of, 2785
 diagnosis of, 2785–2786
 pathophysiology of, 2785
 prognosis and complications of, 2786
 with RDS, 1082–1083, 1082t, 1083f
 relative frequency of, 2763t
 treatment of, 2786
 Patent foramen ovale, 2776
 Patent urachus, 3287, 3287f
 Pathogen-associated molecular patterns (PAMPs), 1315
 Pathogenic fungi, other, 1947–1949
 Pathogenic gene variant, 3078t
 Pathologic fractures, spinal cord injury and, 4391–4393
 Pathologic GERD, in infant, 2264
 Pathologic gynecomastia, 3495
 Pathologic myopia, 3914
 Pathologic startles, 3635
 Patient and family-centered medical home (PFCMH), 7
 Patient education
 for asthma, 1396
 for vasovagal syncope, 596t
 Patient Health Questionnaire-9 (PHQ-9), 218t
 Patient Protection and Affordable Care Act (ACA), 36, 1166
 Patient-Centered Outcomes Research Institute (PCORI), 36
 Patient-controlled analgesia (PCA), 684–685, 688f
 Patients with indwelling medical devices, in infection prevention and control, 1620
 Patient-ventilator asynchrony, 627
 Patrick test, 4306–4307
 Pattern recognition molecules (PRMs), 1320
 Pattern-recognition receptors, 1373
 Paucibacillary leprosy, 1859t
 Pauci-immune vasculitis, 1561–1562
 Pavlik harness, 4235, 4236f
 Paxlovid, 1956–1957
 PBS-RUBACE Severity Scoring Rubric, 3284t
 PCA-by-proxy (PCA-P), 684–685, 688t
 PCAS. *See* Post-cardiac arrest syndrome
 PCLs. *See* Posterior cruciate ligament
 PCR. *See* Polymerase chain reaction
 PCV13 conjugate vaccine, for pneumococcal meningitis, 3772
 PDA. *See* Patent ductus arteriosus
 PDL. *See* Periodontal ligament
 Peak admittance, 3991
 Peak expiratory flow (PEF), 2521
 monitoring, in asthma, 1391t, 1392
 Peak height velocity (PHV), 1160–1161
 Peak inspiratory pressure, 628
 Peanut allergy, 1434–1435
 Pearson syndrome, 1309t, 2424, 2933, 2933f, 2950–2952, 3010
 caused by pathogenic variants in mtDNA, 743t
 liver and, 2485
 Pectus carinatum, 2713–2714, 2714f
 Pectus excavatum, 2713, 2714f
 Pedestrian injuries, 97–98
 death rate, 92t
 Pediatric acute respiratory distress syndrome (PARDS), definition of, 616t
 Pediatric acute-onset neuropsychiatric syndrome (PANS)
 diagnostic criteria for, 254t
 special considerations for, 253–254
 Pediatric Advanced Life Support (PALS), 548, 552, 565, 566f
 Pediatric Appendicitis Score (PAS), 2399, 2399t
 Pediatric autoimmune neuropsychiatric disorders associated with *Streptococcus pyogenes* (PANDAS), 1710
 Pediatric cardiorespiratory emergencies and resuscitation, 552–570
 arrhythmias in, 560–563
 assessment and evaluation of, 552–557
 cardiac arrest and cardiopulmonary resuscitation in, 564–568
 general assessment of, 552, 553f–554f
 nonvascular emergency procedures in, 570
 primary assessment of, 552–556, 555f
 airway and breathing, 552–554, 555f
 circulation, 555
 disability, 555–556, 555t–556t, 556f
 exposure, 556
 procedures in, 569–570
 respiratory distress and failure in, 557–560
 secondary assessment of, 556
 tertiary assessment of, 556–557
 Pediatric Clinical Feature Scale (PCFS), 4388t
 Pediatric clinician, in pediatric palliative care, 63
 Pediatric Diagnosis Likelihood Tool (PDLT), 4389t
 Pediatric early warning scores (PEWS), 45
 Pediatric emergency medicine (PEM), 540
 Pediatric ethics committees, 53
 Pediatric evaluation, of communication disorders, 332–333
 Pediatric heart transplantation, 2902–2905
 acute graft rejection, diagnosis and management of, 2903–2904
 complications of immunosuppression, 2904–2905
 indications for, 2902
 perioperative management for, 2903
 recipient and donor selection for, 2902–2903
 survival after, 2902f
 Pediatric kit, for emergency medical services, 535
 Pediatric palliative care, 58–71, 59f
 advance care planning in, 60–61
 communication and anticipatory guidance in, 61–71
 conditions appropriate for, 59t
 goals of, decision-making and, 58–60, 60f, 60t
 settings of, 61
 Pediatric patients
 neutropenia in, 1117
 platelet count abnormalities in, 1116–1117
 Pediatric PSH-AM, 4389t
 Pediatric renal tumors, 3135
 Pediatric Resuscitation Quality Collaborative (pediRES-Q), 45
 Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), 1381
 Pediatric Risk of Admission II (PRISA II), 543, 543t
 Pediatric Symptom Checklist (PSC), 218t, 3291–3292
 Pediatric transport medicine, 540
 Pediatrician
 role of
 chemical pollutants and, 4427, 4428t
 in childcare, 193–195
 in domestic and international adoption, 72–75
 in evaluation for FASD, 1139
 in grief, 199t, 200
 parenting and, 144–145
 support of newborn development
 assessing parent-infant interactions, 151
 optimal practices, 151
 teaching about individual competencies, 151
 Pediatrics
 national organizations, involved in quality improvement, 41t
 overview of, 1–7
 Pediatric-specific emergency centers, in developing world, 546
 Pediculosis, 4175–4177, 4176f–4177f, 4176t
 Pediculosis capitis, 1623t–1625t, 4175
 Pediculosis corporis, 4175

- Pediculosis pubis, 4176f, 4177
 Pedigree notation
 assisted reproductive technology symbols, 738f
 autosomal dominant pedigree, 739f
 autosomal recessive pedigree, 740f
 common symbols, 736f
 demonstrating X-linked dominant inheritance, 741f
 demonstrating X-linked recessive inheritance, 740f
 digenic pedigree, 742f
 family history and, 735
 imprinting, 776f
 of mitochondrial disorder, 742f
 of myotonic dystrophy, illustrating anticipation, 747f
 pedigree line definitions, 737f
 pseudodominant inheritance, 740f
 symbols of genetic evaluation and testing information, 739f
 of X-linked dominant disorder with male lethality, 741f
 Peer bullying, 101
 Peer group, 1162
 Peer pressure, 1162
 Peer relationship, in adolescents, 1169–1170
 PEF. *See* Peak expiratory flow
 Pegaspargase, indications and adverse reactions of, 3089t–3090t
 Peginterferon- α_2 , for hepatitis B, 2467
 Pegvisomant, 3379
 Pelizaeus-Merzbacher disease (PMD), 3717
 Pelkan spur, 468
 Pellagra, 461, 4191
 Pellagra-like syndrome, in Hartnup syndrome, 4098
 Pelvic actinomycosis, 1734
 Pelvic examination, 3319–3320, 3319t
 in adolescents, 1170
 in adolescents with special needs, 3355
 Pelvic inflammatory disease (PID), 1242–1243, 1246t
 tuboovarian abscess and, 3341–3342
 Pelvic trauma, secondary survey for, 577
 Pelvis
 musculoskeletal pain syndrome, 1568f
 sports-related injuries, 4307–4308
 tumors, in children, 3133t
 Pembrolizumab, 3109
 Pemphigus, 4084–4086
 Pemphigus foliaceus, 4085, 4085f
 Pemphigus vulgaris, 4085
 Penciclovir, 1954
 Pendred syndrome, 3403, 3987t
 Penetrance, 801
 Penetrating disease, 2317
 Penetrating wounds, of orbit, 3979
 D-Penicillamine, 4435
 for arsenic and mercury intoxication, 4435
 Penicillamine, for Wilson disease, 2458–2459
 Penicillin, 1674
 adverse reactions to, 1685t–1686t
 allergy, 1456–1457, 1457t
 allergy, assessing, 1691t
 for dental infections, 2247–2248
 enterococci resistance, 1722t–1723t
 for osteomyelitis, 4289
 prophylactic, for sickle cell anemia, 2976
 for rat bite fever, 4461
 Penicillin G, 1675t–1685t
 benzathine, 1675t–1685t
 procaine, 1675t–1685t
 Penicillin V, 1675t–1685t
 Penicillin V potassium, for bite wound, 4459t
 Penile injury, 3310–3311
 Penis
 circumcision, 3298
 disorders
 chordée without hypospadias, 3297
 inconspicuous, 3298
 meatal stenosis, 3300–3301
 micropenis, 3298–3300
 other, 3300
 phimosis and paraphimosis, 3297–3298
 priapism, 3300
 in sickle cell anemia, 2971
 torsion, 3298
 trapped, 3298, 3300f
 sexual maturity rating in, 1160t
 Pennyroyal (squawmint oil), 2492t
 Penoscrotal hypospadias with chordée, 3297f
 Penoscrotal transposition, 3296
 Pentamidine isethionate, for human African trypanosomiasis, 2162–2163
 Pentazocine, equianalgesic doses of, 685t
 Pentobarbital, 671
 infusion, for traumatic brain injury, 586–588
 Pentose metabolism, defects in, 900t–901t, 919–920
 essential pentosuria, 919–920
 ribose-5-phosphate isomerase deficiency, 920
 transaldolase deficiency, 920
 PEPD. *See* Paroxysmal extreme pain disorder
 Pepper syndrome, 3126t
 Peppermint, 56t
 Pepsin, detection of, in tracheal fluid, 2266
 Pepsinogen, 2277
 Peptic ulcer disease, in children, 2305–2308, 2305t
 clinical manifestations of, 2305
 diagnosis of, 2305
 idiopathic ulcers in, 2306
 pathogenesis of, 2305–2308
 acid secretion, 2305
 mucosal defense, 2305
 primary ulcers of, 2306
 Helicobacter pylori gastritis, 2306, 2306f, 2307t
 secondary ulcers of, 2306
 stress ulceration in, 2306
 treatment for, 2306–2308, 2307t, 2308f
 Zollinger-Ellison syndrome and, 2308
 Peptide absorption, disorders of, 2349–2350
Pectostreptococcus, 1828
 Per- and poly-fluoroalkyl substances (PFAS), 4425
 Peramivir, 1956
 for influenza, 2024t
 Perampanel
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Percentile, 142, 142f
 Perceptual processes, and elementary school success, 170t
 Perchlorate, as goitrogen, 3415t
 Percutaneous umbilical blood sampling, 1124
 Perennial allergens, 1374
 Perennial allergic conjunctivitis (PAC), 1422, 1422t
 Perennial allergy, 1420
 Perforation
 esophageal, 2271–2272
 spontaneous, of augmented bladder, 3290
 Perforin, 1287
 Performance-enhancing aids, 4325, 4325t–4326t
 Perfusion, in shock, 606t
 Perfusion pressure, cerebral, 581
 Perianal abscess, 2317, 2408–2409, 2409f
 Perianal candidiasis, 4166
 Perianal dermatitis, 1707–1708
 Perianal fistula, 2408–2409, 2409f
 Perianal infectious dermatitis, 4155, 4155f
 Perianal pruritus, 2204
 Pericardial disease, in tuberculosis, 1842
 Pericardiocentesis, 570
 for pneumopericardium, 1098
 Pericarditis, 1932–1933
 acute, 2889–2891
 constrictive, 2891
 enteroviral, 1982
 Haemophilus influenzae in, 1758
 infectious, 2890–2891
 noninfectious, 2891
 purulent, 2891
 Pericardium, diseases of, 2889–2891
 acute pericarditis, 2889–2891
 etiology of, 2890t
 Pericentric inversions, 767
 Perichondritis, of external ear, 4002
 Pericystitis, 3937
 Perifollicular zone, 3060
 Perilymphatic fistula, 4021–4022, 4022f
 Perinatal causes, intellectual disability caused by, 349t
 Perinatal disease, in tuberculosis, 1846
 prevention of, 1855
 Perinatal factors, neurodevelopmental dysfunction, 300
 Perinatal infections, 1154–1157
 Campylobacter, 1790
 clinical manifestations of, 1154
 cytomegalovirus (CMV), 2013
 diagnosis of, 1156t, 1157
 general approach to, 1154
 herpes simplex virus (HSV), 1995, 1995f–1996f
 infectious agents in, 1154–1157
 pathogenesis of, 1154
 Perinatal period, 992
 Perinatal stroke, 3746
 Perineal hypospadias, 3297f
 Perinephric abscess, 3267
 Period of PURPLE Crying, 157
 Periodic alternating nystagmus, 3931t
 Periodic fetal heart rate deceleration, 1019f
 Periodic fever, 1640–1641
 Periodic fever syndrome, hyperimmunoglobulinemia D and, 833
 Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA), 1518t, 1529
 Periodic limb movement disorder, 210–211
 Periodic paralysis, 3848–3850, 3850t
 Periodic reevaluation, of child with intellectual disability, 360
 Periodicity schedule, 84–85, 86f–87f
 Periodontal diseases, 2249–2250
 associated with Down syndrome, 367–369
 Periodontal ligament, 2247f, 2250f
 Periodontal structures, injuries to, 2251–2252
 Perioperative agents, adverse reactions to, 1459
 Perioperative care, 664–675
 Perioperative fluids, 533
 Perioral cyanosis, BRUE and, 2541
 Perioral dermatitis, in food allergy, 1445
 Periorbital cellulitis, 2556, 3940t
 Periorbital necrotizing fasciitis, 3974
 Perosteal osteosarcoma, 3141
 Periostitis, in newborn with congenital syphilis, 1868, 1868f
 Peripheral adenopathy, 3081–3082
 Peripheral arterial thrombosis, 3040
 Peripheral blood smear, for hereditary elliptocytosis, 2961
 Peripheral IV infiltrates, 45t
 Peripheral nerves, injury to, during birth, 1068–1069
 Peripheral neuropathies
 chemotherapy drugs associated with, 3893t
 in Guillain-Barré syndrome, 3901t
 medications associated with, 3893t–3894t
 mitochondrial disease and, 935t
 morbidities of perinatal and neonatal illness, 998t
 in tyrosinemia type I, 816
 Peripheral pulmonary stenosis, 2790
 Peripheral retina, 3909
 Peripherally acting calcium blockers, for spasticity, 4394
 Periporitis staphylogenies, 4134
 Peritoneal abscess, 2512
 Peritoneal dialysis
 in acute kidney injury, 3246t, 3252–3253
 catheters, 1670
 in ESRD, 3252
 Peritoneal malformations, 2509
 Peritoneum
 epigastric hernia in, 2512
 peritonitis, 2510–2512
 Peritonitis, 1100–1102, 1700, 2510–2512
 acute primary, 2511
 acute secondary, 2511
 tuberculous, 1845
 Peritonissular cellulitis, and abscess, 2567–2568
 Peritonissular infection, 2565
 Periungual fibroma, 3659f
 in tuberous sclerosis complex, 3659f
 Periungual infections, in immunocompetent patient, 1923
 Periungual warts, 4166–4167, 4167f
 Periventricular leukomalacia (PVL), 1058, 1060f, 1061t, 3689, 3964
 Periventricular nodular heterotopia, 3569
 Perkins line, 4234
 Perlèche, 4147, 4148f
 Perlman syndrome, 3131t–3132t, 3382, 3384t

- Permanent neonatal diabetes (PND), 3515–3516, 3543, 3544f
- Permethrin, 719
- for scabies, 4173–4174
- Permissive hypercapnia, 1081
- Permissive parenting, 143
- Pernicious anemia, 2942
- Pernio, 661f, 662, 4132
- Peroneal muscular atrophy
- axonal type, 3886
 - Charcot-Marie-Tooth disease, 3876–3886, 3877t–3879t
- Peroneal spastic flatfoot, 4206
- Peroxisomal disorders, 865–869, 2451
- atypical autosomal dominant, 868
 - complications of, 869
 - diagnosis of, 868
 - epidemiology of, 866
 - etiology of, 865–866, 866t
 - genetic counseling, 869
 - hepatocellular dysfunction and, 808t
 - inborn errors of metabolism associated with, 809t
 - laboratory findings of, 868, 869t
 - pathogenesis of, 866–868, 866t
 - pathology of, 866
 - treatment of, 869
- Peroxidosomal fatty acid oxidation, isolated defects of, 867
- Perrault syndrome, in XX gonadal dysgenesis, 3499
- Perseverative behaviors, Down syndrome and, 373
- Persistent asthma
- management of, 1399t–1400t
 - risk factors for, 1387t
- Persistent complex bereavement disorder, 197, 198t
- Persistent depressive disorder, 254, 257t
- Persistent diarrhea, 2227, 2355, 2372f, 2376
- Persistent fetal vasculature (PFV), 3957
- Persistent hypoglycemias, 982, 984
- Persistent (chronic) motor or vocal tic disorder (PTD), 241, 242t
- Persistent Müllerian duct syndrome, 3511
- Persistent pulmonary hypertension of newborn (PPHN), 1091–1093, 1092f, 2736
- clinical manifestations of, 1091–1092
 - diagnosis of, 1092–1093
 - etiology of, 1092t
 - pathophysiology of, 1091
 - prognosis for, 1093
 - treatment of, 1092f, 1093
- Persistent pupillary membrane, 3924
- Personal decisions, in adolescents, 1169–1170
- Personal flotation device (PFD), 638
- Pertussis, 1623t–1625t, 1761–1765, 2552t
- clinical manifestations of, 1762
 - complications of, 1764
 - diagnosis of, 1762–1763
 - epidemiology of, 1761
 - etiology of, 1761
 - pathogenesis of, 1761–1762
 - prevention of, 1764–1765
 - DTaP vaccines, 1765
 - Tdap vaccines, 1765
 - treatment of, 1763–1764, 1763t
 - adjunct therapies, 1763
 - antibiotics, 1763, 1764t
 - care of close contacts, 1763–1764
 - isolation, 1763
- Pes planus, 4313
- Pesticides, 4425–4426
- food-borne noninfectious illnesses and, 2362t–2364t
 - poisoning, 4411t–4413t
- PET. See Positron emission tomography
- Pet therapy, in pain management, 693
- Petechia, 4027
- in HIDS, 1525f
 - in SLE, 1497t
 - in streptococcal pharyngitis, 2559
- Petechial rash
- in parvovirus B19, 1989f
 - treatment algorithm for, 1744f
- Peters anomaly, 3944–3945, 3945f
- Peters plus syndrome, 2764t–2766t, 3944
- Peutz-Jeghers syndrome, 2411–2413, 2412f–2413f, 3502, 4067
- PEWS. *See* Pediatric early warning scores
- Peyer patches, reexposed to *Salmonella typhi*, 1773f
- Pfaundler-Hurler syndrome, 940t
- Pfeiffer syndrome, 794t–795t
- PFV. *See* Persistent fetal vasculature
- PFZ. *See* Perifollicular zone
- PGK. *See* Phosphoglycerate kinase
- PGIs. *See* Paragangliomas
- pH monitoring, for acidic GER episodes, 2257
- PHACE syndrome, 3662, 4056, 4056f, 4057t
- associated with congenital heart disease, 2739t–2740t
- Phaeochromocytosis, 1947–1948
- Phagocyte disorders, 1296–1303
- Chédiak-Higashi syndrome, 1297t–1298t, 1301
 - chronic granulomatous disease, 1297t–1298t
 - classification of, 1302t
 - clinical manifestations of, 1302–1303, 1303f
 - genetic counseling for, 1303
 - genetics and pathogenesis of, 1301–1302, 1302f
 - laboratory findings of, 1303
 - prognosis for, 1303
 - treatment of, 1303
- leukocyte adhesion deficiency, 1297t–1298t, 1299–1301, 1300t
- clinical manifestations of, 1299–1300
 - genetics and pathogenesis of, 1299
 - laboratory findings of, 1300
 - prognosis for, 1301
 - treatment of, 1300
- myeloperoxidase deficiency, 1297t–1298t, 1301
- Phagocytosis, 1315
- Phagosome, 1292
- Phakomata, 3960
- Phakomatosis pigmentovascularis, 4053
- Phalangeal fractures, 4279
- Phallotoxins, 4442
- Pharmaceuticals, in pediatric poisoning, 710–719
- adjuvantive therapies, 711–713
 - analgesics, 710–711, 710t
 - antidepressants, 716–717
 - antipsychotics, 717–719
 - cardiovascular medications, 713–715
 - oral hypoglycemics, 715–716
 - psychiatric medications, 716–719
- Pharmacist-based interventions, 1691t
- Pharmacobezoars, 2304
- Pharmacodynamics, 3606
- Pharmacogenetics, 751–753, 752f–753f, 755f
- Pharmacogenomics, 3606
- for cancer treatment, 3088, 3091f
- Pharmacokinetics, 3604–3606
- age-related differences in, 2437
- Pharmacotherapy
- for asthma, 1398–1400
 - for HAPE, 635
 - for JIA, 1481t
 - for neonatal abstinence syndrome, 1133t
 - for nocturnal enuresis, 3296
 - for RDS, 1081
 - for schizophrenia, 290
- Pharyngeal reflex, chronic recurrent aspiration and, 2608
- Pharyngitis
- acute, 2558–2562
 - chronic group A streptococcus carriers, 2561
 - complications and prognosis, 2562
 - diagnosis of, 2559–2560
 - infectious etiologies, 2558–2559, 2558t
 - prevention, 2562
 - recurrent, 2561–2562
 - treatment of, 2560–2561, 2561t
- in PFAPA, 1529
- Pharyngoconjunctival fever, 2558, 3941
- Pharyngoplasty, 2244
- Pharyngotonsillitis, 2562, 2563f
- Phasic sinus arrhythmia, 2847f
- Phencyclidine (PCP), 1204–1205
- Phenobarbital
- adverse effects of, 3611t
 - adverse reactions in premature infant, 1045t
 - dosages of, 3609t–3610t
 - for neonatal abstinence syndrome, 1133t
 - for neonatal seizures, 3623
- Phenocopy, 801
- Phenol injections, for spasticity, 4394–4396
- Phenotype, 801
- of mitochondrial cytopathies, 2483t
 - for polycystic ovary syndrome, 3335t
- Phentermine, 447
- Phenylalanine, metabolism defects, 813f
- classic phenylketonuria, 812–814
 - hyperphenylalaninemia, 814–815
- Phenylalanine hydroxylase deficiency, 812–814
- Phenylephrine
- for allergic rhinitis, 1384t
 - for shock, 610t
- Phenylephrine HCl, for allergic rhinitis, 1383t
- Phenylketonuria (PKU), 812–814, 1021
- clinical manifestations of, 812
 - diagnosis of, 812
 - maternal, 814
 - treatment of, 813–814
- Phenytoin, 2845t–2846t
- adverse effects of, 3611t
 - dosages of, 3609t–3610t
 - for neonatal seizures, 3623
- Phenytoin-induced gingival overgrowth, 2249–2250
- Pheochromocytoma, 247t–248t, 3166, 3167t, 3479–3480
- clinical manifestations of, 3479–3480
 - differential diagnosis of, 3167t, 3480
 - laboratory findings of, 3480, 3480f–3481f
 - MEN2 and, 3432
 - treatment of, 3480
- Philadelphia chromosome, 3077, 3104
- Philadelphia craniostenosis, 794t–795t
- Phimosis, 3297–3298
- Phlebotomy
- for porphyria cutanea tarda, 974–975
 - for thrombosis, 2997
- Phlyctenules, 3945
- Phobia, 305
- social, diagnostic criteria for, 248t
 - specific, 246, 254
 - core diagnostic features and characteristics of, 252t
 - diagnostic criteria for, 248t
- Phonemes, 324
- Phonemic awareness, 317
- Phonologic deficit, 317
- Phonologic disorders, 331
- Phonologic processes, definition of, 325t, 331
- Phonology, 301
- development of, 325t
- Phonophobia, migraine with, 3643
- Phorias, 3925
- Phosgene, poisoning, 4448–4449, 4454t
- Phosphatase, reference intervals, 4472.e9t
- Phosphatase and tensin homolog hamartoma tumor syndromes, 2413
- Phosphate
- homeostasis, 4378
 - tubular reabsorption of, 3233
 - urinary, 512
- Phosphate binders, 3250
- Phosphatonins, 4378
- Phosphodiesterase inhibitors
- for atopic dermatitis, 1414
 - for heart failure, 2899–2900
- Phosphoenolpyruvate carboxykinase (PEPCK) disease, 900t–901t, 915
- Phosphofructokinase deficiency, 2989–2990
- Phosphoglucomutase-1 deficiency, 929
- 3-Phosphoglycerate dehydrogenase deficiency, 841
- Phosphoglycerate kinase (PGK), 2990
- Phosphoglycerate kinase deficiency, 900t–901t
- Phosphoglycerate mutase deficiency, 900t–901t
- Phosphomannomutase-2 deficiency, 925
- clinical manifestations of, 923f, 925, 925f
 - diagnosis of, 925–926
 - pathophysiology, 925
 - treatment of, 926
- Phosphoribosylpyrophosphate (PRPP) synthetase hyperactivity, 945t
- Phosphorus
- conversion factor, 503t
 - deficiency, rickets caused by, 477–478

- Phosphorus (Continued)**
 excretion, 506
 hyperphosphatemia, 508–509
 hypophosphatemia, 506–508
 metabolism, 505–506
 reference intervals, 4472.e9t
 serum, 505t
- Phosphorylase kinase deficiency**, 900t–901t, 905
PHKA2 variant, 900t–901t, 905
PHKB variant, 900t–901t, 905
PHKG2 variant, 900t–901t, 905–906
- Phosphoserine aminotransferase deficiency**, 841
- Photic stimulation**, in reflex seizures, 3629
- Photoallergic reactions**, 4093
- Photoparoxysmal epilepsy**, 3601
- Photophobia**, 3969
 migraine with, 3643
- Photopsia**, 3643
- Photosensitive seizures**, 3629
- Photosensitivity**, 4093–4098, 4093t
 actinic prurigo, 4096, 4097f
 acute sunburn reaction, 4093, 4094f, 4094t
 Bloom syndrome, 4098
 Cockayne syndrome, 4096–4097
 colloid milium, 4095
 Hartnup disease, 4098
 hydrea vacciniforme, 4095–4096
 polymorphous light eruption, 4096
 porphyrias, 4094–4095, 4095f–4096f
 reactions, 4093–4094, 4094t, 4095f
 Rothmund-Thomson syndrome, 4097, 4098f
 solar urticaria, 4096, 4096f
 xeroderma pigmentosum, 4097, 4097f
- Phototherapy**
 for atopic dermatitis, 1416
 for glucuronidyl transferase deficiency, 2456
 for hyperbilirubinemia, 1114–1115
 for psoriasis, 4100
- Phototoxic reactions**, 4093–4094
- PHOX2B gene**, 2719
- Phrenic nerve paralysis**, 1069
- Phthalates**, 4423
- Phthirusiasis palpebrarum**, 4176t
- PHV. See Peak height velocity**
- Phyllodes tumor**, 3332
- Phylloquinone**, 481
- Physeal fractures**, 4280–4281
- Physeal injuries**, 4299
- Physes**, 4193, 4276
- Physical abuse**, 114
- Physical activity**, 438
 for children with disabilities, 4406–4407, 4406t
- Physical concomitants**, 334
- Physical counterpressure maneuvers**, for vasovagal syncope, 596t
- Physical development**
 adolescent, 1158–1163
 age 0–2 months, 152–153
 age 2–6 months, 152f, 153–154, 153t, 155f
 age 6–12 months, 152f, 153t, 155f, 156
 age 12–18 months, 158
 age 18–24 months, 158
 middle childhood, 167, 168f
- Physical examination**
 of acutely ill child, 550–551
 for ADHD, 312–313
 of adolescent, 1170
 for appendicitis, 2398–2399
 in cancer, 3081–3084, 3083f
 cardiac, 2737–2746
 diagnostic approach to respiratory disease, 251s
 for facial anomalies, 784, 785f
 general, 2737–2740
 gynecologic, 3317–3320
 adolescents, 3319
 in infants and prepubertal girls, 3317–3319
 in neonates, 3317
 of hematuria, 3184
 in hemophagocytic lymphohistiocytosis, 3176
 in hemostasis, 3025
 of newborn, 149, 1000–1004
 for physical abuse and neglect, 119–120
 of rape victims, 1236
- Physical maturity**, 1043f
- Physical punishment**, in preschoolers, 167
- Physical therapy**
 for CRPS, 1571
 for Down syndrome, 371
 for Ehlers-Danlos syndrome, 4374
 for osteomyelitis, 4291
 in pain management, 693
- Physician orders for life treatment (POLST)**, 61
- Physician-patient relationship**, in adolescents, 1169
- Physiologic anemia**, of infancy, 2939
- Physiologic buffers**, 510
- Physiologic leukorrhea**, 3323
- Physiologic myoclonus**, 3679
- Physiologic studies**, SIDS and, 2537–2538
- Physiologic therapies**, 756–757
- Physiologic tremor**, enhanced, 3678
- Physiotherapy**, for nontuberculous mycobacteria infection, 1865
- Phytobezoars**, 2304
- Phytophotodermatitis**, 4093–4094, 4095f
- PI3K-related syndromes**, 3384t
- Piaget's cognitive theory**, 140t
- Piaget's preoperational stage**, 165
- Pica**, 241
 in blood lead testing, 4438
- Picaridin**, 2181
- Picobirnaviruses**, 2051
- PIE. See Pulmonary interstitial emphysema**
- Piebaldism**, 820, 4070t–4071t, 4072, 4073f
- Pierre Robin syndrome**, 779, 1053t, 2245, 2245f, 4341
- Pierson syndrome**, 3232
- PIEZ01 gene**, in hereditary xerocytosis, 2961
- Piezogenital papules**, 4372f
- PIGA deficiency**, 928
- Pigment gallstones**, 2502–2503
- Pigmented hamartomas**, of iris, 3655f
- Pigmented villonodular synovitis (PVNS)**, 1582
- Pigtail**, chest tube, 2655f
- PIK3CA-related overgrowth spectrum (PROS)**, 3158, 3158t, 4053f, 4054t
- Pilar cyst**, 4185, 4186f
- Pili annulati**, 4141
- Pili torti**, 3719, 4140–4141
- Pill esophagitis**, 2271, 2271f, 2271t
- Pills**, progestin-only, 1218t–1219t, 1222
- Pilocarpine test**, 3921
- Pilocytic astrocytoma**, 3119f–3120f
- Pilomatricoma**, 4185, 4186f
- Pilomatricoma**, 4185
- Pilomyxoid astrocytoma**, 3120
- Pilonidal sinus and abscess**, 4044
- Pineal parenchymal tumors**, 3124
- Pinguicula**, 3942, 3942f
- Pinhole effect**, 3914
- Pinkeye**, in exclusion or inclusion in daycare, 187t–192t
- Pinna malformations**, 3995–3996, 3996f
- Pinpoint papular polymorphous light eruption**, 4096
- Pinta (*Treponema carateum*)**, 1877
- Pinworm infection**, 2204
 drugs for, 2126t–2144t
 vulvovaginal, 3322t, 3325
- Pioglitazone**, for nonalcoholic steatohepatitis, 2482t
- Pioglitazone**, for T2DM, 3542t
- Piperacillin**, 1675t–1685t
- Piperacillin-tazobactam**, 1675t–1685t
- Piperazine citrate**, for ascariasis, 2199
- PIRDs. See Primary immune dysregulatory diseases**
- Piriform sinus fistula**, 3411
- Pit vipers**, 4467f, 4469t
- Pitch count**, 4327
- Pits**, preauricular, 4044
- Pitted erythrocytes**, detection of, 3064f, 3064t
- Pitted keratolysis**, 4157, 4157f
- Pitt-Hopkins syndrome**, 3899t
- Pituitary adenoma**, 3475
- Pituitary dysfunction**, in Langerhans cell histiocytosis, 3170
- Pituitary gland**
 anatomy of, 3359
 anterior pituitary cell types, 3359–3361
 disorders
 corticotropinoma, 3381
- Pituitary gland (Continued)**
 excess growth hormone secretion and pituitary gigantism, 3378–3379
 hyperpituitarism, 3378–3384
 hyponatremia, 3375–3376
 hypopituitarism, 3364–3371
 overgrowth syndromes, 3381, 3382f, 3383t–3384t
 prolactinoma, 3380–3381
 tall stature, 3378
 embryology of, 3359
 hormones, 3361t
 hypersecretion of, 3380–3381, 3380f
 primary hypersecretion of, 3378
 hypothalamic-pituitary-gonadal axis, 3363f
 hypothalamic-pituitary-growth hormone axis, 3362f
 hypothalamic-pituitary-thyroid axis, 3359f–3360f
 posterior pituitary cell types, 3361–3363
 vascular supply of, 3359
- Pituitary hormone deficiencies**, hypogonadotropic hypogonadism associated with, 3493
- Pityriasis alba**, 4090–4091, 4091f
- Pityriasis lichenoides**, 4102–4103, 4103f
- Pityriasis lichenoides et varioliformis acuta (PLEVA)**, 1582, 1582f, 4103, 4103f
- Pityriasis rosea**, 4104, 4104f
- Pityriasis rubra pilaris**, 4104–4105, 4105f
- Pivot shift test**, 4230
- PJS. See Peutz-Jeghers syndrome**
- PKWS. See Parkes-Weber syndrome**
- Placement instability**, 75
- Placenta**, surgery, indications and rationales, 1029t
- Placental abruption**, in delivery room, 1072
- Plagiocephaly**, 784t
- Plague (*Yersinia pestis*)**, 1794–1795, 4449, 4452t
 clinical manifestations of, 1794–1795
 diagnosis of, 1795
 differential diagnosis of, 1795
 epidemiology of, 1794
 etiology of, 1794
 pathogenesis of, 1794
 prevention of, 1795
 treatment of, 1795
- Plain radiographs**
 for appendicitis, 2399–2400, 2400f
 for orthopedic evaluation, 4200
 for osteomyelitis, 4286
 of septic arthritis, 4292
- Plan-do-study-act (PDSA) cycle**, 15, 37, 37f
- Plant thorn synovitis**, 1582
- Plantar fasciitis**, 4313, 4331
- Plantar response**, in neurologic evaluation, 3556
- Plantar warts**, 4166–4167, 4167f
- Plaque morphea**, 1508t
- Plaque psoriasis**, 4098
- Plaques**, 4027
 papulosquamous, in infants with syphilis, 1868f
- Plasma**, cations and anions, 486f
- Plasma lipoprotein metabolism**, and transport, 872–874
- Plasma membrane**
 carnitine transport defect, 864
 transporters, disorders of, 2449–2450
- Plasma transfusions**, 3019, 3019t
 in children, 3019
 in neonates, 3019
 products and patient testing, 3019
- Plasma volume**, decreased effective, 3375
- Plasmalogen synthesis**, isolated defects of, 868
- Plasmapheresis**, for thrombotic thrombocytopenic purpura, 3055
- Plasminogen activator inhibitor deficiency**, 3034
- Plasmodium**, 2168–2169
- Plasmodium falciparum**, 2169, 2175, 2176t
- Plasmodium knowlesi**, 2169, 2175, 2178t
- Plasmodium malariae**, 2169, 2175, 2178t
- Plasmodium ovale**, 2169, 2175, 2177t–2178t
- Plasmodium vivax**, 2169, 2175, 2177t–2178t
- Plastic bronchitis**, 2589–2590, 2589f, 2589t
- Plastic composite**, for dental caries, 2247
- Plastic deformation**, 4277, 4277f–4278f
- Plateau pressure (P_{plat})**, 628, 629f
- Platelet adhesion**, 3049
 defects in, 3051t–3052t

- Platelet aggregation, 3027
 defects of, 3051t–3052t
 in megakaryopoiesis, 3049
- Platelet count, 2923f, 3025
 abnormalities, in pediatric patients, 1116–1117
 reference intervals, 4472.e9t
- Platelet cytoskeletal defects, 3051t–3052t
- Platelet disorders, 3049–3060
 acquired disorders of platelet function and, 3058–3059
 congenital abnormalities of platelet function and, 3051t–3052t, 3059–3060, 3059t
 congenital thrombocytopenic syndromes and, 3051t–3052t, 3057f–3058t
 drug-induced thrombocytopenia and, 3055
 function disorders, 3058
 hemolytic-uremic syndrome and, 3055
 immune thrombocytopenia in, 3049–3055
 inherited, 3051t–3052t
 Kasabach-Merritt syndrome and, 3055
 megakaryopoiesis in, 3049, 3049f
 neonatal thrombocytopenia and, 3053t, 3057
 nonimmunologic platelet destruction and, 3055
 sequestration and, 3056
 thrombocytopenia from acquired disorders and, 3058
 thrombocytopenia in, 3049, 3050t–3053t, 3053f
 thrombotic thrombocytopenic purpura and, 3055, 3056f, 3056t
- Platelet function disorders, 3058
- Platelet granules defects, 3051t–3052t
- Platelet transfusions, 3016–3017
 in children and adolescents, 3016, 3016t
 in infants and neonates, 3016–3017, 3016t
 products and dosing, 3017
- Platyspondyl dysplasia, Torrance type, 4340
- Play, in preschool years, 165–166
- Play audiometry, 3990
- PLCG2-associated antibody deficiency and immune dysregulation (PLAID), 663
- PLE. *See* Protein-losing enteropathy
- PLEKHM1-related autosomal recessive osteopetrosis, 4351t
- Pleomorphic autoimmunity, 1257, 1261t
- Pleomorphic type, of rhabdomyosarcoma, 3136
- Plesiomonas shigelloides*, 1797–1798
 clinical manifestations of, 1798
 diagnosis of, 1798
 epidemiology of, 1797–1798
 etiology of, 1797
 pathogenesis of, 1798
 treatment of, 1798
- Pleural effusion, 2654–2657
 in eosinophilic pneumonia, 2627f
 in tuberculosis, 1841–1842, 1842f
- Pleural fluid, differentiation of, 2649t
- Pleurisy, 2654–2657
- Pleuropulmonary blastoma (PPB), 2600–2601
- PLEVA. *See* Pityriasis lichenoides et varioliformis acuta
- Plumb line, 4242
- Pluripotential stem cells, 1290
- PMAD. *See* Postpartum mood and anxiety disorder
- PMBCL. *See* Primary mediastinal B-cell lymphoma
- PMH. *See* Pseudomyogenic hemangioendothelioma
- PND. *See* Permanent neonatal diabetes
- Pneumatoceles, 1697f, 2660
- Pneumococcal conjugate vaccine (13 valent) (PCV13), 1588t–1589t, 1602, 1604–1605, 1704t
- Pneumococcal conjugate vaccine (PCV7), 4007–4008
- Pneumococcal pneumonia, 2645f
- Pneumococcal polysaccharide vaccine (23 valent) (PPSV23), 1588t–1589t, 1605, 1705t
- Pneumococcal-induced HUS, 2996
- Pneumococcus, 1701–1705
 vaccine, 30–31t
- Pneumocystis jirovecii*, 1945–1947
 clinical manifestations of, 1946
 complications of, 1947
 diagnosis of, 1946
 epidemiology of, 1945
 etiology of, 1945
 laboratory findings of, 1946, 1946f
 pathogenesis of, 1945–1946
 pathology of, 1946
- Pneumocystis jirovecii* (*Continued*)
 pneumonia, HIV and, 2092–2093, 2111t
 prevention of, 1947
 prognosis for, 1947
 supportive care for, 1947
 treatment of, 1947
- Pneumocystis pneumonia*, HIV in, prophylaxis to prevent, 2111t–2113t
- Pneumomediastinum, 1097–1098, 1098f, 2707–2708
 clinical manifestations of, 2707
 complications of, 2708
 laboratory findings of, 2707, 2708f
 pathogenesis of, 2707
 treatment of, 2707–2708
- Pneumonia, 1800t
 aspiration, 1089, 1090f
 Chlamydia trachomatis, 1896–1897
 community-acquired, 2642–2651
 clinical manifestations of, 2644–2645
 complications of, 2647–2648, 2647f–2648f, 2649t
 diagnosis of, 2645–2646, 2645f–2646f, 2646t
 etiology of, 2642–2648, 2643t–2644t
 pathogenesis of, 2642–2644
 prevention of, 2648
 prognosis for, 2647
 treatment of, 2646–2647
 cryptococcosis and, 1926
 diffuse, treatment of, 1939
 eosinophilic
 acute, 2625–2627, 2626t
 chronic, 2627–2628
 Francisella tularensis, 1805
 Haemophilus influenzae in, 1757
 hypersensitivity, 2612–2615
 antigen sources of, 2613t
 clinical manifestations of, 2612, 2614t
 diagnosis of, 2612–2614, 2614t
 etiology of, 2612
 laboratory for, 2614–2615
 pathogenesis of, 2612–2614
 treatment of, 2615
 infectious, 2643t
 manifestation of blastomycosis, 1935
 measles and, 1961
 neonatal, etiologic agents of, 1145t
 nosocomial, *Pseudomonas aeruginosa* infection, 1800–1801
 Pneumocystis jiroveci, 1945
 recurrent, 2644, 2645f
 Staphylococcus aureus, 1695, 1697f
 Streptococcus pneumoniae, 1702f
 varicella, 2002
 ventilator-associated, 629
- Pneumonic plague, 1794, 4450
- Pneumonitis
 hypersensitivity, 2613t
 radiation and, 4417–4418
- Pneumoperitoneum, 1097–1098
- Pneumothorax, 1097–1098, 1098f, 2703–2706
 causes of, 2704t
 clinical manifestations of, 2704
 cystic fibrosis and, 2675
 in delivery room, 1072
 diagnosis and differential diagnosis of, 2704, 2705f–2707f, 2707t
 etiology and epidemiology of, 2703
 pathogenesis of, 2704
 treatment of, 2704–2706
- PNH. *See* Paroxysmal nocturnal hemoglobinuria
- PNKD. *See* Paroxysmal nonketogenic dyskinesia
- Pocket Book of Hospital Care for Children*, 547
- POCUS. *See* Point-of-care ultrasound
- Podocyte, in nephrotic syndrome, 3223, 3226t, 3227f
- Poikiloderma congenitale, 4097, 4098f
- Point-of-care ultrasound (POCUS), for shock, 605–606
- Poison ivy lesions, 4090f
- Poisoning, 263, 700–725, 701t
 antidotes for, 707t–708t
 ciguatera fish, 4411t–4413t
 compounds in, 710–725
 household products, 719–721
 miscellaneous toxic agents at home, 724–725
 pharmaceuticals, 710–719
- Poisoning (*Continued*)
 plants, 721
 toxic gases, 722–724
 death rates, 91, 92t
 lead, 4436–4441
 assessment tools for, 4439
 clinical effects of, 4437–4438
 clinical symptoms of, 4438
 diagnosis of, 4438–4439, 4439f
 metabolism of, 4436–4437
 public health history of, 4436
 screening for, 4438–4439, 4439t
 sources of exposure in, 4436, 4437t
 treatment for, 4440–4441, 4441t
- management principles, 706–709
 decontamination, 706–709
 directed therapy, 709
 enhanced elimination, 709
 supportive care, 706
- patient approach to, 701–705, 702t–704t
 additional diagnostic testing, 705, 706t
 history, 701
 laboratory evaluation, 704–705
 past medical and developmental, 701
 physical examination, 704
 social, 701
 symptoms, 701
 prevention of, 700
- Poland syndrome, breast hypoplasia secondary, 3329, 3329f
- Poliomyelitis, Alpers hepatopathetic, 2484
- Polioencephalitis, 1973–1974
- Poliomyelitis
 abortive, 1972
 treatment of, 1977
 in differential diagnosis of cases of paralysis, 1974
 nonparalytic, 1972–1973
 treatment of, 1977
 paralytic, 1973–1974
 treatment of, 1977
 with ventilatory insufficiency, 1974
 vaccine (inactivated, enhanced potency), 1588t–1589t, 1602
- Polioviruses, 1972–1979
 abortive poliomyelitis, 1972
 treatment of, 1977
 clinical manifestations of, 1972–1974
 complications of, 1977
 diagnosis of, 1974
 differential diagnosis of, 1974, 1975t–1976t
 epidemiology of, 1972
 etiology of, 1972
 nonparalytic poliomyelitis, 1972–1973
 treatment of, 1977
 paralytic poliomyelitis, 1973–1974
 treatment of, 1977
 with ventilatory insufficiency, 1974
- pathogenesis of, 1972
 postpolio syndrome, 1977
 prevention of, 1977–1979, 1978f
 prognosis for, 1977
 transmission of, 1972
 treatment of, 1974–1977
- Pollakiuria, 3295
- Pollens, 1374
- POLST. *See* Physician orders for life treatment
- Polyalanine repeat expansion pathogenic variant (PARPV), 2719
- Polyarteritis, 1555t
- Polyarteritis nodosa (PAN), 1553t, 1560–1561
 clinical manifestations of, 1560, 1560f
 complications of, 1561
 diagnosis of, 1560, 1561f
 differential diagnosis of, 1560, 1561f
 epidemiology of, 1560
 laboratory findings of, 1560
 pathogenesis of, 1560
 pathology of, 1560
 pediatric-onset, 1561t
 prognosis for, 1561
 treatment of, 1561
- Polyarthritis, 1472t–1473t, 1474–1475
 migratory, 1712

- Polybrominated diphenyl ethers, 4423
 Polychlorinated biphenyls (PCBs), 4422
 Polychondritis, relapsing, 1581–1582, 1581t
 Polychromasia, 2991
 Polychromatophilia, 2989
 Polycystic kidney disease, 3255
 autosomal dominant, 2502
 autosomal recessive, 2500–2501
 Polycystic liver disease, autosomal dominant, 2502
 Polycystic ovary syndrome, 3334–3337, 3394
 clinical manifestations of, 3334
 complications and long-term outlook of, 3336, 3336t
 diagnostic criteria for, 3334t
 etiology and definition of, 3334
 laboratory findings, diagnosis, and differential diagnosis of, 3334–3336
 pathology, pathogenesis, and genetics of, 3334, 3335f
 phenotypes for, 3335t
 in T2DM, 3543t
 treatment of, 3336–3337
 Polycythemia, 2754, 2997, 2998f, 2998t
 in infants of diabetic mothers, 1141
 neonatal, 1126
 nonclonal, 2998–2999, 2998t
 Polycythemia vera, 2997, 2998t
 Polydactyly, 4209, 4268, 4268t, 4269f
 Polydipsia
 in diabetes insipidus, 3373
 primary, 3376
 Polyenes, 1916–1917
 Polyester, burn injuries from, 646
 Polygenic autoimmune polyglandular syndrome, 3428–3430
 Polygenic disorders, 728
 Polygenic hypercholesterolemia, 876–877
 Polyglandular syndromes, autoimmune, 3408, 3408t, 3425–3430
 Polyglucosan body myopathy 2, *GYG1* variant, 900t–901t, 908–909
 Polyglucosan disease, 900t–901t, 904
 Polyhydramnios, 1012, 1014t, 2255, 2280
 history of, chronic diarrhea and, 2380
 Polymastia, 3329
 Polymerase chain reaction (PCR)
 in CNS infection, 3758
 for *M. pneumoniae*, 1889
 polyomaviruses and, 2085
 viral, 2463t
 Polymicrogyria, 3569, 3570f, 3571t–3572t
 Polymorphisms, 733, 751, 753f, 754t
 in SIDS, 2535t, 2536
 single-nucleotide, 762, 801
 Polymorphous light eruption, 4096
 Polyneuropathies
 in infancy, in HMSN, 3881t–3883t
 small fiber, 1569, 1570f, 1571t–1572t
 Polynucleotide repeat expansions, diseases with, 745t–746t
 Polyomavirus nephropathy, 3258
 Polyomaviruses, 2084–2086
 Polyostotic fibrous dysplasia, precocious puberty with, 3392, 3393f
 Polypectomy, for hamartomatous tumors, 2411
 Ploidy, 763–766
 Polyposis, 4067
 Polyps
 juvenile, 2411, 2412f
 nasal, 2550
 clinical manifestations of, 2550
 diagnosis and differential diagnosis, 2550
 treatment of, 2550
 Polysaccharide vaccines, pneumococcal capsular, 1704t
 Polysaccharides, 394, 1589, 1589t
 Polysomnogram, overnight, 206
 Polysomnography, long-term mechanical ventilation and, 2729
 Polysplenia syndrome, congenital heart disease, 2739t–2740t
 Polysplenism, congenital, 3061
 Polysyllabic jargoning, 158
 Polythelia, 3329
 Polyunsaturated fatty acids (PUFAs), 389t–390t, 392, 480
- Polyuria, in diabetes insipidus, 3372t, 3373
 Poly-X syndromes, 3490
 Pompe disease, 906–908, 908f, 3851, 3852t
 Pompholyx, 4091, 4092f
 Ponseti method, 4203
 Pontiac fever, 1810–1811
 Pontine tuberculomas, 1844–1845, 1845f
 Pontocerebellar hypoplasia, 951–952
 in brainstem and cerebellar disorders, 3577
 with SMA (PCH1), 3874
 type 2A (PCH-2A), 3677–3678
 Poor neonatal adaptation syndrome (PNAS), 1022
 Popliteal angle, 3554–3555
 Popliteal artery entrapment syndrome, 4311
 Popliteal cysts, 4225–4226
 Popliteal tendinitis, knee pain caused by, 4331
 Population health, 6–7, 15–16
 POR. See Cytochrome P450 oxidoreductase
 Porencephaly, 3581, 3581f
 Pork tapeworm, 2215–2216, 2218
 Porokeratosis, 4107, 4108f
 Porphobilinogen, 963, 966
 Porphobilinogen deaminase, 966
 Porphyria cutanea tarda, 964–965, 965t
 clinical manifestations of, 973–974
 complications of, 974
 diagnosis and differential diagnosis, 974
 epidemiology of, 973
 etiology of, 972
 laboratory findings, 974
 pathology and pathogenesis, 973
 prevention and genetic counseling, 975
 prognosis of, 975
 susceptibility factors, 973
 treatment of, 974–975
 Porphyria variegata, 3899t
 Porphyrias, 963–979
 acute, 969t
 acute intermittent, 964t, 966–970
 δ-aminolevulinic acid dehydratase, 965–966
 classification and diagnosis of, 964–965
 congenital erythropoietic, 970–972
 erythropoietic protoporphyria, 977–979
 heme biosynthetic pathway, 963–964
 hepatoerythropoietic, 975
 hereditary coproporphyria, 975–976
 laboratory diagnostic testing
 first-line, 965
 second-line, 965
 for subclinical porphyria, 965
 porphyria cutanea tarda, 972–975
 symptom-based classifications, 964t
 variegate, 976–977
 Portable medical summary, 1171t
 Portacaval shunting
 in congestive splenomegaly, 3061
 for portal hypertension, 2506
 Portal hypertension, 2504–2506
 causes of, 2504t
 clinical manifestations of, 2505
 diagnosis of, 2505–2506
 etiology of, 2504–2505, 2504f
 liver disease and, 2439
 pathophysiology of, 2505
 prognosis of, 2506
 treatment of, 2506
 Portal hypertensive biliopathy, 2505
 Portal vein thrombosis, 1125, 2504, 3040
 Portopulmonary hypertension, 2442, 2505
 Porto-sinusoidal vascular disease, 2478
 Port-wine stain, 3660f
 associated syndromes, 3660t, 4051t
 Posaconazole, 1917t, 1919–1920
 for mucormycosis, 1944
 for paracoccidioidomycosis, 1941
 Positional clubfoot, 4202
 Positional plagiocephaly, 3584
 Positioning
 for infants, 2266–2267
 of prepubertal girls, for gynecologic examination, 3318f, 3319
 Positive end-expiratory pressure (PEEP), 621f, 627
 in auto-PEEP, 628–629
- Positive parenting
 definition of, 143
 program, 279
 and support, 142–145
 Positive pressure respiratory support, for respiratory distress and failure, 619
 Positive pressure ventilation
 in CCHS, 2723
 in heart failure, 2897
 Positron emission tomography (PET), in neuroradiologic procedures, 3560
 Post neonatal period, 992
 Postadoption medical care, 73–75
 Postanesthesia care unit (PACU), 673–675, 673t
 Postaxial hemimelia, 4217–4218
 Postaxial polydactyly, 784t
 Post-cardiac arrest syndrome (PCAS), 568
 Postcoarctectomy syndrome, 2795
 Postconcussion Symptom Scale, 4316t
 Post-COVID-19 condition, 1579t
 Postenteritis diarrhea syndrome, chronic diarrhea and, 2377
 Posterior auricular lymphadenopathy, 3070t
 Posterior cruciate ligament (PCL) injury, 4308
 Posterior deformational plagioccephaly, 3586, 3586f
 Posterior fossa, dysgenesis of, 3575–3577
 Posterior fossa tumors, of childhood, 3118t
 Posterior hair whorl, 784t
 Posterior impingement syndrome, 4332
 Posterior labial fusion, in female-appearing genitalia, 3506t
 Posterior laryngeal cleft, 2576–2577
 Posterior lenticonus, 3952
 Posterior pituitary cell types, 3361–3363
 oxytocin, 3363
 vasopressin, 3362–3363
 Posterior probability error, 48t
 Posterior reversible encephalopathy syndrome (PRES), 2972, 3700–3701, 3701f
 Posterior urethral valves, 3255, 3282–3284
 Posterior uveitis, 3940t, 3953t
 Posteroemedial tibial bowing, 4216
 Postexertion malaise, 1576–1577
 Postexposure prophylaxis, 1586
 for measles, 1964
 for pertussis, 1764t
 for rabies, 2083–2084, 2084f
 for varicella-zoster virus, 2005
 Postextubation upper airway obstruction, 629
 Posthemorrhagic hydrocephalus, 1060
 Posthemorrhagic ventricular dilation (PHVD), 1058–1059, 1061t
 Posthypcapnic metabolic alkalosis, 521
 Postinfectious arthritis, 1488–1489
 Postinfectious diarrhea, 2342
 Postinflammatory pigmentary changes, 4068
 Postligation cardiac syndrome, PDA and, 1083
 Postmenopausal complications, of polycystic ovary syndrome, 3336t
 Postnatal androgen excess, in 21-hydroxylase deficiency, 3466
 Postnatal causes, intellectual disability caused by, 349t
 Postneonatal vitamin K deficiency, 3046
 Postoperative management, pain, 675
 Postoperative stridor, 673–674
 Postpartum aspiration, 1090–1091
 Postpartum depression, 152–153
 Postpartum mood and anxiety disorder (PMAD), 149
 Postpericardiotomy syndrome (PPS), findings of, 2837t
 Postpolio syndrome, 1977
 Postprandial hyperlipidemia, 873–874
 Postpyloric feedings, for chronic recurrent aspiration, 2611
 Post-receptor forms, of GH insensitivity, 3367–3368
 Postrenal acute kidney injury, 3244
 Postseptal cellulitis, 3940t
 Post-steroid panniculitis, 4130
 Poststreptococcal arthritis, 1489
 Poststreptococcal glomerulonephritis, 2565, 4150
 Poststreptococcal reactive arthritis (PSRA), 1710
 Posttransplant acute limbic encephalitis (PALE), 2018

- Posttransplant diabetes mellitus, kidney transplant immunosuppression and, 3258–3259
- Posttransplant lymphoproliferative disorder (PTLD), 2354, 2508
- Posttraumatic seizure, traumatic brain injury and, 4388
- Posttraumatic stress disorder (PTSD), 108, 246–254, 247
- anxiety disorders and, 248t
 - consequences of injuries, 98–99
 - diagnostic criteria for, 250t–252t
- Posttreatment Lyme disease syndrome, 1884
- Postural kyphosis, 4250
- Postural orthostatic tachycardia syndrome (POTS), 597, 597f–598f
- clinical presentation of, 598
 - comorbidities of, 1574
 - diagnosis of, 598–599
 - management for, 599, 599t
- Postural tachycardia syndrome, 3632
- Postural tremor, 3678
- Postures, that mimic seizures, 3635–3637
- Potassium
- dietary reference intake, 404t–407t
 - hyperkalemia, 496–498
 - hypokalemia, 498–501
 - intracellular, 486
 - metabolism, 495–496
 - reference intervals, 4472.e9t
 - tubular function in homeostasis, 3233
- Potassium channel periodic paralysis, 3840t
- Potassium hydroxide preparation, 4027
- Potassium supplementation, in fluid resuscitation, 651
- Potocki-Lupski syndrome, 768t–769t
- POTS. *See* Postural orthostatic tachycardia syndrome
- Pott disease, 1845, 2567f
- Potter facies, 3261f
- Potter syndrome, 1053t, 3213, 3260–3261
- POU1F1, 3364
- Pouchitis, 2316
- Poverty, food security and, 422
- Powassan encephalitis, 2061–2062
- Powders, 4039
- PPB. *See* Pleuropulmonary blastoma
- PPHN. *See* Persistent pulmonary hypertension of newborn
- PPIs. *See* Proton pump inhibitors
- PPNAD. *See* Primary pigmented nodular adrenocortical disease
- Practical skills, 346
- Practice Enhancement Tool, 102, 103f–105f
- Practitioners, in developing world, 546
- Prader-Willi syndrome, 442, 742–743, 768t–769t, 773–774, 786t
- diagnostic criteria for, 776t
 - imprinting and, 777
 - molecular mechanisms, 777t
 - nutritional phases in, 777t
 - obesity associated with, 775f
 - ROHHAD and, 2725–2726
 - uniparental disomy and, 773–774
- Pragmatic language, 322
- Pragmatics, 301
- development of, 324–326, 325t
- Pralidoxime, 719
- autoinjector recommendations, 4455t
 - Pramlintide, for T2DM, 3542t
 - Pramlintide acetate, for T1DM, 3529–3530
- Praziquantel, 2145
- for cysticercosis, 2219
 - for schistosomiasis, 2214
- Preadoption medical record reviews, 72–73
- Prealbumin, reference intervals, 4472.e9t
- Preanesthetic evaluation, 664–675, 665t
- airway evaluation, 664
 - cardiovascular system, 664
 - genetic evaluation, 665
 - hematologic system, 664
 - neurologic system, 664–665
 - psychologic assessment, 665
 - respiratory system, 664–665
- Preauricular sinuses and pits, 3996f, 4044
- Preaxial polydactyly, 784t
- Prebiotics, 395
- Prebronchiectasis, 2658
- Precipitation-crystallization, 3312
- Precision, of laboratory testing, 4472.e3
- Precision genetic-based therapy, 3614
- Precision medicine, 54
- Preclinical autoimmunity, with progressive loss of β-cell function, 3520–3521, 3521f–3522f
- Precocious puberty, 3327, 3378
- after irradiation of brain, 3391
 - central, 3329, 3386–3390
 - chorionix gonadotropin-secreting tumors, 3392
 - familial male gonadotropin-independent, 3393
 - hypothyroidism and, 3391
 - incomplete (partial) precocious development, 3393–3394
 - McCune-Albright syndrome, 3392–3393
 - medicational, 3394
 - peripheral, 3387t, 3392
 - precocious puberty resulting from, 3390–3391, 3390f–3391f
 - type Ia pseudohypoparathyroidism with, 3440
- Precordial bulge, 2740
- Prediabetes, 3516–3517
- Predictable drug reactions, 1453
- Predictive genetic testing, 729, 750
- Predictive validity, 181
- Predisposing factors, for obstructive sleep apnea, 206t
- Predispositional genetic testing, 751
- Prednisolone, 3449
- for asthma, 1405t–1406t
 - for nephrotic syndrome, 3229
- Prednisone, 3449
- for asthma, 1405t–1406t
 - for autoimmune hepatitis, 2489
 - indications and adverse reactions of, 3089t–3090t
 - for toxocariasis, 2210
- Predominant neuropathic pain, toxic causes of, 3895t
- Predominantly antibody deficiencies, 1345–1346
- Preeclampsia-eclampsia, 1020
- Preemptive pain control, 653–654
- Preemptive transplantation, renal, 3254
- Pre-erythrocytic phase, in *Plasmodium* life cycle, 2169–2170
- Preexposure prophylaxis, for rabies, 2084
- Prefreeze, in frostbite, 661–662
- Pregabalin
- adverse effects of, 3611t
 - dosages of, 3609t–3610t
 - in pain management, 689t–690t, 691
- Pregestational diabetes, of birth defects, 1023
- Pregnancy
- and acute porphyria, 970
 - adolescent, 1187t, 1228–1234
 - adolescent fathers, 1229
 - clinical manifestations of, 1228
 - counseling and initial management, 1229
 - diagnosis of, 1228–1229, 1229t
 - epidemiology of, 1228–1231
 - etiology of, 1228
 - medical complications of mothers and babies, 1229–1230
 - preventive strategies of, 1231, 1231t
 - psychosocial outcomes/risks for mother and child, 1230–1231
- congenital heart disease in, 2839t, 2842f–2843f, 2842
- congenital infections and, 1153
- high-risk, 1010–1014, 1010f
- disorders of amniotic fluid volume, 1014t
 - identified by ultrasound, 1012–1014
 - labor and delivery, 1014
 - maternal factors, 1010t
- Listeria monocytogenes* in, 1730
- Marfan syndrome and, 4368
- outcomes of disparities in, 12–13
- pedigree symbols for, 736f
- syphilis during, treatment of, 1874–1875
- termination of, 1028
- Toxoplasma gondii* infection in, 2197–2198
- untreated syphilis during, 1868
- in women with PAH deficiency, 814
- Pregnancy-related risk factors, for SIDS, 2533
- Prehospital care
- in developing world, 544–545
 - in emergency medical services, 536–537
 - access to, 536
 - destination determination in, 537, 537f
 - provider capability in, 536
- Preimplantation genetic diagnosis, 728
- Prekallikrein, 3033
- Premature atrial contraction, 2847f
- Premature closure, 48t
- Premature death, in ADHD, 312f
- Premature infants, 176
- discharge from hospital, 1049–1050, 1049t
 - electrocardiogram of, 2750f
 - heart failure in, 2896t
 - neonatal problems associated with, 1046t
 - nursery care, 1043–1045
 - transportation of, 96
 - twins, 1042
- Premature menarche, 3394
- Premature pubarche, 3394
- Premature rupture of membranes, 1013
- Premature thelarche, 3329, 3393–3394
- Premature ventricular contractions, in bigeminal rhythm, 2848f
- Prematurity
- definitions, 1042
 - and immaturity of drug metabolism, 1045
 - incidence, 1042
 - physiologic anemia of, 2939
 - SIDS and, 2537
- Premenstrual dysphoric disorder (PMDD), 1216, 1216t
- Premenstrual syndrome (PMS), 1216
- Prenatal alcohol exposure (PAE), 1135
- Prenatal androgen excess, in 21-hydroxylase deficiency, 3463–3466
- Prenatal pediatric visit, 151
- Prenatal screening, 728
- Preoperative fasting, 665–667, 667t
- Preparticipation sports examination (PSE), 4294–4297
- Prepatellar bursitis, 4330
- Prepubertal girl, sexual abuse in, 123, 124f–125f
- Prepubertal periodontitis, 2249
- Prerenal acute kidney injury, 3244
- PRES. *See* Posterior reversible encephalopathy syndrome
- Presbyopia, 3914
- Preschool Confusion Assessment Method for the ICU (psCAM-ICU), 296f, 297
- Preschoolers, 164–167, 303–304
- cognition, 165
 - emotional and moral development, 166
 - implications for parents and pediatricians, 166
 - language, 164–165
 - physical development of, 164
 - play, 165–166
 - psychosocial assessment, 216
 - responses to death, 199
 - sleep in
 - BEARS sleep screening algorithm, 215t
 - normal developmental changes in, 204t
 - structural development of brain, 164
- Presenting problems
- explication of, 221
 - psychosocial, 216
- Preseptal cellulitis, 3940t, 3973–3974, 3974f
- Haemophilus influenzae* in, 1757
- Pressure injuries, 45t
- Pressure load, increased, congenital heart lesions resulting in, 2775
- Pressure overload pattern, 2750
- Pressure rise time, 626
- Pressure therapy, 654
- Pressure ulcers, spinal cord injury and, 4391
- Pressure-controlled ventilation (PCV), 624–625, 625t, 626f
- Pressure-regulated volume control (PRVC), 625
- Pressure-support ventilation (PSV), 625
- Presumed symptomatic epilepsy, 3589
- Presyncope, 594t
- Preterm birth
- causes of, 1043t
 - disparities in, 12–13
 - in high-risk pregnancy, 1011–1012
 - low birthweight due, 992

- Preterm infants, red blood cell transfusions in, 3015
 Pretravel consultation, 1626, 1627t
 Prevalence
 of congenital heart disease, 2763–2771
 of respiratory microorganisms, 2670f
 worldwide, of cystic fibrosis, 2663f
 Preventative care, for children with disabilities, 4405
 Preventive nutrition counseling, in pediatric primary care, 420
 Preventive pediatric healthcare, 86f–87f
 Preventive therapy, for migraine, 3648–3649
 Priapism
 in sickle cell disease, 2971
 subtypes of, 3300
 Prick/puncture technique, 1378
 Primaquine, for malaria prophylaxis, 1637, 2181t–2182t
 Primary adrenal insufficiency, 3450–3458
 acquired etiologies of, 3455–3457
 biochemical findings, 3456t
 causes of, 3451t–3452t
 differential diagnosis of, 3457, 3457f
 etiologies of, frequencies of, 3454t
 inherited etiologies of, 3450–3455
 adrenal hypoplasia congenita, 3450
 corticosteroid-binding globulin deficiency, 3455
 decreased cortisol-binding affinity, 3455
 deficiency of mitochondrial reactive oxygen species detoxification, 3454
 disorders of lipid metabolism, 3450–3453
 familial glucocorticoid deficiency, 3450
 inborn defects of steroidogenesis, 3450
 multisystem syndromes associated with growth restriction, 3453–3454
 type 1 autoimmune polyendocrinopathy syndrome, 3454–3455
 laboratory findings of, 3457
 other genetic etiologies for, 3454t
 treatment of, 3457–3458
 Primary adult-type hypocalcemia, 2347
 Primary aldosteronism, 3478–3479
 Primary alveolar proteinosis, 2686
 Primary amebic meningoencephalitis, 2145–2146
 clinical manifestations of, 2146
 diagnosis of, 2146
 epidemiology of, 2145
 etiology of, 2145
 pathogenesis of, 2145
 treatment of, 2146
 Primary amenorrhea, 1211, 1211t, 3351
 Primary angioedema, 1320–1321
 Primary antibody deficiency disorders, genetic basis of, 1278t
 Primary bile acid malabsorption, chronic diarrhea and, 2378
 Primary care
 behavioral health, 234
 for child with intellectual disability, 357–361
 psychotropic prescribing in, principles for, 230
 for rheumatic diseases, 1464
 Primary care physician, in emergency medical services, 534–539
 Primary care professionals (PCPs)
 in primary care, 230
 role of, in assessment and management of sexual abuse, 122–126
 Primary caregiving, 183
 Primary carnitine deficiency, 864
 Primary central nervous system vasculitis, 1553t
 Primary ciliary dyskinesia, 792t, 2679–2682
 clinical manifestations of, 2680–2681
 diagnosis of, 2681–2682, 2681t
 genetics of, 2680, 2680f
 normal ciliary ultrastructure and function, 2679–2680, 2679f–2680f
 prognosis for, 2682
 treatment of, 2682
 Primary CNS vasculitis, 3754–3755, 3756t–3757t
 Primary dysmenorrhea, 1214
 Primary effusion-based lymphoma, 2019
 Primary headaches, 3639
 Primary hemophagocytic lymphohistiocytosis, 3168–3169
 treatment for, 3177
 Primary hepatic malignancies, liver transplantation for, 2507
 Primary hypermethioninemias, 823
 Primary hyperoxaluria
 type 1, 839
 type 2, 839
 type 3, 839–840
 Primary hypoalphalipoproteinemia, 880
 Primary hypogonadism, male, 3487–3491
 clinical manifestations of, 3489
 diagnosis of, 3489
 etiology of, 3488t
 Klinefelter syndrome in, 3489–3491
 Noonan syndrome in, 3489
 45,X males in, 3491
 XX males in, 3491
 47,XXX males, 3491
 Primary hypothyroidism, 3370, 3402–3404, 3403t
 deiodination, defects in, 3403
 iodide transport, defective, 3403
 iodine deficiency, 3404
 iodine exposure, 3404
 iodine organification, defects of, 3403
 radioiodine administration from, 3404
 thyroglobulin synthesis, defective, 3403
 thyroid dysgenesis, 3402–3403
 thyroid hormone transport, defects in, 3403–3404
 thyrotropin receptor-blocking antibodies, 3404
 Primary immune dysregulatory diseases (PIDRs), 1324
 Primary immunodeficiencies, 1310, 1659–1661
 abnormalities of phagocytic system, 1659–1660
 approaches to treatment, 1344–1350
 administration details, 1350
 combined immunodeficiencies with associated or syndrome features, 1345
 complement deficiencies, 1346
 congenital phagocyte defects, 1346
 considerations for product selections, 1349–1350
 COVID-19 vaccine, 1344
 defects in intrinsic and innate immunity, 1346
 dosing considerations, 1350
 general infection prevention and management strategies, 1344
 hyper-IgM/CD40LG deficiency, 1345
 immunizations, 1344, 1345t
 immunodeficiencies affecting cellular and humoral immunity, 1344–1345
 immunoglobulin G replacement therapy, 1346, 1347t–1348t
 NF-kB essential modulator (NEMO) deficiency, 1345
 normal immunoglobulin levels with impaired specific antibody production, 1346–1349
 predominantly antibody deficiencies, 1345–1346
 prophylaxis, 1344
 STAT3 hyper-IGE syndrome (Job syndrome), 1345
 β-cell defects (humoral immunodeficiencies), 1660
 Candida infections in immunocompromised patient, 1924
 combined B-cell and T-cell defects, 1661
 defective splenic function, opsonization, or complement activity, 1660
 noninfectious presentations suggesting, 1256–1261
 autoimmunity, 1256–1257
 inflammatory diseases, 1258–1261
 patterns of infection of, 1252t
 risk of hemophagocytic lymphohistiocytosis and, 1256t
 sentinel infections and related genes of, 1254t
 T-cell defects (cell-mediated immunodeficiencies), 1660–1661
 types of, 1253t
 Primary lesions, 4027
 Primary lymphedemas, 3066
 Primary mediastinal B-cell lymphoma (PMBCL), 3113–3115
 Primary mitochondrial hepatopathies, 2484–2486
 Alpers syndrome, 2484
 GRACILE syndrome, 2485
 mitochondrial DNA depletion syndrome, 2484
 Navajo neurohepatopathy, 2484–2485
 neonatal liver failure, 2484
 Pearson syndrome, 2485
 Primary mitochrondrial hepatopathies (*Continued*)
 phenotypic classification of, 2451t
 villous atrophy syndrome, 2485
 Primary obstructed nonrefluxing megaureter, 3281, 3282f
 Primary pigmented nodular adrenocortical disease (PPNAD), 3476
 Primary pulmonary disease, in tuberculosis, 1840–1841, 1841f
 Primary pulmonary hypertension, 2831–2832
 Primary spontaneous pneumothorax, 2703
 Primary survey, in multiple trauma, 571–575
 airway, 571
 breathing, 571–573, 574t
 circulation, 573–574, 574t–575t
 disability/neurologic deficit, 574–575, 575f
 exposure and environmental control, 575
 Primary syphilis, 1866–1867
 Primary tracheomalacia, 2581t
 Primary yaw, 1876
 Primate bites, 4458t
 Primidone
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Primitive reflexes, 153
 in neurologic evaluation, 3556–3557, 3556t, 3557f
 Primordium, of fetal adrenal gland, 3444
 Prion diseases, 2119t
 Prion proteins, 2118
 Privacy, in adolescent healthcare, 54
 PRKAG2 deficiency, 900t–901t, 908
 PRMs. *See* Pattern recognition molecules
 Proband, 735
 Probiotics, 56t
 for atopic dermatitis, 1417
 Problem, adolescent, 1164t–1165t
 Problem solving, 231
 math disabilities and, 320
 Procainamide, 2845t–2846t
 Procedural errors, math disabilities and, 320
 Procedural sedation, 676, 676t
 Process indicators, for outcome measures, 542
 Processing speed, math disabilities and, 320
 Processus vaginalis, patent, laparoscopic image of, 2415, 2420f
 Prochlorperazine, for migraine, 3646t–3647t, 3648
 Procidentia, 2410
 Procollagen propeptides, type I, processing defects of, 4361
 Proctocolectomy, for familial adenomatous polyposis and, 2413
 Prodromal phase, 4418–4419
 of schizophrenia, 287
 Progeria, 956–962
 appearance, 961f
 clinical manifestations of, 956–959, 957f–958f
 diagnosis and differential diagnosis, 960–961
 laboratory findings, 959
 molecular pathogenesis, 959–960
 treatment of, 961
 Progerin, in progeria, 960f
 Progerin farnesylation, 960f
 Progesterone intrauterine device, 3356
 Progestin-only contraception
 hormones and antiepileptic drugs, 3356
 implants, 3356
 injection, 1218t–1219t, 1221–1222
 intramuscular medroxyprogesterone acetate, 3356
 oral progestin, 3356
 pills, 1222
 progesterone intrauterine device, 3356
 Progestins, for pubertal blockade, 1176t
 Programmed-death protein 1 (PD-1), 3109
 Programming, fetal, 148
 Progressive deformity, 4277, 4277f
 Progressive disseminated histoplasmosis, 1932–1934
 chronic, 1933
 Progressive familial intrahepatic cholestasis, 2449–2450, 2450t
 Progressive multifocal leukoencephalopathy (PML), 2086
 Progressive muscle relaxation, in pain management, 693

- Progressive myoclonic epilepsy, 3602
mitochondrial disease and, 935t
type 1, 745t–746t
- Progressive primary pulmonary disease, in tuberculosis, 1841
- Progressive rubella panencephalitis (PRP), 1967
- Progressive varicella, 2002
- Progressive vasculitis, 3744–3745
- Project Implicit Race Implicit Association Test, 21–22
- Prokinetic agents, for GERD, 2267
- Prolactin, 3360
- Prolactinoma, 3380–3381
- Prolapse
mitral valve, 2797–2798
urethral (female), 3301f, 3327
- Prolapsed ectopic ureterocele, 3301, 3301f
- Prolidase deficiency, 841–842
- Proline, metabolism defects, 838f, 841–842
hyperprolinemia type I, 841
hyperprolinemia type II, 841
prolidase deficiency, 841–842
- Prolonged diarrhea, 2342, 2355
- Prominent lateral palatine ridges, 784t
- Promoter variants, 732f
- Promyelocytes, 1290
- Pronator drift, 3555
- Pronator sign, 3673–3674
- Proopiomelanocortin (POMC) deficiency, 438–442
- PROPL*, 3364
- Propafenone, 2845t–2846t
- Propaganda, 108
- Propane, inhaled, 1203t
- Properdin, 1316, 1320
deficiency, 1320
- Prophase, 761
- Prophylactic penicillin, for sickle cell disease, 2976
- Prophylactic therapy, for migraine, 3648–3649
- Prophylaxis, 1344
antimicrobial, 1344
in vesicoureteral reflux, 3273
in hemophilia, 3032
penicillin, for sickle cell anemia, 2976
for people who have had rheumatic fever, 1715t
pharmacologic, for acute GVHD, 1357
- postexposure
for hepatitis B, 2469
for measles, 1964
for pertussis, 1764t
for varicella-zoster virus, 2005
- pregnancy, for sexual assault victims, 1237t
- for rabies
postexposure, 2083–2084, 2084f
preexposure, 2084
- Propionic academia, 833–835, 1309t
- Propionyl-CoA carboxylase deficiency, 833–835
- Propofol, 669t, 670
infusion syndrome, 670
for intubation, 620t
- Proportionate dwarfism, 4098
- Propranolol, 713, 2845t–2846t
for migraine, 3646t–3647t
for POTS, 599t
- Protein convertase 1/3 deficiency, 2339–2340
- Proptosis, 3082, 3971, 3974
- Prospective audit and feedback, 1691t
- Prostaglandin E₁, for shock, 610t
- Prostate, 2492t
- Prostate, screening in, in transgender, 1180t
- Prostatic utricle, 3297
- Prostheses, 4402
- Prosthetic fitting, 4223, 4223f
- Prosthetic valves, infective endocarditis and, 2865t
- Prostration, 2180
- Protamine, 708t
- Protease inhibitors, for HIV, 2098t–2107t
- Proteases, 1368
- Proteasome-associated autoinflammatory syndrome (PRAAS), 1530t
- Protective factors
for adolescent health behaviors, 1187t
suicide and, 264, 266t
- Protein(s), 389t–390t, 393–394, 394t
digestion, 2277
- Protein(s) (Continued)
glycosylation, 921, 922f
malnutrition, 2201
metabolism of, 2436
disorders of, liver and, 2455t
misfolding, in amyloidosis, 1536
prion, 2118
product, types of sequence variants on, 732t
total, reference intervals, 4472.e9t
urine dipstick measurement of, 3219
- Protein 4.2, in hereditary spherocytosis, 2956t
- Protein B deficiency, surfactant and, 2683–2684
- Protein C deficiency, 3038t–3039t
- Protein C-associated interstitial lung disease, surfactant, 2684
- Protein hydrolysate formulas, 413
- Protein kinases, in normal liver development, 2435t
- Protein N-glycosylation, congenital disorders of, 925–928
glucosyltransferase-1 deficiency, 926
mannosephosphoisomerase deficiency, 926
phosphomannomutase-2 deficiency, 923f, 925
UDP-GlcNAc:Dol-P-GlcNAc-P transferase deficiency, 926–928
- Protein O-glycosylation, congenital disorders of, 928
- Protein S deficiency, 3039t
- Protein supplements, as performance-enhancing aids, 4325t–4326t
- Protein tyrosine kinase inhibitors, for malignancies, 3088t
- Protein-energy malnutrition, 426
- Protein-losing enteropathy, 1320, 2341–2342, 2342f–2343f
chronic diarrhea and, 2378
etiology of, 2337t
investigations for, 2334–2336
- Proteins induced by vitamin K absence (PIVKA), 482
- Proteinuria, 3248, 3887
algorithm for investigating, 3221f
causes of, 3222t
in CKD, 3252
clinical considerations for, 3219
clinical evaluation of, 3218–3219, 3219t
conditions associated with, 3220–3222
fixed, 3220–3222
glomerular, 3220–3221, 3222f, 3222t
orthostatic, 3220, 3221f
pathophysiology of, 3218
transient, 3220, 3221f
tubular, 3221–3222, 3222t
- Proteus syndrome, 3159, 4188
- Proteus syndrome myopathy, 3819–3820
- Prothionamide, for drug-resistant tuberculosis, 1852t–1853t
- Prothrombin 2020 gene pathogenic variant, 3038, 3038t–3039t
- Prothrombin (factor II) deficiency, 3033
- Prothrombin time (PT), 3024f, 3025, 3027t
- Protocols, for emergency medical services, 535
- Protoconversations, 324
- Proton MR spectroscopy, in neuroradiologic procedures, 3559–3560
- Proton pump inhibitors
for gastrinoma, 2414
for GERD, 2264
for peptic ulcer disease, 2308
- Proton-beam radiotherapy, 3091
- Protooncogenes, 3077
- Protoporphyrin, erythropoietic, 977–979
- Protoporphyrinogen oxidase (PPOX), 976
- Protozoal diarrhea, 2359t, 2367
- Protozoan diseases
amebiasis, 2147–2149
antiparasitic drugs for, 2125–2144
balantidiasis, 2151
Cryptosporidium, 2152
Cyclospora, 2153
Cystoisospora, 2153
giardiasis, 2149–2151
leishmaniasis (*Leishmania*), 2155–2160
microsporidia, 2153–2154
primary amebic meningoencephalitis, 2145–2146
trichomoniasis (*Trichomonas vaginalis*), 2154–2155
- Protracted diarrhea, 2376
- Provisional tic disorder, 241, 242t
- Provitamins A, 453t
- Provocation testing, 1378
- Proximal humeral stress fracture, 4302–4303
- Proximal humerus fractures, 4280–4281
- Proximal intestinal bacterial overgrowth, 2342–2343
- Proximal myotonic myopathy, 3837
- Proximal (type II) renal tubular acidosis, 3234–3235, 3235t
- Proximal tibia fractures, 4282
- Proximal white subungual onychomycosis, 4146
- Proxy, 51
- Prozac. *See* Fluoxetine
- Prozone effect, 1870
- PRP. *See* Progressive rubella panencephalitis
- PRP1*-associated deficiency, 954–955
- PRPS1*-associated deficiency, 954–955, 955t, 956f
- Prune-belly syndrome, 3281–3282, 3283f
- Pruritus, 1374
atopic dermatitis and, 1411
chronic cholestasis and, 2448
liver disease and, 2438–2439
opioid-induced adverse effects, 684t
in pediatric palliative care, 65t–69t
- Prussian blue, 4421–4422
- PSC. *See* Pediatric Symptom Checklist
- PSC-autoimmune hepatitis overlap, 2476
- Pseudoachalasia, 2261–2262
- Pseudoachondroplasia, 745t–746t, 4341–4343, 4343f–4344f
- Pseudoallergic reactions, 1453
- Pseudoautosomal region, 3481
- Pseudo-Darrier sign, 4066
- Pseudodominant inheritance, 738, 740f
- Pseudoesotropia, 3925–3926
- Pseudogenetic inheritance, and familial clustering, 740–742
- Pseudogynecomastia, 1210
- Pseudo-Hurler polydystrophy, 887t, 897
- Pseudohyperkalemia, 496
- Pseudo-hypertriglyceridemia, 913–915
- Pseudohypertrophy, 3554
- Pseudohypoaldosteronism, 3236, 3242, 3377t, 3460–3461
type 1, 497, 3377t
type 2, 497, 3377t
- Pseudohyponatremia, 487, 491, 492t, 3376
- Pseudohypoparathyroidism, 3439–3440, 3439t
acrodysostosis with hormone resistance, 3440
type Ia, 3393, 3439–3440
type Ib, 3440
- Pseudohypophosphatasia, 4380–4381
- Pseudo-Lennox-Gastaut syndrome, 3600
- Pseudomembranous colitis, 1825
- Pseudomigraine syndrome with CSF pleocytosis, 3711
- Pseudomonal folliculitis, 4156, 4157f
- Pseudomonas aeruginosa*, 1799–1802
in burns and wound infection, 1799–1800
clinical manifestations of, 1799–1801
in cystic fibrosis, 1800
diagnosis of, 1801
epidemiology of, 1799
etiology of, 1799
in immunocompromised persons, 1800, 1800f
in infants, 1801
infections, 1800t
in nosocomial pneumonia, 1800–1801
pathogenesis of, 1799
prevention of, 1801–1802
prognosis for, 1801
supportive care in, 1801
treatment of, 1801
- Pseudomonas infection*, 4144, 4144f
- Pseudomyogenic hemangiopericytoma, 3163
- Pseudoparalysis, 4292
in newborn, 1052
vitamin C deficiency and, 468
- Pseudoporphyria, 974, 4095
- Pseudoprecocity, resulting from lesions of ovary, 3502–3503
androgenic lesions, 3503
estrogenic lesions, 3502–3503

- Pseudoprecocity, resulting from lesions of ovary
(Continued)
 clinical manifestations and diagnosis of, 3502
 follicular cyst, 3502–3503
 juvenile granulosa cell tumor, 3502
 treatment and prognosis of, 3502
- Pseudoscleroderma, 1510
- Pseudosplenomegaly, 3061
- Pseudo-status epilepticus, 3627
- Pseudostrabismus, 3925–3926
- Pseudotumor, 3973
- Pseudotumor cerebri, 3782–3785
- Pseudoxanthoma elasticum (PXE), 4123, 4123f
- Psilocybin intoxication, 4443
- Psittacosis (*Chlamydia psittaci*), 1655t–1656t, 1897–1898
 clinical manifestations of, 1898
 diagnosis of, 1898
 epidemiology of, 1898
 etiology of, 1897–1898
 prevention of, 1898
 prognosis for, 1898
 treatment of, 1898
- Psoas abscess, 2317
- Psoas sign, appendicitis and, 2398–2399
- Psoriasis, 4098–4102, 4099f–4100f, 4101t–4102t, 4144
 vulvar, 3321t–3322t, 3324
- Psoriasis Area and Severity Index-75 (PASI-75), 4100–4102
- Psoriatic arthritis, 1472t–1473t, 1478
 characteristics, 1483t
 disease onset, 1484–1485, 1485t, 1486f
- Psychiatric and psychosocial sequelae, in drowning, 643
- Psychiatric diagnostic evaluation, 218–221
- Psychiatric disorders
 anesthetic implications in, 666t
 assessment and interviewing, aims of assessment, 216
 presenting problems, 216
 psychosocial interview, 216–218
- Psychiatric evaluation, prior to renal transplantation, 3256
- Psychiatric manifestations, Wilson disease and, 2458
- Psychiatric medications, 716–717
- Psychoanalytic theories, 139
- Psychodynamic psychotherapy, 232–233
- Psychoeducation, 233, 290
- Psychogenic cough, 2527–2528
- Psychogenic disturbances, in vision disorders, 3920
- Psychogenic nonepileptic seizures (PNESs), 3633
- Psychogenic voice disorders, 332
- Psychologic evaluation, in communication disorders, 332
- Psychologic factors, affecting other medical conditions, 237t
- Psychologic influences, 137
- Psychologic safety, 44
- Psychologic stress, in T1DM, 3520
- Psychologic symptoms, of school violence, 102
- Psychologic trauma, 300
- Psychological abuse, 114
- Psychopharmacology, 222–230
 antidepressants, 224–226, 227t
 antipsychotics, 226–228, 228t
 mood stabilizers, 228–229, 228t
 physical illness, medication use in, 229–230
 for somatic symptom and related disorders, 240
 stimulants, 222–224
- Psychosis
 associated with epilepsy, 291
 causes of, 219t
 childhood, 285–294
 differential diagnosis of, 297t
 medications for, 228t
 secondary etiologies of, 288t
- Psychosocial assessment, 216–222
 of adolescent, 1169–1170, 1169t
- Psychosocial conditions, language disorders and, 331
- Psychosocial consequences of injuries, 98–99
- Psychosocial development, in adolescence, 1162–1163
- Psychosocial interview, 216–218
- Psychosocial problems, among GLB youth, 1184–1185
- Psychosocial stress, 9–10
- Psychosocial support
 in β-thalassemia, 2986
 in ulcerative colitis, 2316
- Psychosocial well-being, in deaf/hard of hearing, 344
- Psychotherapeutic elements, coordination of, 233
- Psychotherapy, 201, 231–235, 308
 in pain management, 692
 for somatic symptom and related disorders, 240
- Psychotic disorder
 due to another medical condition, 291, 291t
 substance/medication induced, 291, 291t
- Psychotropic medications, 76
 for children with burns, 654
 in primary care, 230
 principles of, 222, 223t
- Psych-out bias, 48t
- PTC. *See* Papillary thyroid carcinoma
- PTEN-hamartoma syndromes, 3384t, 4070t–4071t, 4149
- Pterygium, 3942–3943, 3943f
- Phthirus pubis*, management guidelines, 1248t
- PTLD. *See* Posttransplant lymphoproliferative disorder
- Ptosis, 3933, 3935f
 mitochondrial disease and, 935t
- PTSD. *See* Posttraumatic stress disorder
- PTT. *See* Partial thromboplastin time
- Pubarche, 1159, 3386
 premature, 3394
- Pubertal delay, syndromes associated with, 3395t
- Pubertal gynecomastia, 1210, 3495
- Puberty
 blockers, 1175–1178
 alternative therapy side effects of, 1177
 bone health in, 1176, 1176t–1177t
 brain development in, 1176–1177
 fertility in, 1176, 1177t
 goals of, 1175
 metabolism in, 1177
 monitoring protocol in, 1177–1178, 1178t
 potential adverse effects of, 1175–1176
 treatment criteria and timing of, 1175
 treatment options of, 1175, 1176t
 disorders of pubertal development, 3386–3399
 delayed or absent, 3394–3399
 classification of, 3395t
 constitutional, 3396
 diagnostic approach to, 3397–3398, 3398f–3399f
 differential diagnosis of, 3394–3397
 treatment of, 3398–3399
 impact on arousal and motivation, 1186f
 onset of, 1159–1160, 1161f
 physiology of, 3385–3386
 timing of changes in, 1163
- Pubic hair, 3386
 sexual maturity rating in, 1159f, 1160t
- Pubic lice, management guidelines, 1248t
- Pubis, 4231
- Public health
 approach to pandemics, 1583–1585
 authorities and partners, 1583
 communication and education, 1584–1585
 mitigation/prevention, 1583
 preparedness, 1584
 recovery, 1584
 response, 1584
 preparedness, bioready and, in infection prevention and control, 1620
- Public health policy, 15
- Puddle sign, 2509
- PUFAs. *See* Polyunsaturated fatty acids
- Pufferfish
 food-borne illness, 4411t–4413t
 noninfectious, 2362t–2364t
 poisoning, 3892–3894, 4445
- Pulmonary abscess, 2660–2661, 2661f, 2662t
- Pulmonary agenesis, 2599
- Pulmonary air leaks, 1097–1098
 RDS and, 1080–1082
- Pulmonary airway malformation, congenital, 2599–2601, 2600f–2601f
- Pulmonary alveolar microlithiasis, 2596–2598, 2598f
- Pulmonary alveolar proteinosis, 2634t, 2686–2687, 2687f, 2687t
- Pulmonary and asthma screening, in sickle cell disease, 2977
- Pulmonary aplasia, 2599
- Pulmonary arterial hypertension, 1508–1509
- Pulmonary arteriography, 2518
- Pulmonary arteriovenous fistula, 2830
- Pulmonary artery
 anomalous origin of left coronary artery from, 2828–2829
 anomalous origin of right coronary artery from, 2829
 branch, absence of, 2803
- Pulmonary artery sling, 2592
- Pulmonary ascariasis, 2199
- Pulmonary aspergilloma, 1929
- Pulmonary atresia
 with intact ventricular septum, 2805–2806, 2805f
 tetralogy of Fallot with, 2804–2805
 transposition of the great arteries with, 2809
- Pulmonary blood flow
 decreased, cyanotic congenital heart disease and, 2800–2811
 increased, 1074, 1074f
 cyanotic congenital heart disease and, 2812–2826
 obstructed, in newborn, 1054t
- Pulmonary capillaritis, 2688
- Pulmonary capillary pressure, increased, 2604t
- Pulmonary complications
 associated with sickle cell disease, 2973–2974, 2973f, 2973t
- Cystic fibrosis and, 2662t
- Pulmonary contusions, 576
- Pulmonary diseases
 associated with primary and secondary immune deficiency, 2632t
 in delivery room, 1072
 obesity-associated comorbidities, 444t
 in systemic scleroderma, 1508–1509
- Pulmonary edema, 2604–2606
 clinical manifestations of, 606t, 2605
 etiology of, 2604–2605, 2604t
 high-altitude, 634–635, 635f
 malaria and, 2180
 pathophysiology of, 2604
 treatment of, 2605–2606
- Pulmonary embolism, 2692–2697, 3040
 clinical manifestations of, 2693
 clinical prediction rules for, 2694t–2695t
 epidemiology of, 2692–2693
 etiology of, 2692
 laboratory findings and diagnosis of, 2695–2696, 2696f
 prognosis for, 2697
 risk factors for, 2693t
 spinal cord injury and, 4389
 treatment of, 2696, 2697t
- Pulmonary fibrosis, chemotherapy and, 3093–3094
- Pulmonary function testing, 2519–2522
 in anti-glomerular basement membrane disease, 2637
 in asthma, 1391–1392, 1391t
 in cystic fibrosis, 2670
 for EVALI, 2653
 in interstitial lung disease, 2635–2636
 long-term mechanical ventilation and, 2729
 in primary immune deficiency, 2624
 skeletal diseases influencing, 2713–2716
- Pulmonary hemorrhage, 1099, 2698–2700, 4411
 clinical manifestations of, 2699
 epidemiology of, 2699
 etiology of, 2698–2699, 2698t
 in infancy, 2689
 laboratory findings and diagnosis of, 2699–2700, 2699f
 pathophysiology of, 2699
 risk of, 1099
 treatment of, 1099, 2700
- Pulmonary hemosiderosis, 2688–2691
 clinical manifestations of, 2690
 epidemiology of, 2688–2689
 etiology of, 2688, 2688t
 laboratory findings and diagnosis of, 2690–2691
 pathology of, 2689
 pathophysiology of, 2689–2690
 prognosis for, 2691
 treatment of, 2691

- Pulmonary hypertension, 2831–2835
 BPD and, 1084
 classification of, 2832t
 cystic fibrosis and, 2676
 developmental and genetic lung disease associated with, 2832t
 drugs used for, 2834t
 persistent, of newborn, 1091–1093, 1092f
 clinical manifestations of, 1091–1092
 diagnosis of, 1092–1093
 etiology of, 1092t
 pathophysiology of, 1091
 prognosis for, 1093
 treatment of, 1092f, 1093
 in pertussis, 1764
 primary pulmonary hypertension, 2831–2832
 pulmonary vascular disease, 2831–2835
 in sickle cell anemia, 2974
 Pulmonary hypoplasia, 2599
 pneumothorax and, 1097
 PPHN and, 1091
 Pulmonary infarction, 2692–2697
 Pulmonary infection
 complicated, coccidioidomycosis, 1937
 nontuberculous mycobacterial and, 1863–1864
 primary, coccidioidomycosis, treatment of, 1939
 residual, coccidioidomycosis, 1937
 Pulmonary injury, in drowning, 639–640
 Pulmonary interstitial emphysema (PIE), 1097–1098, 1098f
 Pulmonary lymphangiectasia, congenital, 2602, 2603f
 Pulmonary manifestations
 extrapulmonary diseases with, 2530
 of SLE, 1492t
 systemic disorders with, 2632t
 of tuberous sclerosis, 3658f
 Pulmonary mucormycosis, 1943, 1943f
 Pulmonary pathology, localizing signs for, 612t
 Pulmonary pressure-volume relation, in acute lung injury, 621f
 Pulmonary renal syndromes, 2689
 Pulmonary sequestration, 2601–2602, 2601f
 Pulmonary sling, 2827t
 Pulmonary stenosis
 in combination with intracardiac shunt, 2790
 infundibular, double-chamber right ventricle, 2789–2790
 peripheral, 2790
 Pulmonary tract, abnormalities of, 332
 Pulmonary tumors, 2702–2703, 2702f–2703f, 2702t
 Pulmonary valve disease, in rheumatic heart disease, 2875
 Pulmonary valve stenosis, 2841
 with intact ventricular septum, 2787–2789
 clinical manifestations for, 2787–2789
 laboratory findings for, 2787–2789
 pathophysiology of, 2787
 prognosis and complications of, 2789
 treatment of, 2789
 relative frequency of, 2763t
 Pulmonary valvular insufficiency, 2797
 Pulmonary vascular disease (Eisenmenger syndrome), 2831–2835
 clinical manifestations of, 2834–2835
 diagnosis of, 2835
 pathology of, 2833–2834
 pathophysiology of, 2833–2834
 treatment of, 2835
 Pulmonary vascular resistance, 1074
 Pulmonary vascular resistance, neonatal, 1091
 Pulmonary venolobar syndrome, 2592
 Pulmonary venous hypertension, 2796
 Pulmonary venous return, partial anomalous, 2779
 Pulp, 2247f, 2250f
 Pulpectomy, 2247
 Pulpitis, 2247
 Pulpotomy, 2247
 Pulse oximetry, 548
 in respiratory distress and failure, 616
 screening, 2774
 Pulse pressure, shock and, 607t
 Pulse rates, at rest, 2743t
 Pulsed dye laser, for common warts, 4168–4169
 Pulseless disease. *See* Takayasu arteritis
 Pulses, evaluation of, 2738
 Pulsus paradoxus, 607t, 1374–1375
 Punishment, in parenting, 145, 145t
 Pupil, abnormalities, 3920–3924
 anisocoria, 3921, 3922f–3923f
 congenital mydriasis, 3921
 dilated fixed, 3921, 3922f
 dyscoria and corectopia, 3921
 Horner syndrome, 3923–3924, 3923f, 3924t
 leukocoria, 3924, 3924f
 Marcus Gunn, 3922–3923, 3923f
 microcoria, 3920–3921
 paradoxical pupil reaction, 3924
 persistent pupillary membrane, 3924
 tonic, 3922
 Pupillary examination, 3910
 Pupillary light reflex, 591t
 Pupillary membrane, 3909
 Pupillary response, 556, 556f, 556t
 Purine metabolism, 944, 945f–946f
 disorders of, 947–948
 ADSL-associated disorders, 952
 AMP-deaminase, 951–952
 APRT-associated disorders, 950–951
 HPRT1-associated deficiency, 949–950, 951f
 uric acid, 947, 949t
 Purposeful parenting, 143, 144t
 Purpura, Henoch-Schönlein, 1552–1556, 1553t
 classification of, 1557t
 clinical manifestations of, 1554, 1557f
 complications of, 1555
 diagnosis of, 1554–1555
 differential diagnosis of, 1555
 epidemiology of, 1554
 laboratory findings of, 1555
 pathogenesis of, 1554
 pathology of, 1554
 prognosis for, 1555–1556
 treatment of, 1555
 Purpura fulminans, 3038
 Purpuric rash
 in meningoencephalitis, 1741f
 suggestive of rheumatic disease, 1461t
 Purtscher retinopathy, 3963
 Purulent pericarditis, 2891
 Pustular psoriasis, 4098
 Pustular rash, in IL-1-mediated diseases, 1528f
 Pustules, 4027, 4177, 4178f
 caused by *Nocardia brasiliensis*, 1736f
 PVL. *See* Periventricular leukomalacia
 PVNS. *See* Pigmented villonodular synovitis
 P waves, 2748–2749
 PWS. *See* Prader-Willi syndrome
 PXE. *See* Pseudoxanthoma elasticum
 Pycnodystostosis, 4353
 PYCR1-related progeroid syndrome, 4376t
 Pyelogram
 antegrade, 3278–3279
 retrograde, 3279f
 Pyelonephritis, 3205, 3263–3264, 3264f
 Pyemotes ventricosus, 4170t
 Pyloric stenosis, 533
 hypertrophic, 2278–2280, 2278f–2279f, 2278t, 2280t
 Pyoderma, streptococcal, 1707
 Pyoderma gangrenosum, in PAPA syndrome, 1523, 1528f
 Pyoderma vegetans, 4154, 4155f
 Pyogenic granuloma, 3162, 4058–4059, 4059f
 Pyogenic liver abscess, 2474
 Pyomyositis, 4286–4287, 4288f
 Pyramiding, steroids, 4325
 Pyrantel pamoate
 for ascariasis, 2199
 for enterobiasis, 2204
 for hookworms, 2202
 Pyrazinamide
 for drug-resistant tuberculosis, 1852t–1853t
 for tuberculosis, 1849t, 1831–1832
 Pyrethrins, 719–720
 Pyrethroid, 719–720
 Pyridostigmine, for POTS, 599t
 Pyridoxal phosphate, for gyromitrin poisoning, 4443
 Pyridoxal phosphate-responsive neonatal epileptic encephalopathy, 3603
 Pyridoxal-dependency disorders, in neonatal seizures, 3620
 Pyridoxine (vitamin B₆), 56t, 456t–457t, 463, 707t–708t
 deficiency, 463
 clinical manifestations of, 463
 diagnosis of, 463
 prevention of, 456t–457t, 463
 treatment of, 463
 dietary reference intake, 397t–403t
 in neonatal seizures, 3620
 toxicity, 463
 Pyridox(am)ine 5-phosphate oxidase (PNPO) deficiency, 855
 Pyridoxine-dependent epilepsy (PDE), 463, 855–856, 3603
 Pyriform aperture stenosis, 2546, 2546f
 Pyrimethamine, for toxoplasmosis, 2196
 Pyrimidine 5'-nucleotidase deficiency, 955
 Pyrimidine analogs, 1917
 Pyrimidine metabolism, 944–947, 945f, 948f
 disorders, 952–953
 CAD deficiency, 952–953
 dihydroorotate dehydrogenase deficiency, 953
 dihydropyrimidinase deficiency, 953–954
 dihydropyrimidine dehydrogenase deficiency, 953–954
 hereditary orotic aciduria, 953
 pyrimidine 5'-nucleotidase deficiency, 955
 thymidine kinase, disorders associated with, 954
 thymidine phosphorylase deficiency, 953
 β-ureidopropionase deficiency, 954
 Pyropoikilocytosis, hereditary, 2960–2961
 Pyruvate, reference intervals, 4472.e9t
 Pyruvate carboxylase deficiency, 900t–901t, 916
 Pyruvate dehydrogenase complex deficiency, 900t–901t, 915–916
 clinical manifestations of, 915
 treatment of, 915–916
 Pyruvate kinase deficiency, 2988–2989, 2988f, 2989t
 Pyruvate metabolism, disorders of, 900t–901t, 915–919
 Leigh disease, 919
 oxidative phosphorylation disease, 916–919, 917t, 918f, 920t
 pyruvate carboxylase deficiency, 916
 pyruvate carboxylase secondary to deficiency of holocarboxylase synthase/biotinidase, 916
 pyruvate dehydrogenase complex deficiency, 915–916
 Pyuria, in UTI, 3266

Q

- Q angle, 4228–4229
 Q fever (*Coxiella burnetii*), 1655t–1656t, 1900t–1902t, 1914–1916
 clinical manifestations and complications of, 1915
 diagnosis and differential diagnosis of, 1915–1916
 epidemiology of, 1914
 etiology of, 1914
 laboratory findings of, 1915
 pathology and pathogenesis of, 1914–1915
 persistent localized infection, 1915
 prevention of, 1916
 primary (acute), 1915
 transmission of, 1914
 treatment of, 1916
 Qelbree. *See* Viloxazine
 Qnasl, for allergic rhinitis, 1384t–1385t
 QRS complex, 2749–2752
 QRS frontal-plane axis, 2747
 QRS prolongation, electrocardiogram, 706t
 QT prolongation, acquired causes of, 2858t
 QT syndromes, 2770
 QTC prolongation, electrocardiogram, 706t
 Quadruple Aim approach, 36

Quality, 36
 Six Dimensions of, 36
 Quality improvement (QI), 15, 36
 analyzing quality data, 39–40, 40f
 comparing and reporting quality, 40–41
 expanding individual, initiatives to scale, 40, 40f, 41t
 framework for, 36–38
 implications of U.S. healthcare reform, 41
 lean methodology, 37–38, 37f
 measuring quality, 38–39, 38t, 39f
 model for improvement, 37
 need for, 36
 office system change for, 90
 Six Dimensions of Quality, 36
 Six Sigma, 37, 37f
 theory and execution, tools for organizing, 38
 Quality of life, 199
 health-related, congenital diaphragmatic hernia and, 1096
 Quality ratings and improvement systems, 184
 Quality-of-care, in adolescents, 1165
 Quantitative trait, 801
 Quartan fever, 1640–1641
 Quebec platelet syndrome, 3059–3060
 Queensland tick typhus, 1900t–1902t
 Questionnaires
 Dysfunctional Voiding Symptom Score, 3292f
 Pediatric Symptom Checklist, 3291–3292
 Quetiapine (Seroquel), for psychosis and mania, 228t
 Quick-reliever medications, for asthma, 1404
 Quinidine, 2845t–2846t
 Quinine
 for babesiosis, 2185
 toxicity, 701t
 Quinolones, 1689
 enterococci resistance, 1723t
 for *Legionella*, 1811
 for *Shigella*, 1779
 Quinupristin-dalfopristin, 1675t–1685t
 enterococci resistance, 1723t
 Qvar. See Beclomethasone

R

Rabies, 2081–2084
 clinical manifestations of, 2082
 diagnosis of, 2082–2083
 differential diagnosis of, 2082
 epidemiology of, 2081–2082
 immunoglobulin, 1586t
 pathogenesis of, 2082
 prevention of, 2083–2084
 immunization and fertility control of animal reservoirs, 2083
 postexposure prophylaxis, 2083–2084, 2084f
 preexposure prophylaxis, 2084
 prognosis for, 2083
 transmission of, 2082
 treatment of, 2083
 vaccines, 1588t–1589t, 4459–4460
 Rac2 deficiency, 1297t–1298t
 Raccoon eyes, 117
 Race
 adolescent health outcomes by, 1188t
 infant mortality rate and, 998–999
 Race Forward, 22
 Race Matters Institute, 22
 Racemic epinephrine
 for airway obstruction, 558
 nebulized, 2571
 Rachitic “rosary,” 470, 472f
 Racial domination, 18–19
 Racial identity development, in adopted children, 74
 Racial wealth gap, 9
 Racism, 5
 child health and, 16–22
 definition of, 18–19
 health and, pathways of, 19t
 health disparities and, 10f
 institutional, 20–21, 20f
 internalized, 19

Racism (Continued)
 interpersonal, 19–20
 opportunities to address, 21–22
 as social determinant of health and health inequities, 13f, 16–18, 17t
 structural, 21
 taxonomy of, 18–21
 Radial longitudinal deficiency, 4264–4265, 4265t–4266t, 4266f
 Radial-femoral delay, 2738
 Radiation
 in heat transfer, 657
 oncogenesis and, 3081
 Radiation damage, 3488–3489
 Radiation exposure
 acute and late effects of, 4417–4418, 4418t–4419t
 biologic effects of, 4414–4417, 4416f, 4416t–4417t
 cancer risk over lifetime, 4416, 4416f
 decreasing, 4417
 deterministic dose levels, 4416t
 diagnostic imaging, 4413–4414, 4414t–4416t, 4415f, 4417
 effects on fetus, 1024
 external contamination, 4419f, 4422
 internal contamination, 4421t, 4419–4422, 4422t
 measurements, 4415t
 radiation dose by imaging test, 4416t
 tissue radiosensitive weighting factors, 4414t
 whole body irradiation, 4418–4419
 localized, 4419, 4421t
 uncontrolled large- or small-scale exposure to, 4418–4419, 4419f, 4420t
 Radiation myelitis, 4418
 Radiation sickness, 4419f
 Radiation therapy
 for cancer treatment, 3086, 3091
 for colorectal carcinoma, 2414
 for hepatoblastoma, 3154–3155
 Radiation thyroiditis, 3411
 Radiation-induced hypogonadism, chemotherapy and, 3488–3489
 Radioactive iodine, 3409
 for differentiated thyroid carcinomas, 3165
 for hyperthyroidism, 3420t
 Radiocontrast media, adverse reactions to, 1459
 Radiographic features, of pulmonary edema, 2605t
 Radiographic sacroiliitis, in ankylosing spondylitis, 1485, 1486f
 Radiographs
 of ankle injuries, 4312
 from asplenic male neonate, 2823f
 cervical spine, of patient with JIA, 1477f
 of chronic recurrent aspiration, 2610, 2611f
 of cystic fibrosis, 2669f
 in esophageal perforation, 2271–2272
 of hand, showing changes in JIA, 1480f
 for interstitial lung disease, 2635
 of left isomerism with polysplenia, 2823f
 long-term mechanical ventilation and, 2729
 of patient with bacterial tracheitis, 2572f
 plain
 for appendicitis, 2399–2400, 2400f
 for osteomyelitis, 4286
 for septic arthritis, 4292
 for primary immune deficiency, 2624
 of primary pulmonary hypertension, 2833f
 for respiratory disease, 2517–2519
 of right isomerism with asplenia, 2823f
 of valvular pulmonary stenosis, 2788f
 of ventricular septal defect, 2783f
 Radioiodine administration, hypothyroidism and, 3404
 Radioisotope studies, in urinary tract obstruction, 3278
 Radiologic cardiac assessment, 2746–2762
 Radiology
 for allergic bronchopulmonary aspergillosis, 2629, 2630f
 in asthma, 1392, 1393f
 for cystic fibrosis, 2669–2670, 2669f–2670f
 diagnostic, in dental assessment, 2255
 for hypersensitivity pneumonia, 2614
 of hypopituitarism, 3369–3370, 3370f
 for sarcoidosis, 2623
 Radionuclide angiography, 2758
 for brain death, 591t
 Radionuclide cerebral blood flow study, for brain death, 589–592
 Radionuclide cystogram, of vesicoureteral reflux, 3272f
 Radionuclide lung scans, 2518–2519
 Radionuclide scanning, for liver, 2445
 Radionuclide scintigraphy scans, 2257
 Radionuclide studies
 for osteomyelitis, 4286
 of thyroid, 3401
 Radiopaque flecks, 4439
 Radiopaque substance, on KUB, in toxicologic diagnosis, 705t
 Radon, 4424
 RAG1 deficiency, 1263t
 RAG2 deficiency, 1263t
 RAG-independent adaptive immunity, 1286
 Raine syndrome, 477
 RALD. See RAS-associated autoimmune leukoproliferative disorder
 Rales, 2513
 Raloxifene, for gynecomastia, 3496
 Raltegravir, for HIV, 2098t–2107t
 Ramsay Hunt syndrome, 3673, 3907, 4002
 Ramstdet procedure, 2279
 Rancho Los Amigo scale (RLAS), 4387, 4387t
 Randomized clinical trials (RCTs), children and adolescents with PTSD, 253
 Range of motion, in deformational plagiocephaly, 3584–3585
 Ranula, 2254
 in mucocele, 4148
 Rape
 clinical manifestations of, 1235–1236
 epidemiology of, 1234–1235
 interview and physical examination, 1236
 laboratory data, 1236
 prevention, 1237–1238
 treatment of, 1236–1237
 types of, 1235
 Rapid antigen-detection tests, for GAS pharyngitis, 2559
 Rapid eye movement (REM) sleep, 201–202 disorders, 3638
 Rapid healing, 4277
 Rapid plasma reagins (RPR), 1246 test, 1870
 Rapid psychosocial history, screening interview for taking, 217, 217t
 Rapid respiration, predicting toxicity from vital signs in, 704t
 Rapid response systems, 44–45
 Rapid sequence intubation (RSI), 560, 560f, 619
 Rapidly progressive glomerulonephritis, 3194–3195, 3195f, 3195t
 Rapidly progressive thrombosis, 3041, 3041t
 Rapid-onset dystonia parkinsonism (RODPP), 3686
 Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD), 2723–2726, 3126t, 3430, 3705t–3707t
 clinical manifestations of, 2723–2724, 2724f
 diagnosis of, 2724, 2725f
 Rapunzel syndrome, 2304
 RAR. See Retinoic acid receptor
 Rare tumors, 3164–3168
 Ras homolog enriched in brain (RHEB), 3657
 RAS-associated autoimmune leukoproliferative disorder (RALD), 1332t–1333t
 Rash
 in exclusion or inclusion in daycare, 187t–192t
 in Henoch-Schönlein purpura, 1554
 of HIDS, 1524f, 1526f
 of JDM, 1503f
 malar, suggestive of rheumatic disease, 1461t
 of NOMID, 1527f
 petechial
 in parvovirus B19, 1989f
 treatment algorithm for, 1744f
 purpuric
 in meningococcemia, 1741f
 suggestive of rheumatic disease, 1461t
 in Rocky Mountain spotted fever, 1904, 1904f
 of rubella, 1966f
 in SLE, 1460–1461, 1492f, 1497t

- Rash (*Continued*)
 of systemic JIA, 1478f
 varicelliform, in vaccinated persons, 2000–2001
- Rashkind balloon atrial septostomy, 2813f
- RAS/MAPK pathway, 787–789, 787f
 diagnosis of, 788
 genes and features of, 788t
- Rasmussen encephalitis, 3600, 3705t–3707t, 3711
- RASopathies, 3159
- Rastelli operation, 2809, 2810f
- Rat bite fever, 4460–4461, 4460f
- Rat lungworm, 2208
- Rat poison, 3046
- Rat snakes, 4467f
- Rat-bite fever (*Streptobacillus moniliformis*), 1655t–1656t
- Rate, electrocardiography, 2748
- Rattlesnakes, 4467, 4467f–4468f
- Raxibacumab, 4455
- Raynaud phenomenon, 1507–1513, 1509f, 1511f, 4129
- RBCs. *See* Red blood cells
- RCA. *See* Root cause analysis
- RCC. *See* Renal cell carcinoma
- RCTs. *See* Randomized clinical trials
- RDA. *See* Recommended dietary allowance
- RDD. *See* Rosai-Dorfman disease
- RDS. *See* Respiratory distress syndrome
- Reach Out and Read program, 166
- Reaching Every Child through Quality Improvement (REC-QI), 29
- Reactivation tuberculosis, 1841
- Reactive airways disease syndrome, 2619
- Reactive arthritis, 4291
Campylobacter in, 1791
 CDI-associated, 1825
 characteristics, 1483t
 clinical manifestations of, 1488–1489
 complications and prognosis, 1489
 diagnosis of, 1489
 differential diagnosis of, 1488–1489
 etiologic microorganisms, 1484t
 pathogenesis of, 1488
 poststreptococcal, 1710
 treatment of, 1489
- Reactive attachment disorder, 376–378, 381t
- Reactive infectious mucocutaneous eruption (RIME), 4078, 4078f, 4079t, 4149
- Reactive perforating collagenosis, 4124, 4124f
- Readiness assessments, 1171
- Reading
 disorders of, 300, 304t
 and IQ, uncoupling over time, 315f
 lack of fluency in, 317
 typical and dyslexic, 316f
- Ready-to-use therapeutic food (RUTF), 430–431
- Rearrangements, balanced and unbalanced, 760t
- Rebound, 3557
- Receptive language, 170t, 325t
- Receptors, in normal liver development, 2435t
- Recessive oncogenes, 3077
- Reciprocal translocations, 766
- Recognition molecules, in lectin pathway, 1316
- Recombinant human growth hormone (rHuGH), in CKD, 3251
- Recombinant influenza vaccine (RIV4), 1588t–1589t
- Recombination, 734
- Recommended caloric intake, 447t
- Recommended dietary allowance (RDA), 389t–390t
 for vitamin A, 454–455, 454t
- Recovery, 258
- Recovery phase, of schizophrenia, 287
- RECQL4 gene, 4097
- Recreational activities, for child with intellectual disability, 361
- Recruitment, 622
- Rectal atresia, 2406
- Rectal mucosal prolapse, 2410, 2410f
- Rectal prolapse, in cystic fibrosis, 2677
- Rectal suction biopsy, 2296
- Rectobulbar urethral fistulas, 2406
- Rectocele, 2410
- Rectovesicular fistulas, 2406
- Rectum, surgical conditions of, 2404–2410
- Recumbent length, measurement of, 172
- Recurrence risk estimates, for facial anomalies, 787
- Recurrent bilateral otitis media, in Turner syndrome, 3498
- Recurrent cholangitis, liver disease and, 2442
- Recurrent hernia, 2420–2421
- Recurrent herpes labialis, 2253
- Recurrent otitis media, *Moraxella catarrhalis* in, 1760
- Recurrent pancreatitis
 acute, 2429–2431
 etiology of, 2427t
- Recurrent parotitis, 2254
- Recurrent patellofemoral subluxation, 4229
- Recurrent pharyngitis, 2561–2562
- Recurrent pneumonia, 2644, 2645t
- Recurrent respiratory papillomatosis, 2583, 2583f
- Red blood cell (RBC) count, reference intervals, 4472.e9t
- Red blood cells (RBCs), 2952, 2967
 acquired pure red blood cell anemia, 2934–2935
 with parvovirus B19 infection, 2934–2935
 transient erythroblastopenia, 2934, 2934t
- loss, hemorrhage and, 1120–1122, 1122f
- morphology, abnormal, 2930f
- production, inadequate, 1118–1119, 1121t
- transfusions, 1122, 1122t, 3014–3016
 in children and adolescents, 3014–3015, 3014t
 in preterm infants and neonates, 3015
 product and dose, 3015
 for sickle cell disease, 2975–2977
 storage age of RBC units, 3016
- Red cell aplasia, in sickle cell anemia, 2968
- Red eye, 3940t
- Red pulp, 3060
- Red reflex, 3924f
- Red tides, 4444
- Red urine, causes of, in hematuria, 3185t
- Redlined communities, 8
- Redlining, 8, 21
- Reductive adaptation, 427
- Redundant skin, 4043
- Reed-Sternberg cell, in Hodgkin lymphoma, 3106
- Reentry HAPE, 635–636
- Refeeding hypophosphatemia, 507
- Refeeding syndrome, 431–432, 432t
- Reference intervals, 4472.e9t
- Referred pain, 2234, 2236f
- Reflective listening, in motivational interviewing, 134
- Reflex seizures, 3629
- Reflex syncope, 597, 597f
- Reflexes, in neurologic evaluation, 3556–3557
- Reflux
 intrarenal, 3268f
 nephropathy, 3270
 -related renal injury, 3270
 vesicoureteral, 3270–3274
- Reflux laryngitis, GERD and, 2268
- Refractile polychromatic crystals, 3946–3947
- Refraction
 abnormalities, 3912–3915, 3913f
 accommodation, 3914–3915
 anisometropia in, 3914
 astigmatism in, 3914
 hyperopia in, 3912–3914
 myopia in, 3914, 3914f
 in eye examination, 3912
- Refractory cytopenia of childhood, 3013
- Refractory disease, treatment of, 1940
- Refractory status epilepticus, 3624
- Refsum disease, 868, 3886
- Refsum syndrome, 4118
- Refugees, separation and loss in, 201
- Refusal waiver, for immunization, 1611
- Regional anesthesia, 675, 694
 definition of, 668t
- Regional lymphadenitis, 1707
- Regionalization, in emergency medical services, 537, 537f
- Registration, Evaluation, Authorization, and Restriction of Chemical Substances (REACH), 4423
- Regression, 179
- Regurgitant lesions, in acyanotic congenital heart disease, 2797–2798
- congenital absence of the pulmonary valve, 2797
- congenital mitral insufficiency, 2797
- mitral valve prolapse, 2797–2798
- pulmonary valvular insufficiency, 2797
- tricuspid regurgitation, 2798
- Regurgitation, 2223, 2226, 2226t
 infant, 2385, 2387t
 tricuspid, 2798
- Rehabilitation
 for ankle injuries, 4312
- for burn injuries, 654
- for heart transplantation, 2905
- for musculoskeletal injury, 4297
- to somatic symptom and related disorders, 239–240
- for traumatic brain injury, 4386–4389
 medical complications of, 4387–4388
 cognitive-behavioral disorders, 4387, 4387t
 consciousness disorders, 4387, 4387t
 neuroendocrine disorders, 4388
 paroxysmal sympathetic hyperactivity, 4388
 posttraumatic seizure, 4388
 spasticity, 4388
 outcome associated with, 4388–4389
- Rehospitalization, for BPD, 1087
- Rehydration, in cholera, 1787
- Reifenstein syndrome, 3512
- Rejection
 after liver transplantation, 2508
 in renal transplantation, 3257–3258
- Relapse
 Hodgkin lymphoma, 3109
 nephrotic syndrome, 3229
 non-Hodgkin Lymphoma, 3115
 treatment for, in acute lymphoblastic leukemia, 3101, 3102f
- Relapsing fever (*Borrelia*), 1640–1641, 1655t–1656t, 1880–1881
 clinical manifestations of, 1880
 diagnosis of, 1880, 1881f
 epidemiology of, 1880, 1880f
 etiology of, 1880
 pathogenesis of, 1880
 pathology of, 1880
 prevention of, 1881
 prognosis for, 1881
 treatment of, 1880–1881
- Relapsing polychondritis (RP), 1581–1582, 1581t
- Relational bullying, 283
- Relative afferent pupillary defect, 3922–3923
- Relative energy deficiency in sport (RED-S), 4322, 4322f
- Relative polycythemia, 2997
- Relative rest, 4299
- Relaxation, 233
 training, in pain management, 693
- Reliability, 181
- Reliability science, 44
- Religious beliefs, to treatment, 53
- Remdesivir, 1956–1957
- Remediation of skills, 307
- Remeron. *See* Mirtazapine
- Remifentanil, in hepatic and renal dysfunction, 685t
- Remission, 258
 induction, for acute lymphoblastic leukemia, 3100
 in nephrotic syndrome, 3229
- Remittent fever, 1640–1641
- Remodeling
 in asthma, 1372
 of ductal plate, 2435
- Remote management, 700
- Renal abscess, 3267
- Renal agenesis, 1053t, 3260–3261
 consequences of, 782f
- Renal angiogram, for hypertension, 2917f
- Renal anomaly, and sensorineural deafness and hypoparathyroidism, 3435–3436
- Renal arterial disease, 1509
- Renal biopsy, of IgA nephropathy, 3187
- Renal calculi
 calcium oxalate and calcium phosphate, 3313–3314
 cystine, 3314

- Renal calculi (*Continued*)
 indinavir, 3315
 nephrocalcinosis, 3315
 struvite, 3314
 uric acid, 3314–3315
- Renal cell carcinoma, 3135
 associated with sickle cell trait, 3211–3212
- Renal cysts and diabetes syndrome, 504
- Renal damage, due to neuropathic bladder, 3288–3289, 3289f
- Renal disease
 anemia of, 2936–2937
 anesthetic implications in, 666t
 hemolytic anemias and, 2997
 medications for, 230
 primary, as acute glomerulonephritis, 3190t
 rickets and, 473
 in secondary intracranial hypertension, 3783t
 in sickle cell disease, 2974, 2977
 in type I GSD, 899–902
- Renal dysfunction
 chemotherapy and, 3093–3094
 liver disease and, 2440–2442
- Renal dysgenesis, 3261–3262
- Renal failure, 3242–3253
 acute kidney injury, 3242–3247
 chemotherapy and, 3088
 chronic kidney disease, 3247–3252
 end-stage renal disease, 3252–3253
 metabolic acidosis and, 516
 toxic causes of, 3895t
- Renal hyperuricemia, 945t, 947
- Renal hypoplasia, 3262
- Renal hypouricemia, 3242
- Renal injuries
 grading of, 3310t
 treatment of, 3309
- Renal involvement, of Henoch-Schönlein purpura, 1554
- Renal losses
 hypokalemia and, 499t
 hypomagnesemia and, 503t
 hyponatremia and, 492t
 hypophosphatemia and, 506t
- Renal malformations, in Turner syndrome, 3497–3498
- Renal manifestations
 in childhood lupus, 1497t
 of SLE, 1492t
- Renal osteodystrophy, 3249, 3250t
- Renal papillary necrosis (RPN), 3209
- Renal pelvis, obstruction, 3275t
- Renal syndromes, nephrotoxins produced by, 3203t
- Renal system, shock in, 607t
- Renal transplantation, 3253–3259
 characteristics of donors and recipients for, 3254
 common causes of ESRD in recipients, 3254t
 evaluation and preparing for, 3254–3256
 fluid management in infants and small children, 3257
 graft survival, 3258
 immunosuppression for, 3256–3257
 complications of, 3258–3259
 induction therapy, 3256
 maintenance, 3256–3257
- incidence and etiology of, 3253, 3253t
 indications for, 3253–3254
 kidney biopsy, 3258
 long-term outcome, 3259
 rejection of, 3257–3258
- Renal tubular acidosis (RTA), 3234–3238
 autosomal recessive osteopetrosis with, 4351t
 distal, 473f, 479, 514–515, 3234f, 3235–3236, 3236t, 3238f
- hyperkalemic, 515, 3236–3238, 3237t, 3238f
 normal urinary acidification, 3234, 3234f
 predisposition to renal calculi and, 3313
 proximal, 515, 3234–3235, 3235t
 rickets associated with, 3238
 type IV, gene variants associated with, 3377t
- Renal tubulopathy/failure, mitochondrial disease and, 935t
- Renal tumors, associated with hematuria, 3217
- Renal vein thrombosis, 529–530, 3040, 3211
- Renin-angiotensin system, 488
- Renovascular hypertension
 on children, 2917t
 diagnostic algorithm pathway for, 2919f
- Repaglinide, for T2DM, 3542t
- Repeat pregnancy, among teen mothers, 1230
- Repeated supratherapeutic ingestion, 711
- Replacement fluids, 527–529, 528t
 for diarrhea, 528t
 for emesis or nasogastric losses, 528t
- Replacement therapy, 525–529, 1586
 enzyme, 757
 transplantation, 757
- Reporting, in infection prevention and control, 1620
- Reporting quality, 40–41
- Repositioning and physiotherapy (RPPT), for deformational plagioccephaly, 3587
- Representative bias, 48t
- Reproductive issues, in polycystic ovary syndrome, 3336t
- Reptilase time, in hemostasis, 3026
- Rescue breathing, 558f, 559
- Research, definition of, 55
- Research to Accelerate Cures and Equity for Children Act, 54
- Residential housing segregation, 8–9
- Residential segregation, 21
- Residual phase, of schizophrenia, 287
- Residual volume, 2519
- Resilience, 138–139
 of GLB youth, 1183
- Resistance
 antibiotic, of *Haemophilus influenza*, 1756
 antimicrobial
 in *Enterococcus*, 1722–1723, 1722t–1723t
 in *Neisseria gonorrhoeae*, 1750
 antimicrobial, patterns of, 1671, 1672t
 in equation of motion, 621
 generalized, to glucocorticoids, 3460
 IVIG, 1547, 1547t
 steroid, in nephrotic syndrome, 3229
 to thyroid hormone, 3416, 3422
- Reslizumab, for asthma, 1404
- Resonance, disorders of, 332
- Resorption, filtered bicarbonate, in proximal tubules, 511f
- Resource-based outcome measure, 543
- Resources
 for information on childcare, 194t
 of pediatric emergency care, 545t
 for youth, parents, and providers, 1174t
- Respiration
 failure to initiate or sustain, 1070
 paradoxical, 579
- Respiratory acidosis, 513t, 521–523
 causes of, 522t
- Respiratory alkalosis, 513t, 523–525
 causes of, 524t
- Respiratory depression, opioid-induced adverse effects, 684t
- Respiratory disease, 248t
 acute, in adenoviruses infection, 2034
 anesthetic implications in, 666t
 diagnostic approach to, 2513–2525
 airway visualization and lung specimen-based
 diagnostic tests, 2523–2525
 blood gas analysis, 2513–2517
 examination of lung secretions, 2522–2523
 exercise testing, 2523
 history of, 2513
 laryngoscopy, 2523
 microbiome, 2523
 physical examination of, 2513
 pulmonary function testing, 2519–2522
 radiographic techniques for, 2517–2519
 transillumination of the chest, 2517
- medications for, 230
- in newborn, 1054t
- Respiratory distress, 612–629. *See also* Respiratory failure
 in acutely ill child, 549
 cardiovascular disease manifesting as, 612–613, 614t
 clinical examination in, 616
- Respiratory distress (*Continued*)
 critically ill neonate with cyanosis, 2798–2799, 2799f
 definition of, 612–620
 in delivery room, 1072
 localizing signs for pulmonary pathology in, 612t
 management of, 618–620
 monitoring a child in, 616–618
 neurologic disease manifesting as, 612–613
 nonpulmonary causes of, 613t
 other nonpulmonary entities manifesting as, 613
 recognition and treatment of, 557–560
 respiratory disease manifesting as, 612–613
 toxic metabolic states manifesting as, 613
 without respiratory disease, 612–613
- Respiratory distress syndrome (RDS), 1028, 1077–1083
 clinical manifestations of, 1077
 diagnosis of, 1077–1079, 1079f
 etiology and pathophysiology, 1077
 incidence of, 1077–1082
 in infants of diabetic mothers, 1141
 pharmacologic therapies for, 1081
 prevention of, 1079–1080
 prognosis for, 1081–1082
 treatment of, 1080–1081
- Respiratory failure, 613–615
 anatomic sites of lesions causing, 613t
 definition of, 612
 in delivery room, 1070
 diffusion in, 615
 hypercarbic, 614
 hypoxic, 614
 management of, 618–620
 monitoring a child in, 616–618
 acid-base abnormalities in, 617
 assessment of oxygenation and ventilation deficits in, 617–618
 blood gas abnormalities in, 617
 clinical examination as, 616
 pathophysiology of, 614–615
 recognition and treatment of, 557–560
 ventilation-perfusion mismatch in, 614–615
- Respiratory illness, in childcare, 193
- Respiratory infections, associated with Down syndrome, 369
- Respiratory manifestations
 of enterovirus infections, 1982
 in food allergy, 1445
- Respiratory mechanics, monitoring, 628–629
 in auto-PEEP, 628–629
 in dead space ventilation, 628–629
 in exhaled tidal volume, 628
 in peak inspiratory pressure, 628
 in respiratory system dynamic compliance, 628
 in static compliance, 628
- Respiratory patterns, in neurologic disease, 615t
- Respiratory (“atypical”) presentations, as complications of GERD, 2268
- Respiratory secretions, in pediatric palliative care, 65t–68t
- Respiratory support, modalities for, 2716–2717
- Respiratory symptoms, in newborn, 1148
- Respiratory syncytial virus (RSV), 2028–2031
 antiviral therapies for, 1953t–1954t, 1955–1956
 amantadine and rimantadine, 1956
 baloxavir, 1956
 oseltamivir, peramivir, and zanamivir, 1956
 ribavirin, 1955–1956
- bronchiolitis and, 2585
- clinical manifestations of, 2030
- in common cold, 2551
- diagnosis of, 2030
- epidemiology of, 2028–2029
- etiology of, 2028
- passive immunoprophylaxis for, 2031
- pathogenesis of, 2029
- pneumonia, 2645f
- prevention of, 2031
- prognosis of, 2030–2031
- treatment of, 2030
- vaccine for, 2031
- Respiratory system
 chronic/recurrent symptoms in, 2526–2531
 cystic fibrosis and, 2662t

- Respiratory system (*Continued*)
 dynamic compliance, 628
 dysfunction of, fetal therapy for, 1027t
 morbidities of perinatal and neonatal illness, 998t
 shock in, 607t
 static compliance, 628
 Respiratory tract
 complications, disorders with, 2531t
 cystic fibrosis and, 2666–2667
 Respiratory tract disease, *Mycoplasma pneumoniae* and, 1888
- Respiratory tract infections
 diphtheria, 1725–1727, 1726f
 Staphylococcus aureus, 1695
- Response, in nephrotic syndrome, 3229
- Response to intervention (RTI) model, 305–306, 319
- Responsive feeding, 414, 414t, 417, 417t
- Responsive neurostimulation (RNS), in epilepsy surgery, 3615–3616
- Rest tremor, 3678
- REST*-associated WT predisposition, 3131t–3132t
- Restless legs syndrome (RLS), 210, 210t, 1569, 3638
- Restraint methods, 95t
- Restrictive cardiomyopathy, 2886–2887
 clinical manifestations of, 2886
 diagnosis of, 2886
 echocardiogram of, 2881f
 etiology of, 2879t
 pathogenesis of, 2886
 prognosis and management of, 2887
- Restrictive dermopathy, 962t
- Restrictive feeding patterns, 379
- Resuscitation
 equipment, 535, 535t
 neonatal, 1070–1073, 1070f–1072f
 status, 60–61
- Retentive encopresis, 2293
- Reticular dysgenesis, 1263t, 3010
- Reticulocyte count, reference intervals, 4472.e9t
- Reticulocyte hemoglobin content, in iron-deficiency anemia, 2947t
- Reticulocyte percentage, in hemolysis, 2952
- Reticulocytosis, 2989
- Retiform hemangioendothelioma, 3162
- Retina, gyrate atrophy of, 854
- Retinalacular vessels, 4231, 4232f
- Retinal detachment, 3960–3961
- Retinal disorders, 3955–3963
 Best vitelliform degeneration, 3960
 blood disorders, 3962
 cherry-red spot, 3960
 chorioretinal coloboma, 3963
 Coats disease, 3961
 diabetic retinopathy, 3961–3962
 familial exudative vitreoretinopathy, 3961
 hypertensive retinopathy, 3961
 inherited retinal dystrophies, 3958–3959
 myelinated nerve fibers, 3963
 persistent fetal vasculature, 3957
 phakmas, 3960
 retinal detachment, 3960–3961
 retinoblastoma, 3957–3958
 retinopathy
 of prematurity, 3955–3957
 trauma-related, 3962–3963
 retinoschisis, 3960
 Stargardt disease, 3959–3960
 subacute bacterial endocarditis, 3962
- Retinal hamartoma, 3658f
- Retinal hemorrhage, 117, 120f
- Retinal vasculopathy with cerebral leukodystrophy (RVCL), 1530t
- Retinitis pigmentosa, 3958–3959, 3959f
 inborn errors of metabolism and, 809t–810t
- Retinoblastoma, 3077, 3149–3150, 3149f–3150f, 3957–3958, 3958f, 3972–3973
 clinical manifestations of, 3149
 diagnosis of, 3149–3150, 3149f
 epidemiology of, 3149
 pathogenesis of, 3149
 prognosis of, 3150
 screening of, 3149
 treatment of, 3150
- Retinoic acid, 451
- Retinoic acid embryopathy, 780t
- Retinoic acid receptor (RAR), 452
- Retinoid X receptor (RXR), 452
- Retinoids, 452
 for acne vulgaris, 4179
 for erythrokeratoderma variabilis, 4117
 for psoriasis, 4100
- Retinol
 low plasma, inflammation causing, 452
 structure of, 451f
- Retinopathy
 diabetic, 3961–3962, 3962f
 for sickle cell disease, 2977
 stellate macular, in cat-scratch disease, 1814
 trauma-related, 3962–3963, 3963f
- Retinopathy of prematurity (ROP), 3955–3957
 classification of, 3956f
 diagnosis of, 3956t
 treatment for, 3956t
- Retinoschisis, 3960
- Retractile testes, 3302
- Retraction pocket, 4015–4016
- Retrocaval ureter, 3280
- Retrocochlear hearing loss, 3983–3984
- Retrograde urethrogram, 3285
- Retropharyngeal abscess, 2566–2567, 2567f
- Retropharyngeal space infection, 2248t, 2565
- Rett syndrome, 3720, 3899t
- Return to play (RTP)
 graduated, sports-related TBI, 4317, 4317t
 transition from immediate management to, 4298–4299
- Reversal reactions, in Hansen disease (*Mycobacterium leprae*), 1857
- Reverse cholesterol transport, high-density lipoprotein and, 874
- Reverse transport, critically ill newborn, 1052
- Reverse-sequence syphilis screening, 1246, 1247f
- Reversible infantile respiratory chain deficiency, 3698
- Review of systems, approach to malnutrition on, 435t
- Revised Pediatric Emergency Assessment Tool (Re-PEAT), 543–544, 543t
- Revised World Health Organization Classification of Lymphoid Neoplasms, 3106, 3107t
- Reye syndrome, 2485, 2485t–2486t
- Rh deficiency syndrome, 2963
- Rh incompatibility, hemolytic disease of newborn caused by, 1123–1125, 1124f
- Rhabditiform larvae, 2204
- Rhabdoid tumor, 3135
- Rhabdomyolysis, 3793, 3795f, 3803f
 causes of, 3800t
 inherited neuromuscular disorders associated with, 3801t–3802t
 mitochondrial disease and, 935t
 with myoglobinuria, 3218
 in toxicologic diagnosis, 704–705, 705t
- Rhabdomyomas, 2892, 2892f
- Rhabdomyosarcoma, 2584, 3083–3084, 3136–3138, 3327
 clinical manifestations of, 3137
 diagnosis of, 3137, 3137f
 in ear, 4023–4024, 4023f
 epidemiology of, 3136, 3136t
 pathogenesis of, 3136
 prognosis of, 3138
 risk groups and outcome for, 3138t
 staging system for, 3138t
 treatment of, 3137–3138, 3138t
 uterine, 3344
- Rhagades, 1869t
- Rheumatic disease
 suspected
 autoantibody specificity and disease associations, 1462t
 C-reactive protein levels, 1463t
 diagnosis, evaluation based on, 1463t
 evaluation, 1460–1463
 imaging studies, 1463
 laboratory testing, 1461–1463
 signs suggestive of, 1460–1461
 symptoms suggestive of, 1460
- Rheumatic disease (*Continued*)
 treatment, 1464–1470
 biologic agents, 1469–1470, 1469t
 β-cell depletion, 1470
 IL-1 antagonists, 1470
 IL-6 receptor antagonist, 1470
 IVIG, 1470, 1470t
 modulator of T-cell activation, 1469–1470
 TNF-α antagonists, 1469
- cytotoxics
 azathioprine, 1470
 cyclophosphamide, 1470
- nonbiologic disease-modifying antirheumatic drugs, 1464–1469
 glucocorticoids, 1465–1469
 hydroxychloroquine, 1465
 leflunomide, 1465
 methotrexate, 1464–1465
 mycophenolate mofetil, 1465
 sulfasalazine, 1465
- NSAIDs, 1464–1469
 rheumatology teams and primary care physicians, 1464, 1465t
- Rheumatic fever, 1711–1715
 chemoprophylaxis for, 1715t
 clinical manifestations and diagnosis of, 1711–1714, 1712t
- complications of, 1714
- epidemiology of, 1711
- major criteria, 1712–1713
 carditis, 1712–1713
 chorea, 1713
 erythema marginatum, 1713
 migratory polyarthritis, 1712
 subcutaneous nodules, 1713
- minor criteria, 1713–1714
 differential diagnosis of, 1713–1714, 1714t
 recent GAS infection, 1713
- pathogenesis of, 1711
- prevention of, 1715
- prognosis of, 1714–1715
- treatment of, 1714
 antibiotic, 1714
 antiinflammatory, 1714
 Sydenham chorea, 1714
- Rheumatic heart disease, 2872–2875
 aortic insufficiency, 2875
 definitions of, 2873t
- Doppler echocardiography for, 2872, 2873f, 2873t–2874t
 mitral insufficiency, 2872–2873, 2874t
 mitral stenosis, 2873–2875, 2874f–2875f
 pulmonary valve disease, 2875
 tricuspid valve disease, 2875
- Rheumatic valvulitis
 echocardiographic findings in, 2874t
 morphologic findings in, 2874t
- Rheumatoid arthritis (RA), associated with AA amyloidosis, 1536
- Rheumatologic disease
 anesthetic implications in, 666t
 eosinophilia caused by, 1295t
 Kawasaki disease and, 1546t
- Rhinitis
 asthma with, 1398
 physical examination in, 1374
- Rhinitis medicamentosa, 1380, 2552t
- Rhinocerebral mucormycosis, 1943
- Rhinoconjunctivitis, physical examination in, 1374
- Rhinocort Aqua, for allergic rhinitis, 1384t–1385t
- Rhinorrhea, 1374
 in common cold, 2553
 respiratory syncytial virus (RSV) and, 2030
- Rhinosinusitis
 bacterial, 2555f
 cystic fibrosis and, 2678
- Rhinoviruses, 2035–2036
 clinical manifestations of, 2036
 complications of, 2036
 diagnosis of, 2036
 epidemiology of, 2036
 etiology of, 2035
 pathogenesis of, 2036

- Rhinoviruses (*Continued*)
 prevention of, 2036
 treatment of, 2036
- Rhizomelic chondrodysplasia punctata, 867, 868f
- Rhizomelic shortening, 4336
- Rhodesian trypanosomiasis, 2161
- Rhodnius prolixus*, 2163
- Rhododendron, toxicity, 722t
- Rhombencephalosynapsis, in brainstem and cerebellar disorders, 3577
- Rhus dermatitis, 4089
- Rhythm, electrocardiography, 2748
- Rhythmic movements, sleep-related, 211
- Rib fractures
 hem thorax and, 2709f
 in spinal trauma, 576
- Rib vertebral angle difference (RVAD), measurement of, 4244, 4244f
- Ribavirin, 1955–1956
 for hepatitis C, 2471
 for parainfluenza viruses, 2028
- Riboflavin (vitamin B₂), 56t, 456t–457t, 460–461
 deficiency, 461
 clinical manifestations of, 461, 461f
 diagnosis of, 461
 prevention of, 456t–457t, 461
 treatment of, 461
- dietary reference intake, 397t–403t
 for migraine, 3646t–3647t
 toxicity, 461
- Riboflavin transporter deficiency (RTD), 461, 3603
- Ribonucleic acid (RNA)
 flow of information from DNA to, 731f
 messenger, 730
- Ribonucleotide reductase, disorders associated with, 955
- Ribose-5-phosphate isomerase deficiency, 900t–901t, 920
- Ribosopathy, 2931
- Richner-Hanhart syndrome, 816–817
- Ricin, 4449
- Rickets, 470–474
 associated with renal tubular acidosis, 3238
 autosomal dominant hypophosphatemic, 473t, 477
 autosomal recessive hypophosphatemic, 473t, 477
 calcium-deficient, 4379–4380
 causes of, 471t
 clinical evaluation of, 472–474
 clinical manifestations of, 470–472, 471t, 472f
 clinical variants of, 4379t–4380t
 congenital, 475
 diagnosis of, 472, 473t
 etiology of, 470
 hereditary hypophosphatemic, with hypercalcemia, 473t, 478
 hypophosphatemic, with hypercalcemia, 508
 nutritional, risk factors for, 474t
 phosphate-deficient, 4379–4380
 of prematurity, 478–479
 radiology of, 472, 473f
 vitamin D-dependent
 type 1, 473t, 476
 type 2, 473t, 476
- X-linked hypophosphatemic, 473t, 477
- Rickettsia akari*, 1900t–1902t, 1907
- Rickettsia conorii*, 1906–1907, 1907f
- Rickettsia prowazekii*, 1910–1911
- Rickettsia* spp., 364D genotype, 1900t–1902t
- Rickettsia typhi*, 1909–1910
- Rickettsial infections
 associated with hemophagocytic syndrome, 3173t
 causing infectious pneumonia, 2643t
- Rickettsialpox (*Rickettsia akari*), 1900t–1902t, 1907
- Rickettsioses
 spotted fever group, 1899–1907, 1900t–1902t
 flea-borne spotted fever, 1900t–1902t, 1907
 Mediterranean spotted fever or boutonneuse fever, 1900t–1902t, 1906–1907, 1907f
 rickettsialpox (*Rickettsia akari*), 1900t–1902t, 1907
- Rocky Mountain spotted fever, 1899–1906, 1900t–1902t
- typhus group, 1909–1911
 epidemic (louse-borne) typhus, 1910–1911
 murine (endemic or flea-borne) typhus, 1909–1910
- Ridley-Jopling scale, 1856–1857
- Rifabutin, 1690
 for tuberculosis, 1849t, 1830
- Rifampin, 1690
 for bacterial meningitis, 3771
 for Hansen disease, 1858
 against *M. tuberculosis*, 1830
 for nontuberculous mycobacteria infection, 1865
 resistance, in tuberculosis, 1848
 for *Staphylococcus aureus*, 1697
 for tuberculosis, 1849t, 1853
- Rifamycin, against *M. tuberculosis*, 1830–1831
- Rifapentine, for tuberculosis, 1849t, 1830, 1853
- Rifaximin, 1690
- Rift Valley fever, 2073
 clinical manifestations of, 2076
- Riga-Fede disease, 2240
- Right aortic arch, 2826
- Right middle lobe syndrome, 2658
- Right to consent, by minors, 1168
- Right ventricle
 double-chamber, 2789–2790
 double-outlet, 2808–2809
 with malposition of the great arteries, 2815
 without pulmonary stenosis, 2815
- Right ventricular hypertrophy, 2747, 2749–2750, 2751f
- Right-sided hilar lymphadenopathy, of tuberculosis, 1839f
- Right-to-left shunt, in newborn, 1054t
- Rigidity, 3555
 in choreoathetosis, 3678
- Riley-Day syndrome, 3890, 3900
- Rilonacept, for amyloidosis, 1537
- Rilpivirine, for HIV, 2098t–2107t
- Rimantadine, 1956
- RIME. *See* Reactive infectious mucocutaneous eruption
- RIN2-related cutis laxa, 4376t
- Ring chromosome syndrome, 4070t–4071t
- Ring chromosomes, 770
- Ringed sideroblasts, 2950
- Ringworm, in tinea capitis, 4160–4161
- Riociguat, 2834t
- Risdiplam, 3873
- Risk adjustment
 in emergency medical services, 543–544
 tools, for ED, 543–544
- Risk area, adolescent, 1164t–1165t
- Risk factors
 for adolescent health behaviors, 1187t
 for *Bartonella*, 1812t
 for deformational plagioccephaly, 3584, 3584t
 for Legionnaires disease, 1810–1811
 for persistent asthma, 1387t
 for poor outcome, in active coccidioidomycosis, 1937t
 for pulmonary embolism, 2693t
 for UTIs, 3265t
- Risk group
 for neuroblastoma, 3126t
 for pneumococcal infection, 1702t
- Risk priority number, 43–44
- Risk reduction, for SIDS, 2538–2539
- Risks
 of adolescent pregnancy, for mother and child, 1230–1231
 of tonsillectomy and adenoidectomy, 2565t
- Risk-stratified therapy, for acute lymphoblastic leukemia, 3099–3100
- Risperidone
 for aggressive behavior, 280
 for psychosis and mania, 228t
- Ristocetin cofactor, 3036
- Ritus sardonicus, 1822
- Ritalin. *See* Methylphenidate
- Ritonavir, for HIV, 2098t–2107t
- Ritter disease, 4153–4154, 4153f
- Rituximab, 1470, 1481t, 3088t, 3108–3109
 for ANCA-associated vasculitis, 1563–1564
 for immune thrombocytopenia, 3054
 for lupus nephritis, 3197–3198
 for nephrotic syndrome, 3230
 for warm autoimmune hemolytic anemia, 2995
- River blindness, 2207
- Rizatriptan, for migraine, 3646t–3647t
- RLS. *See* Restless legs syndrome
- RNA polymerase III deficiency, 1339t
- RNA-targeted therapy, 758–760, 759f, 759t
- Roberts syndrome, 2764t–2766t
- Robertsonian translocations, 766
- Roberts-SC phocomelia syndrome, 774t
- Robinow syndrome, 2764t–2766t, 3299–3300
- Robotic devices, 4404
- Rochester method, 341t
- Rocker-bottom foot, 4204, 4205f
- Rockwood's classification, 4302f
- Rocky Mountain spotted fever, 1655t–1656t, 1899–1906, 1900t–1902t
 clinical manifestations of, 1904–1905, 1904f
 complications of, 1906
 diagnosis of, 1905
 differential diagnosis of, 1905
 epidemiology of, 1899, 1903f
 etiology of, 1899
 in Kawasaki disease, 1544–1545
 laboratory findings of, 1905
 pathology and pathogenesis of, 1903–1904, 1903f
 prevention of, 1906
 prognosis for, 1906
 supportive care for, 1905–1906
 transmission of, 1899–1903, 1903f
 treatment of, 1905
- Rocuronium, 669t, 671
 for intubation, 620t
- Rodent bites, 4458t
- RODP. *See* Rapid-onset dystonia parkinsonism
- Rogers syndrome, 458t, 2944
- ROHHAD. *See* Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation
- Role-play activity, 165
- Romană sign, 2167
- Romano-Ward syndrome, 595t
- Rome IV diagnostic criteria, for defecatory disorders, 2292t
- Rome Statute of the International Criminal Court, 108–109
- Romiplostim, for chronic ITP, 3054–3055
- Root, of tooth, 2250f
- Root cause analysis (RCA), 43
- Rooting reflexes, 591t
- ROP. *See* Retinopathy of prematurity
- Rosai-Dorfman disease, 3070–3071, 3169, 3170t
- Rosenberg-Chutorian syndrome, 954
- Rosenthal fibers, 3119, 3717
- Roseola (human herpesviruses 6 and 7), 2016–2018
 clinical manifestations of, 2016–2017, 2017f
 complications of, 2018
 diagnosis of, 2017–2018
 differential diagnosis of, 2017–2018
 epidemiology of, 2016
 etiology of, 2016
 laboratory findings of, 2017
 pathogenesis of, 2016
 pathology of, 2016
 prevention of, 2018
 prognosis for, 2018
 treatment of, 2018
- Roseola infantum, 2016–2017
- Rosiglitazone, for T2DM, 3542t
- Ross procedure, 2792
- Ross syndrome, 3922
- Rotator cuff injury, 4302–4303
- Rotaviruses, 2050–2053
 clinical manifestations of, 2051–2052
 diagnosis of, 2052
 differential diagnosis of, 2052
- epidemiology of, 2051
- etiology of, 2050–2051
- immunization, 2375
- laboratory findings of, 2052
- pathogenesis of, 2051, 2365f
- prevention of, 2052–2053
- prognosis for, 2052
- seasonality of, 2359
- treatment of, 2052
- vaccines for, 30–31t, 1588t–1589t, 1604, 2052–2053
- in viral AGE, 2361

Roth spots, in subacute bacterial endocarditis, 3962, 3962f
 Rothmund-Thomson syndrome, 962t, 3141, 4097, 4098f
 Rotor syndrome, 2456
 "Round" pneumonia, 1702f
 Roundworm, 2198
 Roussy-Lévy syndrome, 3673, 3886
 Routine immunizations, 2835
 Routine mental health assessment, 264
 Routine testing, 54
 Rovsing sign, appendicitis and, 2398–2399
 RPN. *See* Renal papillary necrosis
 RPPT. *See* Repositioning and physiotherapy
 RPR. *See* Rapid plasma reagins
 RSI. *See* Rapid sequence intubation
R-spondin1 gene, 3481, 3486
 RSV. *See* Respiratory syncytial virus
 RTA. *See* Renal tubular acidosis
 RTD. *See* Riboflavin transporter deficiency
RTEL1 deficiency, 1288
 Rubella, 1623t–1625t, 1965–1968. *See also* German measles
 clinical manifestations of, 1965–1966, 1966f
 complications of, 1967
 congenital rubella syndrome, 1967, 1967t, 1968f
 diagnoses of, 1966–1967
 differential diagnoses of, 1967
 epidemiology of, 1965, 1965f
 etiology of, 1965
 laboratory findings of, 1966
 pathogenesis of, 1965, 1966f
 pathology of, 1965, 1966t
 prevention of, 1968
 prognosis for, 1968
 roseola and, 2017–2018
 supportive care for, 1968
 treatment of, 1967
 vaccination for, 30–31t, 1968
 Rubinstein-Taybi syndrome, 768t–769t, 780t, 796–797, 2764t–2766t
 Rufinamide
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Rule of nines, 649
 Rumack-Matthew nomogram, for acetaminophen poisoning, 710f
 Rumbling mid-diastolic murmur, 2745
 Rumination, 3635
 infant, 2385, 2387t, 2389t
 Rumination disorder, 240
 Runaway children, among GLB youth, 1184–1185
 Running
 hyponatremia, 3375
 injuries associated with, 4331
 Ruptured globe, 3978
 Ruptures
 sinus of Valsalva aneurysm, 2787
 tunica albuginea, 3311f
 Rural-urban location, childhood injuries and, 95
 Russel-Silver syndrome, 4070t–4071t
 RUTF. *See* Ready-to-use therapeutic food
 RVT. *See* Renal vein thrombosis
 RXR. *See* Retinoid X receptor
 Ryanodine 1 (*RYR1*) variant-related central core disease, 3813

S

Saber shins, 1869t
 Sabin-Feldman dye test, 2193
 Saccular (cystic) bronchiectasis, 2658
 Saccular cysts, 2576, 2576f
 Sacral agenesis, 3291
 Sacral dimples, 4043
 SACRAL syndrome, 3662
 Sacrococcygeal teratoma (SCT), 1034, 1034f
 Sacrococcygeal tumors, 3150, 3152f
 Sacroiliitis
 imaging of, 1485–1486, 1486f
 sports-related, 4306–4307
 S-adenosylhomocysteine hydrolase (SAHH) deficiency, 823

Saethre-Chotzen syndrome, 794t–795t, 2764t–2766t
 in craniosynostosis, 3583
 Safe and equitable care, 50
 Safety
 ambulatory, 49–50
 in healthcare, for children, 42–50
 culture of, 44
 frameworks of, 42, 43f
 opportunities and gaps in, 44–50
 research and improvement of, 50
 in interfacility transport, 542
 occupational, 50
 surgical, 49
 Safety net providers and programs, in adolescents, 1165
 Safety-II, 42
 Sagittal plane imbalances, 4242
 Salbutamol, for transient tachypnea of newborn, 1088
 Salicylates
 intoxication, 516, 991
 poisoning, 703t, 707t–708t, 711–712
 Salicylic acid, for common warts, 4168–4169
 Salivary glands
 diseases of, 2254
 ligation, for chronic recurrent aspiration, 2611
 Salmon patch. *See* Nevus simplex
Salmonella, 1765–1776
 antibiotic therapy for, 2373t–2375t
 bacterial gastroenteritis and, 2357t–2358t
 enteric fever (typhoid fever), 1771–1776
 nontyphoidal salmonellosis, 1765–1771
 seasonality of, 2359
 serotypes *typhi* or *paratyphi* infection, 1623t–1625t
Salmonella typhi, 4446
 Salmonellosis, nontyphoidal, 1765–1771
 acute enteritis, 1767
 bacteremia, 1767–1768, 1770f
 chronic *Salmonella* carriage, 1768
 diagnosis of, 1768–1769
 epidemiology of, 1766
 etiology of, 1766
 extraintestinal focal infections, 1768
 formation of *Salmonella*-containing vacuole, 1769f
 pathogenesis of, 1766–1767, 1769f
 prevention of, 1771
 prognosis for, 1771
 treatment of, 1769–1771
 virulence system of, 1768f
 Salpingitis, 1896
 Salt
 cerebral salt wasting, 3376
 depletion, cystic fibrosis and, 2678
 loss, primary, 3376
 supplementation, for POTS, 599
 Salter-Harris classification, 4278, 4278t, 4279f
 Salt-wasting form, in 21-hydroxylase deficiency, 3462–3463
 Salvaged autologous blood, 3016
 SAMD9/9L-related disorder, 3001t, 3009
 Sampling
 chorionion villus, 1025
 fetal blood, 1019
 mycobacterial, in tuberculosis, 1848–1849
 percutaneous umbilical blood, 1124
 Sanders skeletal maturity staging system, 4244
 Sandhoff disease, 3714
 Sandifer syndrome, 2264, 3635
 Sanfilippo syndrome, 939f, 940–941, 940t, 941f
 Santavuori disease, 3716
 Santavuori-Haltia syndrome, 887t
 SAO. *See* Southeast Asian ovalocytosis
 Saphris. *See* Asenapine
 Saprophytic (noninvasive) syndromes, 1929–1930
 α-Sarcoglycan, 3839–3842
 Sarcoglycanopathy, in limb-girdle muscular dystrophies, 3842
 Sarcoidosis, 1548–1552, 2622–2623
 clinical manifestations of, 1549–1550, 1549f–1551f, 1550t, 2622
 Sarcoidosis (*Continued*)
 CSF findings in, 3759t–3760t
 diagnosis of, 1550
 diagnostic laboratory testing for, 2622
 differential diagnosis of, 1551, 1551t
 epidemiology of, 1548, 2622
 etiology of, 1548
 histopathology of, 2622, 2623f
 laboratory findings of, 1550, 1551f
 pathogenesis of, 1548–1549, 2622
 pathology of, 1548–1549
 prognosis for, 1551–1552
 radiology for, 2623
 treatment of, 1551, 2623
 Sarcolemma, 2734
 Sarcoma botryoides, 3137, 3345
 Sarcomas, pancreatic, 2433
 Sarcomere, 2734
 Sarcoplasmic reticulum (SR), 2734
Sarcopetes scabiei
 management guidelines, 1248t
 mites, 4170t
 Sarcosinemia, 838
 Sassafras, 2492t
 Saturated fatty acids, 389t–390t, 392f
 Saucerization, 4224–4225, 4225f
 Saxagliptin, for T2DM, 3542t
 Saxitoxins, 4444
 SBAR. *See* Situation Background-Assessment-Recommendation
 SCA. *See* Spinocerebellar ataxia
 Scabies, 1623t–1625t, 4171–4175, 4172t
 canine, 4175
 clinical manifestations of, 4172–4173, 4172f–4173f
 differential diagnosis of, 4173f
 drugs for, 2126t–2144t
 etiology and pathogenesis of, 4172
 management guidelines, 1248t
 Norwegian (crusted), 4174, 4175f
 other types of, 4175
 treatment for, 4173, 4174t
 Scales, 4027
 Scalp, assessment in newborn, 1001
 Scanogram, 4219, 4221f
 Scaphocephaly, 784t
 in craniosynostosis, 3582–3583
 Scaphoid fractures, 4279
 Scaphoid scapula, 1869t
 Scapholunate dissociation, 4332
 Scapulohumeral dyskinesia, 4329
 Scapuloperoneal SMA, 3875
 SCARED. *See* Self-Report for Childhood Anxiety Related Emotional Disorders
 Scarf sign, 3554–3555
 Scarletiform erythema, 4153
 Scarlet fever, 1707, 1707f
 in Kawasaki disease, 1544
 Scars, 4027
Scedosporium spp., 1948–1949
 SCFE. *See* Slipped capital femoral epiphysis
 Schatzki ring, 2261
 Schedules, for hepatitis B vaccine, 2469t, 2461t
 Scheie disease, 939
 Scheie syndrome, 940t
 Scheuermann disease, 4250–4251, 4332
 Schilling test, for cobalamin malabsorption, 2350
 Schimke immunoosseous dysplasia, 1309t, 3010
 Schindler disease, 887t, 895–896
 Schirmer test, for Sjögren syndrome, 1517
Schistosoma spp., 2212
 Schistosomiasis, 2212–2214
 acute, 2212
 chronic, 2213
 clinical manifestations of, 2212–2213
 diagnosis of, 2213
 drugs for, 2126t–2144t
 epidemiology of, 2212, 2213f
 etiology of, 2212, 2213f
 intestinal, 2212
 pathogenesis of, 2212
 prevention of, 2214
 treatment of, 2214
 urogenital, 2212

- Schizencephaly, 3569
 Schizont, 2169–2170
 Schizophrenia, 286t, 289, 331
 Schizophrenia spectrum, 285–290
 assessment, 290
 clinical course, 286–287
 comorbidity, 289
 description, 285–286
 differential diagnosis of, 287–288, 287t–288t
 epidemiology of, 286
 etiology and risk factors, 289
 neuroanatomic abnormalities, 289
 pharmacotherapy for, 290
 prevention, 289
 screening, 289–290
 sequela, 289
 Schizophreniform disorder, 285, 286t
 Schmid metaphyseal dysplasia, 4334, 4343–4344, 4344f
 Schmorl nodes, 4250
 School Breakfast Program, 416, 416t
 School climate, 102
 School reentry program, for burn injuries, 654, 655t
 School report cards, 305
 School segregation, 9
 School violence, 101–102
 epidemiology of, 101
 risk factors for, 101–102
 screening for, 102, 103f–105f
 signs and symptoms of, 102
 treatment and prevention of, 102
 School-age children
 BEARS sleep screening algorithm, 215t
 drowning, 637–638
 neurodevelopmental function and dysfunction, 300–309
 responses to death, 199
 School-based intervention, for problem behaviors, 278–279
 Schools
 adolescent, 1164t–1165t
 in adolescents, 1169–1170
 chemical pollutants in, 4427
 elementary, success in, 170t
 in pediatric palliative care, 62
 suicide screening for, 268
 Schwannomatosis, 3656
 Schwartz-Jampel disease, 3838, 3850
 SCI. *See* Spinal cord injury
 Sciatic nerve blocks, in pain management, 695
 SCID. *See* Severe combined immunodeficiency
 Scientific racism, 21
 SCIG. *See* Subcutaneous immunoglobulin
 Scimitar syndrome, 2592
 Scintigraphy, renal, 3278
 SCIWORA. *See* Spinal cord injury without radiographic abnormalities
 Sclera, 3909
 Scleredema, 1510, 4122
 Sclerema neonatorum, 4131–4132
 Sclerocornea, 3943–3944
 Sclerodactyly, 1509f
 Scleroderma, 1507–1513
 classification, 1507
 diagnosis of, 1510
 differential diagnosis of, 1510–1511
 epidemiology of, 1507
 etiology and pathogenesis, 1507, 1507t
 evaluation based on suspected diagnosis, 1463t
 laboratory findings, 1510–1511
 localized (morphea), 1507–1508
 prognosis of, 1513
 Raynaud phenomenon, 1510, 1511f
 systemic, 1507
 clinical manifestations of, 1508–1509
 provisional criteria, 1508t
 severity scale, 1510t
 treatment of, 1511–1513, 1512f
 Sclerosing cholangitis, primary, 2475–2476, 2476f
 Sclerosis, 3183
 SCN. *See* Severe congenital neutropenia
- Scoliosis
 in adolescents, 1170
 arthrogryposis in, surgery for, 4275
 congenital, 4247–4248
 idiopathic, 4242–4247, 4243f–4244f, 4246f–4247f
 in Klippel-Feil syndrome, 4261
 neuromuscular, 4248–4250
 spinal cord injury and, 4393
 Scombroid (histamine), food-borne noninfectious illnesses and, 2362t–2364t
 Scombroid fish
 foodborne illness, 4411t–4413t
 poisoning, 4444, 4445f
 Scorbutic rosary, 468, 469f
 Scorpaenidae, 4472
 Scorpion stings, 4471
 Screening
 for cervical cancer, 3347
 in children's health, 84–90
 for hepatitis C, 2470
 for HPV, 3346f, 3347
 for lead poisoning, 4438–4439, 4439t
 newborn, 1005–1006
 prenatal, 728
 pulmonary and asthma, in sickle cell anemia, 2977
 questionnaires, Pediatric Symptom Checklist, 3291–3292
 of retinoblastoma, 3149
 for STIs, 1240
 for substance use disorders, 1197–1198
 Screening tests, for infectious diseases, 79t
 Scrofula, 1843, 1843f
 Scrofuloderma, 4158
 Scrotal contents, disorders and anomalies, 3302–3309
 epididymitis, 3307
 hydrocele, 3308
 spermatocele, 3308
 swelling, 3304–3306
 testicular torsion, 3306–3307
 torsion of appendix testis, 3307
 undescended testis, 3302–3304
 varicocele, 3307–3308
 Scrotal orchiopexy, 3306–3307
 Scrotal swelling, 3304–3306, 3305t
 clinical manifestations of, 3305–3306
 differential diagnosis of, 3305t
 laboratory findings and diagnosis of, 3306, 3306f
 Scrotal tongue, 2253
 Scrotum
 acute inguinal-scrotal swelling in, 2417–2420
 examination, in adolescents, 1170
 hypospadias, 3297f
 ultrasonographic assessment, 1026f
 Scrub typhus (*Orientia tsutsugamushi*), 1900t–1902t, 1908–1909
 clinical manifestations and laboratory findings of, 1908
 complications of, 1909
 diagnosis and differential diagnosis of, 1908
 epidemiology of, 1908
 etiology of, 1908
 pathology and pathogenesis of, 1908
 prevention of, 1909
 transmission of, 1908
 treatment and supportive care in, 1908–1909
 Scurvy, 468, 469f, 4192, 4192f
 SDB. *See* Sleep-disordered breathing
 SDGs. *See* Sustainability Development Goals
 SDM. *See* Shared decision-making
 SDQ. *See* Strength and Difficulties Questionnaire
 SDR. *See* Selective dorsal rhizotomy
 SDS. *See* Shwachman-Diamond syndrome
 Seabather's eruption, 4177
 Seafood poisoning, 4444–4445
 amnesic shellfish, 4445
 azaspiracid, 4445
 ciguatera fish, 4444
 diarrhetic shellfish, 4445
 neurotoxic shellfish, 4444–4445
 paralytic shellfish, 4444
 pufferfish, 4445
 scombroid fish, 4444, 4445f
 Seasonal allergic conjunctivitis (SAC), 1422, 1422t
 Seasonal influenza, 2021
 Seasonality, of diarrheal pathogens, 2359
 Seattle Social Development Project, 278–279
 Sebaceous cysts, 4185
 Sebaceous glands, 4025f, 4026
 Sebaceous hyperplasia, 4041, 4041f
 Seborrheic blepharitis, 3935
 Seborrheic dermatitis, 4002, 4091–4092, 4092f
 vulgar, 3321t–3322t
 Seckel syndrome, 3010
 Second cancers, 3094–3096
 Second impact syndrome, 4318
 Second year of life, 158–163
 age 12–18 months, 158
 age 18–24 months, 158–163
 emerging patterns of behavior, 163t
 head circumference and weight-for-age percentiles, 159f
 length-for-age and weight-for-age percentiles, 161f
 Secondary adrenal insufficiency, 3458–3459
 causes of, 3453t
 clinical presentation of, 3458–3459
 laboratory findings of, 3459
 treatment of, 3459
 Secondary alveolar proteinosis, 2686
 Secondary amenorrhea, 1211
 Secondary CNS vasculitis, 3754, 3755t
 Secondary congenital nephrotic syndrome, 3232, 3232t
 Secondary drowning, 642
 Secondary dysmenorrhea, 1215
 Secondary gain, 237
 Secondary headaches, 3639, 3650–3651, 3651t
 Secondary hemophagocytic lymphohistiocytosis, 3168–3169
 treatment for, 3177–3179
 Secondary hyperoxaluria, 839
 Secondary hypogonadism, male, 3488t, 3491–3494
 diagnosis of, 3493
 etiology of, 3492t
 other disorders with, 3493
 treatment of, 3493–3494
 without anosmia, 3492–3493
 Secondary intracranial hypertension, 3783t
 Secondary lactose intolerance, 2347
 Secondary lesions, 4027
 Secondary mitochondrial hepatopathies, 2485–2486
 Secondary myocardial disease, etiology of, 2879t
 Secondary nephrotic syndrome, 3224t–3226t, 3232
 Secondary sclerosing cholangitis, 2476
 Secondary spontaneous pneumothorax, 2703
 Secondary survey, in multiple trauma, 575–578
 abdominal trauma, 576–577, 577f
 advanced imaging, 576t, 578, 578t
 extremity trauma, 577–578
 genitourinary trauma, 577
 head trauma, 575–576
 pelvic trauma, 577
 spinal trauma, 576
 Secondary syphilis, 1867–1868, 1867f
 Secondary tracheomalacia, 2581t
 Secondary vitamin D deficiency, 475–476
 Second-degree burn, 648–649, 650t
 Second-degree frostbite, 660t, 662
 Second-generation antipsychotics (SGAs), 226–227
 Second-line vasoactive therapy, for refractory shock, 611
 Second-wind phenomenon, 910
 Secretions
 lung, microbiological examination, 2522–2523
 nasal, 2545
 Secretary diarrhea, 2227–2232, 2376, 2376f
 Sedation, 664, 667, 676t
 conscious, 676
 deep, 676
 in mechanical ventilation, 628
 in pediatric palliative care, 71
 procedural, 676
 radiation and, 4417
 Sedative-anxiolytics, 669t
 Sedative-hypnotics, toxidrome, 703t

- Sedatives
 intoxication, 1197t
 for intubation, 620t
 in pain management, 691
 Seesaw nystagmus, 3931t
 Segawa syndrome, autosomal recessive form, 844
 Segmental hypoplasia, 3262
 SEID. *See* Systemic exertion intolerance disease
 SEIPS. *See* Systems Engineering Initiative for Patient Safety
 Seizures, 532, 2242t, 3588–3630
 acute kidney injury, 3246
 in acute porphyria, 970
 anesthetic implications in, 666t
 associated with meningitis, 3762
 classification of, 3588f–3589f, 3590t–3594t, 3594f
 conditions that mimic, 3631–3638, 3632f
 movement disorders and other paroxysmal movements, 3635–3637
 oculomotor and visual abnormalities in, 3631t, 3637–3638
 sleep-related disorders in, 3631t, 3638
 syncope and other generalized paroxysms in, 3631–3633, 3631t
 febrile, 3594–3597, 3596t
 evaluation of, 3596–3597, 3597f
 genetic and other factors leading to, 3595–3596, 3596f
 measles and, 1961
 risk factors for recurrence of, 3596t
 treatment for, 3597, 3609t–3610t
 first, evaluation of, 3589–3595, 3595t
 focal, 3599–3600
 benign epilepsy syndromes with, 3590t–3591t, 3600
 to bilateral tonic-clonic seizures, 3599–3600, 3599f–3600f
 with impaired awareness, 3599
 with preserved awareness, 3599
 severe epilepsy syndromes with, 3600
 generalized, 3600–3603
 absence seizures in, 3600–3601
 benign generalized epilepsies in, 3601
 comparison of, in disorders that can mimic them, 3634t
 generalized motor seizures in, 3601
 severe generalized epilepsies in, 3593t, 3599f, 3601–3603, 3602t
 jitteriness vs., 3619
 mechanisms of, 3592t–3593t, 3603–3604
 medical child abuse and, 128
 neonatal, 1052, 3617–3623, 3617f–3618f, 3617t–3618t
 diagnosis of, 3620–3622
 etiology of, 3617t, 3617t, 3619–3620, 3620t–3621t
 pathophysiology of, 3617
 prognosis of, 3622
 treatment for, 3622–3623
 types of, 3617–3619, 3618f, 3618t
 in neurocysticercosis, 2218
 nocturnal, 209t
 nodding syndrome in, 3630, 3630t
 in pediatric palliative care, 65t–68t, 70
 reflex, 3629
 in severe malaria, 2180
 in SLE, 1497t
 status epilepticus in, 3623–3629, 3624f–3626f, 3624t
 etiology of, 3626
 mechanisms of, 3627
 therapy for, 3627–3629, 3627f, 3628t
 stroke and, 3754
 syncope vs., 593t
 treatment of, 3604–3616
 additional, 3613–3614, 3614t
 antiepileptic drugs for. *See* Antiepileptic drugs
 approach to epilepsy surgery for, 3615–3616, 3615f
 choice of drugs, 3607–3608, 3608t–3611t
 counseling for, 3604, 3605t
 discontinuation of therapy in, 3616, 3628t
 drug therapy, principle of, 3604–3606
 initiating and monitoring therapy for, 3609t–3611t, 3612–3613
 diagnosis of, in international setting, 1147t
- Seizures (*Continued*)
 long-term therapy, deciding on, 3604, 3605f
 side effects of, 3613
 sudden unexpected death in epilepsy, 3616, 3616t
 unprovoked, 3588f, 3590t–3595t, 3597–3599
 Selectins, 1291–1292
 Selective dorsal rhizotomy, 4396
 Selective IgA deficiency, 1285, 1660
 Selective mutism, 330
 core diagnostic features and characteristics of, 252t
 Selective serotonin reuptake inhibitors (SSRIs), 1216
 for anxiety disorders, 253
 for pain, 688
 poisoning, 717, 717t
 for vasovagal syncope, 596t
 Selenium, 483t
 Selenium deficiency, as goitrogen, 3415t
 Selenoprotein N, 3815
 Selexipag, 2834t
 Self-advocacy, for child with intellectual disability, 361
 Self-concept/self-image, strategies for, 130t
 Self-conscious awareness, 163
 Self-efficacy, strategies for, 130t
 Self-examination, breast, 3329
 Self-help, 179
 Self-image, in adolescents, 1169–1170
 Self-injecting, fear of, in T1DM, 3535
 Self-injurious behaviors, 283–284
 in Lesch-Nyhan disease, 950
 Self-instruction, in psychotherapy, 231
 Self-monitoring, 233
 in psychotherapy, 231
 Self-regulated strategy development (SRSD), 323
 Self-reinforcement, in psychotherapy, 231
 Self-Report for Childhood Anxiety Related Emotional Disorders (SCARED), 218t
 Self-testing, fear of, in T1DM, 3535
 Semaglutide, for T2DM, 3542t
 Semantics, 301
 Semen analysis
 in schistosomiasis, 2213
 for varicocele, 3308
 Seminomas, 3302
 Sengstaken-Blakemore tube, for portal hypertension, 2506
 Senna, 2492t
 Sennetsu neorickettsiosis, 1900t–1902t
 Sensenbrenner syndrome, 792t
 Sensitivity, 181
 Sensorineural deafness, and renal anomaly, and hypoparathyroidism, 3435–3436
 Sensorineural hearing loss (SNHL), 3983
 gross hematuria and, 3188
 syndromic, 3987t
 Sensory and motor development, 301
 Sensory auras, in migraine, 3643
 Sensory examination, in neurologic examination, 3555–3556
 Sensory nystagmus, congenital, 3930
 Sensory predominant, toxic causes of, 3895t
 Sentinel bacterial infections, 1256
 Sentinel events, 42
 Sentinel injury, 115
 Separation
 because of hospitalization, 196
 divorce, 195–196
 grief and bereavement, 197–198, 197t–198t
 and loss, 195
 military families, 196
 move/family relocation, 196
 parental/sibling death, 196–197
 from parents, 1162
 Separation anxiety disorder, 163, 246
 core diagnostic features and characteristics of, 252t
 Sepiapterin reductase deficiency, 846
 Sepsis
 bacterial
 liver disease and, 2476, 2480f
 neonates with, 1146–1147
 cryptococcosis and, 1926
 culture-based and non-culture-based diagnostics for, 1150t
 diagnosis of, in international setting, 1147t
- Sepsis (*Continued*)
 in hyposplenism, 3063
 management and prevention, 1151t
 manifesting as respiratory distress, 613
 neonatal, 1143
 in neonate, 548
 in newborn, evaluation for, 1149t
 serious systemic illness, 1147t
 Staphylococcus aureus, 1695
 Septal reduction therapy, 2887f
 Septate uterus, 3351–3352
 arcuate, 3352
 bicornuate, 3352
 treatment of, 3352
 unicornuate, rudimentary horns and, 3352
 uterine didelphys, 3352
 Septation, cardiac, 2732–2733
 Septic arthritis, 1800t, 4291–4294
 clinical manifestations of, 4292, 4292t
 diagnosis of, 4292–4293
 differential diagnosis of, 4293
 epidemiology of, 4291
 etiology of, 4291
 Kingella kingae-driven, 1753
 pathogenesis of, 4291–4292
 prognosis of, 4294
 radiographic evaluation of, 4292–4293, 4293f
 treatment for, 4293–4294
 Septic fever, 1640–1641
 Septic shock
 clinical manifestations of, 605
 management for, 609f, 610–611
 manifesting as respiratory distress, 613
 pathophysiology of, 604
 red flags for, 548
 Septic thrombophlebitis, 1829
 Septicemia
 acute meningococcal, 1739–1741, 1741f
 Aeromonas in, 1797
 Septo-optic dysplasia (SOD), 3364, 3367f, 3963–3964
 schizencephaly and, 3569
 Septostomy, Rashkind balloon atrial, 2813f
 Septum pellucidum, absence of, 3573, 3575f
 Sequence, defined, 778t, 779
 Sequential bilinguals, 327
 Sequential seizures, 3619
 Sequestration
 pulmonary, 2601–2602, 2601f
 reticuloendothelial, neutropenia secondary, 1308
 splenic, in sickle cell anemia, 2968–2969
 thrombocytopenia and, 3056
 Serdexmethylphenidate/dexmethylphenidate (Azstar-ys), for ADHD, 225t–226t
 Serial body casting, 4245
 Serine, metabolism defects, 840–841, 840f
 3-phosphoglycerate dehydrogenase deficiency, 841
 phosphoserine aminotransferase deficiency, 841
 Serious harm events, 44
 Serious safety events (SSEs), 42
 Seriousness
 of adolescent drug abuse, 1194t
 of chronic/recurrent symptoms, 2526–2530
 Serofibrinous pleurisy, 2654–2656
 Serologic testing, 447.e7
 in *M. pneumoniae*, 1889
 for syphilis, 1872f, 1873t
 Serology
 in *Coccidioides* spp., 1938
 in Lyme disease, 1884–1885
 Seroquel. *See* Quetiapine
 Serosanguineous pleurisy, 2654–2656
 Serotonin receptor inhibitors, for Ehlers-Danlos syndrome, 4374
 Serotonin syndrome, 224, 703t, 717, 718t, 3633
 drugs associated with, 717t
 malignant hyperthermia vs., 718t
 Serotonin-norepinephrine reuptake inhibitors (SNRIs)
 for ADHD, 224
 for anxiety disorders, 253
 for pain, 688–689
 Sertoli cell tumors, large-cell calcifying, of testes, 3494
 Sertoli cell-only syndrome, 3489

Sertoli-Leydig cell tumors, 3152–3153, 3343, 3345f
of ovary, 3503
Sertraline (Zoloft), for depression and anxiety, 227t
Serum 1,25(OH)2D levels, 4378–4379
Serum bactericidal antibody, complement-dependent, 1739
Serum enzymes, in neuromuscular disorders, 3793
Serum ferritin, in iron-deficiency anemia, 2947t
Serum IgE concentrations, increased, nonallergic associated with, 1377t
Serum sickness, 1441–1442, 1441t
 clinical manifestations of, 1441–1442, 1441f
 diagnosis of, 1442
 differential diagnosis of, 1442
 etiology of, 1441
 pathogenesis of, 1441
 prevention of, 1442
 treatment of, 1442
Serum sickness-like reaction, 1441–1442, 1441f, 4037–4038, 4037f
Serum thyroid hormones, 3401
Serum thyroxine-binding globulin, 3401
Serum transferrin receptor, in iron-deficiency anemia, 2947t
Setting-sun sign, 3930
Sever disease, 4208, 4300, 4300f, 4313
 football associated with, 4327
 soccer associated with, 4329
Severe acute pancreatitis, 2426
Severe acute respiratory syndrome-associated coronavirus, 2038
Severe combined immunodeficiency (SCID), 952, 1262–1265, 1288, 1309t, 1344–1345
 clinical manifestations of, 1263–1264
 diagnosis of, 1264, 1265f
 genetics, 1262–1263, 1263t, 1264f
 pathogenesis of, 1262–1263
 reticular dysgenesis, 1263t, 1264
 treatment of, 1264–1265
 X-linked, 1264–1265
Severe congenital neutropenia (SCN), 1308, 1309t
Severe generalized epilepsies, 3593t, 3599f, 3601–3603, 3602t
Severe (profound) hypothermia, 659
Severe malaria, 2172f, 2172t, 2173
 treatment of, 2175–2176, 2180t
Severe multiorgan disease, cytomegalovirus (CMV), 2012–2013
Severe myoclonic epilepsy of infancy, 3601
Severe neutropenia, 3018
Severe obesity, 409
Severe wasting, 426, 427f
Severity
 of asthma, 1393, 1394t
 of germinal matrix intraventricular hemorrhage, 1059f
 of illness, as outcome measure, 543
Sevoflurane, 668–670, 669t
Sex
 child trafficking for, 110–113
 definition of, 1171
Sex chromosome abnormalities, 770t
Sex chromosome aneuploidy, 760t, 770–771, 770t
 Klinefelter syndrome, 771
 Turner syndrome, 770–771, 771t, 772f
 47,XYY, 771
Sex cord stromal tumors, ovarian, 3343, 3343t, 3344f–3345f
Sex cord tumors, with annular tubules, 3494, 3502
Sex development, disorder of, 3297, 3302
Sex differentiation, 3503–3505, 3504f, 3504t, 3506f
Sex steroids, biosynthesis of, 3485f
Sex trafficking, 1235
Sexual abuse, 122, 1235
 in adolescents with special needs, 3355
 assessment and management, role of PCPs, 122–126
 definition of, 122
 integration of information in, 126
 interpretation of findings in, 126–127
 presentation of, 122
 prevention of, 127
 recommendations for children and families, 127
 suspected, physical examination of child with, 123
 triage protocol, 123f

Sexual assault, 1234–1238
 clinical manifestations of, 1235–1236
 epidemiology of, 1234–1235
 interview and physical examination of, 1236
 laboratory data of, 1236
 prevention of, 1237–1238
 treatment of, 1236–1237
 types of, 1235
Sexual awareness and interest, 1162–1163
Sexual development
 in adolescent, 1159–1160
 in progeria, 959
Sexual education, for adolescents with special needs, 3355
Sexual Maturation Index, 3327
Sexual Maturity Rating (SMR), 1159, 1159f–1160f, 1210, 3329
Sexual orientation
 in childhood and adolescence, 1182t, 1183
 definition of, 1172
 GLB, 1182
Sexual precocity
 classifications of, 3387t
 differential diagnosis of, 3388t–3389t
Sexual transmission, for HIV prevention, 2116–2117
Sexually explicit behavior, 122
Sexually transmitted infections (STIs), 3320–3323
 in adolescents, 1187t, 1239–1251
 cervicitis, 1242
 diagnosis of, 1244–1246
 epidemiology of, 1239–1240
 epididymitis, 1241–1242
 etiology of, 1239, 1239t
 genital lesions and ectoparasites, 1244
 genital ulcer syndromes, 1243–1244
 HIV and hepatitis B, 1244
 pathogenesis of, 1240
 pathologic vaginal discharge, 1246t
 PID, 1242–1243, 1246t
 prevention, 1250–1251
 reverse-sequence syphilis screening, 1247f
 screening, 1240, 1241t
 signs and symptoms, 1243t
 treatment of, 1248–1250
 uncomplicated bacterial, 1247t–1248t
 uncomplicated genital warts and genital herpes, 1249t–1250t
 urethritis, 1240–1241
 vaginitis, 1242
among GLB youth, 1183, 1184t
maternal, 1152
screening for, in adolescents, 1165, 1170
sexual abuse
 implications for, 126t
 indications for, 125t, 126
 testing for, 125
Seymour fracture, 4279
SF-1 pathogenic variants, 3508
 46,XY DSD and, 3509
SFTP/C variants, 2686f
SGAs. *See* Second-generation antipsychotics
SGLT2 inhibitors, for nonalcoholic steatohepatitis, 2482t
SGS. *See* Shprintzen-Goldberg syndrome
Shagreen patch, 3658f
Shaken baby syndrome, 157, 3963f, 3979
Shampoos, 4039
Shape
 of foot, 4212, 4215f
 of kidney, 3262–3263
 of nail, 4142–4143
 of teeth, 2240
Shape Up Somerville, 449–450
Shared decision-making (SDM), 15, 134–135
Sharp objects, ingestion of, 2304
Shawl scrotum, 784t
SHCN. *See* Special healthcare needs
Shellfish toxins, 4411t–4413t
 food-borne noninfectious illnesses and, 2362t–2364t
Shenton's line, 4234
Shiatsu, 57–58

Shiga toxin-producing *Escherichia coli* (STEC), 1623t–1625t, 1783, 3200
Shigella, 1776–1780
 antibiotic therapy for, 2373t–2375t
 bacterial gastroenteritis and, 2357t–2358t
 clinical manifestations of, 1777–1778, 1778t
 complications of, 1777–1778, 1778t
 diagnosis of, 1778–1779
 differential diagnosis of, 1778
 epidemiology of, 1776–1777
 etiology of, 1776
 immunity of, 1777
 infection, pathogenesis of, 2366f
 pathogenesis of, 1777
 prevention of, 1779–1780
 seasonality of, 2359
 treatment of, 1779, 1780f
in viral AGE, 2361
vulvovaginal infection, 3322t
Shigellosis, 1623t–1625t
Shin splints, 4331
Shock, 600–611
 cardiogenic, 560
 clinical manifestations of, 606t, 605
 compensated, 560
 decompensated, 560
 diagnosis of, 605–606, 607t
 dissociative, 560
 distributive, 560
 epidemiology of, 600
 hypovolemic, 560
 laboratory findings, 606
 in malaria, 2180
 management of, 606–610, 608f
 general principles of, 606–610
 specific considerations by type, 610–611
in multiple trauma, 573–574
obstructive, 560
pathophysiology of, 600–605, 602f
prognosis for, 611
recognition and treatment of, 560
spinal, 579
treatment of, 606–611
types of, 603t, 600, 601t
Shock index, 607t
Shock reversal, targets for, 611
Shoe dermatitis, 4089
Shoes, foot disorders, 4211
Short bowel syndrome, 2345–2346, 2345f, 2345t
 causing intestinal failure, 2352t
 chronic diarrhea and, 2378
Short chain acyl-CoA dehydrogenase (SCAD) deficiency, 863
Short chain 2-enoyl-CoA hydratase deficiency, 863
Short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency, 863
Short lingual frenulum, 2223
Short palpebral fissures, 784t
Short QT syndrome, SIDS risk factors and, 2535
Short rib polydactyly syndromes, 792t, 2764t–2766t
Short stature, 176, 177t
Short-acting inhaled β-agonists, for asthma, 1404, 1405t–1406t
Short-chain fatty acids (SCFAs), 395
Short-limbed skeletal dysplasia, 3509
Short-rib polydactyly syndromes, 4355
Short-term memory, 302
Short-term prophylaxis (STP), for HAE with C1-INH deficiency, 1323
Shoshin beriberi, 459
Shoulder
 arthrograpysis in, surgery for, 4275
 disorders of, 4263–4264
 congenital pseudarthrosis of clavicle, 4264, 4264f
 Sprengel deformity, 4264
 musculoskeletal pain syndrome, 1568t
 sports-related injuries, 4300–4303
Shou-wu-pian, 2492t
SHOX gene-related conditions, 4350
Shprintzen-Goldberg syndrome (SGS), 794t–795t, 2766–2770, 4364, 4367t
Shuddering attacks, 3637

- Shunts
 bidirectional Glenn, 2808f
 Blalock-Taussig, 2803, 2804f
CSF
 associated infection, 1669–1670
 coagulase-negative staphylococci, 1699–1700
intracardiac, pulmonary stenosis in combination with, 2790
right-to-left, in newborn, 1054t
ventriculoperitoneal, 1061
- Shwachman-Diamond syndrome (SDS), 1309t, 1310, 2424, 2424f, 3004–3006
- cancer, predisposition to, 3005
- chronic diarrhea and, 2378
- clinical manifestations of, 3004–3005
- diagnosis of, 3005
- etiology and epidemiology of, 3004, 3004t
- laboratory findings of, 3005
- pathology of, 3004
- prognosis of, 3005–3006
- treatment of, 3005
- Sialic acid storage disease, infantile, 888t
- Sialidosis, 887t–888t, 920–921, 3716
- Siblings
 death of, 196–197
 in pediatric palliative care, 62
 at risk for SIDS, 2537
- SIBO. *See* Small intestinal bacterial overgrowth
- Sick day guidelines, 3535, 3535t
- Sick daycare, 193
- Sick sinus syndrome, 2855–2858
- Sickle cell crisis, hepatic, 2479–2480
- Sickle cell disease, 2, 2966–2977
 anesthetic implications in, 666t
 anticipatory guidance in, 2976–2977
 clinical manifestations and treatment of, 2968–2974, 2970t–2971t
 diagnosis and epidemiology of, 2967–2968, 2967t
 gain-of-function variant in, 732–733
 high-altitude illness and, 636
 HSCT for, 1354
 newborn screening results, 2967
 other syndromes in, 2976
 pathophysiology of, 2967
 priapism secondary to, 3300
 screening of, 4472.e6
 therapeutic considerations in, 2974–2976
 hematopoietic stem cell transplantation, 2975
 hydroxyurea, 2974–2975
 iron overload, 2975–2976
 red blood cell transfusions, 2976–2977
- Sickle cell intrahepatic cholestasis, 2479–2480
- Sickle cell nephropathy, 3211–3212
- Sickle cell pain, 2969–2971, 2969f
- Sickle cell trait, 2977, 2978f
 complications with, 2978t
 high-altitude illness and, 636
- Side effects
 of drugs, for migraine, 3646t–3647t
 of stimulants, 222
- Side splash, in lightning burns, 655
- Sideroblastic anemia, 935t, 2950
- Sideroblastic macrocytic anemia, 2933
- Side-sleeping, SIDS risk factors and, 2534
- SIDS. *See* Sudden infant death syndrome
- Sign language, 324, 340, 3993
- Signal transducers, 3077
- Signaling pathway disorders, 787–793
 ciliopathies, 791, 792f, 792t
 craniosynostosis, 793, 793f, 794t–795t
 RAS/MAPK pathway, 787–789, 787f
 sonic hedgehog pathway, 789–791, 791f
- Signs and symptoms
 of genital ulcers, 1243t
 of infection in newborns, 1146t
 of intoxication and withdrawal, 1206t
 of liver abscess, 2474
 of meningococcal disease, 1740t–1741t
 respiratory, originating from outside respiratory tract, 2531t
 suggestive of rheumatic disease, 1460
- Sildenafil, 2834t
 for BPD, 1087
- Silent cerebral infarct, 2972
- Silk glove sign, 2417
- Silver amalgam, for dental caries, 2247
- Silver diamine fluoride application, for dental caries, 2247
- Silver nitrate, for burns, 652t
- Silver sulfadiazine cream (Silvadene), 652–653, 652t
- Simple febrile seizure, 3595
- Simple goiter, 3415
- Simple kinetic tremor, 3678
- Simple mask, for respiratory distress and failure, 618
- Simple renal cyst, 3262
- Simple tics, 3636–3637
- Simple View of Writing, 322f, 323
- Simple virilizing disease, 3462–3463
- Simpson-Golabi-Behmel syndrome, 2764t–2766t, 3131t–3132t, 3382, 3382f, 3384t
- Simulation, 43
- Simulation-based learning, critically ill newborn, 1051
- Simultaneous bilinguals, 327
- SIMV. *See* Synchronized intermittent mechanical ventilation
- Sinding-Larsen-Johansson syndrome, 4226–4228, 4227f–4228f, 4310
 basketball associated with, 4328
 soccer associated with, 4329
- Single nucleotide polymorphisms, 3080
- Single ventricle, relative frequency of, 2763t
- Single-gene disorder, 726
- Single-nucleotide polymorphisms (SNPs), 801f arrays, 762, 801
- Single-photon emission computed tomography (SPECT)
 for brain death, 591t
 in neuroradiologic procedures, 3560
- Single-system disease, treatment of, 3172–3173
- Singleton-Merten syndrome (SMS), 1530t, 1535
- Single-use detergent sacs, 724
- Singulair, for allergic rhinitis, 1382t
- Sinonasal disease, invasive, 1931
- Sinopulmonary infections, recurrent, 1253–1254
- Sinus arrhythmia, general physical examination for, 2738
- Sinus bradycardia, 2844
- Sinus histiocytosis, with massive lymphadenopathy, 3070–3071, 3170t
- Sinus node dysfunction, 2855–2858
- Sinus tachycardia, 563
- Sinus venosus atrial septal defect, 2779
- Sinuses
 headache, 3650
 images, diagnostic approach to respiratory disease, 2517
 preauricular, 4044
 thyroglossal, 4044
- Sinusitis, 2552t, 2553–2556
 allergic *Aspergillus*, 1929
 asthma with, 1398
 clinical manifestations of, 2554–2555, 2555t
 complications, 2556
 diagnosis of, 2555
 epidemiology of, 2554
 Haemophilus influenzae in, 1758
 Moraxella catarrhalis in, 1760
 orbital complications of, 3973t
 pathogenesis of, 2554
 prevention, 2556
 treatment of, 2555, 2556t
- Sinusoidal obstruction syndrome (SOS), 2479, 2479t, 2505
- Sirolimus
 for lymphangiomyomatosis, 3068
 for lymphatic malformations, 3066
 in maintenance immunosuppression, 3257
 for vascular malformations, 3156
- SIRS. *See* Systemic inflammatory response syndrome
- Sitagliptin, for T2DM, 3542t
- Sitosterolemia, 876, 2341, 2963
- Situation awareness, 45
- Situation Background-Assessment-Recommendation (SBAR), 44
- Situs inversus, 2748
- Six Sigma, 37, 37f
- Sixth disease, 2016
- Sixth nerve palsy, 3928–3929
- Sjögren syndrome, 1462t, 1516–1517
 clinical manifestations of, 1516–1517
 complications and prognosis, 1517
 diagnosis of, 1516t, 1517, 1517f
 differential diagnosis of, 1517
 epidemiology of, 1516
 etiology and pathogenesis, 1516
 treatment of, 1517
- Sjögren-Larsson syndrome, 4117
- Skateboarding, injuries associated with, 4330
- Skeeter syndrome, 1419–1420, 4151, 4170–4171
- Skeletal development, inherited disorders of, 4354–4358
 asphyxiating thoracic dystrophy, 4355, 4356f
 Caffey disease, 4357–4358, 4358f
 cartilage-hair hypoplasia, 4355–4356, 4356f
 Ellis-van Creveld syndrome, 4354–4355, 4355f
 fibrodysplasia ossificans progressiva, 4358
 filamins, disorders involving, 4357
 juvenile osteochondroses, 4357, 4357t
 metatropic dysplasia, 4356, 4357f
 short-rib polydactyl syndromes, 4355
 spondylometaphyseal dysplasia, Kozlowski type, 4357
- TRPV4-spectrum disorders, 4356
- Skeletal diseases, influencing pulmonary function, 2713–2716
- Skeletal dysplasias
 general considerations in, 4333–4340, 4334f, 4335t–4337t, 4337f
 clinical manifestations of, 4336–4338
 family and reproductive history, 4337
 growth, 4336, 4337t
 non-growth-related, 4336–4337, 4336t
 radiographic features, 4338, 4338f, 4338t
 diagnosis of, 4338
 molecular genetics of, 4335t, 4338–4339
 pathophysiology of, 4335t, 4339
 treatment for, 4337t, 4339–4340
 inborn errors of metabolism and, 809t–810t
- Skeletal infection
 cryptococcosis and, 1926
 nontuberculous mycobacteria infection and, 1861t
- Skeletal maturation, in postnatal androgen excess, 3466
- Skeletal maturity, 4307t
- Skeletal system, Marfan syndrome in, 4364
- Skeletal tuberculosis, 1845
- Skew deviation, 3553
- Ski- and snowboard-related head injuries, 97
- Skier's thumbs, 4330
- Skiing, injuries associated with, 4330
- Skills training, 1171
- Skin
 arsenic effects in, 4432t
 breakdown, spinal cord injury and, 4391
 in congenital erythropoietic porphyria, 971f
 glucocorticoid effects, 3448
 minor malformations, 785t
 morphology of, 4025–4026
 appendageal structures of, 4026
 dermis, 4026
 epidermis, 4025
 subcutaneous tissue, 4026
 newborn
 antiseptic care of, 1005
 assessment of, 1000–1001
 ontogeny of, 1144f
 physical examination of, 550
 shock in, 607t
 stage of GVHD, 1358t
 toxoplasmosis in, 2190–2191
- Skin care issues, in pediatric palliative care, 70
- Skin dimples, 4043
- Skin disease
 anesthetic implications in, 666t
 nontuberculous mycobacteria infection and, 1861t
- Skin infection
 Aeromonas in, 1797
 in blastomycosis, 1935
 catheter-associated, 1667

- Skin infection (*Continued*)
 in leukocyte adhesion deficiency type 1, 1300f
 in newborn, 1148
 primary and secondary, 1800t
Skin involvement
 in Hansen disease (*Mycobacterium leprae*), 1857
 in Langerhans cell histiocytosis, 3169
Skin lesions
 in Behcet disease, 1515
 human papillomaviruses (HPVs), 2055, 2055f
 post-kala-azar dermal leishmaniasis, 2159
 in tuberous sclerosis, 3658
Skin manifestations
 in food allergy, 1445
 of Lyme borreliosis, 1883f
Skin tags, pinna malformations and, 3995
Skin tumors, 4185–4189
 basal cell carcinoma, 4188
 dermatofibroma, 4187, 4187f
 eruptive vellus hair cysts, 4186, 4187f
 fibrofolliculomas, 4185, 4186f
 infantile digital fibroma, 4186
 infundibular follicular cyst, 4185, 4186f
 juvenile xanthogranuloma, 4187–4188, 4187f
 lipoma, 4188, 4188f
 melanoma, 4189
 milium, 4185
 mucosal neuroma syndrome, 4189
 nevoid basal cell carcinoma syndrome, 4188–4189
 pilar cyst, 4185, 4186f
 pilomatricoma, 4185, 4186f
 steatocystoma multiplex, 4186
 syringoma, 4186, 4187f
 trichoeplithelioma, 4185–4186
Skin-prick test (SPT), 1378
Skull
 assessment in newborn, 1000–1001
 fractures, 584f–585f
 X-rays, in neuroradiologic procedures, 3558
Skullcap, 2492t
Slate gray nevus. *See* Congenital dermal melanocytosis
SLC6A3-related dopamine transporter protein, 847
SLD. *See* Specific learning disability
SLE. *See* Systemic lupus erythematosus
Sleep, 438
 for children with disabilities, 4407
 concerns, in adopted children, 74
 debt, 202
 developmental changes in, 202, 202f–203f
 health supervision and, 214
 normal developmental changes in, 204t
 problems of, evaluation of, 214–215
 requirements in children, 155f
Sleep apnea
 obstructive, 206–209, 1075, 2723–2724
 associated with Down syndrome, 369
 BRUE and, 2541–2542
 clinical manifestations of, 207
 diagnosis of, 207–208, 208t
 epidemiology of, 207
 etiology of, 206–207
 management of, 208t
 pathogenesis of, 207
 treatment of, 208–209
 in T2DM, 3543t
Sleep deprivation, 305
Sleep diary, 4387
Sleep disorders
 BEARS sleep screening algorithm, 215t
 delayed-sleep-wake phase disorder, 214
 evaluation of, 214–215
 insomnia, 203–205, 205f
 narcolepsy, 212–213
 obstructive sleep apnea, 206–209
 parasomnias, 209–210
 that mimic seizures, 3631t, 3638
 Sleep disturbance, in pediatric palliative care, 65t–68t
Sleep hygiene, 382
Sleep medicine, 201–215
 Sleep transition disorders, that mimic seizures, 3638
Sleep-disordered breathing (SDB), 2723–2724
 cystic fibrosis and, 2676
Sleeping position, in deformational plagiocephaly, 3584
Sleep-related breathing disorder (SRBD), 206
Sleep-related deaths (SUID, SIDS), 997
SLI. *See* Specific language impairment
Sliding hernias, 2263, 2417
Slipped capital femoral epiphysis (SCFE), 4214,
 4239–4241, 4307
 classification of, 4239
 clinical manifestations of, 4240, 4240f
 complications of, 4241
 diagnostic studies of, 4240, 4241f
 epidemiology of, 4240
 etiology and pathogenesis of, 4240
 treatment for, 4240–4241, 4241f
Slipped rib syndrome, 2234
Slipped vertebral apophysis, 4256–4257, 4257f
Slit-lamp eye examination, 1482f, 3912
SLJ. *See* Sinding-Larsen-Johansson syndrome
Slow respiration, predicting toxicity from vital signs
 in, 704t
Slow-wave sleep (SWS), 201–202
SLP76 deficiency, 1263t
Sly syndrome, 940t, 942
SMA. *See* Spinal muscular atrophies
Small bowel
 development of, 2277
 mucosal biopsies, 2333–2334
Small fiber polyneuropathy, 1569, 1570f, 1571t–1572t
Small gonads, in male-appearing genitalia, 3506t
Small intestinal bacterial overgrowth, chronic diarrhea
 and, 2377
Small left colon syndrome, in infants of diabetic mothers, 1141–1142
Small nail, 784t
Small vessel disease, 1565
Small-for-gestational-age infants, 1047–1048, 1047f,
 1048t
Smallpox, 4450, 4452t
 vaccine, 1588t–1589t
Smith-Lemli-Opitz syndrome (SLOS), 789, 881, 881t–
 882t, 2764t–2766t, 3513
Smith-Magenis syndrome, 768t–769t, 786t
Smokeless tobacco, 1199–1200
Smoking
 by adolescents, 1187t, 1199
 bronchitis and, 2589
 cessation, 1201t
 as goitrogen, 3415t
 marijuana, 1201–1202, 1201f
 in porphyria cutanea tarda, 973
 in pregnancy, 1022
 Smooth muscle, 2261–2262
 hamartoma, 4066, 4066f
SMR. *See* Sexual Maturity Rating
Snake bites, 4466–4468
 disposition, 4468
 management, 4467–4468
 venoms and effects, 4467
Snapping hip syndrome, 4308
Snapping knee syndrome, 4224
Snellen acuity chart, 3910
Snowboarding, injuries associated with, 4330
SNP. *See* Single nucleotide polymorphisms
SNRIs. *See* Serotonin-norepinephrine reuptake inhibi-
 tors
SNX10-related autosomal recessive osteopetrosis, 4351t
SOAP MM mnemonic, in endotracheal intubation, 559
Soaps, 4039
Soccer, injuries associated with, 4329
Social anxiety, 246
 core diagnostic features and characteristics of, 252t
 diagnostic criteria for, 248t
Social cognition, 302
Social cognitive theory, 141t
Social (pragmatic) communication disorder (SPCD),
 329, 330t, 376
Social contagion, 4456
Social development
 in adolescent, 1158–1163
 in adopted children, 74
 in middle childhood, 171
Social distancing, in pandemic, 1584
Social language, 179
Social marketing, adolescent, 1164t–1165t
Social media, violence in, 106
Social norms, strategies for, 130t
Social phobia, diagnostic criteria for, 248t
Social skills program, 380–381
Social stratification, 8–9, 9f
Socioeconomic status, childhood injuries and, 94–95
SOD. *See* Septo-optic dysplasia
Sodium
 dietary reference intake, 404t–407t
 excretion, 489
 extracellular, 486
 hypernatremia, 489–491
 hyponatremia, 491–495
 metabolism, 489
 reference intervals, 4472.e9t
 retention, during volume depletion, 488
 tubular transport, 3233
 urine, in hyponatremia, 3375t
Sodium bicarbonate, 707t–708t
 for pediatric resuscitation and arrhythmias, 563t
 tablets, 3250
Sodium channel blockers, toxicodrome, 704t
Sodium channel myotonias, 3849t
Sodium channel periodic paralysis, 3840t
Sodium fluoride
 foodborne illness, 4411t–4413t
 food-borne noninfectious illnesses and, 2362t–2364t
Sodium methoxyhexil, 671
Sodium nitroprusside, for severe hypertension in
 children, 2919t
Sodium retention, in refeeding syndrome, 432t
Sodium supplementation, in fluid resuscitation, 651
Sodium valproate, for migraine, 3648
Sodium wasting, in CKD, 3250t
Soft spinal orthosis, for neuromuscular scoliosis, 4249
Soft tissue cold injury, 659
Soft tissue disease, nontuberculous mycobacteria infec-
 tion and, 1861t
Soft tissue infections
Aeromonas in, 1796–1797
 catheter-associated, 1667
 in newborn, 1148
Soft tissue injury, 4318
Soft tissue mucormycosis, 1943
Soft tissue sarcomas, 3136–3138
 nonrhabdomyosarcoma, 3139t–3140t
 rhabdomyosarcoma, 3136–3138
Softball, injuries associated with, 4327–4328
Sokolow index, 2750–2752
Solanine poisoning, 4444
Solar urticaria, 1428, 4096, 4096f
Soldiers, 107
Solid tumors, mass effects of, 3081
Solid-organ transplantation, 1664–1666, 1665t
Solitary left testis, 3304f
Solu-Medrol (IV), for asthma, 1405t–1406t
Solutions for Patient Safety (SPS), 42
Somatic cough disorder, 2527–2528
Somatic development, 146
Somatic disorders, 248t
Somatic growth, 1160–1161
 in postnatal androgen excess, 3466
Somatic pain, 678t, 2234
Somatic symptom and related disorders (SSRDs),
 235–240
 assessment of, 237–238, 238t
 medical, 237, 238t
 psychosocial, 238
 differential diagnosis of, 238, 239t
 DSM-5 diagnostic criteria for, 235t
 management of, 238–240
 pediatric practitioner in, role of, 239
 psychotherapy and psychopharmacology for, 240
 rehabilitation approach to, 239–240
 specified and unspecified, 236t
Somatization, 236–237
 cognitive and learning difficulties in, 237
 family factors in, 237
 genetic and biologic factors of, 237
 learned complaints in, 237
 personality traits and coping styles in, 237
 sociocultural background of, 237
 stressful life events in, 237

- Somatomedin, 3360
 Somatosensory amplification, 237
 Somatosensory evoked potentials (SSEPs), 3560
 Somatostatin analogs, for carcinoid syndrome, 2414
 Somnolence, cancer and, 3091
 Somogyi phenomenon, in T1DM, 3534
 Sonic hedgehog pathway, 789–791, 791f
 adrenal cortex, 3444
 medulloblastoma and, 3123–3124
 Sorafenib, for hepatocellular carcinoma, 3156
 Sore throat
 in common cold, 2553
 in exclusion or inclusion in daycare, 187t–192t
 Sotos syndrome, 768t–769t, 2764t–2766t, 3131t–3132t, 3383–3384, 3384t
 in megalencephaly, 3580
 Sounds
 heart, 2742–2743
 respiratory, 2514t
 Southeast Asian ovalocytosis (SAO), 2961
 SOX9, 3481–3482
 Soy protein-based formulas, 412–413
 Space-occupying lesions, 3092t–3093t
 Spacer devices, for asthma, 1406
 Spasmodic croup, 2570
 Spasmus nutans, 3931–3932, 3931t
 that mimic seizures, 3637
 Spastic diplegia, 3690t
 Spastic paraparesis, 955
 Spastic quadriplegia, 3690t
 Spasticity, 3555, 4197, 4394–4396
 in choreoathetosis, 3678
 injection management, 4394–4396
 spinal cord injury and, 4391
 surgical management, 4396
 systemic medications, 4394
 α_2 -adrenergic agents, 4394
 GABAergic medications, 4394
 peripherally acting calcium blockers, 4394
 traumatic brain injury and, 4388
 Spatula test, in tetanus, 1822–1823
 Spear tackler's spine, 4318–4319
 Special education, 323
 Special healthcare needs (SHCN), 1171
 Special needs children, 3319–3320
 adolescents with, gynecologic care for, 3355–3356
 childcare and, 186
 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), 420
 Specialized growth charts, 175
 Specific developmental disorders of scholastic skills, 300
 Specific granule deficiency, 1297t–1298t
 Specific language impairment (SLI), 328
 Specific learning disability (SLD), 300, 318–319
 with impairment in written expression, 321, 321t
 involving mathematics, risk factors for, 321t
 Specific phobia, 246, 254
 core diagnostic features and characteristics of, 252t
 diagnostic criteria for, 248t
 Specific tumors, of central nervous system, 3119–3125
 Specificity, 4472.e4, 181
 Speckled lentiginous nevus, 4064, 4064f
 SPECT. See Single-photon emission computed tomography
 α -Spectrin, in hereditary spherocytosis, 2956t
 β -Spectrin, in hereditary spherocytosis, 2956t
 Speculum, in pelvic examination, 3320
 Speech
 definition of, 325t
 evaluation, 332
 milestones in, 326t, 327f
 in myotonia, 3836
 organs of, structural anomalies of, 331
 Speech and language pathology, childhood-onset fluency disorder and, 335
 Speech disorders, 328–332
 assessment of, 332–333
 clinical presentation of, 328
 diagnostic evaluation of, 332–333
 epidemiology of, 328
 etiology of, 328–329
 pathogenesis of, 329
 screening of, 332
 treatment of, 333
 Speech perception, 324
 Speech production, 324
 difficulties in, 301
 Speech sound disorder, 330t, 331–332
 Speech therapy, for Down syndrome, 371
 Speech-language pathologists, 307
 Speech-recognition threshold (SRT), 3990
 Spelling impairment, 304
 Spells, breath-holding, 281
 Spermatic cord torsion
 diagnosis of, 3306
 etiology of, 3306
 treatment of, 3306–3307, 3306f
 Spermatocele, 3308
 Spermicides, 1218t–1219t
 Spherocytic hereditary elliptocytosis, 2960t
 Spherocytosis, hereditary, 2955–2959
 clinical manifestations of, 2955, 2956f, 2958t, 2959f
 diagnosis of, 2956–2957, 2959f
 differential diagnosis of, 2957
 etiology of, 2955, 2956f–2957f, 2956t
 gene variants in, 2956t
 treatment of, 2957–2959
 general supportive care, 2957
 guidelines for splenectomy, 2957–2959
 Sphingolipidoses, 3711–3715
 gangliosidoses, 3711–3714, 3713f–3714f
 Krabbe disease, 3714
 metachromatic leukodystrophy, 3714–3715
 Spider angioma, 2439, 3162, 4059, 4059f
 Spider bites, 4468–4471
 Spiders, 4170t
 Spielmeyer-Vogt syndrome, 887t, 3716
 Spina bifida occulta, 3288
 Spinal and bulbar muscular atrophy, 745t–746t
 Spinal arteriovenous malformations, 3790, 3790f
 Spinal cord compression
 an oncologic emergency, 3092t–3093t
 in pediatric palliative care, 70
 Spinal cord concussion, 4319
 Spinal cord disorders, 3785–3790
 diastematomyelia in, 3786–3787, 3787f
 spinal arteriovenous malformations in, 3790, 3790f
 syringomyelia in, 3787–3788, 3788f
 tethered cord in, 3785–3786, 3785f–3786f
 tumors in, 3789–3790, 3789f
 Spinal cord embolism, 3749
 Spinal cord injuries, 579–581, 579t, 4320, 4389–4394
 during birth, 1068
 clearing the cervical spine, 579–580, 580f,
 580t–581t
 clinical manifestations of, 579, 580f, 4389–4393,
 4391f–4392f
 prevention of, 581
 prognosis of, 4393–4394, 4393t
 treatment of, 580, 581f
 Spinal cord injury without radiographic abnormalities (SCIWORA), 576, 579
 Spinal cord lesions
 associated with vascular processes, 3749
 in Guillain-Barré syndrome, 3901t
 Spinal cord tumors, 3117–3118
 Spinal dysraphism, 4043
 congenital scoliosis and, 4247
 occult, 3290–3291
 Spinal epidural abscess, CSF findings in, 3759t–3760t
 Spinal immobilization, 576
 Spinal muscular atrophies (SMA), 3866–3874,
 3867t–3868t
 atypical, 3867t–3868t, 3874
 clinical manifestations and course of, 3866–3869,
 3869f
 diagnosis of, 3869–3870, 3870t
 differential diagnosis of, 3869t
 genetics of, 3870–3871, 3871f–3872f
 laboratory findings in, 3869, 3870f
 with lower extremity predominance (SMALED),
 3875
 management of, 3871, 3872t–3873t
 with progressive myoclonic epilepsy (SMAPME),
 3875
 with respiratory distress (SMARD), 3874
 therapeutic advances for, 3871–3874, 3873t
 Spinal paralytic poliomyelitis, 1973
 Spinal shock, 579, 3749
 spinal cord injury and, 4393–4394
 Spinal stenosis, congenital, 4320
 Spinal trauma
 evaluation of, 576, 576t
 secondary survey for, 576
 Spindle and epithelioid cell nevus, 4063–4064, 4064f
 Spindle/sclerosing subtype, of rhabdomyosarcoma, 3136
 Spine, 4242–4257
 abnormal spinal curvatures, overview of, 4242, 4243t
 back pain, in children, 4252–4253, 4252t–4253t
 congenital scoliosis, 4247–4248, 4248f–4249f
 idiopathic scoliosis, 4242–4247, 4243f–4244f, 4246f–
 4247f
 infection, 4255–4256, 4255f–4256f
 injury to, during birth, 1068
 intervertebral disk herniation/slipped vertebral
 apophysis, 4256–4257, 4257f
 kyphosis, 4250–4251, 4250t
 musculoskeletal pain syndrome, 1568t
 neuromuscular scoliosis, genetic syndromes, and
 compensatory scoliosis, 4248–4250, 4249f
 normal spinal curvatures, 4242
 spondylolisthesis, and spondylolisthesis, 4253–4255,
 4254f
 tumors, 4257, 4257f
 Spinning-top deformity, 3293, 3293f
 Spinocerebellar ataxia (SCA), 3673f
 type 1, 745t–746t
 type 2, 745t–746t
 type 3, 745t–746t
 type 6, 745t–746t
 type 7, 745t–746t
 type 10, 745t–746t
 type 12, 745t–746t
 type 17, 745t–746t
 type B, 745t–746t
 Spinous layer, of epidermis, 4025
 Spiral CT, of large arteriovenous fistula, 2698f
 Spiramycin, for toxoplasmosis, 2196
 Spirometer, 2521
 Spirometry, in asthma, 1391, 1391f, 1391t
 Spiranolactone, for heart failure, 2898t, 2899
 Spitz nevus, 4063–4064, 4064f
 Spleen
 anatomy and function of, 3060–3061
 palpation, for sickle cell disease, 2976
 Splenectomy, 3063–3064
 for hemolysis, 2961
 for hereditary spherocytosis, 2957–2959
 in immune thrombocytopenia, 3054
 for thalassemia, 2986
 Splenic abscess, 2317
 Splenic capsule, 3060
 Splenic cords, 3060
 Splenic cysts, pseudosplenomegaly and, 3061
 Splenic enlargement, 1308
 Splenic hematopoiesis, 3060–3061
 Splenic hypofunction, 3063
 Splenic sequestration, in sickle cell anemia, 2968–2969
 Splenic trauma, 3063
 Splenomegaly, 2981, 3061, 3062t
 clinical manifestations of, 3061
 differential diagnosis of, 3061, 3062t
 congestive splenomegaly, 3061
 hypersplenism, 3061
 pseudosplenomegaly, 3061
 portal hypertension and, 2505
 Splenosis, in pseudosplenomegaly, 3061
 Splinter hemorrhages, 4144, 4144f
 Splinting, for birth brachial plexus palsy, 4399
 Split-cord malformation, 3786–3787, 3787f
 SpO₂/FiO₂ ratio, 617–618
 Spondylitis, 4255
 tuberculous, 1845
 Spondyloarthritides, 1483–1487
 classification, 1484t
 clinical manifestations and diagnosis of, 1483–1485
 differential diagnosis of, 1486
 epidemiology of, 1483
 etiology and pathogenesis, 1483

- Spondyloarthritides (Continued)**
- imaging of, 1485–1486, 1487f
 - laboratory findings, 1485–1486
 - overlapping characteristics of, 1483t
 - prognosis of, 1487
 - treatment of, 1487
- Spondyloarthropathies**, seronegative, 1479t
- Spondylocostal dysostosis syndromes**, 780t
- Spondylodiscitis**, *Kingella kingae* in, 1753–1754
- Spondylodiscitis infection**, 4255
- Spondyloenchondroplasia (SPENCD)**, 1530t, 1532
- Spondyloepiphyseal dysplasia**, 4340
- Spondyloepiphyseal dysplasia congenita**, 4340, 4342f
- Spondyloolisthesis**, 4253–4255, 4254f, 4306
- Spondylolysis**, 4253–4255, 4254f, 4305–4306
 - football associated with, 4327–4329
 - gymnastics associated with, 4332
- Spondylometaphyseal dysplasia**, Kozlowski type, 4357
- Spondylophtosis**, 4253
- Sponge contraception**, 1227
- Spongiform encephalopathies**, transmissible, 2118–2124
- Sponging**, for yellow fever, 2072
- Spontaneous abortions**, 1022
- Spontaneous bacterial peritonitis**, 3223–3225
- Spontaneous breathing trial (SBT)**, 629
- Spontaneous esophageal rupture**, 2271
- Sporadic diseases**, 1583
- Sporadic retinoblastoma**, 3149
- Sporothrix schenckii**, 1941–1942, 1942f
- Sporotrichosis (*Sporothrix schenckii*)**, 1941–1942, 1942f
- Sport Concussion Assessment Tool version 5 (SCAT5)**, 4314–4315
- Sports**
 - drowning and, 638
 - eye injuries related to, 3979
 - hernia, 4329
- Sports injuries**, 4326–4332
 - in adaptive sports, 4332
 - in baseball/softball, 4327–4328, 4328f
 - in basketball/volleyball, 4328
 - burnout and, 4326–4327
 - in cheerleading, 4331
 - in cycling and motocross, 4330
 - in dance, 4332
 - early specialization, 4326–4327
 - in field hockey, 4330
 - in football, 4327
 - in gymnastics, 4331–4332
 - in ice hockey, 4329–4330
 - injury risk, 4326–4327
 - in lacrosse, 4329
 - in running, 4331
 - in skateboarding, 4330
 - in skiing and snowboarding, 4330
 - in soccer, 4329
 - in sports participation, 4326–4327
 - in swimming/diving, 4329
 - in tennis, 4328–4329
 - in wrestling, 4330–4331
- Sports medicine**, prevention of injuries, 4294–4297
 - history and physical examination, 4294–4297, 4295t, 4296f, 4297t
 - objectives of, 4295t
 - preparticipation sports examination, 4294–4297
- Sports specialization**, 4327
- Spotted fever group rickettsioses**, 1899–1907, 1900t–1902t
 - flea-borne spotted fever, 1900t–1902t, 1907
 - Mediterranean spotted fever or boutonneuse fever, 1900t–1902t, 1906–1907, 1907f
 - rickettsialpox (*Rickettsia akari*), 1900t–1902t, 1907
 - Rocky Mountain spotted fever, 1899–1906, 1900t–1902t
 - clinical manifestations of, 1904–1905, 1904f
 - complications of, 1906
 - diagnosis of, 1905
 - differential diagnosis of, 1905
 - epidemiology of, 1899, 1903f
 - etiology of, 1899
 - laboratory findings of, 1905
 - pathology and pathogenesis of, 1903–1904, 1903f
 - prevention of, 1906
- Spotted fever group rickettsioses (Continued)**
- prognosis for, 1906
 - supportive care for, 1905–1906
 - transmission of, 1899–1903, 1903f
 - treatment of, 1905
- Sprain**, 4297
- Sprengel deformity**, 4264
- SPS**. *See* Solutions for Patient Safety
- SPT**. *See* Skin-prick test
- Spun-glass hair**, 4141–4142, 4142f
- Spurling compression test**, 4319
- Squamous cell carcinoma**, 4166–4167
- Squamous epithelium**, 2255–2256
- Squamous intraepithelial lesions**, HPV, 2055
- SRD**. *See* Steroid 5 α -reductase deficiency
- SREAT**. *See* Steroid-responsive encephalopathy with autoimmune thyroiditis
- SRP72-related disorder**, 3009
- SRSD**. *See* Self-regulated strategy development
- SSEPs**. *See* Somatosensory evoked potentials
- SSEs**. *See* Serious safety events
- SSPE**. *See* Subacute sclerosing panencephalitis
- SSRDs**. *See* Somatic symptom and related disorders
- SSRIs**. *See* Selective serotonin reuptake inhibitors
- St. John's wort**, 57t
- St. Louis encephalitis**, 2061
- Stability**, in food security, 421
- Stachybotrys**, 4411
- Stacking**, steroids, 4325
- Staff**
 - in communications and dispatch centers, 540
 - in pediatric palliative care, 62–63
 - training of, for emergency medical services, 534–536
- Staging**
 - of allergic bronchopulmonary aspergillosis, 2629t of GVHD, 1358t
 - of Hodgkin lymphoma, 3110t
 - for neuroblastoma, 3127t
 - non-Hodgkin Lymphoma, 3113t
 - for rhabdomyosarcoma, 3138t
 - of sarcoid, radiography for, 2623
- Stainless steel crowns**, for dental caries, 2247
- Stammering**, 333, 333t
- Standard deviation (SD)**, 141t, 142
- Standard value**, 172
- Standardized developmental screening questionnaires**, 305
- Standardized rating scales**, 305
- Standing examination**, 4219, 4221f
- Staphylococcal blepharitis**, 3935
- Staphylococcal scalded skin syndrome**, 4153–4154, 4153f
- Staphylococci**
 - coagulase-negative, 1699–1700
 - endocarditis caused by, 2870t
- Staphylococcus**, 1693–1700
- Staphylococcus aureus infection**, 1693–1698
 - in bacterial arthritis, 4291
 - bacterial gastroenteritis and, 2357t–2358t
 - causing spine infection, 4255
 - clinical manifestations of, 1695–1696
 - diagnosis of, 1696
 - differential diagnosis of, 1696
 - epidemiology of, 1694
 - etiology of, 1694
 - in out-of-home childcare, 1623t–1625t
 - parenteral antimicrobial agents for, 1698t
 - pathogenesis of, 1694–1695, 1695f
 - prevention of, 1697–1698
 - prognosis of, 1697
 - toxic shock syndrome, 1696
 - treatment of, 1696–1697
 - vulvovaginal infection, 3322t
- Starch-iodine test**, for hypohidrotic ectodermal dysplasia, 4048
- Stargardt disease**, 3959–3960
- START/Jump START triage**, 539, 540f
- Starvation ketoacidosis**, 516
- STAT2 deficiency**, 1339t
- STAT3 hyper-IGE syndrome (Job syndrome)**, 1345
- State appropriations**, 1590
- Static acoustic admittance**, 3991
- Static compliance**, 628
- Statin-induced rhabdomyolysis**, with myoglobinuria, 3846
- Statins**, in polycystic ovary syndrome, 3335f
- Station**, in neurologic evaluation, 3557
- Statistics**, in describing growth and development, 140–142
- Stature**
 - height, 168f
 - in Turner syndrome, 3497
- Status asthmaticus**, 1405t–1406t, 1406
- Status epilepticus**, 3623–3629, 3624f–3626f, 3624t, 3628t
 - autoimmune encephalitis associated with, 3711
 - etiology of, 3626
 - mechanisms of, 3627
 - therapy for, 3627–3629, 3627f
- Status migrainosus**, inpatient management of, 3648
- Stealing**, 282
- Steam inhalation**, 646
- Steatocystoma multiplex**, 4186
- Steatohepatitis, nonalcoholic**, 2480
- Steely or kinky hair**, inborn errors of metabolism and, 809t–810t
- Steeple sign**, 2026
 - in croup, 2569, 2569f
- Stellate ganglion block**, 696
- Stellate macular retinopathy**, in cat-scratch disease, 1814
- Stem cell transplantation**, 1664
 - for mucopolysaccharidoses, 943t
 - for primary hemophagocytic lymphohistiocytosis, 3177
- Stenosis**
 - aortic, 2790–2793
 - clinical manifestations of, 2791
 - laboratory findings and diagnosis for, 2791–2792
 - prognosis of, 2792–2793
 - treatment of, 2792
 - congenital
 - of external auditory canal, 3996–3997, 3997f
 - mitral, 2796
 - intestinal, 2282–2285
 - mitral, in rheumatic heart disease, 2873–2875, 2874f–2875f
 - pulmonary
 - in combination with intracardiac shunt, 2790
 - infundibular, double-chamber right ventricle, 2789–2790
 - with intact ventricular septum, 2787–2789
 - peripheral, 2790
 - pyriform aperture, 2546, 2546f
 - subglottic, congenital, 2574, 2575f
 - valvar aortic, sudden death and, 2860
 - Stenotrophomonas*, 1803
- Stereotype threat**, 19
- Stereotypic movement disorder (SMD)**, 244–246, 378
 - clinical course, 245
 - comorbidity, 245
 - description of, 245
 - differential diagnosis of, 245
 - epidemiology of, 245
 - etiology of, 245
 - treatment of, 245
 - Stereotypes, 243t, 3637
 - Sterile pyuria, 3266
 - Sternal clefts, 2713–2714
 - Sternal malformations, in Turner syndrome, 3498
 - Steroid(s)**, 4453
 - adrenal, biosynthesis of, 3444–3446
 - adrenal androgens, actions of, 3448–3449
 - mineralocorticoids, actions of, 3448
 - Steroid 5 α -reductase deficiency (SRD)**, 928, 3511
 - Steroid-hormone induced myopathy**, 3846, 3848t
 - Steroidogenesis**, inborn defects of, 3450
 - Steroidogenic factor-1**, overexpression of, 3473t
 - Steroid-resistance**, in nephrotic syndrome, 3229
 - Steroid-resistant nephrotic syndrome (SRNS)**, 3228f, 3229–3230
 - Steroid-responsive encephalopathy with autoimmune thyroiditis**, 3708–3710

- Stevens-Johnson syndrome (SJS), 1455, 4078–4080, 4149
 clinical manifestations of, 4078–4079, 4079f
 differential diagnosis of, 4079
 etiology of, 4078–4080
Mycoplasma pneumoniae and, 1889
 pathogenesis of, 4079
 treatment of, 4079–4080
- Stickler syndrome, 1053t, 2245, 3987t
 dysplasia, 4341, 4341t, 4343f
- Stiff baby syndrome, 3635
- Stiff-Person syndrome, 3546–3548
- Stigma, regarding GLB youth, 1183
- Still murmurs, 2737
- Stillbirth, 24–25, 1021, 1021t
- Stillborn, 23–24
- Stimson maneuver, 4301
- Stimulants
 abuse of, 1195t–1196t
 as performance-enhancing aids, 4325t–4326t
 side effects of, 222
- Stimulus-precipitated seizures, 3629
- STING-associated vasculopathy with onset in infancy (SAVI), 663, 1530t, 1532–1534, 1534f, 1560, 2634t, 3890–3891
- Stingers, 4319
 football associated with, 4327
 wrestling associated with, 4330
- Stingray, 4472
- STIs. *See* Sexually transmitted infections
- Stochastic effects, 4414
- Stomach, 2276–2277
 congenital anomalies of, 2278–2281
 congenital gastric outlet obstruction, 2278t, 2280, 2280t
 gastric duplication, 2280–2281, 2280t
 gastric volvulus, 2281
 hypertrophic gastropathy, 2281
 hypertrophic pyloric stenosis, 2278–2280, 2278f–2279f, 2278t, 2280t
 fetal, ultrasonographic assessment, 1026t
 foreign bodies in, 2302–2304
 full, 667
- Stomachache, in exclusion or inclusion in daycare, 187t–192t
- Stomatitis, aphthous, in PFAPA, 1529
- Stomatocytes, 2963
- Stomatocytosis, hereditary, 2961–2963, 2962t, 2963f
- Stones
 calcium, 3312t
 cholesterol gallstones, 2503
 formation, 3311–3312
 prevention, 3315–3316
 size and location vs. surgical treatment, 3315t
- Stool frequency, in infants, 2223
- Stool osmolar gap, 2381
- Stools
 Bristol Stool Chart, 3293f
 in cholera, 1787f
- Storage diseases
 glycogen, 991
 glycogen, type 1b, 1309t, 1310–1311
- Strabismic amblyopia, 3915
- Strabismus, 3553, 3925–3930, 3926t
 clinical manifestations and treatment of, 3925–3929, 3927f–3928f, 3929t
 comitant, 3925–3927, 3927f–3928f
 diagnosis of, 3925, 3926f
 evaluation of, 3927f
 fourth nerve palsy, 3928
 noncomitant, 3927–3928, 3929t
 sixth nerve palsy, 3928–3929
 syndromes of, 3929–3930, 3929f–3930f
 third nerve palsy, 3928
- Strabismus syndromes, 3929–3930
 Brown syndrome, 3930, 3930f
 Duane syndrome, 3929–3930
 Möbius syndrome, 3930
 monocular elevation deficiency, 3929f
 Parinaud syndrome, 3930
- Straddle injuries, 3328, 3328f
- Strains, lumbar, 4306–4307
- Stranger anxiety, 156
- Stranger rape, 1235
- Strangulated hernia, 2417–2418
- Strattera. *See* Atomoxetine
- Strawberry tongue
 in Kawasaki disease, 1542f
 in scarlet fever, 1707f
- Streams of development, 88t–89t
- Strength, in motor examination, 3555
- Strength and Difficulties Questionnaire (SDQ), 218t
- Streptococcus moniliformis*, in rat bite fever, 4460
- Streptococcal infection
 group A, 1706–1715
 pharyngitis, 2559
 rheumatic fever, 1711–1715
 group B, 1716–1720
 groups C and G streptococci, 1721
 Lancefield grouping, 1721t
 non-group A or B streptococci, 1721–1722
 pharyngitis, 1623t–1625t
 viridans group, native valve endocarditis caused by, 2870t
 vulvovaginal, 3322t
- Streptococcal pyoderma (impetigo, pyoderma), 1706
- Streptococcosis, 2552t
- Streptococcus dysgalactiae* subspecies *equisimilis*, 1721
- Streptococcus mutans*, 2246f
- Streptococcus pneumoniae* infection, 1701–1705
 in bacterial arthritis, 4291
 clinical manifestations of, 1702, 1702f
 diagnosis of, 1702–1703
 epidemiology of, 1701
 etiology of, 1701
 pathogenesis of, 1701–1702
 in pneumococcal meningitis, 3758–3760
 prevention of, 1703–1705
 prognosis of, 1703
 sensorineural hearing loss and, 3984
 treatment of, 1703
 vulvovaginal infection, 3322t
- Streptococcus pyogenes*, vulvovaginal infection, 3322t
- Streptogramins, 1689–1690
- Streptomycin, 4455
 for drug-resistant tuberculosis, 1852t–1853t
- Stress fracture
 gymnastics associated with, 4331–4332
 running associated with, 4331
- Stress test, 4295
- Stress ulceration, 2306
- Stress-dose corticosteroids, for refractory shock, 611
- Stressful life events, in somatization, 237
- Stress-produced hyperglycemia, 3524
- Stretch marks, 4120, 4120f
- Stretch syncope, 3632
- Stretching exercises, for birth brachial plexus palsy, 4399
- Striae cutis distensae, 4120, 4120f
- Striate palmar xanthomata, 875f
- Striated muscle, 2261
- Stricture
 esophageal, 2275
 urethral, 3285
- Stridor, 2513
 in acutely ill child, 549
 GERD and, 2268
 recurring/persistent, 2528, 2528t
- Stroke, 3742–3754
 arterial ischemic, 3742–3747, 3742f, 3743t–3745t, 3746f
 cardioembolic, 3745
 cerebral sinus venous thrombosis in, 3747–3749, 3748t, 3749f
 heat, 4320–4321
 hemorrhagic, 3749–3752, 3750f–3752f, 3751t–3752t
 language disorders and, 330
 metabolic, 833
 in progeria, 959
 spinal cord lesions associated with vascular processes in, 3749
 stroke-like events, differential diagnosis of, 3753–3754, 3753t
- Stroke-like events, differential diagnosis of, 3753–3754, 3753t
- Strongyloides stercoralis*, 2204
- Strongyloidiasis, 2204–2206, 2205f–2206f
 drugs for, 2126t–2144t
- Structural competency, 22
- Structural defects, of hair, 4140
- Structural elements, for outcome measures, 542
- Structural epilepsy, 3589
- Structural family therapy, 233
- Structural kyphosis, 4250–4251, 4251f
- Structural problems, adolescent, 1164t–1165t
- Structural racism, 21
- Structure-function claims, 56
- Struvite calculi, 3314
- Struvite stones, 3312t
- Sturge-Weber syndrome, 3656f, 3659–3661, 3660f–3661f, 3660t, 4050–4051
 clinical manifestations of, 3659–3660, 3660f, 3660t
 diagnosis of, 3660–3661, 3660f–3661f
 etiology of, 3659
 management of, 3661
 in phakmas, 3960
- Stuttering, 165, 333, 333t
 developmental, 333–334
 emotional symptoms and, 334
 speech disorders and, 332
- Stuttering priapism, 3300
- Stx1, 1783
- Stx2, 1783
- Stye, 3936
- Subacute bacterial endocarditis, 3962, 3962f
- Subacute sclerosing panencephalitis (SSPE), 1961–1962
- Subacute thyroiditis, 3411, 3412t
- Subacute toxicity in arsenic intoxication, 4432
- Subarachnoid disease, 2219
- Subarachnoid hemorrhage, 1057–1058
- Subarachnoid neurocysticercosis, 2218
- Subclinical form of measles, 1959
- Subclinical porphyria, 965
- Subconjunctival hemorrhage, 3942
- Subcoronal hypospadias, 3297f
- Subcortical heterotopia, 3569
- Subcutaneous emphysema, 1097, 2593, 2593f
- Subcutaneous fat necrosis, 4131, 4131f
- Subcutaneous immunoglobulin (SCIG), 1586t
- Subcutaneous insulin therapy, for T1DM, 3528–3534
- Subcutaneous morphea, 1508t
- Subcutaneous nodules, in rheumatic fever, 1713
- Subcutaneous tissue, 4025f, 4026
 diseases of, 4129–4133
- Subdural empyema, CSF findings in, 3759t–3760t
- Subdural hematoma, in traumatic brain injury, 584f–585f
- Subdural hemorrhage, 1057
- Subependymal calcification, 3658f
- Subependymal giant cell astrocytomas, 3657
- Subependymal nodules, 3657
- Subgaleal hemorrhage, 1001, 1057
- Subglottic hemangioma, congenital, 2576, 2576f
- Subglottic stenosis, 2580–2581
 congenital, 2574, 2575f
- Sublingual immunotherapy, for allergic rhinitis, 1382
- Sublingual space infection, 2248t
- Subluxation, of periodontal structures, 2251
- Submandibular space infection, 2248t
- Submental space infection, 2248t
- Submersion injury, 637–645
- Subperiosteal abscess, 3973t, 3975
- Subperiosteal new bone formation, 116–117
- Substance abuse
 among GLB youth, 1183–1184
 among teen mothers, 1230
 in early childhood trauma, 75
- Substance use, 247t–248t
 in adolescents, 1169–1170
 minor consent laws for, 1168
- Substance use disorder, 1193–1209
 alcohol, 1198–1199
 amphetamines, 1206–1207
 annual prevalence use, 1195t–1196t
 bath salts, 1208–1209
 clinical manifestations of, 1197
 cocaine, 1205–1206
 complications, 1198
- CRAFFT mnemonic tool, 1197t

- Substance use disorder (*Continued*)
 diagnosis of, 1198
 epidemiology of, 1194–1197
 etiology of, 1193–1198
 hallucinogens, 1204
 inhalants, 1202–1203
 marijuana, 1201–1202, 1201f
 opiates, 1207–1208, 1208t
 prevention, 1198
 prognosis of, 1198
 protection and risk model, 1193f
 risk and protective factors, 1199t
 screening for, 1197–1198
 seriousness of drug abuse, 1194t
 stages of, 1194t
 stimulant abuse and diversion, 1207
 tobacco, 1199–1200
 toxic syndromes, 1197
 treatment of, 1198
 Substernal heave, 2740
 Substitution, 730–731, 732t
 Subsyndromal disorder, 277
 Subtelomeres, 770
 Subtelomeric regions, 770
 Subungual exostosis, 3145–3147, 3146f–3147f, 4210
 Subungual hemorrhage, disorders associated with, 4144t
 Subvalvular (subaortic) stenosis, 2791
 Succimer, for arsenic and mercury intoxication, 4435
 Succinic semialdehyde dehydrogenase deficiency, 847
 Succinimides, adverse effects of, 3611t
 Succinylcholine, 669t
 Succinyl-CoA:3-ketoacid-CoA transferase (SCOT) deficiency, 865
 Succinyl-CoA:3-oxoacid-CoA transferase deficiency, 832
 Sucking blisters, 4041
 Sucking reflexes, 591t
 Sucrase-isomaltase deficiency, 2347
 Sudafed Sinus & Allergy, for allergic rhinitis, 1383t
 Sudden death, 2860–2864
 cardiac arrhythmia, 2861
 cardiomyopathy, 2861
 causes of, 2860f, 2861t
 congenital heart disease and, 2860
 mechanism of, 2860
 medication for attention-deficit/hyperactivity disorder, 2862
 mimics, 2861t
 miscellaneous causes of, 2861–2862
 prevention of, 2862–2864
 resuscitated patients, 2862
 in sports, 4295
 Sudden infant death syndrome (SIDS), 193, 564, 2532–2540
 apnea and, 1076
 clinical strategies for, 2538–2539
 conditions causing, 2533t
 differential diagnosis of, 2532t
 environmental risk factors for, 2533–2535, 2533t
 epidemiology of, 2532–2539
 gene-environment interactions, 2536–2537, 2536f–2537f, 2536t
 genetic risk factors for, 2535–2536, 2535f, 2535t
 infant groups at increased risk for, 2537–2538
 pathology of, 2532–2533
 Sudden unexpected death in epilepsy (SUDEP), 3616, 3616t
 Sudden unexpected postnatal collapse (SUPC), 2539–2540
 diagnosis and differential diagnosis of, 2540
 outcome of, 2540
 pathogenesis of, 2539–2540
 prevention of, 2540
 risk factors for, 2540
 treatment of, 2540
 Sufentanil, equianalgesic doses of, 685t
 Suffocation, 263
 death rates, 91, 92t
 Sugar alcohols, 394
 Suicidal ideation, 263
 Suicide, 263–268, 264f, 284
 among GLB youth, 1183
 assessment of, 264–266
 completions, 263, 266f
 death rates, 91, 92t
 epidemiology of, 263
 firearm injuries, 98
 intervention of, 264–266
 prevention of, 266–267, 266t
 risk factors of, 263–264, 264f, 265t
 screening and early treatment of, 267–268, 267f, 268t
 Sulfadiazine, 1675t–1685t
 for toxoplasmosis, 2196
 Sulfadoxine-pyrimethamine, 2184
 Sulfamethoxazole, 1675t–1685t
 Sulfasalazine
 for rheumatic diseases, 1465
 for ulcerative colitis, 2313–2314
 Sulfoxazole, 1675t–1685t
 Sulfite oxidase deficiency, 824, 855
 Sulfonamides, 1688–1689
 adverse drug reactions to, 1458
 Sulfonylureas, toxicity, 701t, 707t–708t
 Sulfur-containing amino acids, 821f
 Sulthiame, dosages of, 3609t–3610t
 Sumatriptan, for migraine, 3646t–3647t
 Summarizing, in motivational interviewing, 134
 Sun protection, 4093
 Sunitinib, for gastrointestinal stromal cell tumors, 2414–2415
 Sunlight exposure, cutaneous synthesis mediated by, 472
 Sunscreens, 4040
 Superfecundation, 1040
 Superior mediastinal syndrome, 3112–3113
 Superior mesenteric artery syndrome, 2299
 Superior vena cava syndrome, 3092t–3093t
 Supernumerary nipples, 4044
 Supernumerary teeth, 2240
 Superrefractory status epilepticus (SRSE), 3624, 3629
 Superwarfarin, 3046
 Supplemental Nutrition Assistance Program (SNAP), 420
 Supplemental oxygen, for HAPE, 635
 Supplementation
 folic acid, 1028
 with neurotransmitter precursors, 815
 Support groups, on genetic conditions, 756
 Support modes
 in invasive mechanical ventilation, 625
 in patient-ventilator asynchrony, 628
 Supportive care
 for acute lymphoblastic leukemia, 3101
 for acute porphyria, 969
 for acute promyelocytic leukemia, 3103
 for botulism, 1820
 cancer treatment and, 3093
 for common cold, 2552–2553
 for human metapneumovirus, 2033
 for intellectual disability, 357–361
 for meningococcal disease, 1742–1743
 for tetanus, 1823
 for tuberculosis, 1853
 Supportive hospital policies, for newborn, 151
 Supportive psychotherapy, 233, 258–259
 Supportive therapy, for adrenoleukodystrophy, 871
 Suppression, in vision disorders, 3915
 Suppurative arthritis
Haemophilus influenza in, 1757–1758 syndrome, 1749
 Suppurative parotitis, 2254
 Supraclavicular lymphadenopathy, 3070t
 Supracondylar fractures, 4280
 Supracondylar humeral fractures, 4303, 4303f
 Supracristal ventricular septal defect, with aortic insufficiency, 2784
 Supraglottitis, 2569–2570, 2570f
Haemophilus influenza in, 1757
 Supratentorial primitive neuroectodermal tumors, 3124
 Supratentorial tumors, brain tumor and, 3117–3118
 Supravalvular aortic stenosis, 2791
 Supraventricular tachycardia (SVT), 563, 2848–2853
 clinical manifestations of, 2848–2850
 treatment of, 2850–2853
 Sural nerve biopsy, in peroneal muscular atrophy, 3886
 Suramin, for human African trypanosomiasis, 2162
 Surface area
 body weight, adult dosage and, 4472.e8t
 nomogram for estimation of, 4472.e8t
 Surface furrowing, of tongue, 2223
 Surface tension, 1077, 1077f
 Surfactant, 1074
 biosynthesis of, 1078f
 composition of, 1078f
 deficiency of, in RDS, 1077, 1077f
 replacement therapy, for RDS, 1080
 Surfactant C genes, abnormalities in, 1079
 Surfactant dysfunction disorders
 comparison of, 2683t
 treatment of, 2685–2686
 Surfactant metabolism disorders, 2633, 2635f, 2635t
 inherited, 2683
 pathology of, 2683
 deficiency in surfactant protein B, 2683–2684
 disease caused by variants in ABCA3, 2684–2685
 disease caused by variants in NKX2-1, 2685
 surfactant protein C-associated interstitial lung disease, 2684
 treatment of, 2685–2686
 Surfactant protein B deficiency, 1079, 2634t, 2683–2684
 Surfactant protein C variant, 2634t
 Surfactant protein C-associated interstitial lung disease, 2684
 Surgery
 for cancer treatment, 3091
 for chronic recurrent aspiration, 2611
 for congenital diaphragmatic hernia, 1095, 1096f
 for cystic fibrosis, 2678
 for ependymal tumors, 3120–3121
 for Ewing sarcoma, 3144
 fetus, indications and rationales, 1029t
 for fractures, 4283–4284, 4283t
 for glaucoma, 3970
 for hyperthyroidism, 3420t
 for inguinal hernia, 2418–2419
 for nontuberculous mycobacteria infection, 1865
 for osteomyelitis, 4291
 for septic arthritis, 4293
 Surgical excision, for angiokeratoma circumscriptum, 4052
 Surgical ligation, for patent ductus arteriosus, 1083
 Surgical management
 for burn injuries, 651–652, 652t
 vesicoureteral reflux, 3273, 3274f
 Surgical resection
 for gastrointestinal tumors, 2414–2415
 for gnathostomiasis, 2209
 Surgical safety, 49
 Surgical site infections, 45t
 Surrogate, 51
 Surveillance
 in infection prevention and control, 1620
 in well-child care, 85
 Susac syndrome, 3984
 Susceptibility factors, in porphyria cutanea tarda, 973
 Susceptibility testing results, selective reporting of, 1691t
 Sustainability Development Goals (SDGs), 27–28, 27f, 422
 Sustained fever, 1640–1641
 Sustained viral response, 2471
 Sutter-Eyberg Student Behavior Inventory-Revised, 280t
 Sutton's slip, 48t
 SVT. See Supraventricular tachycardia
 Swab test, cervical, 1242f
 Swallowing, dysfunction of, 1091
 Swanson Nolan and Pelham (SNAP)-IV-26, 218t
 Sweat glands
 cystic fibrosis and, 2667
 disorders of, 4134–4136
 anhidrosis, 4134
 Volume 1 pp. 1-2222 • Volume 2 pp. 2223-4472

Sweat glands (*Continued*)
 bromhidrosis, 4135
 Fox-Fordyce disease, 4136
hidradenitis suppurativa, 4135–4136, 4136f
hyperhidrosis, 4134, 4135f
miliaria, 4134–4135, 4135f
 Sweat testing, cystic fibrosis and, 2668t
 Sweet syndrome, 1582, 1582t, 4031t, 4033–4034, 4033f
 Swelling
 acute inguinal-scrotal, 2417–2420
 allergic laryngeal, 2571
 eyelids, 3976–3977, 3976f
 scrotal, 3304–3306, 3305t
 clinical manifestations of, 3305–3306
 differential diagnosis of, 3305t
 laboratory findings and diagnosis of, 3306, 3306f
 Swimmer's ear, 3999, 4329
 Swimmer's shoulder, 4329
 Swimming, injuries associated with, 4329
 Swine bites, 4458t
 Swing phase, 4198
 Swollen glands, in exclusion or inclusion in daycare, 1871–192t
 Swyer syndrome, 3509
 Swyer-James syndrome, 2591
 Sycosis barbae, 4156
 Sydenham chorea, 3673
 in rheumatic fever, 1713–1714
 Sylvian aqueduct syndrome, 3930
 Symblepharon, 3943
 Symmetric IUGR, 1048
 Sympathetic blocks, in pain management, 695–696, 695t
 Sympathetic ophthalmia, 3953
 Sympathomimetic toxicodrome, 703t, 1197t
 Symptom management, in pediatric palliative care, 63–71, 64f
 Symptom model, 237
 Symptom review, 221
 Symptomatic therapy, for mucopolysaccharidoses, 943–944, 943t–944t
 Synchronized cardioversion, 563
 Synchronized intermittent mandatory ventilation (SIMV), 624, 625f
 Synchronized intermittent mechanical ventilation (SIMV), pressure-limited, for RDS, 1081
 Syncope, 592–599
 cardiac causes of, 592, 594t–595t
 evaluation for, 594–596, 595t–596t
 heat, 4320
 mechanisms of, 592
 noncardiac causes of, 592, 593t
 seizures vs., 592, 593t
 that mimic seizures, 3631–3633, 3631t
 treatment for, 596
 Syndactyly, 784t, 4049t–4050t, 4210, 4210f, 4269, 4270f, 4270t
 Syndesmosis ligament injury, basketball and, 4328
 Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 492t, 493
 disorders associated with, 3376t
 hyponatremia and, 3375
 treatment of, 3376–3378
 Syndrome of pyogenic arthritis with pyoderma gangrenosum and acne (PAPA syndrome), 1523, 1528f
 Syndromes of hereditary persistence of fetal hemoglobin, 2981–2987
 Syndromic cleft palate, 331
 Syndromic craniostenosis, 3582t
 Syndromic ichthyoses, 4117–4118
 chondrodyplasia punctata, 4118
 diffuse hyperkeratosis of palms and soles, 4118–4119, 4118f
 mal de Meleda, 4119
 Netherton syndrome, 4114t, 4117–4118, 4117f
 palmoplantar keratoderma, 4118
 Papillon-Lefèvre syndrome, 4119
 Refsum syndrome, 4118
 Sjögren-Larsson syndrome, 4117
 Vohwinkel palmoplantar keratoderma, 4119
 Syndromic neuropathies, in HMSN, 3879t–3881t
 Syndromic sensorineural hearing loss, 3987t
 Synkinesis, 3907

Synophrys, 784t
 Synovial sarcoma, 3139t–3140t
 Synovitis, toxic, 4289–4237
 Synpolydactyly, 745t–746t
 Syntax, 301
 development of, 324, 325t
 Syntelencephaly, 3569–3570
 Synthetic cannabinoids, 1208–1209
 toxicodrome, 704t
 Synthetic chemicals, 4424
 human health and, 4422–4427
 safety testing of, 4423–4424
 susceptibility to, 4423
 Syo-saiko-to, 2492t
 Syphilis, 1866–1875
 acquired, 1866
 treatment of, 1873–1874
 clinical manifestations of, 1866–1869, 1867f
 congenital, 1866, 1871–1872
 diagnosis of, 1873t
 late manifestations of, 1869t
 prevention of, 1875
 treatment of, 1875
 congenital infection in, 1868–1869, 1868f–1869f
 CSF findings in, 3759t–3760t
 diagnosis of, 1869–1872, 1871f
 epidemiology of, 1866, 1866f
 etiology of, 1866
 infants born to mothers with reactive serologic tests, 1872f, 1873t
 laboratory findings of, 1866–1869
 laboratory screening, 1241t
 laboratory testing algorithm for, 1870f
 prevention of, 1875
 screening, 1246, 1247f
 signs and symptoms of, 1243t
 treatment of, 1872–1875, 1874t
 Syringoma, 4186, 4187f
 Syringomyelia, 3787–3788, 3788f
 SYROCOOT. *See* Systemic Review on Congenital Toxoplasmosis (SYRO-COT) study, 2198
 Systemic sclerosis, 1513t, 4032
 Systems Engineering Initiative for Patient Safety (SEIPS), 42
 Systolic blood pressure, shock and, 607t
 Systolic ejection murmurs, 2743

T

T cells, in allergic diseases, 1368–1370, 1369f–1370f
 Tabanid species, 1419–1420
 Tachyarrhythmias, 562–563, 562f
 in syncope, 594, 594t
 “Tachy-brady” syndrome, 2858f
 Tachycardia, 548, 555, 1017
 general physical examination for, 2738
 predicting toxicity from vital signs in, 704t
 supraventricular, 2848–2853
 Tachypnea, 548, 554
 in infants of diabetic mothers, 1141
 as respiratory distress, 612–613
 transient, of newborn, 1088, 1089f
 Tachyzoites, 2186
 Tadalafil, 2834t
Taenia asiatica, 2215–2216
Taenia coli, 2277
Taenia saginata, 2215–2216
Taenia solium, 2215–2216, 2218
 TAFAZZIN-related disorder, 829
 TAFI. *See* Thrombin-activatable fibrinolysis inhibitor
 TAFRO syndrome, 3072, 3072f
 Tai chi, 58t
 Takayasu arteritis (TA), 1553t, 1557–1559
 clinical manifestations of, 1558
 complications of, 1559
 diagnosis of, 1558
 differential diagnosis of, 1558
 epidemiology of, 1557
 laboratory findings of, 1558–1559, 1559f
 pathogenesis of, 1558
 pathology of, 1557–1558
 pediatric-onset, 1558t
 prognosis for, 1559
 treatment of, 1559
 Take 5 Safety Plan for Crying, 157
 Talar dome fracture, 4312
 Talipes equinovarus, 4202–4203, 4203f–4204f

- Tall stature, 177t, 3378
 differential diagnosis of, 3383t
 normal variant of, 3380
- TAM. *See* Transient abnormal myelopoiesis
- Tamm-Horsfall protein, 3218
- Tamoxifen, for gynecomastia, 3496
- Tamponade, 3029
 cardiac, cardiac arrest and, 567t
- Tandem mass spectrometry, 4472.e6, 728, 803
- Tangier disease, 880, 2341, 2963
- Tanner stages, of sexual development, 1159, 3329
- Tantrums, 281
- Tapeworm infections, 2215–2218, 2216t
 clinical manifestations of, 2216
 diagnosis of, 2216, 2217f
 differential diagnosis of, 2216
 diphyllobothriasis, 2217
 drugs for, 2126t–2144t
 epidemiology of, 2216
 etiology of, 2215–2216
 hymenolepiasis, 2217–2218
 pathogenesis of, 2216
 prevention of, 2217
 treatment of, 2216
- TAR. *See* Thrombocytopenia-absent radius syndrome
- Tar compounds, 4039
- Tar preparations, for atopic dermatitis, 1415
- Tardive dyskinesias, 3681–3682
- Target symptoms
 of ADHD, 225t–226t
 approach to psychopharmacologic management, 224t
 of depression and anxiety, 227t
 of psychosis and mania, 228t
- Targeted CMAs, 762
- Targeted temperature management (TTM), 568
- Tarui disease, 900t–901t, 909–910, 3851, 3852t
- Tatton-Brown syndrome, 3384
- Taurodontism, 2240
- Taussig-Bing malformation, 2808–2809, 2810f
- Tay-Sachs disease (TSD), 3713–3714
- TB. *See* Tuberculosis
- TBI. *See* Traumatic brain injury
- TBMD. *See* Thin basement membrane disease
- TBNK1 deficiency, 1339t
- TCAs. *See* Tricyclic antidepressants
- TCD. *See* Transcranial Doppler ultrasonography
- T-cell activation, modulators of, 1466t–1468t, 1469–1470
- T-cell acute lymphoblastic leukemias, 3077
- T-cell and combined deficiencies, 1262–1276, 1262f
- T-cell antibodies, in induction therapy, 3256
- TCF12-related craniostenosis, 794t–795t
- TCIRG1-related autosomal recessive osteopetrosis, 4351t
- Tdap vaccines, 1765
- Tea tree oil, 56t
- Team, in interfacility transport, 541
- Tear film, 3936–3937, 3937f
- Technical Resources, Assistance Center, and Information Exchange (TRACIE), 109
- Tecovirimat, for orthopoxviruses, 4451, 4455
- Teeth
 calcification of, 2239, 2239t
 in congenital erythropoietic porphyria, 971f
 development and developmental anomalies of, 2239–2241
 color, 2241
 number, 2240
 shape, 2240
 size, 2240
 structure, 2241
 eruption, 2239–2240, 2239t
 histodifferentiation-morphodifferentiation of, 2239
- Hutchinson, 1868–1869, 1869f, 1869t
- initiation of, 2239
 injuries to, 2250–2251, 2250f, 2251t
 syndromes with natal, 2240t
- Teething, 2241
- Telangiectasia macularis eruptiva perstans (TMEP), 4125
- Telangiectasias, liver disease and, 2439
- Telangiectatic osteosarcoma, 3141
- Telecanthus, 784t
- Telemedicine, 540
- Teleoroentgenogram, 4219
- Telogen effluvium, 4140
- Telomerase, oncogenesis and, 3081
- Telomere biology disorders, 1309t, 1310
- Telophase, 761
- Temper tantrums, 281
 in preschoolers, 166
- Temperament
 characteristics of, 138t
 child, parenting in, 143
 dimensions of, 137
- Temperature
 instability in newborn, 1147–1148
 shock and, 607t
- Temporal bone
 fractures, 4022–4023, 4022f
 traumatic injuries of, 4021–4023
- Temporal lobe, seizures, 3638
- TEN. *See* Toxic epidermal necrolysis
- TEN-4 FACESp mnemonic, 115
- Tendon stretch reflexes, 3791
- Tenex. *See* Guanfacine
- Tennis, injuries associated with, 4328–4329
- Tennis elbow, 4328
- Tennis leg, 4328
- Tenofovir, for hepatitis B, 2467
- Tenofovir alafenamide, for HIV, 2098t–2107t
- Tenosynovitis, 1753
- Tenosynovitis-dermatitis syndrome, 1749
- Tension pneumothorax, 1097
 cardiac arrest and, 567t
 in multiple trauma, 571–573
- Tension-type headaches, 3652, 3652t
- Teratogens, 147, 1021–1022
 arsenic, 4432t
 exposure, 1021
 exposure, effects on fetus, 1021–1022
 vitamin A and, 455
- Teratologic hip dislocations, 4232, 4273–4275
- Teratomas, 3083–3084, 3152, 3152f
 ovarian, 3340–3341, 3341f
- Terbinafine
 for paracoccidioidomycosis, 1941
 for sporotrichosis, 1942
- Terbutaline, for asthma, 1405t–1406t
- Terizidone, for drug-resistant tuberculosis, 1852t–1853t
- Terlipressin, for shock, 610t
- Terminal hematuria, 3295
- Terminal pathway, of complement system, 1315
- Terminal restlessness, in pediatric palliative care, 69t
- Terminally ill adolescents, decisions in, 55
- Terrorism, 108
- Terrors, sleep, 209t
- Terry nails, 4143, 4144f
- Tertian fever, 1640–1641
- Tertiary adrenal insufficiency, 3458–3459
 causes of, 3453t
 clinical presentation of, 3458–3459
 laboratory findings of, 3459
 treatment of, 3459
- Test of Word Reading Efficiency (TOWRE), 317
- Testes
 development of, 3481
 function of, 3485–3486, 3485f
 growth, 3386
 hypofunction of, 3487–3494
 other causes of, 3489
 primary hypogonadism in, 3487–3491
 clinical manifestations of, 3489
 diagnosis of, 3489
 etiology of, 3488t
 Klinefelter syndrome in, 3489–3491
 Noonan syndrome in, 3489
 45,X males in, 3491
 XX males in, 3491
 47,XXX males, 3491
- secondary hypogonadism in, 3488t, 3491–3494
 diagnosis of, 3493
 etiology of, 3492t
 other disorders with, 3493
 treatment of, 3493–3494
 without anosmia, 3492–3493
- Testes (*Continued*)
 sexual maturity rating in, 1160t
 tumors of, resulting from, 3494
 undescended, 3302–3304
- Testicular adrenal rest tumors, 3466–3467
- Testicular adrenal rests, 3494
- Testicular cancer, 3150
- Testicular differentiation, defects in, 3509–3510
- Testicular dysgenesis syndrome, 3489
- Testicular feminization syndrome, 2416–2418
- Testicular GCT, 3150
- Testicular hormone production, deficiency of, 3510–3511
- Testicular injuries, 331t
- Testicular microlithiasis, 3309
- Testicular regression syndrome, 3488–3489
- Testicular relapse, incidence of, 3101
- Testicular tumor, 3309
- Testosterone
 gender-affirming hormone therapy and, 1179, 1179t
 precursors, as performance-enhancing aids, 4325
 puberty blockers and, 1178t
 synthesis, block in, 3508t
 therapy of, risks with, 1180
- Tetanospsamin, 1821
- Tetanus, 1821–1824
 in bite injuries, 4459–4460
 clinical manifestations of, 1822
 complications of, 1823
 diagnosis of, 1822–1823
 differential diagnosis of, 1823
 epidemiology of, 1821–1822, 1822f
 etiology of, 1821
 in newborn, 1148
 pathogenesis of, 1821–1822
 prevention of, 1824
 prognosis for, 1824
 supportive care in, 1823
 toxin, 1821
 treatment of, 1823
 wound management in, 1824, 1824t
- Tetanus and diphtheria toxoids adsorbed (Td, adult use), 1588t–1589t
- Tetanus and diphtheria toxoids adsorbed plus acellular pertussis (Tdap) vaccine, 1588t–1589t
- Tetanus immunoglobulin (IM), 1586t
- Tetanus toxoid, reduced-diphtheria toxoid, and acellular pertussis (Tdap), 1765
- Tetany, heat, 4320
- Tethered cord, 3785–3786, 3785f–3786f
 myelomeningocele and, 4400–4401
- Tetracyclines, 1688
 for acne vulgaris, 4180
 adverse reactions in premature infant, 1045t
 enterococci resistance, 1722t
 for psittacosis, 1898
 for Rocky Mountain spotted fever, 1905
- Tetraethyl lead, 4422
- Tetrahydrobiopterin (BH₄), 813f
 deficiency, 3603
 hyperphenylalaninemia caused by, 814–815, 814f
 sepiapterin reductase deficiency, 846
 without hyperphenylalaninemia, 844–846
- oral administration of, 814
- Tetrahydrocannabinol, 1201
- Tetralogy of Fallot, 2800–2804, 2800f, 2841
 associated anomalies with, 2803
 clinical manifestations of, 2800–2801
 complications of, 2802
 diagnosis of, 2801–2802
 pathophysiology of, 2800
 prognosis of, 2803–2804
 with pulmonary atresia, 2804–2805
 relative frequency of, 2763t
 treatment of, 2803
- Tetrasomy 12p, 363t, 773t
- Tetrodotoxin, 4445
 from puffer fish, 4411t–4413t
- TGD. *See* Transgender and gender diverse
- TH17 cells, 1369
- α-thalassemia syndrome, 2981, 2987
- β-thalassemia syndrome, 2981
 transfusion therapy, 2982–2983

- Thalassemia syndromes, 2981–2987
 epidemiology of, 2981
 homozygous β -thalassemia, 2981–2986
 HSCT for, 1354, 1354f
 laboratory findings in, 2981–2982, 2983f
 laboratory studies of, 2948t
 management and treatment of, 2982–2986, 2984f
 pathophysiology of, 2981, 2982t, 2983f
 preventive monitoring of patients with, 2986, 2986t
 α -thalassemia, 2987
 α -Thalassemia trait, 2987
 Thalidomide, for Hansen disease, 1859
 Thallium, food-borne illness, 4411t–4413t
 noninfectious, 2362t–2364t
 Thanatophoric dysplasia, 794t–795t, 4345, 4346f
 TTHE. See Tricho-hepato-enteric syndrome
 Theater sign, 4228
 Thecomas, 3343
 Thelarche, 1159, 1210, 3328
 exaggerated or atypical, 3344
 premature, 3393–3394
 T-helper type 1 (Th1) cells, 1367
 T-helper type 2 (Th2) cells, 1367
 Theophylline
 for apnea, 1076
 toxicity, 701t
 Theory of planned behavior, 141t
 Theory of reasoned action, 141t
 Therapeutic hypothermia, in drowning victims, 640
 Therapeutic irradiation, 3409
 Therapeutic yoga, in pain management, 693
 Therapeutics targeting the interferon pathway, 1535
 Thermal burns, 646
 Thermal control, for high-risk infant, 1043–1044
 Thermal effect, of food, 391
 Thermal injury, hemolytic anemias and, 2996
 Thermoregulation, anesthesia and, 674
 Thiabendazole, for hookworms, 2202
 Thiamine (vitamin B₁), 456–460, 456t–457t
 deficiency, 458–460, 458t
 with cardiopathy and peripheral neuropathy, 459
 clinical manifestations of, 459
 diagnosis of, 459, 459t, 460f
 prevention of, 460
 in refeeding syndrome, 432t
 treatment for, 460
 dietary reference intake, 397t–403t
 metabolism of, genetic pathogenic variants affecting, 458t
 toxicity, 460
 Thiamine metabolism dysfunction syndrome 3 (THMD3), 458t
 Thiamine metabolism dysfunction syndrome 4 (THMD4), 458t
 Thiamine metabolism dysfunction syndrome 5 (THMD5), 458t
 Thiamine transporter variants, with acute basal ganglia disease, 3603
 Thiamine-responsive maple syrup urine disease, 826
 Thiamine-responsive megaloblastic anemia (TRMA) syndrome, 458, 458t, 2944
 Thiazide, 3241, 3252
 diuretics, 519
 for nephrogenic diabetes insipidus, 3239
 Thigh-foot angle, 4212, 4215f
 Thimerosal, 4433
 Thin basement membrane disease, 3189
 Thinking in silo, 48t
 Thiopental, for intubation, 620t
 Thiopurine S-methyltransferase (TPMT), 3088
 pharmacology testing of, 3101
 Thioridazine, toxicity, 701t
 Thiosulfate, 4453
 Third nerve palsy, 3928
 Third Optional Protocol, 108–109
 Third space losses, 529
 Third-degree burns (full-thickness), 649, 650f
 Third-degree frostbite, 660t, 662
 Thomsen disease, 3838
 Thoracentesis, 570, 2525
 Thoracic actinomycosis, 1734
 Thoracic insufficiency syndrome, 4248
 Thoracic outlet syndrome, 4264
 Thoracic trauma, 574t, 576, 577t
 Thoracic-pelvic-phalangeal dystrophy, 2714
 Thoracoabdominal situs, variations in, congenital heart disease, 2822f
 Thoracoscopy, 2525
 3-day measles, 1965
 3MC syndrome 2, 794t–795t
 Three-dimensional echocardiography, 2757, 2757f
 Three-step process, for interpreting acid-base disturbances, 514f
 Threshold effect, 1021–1022
 Thrills, 2740
 Throat
 cultures, for GAS pharyngitis, 2559
 physical examination of, 551
 sore, in common cold, 2553
 Thrombectomy, 3745
 Thrombin time (TT), in hemostasis, 3026
 Thrombin-activatable fibrinolysis inhibitor (TAFI), 3033
 Thrombocytopenia, 1117, 3016, 3049, 3050t–3053t, 3053f, 3092t–3093t, 3204
 from acquired disorders, 3058
 for antivenom in, 4469t
 congenital amegakaryocytic, 3056
 drug-induced, 3055
 hematuria and, 3185–3186
 in HIV, 2095
 immune, 3049–3055
 in lumbar puncture, 3762
 MYH9-related, 3056
 neonatal, 3053t, 3057
 Thrombocytopenia-absent radius syndrome, 3056, 3057f
 Thrombocytopenic syndromes, congenital, 3051t–3052t, 3057f–3058f
 Thrombocytosis, 1116–1117, 3025, 3060–3061
 in polycythemia, 2997
 Thromboembolic events (TEs), 3040
 Thromboembolism
 due to nephrotic syndrome, 3229
 venous, estrogen-containing contraceptives and, 3356
 Thrombolysis, 3745
 Thrombolytic therapy, 3042–3045, 3043t–3045t
 Thrombophilia testing, 3039
 Thrombopoiesis, fetal, 2922–2924
 Thrombopoietin (TPO), 2924, 3016–3017, 3049
 Thromboprophylaxis, 3045
 Thrombosis
 coronary, cardiac arrest and, 567t
 deep venous, 2692
 hereditary predisposition to, 3038–3039, 3038t–3039t
 pulmonary, cardiac arrest and, 567t
 in SLE, 1497t
 venous, evaluation prior to renal transplantation, 3255
 Thrombotic disorders, in children, 3040–3045
 anticoagulant and thrombolytic therapy, 3042–3045
 clinical manifestations of, 3040–3041
 complications of, 3042
 diagnosis of, 3041, 3042f
 epidemiology of, 3040, 3041t
 laboratory testing of, 3041–3042
 treatment of, 3042, 3043t
 Thrombotic microangiopathy (TMA), 2996t, 3200, 3200f
 Thrombotic predisposition, testing for, 3027–3028
 Thrombotic thrombocytopenic purpura (TTP), 2996, 3019, 3055, 3056f, 3056t
 Throwing injuries, 4327
 Thrush. *See* Oral candidiasis
 Thumb
 anomalies of, in Diamond-Blackfan anemia, 2932t
 hypoplasia, 4268–4269, 4269f
 sucking, 246
 trigger, 4269–4270, 4270f
 Thunderclap headache, 3749–3750
 Thymic disorders, 1270t, 1275–1276
 Thymic stromal lymphopoietin (TSLP), 1368
 Thymidine kinase, disorders associated with, 954
 Thymidine phosphorylase deficiency, 953
 Thyroglobulin synthesis, defects of, 3403
 Thyroglossal cysts and sinuses, 4044
 Thyroglossal duct, 3411
 cysts, 3405
 Thyroid disease, 247t–248t
 periodic paralysis with, 3840t
 Thyroid dysgenesis, 3402–3403
 Thyroid function tests, 3407t–3408t
 Thyroid gland
 disorders
 carcinoma, 3422–3424
 goiter, 3413–3415
 hypothyroidism, 3402–3410
 thyroid dysgenesis, 3402–3403
 thyroiditis, 3411–3412
 fetal development, 3400–3401
 hormone studies, 3401
 physiology, 3400–3401
 regulation of, 3400
 Thyroid hormone
 intrinsic defect in synthesis of, 3413
 transport, defects in, 3403–3404
 Thyroid myopathies, 3846
 Thyroid nodules, 3423–3424, 3424f, 3424t
 Thyroid storm, 3418, 3419t–3420t
 Thyroid tumors, 3164–3165, 3165f, 3165t
 benign, 3164
 malignant, 3164–3165, 3165f, 3165t
 Thyroidectomy, 3409, 3423
 for thyroid cancer, 3165
 Thyroiditis, 3411–3412
 characteristics of, 3412t
 chronic lymphocytic, 3411
 hyperthyroidism caused by, 3416t
 mumps and, 1971
 other causes of, 3412
 with pain, 3411
 without pain, 3411–3412
 clinical manifestation of, 3411–3412
 etiology of, 3411
 laboratory findings of, 3412
 treatment of, 3412
 Thyroid-related ophthalmopathy, 3971
 Thyroid-stimulating hormone (TSH), 3360–3361, 3400
 reference intervals, 4472.e9t
 Thyrotoxic periodic paralysis, 3849t
 Thyrotoxicosis, 3416–3422, 3846, 3934
 clinical manifestations of, 3418t
 pathogenic mechanisms and causes of, 3416t
 Thyrotropin deficiency, 3404
 Thyrotropin receptor-blocking antibodies, 3404
 Thyrotropin-releasing hormone (TRH), 3400
 reference intervals, 4472.e9t
 Thyroxine (T_4), 3400
 for congenital hypothyroidism, 4472.e5
 reference intervals, 4472.e9t
 serum levels, 3401
 Thyroxine-binding globulin (TBG)
 disorders of, 3402, 3402t
 excess, 3402
 reference intervals, 4472.e9t
 Tiagabine
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 Tibia
 characteristic lesions of, 3147–3148
 hyperostosis, 455f
 Tibia fractures
 proximal, 4282
 shaft, 4282
 Tibia vara, 4215–4216, 4217f–4218f
 Tibial bowing
 anterolateral, 4218
 anteromedial, 4217–4218, 4218f
 posteromedial, 4216
 Tibial longitudinal deficiency, 4218
 Tibial rotation, 4212, 4214f–4215f
 Tibial stress fracture, 4310–4311
 Tibial torsion, 4212
 Tibial tubercle fractures, 4282
 Tic cough, 2527–2528
 Tic disorders, 241–244, 242t
 assessment, 243
 clinical course, 242
 comorbidities, 242, 244f

- Tic disorders (*Continued*)
 differential diagnosis of, 242, 243t
 epidemiology of, 242
 etiology of, 242, 244t
 screening, 243
 sequelae, 243
 treatment of, 243–244, 246t
- Tick paralysis**, 3866
- Tick-borne diseases**
 Colorado tick fever, 2062
 encephalitis, 2064
- Tickborne encephalitis**, vaccine for, 1588t–1589t
- Tickborne lymphadenopathy (TIBOLA)**, 1900t–1902t
- Tick-borne (endemic) relapsing fever**, 1880
- Ticks**, 4170t
- Tics**, definition of, 241
- Tidal recruitment**, 623
- Tidal volume**, 2519
 exhaled, 628
 and rate, settings of, 627
- TIDE**. *See* Treatable Intellectual Disability Endeavor
- Tigecycline**, 1675t–1685t, 1724
- Tillaux fractures**, 4283, 4283f
- Tilted disc**, 3964
- Time constant**, 622, 622f
- Timed (24-hour) urine collections**, in proteinuria, 3219
- Time-sensitive automatic stop orders**, 1691t
- Timing**, of changes in puberty, 1163
- TIN**. *See* Tubulointerstitial nephritis
- Tin**
 foodborne illness, 4411t–4413t
 food-borne noninfectious illnesses and, 2362t–2364t
- Tinea capitis**, 4160–4162, 4161f
- Tinea corporis**, 4162, 4162f
- Tinea cruris**, 4163
- Tinea nigra palmaris**, 4164
- Tinea pedis**, 4163, 4163f
- Tinea unguium**, 4164, 4164f
- Tinea versicolor**, 1928, 1928f, 4159–4160, 4160f
- Tinidazole**, 2125
 for trichomoniasis, 2155
- Tinnitus**, 3981
- Tiotropium**, for asthma, 1403
- TIRAP deficiency**, 1341t
- Tissue analysis**, fetal, 1018t
- Tissue engineered neobladder**, 3290f
- Tissue histopathology**, in anti-glomerular basement membrane disease, 2637
- Tissue injury**, DIC caused by, 3048t
- Tissue nematodes**, 2207–2209
- Tissue transglutaminase**, in celiac disease, 2327
- Tissue-based diagnostic testing**, 936–937
- Titration**, in antiepileptic drugs, 3612–3613
- Tizanidine**, 689t
 for spasticity, 4394, 4395t
- TLR3 deficiency**, 1339t
- TLS**. *See* Tumor lysis syndrome
- T-lymphocyte-dependent vaccines**, 1589
- T-lymphocyte-independent vaccines**, 1589
- T lymphocytes**, autoimmune hepatitis and, 2487
- TMA**. *See* Thrombotic microangiopathy
- TMD**. *See* Transient myeloproliferative disorder
- TMEP**. *See* Telangiectasia macularis eruptiva perstans
- TMP-SMX**. *See* Trimethoprim-sulfamethoxazole
- TND**. *See* Transient neonatal diabetes
- TNF inhibitors**, for amyloidosis, 1537
- Tobacco exposure**, 722t, 4427–4430
 as health risk disparity, 4428
 postnatal secondhand smoke, 4429
 during pregnancy, 4429
 secondhand smoke, 4427–4428
 thirdhand smoke, 4428
 treatment for, 4430
- Tobacco use**, in adolescents, 1195t–1196t
 cigarettes, 1199–1200
 clinical manifestations of, 1200
 e-cigarettes, 1200
 hookah, 1200
 pharmacology, 1200
 smokeless tobacco, 1199–1200
 treatment of, 1200
- Tobramycin**, 1675t–1685t
- Tocilizumab**, 1470
 for amyloidosis, 1537
- α-Tocopherol**, 480
- Todd paresis**, 3754
- Toddlers**
 antibiotics use in, 1672
 fractures, 4282–4283, 4282f, 4312–4313
 heart failure in, 2896t
 psychosocial assessment, 216
 sleep
 BEARS sleep screening algorithm, 215t
 normal developmental changes in, 204t
- Toddler's diarrhea**, 2223, 2378, 2385
- Toe deformities**, 4208–4211
 annular bands, 4210, 4211f
 claw toe, 4210
 curly toes, 4209, 4210f
 hammer toe, 4210
 ingrown toenail, 4210–4211
 juvenile hallux valgus, 4208–4209, 4209f
 macrodactyly, 4210, 4211f
 mallet toe, 4210
 overlapping fifth toe, 4209
 polydactyly, 4209
 subungual exostosis, 4210
 syndactyly, 4210, 4210f
- Toe phalangeal fractures**, 4283
- Toe walking**, 164
- Togaviruses**, Dengue-like diseases, 2067t
- Toilet training**, 164
 normal, 3291
- Tolosa Hunt syndrome**, 3971, 3972f
- Toluene**, 720
 inhaled, 1203t
- Tone**, in motor examination, 3554–3555, 3555f
- Tongue**, 2248f
 aphthous ulceration in HIDS, 1525f
 fissured, 2253
 geographic, 2253
 scrotal, 2253
 strawberry
 in Kawasaki disease, 1542f
 in scarlet fever, 1707f
- Tongue-tie**, 410–411, 2253
- Tonic neck reflex**, 3556–3557
- Tonic pupil**, 3922
- Tonic seizures**, 3619
- Tonometry**, 3912
- Tonsillar neoplasm**, 2563
- Tonsillectomy**, 2563–2565
 in children, 2564f
 comparison of guidelines for, 2565t
 Paradise criteria for, 2563t
 risks and benefits, 2565t
- Tonsillitis**, in infectious mononucleosis, 2007f
- Tonsils**, 2562–2566
 chronic airway obstruction, 2565–2566
 clinical manifestations of, 2562–2563
 diphtheria of, 1726f
 normal function, 2562
 pathology, 2562
 pharyngotonsillitis, treatment, 2563–2565
- Topical antibiotics**, 4040
- Topical calcineurin inhibitors**, 4040
 for atopic dermatitis, 1413–1414
- Topical corticosteroids**, 4039t, 4040
- Topical nonsteroidal antiinflammatory agents**, 4040
- Topical ophthalmic medications**, for allergic conjunctivitis, 1424t–1425t
- Topiramate**
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 for migraine, 3646t–3647t
 in pain management, 691
- TORCH acronym**, congenital infections and, 1153
- Torsades de pointes**, 2752, 2862f
- Torsion**
 adnexal, 3342
 of appendix testis, 3307
 penile, 3298
 testicular, 3306–3307
- Torsion dystonia**, 3680
- Torsional and angular deformities**, of limb, 4212–4218
 congenital angular deformities, 4216–4218
 coronal plane deformities, 4213f, 4215–4216
 evaluation of, 4212
 normal limb development of, 4212, 4213f
 torsional deformities, 4212–4215
- Torsional deformities**, 4212–4215
 external femoral torsion, 4214
 femoral anteversion, 4212
 lateral tibial torsion, 4214
 medial tibial torsion, 4214
 metatarsus adductus, 4215
- Torticollis**, 4258–4260, 4258t, 4259f
 benign paroxysmal, of infancy, 3635
 brain tumor and, 3117–3118
- Torus fracture**, 4277, 4278f
- Total anomalous pulmonary venous return**, 2815–2817, 2816f, 2816t
- Total body irradiation (TBI)**, growth impairment due to, 1365
- Total body surface area**, estimation of, for burn injuries, 649, 650f
- Total body water (TBW)**, 485, 485f
- Total communication**, 3993
- Total energy expenditure (TEE)**, 391
- Total fetal cardiac output**, 2735
- Total lung capacity (TLC)**, 2519
- Total protein**, reference intervals, 4472.e9t
- Total-body radionuclide scan**, 4200
- Tourette syndrome**, 241, 242t, 3636–3637
 medications for, 228t
- Townes-Brooks syndrome**, 2764t–2766t
- Toxic alcohols**, 720–721
- Toxic alopecia**, 4140, 4140t
- Toxic cardiomyopathy**, 1727
- Toxic epidermal necrolysis (TEN)**, 1455, 4080
 clinical manifestations of, 4080, 4080f
 differential diagnosis of, 4080
 epidemiology of, 4080
 etiology of, 4080
 treatment of, 4080
- Toxic gases**, 722–724
 in inhalation injury, 653
- Toxic goiter**, 3415
- Toxic metabolic states**, manifesting as respiratory distress, 613
- Toxic myopathies**, 3846–3848, 3848t
- Toxic nephropathy**, 3203–3204, 3203t
- Toxic neuropathies**, 1727, 3892–3895, 3892t–3895t
- Toxic shock syndrome**, 1545, 1698–1699
 diagnostic criteria of, 1699t
 GAS, 1708, 1708t
Staphylococcus aureus, 1696
- Toxic shock syndrome toxin-1 (TSST-1)**, 1694
- Toxic stress**, 5–6, 19–20
 in adopted children, 74
- Toxic substances control act (TSCA)**, 4423
- Toxic syndromes**, 1197t
- Toxic synovitis**, 1489, 4236–4237
- Toxicant**, 4409
- Toxidromes**, 548, 701, 702t–704t
- Toxigenic infection with skin**, 1695
- Toxin A**, 1825
- Toxin B**, 1825
- Toxins**
 acute pancreatitis and, 2427t
 cardiac arrest and, 567t
 DIC caused by, 3048t
 hemolytic anemias and, 2997
 liver injury induced by, 2490–2493
 prevention of, 2493
 prognosis of, 2493
 treatment of, 2493
 mushroom, 4411t–4413t
 toxicants vs., 4409
- Toxocara canis**, 2209
- Toxocara cati**, 2209
- Toxocariasis (visceral and ocular larva migrans)**, 2209–2210
 clinical manifestations of, 2210, 2210t
 diagnosis of, 2210

- Toxocariasis (visceral and ocular larva migrans)
(Continued)
 epidemiology of, 2209
 pathogenesis of, 2209–2210
 prevention of, 2210
 treatment of, 2210
- Toxoid, 1587
- Toxoplasma gondii*
 detected in breast milk, 1009
 HIV in, prophylaxis to prevent, 2111t–2113t
- Toxoplasmic encephalitis, 2189
- Toxoplasmosis, 2186–2198
 acquired, 2188–2189
 clinical manifestations of, 2188–2190
 congenital, 2189–2190
 diagnosis of, 2193–2196, 2194t
 drugs for, 2126t–2144t
 epidemiology of, 2186
 etiology of, 2186, 2187f
 in immunocompromised persons, 2189
 isolation for, 2193
 ocular, 2189
 pathogenesis of, 2188, 2188f
 in pregnant women, 2197–2198
 prevention of, 2187f, 2198
 prognosis of, 2198
 serologic testing in, 2193–2195
 systemic signs of, 2190–2193
 treatment of, 2196–2198
- TP53, germline variants in, 3472
- TP53 tumor-suppressor protein, 3077
- TPMT. *See* Thiopurine S-methyltransferase
- TPO. *See* Thrombopoietin
- Trabecular meshwork, 3969
- Trace element, 483, 483t
- Trachea
 normal appearance of, on chest radiography, 2517f
 stenoses, webs, and atresia, 2577
- Tracheal compression, 3092t–3093t
- Tracheal foreign bodies, 2579–2580
- Tracheal neoplasms, 2584, 2584f
- Tracheal tubes, dimensions for, 619t
- Tracheitis, bacterial, 2572–2573
- Tracheobronchomalacia, 1389
- Tracheoesophageal fistula, 1053t, 2255, 2258–2259, 2258f–2259f, 2259t
- Tracheomalacia, 2581–2582, 2581t, 2582f
- Tracheostomy, for chronic recurrent aspiration, 2611–2612
- Tracheotomy, in infectious upper airway obstruction, 2571–2572
- Trachoma, 1895
- Trachyonychia, 4145, 4146f
- Traction alopecia, 4137, 4139f
- Traction apophysitis, 4227
- Traction response, 3554–3555
- Traditional media, violence in, 106
- TRAF3 deficiency, 1339f
- “Traffic light” diet, 446–447, 447t
- Traffic-related air pollution, 4424
- Traffic-related injuries, prevention of, in developing world, 544
- Training, staff, for emergency medical services, 534–536
- TRAIL. *See* Transfusion-related acute lung injury
- Tramadol, 713t
 equianalgesic doses of, 685t
- Trametinib, for lymphatic malformations, 3066
- Trans fatty acids, 389t–390t, 392
- Transactional model, 138–139
- Transaldolase deficiency, 900t–901t, 920
- Transbronchial and endobronchial biopsies, 2524
- Transcatheter closure, 2907
 of patent ductus arteriosus, 2786f
- Transcatheter occlusion, of atrial septal defect, 2778f
- Transcellular shifts
 hyperkalemia and, 496t
 hyperphosphatemia and, 508t
 hypokalemia and, 499t
 hypophosphatemia and, 506t
- Transcobalamin, absence of, 2943
- Transcobalamin II-cobalamin complex, 835
- Transcranial diagonal difference, in deformational plagioccephaly, 3586
- Transcranial Doppler ultrasonography (TCD)
 for brain death, 591t
 in sickle cell disease, 2972–2973, 2976
- Transcription, 730
 writing disabilities and, 322
- Transcription factors, 3077
 chamber-specific, 2731
 in development of, adrenal glands, 3444
GATA1, 2931
 in normal liver development, 2435t
- Transcription factors disorders, 4349–4350
 campomelic dysplasia, 4349, 4349f
 cleidocranial dysplasia, 4349–4350, 4349f
 nail-patella syndrome, 4350, 4350f
SHOX gene-related conditions, 4350
- Transcutaneous electrical nerve stimulation (TENS), in pain management, 693
- Transdermal patch, contraceptive, 1224
- Transdiagonal difference, in deformational plagioccephaly, 3586
- Transesophageal echocardiography (TEE), 2754, 2757
- Transferrin saturation, 2948t
 in iron-deficiency anemia, 2947t
- Transfusion-related acute lung injury (TRALI), 3021
- Transfusions
 blood
 HIV and, 2090
 for homozygous β-thalassemia, 2982–2983
 for sickle cell anemia, 2975–2977
 neutrophil (granulocyte), 3018, 3018t
 plasma, 3019, 3019t
 red blood cell, 3014–3016
 risks of, 3020–3021
 infectious, 3020–3021, 3020t, 3021f
 noninfectious, 3020t, 3021, 3022f
- Transfusion-transmission cytomegalovirus, 3015
- Transgender and gender diverse (TGD)
 affirming clinic for, components of, 1174f
 definition of, 1172
 strategies for, 1174t
- Transgender care, 1171–1181
 clinical presentation of, 1172
 diagnostic evaluation of, 1172
 epidemiology of, 1172–1174
 mental health considerations for, 1174–1175
 puberty blockers for, 1175–1178
 alternative therapy side effects of, 1177
 bone health in, 1176, 1176t–1177t
 brain development in, 1176–1177
 fertility in, 1176, 1177t
 goals of, 1175
 metabolism in, 1177
 monitoring protocol in, 1177–1178, 1178t
 potential adverse effects of, 1175–1176
 treatment criteria and timing of, 1175
 treatment options of, 1175, 1176t
- Transgenerational effect, 108
- Transglutaminase deficiency, 3034
- Transient abnormal myelopoiesis, Down syndrome and acute leukemia and, 3104t, 3104f
- Transient aplastic crisis, in parvovirus B19 infection, 1989
- Transient bacteremia, 2864–2865
- Transient cerebral arteriopathy, 3743–3744, 3745f
- Transient erythroblastopenia of childhood, 2934, 2934t
- Transient hyperammonemia of the newborn, 854
- Transient hypogammaglobulinemia of infancy, 1280–1283, 1282t, 1285
- Transient idiopathic hypertrophic subaortic stenosis, in infants of diabetic mothers, 1141
- Transient monoarticular synovitis (toxic synovitis), 4236–4237
- Transient myeloproliferative disorder (TMD), associated with Down syndrome, 371
- Transient neonatal diabetes (TND), 3515–3516, 3542–3543, 3544f
- Transient neonatal hyperparathyroidism, 3441
- Transient neonatal myasthenic syndrome, 3858
- Transient neonatal pustular melanosis, 4042, 4042f
- Transient neonatal zinc deficiency, 2351
- Transient neurapraxia, 579
- Transient nonketotic hyperglycinemia, 837
- Transient proteinuria, 3220, 3221f
- Transient quadriplegia, 579, 4319–4320, 4319t
- Transient synovitis, 1489, 4307
- Transient tachypnea of newborn (TTN), 1088, 1089f
 RDS and, 1077–1078
- Transient tyrosinemia of newborn, 817
- Transient visual obscuration (TVO), 3782–3784
- Transillumination
 for acute inguinal-scrotal swelling, 2417
 of popliteal cyst, 4225
- Transition to adulthood, of child with intellectual disability, 361
- Transitional circulation, 2735
- Transitional object, 156
- Transitioning youth registry, 1171t
- Transjugular intrahepatic portosystemic shunt, for portal hypertension, 2506
- Translocations, 766–767
 aortopulmonary, 2792
 of coronary arteries, in arterial switch (Jatene) procedure, 2814f
- Translocation-type RCC, 3135
- Transmalleolar angle, 4212, 4214f
- Transmembrane receptor disorders, 4345–4347, 4345t
 fibroblast growth factor receptor 3 (FGFR3) chondrodyplasia group, 4345–4347, 4345t
 achondroplasia, 4345–4347, 4346f–4347f
 hypochondroplasia, 4347
 thanatophoric dysplasia, 4345, 4346f
- Jansen metaphyseal dysplasia, 4347
- Transmissible spongiform encephalopathies, 2118–2124
 clinical manifestations of, 2122, 2123
 diagnosis of, 2122–2123
 epidemiology of, 2120–2121, 2122t
 etiology of, 2118–2120
 family support in, 2124
 genetic counseling in, 2123–2124
 laboratory findings of, 2123
 pathogenesis of, 2121–2122
 pathology of, 2121–2122
 prevention of, 2124
 prognosis for, 2124
 treatment of, 2123
- Transmission
 by contact, 1618
 by droplets, 1618
 in healthcare setting, 1618
- Transmission-based precautions, in pandemic, 1584
- Transplacental exposure, chemical pollutants in, 4426t
- Transplacental infections, hematogenous, 1152f
- Transplantation
 bone marrow, liver disease and, 2479, 2479t
Candida infections in immunocompromised patient, 1924
 for genetic disorders, 757
 heart, pediatric, 2902–2905
 liver, 2507–2508
 for acute porphyria, 970
 complications of, 2508
 contraindications to, 2507
 immunosuppression in, 2508
 indications for, 2507
 orthotopic, 2499, 2499t
 for portal hypertension, 2506
 outcomes of, 2508
 technical innovations in, 2507–2508
 stem cell, for mucopolysaccharidoses, 943t
- Transport staff, critically ill newborn, 1051
- Transport vehicle, critically ill newborn, 1051
- Transportation
 destination determination in, 537, 537f
 in emergency medical services, 535–536
 interfacility, 537, 540
 medical air, 535–536
 methods of, in developing world, 545–546
 of premature infants, 96
- Transposition of the great arteries, 2841
 d-, 2812, 2812f
 with intact ventricular septum, 2812–2813
 l-, 2814–2815, 2815f
 with ventricular septal defect, 2814
 with ventricular septal defect, and pulmonary stenosis, 2809
- Transracial adoption, 74

- Transsphenoidal pituitary microsurgery, for Cushing syndrome, 3477
- Transtheoretical model, 141t
- Transthoracic echocardiography (TTE), 2754
- Transthyretin-related hereditary amyloidosis, 1537
- Transudates, 2525
- Transudative pleural effusion, 2649t
- Transverse fractures, 4278–4279
- Transverse myelitis (TM), 3727–3731, 3727t–3728t
 clinical manifestations of, 3729–3730
 diagnostic evaluation of, 3727t–3728t, 3730, 3731f
 epidemiology of, 3727–3729, 3729f, 3730t
 poliomyelitis and, 1974
 prognosis of, 3731
 treatment of, 3730–3731
- Transverse sonogram, of pyloric muscle wall thickness, 2279f
- Transverse vaginal septum, 3351, 3353
- Trapped penis, 3298, 3300f
- Trapped testicle, inguinal hernia and, 2421
- TRAPS. *See* Tumor necrosis factor receptor-associated periodic syndrome
- Trastuzumab, 3088t
- Trauma, 4276
 acoustic, 4023
 acute pancreatitis and, 2427t
 associated with hematuria, 3217
 to breast, 3331
 cataracts, 3950, 3951f
 in developing-world hospitals, 546
 genitourinary tract, 3309–3311
 multiple, 571–578
 ATLS, 571
 disposition of, 578
 epidemiology of, 571
 primary survey in, 571–575
 psychologic and social support in, 578
 regionalization and trauma teams in, 571, 572f–573f, 573t
 secondary survey in, 575–578
 nonaccidental
 in acutely ill child, 549
 mimics of, 117t
 optic nerve, 3978
 pediatric patients of, transport of, 537
 splenic, 3063
 vulvovaginal, 3328
- Trauma-focused cognitive-behavioral therapy (TF-CBT), 231
- for anxiety disorders, 253
- Trauma-informed care, 5, 99
- Trauma-informed office, 76
- Trauma-related retinopathy, 3962–3963, 3963f
- Traumatic alopecia, 4137–4138
- Traumatic brain injury (TBI), 583–588
 clinical manifestations of, 583
 diagnosis and differential diagnosis of, 583
 epidemiology of, 583
 etiology of, 583
 laboratory findings in, 583, 584f–586f
 nonaccidental, 4386
 pathogenesis of, 583
 pathology of, 583
 pathophysiology of, 4386–4387, 4386f
 prognosis of, 588
 rehabilitation for, 4386–4389
 medical complications of, 4387–4388
 cognitive-behavioral disorders, 4387, 4387t
 consciousness disorders, 4387, 4387t
 neuroendocrine disorders, 4388
 paroxysmal sympathetic hyperactivity, 4388
 posttraumatic seizure, 4388
 spasticity, 4388
 outcome associated with, 4388–4389
 severity of, 4387
 sports-related, 4314–4318
 complications of, 4318
 definition of, 4314, 4315f
 epidemiology of, 4314
 initial assessment of, 4314–4316
 management of, 4315f, 4316–4318, 4317t
 persistent postconcussion symptoms, risk for, 4317–4318
- Traumatic brain injury (TBI) (*Continued*)
 retiring young athletes, 4318
 return to play, 4317, 4317t
 return to school, 4317, 4318t
 pathophysiology of, 4314
 prevention of, 4318
 signs and symptoms of, 4314, 4315f, 4316t
 supportive care for, 588
 treatment of, 583–588, 587f–588f
- Traumatic encephalopathy (CTE), 4318
- Traumatic neuritis, poliomyelitis and, 1974
- Traumatic optic neuropathies, 3968
- Travel medicine, 1626
- Traveler's diarrhea, 2375–2376
- Treacher Collins syndrome. *See* Mandibulofacial dysostosis
- Treatable Intellectual Disability Endeavor (TIDE)
 Diagnostic Protocol, 355t
- Treatment engagement interventions, elements of, 233, 235t
- Tregopathies, 1324, 1324f, 1325t
- T-regulatory cell (Treg), 1367, 1369–1370, 1370f
- Trehalose deficiency, 2348
- Trembling, chin, hereditary, 3637
- Tremor, 3673–3678, 3679t
 toxic causes of, 3895t
- Trench fever (*Bartonella quintana*), 1815–1816
- Trench foot, 662
- Trench mouth, 2250
- Trendelenburg gait, 4199–4200
- Trendelenburg sign, 4199–4200, 4234
- Treponema carateum*. *See* Pinta
- Treponema pallidum*, 1866–1875
 acquired, 1866
 treatment of, 1873–1874
 clinical manifestations of, 1866–1869, 1867f
 congenital, 1866, 1871–1872
 diagnosis of, 1873
 late manifestations of, 1869t
 prevention of, 1875
 treatment of, 1875
- congenital infection in, 1868–1869, 1868f–1869f
- CSF findings in, 3759t–3760t
- diagnosis of, 1869–1872, 1871f
- epidemiology of, 1866, 1866f
- etiology of, 1866
- infants born to mothers with reactive serologic tests, 1872f, 1873t
- laboratory findings of, 1866–1869
- laboratory screening, 1241t
- laboratory testing algorithm for, 1870f
- management guidelines, 1247t–1248t
- prevention of, 1875
- screening, 1246, 1247f
- signs and symptoms of, 1243t
- treatment of, 1872–1875, 1874t
- Treponema pertenue*. *See* Yaws
- Treponemal infections, nonvenereal, 1876–1877
- Treprostинil, 2834t
- Tretinoin, indications and adverse reactions of, 3089t–3090t
- Triad syndrome, 3281
- Triage
 of acutely ill child, 548–552
 disposition in, 551–552
 history in, 548–550, 549t
 management in, 551
 physical examination in, 550–551
 vital signs assessment in, 548, 550t
 in developing-world EDs, 546
 in disaster pediatric medical care, 539,
 539f–540f
 for multiple trauma, 571
- Triamcinolone, for allergic rhinitis, 1384t–1385t
- Triatoma, 1419
- Triatomina infestans*, 2163
- Triatomines, 2163
- Tribendimidine, for hookworms, 2202
- Trichilemmal cyst, 4185
- Trichinella spiralis*, 2211
- Trichinellosis, 2211
 drugs for, 2126t–2144t
- Trichinosis, 2211
- Trichloroethylene, inhaled, 1203t
- Trichobezoars, 2304, 2304f, 4138
- Trichodysplasia spinulosa, 2084
- Trichoepithelioma, 4185–4186
- Tricho-hepato-enteric syndrome, 2339
- Trichohepatoenteric syndrome (THES), 1530t
- Trichomonas vaginalis*, 2154–2155
- Trichomoniasis (*Trichomonas vaginalis*), 1242,
 2154–2155
 clinical manifestations of, 2154–2155
 complications of, 2155
 diagnosis of, 2155
 drugs for, 2126t–2144t
 epidemiology of, 2154
 pathogenesis of, 2154
 prevention of, 2155
 testing for, 125–126
 treatment of, 2155
 trophozoites, 2154f
 vulvovaginal infection, 3322t
- Trichopoliodystrophy, 4141
- Trichorhinophalangeal syndrome, type II, 768t–769t
- Trichorrhesis invaginata, 4141, 4141f
- Trichorrhesis nodosa, 2339, 3719, 4140, 4141f
 inborn errors of metabolism and, 809t–810t
- Trichothiodystrophy, 4141
- Trichotillomania, 4138, 4139f
- Trichuriasis, 2203, 2203f
 drugs for, 2126t–2144t
- Trichuris trichiura*, 2203, 2203f
- Tricuspid atresia, 2806–2808, 2806f
 clinical manifestations of, 2807
 diagnosis of, 2807, 2807f
 relative frequency of, 2763t
 treatment of, 2807–2808
- Tricuspid valve
 Ebstein anomaly of, 2809–2811, 2811f
 in rheumatic heart disease, 2875
- Tricyclic antidepressants (TCAs), 226
 for Ehlers-Danlos syndrome, 4374
 for pain, 686–687, 690t
 toxicity, 701t, 707t–708t, 716–717, 716f
- TRIF deficiency, 1339t
- Trifluridine, 1955
- Trigeminal nerve (cranial nerve V), in neurologic examination, 3553
- Trigger thumb and fingers, 4269–4270, 4270f
- Trigger tool systems, 43
- Triggering the ventilator, in patient-ventilator asynchrony, 627
- Triggers
 asthma, 1388t
 of autoinflammatory syndromes, 1524t
- Triglycerides, 392
- Trigonocephaly, in craniosynostosis, 3583
- Triiodothyronine (T₃), 3400
 reference intervals, 4472.e9t
 serum levels, 3401
- Trilateral retinoblastoma, 3150
- TRIM28-associated WT predisposition, 3131t–3132t
- Trimethoprim, 1675t–1685t
- Trimethoprim-sulfamethoxazole (TMP-SMX), 1675t–1685t, 1736
 for bite wound, 4459t
 for cystoisosporiasis, 2153
 enterococci resistance, 1722t
 against nontuberculous mycobacteria, 1835
 plus rifampin, for brucellosis, 1809t
 for *Pneumocystis jiroveci* pneumonia, 1947
 for *Staphylococcus aureus*, 1697
- Trimethylenimuria, 838
- Triose phosphate isomerase deficiency, 2990
- Triplane fractures, 4283, 4283f
- Triple A syndrome, 2261–2262, 3900
- Triple Aim approach, 36
- Triple P* program, 279
- Triplet repeat expansion disorders, 742, 747f
- Triptans, for migraine, 3646t–3647t, 3648
- Trismus, 1822
- Trisomies, chromosomal, 766t
- Trisomy 8, 363t
- Trisomy 9, 363t, 773t
- Trisomy 13, clinical findings of, 362t, 363f–364f

Trisomy 16, 363t, 773t
 Trisomy 18, 3131t–3132t
 clinical findings of, 362t, 363f
 Trisomy 21, 3408. *See also* Down syndrome
 Trisomy B, 773t
 Trochlear nerve (cranial nerve IV), in neurologic examination, 3553
 Trophozoite, 2169–2170
 Tropical pulmonary eosinophilia, 2206, 2207f
 Tropical sprue, 2343
TRPV4-spectrum disorders, 4356
 Truancy, 282
 True gynecomastia, 1210
 Trümmerfeld zone, 468
 Truncal ataxia, 3557
 Truncus arteriosus, 2817–2818, 2817f–2818f
 Truncus arteriosus, relative frequency of, 2763t
 Trunk blocks, in pain management, 694–695
Trypanosoma brucei gambiense, 2161
Trypanosoma cruzi, 2163
 Trypanosomal chancre, 2161–2162
 Trypanosomiasis
 African, 2161–2163
 American, 2163–2168
 drugs for, 2126t–2144t
 Trypomastigotes, 2163
 Trypsin, 2423
 Trypsinogen deficiency, 2348
 Tryptophan, metabolism defects, 824, 825f
 Tsetse fly, 2161
 TSH receptor (TSHR), 3416
 TSLP. *See* Thymic stromal lymphopoietin
 TTM. *See* Targeted temperature management
 TTN. *See* Transient tachypnea of newborn
 TTP. *See* Thrombotic thrombocytopenic purpura
 Tuberculid, 4158
 Tuberculosis, 1623t–1625t, 1655t–1656t, 1835–1855
 abdominal and gastrointestinal disease in, 1845
 bone and joint disease in, 1845, 1845f
 central nervous system disease in, 1843–1845,
 1844f–1845f
 in children living with HIV, 1846
 clinical manifestations of, 1840–1846
 clinical stages of, 1836
 cutaneous disease in, 1845
 drug-susceptible, 1831t
 epidemiology of, 1836–1838, 1836f–1837f, 1838t
 genitourinary disease in, 1845–1846
 in immigrant children, 80–81
 immunity in, 1839–1840, 1840f
 interferon- γ release assay in, 1847–1848, 1847t–
 1848t
 lymph node disease in, 1843, 1843f
 mycobacterial sampling, susceptibility and culture in,
 1848–1849
 nucleic acid amplification tests in, 1848–1849
 pathogenesis of, 1838–1840, 1838f–1839f
 pericardial disease in, 1842
 perinatal disease in, 1846
 prevention of, 1855
 pleural effusion in, 1841–1842, 1842f
 in pregnancy and newborn, 1846
 prevention of, 1854–1855
 pulmonary disease in
 primary, 1840–1841, 1841f
 progressive primary, 1841
 reactivation, 1841
 renal, 1845
 screening for, in adolescents, 1170
 of skin, 4157–4159
 transmission of, 1838
 treatment of, 1850t, 1849t, 1849–1854, 1850t
 corticosteroids, 1851–1853
 drug-resistant tuberculosis, 1851, 1851t–1853t
 Mycobacterium tuberculosis infection, 1853–1854
 supportive care, 1853
 tuberculin skin testing in, 1846–1847, 1847t–1848t
 upper respiratory tract disease in, 1842–1843
 Tuberculosis verrucosa cutis, 4158
 Tuberculous gummas, 4158
 Tuberculous meningitis, CSF findings in, 3759t–
 3760t
 Tuberin, 3657

Tuberous sclerosis, 3379, 3656f, 3657–3659, 3658f,
 4027, 4070t–4071t
 clinical manifestations and diagnosis of, 3657–3659,
 3658f–3659f, 3658t
 dermatologic, cardiac, and pulmonary manifestations
 of, 3658f
 management of, 3659
 other organ involvement in, 3659
 in phakmas, 3960, 3960f
 pheochromocytomas and, 3479
 skin lesions in, 3658, 3659f
 Tuberous sclerosis complex (TSC), 3657, 4073
 angiomyolipomas and, 3211
 major features of, 3658f
 minor features of, 3658t
 periungual fibroma in, 3659f
 Tuboovarian abscess, and PID, 3341–3342
 Tubular function, 3233
 Tubular proteinuria, 3218, 3221–3222, 3222t
 Tubules, resorption of filtered bicarbonate in, 511f
 Tubulointerstitial disease
 associated with hematuria, 3205–3210
 acute tubular necrosis, 3209–3210, 3210
 nephritis, 3205
 acute, 3205, 3206t
 chronic, 3205–3208, 3206t–3208t
 papillary necrosis, 3209
 pyelonephritis, 3205
 causing hematuria, 3185t
 Tubulointerstitial fibrosis, glomerular disease and,
 3183
 Tubulointerstitial nephritis, 3205
 acute, 3205, 3206t
 chronic, 3205–3208, 3206t–3208t
 with uveitis (TINU syndrome), 3205–3208
 Tufted angioma, 3160
 Tufting enteropathy, 2339
 Tularémia, 1655t–1656t, 1803–1807, 4449, 4452t
 clinical manifestations of, 1804–1805, 1805t
 diagnosis of, 1805–1806
 differential diagnosis of, 1806
 epidemiology of, 1803, 1804f
 etiology of, 1803
 pathogenesis of, 1803–1804
 prevention of, 1806–1807
 prognosis for, 1806
 treatment of, 1806, 1806t
 Tummy time, in deformational plagiocephaly, 3587
 Tumor lysis syndrome (TLS), 947, 3091, 3112–3113,
 3244
 Tumor necrosis factor α (TNF- α) antagonists, for
 rheumatic diseases, 1466t–1468t, 1469
 Tumor necrosis factor receptor-associated periodic
 syndrome (TRAPS), 1522, 1526t, 1536
 Tumor resection, 2384
 Tumor-directed immune therapies, 3088–3090
 Tumor-induced osteomalacia, 478
 Tumor-like processes, of bone, 3144–3148, 3145t,
 3146f
 subungual exostosis, 3145–3147, 3146f–3147f
 tibia, characteristic lesions of, 3147–3148
 vascular tumors of, 3148, 3148t
 Tumors
 adrenal, virilizing and feminizing, 3475
 bronchial, 2584
 causing intestinal failure, 2352t
 central nervous system, in childhood, 3116–3125
 chorionic gonadotropin-secreting, 3392
 CSF findings in, 3759t–3760t
 of digestive tract, 2411–2415, 2412t
 adenomatous, 2413–2414
 adenomatous polyposis coli-associated polyposis
 syndromes as, 2412f, 2413–2414
 carcinoid, 2414
 carcinoma as, 2412t, 2413–2414
 gastrinoma as, 2414
 gastroenteric neuroendocrine as, 2414
 gastrointestinal stromal cell, 2414–2415
 hamartomatous, 2411–2413, 2412f
 juvenile polyposis syndrome as, 2411
 leiomyoma as, 2414
 lymphoma as, 2414
 nodular lymphoid hyperplasia, 2414
 Tumors (*Continued*)
 Peutz-Jeghers syndrome as, 2411–2413,
 2412f–2413f
 phosphatase and tensin homolog hamartoma
 tumor syndromes as, 2413
 vascular, 2415
 of ear and temporal bone, 4023–4024
 of eyelid, 3936
 of heart, 2892–2893
 of jaw, 2254
 markers, 3342–3343, 3344t
 of neural crest origin, 2720
 ovarian, malignant, 3343t
 pancreatic, 2433
 porphyria resulting from, 979
 pulmonary, 2702–2703, 2702f–2703f, 2702t
 of skin, 4185–4189
 basal cell carcinoma, 4188
 dermatofibroma, 4187, 4187f
 eruptive vellus hair cysts, 4186, 4187f
 fibrofolliculomas, 4185, 4186f
 infantile digital fibroma, 4186
 infundibular follicular cyst, 4185, 4186f
 juvenile xanthogranuloma, 4187–4188, 4187f
 lipoma, 4188, 4188f
 melanoma, 4189
 milium, 4185
 mucosal neuroma syndrome, 4189
 nevroid basal cell carcinoma syndrome,
 4188–4189
 pilar cyst, 4185, 4186f
 pilomatricoma, 4185, 4186f
 steatocystoma multiplex, 4186
 syringoma, 4186, 4187f
 trichoeplioma, 4185–4186
 of testes, resulting from, 3494
 testicular, 3309
 umbilical, 1131
 vascular, 3156, 3157t
 Tumor-suppressor genes, 3077
 oncogenesis of, 3077
 Tunica albuginea, ruptured, 3311f
 Turf toe, 4327
 Turner syndrome, 319, 770–771, 770t–771t, 772f, 3126t,
 3397, 3408, 3496–3499, 4350
 clinical manifestations of, 3496–3498, 3497f
 laboratory findings of, 3498
 pathogenesis of, 3496
 treatment of, 3498–3499
 TVO. *See* Transient visual obscuration
 20-nail dystrophy, 4145, 4146f
 22q11 deletion syndrome, 786t, 1345
 22q11.2 deletion syndrome, 4263, 4263f
 math disabilities and, 319
 22q11.2DS syndrome, 2764t–2766t
 22q13.3 deletion, 768t–769t
 Twin reversed arterial perfusion (TRAP) syndrome,
 1041
 Twinning, in teeth, 2240
 Twins
 conjoined, 1040
 monozygotic vs. dizygotic, 1039, 1039f
 Twin-twin transfusion syndrome, 1027t, 1041f–1042f,
 1041
 laser therapy, 1035, 1035f
 2-thumb-encircling hands technique, for infant CPR,
 564f, 565
 Two-dimensional echocardiography, 2755, 2755f–2756f
 Two-finger technique, for infant CPR, 564f, 565
 TYK2 deficiency, 1343
 Tympanic membrane, 3982
 mobility, 3982
 trauma to, 4021–4022, 4022f
 Tympanocentesis, 3982, 3983f
 Tympanometry, 4007
 in acoustic immittance testing, 3991
 in otitis media with effusion, 3991
 Tympanosclerosis, 4015
 Tympanostomy
 for chronic serous otitis media, 329
 tube insertion, in acute otitis media, 4013
 Type 1 autoimmune polyglandular syndrome,
 3411–3412

Type 1 diabetes mellitus (T1DM), 3408, 3515, 3517–3538
 anxiety and depression in, 3535
 autoantibodies in, 3521
 characteristics at presentation for, 3539t
 clinical manifestations of, 3523
 cognitive function in, 3534
 coping styles in, 3534
 diabetic nephropathy in, 3536–3537
 diabetic neuropathy in, 3537–3538
 diabetic retinopathy in, 3536, 3537t
 diagnosis of, 3523–3524
 eating disorders in, 3535–3536
 environmental factors in, 3519–3521
 epidemiology of, 3517, 3517f
 fear of self-injecting and self-testing, 3535
 genetics of, 3517–3519, 3521
 during infections, management of, 3535–3536, 3535t
 key features of, 3518t
 long-term complications, relation to glycemic control, 3536–3537
 nonadherence in, 3534–3535
 onset of clinical disease in, 3522
 other complications of, 3537–3538
 pancreas and islet transplantation and regeneration in, 3538
 pathogenesis and natural history of, 3520–3522, 3520f
 pathophysiology of, 3522–3523, 3523t
 prediction of, 3522
 prevention of, 3522
 prognosis for, 3538
 skeletal effects of, 3537
 during surgery, management of, 3536, 3536t
 treatment of, 3524–3528, 3524t
 adjunct pharmacotherapy in, 3529–3530
 basic and advanced diabetes education in, 3530
 behavioral/psychologic aspects and eating disorders in, 3534
 benefits of improved glycemic control, 3533
 cerebral edema in, 3527
 closed-loop systems in, 3529, 3531f
 continuous glucose monitoring systems in, 3529
 dawn phenomenon in, 3534
 dehydration and hyperglycemia, 3524–3527
 diabetic ketoacidosis in, 3524, 3524t, 3525f–3526f, 3527
 exercise in, 3533
 glycosylated hemoglobin in, 3533
 hypoglycemic reactions in, 3533–3534
 insulin pump therapy in, 3529
 insulin therapy in, 3528–3529, 3528t, 3529f–3530f
 ketoacid accumulation in, 3527
 monitoring in, 3531–3533
 nonketotic hyperosmolar coma in, 3527–3528
 nutritional management in, 3530–3531, 3531t–3532t
 Somogyi phenomenon in, 3534
 subcutaneous insulin therapy in, 3528–3534
 Type 1 necrotizing fasciitis, 4152
 Type 1 reactions, in Hansen disease (*Mycobacterium leprae*), 1857
 Type 2 autoimmune polyglandular syndrome, 3411–3412
 Type 2 diabetes mellitus (T2DM), 3515, 3538–3542
 characteristics at presentation for, 3539t
 clinical features of, 3539–3541
 complications of, 3542, 3543t
 environmental and lifestyle-related risk factors for, 3539
 epidemiology of, 3538–3539, 3540f
 epigenetics and fetal programming in, 3539
 genetics in, 3539
 key features of, 3518t
 natural history of, 3538, 3540f
 prevention of, 3542
 testing for, 3541t
 treatment of, 3541, 3542t
 Type 2 reactions, in Hansen disease (*Mycobacterium leprae*), 1857–1858
 Type A insulin resistance, 3546
 Typhoid fever, 1771–1776
 clinical manifestations of, 1773–1774, 1774f, 1774t–1775t
 complications of, 1774, 1775t
 diagnosis of, 1774
 differential diagnosis of, 1775

Typhoid fever (*Continued*)
 epidemiology of, 1771, 1772f
 etiology of, 1771
 pathogenesis of, 1771–1773, 1773f
 prevention of, 1776
 prognosis for, 1776
 treatment of, 1775–1776
 Typhoid vaccine, 1588t–1589t
 Typhoidal tularemia, 1805
 Typhus group rickettsioses, 1900t–1902t, 1909–1911
 epidemic (louse-borne) typhus, 1910–1911
 clinical manifestations of, 1910–1911
 epidemiology of, 1910
 etiology of, 1910
 prevention of, 1911
 transmission of, 1910
 treatment of, 1911
 murine (endemic or flea-borne) typhus, 1909–1910
 clinical manifestations of, 1909–1910
 complications of, 1910
 diagnosis and differential diagnosis of, 1910
 epidemiology of, 1909
 etiology of, 1909
 laboratory findings of, 1910
 pathology and pathogenesis of, 1909
 prevention of, 1910
 supportive care in, 1910
 transmission of, 1909
 treatment of, 1910
 Typical absence seizures, 3598, 3600–3601
 TYR gene variants, 819
 Tyrosine
 metabolic pathways of, 813f–814f
 metabolism defects, 815–820
 albinism, 817–820
 alkapttonuria, 817
 hawksinsuria, 817
 hepatorenal tyrosinemia, 816
 primary deficiency of 4-hydroxyphenylpyruvate dioxygenase, 817
 Richner-Hanhart syndrome, 816–817
 transient tyrosinemia of newborn, 817
 Tyrosine hydroxylase deficiency, 844
 Tyrosine kinase inhibitors
 for chronic myelogenous leukemia, 3105
 for gastrointestinal stromal cell tumors, 2414–2415
 for pediatric cancers, 3088t
 Tyrosinemia
 type I, 816, 2451
 genetics and prevalence, 816
 laboratory findings, 816
 natural history of, 816
 treatment and outcome, 816
 type II, 816–817
 type III, 817
 Tzanck smear, 4027–4028

U

UCDP. *See* Uppsala Conflict Data Program
 UDDA. *See* Uniform Determination of Death Act
 UDP-GlcNAc:Dol-P-GlcNAc-P transferase deficiency (DPAGT1-CDG), 926–928
 clinical manifestations, 926–927
 diagnosis of, 928
 pathophysiology, 927–928
 treatment of, 928
 UES. *See* Upper esophageal sphincter
 UFH. *See* Unfractionated heparin
 Ulcer
 Buruli, 1862, 1863f
 Ulcerating vesicles, 2558
 Ulcerative colitis, 4033
 chronic, 2309–2316
 clinical manifestations of, 2312, 2312f–2313f, 2312t–2315t, 2315f
 differential diagnosis of, 2312–2313, 2314t–2315t
 prognosis of, 2316
 treatment for, 2313–2316, 2316t
 chronic diarrhea and, 2377–2378
 Ulceroglandular disease, tularemia, 1804–1805
 Ulcers, 2558, 4027
 aphthous, 2252, 2252f, 2253t, 3323f
 in HIDS, 1525f
 corneal, 3945, 3947f
 genital, 1243–1244, 3323, 3324f
 oral
 in Behçet disease, 1515, 1515f
 in SLE, 1492f
 suggestive of rheumatic disease, 1461t
 stress, 2306
 Ulipristal acetate, 1227
 Ulna, hyperostosis, 455f
 Ultradian cycle, within-sleep, 202
 Ultrashort-segment Hirschsprung disease, 2297
 Ultrasound
 of abdominal aorta, 2908f
 for acute inguinal-scrotal swelling, 2417
 for appendicitis, 2400
 of breast masses, 3333
 diagnostic, fetal disease, 1026t
 for esophageal varices, 2272
 for ganglia, 4267
 for liver, 2444
 in neuromuscular diseases, 3794
 for orthopedic evaluation, 4200
 renal, for urinary tract obstruction, 3276–3277, 3277f
 of septic arthritis, 4293
 thyroid, 3401
 transcranial Doppler, 2976
 Ultraviolet phototherapy, 4040
 Umbilical artery
 flow velocity waveforms, 1017f
 single, 1130
 Umbilical cord, 1130
 surgery, indications and rationales, 1029t
 Umbilical cord blood
 samples, 1019
 transplantation, for HSCT, 1355
 Umbilical hernia, 1131
 Umbilical-urachal sinus, 3287
 Umbilicus, 1130–1131
 UNC93B1 deficiency, 1339t
 Uncombable hair syndrome, 4141–4142, 4142f
 Uncompensated shock, 600
 Uncomplicated gonorrhea, 1748–1749
 Uncomplicated grief, 197
 Uncomplicated malaria, 2175
 in pregnant women, 2179t
 Unconjugated hyperbilirubinemia, 1106, 2438, 2440t
 Underactive bladder, 3294
 Underfill hypothesis, of nephrotic edema, 3223
 Under-five mortality rate (U5MR), 1, 23, 23f–24f
 global causes, 2f
 Undernourishment, 421
 Undernutrition, 421, 421f–422f, 423–426, 433
 child mortality and, 24
 classification of, 423t
 clinical manifestations of, 426
 consequences of, 424–425, 424t–425t
 key interventions of, 425–426, 425t
 measurement of, 423–424
 prevalence of, 424
 treatment of, 426
 Undescended testis, 3302–3304
 clinical manifestations of, 3302–3304
 epidemiology of, 3302
 management algorithm for, 3304f
 in neuromuscular disease, 3792
 pathogenesis of, 3302
 treatment of, 3303t, 3304
 Undifferentiated pleomorphic sarcoma, 3139t–3140t
 Unfractionated heparin (UFH), 2696, 3042–3043
 Ungual infections, in immunocompetent patient, 1923
 UNHCR. *See* United Nations High Commissioner for Refugees
 Unicameral bone cysts, 3147
 Unicentric Castleman disease, 3072
 Unicornuate uterus, rudimentary horns and, 3352
 Unidentified bright objects, 3654
 Unified theory of behavior change, 129, 130f, 130t

- Uniform Determination of Death Act (UDDA), 589
- Unilateral cryptorchidism, of testes, 3494
- Unilateral hyperlucent lung, 2591
- Unilateral pulmonary agenesis, 2592
- Unintentional injury, 1–2
 deaths, in United States, 3t
 disparities in, 18
- Uniparental disomy, 743, 762, 773–777, 775f
- United Nations Convention on the Rights of the Child (1990), 108–109
- United Nations High Commissioner for Refugees (UNHCR), 106–107
- Universal screening, 1005
- Universal vaccination, for hepatitis B, 2467–2469
- Unknown epilepsy, 3589
- Unknown immune mechanism, recurrent infections related to, 1349
- Unpacking principle, 48t
- Unpredictable drug reactions, 1453
- Unproven therapies, for atopic dermatitis, 1417–1418
- Unprovoked seizures, 3588f, 3590t–3595t, 3597–3599
- Unrehabilitated injuries, 4294–4295
- Unspecified feeding or eating disorder (UFED), 4323
- Unstable hemoglobin disorders, 2978–2979
- Unverricht-Lundborg disease, 3602
- Upbeat nystagmus, 3931t
- Upper airway, normal anatomy of, 2518f
- Upper airway disease, acute inflammatory obstruction, 2568–2573
- Upper airway edema, in inhalation injury, 653
- Upper airway film, 2517, 2518f
- Upper digestive tract, abnormalities of, 332
- Upper esophageal sphincter, 2255–2256
 dysmotility of, 2261
- Upper extremity
 assistive devices, 4402–4404
 blocks, in pain management, 694
 fractures, 4279–4281
- Upper limb, disorders of, 4263–4270
- elbow, 4264
 nursemaid's, 4265, 4267f
 Panner disease and osteochondritis of capitellum, 4264, 4265f
 radial longitudinal deficiency, 4264–4265, 4265t–4266t, 4266f
- hand, 4267–4270
 camptodactyly, 4268, 4268t
 clinodactyly, 4268f
 fingertip injuries, 4269
 polydactyly, 4268, 4268t, 4269f
 syndactyly, 4269, 4270f, 4270t
 thumb hypoplasia, 4268–4269, 4269f
 trigger thumb and fingers, 4269–4270, 4270f
- shoulder, 4263–4264
 congenital pseudarthrosis of clavicle, 4264, 4264f
 Sprengel deformity, 4264
- wrist, 4265–4267
 ganglion, 4267
 gymnast's, 4265–4267, 4267f
 Madelung deformity, 4265, 4267f
- Upper limit of intake (UL), 391f
- Upper respiratory tract, tuberculosis of, 1842–1843
- Upper urinary tract disease, causing hematuria, 3185t
- Upper-to-lower body segment ratio, 172
- Uppsala Conflict Data Program (UCDP), 107–108
- Upstream, 18f
- Urachal anomalies, 3287
- Urbach-Wiethe disease, 4122–4123
- Urban Renewal, 8–9
- Urea cycle disorders, 848–854, 848f, 849t
- Urea nitrogen, reference intervals, 4472.e9t
- Ureaplasma urealyticum*. See Genital mycoplasmas
- β-Ureidopropionase deficiency, 954
- Ureter ectopic, 3280, 3280f, 3294f–3295f
- Urteral ectopia, 3294
- Urteral injuries, 3310
- Urterocele, 3280
 prolapsed ectopic, 3301f
- Urteropelvic junction obstruction (UPJ), 3279–3280
- Urterosigmoidostomy, 3286
- Ureters, configurations of ureteral orifices, 3270f
- Urethral anomalies, 3296–3301
 hypospadias, 3296–3297
 prolapse (female), 3301, 3301f, 3327
- Urethral disorders
 atresia, 3284–3285, 3301
 diverticula, 3285
 duplication, 3301
 fistula, 3301
 hypoplasia, 3285, 3301
 obstruction, 3275t
 strictures, 3285
- Urethral prolapse, 3327
- Urethral valves
 anterior, 3285
 posterior, 3282–3284
- Urethritis, 1240–1241, 1245, 1748–1749
 infectious causes of, 3218
- Urge incontinence, 3291
- Uric acid, 947, 949t
 calculi, 3314–3315
 reference intervals, 4472.e9t
- Uric acid stones, 3312t
- Uridine diphosphate galactose-4-epimerase deficiency, 900t–901t, 911–912
- Uridine diphosphoglucuronate glucuronyltransferase (UDPGT), 2454–2455
- Uridine-response epileptic encephalopathy, 945t
- Urinalysis
 in acute kidney injury, 3244t
 for fever without a focus, 1644
 monitoring, in nephrotic syndrome, 3231t
- Urinary 17-ketosteroids, 3475
- Urinary acidification, normal, 3234, 3234f
- Urinary alkalization, 709, 712
- Urinary ascites, 3276
- Urinary catheters, 1668–1669
- Urinary concentrating defect, in CKD, 3250t
- Urinary incontinence
 cause of, 3291t
 complications of augmentation cystoplasty, 3290
 future management of, 3290f
- Urinary lithiasis
 caused by metabolic abnormalities, 3315t
 classification of, 3312t
 clinical manifestations of, 3312
 diagnosis of, 3312–3313
 metabolic evaluation of, 3313
 pathogenesis of specific renal calculi, 3313–3315
 stone formation, 3311–3312
 treatment of, 3315
- Urinary potassium wasting, 499
- Urinary retention, opioid-induced adverse effects, 684t
- Urinary system, autonomic dysreflexia in, 4391t
- Urinary tract dilation (UTD), 3276f–3277f
- Urinary tract infections (UTIs), 1800t, 3263–3269
 asymptomatic bacteriuria, 3266
 clinical manifestations and classifications of, 3263–3264
 complication of augmentation cystoplasty, 3290
 cystitis, 3264
 diagnosis of, 3266
 febrile, imaging studies in, 3267–3268, 3269t
 fever without a focus, 1644
 imaging findings of, 3266
 medical child abuse and, 128
 pathogenesis and pathology of, 3264–3266, 3265f
 prevalence and etiology of, 3263
 pyelonephritis, 3263–3264
 risk factors for, 3265t
 S. saprophyticus in, 1700
 sensitivity of urinalysis, 3266t
 treatment of, 3267
- Urinary tract obstruction, 3275–3285
 ancillary studies for, 3278–3279
 anterior urethral valves, 3285
 of bladder neck, 3282
 clinical manifestations of, 3275
 diagnosis of, 3275–3276
 ectopic ureter, 3280
 etiology of, 3275
 hydrocalycosis, 3279
 imaging studies for, 3276–3279
- Urinary tract obstruction (*Continued*)
 male urethral meatal stenosis, 3285
 megaureter, 3280–3281
 midureteral, 3280
 physical findings of, 3276
 posterior urethral valves, 3282–3284
 prune-belly syndrome, 3281–3282
 ureterocele, 3280
 of ureteropelvic junction, 3279–3280
 urethral atresia, 3284–3285
 urethral diverticula in males, 3285
 urethral hypoplasia, 3285
 urethral strictures, 3285
 urine chemistries in, 3244t
- Urine
 in congenital erythropoietic porphyria, 971f
 maple syrup urine disease, 825–827
 maximum osmolality, 488
 minimum osmolality, 488
 sodium, in hyponatremia, 3375t
 in water loss, 528
- Urine anion gap, 3237
- Urine chemistry, normal values, 3314t
- Urine dipstick measurement, of protein, 3219
- Urine output, 528
- Urine protein-to-creatinine ratio measurement, 3219
- Urogenital sinus, 3348
- Urologic disorders
 anomalies of
 bladder, 3285–3287
 penis and urethra, 3296–3301
 scrotal contents, 3302–3309
 congenital anomalies and dysgenesis of kidneys, 3260–3263
 enuresis and voiding dysfunction, 3291–3296
 neurogenic bladder, 3288–3291
 trauma to genitourinary tract, 3309–3311
 urinary lithiasis, 3311–3316
 urinary tract obstruction, 3275–3285
 UTIs, 3263–3269
 vesicoureteral reflux, 3270–3274
- Uromodulin, 3218
- Uroporphyrinogen decarboxylase, specific inhibitor of, 972f
- Urticaria, 1375, 1426–1434, 4037f
 chronic, 1426t
 diagnosis of, 1429t–1431t, 1430, 1430f
 diagnostic testing, 1431t
 etiology and pathogenesis, 1426–1431,
 1426t–1428t
 inducible, 1426–1428
 treatment of, 1431, 1431t
- Urticaria pigmentosa, 1430, 4125
- Urticular vasculitis, 1430
- U.S. food assistance programs, 420
- USDA Child and Adult Care Food Program, 416
- Usher syndrome, 3959, 3987t
- USP18 deficiency, 1534–1535
- Ustekinumab
 for Crohn disease, 2321–2322
 for psoriasis, 4100–4102
- Uterine bleeding, abnormal, 1211, 1213–1214,
 1213t–1214t
- Uterine compression, deformation abnormalities resulting from, 781f
- Uterine didelphys, 3352
- Uterine malignancies, 3344–3345
 leiomyomas, 3344
 leiomyosarcomas, 3344
 rhabdomyosarcomas, 3344
- Uterine septum, 3351–3352
- Uterus, septate, 3351–3352
- Utilization, in food security, 421
- Uveal tract disorders, 3952–3954, 3953f
- Uveitis, 3952–3954
 anterior, 3940t
 in Behcet disease, 1515
 in childhood, 3953t
 chronic anterior, in JIA, 1482f
 posterior, 3940t
 treatment for, 3953–3954, 3954t
- Uveo-meningeal syndromes, 3953t

V

Vaccine Adverse Event Reporting System (VAERS), 1590
 Vaccine Alliance, 1616
 Vaccine Information Statement (VIS), 1591
 Vaccine Safety Datalink, 1590
 Vaccine-derived poliovirus (VDPV), 1616
 Vaccine-preventable diseases, 30–31t, 29
 Vaccines, 1587
 adverse reactions to, 1458–1459
 BCG, 4158
 against tuberculosis, 1854–1855
 cholera, 1788, 1788t
 under development, 1765
 diphtheria and tetanus toxoids and acellular pertussis (DTaP), 1765
 diphtheria toxoid, 1728–1729
 Haemophilus influenza type b, 1758
 hepatitis A, 2464
 influenza, 2025, 2025f
 for measles, 1963–1964, 1963t–1964t
 meningococcal, 1745–1746, 1746t
 parainfluenza viruses, 2028
 pentavalent rotavirus, 2052
 pneumococcal, 1704t–1705t
 pneumococcal conjugate, 2648
 respiratory syncytial virus (RSV), 2031
 for rubella, 1968
 Tdap, 1765
 universal, for hepatitis B, 2467–2469
 varicella, 2004–2005
 Vaccines for Children (VFC) program, 1590, 1609
 Vaccines for Children program (VFC), 14
 Vaccinia immunoglobulin (IV), 1586t
 VACTERL association, 2764t–2766t
 VAERS. *See* Vaccine Adverse Event Reporting System
 Vagabond's skin, 4175
 Vaginal agenesis, 3351
 Vaginal anomalies, 3352–3354
 abnormalities of hymen, 3352–3353
 congenital absence of, 3353
 longitudinal vaginal septa, 3353
 transverse vaginal septa, 3353
 treatment of, 3353–3354
 Vaginal candidiasis, 4164
 Vaginal fluid, microscopic findings, 1245f
 Vaginal foreign bodies, 3326–3327
 Vaginal malignancies, 3345
 Vaginal rhabdomyosarcoma, 3137
 Vaginal ring, 1218t–1219t, 1224–1225, 1226f
 Vaginal voiding, 3294
 Vaginitis, 1242, 3320
 GAS infection, 1708
Vaginulus plebeius, 2208–2209
 Vagovagal reflex, 2264
 Vagus nerve (cranial nerve X), in neurologic examination, 3554
 Vagus nerve stimulation (VNS), in epilepsy surgery, 3615–3616
 Valacyclovir, 1954
 Valerian, 57t, 2492t
 Valganciclovir, 1954–1955, 3994
 Valine, metabolism defects, 825–837
 Valproate
 for benign myoclonic epilepsies, 3607
 dosages of, 3609t–3610t
 Valproate sodium injection, for migraine, 3646t–3647t
 Valproic acid, 1022
 adverse effects of, 3611t
 for migraine, 3646t–3647t
 Valsalva maneuver, 3782–3784
 Valsartan, for heart failure, 2899, 2899f, 2899t
 Valvar aortic stenosis, sudden death and, 2860
 Valvular pulmonary stenosis, physiology of, 2788f
 van der Woude syndrome, 2243
 Vancomycin, 1675t–1685t
 for bacterial meningitis, 3769
 for *Clostridium difficile* infection, 1826, 1826t
 for *Staphylococcus aureus*, 1696–1697
 Vancomycin-resistant enterococci, 1723–1724
 Vanderbilt ADHD Diagnostic Rating Scale, 218t, 280t
 Vanishing bone disease, 3156–3157

Vanishing testes, 3302–3304, 3488, 3510
 Vanishing white matter disease, 3717–3718
 Vapors, 669t
 Variability of fetal heart rate, 1017
 Variable decelerations, 1017
 Variant surface glycoprotein (VSG), 2161
 Variants
 gain-of-function, 732–733
 loss-of-function, 731–732
 missense, 730–731
 in mtDNA
 disorders caused by, 743t
 phenotypes, 744f
 nonsynonymous, 730–731
 Variants, of hypereosinophilic syndrome, 2630t
 Variants of unknown sequences (VUS), 750
 Variceal band ligation, 2272
 Varicella, 1623t–1625t
 progressive, 2002
 treatment of, 2004
 in unvaccinated persons, 2000, 2000f
 vaccine, 1588t–1589t, 1602, 1605–1608
 Varicella-zoster immunoglobulin (VarizIG, IM), 1586t, 1608
 Varicella-zoster virus, 1999–2005
 antiviral therapies for, 1953t–1954t
 clinical manifestations of, 2000–2002
 complications, 2002–2003
 bacterial infections, 2002
 encephalitis and cerebellar ataxia, 2002
 herpes zoster, 2002–2003, 2003f
 pneumonia, 2002
 progressive varicella, 2002
 congenital varicella syndrome, 2001–2002, 2001f
 diagnosis of, 2003
 epidemiology of, 1999
 etiology of, 1999
 involvement in acute facial palsy, 3907f
 neonatal varicella, 2001
 pathogenesis of, 1999–2000
 prevention of, 2004–2005, 2005t
 postexposure prophylaxis, 2005
 vaccine, 2004–2005
 vaccine-associated adverse events, 2005
 prognosis for, 2004
 treatment of, 2004
 herpes zoster, 2004
 varicella, 2004
 varicella in unvaccinated persons, 2000, 2000f
 varicelliform rashes in vaccinated individuals, 2000–2001
 Varicelliform rashes, in vaccinated individuals, 2000–2001
 Varices, portal hypertension and, 2504–2506
 Varicose, 3307–3308, 3308f
 Varicose bronchiectasis, 2658
 Variegate porphyria, 976–977
 Vas deferens, injury to, inguinal hernia and, 2421
 Vascular abnormalities
 associated with hematuria, 3211
 associated with pulmonary arterial hypertension, 2832f
 pulmonary, 2592
 Vascular access, 569–570
 for shock, 606
 Vascular anomalies, 2261, 2577, 2578f, 4050–4060, 4051t
 arteriovenous malformation, 4052
 complex, 3156–3164, 3157t–3158t
 AKT-related overgrowth spectrum, 3159–3160
 angiosarcoma, 3164, 3164f
 benign tumors in, 3161–3162
 blue rubber bleb nevus syndrome, 3157–3158, 3161f
 capillary malformation-arteriovenous malformation syndrome, 3160
 CLOVES, 3159, 3163f
 composite hemangiopericytoma, 3162
 epithelioid hemangiopericytoma, 3163–3164
 epithelioid hemangiomas, 3161–3162
 genetic basis for, 3156, 3158t, 3159f
 glomuromyxomatous malformation, 3158, 3162f
 Gorham-Stout disease and, 3156–3157, 3160f

Vascular anomalies (*Continued*)
 kaposiform hemangioendothelioma, 3160–3161, 3163f
 kaposiform lymphangiomyomatosis, 3157, 3161f
 Kasabach-Merritt phenomenon, 3160–3161
 Klippel-Trenaunay syndrome, 3158, 3162f
 locally aggressive rare, 3162–3163
 lymphatic, 3156–3157, 3160f
 central conducting, 3157, 3161f
 generalized, 3156, 3160f
 macrocephaly-capillary malformation and, 3159, 3163f
 Maffucci syndrome, 3162
 malignant tumors of, 3163–3164
 papillary intralymphatic angiomyxoma, 3162
 Parkes-Weber syndrome, 3160
 PIK3CA-related overgrowth spectrum disorders, 3158, 3158f
 proteus syndrome, 3159
 pseudomyogenic hemangioendothelioma, 3163
 pyogenic granuloma, 3162
 RA-Sopathies, 3159
 retiform hemangiopericytoma, 3162
 spider angioma, 3162
 syndromes associated with, 3158
 treatment of, 3157
 venous, 3157–3158, 3159f
 Klippel-Trenaunay and Parkes-Weber syndromes, 4052
 lymphatic malformations, 4052
 nevus anemicus, 4053–4054
 phakomatosis pigmentovascularis, 4053
 vascular malformations, 4050–4052
 vascular tumors, 4054–4060
 Vascular calcification, in CKD-MBD, 3249–3250
 Vascular diseases, associated with hematuria, 3185t, 3211–3212
 abnormalities, 3211
 idiopathic hypercalcemia, 3212
 nephrocalcinosis, 3212
 renal vein thrombosis, 3211
 sickle cell nephropathy, 3211–3212
 Vascular Ehlers-Danlos syndrome, 4371–4372
 Vascular events, in neonatal seizures, 3619
 Vascular malformations, 2584, 3156, 4050–4052
 Vascular rings, 2577, 2578f, 2826, 2827f–2828f, 2827t
 Vascular stasis, in frostbite, 661–662
 Vascular supply, to pituitary gland, 3359
 Vascular tumors, 3148, 4054–4060
 of digestive tract, 2415
 Vascuilitic rash, of SLE, 1492f
 Vasculitides, 4032–4033
 Vasculitis
 Behcet disease, 1515
 central nervous system, 3754–3757, 3755f
 clinical manifestations of, 3755
 diagnosis of, 3755–3756, 3756t–3757t, 3757f
 epidemiology of, 3755
 prognosis of, 3757
 secondary, causes of, 3755t
 treatment of, 3756–3757
 childhood, classification of, 1554t
 distribution of vessel, 1552f
 granulomatous, 2621f
 systemic
 diagnosis of rare pediatric, 1556t
 nomenclature of, 1553t
 Vasculitis syndromes, 1552–1566
 antineutrophil cytoplasmic antibody-associated
 vasculitis, 1552, 1553t, 1561–1564
 clinicopathologic characteristics of, 1555t
 cutaneous polyarteritis nodosa, 1560–1561
 features suggesting, 1554t
 Henoch-Schönlein purpura, 1552–1556, 1553t
 classification of, 1557t
 clinical manifestations of, 1554, 1557f
 complications of, 1555
 diagnosis of, 1554–1555
 differential diagnosis of, 1555
 epidemiology of, 1554
 laboratory findings of, 1555
 pathogenesis of, 1554
 pathology of, 1554
 prognosis for, 1555–1556
 Volume 1 pp. 1–2222 • Volume 2 pp. 2223–4472

- Vasculitis syndromes (*Continued*)
 treatment of, 1555
Polyarteritis nodosa, 1553t, 1560–1561
 clinical manifestations of, 1560, 1560f
 complications of, 1561
 diagnosis of, 1560, 1561f
 differential diagnosis of, 1560, 1561f
 epidemiology of, 1560
 laboratory findings of, 1560
 pathogenesis of, 1560
 pathology of, 1560
 pediatric-onset, 1561t
 prognosis for, 1561
 treatment of, 1561
Takayasu arteritis, 1553t, 1557–1559
 clinical manifestations of, 1558
 complications of, 1559
 diagnosis of, 1558
 differential diagnosis of, 1558
 epidemiology of, 1557
 laboratory findings of, 1558–1559, 1559f
 pathogenesis of, 1558
 pathology of, 1557–1558
 pediatric-onset, 1558t
 prognosis for, 1559
 treatment of, 1559
 Vasoactive medications, for shock, 608–609, 610t
Vasodilators
 for hypertension, 2918t
 pulmonary, for BPD, 1087
Vasomotor rhinitis, 1380, 2552t
Vasoocclusive pain, in sickle cell anemia, 2969
Vasopressin
 analog, 3374
 aqueous, 3374
 for portal hypertension, 2506
 regulation of secretion of, 3373f
 for shock, 610t
Vasopressors, 714
Vasovagal syncope, 592, 596t, 3632
VATER association, 2739t–2740t
VATER/VACTERL association, 780
VCD. *See* Vocal cord dysfunction
VCFS. *See* Velocardiofacial syndrome
VPDV. *See* Vaccine-derived poliovirus
VDRL test. *See* Venereal Disease Research Laboratory test
Vecuronium, 669t, 671
 for intubation, 620t
Vedolizumab, for Crohn disease, 2321–2322
Vegetarianism, 417–418, 419f
Vein of Galen malformation, 3580f
Velocardiofacial syndrome (VCFS), 331, 768f, 768t–769t, 780t, 1275–1276, 1275f
Velopharyngeal dysfunction, in cleft lip and palate, 2244
Velopharyngeal insufficiency (VPI), speech disorders and, 331
Venereal Disease Research Laboratory (VDRL) test, 1870
Venezuelan equine encephalitis, 2063
Venezuelan hemorrhagic fever, 2073
 clinical manifestations of, 2076
Venlafaxine, 717
 for depression and anxiety, 226, 227t
Venoarterial bypass, for PPHN, 1093
Venoms
 DIC caused by, 3048t
 hemolytic anemias and, 2997
 hymenoptera, 4471
 immunotherapy, against winged Hymenoptera, 1420–1421, 1421t
 marine animals, 4472
 scorpion, 4471
 snake, 4467
 spider, 4469–4470
Venoocclusive disease, 1360
 of liver, 2479
Venous access, 569–570, 569f
 paucity of, intestinal transplantation and, 2352
Venous admixture, in respiratory failure, 614
Venous anomalies, complex, 3157–3158, 3159f
Venous hum, 2745–2746
Venous malformation, 4051–4052, 4051f
Venous stroke, 3747
Venous thromboembolism (VTE), 45t, 2692, 2694t–2695t, 3038, 3040
 estrogen-containing contraceptives and, 3356
Venous thrombosis, evaluation prior to renal transplantation, 3255
Venovenous bypass, for PPHN, 1093
Ventilation
 deficits in, in respiratory failure, 617–618
 strategies for congenital diaphragmatic hernia, 1095
 transient manual, 620
Ventilation-perfusion mismatch, in respiratory failure, 614–615
Ventilation-perfusion ratios, 2516f
Ventilation-perfusion relation, 2518–2519
Ventilator dependence, 2719
Ventilator-associated pneumonia, 629
Ventilator-induced lung injury, 629
Ventilatory insufficiency, paralytic poliomyelitis with, 1974
Ventilatory support equipment, noninvasive, in CCHS, 2722–2723
Ventricles
 cerebral, dilated in fetus, 1026t
 septation of, 2733
Ventricular arrhythmias, 2854f
Ventricular assist device (VAD), for heart failure, 2901, 2902f
Ventricular extrasystoles, 2844–2848, 2848f
Ventricular hypertrophy, 2747
 left, 2750–2752, 2752f
 right, 2749–2750, 2751f
Ventricular output, fetal, 2736f
Ventricular septal defects, 2781–2784, 2840
 coarctation with, 2795
 diagnosis of, 2783
 different types of, 2782f
 pathophysiology of, 2782
 physiology of, 2783f
 prognosis of, 2784
 and pulmonary stenosis, transposition of the great arteries with, 2809
 relative frequency of, 2763t
 transposition of the great arteries with, 2814
 treatment of, 2783–2784
Ventricular septum, intact
 d-transposition of the great arteries, 2812–2813
 pulmonary atresia with, 2805–2806
 pulmonary valve stenosis with, 2787–2789
Ventricular tachyarrhythmias, 2852–2854
Ventricular tachycardia, 563, 592, 595t
Ventriculogram, of tetralogy of Fallot, 2802f
Venturi mask, 618
VEPs. *See* Visual evoked potentials
Veramyst, for allergic rhinitis, 1384t–1385t
Verapamil, 2845t–2846t
Verbal auditory agnosia, 329
Verbal speech and language, 179
Vernal conjunctivitis, 3942, 3942f
Vernal keratoconjunctivitis (VKC), 1422–1423, 1422t, 1423f
Verruca peruviana, 1814, 1815f
Verruca plana, 4166–4167, 4167f
Verruca plantaris, 4166–4167, 4167f
Verrucae vulgaris, 4166
Vertebrae, butterfly, 2448f
Vertebral artery dissection, in spinal cord embolism, 3749
Vertical expandable prosthetic titanium rib (VEPTR), 4246, 4247f
Vertical fusion defects, 3353
Vertical suspension, test of, 3554–3555
Vertical transmission, of HIV, 2089
Vertigo, 592, 594t, 3981
 vestibular migraine with, 3642t
Very early onset inflammatory bowel disease, 2323–2325
Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, 862–863
Very long chain fatty acids, disorders of, 865–871
Very low birthweight infants, 1042
Vesicant-induced injury, 4455
Vesicles, 4027
Vesicoamniotic shunting, 1030, 1030f
Vesicourachal diverticulum, 3287
Vesicoureteral reflux (VUR), 3255, 3270–3274
 classification of, 3270–3271, 3271t
 clinical manifestations of, 3271–3272
 diagnosis of, 3272
 natural history of, 3272–3273, 3273f
 treatment of, 3273
 antimicrobial prophylaxis, 3273
 current guidelines, 3273–3274
 observation, 3273
 surgery, 3273, 3274f
Vesicular monoamine transporter deficiency, 847
Vesicular trafficking disorders, 1309t, 1310
Vesiculobullous disorders, 4076–4087, 4077t
 dermatitis herpetiformis, 4086
 erythema multiforme, 4076–4078
 linear immunoglobulin A dermatosis, 4086–4087
 mechanobullous disorders, 4080–4084
 pemphigus, 4084–4086
 reactive infectious mucocutaneous eruption, 4078
 Stevens-Johnson syndrome, 4078–4080
 toxic epidermal necrolysis, 4080
Vespids, 1419
Vest therapy, 2716–2717
Vestibular migraine, with vertigo, 3642t
Vestibular neuritis, 4020
Vestibular nystagmus, 3931t
Vestibular Ocular Motor Screening Assessment (VOMS), 4315–4316
Vestibulocochlear nerve (cranial nerve VIII), in neurologic examination, 3553–3554
Vestibulopathy, stroke and, 3754
VFC. *See* Vaccines for Children program
Vibration, in transport physiology, 541
Vibrio cholerae, 1785
 bacterial gastroenteritis and, 2357t–2358t
Vibrio parahaemolyticus, bacterial gastroenteritis and, 2357t–2358t
Vibrio vulnificus, bacterial gastroenteritis and, 2357t–2358t
Victimization, rape, 1235t
Victims, of bullying, 283
Vidarabine, 1955
Video capsule endoscopy, in Crohn disease, 2319
Video gaming systems, for children with disabilities, 4406
Videofluoroscopic evaluation, of swallowing, 2257
Vigabatrin
 adverse effects of, 3611t
 dosages of, 3609t–3610t
 for infantile spasm in tuberous sclerosis, 3607
 for tuberous sclerosis, 3657–3658
Vigorous exercise, causing hematuria, 3218
Villous atrophy syndrome, 2485
Viloxazine (Qelbree), for ADHD, 224, 225t–226t
Vinblastine, indications and adverse reactions of, 3089t–3090t
Vincristine, indications and adverse reactions of, 3089t–3090t
Vineland Adaptive Behavior Scale (VABS-3), 356
Violence, 1–2
 bullying, cyberbullying, and school violence, 100–102
 diagnosis and follow-up for, 100
 disparities in, 18
 in early childhood trauma, 75
 impact of, 99–109, 100t
 media, 102
 related injury deaths, in United States, 3t
 teen pregnancy and, 1230
 war, effects of, 106–109, 106f, 107t
Violence Injury and Perpetration Risk Screen (VIPRS Scale), 1191t–1192t
Violent behavior, 1189–1192
 clinical manifestations of, 1190
 diagnosis of, 1190
 epidemiology of, 1189
 etiology of, 1189–1190
 injuries due to, 98
 prevention, 1192
 treatment of, 1190–1192
Violent video game, 106
Viper bites, 4467

Viral conjunctivitis, 3940t, 3941, 3941f
 Viral diarrhea, in rotavirus AGE, 2356t, 2364–2365
 Viral hemorrhagic fevers, 2073–2077, 4452t
 clinical manifestations of, 2075–2076
 Dengue fever, 2067–2071
 diagnosis of, 2077
 differential diagnosis of, 2077
 epidemiology of, 2073–2075
 etiology of, 2073, 2073t
 prevention of, 2077
 treatment of, 2077
 yellow fever, 2071–2072
 Viral hepatitis, 2461–2473
 clinical approach to, 2473f
 issues common to all forms of, 2461
 common biochemical profiles in the acute infectious phase, 2461
 differential diagnosis of, 2461, 2462t
 pathogenesis of, 2461
 Viral infection
 associated with hemophagocytic syndrome, 3173t
 astroviruses, 2050–2053
 caliciviruses, 2050–2053
 as causes of infectious pneumonia, 2643t
 causing neonatal infections, 1145f
 common cold, 2551–2554
 coronaviruses, 2037–2046
 clinical manifestations of, 2038–2039
 diagnosis of, 2039
 epidemiology of, 2039–2041
 etiology of, 2037–2038
 Middle East respiratory syndrome coronavirus, 2039
 prevention of, 2039
 severe acute respiratory syndrome-associated coronavirus, 2038
 treatment of, 2039
 cutaneous, 4166–4169
 molluscum contagiosum, 4169, 4169f
 wart, 4166–4169, 4167f–4168f
 dengue fever and dengue hemorrhagic fever, 2067–2071
 detected in breast milk, 1009t
 in differential diagnosis of Kawasaki disease, 1546t
 fever in older children, 1647
 hantavirus pulmonary syndrome, 2080–2081, 2080f
 HIV and, 2093–2094
 human herpesvirus 8, 2019
 human metapneumovirus, 2032–2033
 human T-leukemia viruses (1 and 2), 2117–2118
 influenza viruses, 2020–2026
 innate immunity defects with predominant susceptibility to, 1337–1339
 lymphocytic choriomeningitis virus, 2078–2080
 maternal, affecting fetus or newborn, 1013t
 myocarditis and, 2888
 neutropenia and, 1304–1305
 nonpolio enteroviruses, 1979–1986
 parainfluenza viruses, 2026–2028
 parvoviruses, 1987–1991
 polyomaviruses, 2084–2086
 rabies, 2081–2084
 respiratory syncytial virus (RSV), 2028–2031
 rhinoviruses, 2035–2036
 roseola (human herpesviruses 6 and 7), 2016–2018
 rotaviruses, 2050–2053
 severe, predisposition to, 1338, 1338f
 in T1DM, 3519
 transmissible spongiform encephalopathies, 2118–2124
 of upper airway, 2568
 varicella-zoster virus, 1999–2005
 yellow fever, 2071–2072
 Viral meningitis, CSF findings in, 3759t–3760t
 Viral meningoencephalitis, 3772–3776
 clinical manifestations in, 3773
 diagnosis of, 3759t–3760t, 3773, 3774f, 3775t–3776t
 differential diagnosis of, 3764t–3769t, 3773–3774
 epidemiology of, 3772
 etiology of, 3772
 pathogenesis and pathology of, 3772–3773
 prevention of, 3776
 prognosis of, 3774–3776
 treatment in, 3774

Viral pneumonia, 2643–2644
 Viral respiratory illness, fever without a focus, 1644
 Viral vectors, for gene transfer, 757
 Viridans group streptococci, native valve endocarditis caused by, 2870t
 Virilizing adrenal tumors, 3475
 Virilizing maternal tumors, in 46,XX DSD, 3507, 3508t
 Virtual violence, 99–100
 Virulence system, nontyphoidal *Salmonella*, 1768f
 Viruses
 associated with, arthritis, 1489t
 cancer treatment and, 3093
 oncogenesis and, 3080–3081
 pharyngitis, 2558
 VIS. See Vaccine Information Statement
 Visceral larva migrans, 1294, 2209
 drugs for, 2126t–2144t
 Visceral leishmaniasis, 2159, 2159f
 Visceral pain, 678t, 2234
 Vision
 in childcare, 193
 in neurologic examination, 3553
 Vision disorders, 3915–3920, 3916t–3919t
 amaurosis, 3915–3916, 3916t, 3918t–3919t
 amblyopia, 3915
 diplopia, 3915, 3919f
 disparities in, 14
 dyslexia, 3920
 nyctalopia, 3920
 psychogenic disturbances, 3920
 suppression, 3915
 Vision testing, in adolescents, 1170
 Vistaril. See Hydroxyzine
 Visual abnormalities, that mimic seizures, 3631t, 3637–3638
 Visual acuity, assessment of, 3910
 Visual Analog Scale (VAS), 679t
 Visual evoked potentials (VEPs), 3560
 Visual field assessment, 3910
 Visual hallucinations, that mimic seizures, 3638
 Visual reinforcement audiometry, 3990
 Visual snow, 3638
 Visual-spatial/visual-perceptual function, 301
 Vital capacity, 2519
 Vital signs
 assessment of acutely ill child, 548
 normal, 552, 555t
 VitalTalk, 63
 Vitamin A
 for acute gastroenteritis, 2373–2375
 characteristics of, 453t
 in children, dietary reference intakes in, 454t
 dietary reference intake, 397t–403t, 454–455
 excess, 451–455
 functions of, 452
 hypervitaminosis A, 455
 low plasma retinol, inflammation causing, 452
 for measles, 1962
 mechanisms of action of, 452
 metabolism, 451–452, 451f
 overview of, 451
 status in neonates, 452, 453f
 toxicity, 455
 Vitamin A deficiency, 423, 451–455, 2349, 4192
 clinical manifestations of, 452–454
 diagnosis of, 454
 epidemiology and public health issues, 454
 as goitrogen, 3415t
 malnutrition in, 454
 treatment of, 455
 Vitamin B complex deficiencies and excess, 456–467
 Vitamin B₂ (riboflavin), 56t, 456t–457t, 460–461
 deficiency, 461
 clinical manifestations of, 461, 461f
 diagnosis of, 461
 prevention of, 456t–457t, 461
 treatment of, 461
 dietary reference intake, 397t–403t
 for migraine, 3646t–3647t
 toxicity, 461
 Vitamin B₅ (pantothenic acid), 456t–457t
 dietary reference intake, 397t–403t
 Vitamin B₁₂, in vegetarian diets, 418
 Vitamin B₁₂ (cobalamin), 456t–457t, 466–467
 absence of transport protein, 2943
 deficiency, 466–467, 2942–2944
 clinical manifestations of, 467, 467f, 2943
 diagnosis of, 467, 2943
 etiology of, 2942–2943
 laboratory findings of, 2943
 treatment of, 467, 2944
 dietary reference intake, 397t–403t
 impaired absorption, 2942–2943
 inadequate intake, 2942
 malabsorption, 2350
 metabolic pathway, 822f
 metabolism, 466f, 2943
 toxicity, 467
 Vitamin B₁₂ deficiency, 2942–2944
 clinical manifestations of, 2943
 diagnosis of, 2943
 etiology of, 2942–2943
 laboratory findings of, 2943
 treatment of, 2944
 Vitamin C (ascorbic acid), 468
 deficiency, 468–470, 4192
 clinical features of, 468, 469f
 differential diagnosis of, 469
 laboratory findings and diagnosis of, 468–469, 469f–470f
 prevention of, 470
 treatment of, 469
 dietary needs and sources of, 468
 dietary reference intake, 397t–403t
 excess, 468–470
 for methemoglobinemia, 2980
 toxicity, 470
 Vitamin D
 for atopic dermatitis, 1418
 dietary reference intake, 396, 404t–407t
 disorders of, 474–476
 excessive, hypercalcemia and, 3442t
 food sources of, 471t
 intoxication, findings in, 480
 metabolism of, 4378, 4378f
 physiology of, 474
 in vegetarian diets, 418
 Vitamin D analogs, for psoriasis, 4100
 Vitamin D deficiency, 470–480
 associated with hypophosphatemia, 507
 congenital, 475
 malabsorption and, 2348
 nutritional, 474–475
 secondary, 475–476
 Vitamin D-dependent rickets, 2242t
 type 1, 473t, 476
 type 2, 473t, 476
 Vitamin E
 dietary reference intake, 397t–403t
 food sources of, 471t
 for nonalcoholic steatohepatitis, 2482t
 Vitamin E deficiency, 480–481
 clinical manifestations of, 481
 diagnosis and differential diagnosis of, 481
 laboratory findings of, 481
 malabsorption and, 2348
 myopathy, 3856
 pathogenesis of, 480–481
 prevention of, 481
 prognosis of, 481
 treatment of, 481
 Vitamin K, 3046
 administered to newborns, 1005
 dietary reference intake, 397t–403t
 food sources of, 471t
 Vitamin K deficiency, 481–482
 malabsorption and, 2348
 postneonatal, 3046
 Vitamin K deficiency bleeding (VKDB), 482, 1127, 1127t
 clinical manifestations of, 482
 diagnosis and differential diagnosis of, 482
 laboratory findings of, 482
 pathogenesis of, 481–482
 Volume 1 pp. 1-2222 • Volume 2 pp. 2223-4472

- Vitamin-responsive epilepsies, 3614
 Vitamins, 1028
 for cystic fibrosis, 2677
 malabsorption, 2350
 water-soluble, 456t–457t
 Vitelline duct, 2286
 Vitiligo, 4074–4075
 clinical manifestations of, 4074f–4075f, 4074t, 4075
 epidemiology of, 4074–4075
 etiology of, 4074–4075
 treatment of, 4075
 vulvar, 3321t–3322t, 3324, 3325f
 Vitreous, disorders of, 3955–3963
 Vitreous seeding, 3149
 Vitrectin, 1316–1317
 VKDB. *See* Vitamin K deficiency bleeding
 VLM. *See* Visceral larva migrans
 VNS. *See* Vagus nerve stimulation
 Vocabulary spurt, 324
 Vocal cord dysfunction (VCD), 1375
 asthma vs., 1389–1390, 1390t
 Vocal nodules, 2583
 Vogt-Koyanagi-Harada syndrome, 4063, 4075
 Vohwinkel palmoplantar keratoderma, 4119
 Voice, disorders of, 332
 Voiding
 disorders, without incontinence, 3295
 Dysfunctional Voiding Symptom Score questionnaire, 3291–3292, 3292f
 infrequent, 3294
 normal, 3291
 vaginal, 3294
 Voiding cystourethrogram (VCUG)
 in ectopic ureterocele, 3281f
 in posterior urethral valves, 3284f
 in urinary tract obstruction, 3277
 in UTI, 3268f–3269f, 3268t
 in vesicoureteral reflux, 3270f–3272f, 3294f
 Volatile hydrocarbons, 720
 Volatile substance abuse, 1203t
 Volitional behaviors, 243t
 Volleyball, injuries associated with, 4328
 Volume, regulation of, 488–489
 Volume depletion, 488
 Volume load, increased, congenital heart lesions resulting in, 2774–2775
 Volume overload, 488, 2750
 Volume resuscitation, for shock, 606–607
 Volume-controlled ventilation (VCV), 624–625, 625t, 626f
 Volume-support ventilation (VSV), 625
 Volume-targeted ventilation, for RDS, 1081
 Volumetric capnography, 616
 Volutrauma, 622, 1084
 Volvulus, gastric, 2281
 Vomiting, 2224t, 2226t, 2227, 2228t
 in acutely ill child, 550
 combined oral contraceptives and, 1224f
 complications of, 2228t
 cyclic, syndrome of, 2392–2396
 in exclusion or inclusion in daycare, 187t–192t
 functional, 2388, 2389t
 Jamaican vomiting sickness, 989
 measles and, 1961
 migraine with, 3642–3643
 in newborn, 1053–1054
 opioid-induced adverse effects, 684t
 in pediatric palliative care, 70
 pharmacologic therapies for, 2229t–2231t
 supportive and nonpharmacologic therapies for, 2231t
 Vomitoxin, foodborne illness, 4411t–4413t
 noninfectious, 2362t–2364t
 von Gierke disease, 898–903, 900t–901t, 3851
 von Hippel-Lindau disease, 2433, 3473t, 3661
 in phakmas, 3960
 pheochromocytomas and, 3166, 3479
 von Willebrand disease (VWD), 1213–1214, 3024, 3035–3036
 classification of, 3035–3036
 type 1, 3035
 type 1C, 3035
 von Willebrand disease (VWD) (*Continued*)
 type 2A, 3035
 type 2B, 3035
 type 2M, 3035
 type 2N, 3036
 type 3, 3035
 laboratory diagnosis of, 3036, 3036t, 3037f
 pathophysiology of, 3035
 platelet-type pseudo-, 3035
 treatment of, 3036, 3037t
 von Willebrand factor (VWF), 3023, 3035
 in megakaryopoiesis, 3049
 Voriconazole, 1917t, 1919
 for paracoccidioidomycosis, 1941
 VPI. *See* Velopharyngeal insufficiency
 VPS45 defects, 1309t
 VSG. *See* Variant surface glycoprotein
 VTE. *See* Venous thromboembolism
 Vulva disorders, 3321t–3322t
 complete vulvar duplication, 3354
 Vulvar malignancies, 3345–3346
 Vulvitis, 3320
 Vulvovaginal anomalies, 3347–3354
 abnormalities of hymen, 3352–3353
 clinical manifestations of, 3351
 clitoral abnormalities, 3354
 cloacal anomalies, 3354
 complete vulvar duplication, 3354
 congenital absence of vagina, 3353
 ductal remnants, 3354
 embryology of, 3347–3348
 epidemiology of, 3348–3351
 laboratory findings of, 3351
 longitudinal vaginal septa, 3353
 transverse vaginal septa, 3353
 treatment of, 3353–3354
 Vulvovaginitis, 1749, 3320–3326
 clinical manifestations of, 3323–3324
 dermatoses, 3323–3324
 diaper dermatitis, 3323
 genital ulcers, 3323
 labial agglutination, 3323
 physiologic leukorrhea, 3323
 diagnosis and differential diagnosis of, 3324–3325
 epidemiology of, 3320–3323
 etiology of, 3320
 in immunocompetent patient, 1923
 treatment and prevention of, 3325–3326
 VURD syndrome, 3283
 VWD. *See* von Willebrand disease
 VWF. *See* von Willebrand factor
 Vyvanse. *See* Lisdexamfetamine
- W**
- Waardenburg syndrome, 780t, 820, 3924, 3987t, 4072–4073, 4074t
 Wada test, in epilepsy surgery, 3615
 WAGR syndrome, 768t–769t, 786t, 3131t–3132t
 Waldeyer ring, 2562
 Walkers, 4403
 Walker-Warburg syndrome, in congenital muscular dystrophy, 3844
 Walleyed, 3925
 Wandering atrial pacemaker, 2844
 War, on children
 effects of, 106–109, 106f, 107t
 pediatricians and allied health professionals in, role of, 109
 protection for, 108–109
 psychologic impact of, 108, 108t
 susceptibility of, 107–108
 Warfarin, 482, 3044
 Warm antibodies, autoimmune hemolytic anemias associated with, 2994–2995
 Warm autoimmune hemolytic anemia (wAIHA), 2994
 Warthin-Finkeldey giant cells, 1958
 Warts, 4166–4169, 4167f–4168f
 genital, 1249t–1250t, 2055, 2055f
 Wasting
 chronic wasting disease, 2118
 definition of, 433
 renal magnesium, 504
 renal phosphate, 508
 renal salt, 493
 urinary potassium wasting, 499
 Watanabe classification system, 4224, 4225f
 Water
 balance, physiology of, 3372
 chemical pollutants in, 4426–4427
 deficit, hyponatremia and, 489t, 490
 dietary reference intake, 396–408, 404t–407t
 ingestion, increased (primary polydipsia), 3376
 maintenance, 526, 526t
 Water hemlock, toxicity, 722t
 Water-soluble vitamins, 456t–457t
 Watery diarrhea-hypokalemia-acidosis syndrome, 2433
 Watson syndrome, 4068
 WBC. *See* White blood cell
 Weakness
 muscle, in JDM, 1500, 1502t
 suggestive of rheumatic disease, 1461t
 Weaning, from mechanical ventilation, 629, 1081
 Weaning foods, 413
 Weapons of opportunity, 4446
 Weathering, 13
 Weaver syndrome, 3382, 3384t
 Webbed penis, 3298, 3299f
 Webs
 glottic, anterior, 2575f
 laryngeal, congenital, 2575, 2575f
 tracheal, 2577
 Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), 356
 Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV), 356
 Wegener granulomatosis, 2620
 evaluation based on suspected diagnosis, 1463t
 Weight
 low birthweight, preterm birth and, 998
 measurement of, 172
 Weight gain velocity, 437t
 Weight loss products, hepatotoxic, 2492t
 Weight-for-age, 423
 Weight-for-age percentiles, birth to 24 months, 161f
 Weight-for-height, 423
 Weight-for-length percentiles, birth to 24 months, 159f
 Weil syndrome, 1878f, 1879
 Well-Marchesani syndrome (WMS), 4367
 Well-child care
 in context of family and community, 90
 evidence, 90
 guidelines, 84–85
 infancy and early childhood, 85
 middle childhood and adolescence, 85–89
 office intervention for behavioral and mental health issues, 89–90
 periodicity schedule, 84–85, 86f–87f
 tasks of, 85, 88t–89t
 Werding-Hoffmann disease, 3866, 3869f
 Werner syndrome, 774t, 962t
 Wernicke encephalopathy, 459
 West African sleeping sickness, 2161
 West Nile encephalitis, 2061, 2061f
 West syndrome, 3601
 Western equine encephalitis, 2060–2061
 Western immunoblotting, 2195
 for Lyme disease, 1885
 Wet dressings, 4038–4039
 Wet flushing, 4127–4128
 Wheals, 4027
 Wheelchair, 4403–4404
 Wheezing, 612
 bronchiolitis and, 2585–2588
 clinical manifestations of, 2587, 2587t
 diagnostic evaluation of, 2587
 differential diagnosis and etiologies of, 2585t
 prevention of, 2588
 prognosis for, 2588
 treatment of, 2587–2588

- W**
- Wheezing (*Continued*)
 - inhalational injury and, 653
 - recurrent/persistent, 2529
 - respiratory signs and symptoms, 2531t
 - strongyloidiasis and, 2205
 - transient nonatopic, 1388t
 - WHIM syndrome, 1309t, 1337, 1339t
 - Whipple disease (*Tropheryma whipplei*), 1655t–1656t, 2343–2344
 - Whipworm, 2203
 - White blood cell (WBC), 2967
 - defects of, phagocyte disorders and, 1297t
 - leukemoid reaction, 1313
 - White line of Fränkel, 468
 - White nail, 4142t
 - White pulp, 3060
 - White pupillary reflex, malignancy and, 3082, 3083f
 - White spot lesion, 2246, 2246f
 - White superficial onychomycosis, 4145–4146
 - White-eyed blow-out fracture, 3979
 - Whitehead, 4177
 - Whole body irradiation, 4418–4419
 - localized, 4419, 4421t
 - uncontrolled large- or small-scale exposure to, 4418–4419, 4419f, 4420t
 - Whole cow's milk, 414
 - Whole exome sequencing (WES), 727
 - Whole genome sequencing, 1737, 3080
 - Whole-bowel irrigation, 709
 - Widal test, 1774
 - Wide-set eyes, 784t
 - Widespread Pain Index (WPI), for fibromyalgia, 1573f
 - Widow's peak, 784t
 - Width, in deformational plagiocephaly, 3586
 - Wiedemann-Rautenstrauch syndrome, 962t
 - Wilkie syndrome, 2299
 - Williams syndrome, 768t–769t, 786t, 2770, 2791, 2791f, 3408–3409, 3443
 - Williams-Beuren syndrome, 2764t–2766t
 - Williams-Campbell syndrome, 2658
 - Wilms tumor, 3130–3135, 3131t, 3254–3255
 - age-related manifestations of, 3084
 - aniridia and, 3920
 - clinical presentation of, 3133, 3133t
 - diagnosis and differential diagnosis of, 3133–3134, 3133t, 3134f
 - epidemiology of, 3130, 3131t–3132t
 - etiology of, 3130–3133, 3131t–3132t
 - genetics of, 3130–3133
 - late effects, 3135
 - molecular biology of, 3130–3133
 - predisposing conditions of, 3131t–3132t
 - prognosis of, 3135
 - recurrent disease, 3135
 - treatment for, 3134–3135, 3134t
 - Wilms tumor suppressor gene pathogenic variants, 3509
 - Wilson disease, 2457–2459, 2457t, 2997, 3684, 3949
 - clinical manifestations of, 2457–2458
 - diagnosis of, 2458
 - pathology of, 2458
 - prognosis for, 2459
 - treatment of, 2458–2459
 - Wimberger lines, 1868
 - Windsock web, 2282
 - Windswept deformity, 470, 472f
 - Wiskott-Aldrich syndrome, 1273, 1288, 1345, 1661, 3056, 3080
 - Withdrawal
 - benzodiazepines, 1206t
 - as contraceptive method, 1228
 - opiate, 1208
 - Witnessing violence, 99
 - WMS. See Weill-Marchesani syndrome
 - Wnt signaling pathway, 3132–3133
 - Wolf-Parkinson-White syndrome, 595t
 - supraventricular tachycardia in, 2849f–2850f
 - Wolf-Hirschhorn syndrome, 767t
 - Wolfram syndrome, 3373, 3518, 3545
 - Wolman disease, 881, 887t–888t, 897, 2341
 - Wood lamp, 4027
 - Woolly hair disease, 4141
 - Woolsorters' disease, 4449
 - Word retrieval, 301
 - Work clothes, chemical pollutants in, 4427
 - Work of breathing, 623, 624f
 - increased, chronic recurrent aspiration and, 2609
 - Working memory, 300, 302–303
 - math disabilities and, 320
 - writing disabilities and, 323
 - World Health Organization (WHO)
 - classification of, lupus nephritis, 3196
 - youth violence prevention strategies, 1192t
 - World Inequality Report, 25–26
 - World Symposium on Pulmonary Hypertension Consensus, 2833f
 - Wound botulism, 1817–1818, 1820t
 - Wound care, in envenomations, 4466
 - Wound infection
 - inguinal hernia repair, 2420
 - Pseudomonas aeruginosa*, 1799–1800
 - Wound management, tetanus prevention measures, 1824, 1824t
 - WPI. See Widespread Pain Index
 - Wrestling, injuries associated with, 4330–4331
 - Wrisberg variant lateral meniscus, 4224
 - Wrist
 - arthrograpysis in, surgery for, 4275
 - disorders of, 4265–4267
 - ganglion, 4267
 - gymnast's, 4265–4267, 4267f
 - Madelung deformity, 4265, 4267f
 - JIA of, MRI, 1480f
 - Writing disabilities, 321–323
 - educational resources for, 323
 - epidemiology of, 322
 - skill deficits associated with, 322–323
 - treatment for, 323
 - Writing impairment, 304, 304t
 - Written asthma action plan, 1397f, 1408
 - Written expression, disorder of, 304–305
 - Written language, 321
 - Written transition plan, 1171t
 - Written transition policy, 1171t
 - WT1-associated WT predisposition, 3131t–3132t
 - Wuchereria bancrofti*, 2206
- X**
- 45,X males, 3491
 - 45,X/46, XY gonadal dysgenesis, in hypergonadotropic hypogonadism, female, 3499–3500, 3500f
 - 45,X/46,XY mosaicism, 770t, 771
 - Xanthine oxidoreductase deficiency, 944
 - Xanthochromia, 3558
 - Xanthogranulomatous pyelonephritis, 3263–3264
 - Xanthomas, 4124
 - liver disease and, 2439
 - Xenodiagnosis, 2167
 - Xenon computed tomography, for brain death, 591t
 - Xerocytosis, hereditary, 2961–2963, 2963f
 - Xeroderma pigmentosum, 3077–3080, 4097, 4097f
 - Xerophthalmia, 453–454, 453f–454f
 - Xerosis, 1375
 - Xerostomia, 2254
 - X-inactivation, 741f
 - X-LAG syndrome, 3379
 - X-linked adrenal hypoplasia congenital, 3492
 - X-linked agammaglobulinemia, 1277, 1278t, 1279f–1281f, 1280t, 1309t
 - X-linked hyper-IgM, caused by CD40 ligand gene, 1283–1284
 - X-linked hypophosphatemic rickets (XLH), 473t, 477
 - X-linked ichthyosis, 4110, 4115f
 - X-linked inheritance, 738–740, 741f
 - X-linked isolated growth hormone deficiency, in hypopituitarism, 3365–3366
 - X-linked lissencephaly, 780t
 - X-linked phosphorylase kinase deficiency, 905
- X-linked lymphoproliferative disease**, 2008
- X-linked macrothrombocytopenia**, 3056
- X-linked nonsyndromic hearing loss**, 954
- X-linked protoporphyrina (XLP)**, 964–965, 4094–4095
- X-linked recessive hypoparathyroidism**, 3435
- X-linked reticulate pigmentary disorder (XLPDR)**, 1535
- X-linked SCID**, 1264–1265
- XMen disease**, 1332t–1333t
- Xolair. See Omalizumab**
- Xp21.2-p21.3 deletion syndrome**, 768t–769t
- Xp21.2-p22.3 deletion syndrome**, 768t–769t
- Xp22.3 microdeletion syndrome**, 768t–769t
- X-ray**
 - chest, 2517, 2517f
 - study, for liver, 2444
- 46,XX DSD**, 3506
 - androgenic drugs, exposure to, by women during pregnancy, 3507–3509
 - aromatase deficiency in, 3507
 - congenital adrenal hyperplasia in, 3506–3507
 - genes mutated in, 3482t–3484t
 - glucocorticoid receptor gene pathogenic variant in, 3507
 - virilizing maternal tumors in, 3507, 3508t
- 46,XX gonadal dysgenesis**, 3508
- XX gonadal dysgenesis, in hypergonadotropic hypogonadism**, female, 3499
- XX males**, 3491, 3508
- 46,XX ovotesticular DSD**, 3508
- 46,XX testicular DSD**, 3508
- XXX females, in hypergonadotropic hypogonadism**, female, 3500
- XXY syndrome**, 3382
- 46,XY DSD**, 3509–3513
 - androgen action, defects in, 3511–3513
 - androgen insensitivity syndromes in, 3512–3513, 3512f, 3513t
 - dihydrotestosterone deficiency in, 3511–3512, 3511f
 - genes mutated in, 3482t–3484t
 - testicular differentiation, defects in, 3509–3510
 - testicular hormone production, deficiency of, 3510–3511
 - undetermined causes of, 3513
- XY gonadal agenesis syndrome**, 3509–3510
- XY pure gonadal dysgenesis**, 3509
- XYY syndrome**, 770t, 3383
- 47,XYY syndrome**, 770t, 771
- Xyzal**, for allergic rhinitis, 1382t–1383t
- Y**
- Yaws (*Treponema pertenue*)**, 1876, 1876f
 - Yellow fever**, 2071–2072
 - clinical manifestations of, 2072
 - complications of, 2072
 - diagnosis of, 2072
 - epidemiology of, 2071
 - etiology of, 2071
 - pathogenesis of, 2071–2072
 - prevention of, 2072
 - treatment of, 2072
 - vaccine, 1588t–1589t
 - vaccine-associated viscerotropism disease, 2072
 - Yellow nail syndrome**, 2658, 4144
 - Yersinia enterocolitica**, 1792–1793
 - bacterial gastroenteritis and, 2357t–2358t
 - clinical manifestations of, 1792–1793
 - complications of, 1793
 - diagnosis of, 1793
 - differentiation diagnosis of, 1793
 - epidemiology of, 1792
 - etiology of, 1792
 - pathogenesis of, 1792
 - prevention of, 1793

Yersinia enterocolitica (Continued)

- treatment of, 1793
- vulvovaginal infection, 3322t
- Yersinia pestis*, 1794–1795
 - clinical manifestations of, 1794–1795
 - diagnosis of, 1795
 - differential diagnosis of, 1795
 - epidemiology of, 1794
 - etiology of, 1794
 - pathogenesis of, 1794
 - prevention of, 1795
 - treatment of, 1795
- Yersinia pseudotuberculosis*, 1793–1794
 - bacterial gastroenteritis and, 2357t–2358t
- Yersinia* spp., antibiotic therapy for, 2373t–2375t
- Yew toxicity, 722t
- YF-VAX, for yellow fever, 2072
- Yin-yang out, 48t
- Y-linked inheritance, 740, 741f
- Yoga, 58t
 - in pain management, 693
- Yolk sac tumors, 3342–3343
- Young children, lying in, 282
- Youth violence, preventing, 1192t

Z

- Zafirlukast (Accolate), for asthma, 1401t, 1403
- Zanamivir, 1956
 - for influenza, 2022, 2024t
- Zebra bodies, 3887
- Zebra retreat, 48t
- Zeitgebers, 201
- Zellweger syndrome, 866–867, 866t–867t, 867f
- Zero Hunger Challenge, 422
- Zetonna, for allergic rhinitis, 1384t–1385t
- ZIC1-craniosynostosis, 794t–795t
- Zidovudine, for HIV, 2098t–2107t
- Zika virus, 2064–2066
 - clinical features of, 2065–2066
 - differential diagnosis of, 2066
 - epidemiology of, 2064f, 2065, 2065t
 - laboratory diagnosis of, 2066
 - management of, 2066
 - prevention of, 2066, 2066t
 - prognosis for, 2066
- Zinc, 56t, 483t
 - in common cold, 2553
 - deficiency, 396, 424, 484
 - dietary reference intake, 396, 404t–407t
 - foodborne illness, 4411t–4413t
 - noninfectious, 2362t–2364t
 - supplementation, for acute gastroenteritis, 2372
 - in vegetarian diets, 418
 - for Wilson disease, 2459
- Zinner syndrome, 3260, 3260f
- Zollinger-Ellison syndrome, 2308
- Zolmitriptan, for migraine, 3646t–3647t
- Zoloft. *See* Sertraline
- Zona fasciculata, 3446
- Zona glomerulosa, 3445
- Zona reticularis, 3446
- Zonisamide
 - adverse effects of, 3611t
 - dosages of, 3609t–3610t
- Zoonotic transmission, of diarrheal pathogens, 2356t–2359t, 2359
- Zosteriform lentiginous nevus, 4064
- Zyprexa. *See* Olanzapine
- Zyrtec, for allergic rhinitis, 1383t